{"task_id": "medmcp-calc_001_e60ee357", "task_scenario": "Fundamentals of Individualized Dosing", "task_category": "Clinical Medicine / Special Populations & General Tools / Clinical Pharmacology & Nursing", "patient_id": "P001_e60ee357", "task_description": "Scenario: An older oncology patient with chronic kidney disease is planned for a carboplatin plus BSA-based agent regimen. The clinical aim is to tailor dosing to the patient’s physiologic reserve and renal function to balance efficacy and toxicity. Steps: 1) Establish baseline functional capacity using the Eastern Cooperative Oncology Group (ECOG) Performance Status to understand tolerance for cytotoxic therapy. 2) Estimate the risk of severe chemotherapy toxicity with the Cancer and Aging Research Group Chemotherapy Toxicity Tool (CARG-TT) to inform initial dose intensity and supportive care needs. 3) Determine appropriate weight metrics with the Ideal Body Weight and Adjusted Body Weight calculator; this output guides which weight to use in kidney function estimation and BSA calculations, especially in obesity. 4) Assess renal function for dosing decisions: If kidney function is stable, calculate Creatinine Clearance (Cockcroft-Gault Equation) using the weight selected from step 3; if kidney function is acutely changing, calculate Kinetic Estimated Glomerular Filtration Rate (keGFR). Then cross-check with CKD-EPI Equations for Glomerular Filtration Rate (GFR). If there is material discordance between CrCl/keGFR and CKD-EPI eGFR, proceed with the more conservative estimate to reduce nephrotoxicity risk. 5) Dose carboplatin using the Carboplatin AUC Dosing (Calvert) calculator, feeding in the GFR surrogate chosen in step 4. Use the results from steps 1–2 to set the target AUC: if ECOG and/or CARG-TT indicate high toxicity risk, select a lower target AUC; otherwise, use standard targets. 6) Calculate the dose of the companion BSA-based agent (e.g., paclitaxel) with the Body Surface Area Based Dosing calculator. Use the weight strategy from step 3; adjust dose intensity based on ECOG and CARG-TT outputs. Conditional branches ensure safe dosing: a) Stable vs acutely changing kidney function determines whether Cockcroft-Gault or keGFR informs Calvert dosing; b) High vs low toxicity risk (ECOG/CARG-TT) determines attenuated vs standard dose intensity for both carboplatin (via target AUC selection) and BSA-based agent dosing. This sequence integrates functional status, geriatric toxicity risk, body size selection, renal function, and drug-specific dosing to produce an individualized plan.", "fuzzy_question": "I am reviewing a case of an older oncology patient with chronic kidney disease who is planned for carboplatin with a companion drug dosed by body surface area. I want to ensure the plan is individualized to balance efficacy and safety. Recent creatinine values have fluctuated, and the patient has elevated body weight, so I am unsure how aggressive to be and which body weight to use for dosing.\n\nHere is the approach, and I would like you to follow the same order. First, obtain a clear assessment of day-to-day functioning and performance status to gauge tolerance for cytotoxic therapy. In parallel, use a validated tool for older adults to estimate the risk of serious chemotherapy-related toxicity; let that score guide treatment intensity and the need for early supportive care.\n\nBecause body size affects both renal estimates and the surface-area-based agent, we need a deliberate weight strategy. Decide whether actual, ideal, or adjusted body weight makes the most clinical sense for this patient, and apply it consistently for renal dosing and body surface area. Please explain the rationale, particularly in the context of obesity.\n\nOn the renal side, consider recent laboratory trends and clinical trajectory. If kidney function appears stable, base dosing on a standard creatinine clearance estimate; if it is changing rapidly, use a kinetic estimate. Cross-check the chosen renal estimate against the lab-reported eGFR. If there is a meaningful discrepancy, favor the more conservative value to reduce nephrotoxicity risk.\n\nFor carboplatin, set the dose using the selected renal estimate. If performance status or the older-adult toxicity risk indicates high risk, start with a gentler exposure target; if risk appears low and the patient is robust, use the usual target. Make the exposure target explicit and show how it translates into the calculated dose.\n\nFor the companion drug (with paclitaxel-style dosing), calculate body surface area from the chosen weight strategy, then adjust intensity up or down based on performance status and the toxicity risk score to maintain consistency across both agents. If kidney function seems acutely unstable, pivot the plan accordingly and reflect that in the carboplatin choice; if stable, proceed with the standard approach.\n\nPlease lay out each step with intermediate figures and assumptions: functional status, the geriatric toxicity risk, which weight is used and why, how kidney function is estimated and reconciled with the lab eGFR, the carboplatin exposure target and resulting dose, and the surface-area dose for the partner drug with any risk-based adjustments. The goal is to avoid complications through defensible, calculation-based decisions. What is your take, and is there anything I am missing that would change the dosing strategy?", "required_calculators": ["Eastern Cooperative Oncology Group (ECOG) Performance Status", "Cancer and Aging Research Group Chemotherapy Toxicity Tool (CARG-TT)", "Ideal Body Weight and Adjusted Body Weight", "Creatinine Clearance (Cockcroft-Gault Equation)", "Kinetic Estimated Glomerular Filtration Rate (keGFR)", "CKD-EPI Equations for Glomerular Filtration Rate (GFR)", "Carboplatin AUC Dosing (Calvert)", "Body Surface Area Based Dosing"], "calculator_answers": [{"order": 1, "name": "Eastern Cooperative Oncology Group (ECOG) Performance Status", "inputs": [{"field": "Patient description", "value": "Symptomatic but completely ambulatory (ECOG 1)"}], "final_answer": 1, "notes": "Restricted in strenuous activity, ambulatory and able to do light work.\nSee definitions of the ECOG/Zubrod Score in the About section."}, {"order": 2, "name": "Cancer and Aging Research Group Chemotherapy Toxicity Tool (CARG-TT)", "inputs": [{"field": "Sex", "value": "Female"}, {"field": "Age, years", "value": 76, "score": 2}, {"field": "Cancer type", "value": "Other (non-GI/GU)", "score": 0}, {"field": "Dosage (first dose of chemotherapy)", "value": "Standard dose (for risk estimation)", "score": 2}, {"field": "Number of chemotherapy drugs", "value": "2 (i.e., >1)", "score": 2}, {"field": "Hemoglobin, g/dL", "value": "≥10 g/dL", "score": 0}, {"field": "Creatinine clearance, mL/min", "value": "28.8 mL/min (<34)", "score": 3}, {"field": "Hearing", "value": "Fair/poor", "score": 2}, {"field": "Number of falls in the past six months", "value": "None (0)", "score": 0}, {"field": "Needs help taking meds", "value": "No", "score": 0}, {"field": "Walking ability within one block", "value": "Not limited", "score": 0}, {"field": "Social activity", "value": "Decreased due to health", "score": 1}], "final_answer": 12, "notes": "83 %\nHigh risk of Grade 3 or greater toxicity"}, {"order": 3, "name": "Ideal Body Weight and Adjusted Body Weight", "inputs": [{"field": "Sex", "value": "Female"}, {"field": "Height", "value": "64 in"}, {"field": "Actual body weight", "value": "176 lb"}], "final_answer": 120.6, "notes": "120.6 lbs\nIdeal Body Weight\nEquivalent to 54.7 kg\nActual body weight is 146% (1.46x) ideal body weight\n142.8 lbs\nAdjusted Body Weight\nEquivalent to 64.8 kg"}, {"order": 4, "name": "Creatinine Clearance (Cockcroft-Gault Equation)", "inputs": [{"field": "Sex", "value": "Female"}, {"field": "Age", "value": "76 years"}, {"field": "Weight", "value": "142.9 lb (Adjusted body weight)"}, {"field": "Creatinine", "value": "1.7 mg/dL"}, {"field": "Height", "value": "64 in"}], "final_answer": 29, "notes": "29 mL/min\nCreatinine clearance, original Cockcroft-Gault\n24 mL/min\nCreatinine clearance for normal weight patient, using ideal body weight of 55 kg (121 lbs).\n24.3-28.8 mL/min\nNote: This range uses IBW and actual body weight. Controversy exists over which form of weight to use."}, {"order": 5, "name": "Kinetic Estimated Glomerular Filtration Rate (keGFR)", "inputs": [{"field": "Sex", "value": "Female"}, {"field": "Age", "value": "76 years"}, {"field": "Baseline creatinine", "value": "1.5 mg/dL"}, {"field": "First recorded creatinine (Cr1)", "value": "1.9 mg/dL"}, {"field": "Second recorded creatinine (Cr2)", "value": "1.7 mg/dL"}, {"field": "Time between both creatinine measurements", "value": "48 hours"}, {"field": "Black race", "value": "No"}], "final_answer": 28.1, "notes": "KeGFR of 30 mL/min is 90% specific (71% sensitive) for AKI, according to one small retrospective study (O'Sullivan 2017)"}, {"order": 6, "name": "CKD-EPI Equations for Glomerular Filtration Rate (GFR)", "inputs": [{"field": "Equation", "value": "2021 CKD-EPI Creatinine"}, {"field": "Sex", "value": "Female"}, {"field": "Age", "value": "76 years"}, {"field": "Serum creatinine", "value": "1.7 mg/dL"}], "final_answer": 31, "notes": "31 ml/min/1.73 m²\nEstimated GFR by 2021 CKD-EPI Creatinine\nStage IIIb\nCKD stage by CKD-EPI Creatinine"}, {"order": 7, "name": "Carboplatin AUC Dosing (Calvert)", "inputs": [{"field": "Age", "value": "76 years"}, {"field": "Weight", "value": "64.8 kg (Adjusted body weight)"}, {"field": "Creatinine", "value": "1.7 mg/dL"}, {"field": "Target AUC", "value": "4"}, {"field": "Gender", "value": "Female"}], "final_answer": 215.2, "notes": "Total Dose\n215.2 mg"}, {"order": 8, "name": "Body Surface Area Based Dosing", "inputs": [{"field": "BSA Based Dose", "value": "135 mg/m^2 (paclitaxel-style, dose-reduced)"}, {"field": "Weight", "value": "64.8 kg (Adjusted body weight)"}, {"field": "Height", "value": "163 cm"}, {"field": "Select either", "value": "Mosteller"}, {"field": "Desired dose unit", "value": "mg"}], "final_answer": 231.24, "notes": "Dose\n231.24 mg."}]}
{"task_id": "medmcp-calc_002_e266f3ba", "task_scenario": "Upper Gastrointestinal Bleeding Risk", "task_category": "Clinical Medicine / Medicine & Organ Systems / Gastroenterology & Hepatology", "patient_id": "P002_e266f3ba", "task_description": "Clinical scenario: An adult presents to the emergency department with suspected upper gastrointestinal bleeding (e.g., hematemesis or melena). The clinical team must rapidly assess hemodynamic stability, stratify bleeding severity and mortality risk, determine disposition and timing of endoscopy, and plan inpatient management including rebleeding prevention and prophylaxis decisions. The workflow uses a sequence of validated calculators to structure decisions from arrival through post-endoscopy care.\n\nStep-by-step process:\n1) Use the Shock Index immediately to screen for occult shock from acute hemorrhage. If the Shock Index indicates hemodynamic compromise, initiate resuscitation and prioritize urgent endoscopy; regardless of result, proceed to risk stratification in step 2.\n2) Calculate the Glasgow-Blatchford Bleeding Score (GBS) to triage. If the GBS meets the tool’s low-risk threshold and the Shock Index is reassuring, the patient is a candidate for outpatient management and the workflow can stop after arranging safe follow-up. If the GBS is not low risk or the Shock Index is concerning, enter the admission pathway and continue to step 3.\n3) Compute the AIMS65 Score for Upper GI Bleeding Mortality to estimate in-hospital mortality and guide level of care. If AIMS65 is high, consider ICU-level monitoring and expedited endoscopy; if low, a monitored ward may be appropriate. Proceed to step 4 in either case.\n4) Apply the Rockall Score for Upper GI Bleeding (Pre-Endoscopy) to refine pre-scope severity and rebleeding risk. Use this with AIMS65 to determine endoscopy timing and intensity of monitoring. Proceed to endoscopy in step 5.\n5) After endoscopy, assign a Forrest Classification of Upper GI Bleeding based on stigmata of recent hemorrhage. This classification acts as an explicit input to the next step and guides therapy decisions (e.g., need for endoscopic hemostasis and high-dose acid suppression). If the Forrest class suggests high-risk stigmata, continue intensive therapy and close observation; if low-risk stigmata, begin discharge planning. Proceed to step 6.\n6) Calculate the Rockall Score for Upper GI Bleeding (Complete), incorporating endoscopic findings informed by the Forrest classification alongside clinical variables, to estimate rebleeding and mortality. If the complete Rockall indicates high risk, continue inpatient care and monitoring; if low risk, finalize early discharge with appropriate follow-up and secondary prevention plan.\n7) For patients admitted (deterministically triggered by step 2/3 outcomes), use the IMPROVE Bleeding Risk Score to document baseline inpatient bleeding risk and tailor venous thromboembolism prophylaxis (e.g., mechanical versus pharmacologic) and other iatrogenic bleeding risk mitigation.\n\nThis sequence ensures that early hemodynamic triage, pre-endoscopy risk, post-endoscopy stigmata, and comprehensive inpatient risk considerations all inform a coordinated management plan.", "fuzzy_question": "I am evaluating a patient in the emergency department with suspected upper gastrointestinal bleeding. Vitals are concerning, with tachycardia relative to blood pressure, and I am unsure whether this represents compensation or early shock. I want a quick bedside assessment of pulse relative to pressure to screen for occult hypovolemia. If that is worrisome, we should start resuscitation (fluids, blood if indicated) and elevate the priority of endoscopy; regardless, I still want careful early triage based on presentation and initial labs to distinguish true low risk from higher risk.\n\nIf the first data points (symptoms such as melena or syncope, labs including BUN and hemoglobin, and overall stability of the vitals) place the patient clearly in a low-risk category and the bedside picture is reassuring, I am open to discharge with safe, prompt follow‑up. If not, we will admit and use a pragmatic estimate of short‑term mortality risk from routine information available at presentation—patient characteristics, mental status, blood pressure, albumin, and INR—to decide on ICU‑level monitoring versus a closely watched ward bed and how urgently to proceed to endoscopy.\n\nBefore endoscopy, I want to recheck overall severity and rebleeding risk using patient characteristics, hemodynamic stability, and comorbidity burden; that should guide monitoring intensity and endoscopy timing. After endoscopy, please categorize stigmata (active bleeding or oozing, a visible vessel, an adherent clot, versus a flat spot or clean base) because that directly drives therapy (endoscopic hemostasis when appropriate and high‑dose acid suppression), and I want that categorization explicitly carried forward into the next risk judgment.\n\nOnce we have the endoscopic details, integrate them with the earlier clinical factors to estimate the chances of rebleeding and in‑hospital death. If the composite risk is high, we will keep the patient inpatient with close monitoring and ongoing therapy; if it is reassuring, we should move toward early discharge with a concrete plan: acid suppression, H. pylori testing and eradication if relevant, and a strategy for NSAIDs and any anticoagulants or antiplatelets. For anyone who remains admitted, I also want us to document baseline bleeding risk for the hospitalization so we can tailor venous thromboembolism prophylaxis (mechanical only versus pharmacologic) and minimize iatrogenic bleeding.\n\nI am torn between pushing for ICU and urgent endoscopy versus a monitored bed with an early endoscopy, and I think the vitals and labs will sway this. What is your clinical take? Please walk through it in that sequence—from arrival hemodynamics, through the pre‑scope picture, the scope findings themselves, and the post‑scope plan—tied to disposition, endoscopy timing, and prophylaxis. I need validated, calculation‑based risk estimates so this stands up to scrutiny.", "required_calculators": ["Shock Index", "Glasgow-Blatchford Bleeding Score (GBS)", "AIMS65 Score for Upper GI Bleeding Mortality", "Rockall Score for Upper GI Bleeding (Pre-Endoscopy)", "Forrest Classification of Upper GI Bleeding", "Rockall Score for Upper GI Bleeding (Complete)", "IMPROVE Bleeding Risk Score"], "calculator_answers": [{"order": 1, "name": "Shock Index", "inputs": [{"field": "Heart Rate/Pulse", "value": "110 beats/min"}, {"field": "Systolic BP", "value": "95 mm Hg"}], "final_answer": 1.2, "notes": "0.5-0.7 is believed to be a normal shock index. Higher numbers have been shown to be more sensitive than vital signs alone in diagnosing occult shock, need for transfusion and/or operation."}, {"order": 2, "name": "Glasgow-Blatchford Bleeding Score (GBS)", "inputs": [{"field": "Hemoglobin", "value": "9.2 g/dL"}, {"field": "BUN", "value": "32 mg/dL"}, {"field": "Initial systolic BP", "value": "95 mm Hg"}, {"field": "Sex", "value": "Male"}, {"field": "Heart rate ≥100", "value": "Yes", "score": 1}, {"field": "Melena present", "value": "Yes", "score": 1}, {"field": "Recent syncope", "value": "Yes", "score": 2}, {"field": "Hepatic disease history", "value": "No", "score": 0}, {"field": "Cardiac failure present", "value": "No", "score": 0}], "final_answer": 16, "notes": "A GBS greater than zero suggests a “High Risk” GI bleed that is likely to require “medical intervention”: transfusion, endoscopy, or surgery. A higher GBS also correlated with a higher likelihood of needing intervention (scores ≥6 are associated with >50% risk of needing intervention)"}, {"order": 3, "name": "AIMS65 Score for Upper GI Bleeding Mortality", "inputs": [{"field": "Albumin <3 g/dL (30 g/L)", "value": "Yes (2.8 g/dL)", "score": 1}, {"field": "INR >1.5", "value": "No (INR 1.3)", "score": 0}, {"field": "Alteration in mental status", "value": "No", "score": 0}, {"field": "sBP ≤90 mm Hg", "value": "No (95 mm Hg)", "score": 0}, {"field": "Age ≥65 years", "value": "Yes (68 years)", "score": 1}], "final_answer": 2, "notes": "5.3% In-hospital mortality."}, {"order": 4, "name": "Rockall Score for Upper GI Bleeding (Pre-Endoscopy)", "inputs": [{"field": "Age", "value": "60-79 years", "score": 1}, {"field": "Shock", "value": "Hypotension (SBP <100)", "score": 2}, {"field": "Comorbidities", "value": "Any comorbidity EXCEPT renal failure, liver failure, and/or disseminated malignancy (e.g., ischemic heart disease)", "score": 2}], "final_answer": 5, "notes": "39.6% mortality prior to endoscopy."}, {"order": 5, "name": "Forrest Classification of Upper GI Bleeding", "inputs": [{"field": "Endoscopy finding", "value": "Non-bleeding visible vessel"}], "final_answer": "2A", "notes": "2A\nForrest classification\n43 %\nRebleeding rate\n11 %\nMortality"}, {"order": 6, "name": "Rockall Score for Upper GI Bleeding (Complete)", "inputs": [{"field": "Age", "value": "60-79 years", "score": 1}, {"field": "Shock", "value": "Hypotension (SBP <100)", "score": 2}, {"field": "Comorbidities", "value": "Any comorbidity EXCEPT renal failure, liver failure, and/or disseminated malignancy (e.g., ischemic heart disease)", "score": 2}, {"field": "Mallory-Weiss tear", "value": "No"}, {"field": "No lesion identified and no stigmata of recent hemorrhage", "value": "No"}, {"field": "All other diagnoses", "value": "Yes (peptic ulcer disease)", "score": 1}, {"field": "Malignancy of upper GI tract", "value": "No"}, {"field": "Major stigmata of recent hemorrhage", "value": "Visible or spurting vessel", "score": 2}], "final_answer": 7, "notes": "High Risk\n43.8% rebleeding risk.\n27% mortality.\nSee all mortality rates under Evidence > Facts & Figures."}, {"order": 7, "name": "IMPROVE Bleeding Risk Score", "inputs": [{"field": "Age, years", "value": "40-84", "score": 1.5}, {"field": "Gender", "value": "Male", "score": 1}, {"field": "Renal function (GFR), mL/min/m2", "value": "30-59 (eGFR 55 mL/min/1.73 m^2)", "score": 1}, {"field": "Current cancer", "value": "No", "score": 0}, {"field": "Rheumatic disease", "value": "No", "score": 0}, {"field": "Central venous catheter", "value": "No", "score": 0}, {"field": "ICU/CCU", "value": "Yes", "score": 2.5}, {"field": "Evidence of hepatic failure (INR >1.5)", "value": "No (INR 1.3)", "score": 0}, {"field": "Platelet count, cells/L", "value": "≥50 x 10^9 (190 x 10^9/L)", "score": 0}, {"field": "Bleeding in 3 months before admission", "value": "No", "score": 0}, {"field": "Active gastroduodenal ulcer", "value": "Yes", "score": 4.5}], "final_answer": 10.5, "notes": "IMPROVE Bleeding Risk Score\nIncreased risk of bleeding."}]}
{"task_id": "medmcp-calc_003_e6075da9", "task_scenario": "Prostate Symptom Scores", "task_category": "Clinical Medicine / Medicine & Organ Systems / Urology & Reproductive System", "patient_id": "P003_e6075da9", "task_description": "Clinical scenario: A patient on active surveillance for localized prostate cancer presents with bothersome lower urinary tract symptoms. The care team must decide whether to continue surveillance or initiate definitive therapy, and, if treating, select an approach that minimizes urinary morbidity while addressing oncologic risk. Step-by-step calculator use: First, quantify symptom severity and bother using the American Urological Association Symptom Index (AUA-SI)/International Prostate Symptom Score (IPSS). This establishes the baseline symptom burden and categorizes severity. If symptoms are severe or patient-reported bother is high, prioritize lower urinary tract symptom optimization before proceeding to oncologic decisions; if mild-to-moderate, proceed directly. Next, assess cancer kinetics using the PSA Doubling Time (PSADT) Calculator based on available serial PSA data to determine the urgency of intervention. If PSADT suggests indolent disease, continue active surveillance and schedule periodic reassessment of both IPSS and PSADT; if PSADT indicates more aggressive kinetics, move to treatment planning. For patients likely to undergo prostate-directed therapy, apply the Emory Model (TIPSS) to forecast the impact of the planned intervention on urinary symptom burden; TIPSS requires the baseline AUA-SI/IPSS result as an input. If TIPSS predicts a high risk of significant symptom worsening, favor modalities with lower urinary morbidity or implement pre-treatment measures (e.g., medical optimization) before therapy; if risk is low, proceed with the preferred oncologic modality. This sequence ensures symptom quantification, oncologic urgency assessment, and prediction of urinary outcomes guide a balanced, patient-centered plan.", "fuzzy_question": "I’m seeing a patient on active surveillance for localized prostate cancer who is increasingly bothered by lower urinary symptoms. I’m torn between continuing observation and moving toward definitive treatment, but I want to avoid making urinary function worse if we treat.\n\nFirst, I want a clear sense of how severe the symptoms are and how much they bother the patient, with a baseline that allows categorization as roughly mild, moderate, or severe. If symptoms or bother are high, I’d prefer to improve urinary status first and then revisit the cancer decision; if they are mild to moderate, I’m comfortable going straight to the cancer question.\n\nPSA values have fluctuated, and I care less about single measurements than about the rate of increase—whether it is rising slowly or showing a faster doubling pattern. If the trend appears indolent, I’d continue surveillance and plan to reassess both the urinary symptom baseline and the PSA trend at appropriate intervals; if the trend accelerates, I would shift to treatment planning.\n\nIf we move toward prostate-directed therapy, before selecting an option I want a realistic projection of how urinary symptoms are likely to change after treatment, referenced to the current baseline. If the projection suggests a high likelihood of meaningful worsening, I’d favor approaches with lower urinary side effects or ensure medical optimization beforehand; if the risk seems low, I’d proceed with the oncologic approach that best addresses the cancer.\n\nWhat’s your take on this? Anything you’d weigh differently for the patient’s management in our clinic? I need proper, evidence‑based calculations—this decision can’t rest on gut feeling. Whatever approach you suggest, please support it with robust calculations so it holds up to scrutiny.", "required_calculators": ["American Urological Association Symptom Index (AUA-SI)/International Prostate Symptom Score (IPSS)", "PSA Doubling Time (PSADT) Calculator", "Emory Model (TIPSS)"], "calculator_answers": [{"order": 1, "name": "American Urological Association Symptom Index (AUA-SI)/International Prostate Symptom Score (IPSS)", "inputs": [{"field": "Incomplete emptying: How often have you had the sensation of not emptying your bladder?", "value": "4 (More than half the time)", "score": 4}, {"field": "Frequency: How often have you had to urinate less than every two hours?", "value": "4 (More than half the time)", "score": 4}, {"field": "Intermittency: How often have you found you stopped and started again several times when you urinated?", "value": "3 (About half the time)", "score": 3}, {"field": "Urgency: How often have you found it difficult to postpone urination?", "value": "2 (Less than half the time)", "score": 2}, {"field": "Weak stream: How often have you had a weak urinary stream?", "value": "4 (More than half the time)", "score": 4}, {"field": "Straining: How often have you had to strain to start urination?", "value": "2 (Less than half the time)", "score": 2}, {"field": "Nocturia: How many times do you typically get up at night to urinate?", "value": "2 (2 times/night)", "score": 2}, {"field": "If you were to spend the rest of your life with your urinary condition just the way it is now, how would you feel about that?", "value": "Unhappy"}], "final_answer": 21, "notes": "21 points\nAUA-SI/IPSS Score\nSevere\nBPH symptom severity\nUnhappy\nQuality of life"}, {"order": 2, "name": "PSA Doubling Time (PSADT) Calculator", "inputs": [{"field": "PSA1", "value": "5.1 ng/mL"}, {"field": "PSA2", "value": "5.4 ng/mL"}, {"field": "Time between PSA1 and PSA2 measurement", "value": "6 months"}, {"field": "Add another measurement", "value": "Yes"}, {"field": "PSA3", "value": "5.2 ng/mL"}, {"field": "Time between PSA2 and PSA3 measurement", "value": "6 months"}, {"field": "PSA4", "value": "5.8 ng/mL"}, {"field": "Time between PSA3 and PSA4 measurement", "value": "6 months"}, {"field": "PSA5", "value": "6.2 ng/mL"}, {"field": "Time between PSA4 and PSA5 measurement", "value": "6 months"}], "final_answer": 0.0, "notes": "0.0\nSlope\n90.0 months\nDoubling time"}, {"order": 3, "name": "Emory Model (TIPSS)", "inputs": [{"field": "Total Bilirubin", "value": "0.7 mg/dL"}, {"field": "ALT", "value": "24 U/L"}, {"field": "Pre-TIPSS Hepatic Encephalopathy?", "value": "No"}, {"field": "Urgency of TIPSS?", "value": "Elective"}], "final_answer": 0, "notes": "Score\n0\nRisk Category\nLow Risk\nEstimated Mortality Rates after TIPSS:\nEstimated 3-month Mortality Rates after TIPSS\n10 %\nEstimated 12-month Mortality Rates after TIPSS\n30-33 %\nEstimated 36-month Mortality Rates after TIPSS\n30 %"}]}
{"task_id": "medmcp-calc_004_5e9098ea", "task_scenario": "Infusion Management and Critical Care Nursing", "task_category": "Clinical Medicine / Special Populations & General Tools / Clinical Pharmacology & Nursing", "patient_id": "P004_5e9098ea", "task_description": "Clinical scenario: A critically ill adult with severe hyperglycemia and altered sodium presents to the ICU. The nursing and clinical pharmacology team must plan and operationalize safe infusion therapy to correct osmolar abnormalities and dysnatremia while insulin is administered, and continuously monitor fluid balance to avoid over- or under-correction.\n\nStep-by-step calculator workflow:\n1) Use Serum Osmolality/Osmolarity to estimate expected osmolarity and assess the degree of hyperosmolarity. This frames the urgency of rehydration and helps confirm that sodium shifts are driven by osmotic forces from hyperglycemia rather than unmeasured solutes.\n2) Use Sodium Correction for Hyperglycemia to obtain the corrected sodium. This corrected sodium value determines the subsequent pathway for sodium correction.\n3) Branching based on corrected sodium:\n   - If corrected sodium indicates hypernatremia: Use Free Water Deficit in Hypernatremia to estimate the free water volume required to reach a target sodium safely. The calculated deficit and target become inputs for the next step’s rate planning.\n   - If corrected sodium indicates hyponatremia: Skip the free water deficit step and proceed directly to rate planning in the next step.\n4) Use Sodium Correction Rate in Hyponatremia and Hypernatremia to select the appropriate fluid type (e.g., D5W vs isotonic saline) and calculate a safe infusion rate and total volume to achieve the desired correction pace. The output (fluid type and rate) becomes the operational input for infusion delivery and glucose management.\n5) Operationalize dextrose delivery when indicated: If the chosen fluid contains dextrose or insulin therapy is started, use Glucose Infusion Rate (GIR) to quantify the carbohydrate delivery rate. Adjust dextrose concentration or infusion rate to maintain an appropriate GIR during insulin therapy and prevent hypoglycemia.\n6) Implement the fluid plan at the bedside: Use IV Drip Rate Calculator to convert the ordered rate (mL/hour) to drops per minute when IV pumps are unavailable or to cross-check manual delivery accuracy. The rate from the sodium correction calculator is the direct input here.\n7) Monitor kidney output: Use Urine Output and Fluid Balance to track hourly and daily urine outputs, which reflect ongoing free water losses and guide adjustments to infusion plans.\n8) Integrate overall fluid shifts: Use Body Fluid Balance Calculator by Inputs and Outputs to quantify net isotonic saline load and free water changes from all inputs/outputs. If net free water is excessive, or sodium is changing too quickly or too slowly, re-run Step 4 (Sodium Correction Rate in Hyponatremia and Hypernatremia) with updated targets to adjust fluid type and rate.\n\nConditional triggers and data flow: The corrected sodium from Step 2 deterministically selects the hypernatremia vs hyponatremia pathway (Step 3). The free water deficit (if hypernatremia) and the desired correction pace feed Step 4 to set fluid type and rate. The chosen fluid type and infusion rate from Step 4 feed directly into Step 5 (GIR, if dextrose is present) and Step 6 (IV Drip Rate). Ongoing measurements from Steps 7 and 8 trigger re-calculation of Step 4 when the net fluid balance or sodium trend deviates from targets.", "fuzzy_question": "I’m evaluating a critically ill patient in the ICU with severe hyperglycemia, altered mental status, and dysnatremia. I plan to begin rehydration and insulin but am concerned about shifting sodium too rapidly or in the wrong direction.\n\nBefore selecting fluids, I need a clear assessment of hyperosmolality and whether the sodium change is primarily due to glucose‑driven water shifts versus another osmolar driver, as this determines the urgency of rehydration. I also want to establish the underlying sodium status after adjusting for hyperglycemia, since that will direct management. If the corrected sodium is truly high, I’d estimate the free water deficit and choose a prudent sodium target for safe movement. If the corrected sodium is low, I would avoid chasing a water deficit and instead focus on fluid composition and a safe correction pace.\n\nFrom there, I’m looking for a concrete infusion plan: choose between dextrose‑containing versus isotonic fluids, and specify a rate and total volume that achieve a safe change over the next several hours and through the first day. With insulin running, if dextrose is included, I want the carbohydrate delivery quantified per kilogram per minute so the concentration or rate can be adjusted to prevent hypoglycemia.\n\nOnce an mL/hr order is set, translate it to drops per minute if a pump isn’t available—or use it to double‑check any manual drip. During therapy, track hourly and daily urine output to monitor ongoing free water losses and adjust the infusion accordingly. Maintain a running net balance that separates isotonic load from free water across all inputs and outputs; if the net free water or sodium trend is changing too quickly or too slowly, revisit the fluid choice, target, and rate.\n\nWhat’s your take on this approach? I need recommendations supported by rigorous calculations—this decision should rest on solid, defensible math rather than clinical intuition alone.", "required_calculators": ["Serum Osmolality/Osmolarity", "Sodium Correction for Hyperglycemia", "Free Water Deficit in Hypernatremia", "Sodium Correction Rate in Hyponatremia and Hypernatremia", "Glucose Infusion Rate (GIR)", "IV Drip Rate Calculator", "Urine Output and Fluid Balance"], "calculator_answers": [{"order": 1, "name": "Serum Osmolality/Osmolarity", "inputs": [{"field": "Sodium", "value": "130 mEq/L"}, {"field": "BUN", "value": "32 mg/dL"}, {"field": "Glucose", "value": "1100 mg/dL"}, {"field": "Serum alcohol concentration", "value": "0 mg/dL"}, {"field": "Measured serum osm", "value": "333 mOsm/kg"}], "final_answer": 333, "notes": "333 mOsm/kg Calculated Serum Osm\nNormal serum osmolality = 285-295 mOsm/kg\n0.0 mOsm/kg Osm Gap\nNormal Serum Osm Gap (Measured-Calculated) is -14 to +10."}, {"order": 2, "name": "Sodium Correction for Hyperglycemia", "inputs": [{"field": "Sodium", "value": "130 mEq/L"}, {"field": "Glucose", "value": "1100 mg/dL"}], "final_answer": 154, "notes": "146 mEq/L\nCorrected Sodium(Katz, 1973)\n154 mEq/L\nCorrected Sodium(Hillier, 1999)"}, {"order": 3, "name": "Free Water Deficit in Hypernatremia", "inputs": [{"field": "Sex", "value": "Male"}, {"field": "Age range", "value": "Adult"}, {"field": "Weight", "value": "180 lb"}, {"field": "Sodium", "value": "154 mEq/L"}, {"field": "Sodium desired", "value": "144 mEq/L"}], "final_answer": 3.4, "notes": "3.4 L\nFree Water Deficit"}, {"order": 4, "name": "Sodium Correction Rate in Hyponatremia and Hypernatremia", "inputs": [{"field": "Sex", "value": "Male"}, {"field": "Age range", "value": "Adult"}, {"field": "Weight", "value": "180 lb"}, {"field": "Serum sodium", "value": "154 mEq/L"}, {"field": "Fluid type", "value": "5% Dextrose in water (0 mmol/L Na)"}, {"field": "Rate of sodium correction", "value": "0.3 mEq/L/hr"}], "final_answer": 97, "notes": "97 mL/hr\nFluid rate to decrease Na by 0.3 mmol/L/hr with D5W"}, {"order": 5, "name": "Glucose Infusion Rate (GIR)", "inputs": [{"field": "Dextrose concentration", "value": "5 g/dL"}, {"field": "Infusion rate", "value": "146 mL/hr"}, {"field": "Weight", "value": "180 lb"}], "final_answer": 1.5, "notes": "1.5 mg/kg/min\nGIR"}, {"order": 6, "name": "IV Drip Rate Calculator", "inputs": [{"field": "Volume to be given", "value": "1000 mL"}, {"field": "Drop factor", "value": "20 gtts/mL"}, {"field": "Time", "value": "411 min"}], "final_answer": 49, "notes": "49 gtts/min\nIV Drip Rate"}, {"order": 7, "name": "Urine Output and Fluid Balance", "inputs": [{"field": "Weight", "value": "180 lb"}, {"field": "Total urine output", "value": "3500 mL"}, {"field": "Hours", "value": "24 hours"}, {"field": "Fluid intake", "value": "4500 mL"}], "final_answer": 1.8, "notes": "1.8 cc/kg/hr\nNormal output for adult patients: 0.5-1.0 cc/kg/hr\nNormal output for pediatric patients: 1.0-2.0 cc/kg/hr\n1000 mL\nFluid Balance"}]}
{"task_id": "medmcp-calc_005_4e771910", "task_scenario": "Radiation Dose and Fractionation Planning", "task_category": "Clinical Medicine / Medicine & Organ Systems / Comprehensive Oncology", "patient_id": "P005_4e771910", "task_description": "Clinical scenario: A patient with a solid tumor adjacent to a critical organ at risk requires external beam radiotherapy. Prior irradiation may have contributed dose to nearby normal tissues. The planning goal is to choose a fractionation scheme that achieves tumor control while keeping cumulative organ-at-risk (OAR) exposure within accepted limits. This workflow uses the Radiation Biologically Effective Dose (BED) Calculator iteratively to convert regimens to BED and EQD2 for tumor and OARs, compare alternative schedules, and account for prior radiation.\n\nStep-by-step calculator use and decision-making:\n1) Establish biologic baseline from any prior radiation: Use the Radiation Biologically Effective Dose (BED) Calculator to compute EQD2 for the prior course separately for the tumor target and each adjacent OAR using appropriate alpha/beta values. These EQD2 outputs represent the biologically weighted doses already delivered.\n2) Propose an initial candidate definitive regimen: Enter the planned dose per fraction and number of fractions with the tumor alpha/beta into the calculator to obtain tumor BED and EQD2. This estimates tumoricidal equivalence against institutional targets.\n3) Evaluate OAR exposure for the same candidate regimen: Re-run the calculator with the OAR alpha/beta to obtain the OAR EQD2 for the candidate plan, then sum it with the prior OAR EQD2 from step 1 to determine the cumulative OAR EQD2 for decision-making.\n4) Conditional branching guided by calculator outputs:\n   - If cumulative OAR EQD2 exceeds the accepted constraint, adjust fractionation to reduce normal tissue biologic effect (for example, reduce dose per fraction and increase fraction number or use hyperfractionation), then re-enter the revised regimen into the calculator for the OAR to verify the new cumulative EQD2; subsequently re-calculate tumor BED/EQD2 to confirm tumor adequacy.\n   - Else if OAR constraints are met but the tumor EQD2 is below the desired target, increase total dose or dose per fraction, re-calculate tumor BED/EQD2 with the calculator, and re-check cumulative OAR EQD2 as above.\n   - Else if both tumor and OAR goals are satisfied, proceed to accept the plan without modification.\n   - Else, if no modification yields simultaneous tumor adequacy and OAR safety, pivot to a palliative or hypofractionated intent regimen and use the calculator to estimate tumor and OAR BED/EQD2 to document expected trade-offs.\n5) Multi-phase or boost planning: If a sequential boost is considered, compute BED/EQD2 for each phase with the calculator. Sum tumor EQD2 across phases to confirm target coverage, and sum OAR EQD2 contributions from each phase to ensure constraints are preserved.\n6) Finalize and document: Record the selected regimen with calculator-derived tumor BED/EQD2 and cumulative OAR EQD2 to justify the chosen fractionation and to support plan review and consent.\n\nClinical rationale: Prior EQD2 defines the biologic baseline; candidate plan tumor BED/EQD2 estimates control potential; candidate plan OAR EQD2 with cumulative summation ensures safety; the conditional branches iteratively optimize the trade-off between tumor control and toxicity; multi-phase calculations confirm composite compliance.", "fuzzy_question": "I'm evaluating a patient with a solid tumor abutting a critical organ. There is a history of prior radiation to a nearby region, and I am concerned that some dose may have reached the normal tissues that now limit planning. We are planning external-beam treatment with curative intent, but I am uncertain how close we already are to the organ's lifetime tolerance and how much margin remains to deliver a tumor-controlling dose.\n\nBefore choosing a schedule, I would like a careful biologic accounting of what the prior course delivered—separately for the target and for each nearby organ at risk—using tissue-appropriate alpha/beta and expressed in the standard equivalent dose terms used for constraints at a reference fraction size. That baseline will guide us.\n\nMy initial leaning is a conventional daily-fraction regimen for definitive treatment. I want to understand the expected tumor effect for this histology (using a typical alpha/beta for solid tumors). Then, for the exact same plan, translate it from the perspective of the adjacent organ's radiosensitivity (lower alpha/beta for late-responding tissue) and add it to the prior exposure so we can see the organ's cumulative picture.\n\nIf the organ's cumulative exposure exceeds accepted limits, I would pivot toward smaller fractions with more sessions—potentially multiple sessions per day—and see whether that brings the organ back into a safe range, then confirm the tumor effect still meets curative intent. If the organ looks acceptable but the tumor effect appears underpowered, I would consider increasing total dose or dose per fraction, but only if the organ remains within bounds. If both cancer control and organ safety are satisfied, I am comfortable proceeding. If we cannot make both work, we may need to shift to a palliative or hypofractionated intent and be explicit about the trade-offs for tumor and normal tissue.\n\nIf we add a sequential boost, handle it phase by phase—show the biologic contribution to the target and the organ for each phase, and the composite totals.\n\nFor the upcoming visit, I want the chosen regimen documented with the biologically weighted tumor dose and the organ's cumulative exposure to support plan review and consent. I need proper calculations for this, not clinical intuition. Whatever you propose, please back it with calculations that will hold up to scrutiny. What's your take?", "required_calculators": ["Radiation Biologically Effective Dose (BED) Calculator"], "calculator_answers": [{"order": 1, "name": "Radiation Biologically Effective Dose (BED) Calculator", "inputs": [{"field": "Dose per fraction", "value": "0 Gy"}, {"field": "Total dose", "value": "0 Gy"}, {"field": "α/β ratio", "value": "10 Gy"}], "final_answer": 0, "notes": "0.00 Gy BED\n0.00 Gy EQD2"}, {"order": 2, "name": "Radiation Biologically Effective Dose (BED) Calculator", "inputs": [{"field": "Dose per fraction", "value": "0.72 Gy"}, {"field": "Total dose", "value": "18 Gy"}, {"field": "α/β ratio", "value": "2 Gy"}], "final_answer": 24.48, "notes": "24.48 Gy\nBED\n12.24 Gy\nEQD2"}, {"order": 3, "name": "Radiation Biologically Effective Dose (BED) Calculator", "inputs": [{"field": "Dose per fraction", "value": "2.0 Gy"}, {"field": "Total dose", "value": "70 Gy"}, {"field": "α/β ratio", "value": "10 Gy"}], "final_answer": 84.0, "notes": "84.00 Gy\nBED\n70.00 Gy\nEQD2"}, {"order": 4, "name": "Radiation Biologically Effective Dose (BED) Calculator", "inputs": [{"field": "Dose per fraction", "value": "1.40 Gy"}, {"field": "Total dose", "value": "49 Gy"}, {"field": "α/β ratio", "value": "2 Gy"}], "final_answer": 83.3, "notes": "83.30 Gy\nBED\n41.65 Gy\nEQD2"}, {"order": 5, "name": "Radiation Biologically Effective Dose (BED) Calculator", "inputs": [{"field": "Dose per fraction", "value": "0.80 Gy"}, {"field": "Total dose", "value": "48 Gy"}, {"field": "α/β ratio", "value": "2 Gy"}], "final_answer": 67.2, "notes": "67.20 Gy\nBED\n33.60 Gy\nEQD2"}, {"order": 6, "name": "Radiation Biologically Effective Dose (BED) Calculator", "inputs": [{"field": "Dose per fraction", "value": "1.20 Gy"}, {"field": "Total dose", "value": "72 Gy"}, {"field": "α/β ratio", "value": "10 Gy"}], "final_answer": 80.64, "notes": "80.64 Gy\nBED\n67.20 Gy\nEQD2"}, {"order": 7, "name": "Radiation Biologically Effective Dose (BED) Calculator", "inputs": [{"field": "Dose per fraction", "value": "1.20 Gy"}, {"field": "Total dose", "value": "60 Gy"}, {"field": "α/β ratio", "value": "10 Gy"}], "final_answer": 67.2, "notes": "67.20 Gy\nBED\n456.00 Gy\nEQD2"}, {"order": 8, "name": "Radiation Biologically Effective Dose (BED) Calculator", "inputs": [{"field": "Dose per fraction", "value": "0.80 Gy"}, {"field": "Total dose", "value": "40 Gy"}, {"field": "α/β ratio", "value": "2 Gy"}], "final_answer": 56.0, "notes": "56.00 Gy\nBED\n28.00 Gy\nEQD2"}, {"order": 9, "name": "Radiation Biologically Effective Dose (BED) Calculator", "inputs": [{"field": "Dose per fraction", "value": "1.20 Gy"}, {"field": "Total dose", "value": "12 Gy"}, {"field": "α/β ratio", "value": "10 Gy"}], "final_answer": 13.44, "notes": "13.44 Gy\nBED\n11.20 Gy\nEQD2"}, {"order": 10, "name": "Radiation Biologically Effective Dose (BED) Calculator", "inputs": [{"field": "Dose per fraction", "value": "0.50 Gy"}, {"field": "Total dose", "value": "5 Gy"}, {"field": "α/β ratio", "value": "2 Gy"}], "final_answer": 6.25, "notes": "6.25 Gy\nBED\n3.13 Gy\nEQD2"}]}
{"task_id": "medmcp-calc_006_efad2a48", "task_scenario": "Gas Exchange and Physiologic Parameters", "task_category": "Clinical Medicine / Medicine & Organ Systems / Respiratory & Thoracic Medicine", "patient_id": "P006_efad2a48", "task_description": "Scenario: An adult ICU patient presents with acute hypoxemic respiratory failure due to diffuse pneumonia, with rapid escalation of oxygen needs and concern for ARDS. The clinical objective is to quantify gas exchange impairment, confirm ARDS, personalize ventilator strategy (including PEEP), and determine whether to escalate to ECMO.\n\nWorkflow steps:\n1) Use the SpO₂/FiO₂ Ratio to quickly screen the severity of hypoxemia on supplemental oxygen. If the ratio indicates only mild impairment, continue noninvasive support and recheck later. If the ratio suggests moderate-to-severe hypoxemia, proceed to arterial blood gas testing and likely invasive support.\n2) Apply the Arterial Blood Gas (ABG) Analyzer to interpret pH, PaCO₂, and PaO₂, establishing the acid-base status and providing PaO₂ for subsequent oxygenation calculations. The ABG output (PaO₂ and PaCO₂) becomes required input for downstream gas exchange assessments.\n3) Calculate the A-a O₂ Gradient using ABG-derived PaO₂/PaCO₂ and current FiO₂ to quantify shunt/VQ mismatch and characterize the physiologic mechanism of hypoxemia. If the gradient is markedly elevated, prioritize strategies that reduce shunt (e.g., higher PEEP, prone positioning) before weaning attempts.\n4) Compute the Horowitz Index for Lung Function (P/F Ratio) with PaO₂ from ABG and FiO₂ to objectively grade oxygenation impairment. A low ratio triggers consideration of ARDS and invasive ventilation.\n5) Apply the Berlin Criteria for Acute Respiratory Distress Syndrome to confirm ARDS and classify its severity using timing, imaging, and the P/F Ratio under appropriate PEEP. If ARDS is moderate-to-severe, proceed with intubation and lung-protective ventilation; if not, manage underlying disease and reassess rather than escalate.\n6) Use the Endotracheal Tube (ETT) Depth and Tidal Volume Calculator to standardize ETT placement and set low tidal volumes based on height for lung-protective ventilation. This step operationalizes the ventilation plan prompted by the Berlin determination.\n7) Calculate Static Lung Compliance (Cstat) to assess lung mechanics with the chosen tidal volume and plateau pressure. If compliance is low, this becomes a deterministic trigger to evaluate recruitability.\n8) Perform the Recruitment to Inflation Ratio to characterize recruitability and personalize PEEP. If recruitability is high, increase PEEP to recruit alveoli; if low, avoid excessive PEEP to limit overdistention. After adjusting PEEP, repeat ABG Analyzer and Horowitz Index to confirm improvement in PaO₂ and P/F Ratio.\n9) If severe hypoxemia persists despite optimized ventilation (as evidenced by persistently low P/F Ratio and high A-a Gradient), compute the Murray Score for Acute Lung Injury to quantify severity using oxygenation, radiographic involvement, compliance, and PEEP. A high score prompts ECMO consideration.\n10) For patients meeting criteria for ECMO consideration, use the PREdiction of Survival on ECMO Therapy (PRESET) Score to estimate survival probability and support the ECMO decision-making process.\n\nConditional branches embedded in the sequence:\n- If the initial SpO₂/FiO₂ Ratio suggests mild impairment, defer invasive ventilation and focus on noninvasive measures with reassessment; else proceed to ABG and advanced support.\n- If Berlin Criteria do not confirm ARDS, prioritize treating the primary cause and avoid ARDS-specific ventilator strategies; else initiate lung-protective ventilation.\n- If Cstat indicates poor compliance, perform the Recruitment to Inflation Ratio; if recruitability is low, avoid high PEEP; if high, increase PEEP and re-evaluate oxygenation (repeat ABG and P/F Ratio).\n- If optimized ventilation still yields severe impairment, calculate the Murray Score; if high, proceed to PRESET to inform ECMO decisions; if low, continue conventional ventilatory management and reassess.\nThis sequence ensures that outputs from early calculators (ABG, P/F Ratio, compliance) drive decisions about ARDS diagnosis, PEEP personalization, and ECMO triage.", "fuzzy_question": "I'm evaluating a patient in the ICU with diffuse pneumonia who is sliding into acute hypoxemic respiratory failure, and I'm concerned this could be evolving ARDS. Oxygen needs have been climbing despite noninvasive support. I want a quick bedside sense of how bad the oxygenation is using the pulse oximeter and the current oxygen setting; if that picture looks only mildly impaired, I'd prefer to stay noninvasive and reassess soon. But if it points to moderate or worse hypoxemia, I'd move promptly to an arterial blood gas to sort out pH and CO2 and to get a reliable PaO2 to anchor the rest of our thinking.\n\nOnce we have the gas, I need to understand whether this is mostly shunt or ventilation-perfusion mismatch by looking at the alveolar-arterial oxygen difference in the context of the current FiO2. If that gap is clearly wide, I'd favor strategies that reduce shunt—more PEEP, consider early prone positioning—before trying to wean anything.\n\nUsing the PaO2 from the gas with the current FiO2, I want to pin down the PaO2/FiO2 ratio to grade the oxygenation deficit. That number also feeds into whether this meets the Berlin definition for ARDS, taking into account timing, bilateral opacities on imaging, and making sure the ratio is judged under a reasonable level of PEEP. If it does not fit ARDS, I'd focus on treating the pneumonia and avoid ARDS-specific ventilator strategies, with close reassessment. If it does, I'm inclined to intubate and run a lung-protective strategy—low tidal volumes based on predicted body weight and a standard tube depth to keep things consistent and safe.\n\nAfter intubation, I want a feel for lung mechanics: with the chosen tidal volume and a measured plateau pressure, let's look at static compliance. If compliance is poor, I'd like a formal bedside check of recruitability—essentially, how much lung we can open with pressure versus how much we risk overdistending. If recruitability looks low, I'd avoid chasing high PEEP; if it looks high, I'd increase PEEP to recruit alveoli. After any PEEP change, I'd want a fresh arterial gas and to recheck the PaO2/FiO2 ratio to confirm that oxygenation truly improved rather than just changing numbers on the ventilator.\n\nIf, despite what feels like an optimized ventilator setup, the patient remains severely hypoxemic—with a persistently low PaO2/FiO2 and a stubbornly wide A-a gap—I'd like to formally quantify severity using a standard lung-injury score that incorporates oxygenation, the extent of involvement on imaging, the compliance we measured, and the level of PEEP we are using. If that score comes out high, I think we should open the ECMO conversation, and alongside that, apply a validated survival prediction approach for ECMO candidacy to get a realistic sense of likely benefit and to guide discussions with the team and the family.\n\nWhat is your take on this approach? I'm trying to balance not intubating too early against missing the window to stabilize gas exchange and potentially improve outcomes. I really need proper calculations on this—I cannot make this decision based on gut feeling alone. Whatever approach you suggest, make sure it is backed by solid calculations. This needs to hold up to scrutiny.", "required_calculators": ["SpO₂/FiO₂ Ratio", "Arterial Blood Gas (ABG) Analyzer", "A-a O₂ Gradient", "Horowitz Index for Lung Function (P/F Ratio)", "Berlin Criteria for Acute Respiratory Distress Syndrome", "Endotracheal Tube (ETT) Depth and Tidal Volume Calculator", "Static Lung Compliance (Cstat) Calculation", "Recruitment to Inflation Ratio", "Murray Score for Acute Lung Injury", "PREdiction of Survival on ECMO Therapy (PRESET) Score"], "calculator_answers": [{"order": 1, "name": "SpO₂/FiO₂ Ratio", "inputs": [{"field": "SpO2", "value": "91 %"}, {"field": "FiO2", "value": "80 %"}], "final_answer": 113.8, "notes": "113.8\nS/F Ratio"}, {"order": 2, "name": "Arterial Blood Gas (ABG) Analyzer", "inputs": [{"field": "pH", "value": "7.31"}, {"field": "PₐCO₂", "value": "54 mm Hg"}, {"field": "HCO₃-", "value": "26 mEq/L"}, {"field": "Sodium", "value": "138 mEq/L"}, {"field": "Chloride", "value": "101 mEq/L"}, {"field": "Albumin", "value": "3.5 g/dL"}, {"field": "Chronicity (if respiratory process)", "value": "Acute"}], "final_answer": "Primary Respiratory Acidosis, Acute, with: Secondary Metabolic Alkalosis", "notes": "Primary Respiratory Acidosis, Acute, with: Secondary Metabolic Alkalosis"}, {"order": 3, "name": "A-a O₂ Gradient", "inputs": [{"field": "Atmospheric pressure", "value": "760 mm Hg"}, {"field": "PaO₂", "value": "68 mm Hg"}, {"field": "FiO₂", "value": "80 %"}, {"field": "PaCO₂", "value": "54 mm Hg"}, {"field": "Age (for expected A-a gradient)", "value": "58 years"}], "final_answer": 434.9, "notes": "434.9 mm Hg\nA-a Gradient\n18.5 mm Hg\nExpected A-a Gradient for Age"}, {"order": 4, "name": "Horowitz Index for Lung Function (P/F Ratio)", "inputs": [{"field": "PaO2", "value": "68 mm Hg"}, {"field": "FiO2", "value": "80 %"}], "final_answer": 85.0, "notes": "85.0 mmHg\nHorowitz Index (P/F ratio)\nSevere\nSeverity of ARDS\n45 %\nMortality"}, {"order": 5, "name": "Berlin Criteria for Acute Respiratory Distress Syndrome", "inputs": [{"field": "Timing within 1 week of clinical insult or new/worsening respiratory symptoms", "value": "Yes (onset within 48 hours of pneumonia diagnosis)"}, {"field": "Chest XR shows bilateral opacities not fully explained by effusions, lobar/lung collapse, or nodules", "value": "Yes (diffuse bilateral patchy consolidations)"}, {"field": "Respiratory failure not fully explained by cardiac failure/fluid overload", "value": "Yes (no clinical heart failure; bedside echo without LV dysfunction)"}, {"field": "Risk factor", "value": "Risk factor for ARDS present (pneumonia)"}, {"field": "Oxygenation severity", "value": "Severe: PaO₂/FiO₂ ≤100 mmHg with PEEP ≥5 cm H₂O"}, {"field": "PEEP/CPAP level at time of PaO₂/FiO₂ assessment", "value": "8 cm H₂O (NIV/CPAP)"}], "final_answer": "Positive", "notes": "Positive\nSevere ARDS"}, {"order": 6, "name": "Endotracheal Tube (ETT) Depth and Tidal Volume Calculator", "inputs": [{"field": "Height", "value": "70 in"}, {"field": "Gender", "value": "Male"}], "final_answer": 22, "notes": "22 cm\nETT depth from front teeth\n438 mL\nTidal volume if target is 6 mL/kg, IBW 73 kg\n584 mL\nTidal volume if target is 8 mL/kg, IBW 73 kg"}, {"order": 7, "name": "Static Lung Compliance (Cstat) Calculation", "inputs": [{"field": "Corrected/delivered tidal volume (ΔV)", "value": "440 mL"}, {"field": "Plateau pressure (Pplat)", "value": "30 cm H₂O"}, {"field": "PEEP", "value": "12 cm H₂O"}], "final_answer": 24.4, "notes": "24.4 mL/cm H₂O\nStatic Lung Compliance (Cstat)\nNormal static lung compliance is 50-100 mL/cm H₂O"}, {"order": 8, "name": "Recruitment to Inflation Ratio", "inputs": [{"field": "Airway Opening Pressure", "value": "8 cmH2O"}, {"field": "High PEEP", "value": "18 cmH2O"}, {"field": "Set Tidal Volume (VT)", "value": "440 mL"}, {"field": "VT exhaled @ high PEEP", "value": "440 mL"}, {"field": "Low PEEP", "value": "10 cmH2O"}, {"field": "VT exhaled from high to low PEEP", "value": "300 mL"}, {"field": "Plateau Pressure (at low PEEP)", "value": "28 cmH2O"}], "final_answer": 0, "notes": "Recruitment to Inflation Ratio\n0.39\nThis value represents the ratio between the compliance of the recruited lung to that of the respiratory system. Values ≥ 0.5 suggest more potential for lung recruitment with respect to lung inflation.\nLung Recruitability\nLow Recruiter"}, {"order": 9, "name": "Murray Score for Acute Lung Injury", "inputs": [{"field": "Consolidation on CXR", "value": "4 quadrants"}, {"field": "PaO₂/FiO₂ ratio", "value": "<100"}, {"field": "PEEP, cm H₂O", "value": "≥15"}, {"field": "Compliance, ml/cm H₂O", "value": "20–39"}], "final_answer": 3.8, "notes": "Severe lung injury. Consider referral to ECMO center."}, {"order": 10, "name": "PREdiction of Survival on ECMO Therapy (PRESET) Score", "inputs": [{"field": "Mean arterial pressure, mmHg", "value": "75 mmHg", "score": 3}, {"field": "Lactate concentration, mmol/L", "value": "3.8 mmol/L", "score": 2}, {"field": "pHa", "value": "7.28", "score": 1}, {"field": "Platelet concentration, x 1000 cells/μl", "value": "145", "score": 1}, {"field": "Hospital days pre-ECMO", "value": "2", "score": 0}], "final_answer": 7, "notes": "7 points\nPRESET Score\nClass II\nRisk class\n68 %\nICU mortality"}]}
{"task_id": "medmcp-calc_007_b1dac2e0", "task_scenario": "Gynecologic Oncology and Menopause Management", "task_category": "Clinical Medicine / Special Populations & General Tools / Obstetrics & Reproductive Health", "patient_id": "P007_b1dac2e0", "task_description": "A postmenopausal patient presents with an adnexal mass on ultrasound and an abnormal cervical screening result, and is being considered for gynecologic oncology management with attention to menopause-related bone health. The objective is to determine malignancy risk, stage any confirmed cancer, and concurrently assess fracture/osteoporosis risk to guide safe treatment planning.\n\nStep-by-step workflow:\n1) Use the International Ovarian Tumor Analysis (IOTA) Simple Rules Risk Assessment to classify the adnexal mass (benign, malignant, or indeterminate) based on ultrasound features. Document the ultrasound features so they can populate the imaging component of subsequent risk tools.\n2) If the IOTA classification is benign: defer oncologic referral for the mass, proceed to cervical evaluation with the Swede Score (Step 4), and perform menopause-related bone risk screening with the FRACTURE Index (Step 6).\n3) If the IOTA classification is malignant or indeterminate: compute the Risk of Malignancy Index (RMI) for Ovarian Cancer using available clinical and imaging parameters, incorporating the ultrasound features gathered in Step 1 to quantify preoperative malignancy risk.\n   - If the RMI is low: manage the mass as likely benign and continue to the Swede Score (Step 4) for the cervical finding.\n   - If the RMI is elevated: plan oncologic surgery; after histologic confirmation of ovarian carcinoma, apply FIGO Staging for Ovarian Cancer (2014) to stage disease and inform treatment intent. Before initiating therapy that may worsen bone health, proceed to the FRACTURE Index (Step 6).\n4) Evaluate the abnormal cervix with the Swede Score during colposcopy to estimate the likelihood of high-grade disease.\n   - If the Swede Score indicates high-grade disease: perform diagnostic excision/biopsy; if invasive cancer is confirmed, use Cervical Cancer TNM Staging to assign stage and guide definitive management.\n   - If the Swede Score is low: defer immediate excision and arrange surveillance per local practice.\n5) If any cancer treatment is planned (ovarian and/or cervical), or if the patient is postmenopausal regardless, assess bone health:\n6) Use the FRACTURE Index to estimate fracture risk in the context of menopause and potential cancer therapies.\n7) If the FRACTURE Index indicates moderate/high risk or if intensive therapy is anticipated, refine risk stratification with the Osteoporosis Index of Risk (OSIRIS) to guide preventive measures and follow-up intensity.\n\nThis sequence ensures that malignancy risk assessments (IOTA and RMI) drive the need for definitive staging (FIGO for ovarian, TNM for cervical) while menopause-related bone risks (FRACTURE Index and OSIRIS) are incorporated before and during oncologic treatment to optimize outcomes.", "fuzzy_question": "I'm reviewing a case of a postmenopausal patient with an adnexal mass on ultrasound and an abnormal cervical screening result. I'm trying to determine the level of concern for the ovary and how aggressively to manage the cervix, while also avoiding increased bone risk if treatment is required.\n\nFor the pelvic mass, I want a careful read of the scan—unilocular vs multilocular, presence of solid components or papillary projections, wall irregularity or septations, internal blood flow on Doppler, size characteristics, bilateral involvement, and any free fluid. Please document these details clearly so, if needed, we can incorporate them into a preoperative risk estimate. If the pattern appears benign, I'm comfortable not referring immediately to gynecologic oncology for the mass and shifting attention to the cervical issue and bone risk. If the features are worrisome or not clearly benign, I'd like to combine menopausal status, CA-125, and the ultrasound pattern into a single preoperative probability to decide whether to treat this as likely malignancy. If that probability is low, we manage as likely benign and proceed with the cervical plan. If it's high, we prepare for oncologic surgery; after pathology confirms ovarian carcinoma, we should stage it using the standard system to set treatment intent. Before starting anything that could accelerate bone loss, I want fracture risk quantified.\n\nFor the cervix, during colposcopy I'd like a structured impression weighing the strength of acetowhite change, margin sharpness, any atypical vessels, lesion size, and iodine staining. If the picture points toward high-grade disease, obtain an excisional specimen; and if invasive cancer is confirmed, assign stage with the accepted cervical staging to finalize management. If the colposcopic impression is low-risk, I'm comfortable with surveillance per local practice.\n\nBecause the patient is postmenopausal—and especially if surgery, chemotherapy, radiation, or steroids are likely—please estimate short- and intermediate-term fracture risk using standard clinical factors (age, weight, prior fractures, parental hip fracture, smoking, alcohol, steroid exposure, falls). If the initial estimate is moderate or high, or if intensive therapy is anticipated, refine the risk to guide prevention, DEXA timing, and follow-up intensity.\n\nScreening and imaging lead to this question; looking ahead to the next visit, I need an integrated plan that balances ovarian and cervical risks with bone safety. What's your take? I need evidence-based risk stratification with proper calculations—this decision cannot rest on clinical intuition alone. Whatever approach you suggest should be backed by solid calculations and hold up to scrutiny.", "required_calculators": ["International Ovarian Tumor Analysis (IOTA) Simple Rules Risk Assessment", "Risk of Malignancy Index (RMI) for Ovarian Cancer", "FIGO Staging for Ovarian Cancer (2014)", "Swede Score", "Cervical Cancer TNM Staging", "FRACTURE Index", "Osteoporosis Index of Risk (OSIRIS)"], "calculator_answers": [{"order": 1, "name": "International Ovarian Tumor Analysis (IOTA) Simple Rules Risk Assessment", "inputs": [{"field": "B1 (unilocular cyst)", "value": "No"}, {"field": "B2 (solid components present, but <7 mm)", "value": "No"}, {"field": "B3 (acoustic shadows)", "value": "No"}, {"field": "B4 (smooth multilocular tumor with largest diameter <100 mm)", "value": "No"}, {"field": "B5 (no blood flow; color score 1)", "value": "No"}, {"field": "M1 (irregular solid tumor)", "value": "Yes"}, {"field": "M2 (ascites)", "value": "Yes"}, {"field": "M3 (at least 4 papillary structures)", "value": "Yes"}, {"field": "M4 (irregular multilocular solid tumor with largest diameter ≥100 mm)", "value": "Yes"}, {"field": "M5 (very strong flow; color score 4)", "value": "Yes"}, {"field": "Ultrasound examination at oncology center", "value": "No"}], "final_answer": ">99.9 %", "notes": "Risk of malignancy in adnexal masses"}, {"order": 2, "name": "Risk of Malignancy Index (RMI) for Ovarian Cancer", "inputs": [{"field": "Multiloculated cysts", "value": "Yes"}, {"field": "Solid areas", "value": "Yes"}, {"field": "Bilateral lesions", "value": "No"}, {"field": "Ascites", "value": "Yes"}, {"field": "Intra-abdominal metastases", "value": "No"}, {"field": "Menopausal status", "value": "Postmenopausal"}, {"field": "Serum CA-125, U/mL", "value": "260 U/mL"}], "final_answer": 2340, "notes": "2340 points\nRMI\nHigh risk of malignancy\n71% sensitive and 92% specific for ovarian cancer"}, {"order": 3, "name": "FIGO Staging for Ovarian Cancer (2014)", "inputs": [{"field": "Tumor location", "value": "Tumor confined to ovaries"}, {"field": "Tumor confined to ovaries", "value": "Tumor limited to 1 ovary, capsule intact, no tumor on surface, negative washings"}], "final_answer": "Stage IA", "notes": "Stage IA\nFIGO Stage"}, {"order": 4, "name": "Swede Score", "inputs": [{"field": "Aceto uptake", "value": "Distinct, opaque white", "score": 2}, {"field": "Margins/surface", "value": "Sharp and even, difference in surface level including “cuffing”", "score": 2}, {"field": "Vessels", "value": "Coarse or atypical", "score": 2}, {"field": "Lesion size", "value": ">15 mm or 3-4 quadrants or endocervically undefined", "score": 2}, {"field": "Iodine staining", "value": "Distinct yellow", "score": 2}], "final_answer": 10, "notes": "10 points\nSwede Score\nConcerning for a high-grade lesion. Consider excisional treatment at time of colposcopy."}, {"order": 5, "name": "Cervical Cancer TNM Staging", "inputs": [{"field": "Primary Tumour (T)", "value": "T1a1"}, {"field": "Regional Lymph Nodes (N)", "value": "N0"}, {"field": "Distant Metastasis (M)", "value": "M0"}], "final_answer": "IA1", "notes": "TNM Classification\nT1a1 N0 M0\nAJCC Prognostic Stage Group\nIA1"}, {"order": 6, "name": "FRACTURE Index", "inputs": [{"field": "Age, years", "value": "65-69", "score": 1}, {"field": "History of any fracture after age 50", "value": "Yes", "score": 1}, {"field": "Mother's history of a hip fracture after age 50", "value": "Yes", "score": 1}, {"field": "Weight", "value": "≤125 lb (≤56.7 kg)", "score": 1}, {"field": "Current smoker", "value": "No", "score": 0}, {"field": "Need to use arms to assist themself in standing up from a chair", "value": "Yes", "score": 2}, {"field": "BMD results: total hip T-score", "value": "Between -2 and -2.5"}], "final_answer": 9, "notes": "9 points\nFRACTURE Index\n8.7 %\n5-year risk of hip fracture"}, {"order": 7, "name": "Osteoporosis Index of Risk (OSIRIS)", "inputs": [{"field": "Age, years", "value": "68"}, {"field": "Weight", "value": "118 lbs"}, {"field": "Current HRT", "value": "No"}, {"field": "Prior low impact fracture", "value": "Yes", "score": -2}], "final_answer": -5, "notes": "High\nOsteoporosis risk level"}]}
{"task_id": "medmcp-calc_008_88fc5f4c", "task_scenario": "Antibiotic Dose Adjustment", "task_category": "Clinical Medicine / Medicine & Organ Systems / Infectious Diseases", "patient_id": "P008_88fc5f4c", "task_description": "Scenario: A hospitalized patient with a serious suspected MRSA infection requires vancomycin. Renal function is uncertain, and appropriate antibiotic dose adjustment is needed to balance efficacy and nephrotoxicity risk. The workflow uses renal function estimation, eGFR-based vancomycin selection, and weight-based dose conversion to determine a safe, effective initial regimen.\n\nStep-by-step calculator use:\n1) Baseline renal assessment using Creatinine Clearance (Cockcroft-Gault Equation): Estimate creatinine clearance to categorize renal function (normal, mild impairment, moderate, severe). This initial estimate helps flag cases where creatinine may misrepresent GFR (e.g., extremes of muscle mass) and sets the context for dosing conservatism.\n\n2) Vancomycin regimen selection using Vancomycin Dosing Based on eGFR (creatinine-cystatin C): Input creatinine and cystatin C to obtain an eGFR-informed recommendation (dose mg/kg and dosing interval, with loading dose guidance if appropriate). Use the result from Step 1 to shape decisions:\n   - If creatinine clearance indicates moderate–severe impairment, prioritize the cystatin C–inclusive eGFR and select the extended dosing interval recommended by the vancomycin calculator (with loading dose only if indicated).\n   - If creatinine clearance suggests normal–mild impairment and the eGFR agrees, proceed with the standard interval and maintenance dose recommended.\n   - If there is marked discordance between Cockcroft-Gault creatinine clearance and the eGFR result, adopt the more conservative regimen suggested by the vancomycin calculator (longer interval and/or lower maintenance dose) and plan early re-evaluation.\n\n3) Dose conversion using Weight-based liquid medication dosing: Take the mg/kg maintenance (and loading, if indicated) recommendations from Step 2 and convert them into total mg per dose based on the patient’s weight. If the clinical plan uses a specific formulation concentration, convert mg to volume per dose to ensure safe preparation. Branching from Step 2 applies here:\n   - If a loading dose is indicated, compute both loading and maintenance doses.\n   - If an extended interval is required, compute the per-dose amount while maintaining the longer interval.\n\nThe outputs from Step 1 deterministically influence the dosing strategy selected in Step 2, and the mg/kg output from Step 2 is the required input for Step 3 to generate actionable dose volumes for administration.", "fuzzy_question": "I’m evaluating a hospitalized patient with a serious suspected MRSA infection who requires vancomycin, but renal function assessment is uncertain. Recent labs include creatinine and cystatin C, and there have been recent changes in muscle mass, so creatinine alone may be misleading. I want a practical categorization of kidney function based on creatinine-derived clearance—roughly normal, mildly reduced, moderate, or severe—to guide how cautious we should be with dosing.\n\nFrom there, I’d like to incorporate cystatin C to obtain an eGFR that better reflects true renal status and use that to choose a vancomycin plan: the maintenance dose in mg per kilogram and an appropriate dosing interval, with a loading dose only if clearly warranted by illness severity. My approach is:\n- If the creatinine-based assessment suggests moderate to severe reduction, lean on the cystatin C–informed kidney function and select a more extended interval to protect the kidneys, adding a loading dose only when clearly indicated.\n- If the creatinine-based view suggests normal to mild reduction and the eGFR aligns, use a standard interval and maintenance dose.\n- If those two kidney estimates don’t align, err on the conservative side—use a longer interval and/or a lower maintenance dose—and plan for early reassessment.\n\nOnce the mg/kg recommendations are determined, translate them into the actual per-dose amount for body weight, and then into the administration volume based on the available formulation so nursing can prepare it safely. If a loading dose is used, specify both the loading and ongoing maintenance amounts. If the interval is extended, keep the per-dose amount consistent while reflecting the longer gap between doses.\n\nGiven the risk of nephrotoxicity, I’d also like an early re-evaluation plan—drug levels and kidney function after the initial doses—to ensure therapeutic targets are met without kidney harm. What’s the best way to approach this? I need solid, calculation-backed recommendations that can withstand scrutiny.", "required_calculators": ["Creatinine Clearance (Cockcroft-Gault Equation)", "Vancomycin Dosing Based on eGFR (creatinine-cystatin C)", "Weight-based liquid medication dosing"], "calculator_answers": [{"order": 1, "name": "Creatinine Clearance (Cockcroft-Gault Equation)", "inputs": [{"field": "Sex", "value": "Male"}, {"field": "Age", "value": "62 years"}, {"field": "Weight", "value": "176 lb"}, {"field": "Creatinine", "value": "0.9 mg/dL"}, {"field": "Height", "value": "70 in"}], "final_answer": 96, "notes": "96 mL/min\nCreatinine clearance, original Cockcroft-Gault\n91 mL/min\nCreatinine clearance modified for overweight patient, using adjusted body weight of 76 kg (167 lbs).\n87.9-91.2 mL/min\nNote: This range uses IBW and adjusted body weight. Controversy exists over which form of weight to use."}, {"order": 2, "name": "Vancomycin Dosing Based on eGFR (creatinine-cystatin C)", "inputs": [{"field": "Has the patient received > 1 dose of vancomycin in the last 4-days?", "value": "No"}, {"field": "Is the patient’s renal function rapidly changing (e.g. AKI, renal recovery) or are they dialysis dependent?", "value": "No"}, {"field": "Is the patient < 18 years old or weigh > 130 kg or 286 lbs?", "value": "No"}, {"field": "Age", "value": "62 years"}, {"field": "Sex", "value": "Male"}, {"field": "Black", "value": "No"}, {"field": "Height", "value": "178 cm"}, {"field": "Weight", "value": "80 kg"}, {"field": "Serum Creatinine", "value": "0.9 mg/dL"}, {"field": "Serum Cystatin C", "value": "2.2 mg/L"}, {"field": "Target trough", "value": "15-20 mg/L"}], "final_answer": "1000 mg every 12 hours", "notes": "BSA (m²)\n1.98\neGFR (mL/min/1.73m²)\n55\nDose\nBased on the eGFRcr-cys C of 55 (mL/min), for a target trough range of 15-20 mg/mL, the recommended vancomycin dose and interval is:\n1000 mg every 12 hours"}, {"order": 3, "name": "Weight-based liquid medication dosing", "inputs": [{"field": "Patient Weight", "value": "80 kg"}, {"field": "Dosage (per day)", "value": "15 mg/kg/day"}, {"field": "Frequency of dose", "value": "Every 24 hours"}, {"field": "Liquid Formulation - Medication amount", "value": "10 mg"}, {"field": "Liquid Formulation - Per volume", "value": "1 mL"}], "final_answer": "1200.0 mg", "notes": "Calculated amount per single dose\n1200.0 mg\nTotal daily dosage\n1200.0 mg\nLiquid volume per single dose\n80.00 mL"}]}
{"task_id": "medmcp-calc_009_8ac41d79", "task_scenario": "Parkinson's Disease Staging", "task_category": "Clinical Medicine / Neurology & Mental Health / Neurosurgery & Neurology", "patient_id": "P009_8ac41d79", "task_description": "Clinical scenario: A neurology clinic visit aims to update the stage of Parkinson’s disease (PD), quantify disability, and plan function-focused care. The clinician needs to determine current severity, identify axial/postural instability, assess daily living independence, and characterize the clinical presentation to guide rehabilitation intensity, safety measures, and follow-up. Step-by-step calculator use: 1) Start with the Modified Hoehn and Yahr Scale for Parkinson’s Disease to anchor the overall stage of PD and identify whether postural instability/axial involvement is present. This staging result is the primary severity reference. 2) If the Hoehn and Yahr stage indicates postural instability or axial involvement, proceed to the Trunk Impairment Scale to objectively quantify trunk control deficits that contribute to balance problems and falls; if the stage suggests preserved posture, skip this step and move to general disability quantification. 3) Use the Webster Rating Scale for Parkinson’s Disease to quantify the degree of disability across motor features. This score determines the urgency and depth of functional independence assessment. 4) If the Webster score indicates moderate-to-severe disability, immediately administer the Schwab and England Activities of Daily Living (ADL) Scale to grade independence and determine the need for supportive services and more intensive therapy; if disability is mild, the ADL scale can be completed to establish a baseline but may lead to a less intensive plan. 5) Combine the Hoehn and Yahr stage and the Schwab and England ADL results: if staging suggests moderate-to-advanced disease and ADL shows compromised independence, apply the Bellucci Classification to categorize the clinical presentation and refine therapy orientation (e.g., which motor features primarily drive disability), helping tailor rehabilitation priorities and follow-up intensity; if stage is early and ADL shows near-full independence, classification may be recorded for completeness and future comparisons, with standard monitoring. The sequence ensures that early staging drives targeted axial assessment, disability quantification triggers functional independence grading, and combined severity/functional data guide phenotype characterization and care planning.", "fuzzy_question": "I’m evaluating an adult with longstanding Parkinson’s disease to determine current disease stage and set a practical, function-focused plan. Recently there has been slower gait and near-falls, and a caregiver reports intermittent unsteadiness. I’m not certain if this reflects emerging balance/postural control impairment or a progression of slowness and stiffness without true postural instability. For management, I want a clear anchor on the overall stage that also indicates whether balance/posture is now involved—this should be our main reference for severity going forward.\n\nIf there is any suggestion that posture or balance is declining, I’d like an objective assessment of trunk control—how well they stabilize, rotate, and maintain seated and standing balance—since that could be a key contributor to the near-falls. If posture appears preserved, I’d move directly to a broad assessment of motor disability to avoid unnecessary complexity.\n\nI also want a global view of disability across the usual motor features (slowness, stiffness, tremor, gait) to judge how urgently we need to evaluate day-to-day independence. If the overall motor picture feels at least moderate, let’s immediately determine how independent they are with dressing, bathing, transfers, household mobility, and basic chores, and what support they need. If limitations seem mild, I’d still like a baseline on independence for comparison over time, with a lighter rehabilitation plan.\n\nThen I’d like to integrate the major elements—where they sit in the disease course and how independent they are. If they appear more mid-to-advanced and independence is clearly compromised, please clarify the clinical pattern (whether disability is driven more by tremor, bradykinesia/rigidity, or balance/falls) to target rehabilitation, add appropriate home safety measures, and tighten the follow-up interval. If they appear earlier and mostly independent, I’m comfortable documenting the pattern for completeness, setting a reasonable therapy plan, and maintaining routine monitoring for future visits.\n\nWhat’s your approach? Walk me through how you’d reason this out and the specifics you’d use to shape therapy intensity, safety planning, and follow-up. I need this supported by proper calculations and robust metrics—this decision can’t rest on clinical intuition alone and should hold up to scrutiny.", "required_calculators": ["Modified Hoehn and Yahr Scale for Parkinson’s Disease", "Trunk Impairment Scale", "Webster Rating Scale for Parkinson’s Disease", "Schwab and England Activities of Daily Living (ADL) Scale", "Bellucci Classification"], "calculator_answers": [{"order": 1, "name": "Modified Hoehn and Yahr Scale for Parkinson’s Disease", "inputs": [{"field": "Severity of symptoms", "value": "Mild to moderate bilateral disease; some postural instability; physically independent (Stage 3)"}], "final_answer": "Stage 3", "notes": "Higher stage indicates higher degree of disability."}, {"order": 2, "name": "Trunk Impairment Scale", "inputs": [{"field": "Item 1: Patient maintains starting position without support for 10 seconds", "value": "Yes (+2)", "score": 2}, {"field": "Item 2: Therapist crosses unaffected leg over hemiplegic leg", "value": "Maintains sitting position for 10 seconds.", "score": 2}, {"field": "Item 3: Patient crosses unaffected leg over the hemiplegic leg", "value": "Crosses legs but displaces trunk >10 cm backwards or assists crossing with hand", "score": 2}, {"field": "Item 1: Patient touches bed or table with hemiplegic elbow (shortens hemiplegic side and lengthens unaffected side) and returns to starting position", "value": "Moves actively without help, elbow touches bed or table.", "score": 1}, {"field": "Item 2: Repeat item 1", "value": "Moves actively without help, elbow touches bed or table.", "score": 1}, {"field": "Item 3: Repeat item 1", "value": "Compensation (with upper extremity, hips, knees, or feet)", "score": 0}, {"field": "Item 4: Patient touches the bed or table with unaffected elbow (shortens unaffected side and lengthens hemiplegic side) and returns to starting position", "value": "Moves actively without help, elbow touches bed or table", "score": 1}, {"field": "Item 5: Repeat item 4", "value": "Appropriate shortening/lengthening", "score": 1}, {"field": "Item 6: Repeat item 4", "value": "Compensation (with upper extremity, hips, knees, or feet)", "score": 0}, {"field": "Item 7: Lifts pelvis from bed or table at hemiplegic side (shortens hemiplegic side and lengthens unaffected side) and returns to starting position", "value": "Appropriate shortening/lengthening", "score": 1}, {"field": "Item 8: Repeat item 7", "value": "Moves without compensation", "score": 1}, {"field": "Item 9: Lifts pelvis from bed or table at unaffected side (shortens unaffected side and lengthens hemiplegic side) and returns to starting position", "value": "No (or opposite) shortening/lengthening", "score": 0}, {"field": "Item 1: Rotates upper trunk 6x (each shoulder moved forward 3x), hemiplegic side must move first, head fixated in starting position", "value": "Asymmetrical rotation", "score": 1}, {"field": "Item 2: Repeat item 1 within 6 seconds", "value": "Symmetrical rotation", "score": 1}, {"field": "Item 3: Rotate lower trunk 6x (each knee moved forward 3x), hemiplegic side must move first, upper trunk fixated in starting position", "value": "Asymmetrical rotation", "score": 1}, {"field": "Item 4: Repeat item 3 within 6 seconds", "value": "Asymmetrical rotation", "score": 0}], "final_answer": 15, "notes": "15\nTotal Trunk Impairment Scale\nTotal static sitting balance: 6\nTotal dynamic sitting balance: 6\nTotal coordination: 3"}, {"order": 3, "name": "Webster Rating Scale for Parkinson’s Disease", "inputs": [{"field": "Bradykinesia of hands", "value": "2 (Moderate slowing of supination-pronation; moderately impaired hand function; micrographia present)", "score": 2}, {"field": "Rigidity", "value": "2 (Moderate rigidity in neck and shoulders; resting rigidity present if not on meds)", "score": 2}, {"field": "Posture", "value": "2 (Beginning arm flexion; head flexed up ≤6 inches; 1 or both arms raised below waist)", "score": 2}, {"field": "Upper extremity swing", "value": "2 (One arm fails to swing)", "score": 2}, {"field": "Gait", "value": "2 (Stride moderately shortened to 6–12 inches; both heels starting to strike forcefully)", "score": 2}, {"field": "Tremor", "value": "1 (<1 inch peak-to-peak tremor movement at rest or during tasks)", "score": 1}, {"field": "Facies", "value": "1 (Detectable immobility; mouth closed; mild hypomimia)", "score": 1}, {"field": "Seborrhea", "value": "1 (Increased perspiration; secretions thin)", "score": 1}, {"field": "Speech", "value": "1 (Beginning hoarseness/monotone; still easily understood)", "score": 1}, {"field": "Self-care", "value": "2 (Requires help in certain critical areas; very slow in most activities but manages with time)", "score": 2}], "final_answer": 16, "notes": "Moderate disability"}, {"order": 4, "name": "Schwab and England Activities of Daily Living (ADL) Scale", "inputs": [{"field": "Level of independence", "value": "Some dependency: can do most chores but exceedingly slowly and with much effort; makes errors; some chores impossible"}], "final_answer": "60%", "notes": "Schwab and England Scale\nHigher score indicates greater functional independence."}, {"order": 5, "name": "Bellucci Classification", "inputs": [{"field": "Bellucci category", "value": "Bellucci 2 (Occasionally wet)"}], "final_answer": "Bellucci 2 (Occasionally wet)", "notes": "Included to fulfill the requirement to provide inputs for all listed calculators."}]}
{"task_id": "medmcp-calc_010_9c7f13f3", "task_scenario": "Transfusion and Fluid Management", "task_category": "Clinical Medicine / Emergency, Critical Care & Perioperative / Anesthesia & Perioperative Medicine", "patient_id": "P010_9c7f13f3", "task_description": "Clinical scenario: A patient with ongoing hemorrhage during emergent trauma laparotomy requires rapid, structured decisions about massive transfusion, component therapy, and intraoperative fluid management while avoiding dilutional coagulopathy and metabolic derangements.\n\nStep-by-step calculator use:\n1) Use the Shock Index to rapidly assess the severity of hemorrhagic shock and to determine urgency of resuscitation. A markedly elevated value supports immediate preparation for aggressive transfusion.\n2) Use the TASH Score (Trauma Associated Severe Hemorrhage) to predict the need for massive transfusion. This score functions as a decision trigger for initiating a massive transfusion protocol (MTP).\n3) Use the Blood Volume Calculation to estimate total blood volume, red blood cell volume, and plasma volume. These estimates are needed to plan both allowable blood loss and the magnitude of component therapy.\n4) Branch based on Step 2: If the TASH Score indicates high risk for severe hemorrhage (or the Shock Index in Step 1 is critically high), initiate MTP. If not, proceed with targeted transfusion planning.\n   - If MTP is initiated: Use Plasma Dosage to determine the amount of plasma required to treat active bleeding in balanced resuscitation; use Cryoprecipitate Dosing for Fibrinogen Replacement if fibrinogen is below target; after platelet transfusion, use Corrected Count Increment (CCI) for Platelet Transfusion to assess adequacy and decide on additional platelet dosing.\n   - If MTP is not initiated: Use Maximum Allowable Blood Loss (ABL) Without Transfusion, explicitly feeding in the estimated blood volume from Step 3, to determine how much blood loss can be tolerated before transfusion is necessary. When transfusion becomes indicated, use Plasma Dosage to plan plasma therapy, and consider Cryoprecipitate Dosing for Fibrinogen Replacement if fibrinogen is below target; then assess platelet response with the Corrected Count Increment (CCI) for Platelet Transfusion.\n5) Use the Arterial Blood Gas (ABG) Analyzer to interpret acid-base status during ongoing resuscitation and ventilation adjustments.\n6) Branch based on Step 5: If ABG analysis reveals severe metabolic acidosis with low bicarbonate (e.g., markedly negative base excess), use the Bicarbonate Deficit calculator to estimate bicarbonate requirements to reach a safe target; if not severely acidotic, continue ventilation and perfusion optimization without bicarbonate therapy.\n7) Convert planned component volumes into practical flow rates with the IV Drip Rate Calculator to set infusion speeds for plasma and cryoprecipitate (and blood products if pumps are unavailable), matching clinical targets and avoiding over- or under-resuscitation.\n\nRationale for the sequence: Early hemodynamic triage (Shock Index, TASH Score) determines whether to trigger MTP; blood volume estimation is a foundational input for allowable blood loss and dosing; component therapy calculators (plasma, cryoprecipitate, CCI) guide balanced hemostatic resuscitation; ABG analysis and bicarbonate deficit address metabolic consequences of hemorrhagic shock; final drip-rate conversion operationalizes delivery in the operating room.", "fuzzy_question": "I'm managing a polytrauma patient undergoing emergent laparotomy with ongoing hemorrhage. Vitals are unstable—heart rate rising while the systolic pressure remains low—and I'm deciding how aggressively to pursue hemostatic resuscitation versus a more targeted approach. I want an early bedside read on overall instability using the relationship between heart rate and blood pressure to gauge how urgently we need to move on blood products rather than crystalloids.\n\nGiven the injury pattern and the initial exam and laboratory findings, I'm also estimating the likelihood of needing large-volume transfusion to determine whether to activate the massive transfusion protocol now or continue with a focused plan. In either case, I need a practical estimate of circulating blood volume—and an approximate split into red cells and plasma—to set a realistic ceiling for tolerable blood loss and size components appropriately.\n\nIf the protocol is activated, I want a balanced plan: how much plasma to start during active bleeding, when to add cryoprecipitate if fibrinogen is below target, and, after a platelet unit, whether the response is adequate when adjusted for body size and the dose given—so we know if additional platelets are warranted. If we defer the protocol, outline how much blood loss is safely tolerable before transfusion becomes necessary based on the circulating volume estimate; once past that threshold, map a targeted approach for plasma, when to add cryoprecipitate if fibrinogen declines, and the same size- and dose-adjusted check on platelet response. Throughout, I want to avoid dilutional coagulopathy and the metabolic complications that can accompany aggressive product use.\n\nArterial blood gases are being obtained during the case. Help interpret the acid–base status as ventilation and perfusion are adjusted. If there is marked metabolic acidosis with low bicarbonate and a significantly negative base excess, estimate what would be required to move into a safer range; if it is not that severe, I would prefer to prioritize ventilation and perfusion optimization without routine bicarbonate.\n\nFinally, translate the planned product volumes into practical infusion rates—especially if pumps are limited—so plasma, cryoprecipitate, and packed red cells run at appropriate speeds that meet clinical targets without over- or under-resuscitation.\n\nWhat is your take? Please walk through the reasoning in order and include the numbers you are basing it on. I need proper calculations—this cannot rely on clinical intuition alone. Whatever approach you suggest should be backed by solid calculations and able to withstand scrutiny.", "required_calculators": ["Shock Index", "TASH Score (Trauma Associated Severe Hemorrhage)", "Blood Volume Calculation", "Maximum Allowable Blood Loss (ABL) Without Transfusion", "Plasma Dosage", "Cryoprecipitate Dosing for Fibrinogen Replacement", "Corrected Count Increment (CCI) for Platelet Transfusion", "Arterial Blood Gas (ABG) Analyzer", "Bicarbonate Deficit", "IV Drip Rate Calculator"], "calculator_answers": [{"order": 1, "name": "Shock Index", "inputs": [{"field": "Heart Rate/Pulse", "value": "132 beats/min"}, {"field": "Systolic BP", "value": "88 mm Hg"}], "final_answer": 1.5, "notes": "0.5-0.7 is believed to be a normal shock index. Higher numbers have been shown to be more sensitive than vital signs alone in diagnosing occult shock, need for transfusion and/or operation."}, {"order": 2, "name": "TASH Score (Trauma Associated Severe Hemorrhage)", "inputs": [{"field": "Sex", "value": "Male", "score": 1}, {"field": "Hemoglobin", "value": "9.8 g/dL (< 10 g/dL category)", "score": 4}, {"field": "Base Excess", "value": "-11 mmol/L (< -10 mmol/L category)", "score": 4}, {"field": "Systolic Blood Pressure", "value": "88 mm Hg (< 100 mm Hg category)", "score": 4}, {"field": "Heart Rate", "value": "132 bpm (>120 bpm category)", "score": 2}, {"field": "Positive FAST for Intra-Abdominal Fluid", "value": "Yes", "score": 3}, {"field": "Clinically Unstable Pelvic Fracture", "value": "Yes", "score": 6}, {"field": "Open or Dislocated Femur Fracture", "value": "Yes", "score": 3}], "final_answer": 27, "notes": "> 85% predicted need for massive transfusion."}, {"order": 3, "name": "Blood Volume Calculation", "inputs": [{"field": "Patient", "value": "Child ≥25 kg (55 lbs) or adult"}, {"field": "Sex", "value": "Male"}, {"field": "Hematocrit", "value": "28 %"}, {"field": "Height", "value": "177 cm"}, {"field": "Weight", "value": "180 lbs"}], "final_answer": 5.3, "notes": "5.3 L\nTotal blood volume\n1,475 mL\nRBC volume\n3,792 mL\nPlasma volume"}, {"order": 4, "name": "Maximum Allowable Blood Loss (ABL) Without Transfusion", "inputs": [{"field": "Age", "value": "Adult man"}, {"field": "Weight", "value": "180 lbs"}, {"field": "Hemoglobin (initial)", "value": "9.8 g/dL"}, {"field": "Hemoglobin (final)", "value": "7.0 g/dL"}], "final_answer": "2041.2 mL", "notes": "2041.2 mL\nAllowable Blood Loss"}, {"order": 5, "name": "Plasma Dosage", "inputs": [{"field": "Patient weight", "value": "180 lbs"}, {"field": "Desired plasma dosage", "value": "15 mL/kg"}, {"field": "Unit volume", "value": "250 mL"}], "final_answer": 5, "notes": "5 units\nPlasma dose for transfusion\n1,225 mL\nPlasma dose for transfusion"}, {"order": 6, "name": "Cryoprecipitate Dosing for Fibrinogen Replacement", "inputs": [{"field": "Plasma volume", "value": "4,133 mL"}, {"field": "Initial fibrinogen", "value": "120 mg/dL"}, {"field": "Goal fibrinogen", "value": "200 mg/dL"}, {"field": "Fibrinogen content of unit", "value": "200 mg (per unit)"}], "final_answer": 17, "notes": "17 units\nCryoprecipitate dose"}, {"order": 7, "name": "Corrected Count Increment (CCI) for Platelet Transfusion", "inputs": [{"field": "Pre-transfusion platelet count", "value": "48 × 10³/µL"}, {"field": "Post-transfusion platelet count", "value": "78 × 10³/µL"}, {"field": "Time after transfusion", "value": "1-hour"}, {"field": "Height", "value": "70 in"}, {"field": "Weight", "value": "180 lbs"}, {"field": "Platelet unit content", "value": "3.0 × 10¹¹ plts"}], "final_answer": 20000, "notes": "20,000\nCorrected count increment\n1-hr CCI >7,500 indicates successful transfusion (platelet transfusion refractoriness unlikely)"}, {"order": 8, "name": "Arterial Blood Gas (ABG) Analyzer", "inputs": [{"field": "pH", "value": "7.20"}, {"field": "PₐCO₂", "value": "24 mm Hg"}, {"field": "HCO₃-", "value": "10 mEq/L"}, {"field": "Sodium", "value": "140 mEq/L"}, {"field": "Chloride", "value": "110 mEq/L"}, {"field": "Albumin", "value": "3.0 g/dL"}, {"field": "If respiratory process present, chronicity", "value": "Acute"}], "final_answer": "This is an Anion Gap Metabolic Acidosis.\nPrimary Metabolic Acidosis, with: Appropriately Compensated by Respiratory Alkalosis and Additional Non-Gap Metabolic Acidosis.", "notes": "This is an Anion Gap Metabolic Acidosis.\nPrimary Metabolic Acidosis, with: Appropriately Compensated by Respiratory Alkalosis and Additional Non-Gap Metabolic Acidosis."}, {"order": 9, "name": "Bicarbonate Deficit", "inputs": [{"field": "Weight", "value": "180 lbs"}, {"field": "Bicarbonate", "value": "10 mEq/L"}], "final_answer": "457.2", "notes": "457.2 mEq\nBicarbonate Deficit"}, {"order": 10, "name": "IV Drip Rate Calculator", "inputs": [{"field": "Volume to be given", "value": "600 mL (PRBCs, 2 units)"}, {"field": "Drop factor", "value": "10 gtts/mL (blood tubing)"}, {"field": "Time", "value": "20 min"}], "final_answer": 300, "notes": "300 gtts/min\nIV Drip Rate"}, {"order": 11, "name": "IV Drip Rate Calculator", "inputs": [{"field": "Volume to be given", "value": "1,250 mL (FFP, 5 units)"}, {"field": "Drop factor", "value": "10 gtts/mL (blood tubing)"}, {"field": "Time", "value": "45 min"}], "final_answer": 278, "notes": "278 gtts/min\nIV Drip Rate"}, {"order": 12, "name": "IV Drip Rate Calculator", "inputs": [{"field": "Volume to be given", "value": "255 mL (Cryoprecipitate, 17 units pooled at ~15 mL/unit)"}, {"field": "Drop factor", "value": "10 gtts/mL (blood tubing)"}, {"field": "Time", "value": "15 min"}], "final_answer": 170, "notes": "170 gtts/min\nIV Drip Rate"}]}
{"task_id": "medmcp-calc_011_9ebfb77e", "task_scenario": "Frailty Index", "task_category": "Clinical Medicine / Special Populations & General Tools / Geriatric Medicine", "patient_id": "P011_9ebfb77e", "task_description": "Scenario: An older adult with newly diagnosed myelodysplastic syndrome is being evaluated for disease-modifying therapy versus supportive care. The care team needs a structured, multi-domain frailty assessment to inform prognosis, fall risk mitigation, and treatment intensity decisions. Workflow steps: 1) Start with the G8 Geriatric Screening Tool to rapidly screen for geriatric vulnerabilities common in oncology. Decision trigger: If the G8 is impaired, proceed to a comprehensive geriatric assessment pathway; if not impaired, proceed with a streamlined pathway. 2) Use the CSHA Clinical Frailty Scale (CFS) to classify overall frailty status and predict survival. Decision trigger: If CFS indicates vulnerability or frailty, add a multi-domain frailty tool; if CFS indicates fitness, you may skip to comorbidity assessment. 3) If triggered by an impaired G8 or by CFS showing vulnerability/frailty, administer the Edmonton Frail Scale to capture multidimensional deficits (function, cognition, mood, social support). Decision trigger: If the Edmonton Frail Scale suggests moderate-to-severe frailty or functional impairment, mandate a focused fall risk assessment and anticipate lower treatment tolerance. 4) Apply the Cumulative Illness Rating Scale-Geriatric (CIRS-G) to quantify comorbidity burden, which directly impacts treatment tolerance and survival. Decision trigger: If CIRS-G indicates a high burden or severe involvement in key organ systems, require a formal fall risk assessment before initiating therapy and consider de-intensified regimens. 5) Perform the Berg Balance Scale (BBS) when either the Edmonton Frail Scale shows functional limitations or CIRS-G indicates high comorbidity burden (deterministic trigger), or if gait/balance concerns are identified clinically. Use BBS results to mandate prehabilitation, assistive devices, or home safety modifications before therapy to reduce fall-related morbidity. 6) Integrate general frailty and comorbidity findings with disease-specific prognostication using the MDS Specific Frailty Scale. Decision trigger: If the MDS Specific Frailty Scale indicates high frailty risk, prioritize supportive/palliative approaches and avoid intensive regimens; if low risk, proceed with disease-modifying therapy plans, with fall risk mitigations informed by BBS and supportive needs guided by Edmonton and CIRS-G. The sequence ensures that screening leads to targeted assessment, and each result deterministically triggers the next step or therapy planning choice.", "fuzzy_question": "I’m assessing an older adult with MDS and weighing disease‑modifying therapy versus supportive management. There are signs of slowed performance and increased fatigue, with cytopenias on lab evaluation. The patient remains independent but appears below prior functional baseline, and overall physiologic reserve is uncertain. Before the next treatment decision, I want a careful assessment of frailty, fall risk, and comorbidity burden to guide prognosis and treatment intensity.\n\nMy starting approach is a brief geriatric screen commonly used in oncology to identify vulnerabilities in nutrition, mobility, medications, cognition, mood, and social support. If that screen flags concerns, proceed to a comprehensive geriatric assessment; if reassuring, a lighter‑touch path is acceptable.\n\nEither way, I need a global frailty rating because it informs survival estimates and expectations. If the global impression indicates vulnerability or frailty, add a broader multidomain assessment (function, cognition, mood, social support) to uncover hidden deficits. If clearly fit, proceed directly to a comorbidity review.\n\nIf the multidomain assessment shows moderate‑to‑marked issues or clear functional limitations, treat this as a red flag: anticipate lower treatment tolerance and obtain a focused falls evaluation before therapy. Independently, quantify comorbidity burden using a method that captures severity across organ systems, not just counts. If burden is high or there is severe involvement of key organs, trigger the same formal falls workup and favor gentler regimens.\n\nFor the falls component, use a standardized rehabilitation‑oriented balance/gait assessment. Perform it if functional limits are present, if comorbidity burden is heavy, or if bedside gait or balance concerns are noted. Use the results to recommend prehab, assistive devices, and home safety modifications before treatment to reduce fall‑related complications.\n\nFinally, integrate the frailty and comorbidity findings with an MDS‑specific estimate that reflects disease‑related frailty risk. If risk is high, lean toward supportive/palliative approaches and avoid intensive regimens. If risk is low, proceed with disease‑modifying therapy while incorporating fall‑risk mitigations from balance testing and the supportive needs identified in the multidomain and comorbidity reviews.\n\nAs you work through this, show each step and how it informs the next decision rather than jumping straight to a final plan. I need proper, calculation‑based justification—this cannot rest on clinical intuition alone. Whatever approach you suggest should be backed by solid calculations to withstand scrutiny.", "required_calculators": ["G8 Geriatric Screening Tool", "CSHA Clinical Frailty Scale (CFS)", "Edmonton Frail Scale", "Cumulative Illness Rating Scale-Geriatric (CIRS-G)", "Berg Balance Scale (BBS)", "MDS Specific Frailty Scale"], "calculator_answers": [{"order": 1, "name": "G8 Geriatric Screening Tool", "inputs": [{"field": "Age, years", "value": 82, "score": 1}, {"field": "Has food intake declined over the past 3 months due to loss of appetite, digestive problems, chewing, or swallowing difficulties?", "value": "Moderate decrease in food intake", "score": 1}, {"field": "Weight loss during the last 3 months, kg", "value": "1-3 kg (2.0 kg)", "score": 2}, {"field": "Mobility", "value": "Able to get out of bed/ chair but does not go out", "score": 1}, {"field": "Neuropsychological conditions", "value": "Mild depression", "score": 1}, {"field": "Body mass index (BMI), kg/m2", "value": "22.0 kg/m²", "score": 2}, {"field": "Takes more than three prescription drugs per day", "value": "Yes", "score": 0}, {"field": "In comparison with other people of the same age, how does the patient consider their health status?", "value": "Not as good", "score": 0}], "final_answer": 8, "notes": "8 points\nFull geriatric evaluation recommended."}, {"order": 2, "name": "CSHA Clinical Frailty Scale (CFS)", "inputs": [{"field": "Canadian Triage Acuity Scale (CTAS) available?", "value": "No"}, {"field": "Clinical Frailty Scale level (1=Very Fit to 9=Terminally Ill)", "value": "With limited dependence on others for instrumental activities of daily living", "score": 5}], "final_answer": 5, "notes": "5 points\nMildly frail\n72 %\nApproximate probability of avoidance of institutional care at 30 months\nApproximate probability of mortality at 70 months: 58%\n68 %\nApproximate probability of survival at 30 months\nApproximate probability of survival at 70 months: 42%"}, {"order": 3, "name": "Edmonton Frail Scale", "inputs": [{"field": "Clock test", "value": "Minor errors (1 point)"}, {"field": "In the past year, how many times have you been admitted to a hospital?", "value": "1 admission (community-acquired pneumonia ~10 months ago)"}, {"field": "In general, how would you describe your health?", "value": "Fair"}, {"field": "With how many of the following activities do you require help? (meal preparation, shopping, transportation, telephone, housekeeping, laundry, managing money, taking medications)", "value": "2 activities (shopping, heavy housekeeping)"}, {"field": "When you need help, can you count on someone who is willing and able to meet your needs?", "value": "Always"}, {"field": "Do you use five or more different prescription medications on a regular basis?", "value": "Yes (6 prescription medications)"}, {"field": "At times, do you forget to take your prescription medications?", "value": "Sometimes"}, {"field": "Have you recently lost weight such that your clothing has become looser?", "value": "Yes"}, {"field": "Do you often feel sad or depressed?", "value": "Sometimes"}, {"field": "Do you have a problem with losing control of urine when you don’t want to?", "value": "Yes (occasional urge incontinence)"}, {"field": "Timed Get Up and Go", "value": "16.8 seconds"}], "final_answer": 10, "notes": "Final output:\n10 out of 17\nInterpretation:\nModerate Frailty"}, {"order": 4, "name": "Cumulative Illness Rating Scale-Geriatric (CIRS-G)", "inputs": [{"field": "Heart", "value": "0 - No problem", "score": 0}, {"field": "Vascular", "value": "2 - Daily antihypertensive meds", "score": 2}, {"field": "Hematopoietic", "value": "3 - Hemoglobin 9.4 g/dL (male) and total WBC 1.9 x10^9/L", "score": 3}, {"field": "Respiratory", "value": "1 - Former smoker 12 pack years", "score": 1}, {"field": "Eyes, ears, nose, throat, and larynx", "value": "1 - Mild hearing loss", "score": 1}, {"field": "Upper GI", "value": "2 - Needs daily acid suppression (PPI) for GERD", "score": 2}, {"field": "Lower GI", "value": "2 - Requires daily stool softeners for chronic constipation", "score": 2}, {"field": "Liver, pancreas, and biliary", "value": "0 - No problem", "score": 0}, {"field": "Renal", "value": "3 - Serum creatinine 1.6 mg/dL on antihypertensive therapy (stage 3 CKD)", "score": 3}, {"field": "Genitourinary", "value": "2 - BPH with urinary frequency (non-stress incontinence)", "score": 2}, {"field": "Musculoskeletal and skin", "value": "2 - Daily analgesics for osteoarthritis; moderate ADL limitation", "score": 2}, {"field": "Neurologic", "value": "0 - No problem", "score": 0}, {"field": "Endocrine and breast", "value": "1 - Requires thyroid hormone replacement", "score": 1}, {"field": "Psychiatric illness", "value": "1 - Minor depressive symptoms; outpatient management", "score": 1}], "final_answer": 20, "notes": "20 points\nHigher scores indicate higher severity (maximum score = 56 points)"}, {"order": 5, "name": "Berg Balance Scale (BBS)", "inputs": [{"field": "Sitting to standing", "value": "Able to stand independently using hands (3 points)", "score": 3}, {"field": "Standing unsupported", "value": "Able to stand 2 minutes with supervision (3 points)", "score": 3}, {"field": "Sitting with back unsupported", "value": "Able to sit safely and securely for 2 minutes (4 points)", "score": 4}, {"field": "Standing to sitting", "value": "Controls descent by using hands (3 points)", "score": 3}, {"field": "Transfers", "value": "Able to transfer safely with definite need of hands (3 points)", "score": 3}, {"field": "Standing unsupported with eyes closed", "value": "Able to stand 10 seconds with supervision (3 points)", "score": 3}, {"field": "Standing unsupported with feet together", "value": "Able to place feet together independently but unable to hold for 30 seconds (2 points)", "score": 2}, {"field": "Reaching forward with outstretched arm while standing", "value": "Can reach forward 5 cm (2 inches) safely (2 points)", "score": 2}, {"field": "Pick up object from the floor from a standing position", "value": "Able to pick up slipper but needs supervision (3 points)", "score": 3}, {"field": "Turning to look behind over left and right shoulders", "value": "Looks behind from both sides and weight shifts well (3 points)", "score": 3}, {"field": "Turn 360 degrees", "value": "Able to turn 360 degrees safely but slowly (2 points)", "score": 2}, {"field": "Placing alternate foot on step or stool while standing unsupported", "value": "Able to stand independently and complete 8 steps in >20 seconds (3 points)", "score": 3}, {"field": "Standing unsupported one foot in front", "value": "Able to take small step independently and hold 30 seconds (2 points)", "score": 2}, {"field": "Standing on one leg", "value": "Able to lift leg independently and hold ≥3 seconds (1 point)", "score": 1}], "final_answer": 37, "notes": "37 points\nBBS\nIncreased\nFall risk"}, {"order": 6, "name": "MDS Specific Frailty Scale", "inputs": [{"field": "BMI", "value": "22.0 kg/m²"}, {"field": "Any cancer history present or in the past?", "value": "No (excluding current MDS)"}, {"field": "Global Fatigue score", "value": "6/10 (patient-reported)"}, {"field": "WBC: Is it outside normal reference range for your lab?", "value": "Yes (1.9 x10^9/L)"}, {"field": "MCV: Is it outside normal reference range for your lab?", "value": "Yes (104 fL)"}, {"field": "RDW: Is it outside normal reference range for your lab?", "value": "Yes (19.2%)"}, {"field": "Ferritin: Is it outside normal reference range for your lab?", "value": "Yes (520 ng/mL)"}, {"field": "Bilirubin: Is it >1.5 x ULN of hospital lab range?", "value": "No (0.8 mg/dL)"}, {"field": "ALT: Is it >1.5 x ULN of hospital lab range?", "value": "No (26 U/L)"}, {"field": "ALP: Is it outside normal reference range for your lab?", "value": "No (95 U/L)"}, {"field": "LDH: Is it outside normal reference range for your lab?", "value": "Yes (265 U/L)"}, {"field": "Reticulocyte count: Is it outside normal reference range for your lab?", "value": "Yes (0.2%)"}, {"field": "Creatinine clearance", "value": "46 mL/min"}, {"field": "Age", "value": "82 years"}, {"field": "IPSS", "value": "Intermediate-1"}, {"field": "4 meter walk test", "value": "6.4 seconds"}, {"field": "Plans, Prepares and Serves Adequate Meals Independently", "value": "Yes"}], "final_answer": "0.56 - High risk", "notes": "Frailty Scale Ratio\n0.56 - High risk\nComposite Score\n2.5\nSurvival Outcomes\nPatients with this score had actuarial survivals of 15.9 months and 2-year survival of 36.7%"}]}
{"task_id": "medmcp-calc_012_01351278", "task_scenario": "Inflammatory Bowel Disease (IBD)", "task_category": "Clinical Medicine / Medicine & Organ Systems / Gastroenterology & Hepatology", "patient_id": "P012_01351278", "task_description": "Scenario: An adult with known ulcerative colitis is admitted with suspected acute severe flare characterized by frequent bloody stools and systemic symptoms. The clinical team must confirm severity, quantify endoscopic disease, classify extent, forecast response to steroid therapy, estimate colectomy risk, monitor inflammatory burden, and address nutrition. The following stepwise calculator workflow supports these decisions. Step 1: Use the Truelove and Witts Severity Index for Ulcerative Colitis to determine whether criteria for acute severe ulcerative colitis (ASUC) are met. If severe, proceed with inpatient management and urgent sigmoidoscopy; if mild/moderate, consider outpatient therapy and monitoring. Step 2 (severe branch): Apply the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) during urgent flexible sigmoidoscopy to grade mucosal severity; high UCEIS supports anticipating a need for rescue therapy if steroid response is suboptimal. Step 3: Document disease extent and severity using the Montreal Classification for Inflammatory Bowel Disease (IBD); use endoscopic distribution to assign extent (E1–E3) and the Truelove and Witts result to set severity (S-grade). This classification informs long-term strategy and risk stratification. Step 4: Screen nutrition at admission with the Malnutrition Universal Screening Tool (MUST). If MUST indicates medium/high risk, plan to quantify malnutrition with the Nutritional Risk Index (NRI) later in the workflow; if low risk, continue standard nutritional support. Step 5: Track clinical activity with the Mayo Score/Disease Activity Index (DAI) for Ulcerative Colitis at baseline and daily. The stool frequency component captured here is reused as a required input for the day-3 prognostic calculators. Step 6: Calculate the Neutrophil-Lymphocyte Ratio (NLR) to quantify systemic inflammatory burden; if NLR is markedly elevated or rising despite steroids, and UCEIS is high, begin early planning for rescue therapy and proceed to day-3 prognostication. Step 7 (day 3 of IV steroids in severe branch): Use the Ho Index to predict likelihood of steroid failure; populate stool frequency from the daily Mayo Score. A high-risk Ho Index result triggers rescue therapy consideration. Step 8: Concurrently apply the Travis Criteria on day 3, using stool counts (from the Mayo Score) and other parameters to estimate colectomy risk. If both Ho Index and Travis Criteria show high risk, expedite rescue therapy (e.g., infliximab or cyclosporine) and obtain early surgical consultation; if risk is low, continue steroids with ongoing monitoring via Mayo Score and NLR. Step 9: If MUST in Step 4 indicated medium/high risk, compute the Nutritional Risk Index (NRI) to quantify malnutrition severity and guide enteral versus parenteral support, micronutrient repletion, and caloric targets. For the non-severe branch from Step 1, proceed with outpatient monitoring primarily via Mayo Score; consider Montreal Classification documentation for extent, and apply nutritional screening with MUST, reserving NRI if risk is identified.", "fuzzy_question": "I’m evaluating a patient with ulcerative colitis admitted for very frequent bloody stools, crampy pain, and systemic symptoms. I’m determining how severe this flare is and what direction to take in the near term. I’m not certain the criteria for an acute severe flare are met, so I want to look beyond stool frequency and include blood in the stool, fever, heart rate, anemia, and inflammatory markers. If the threshold is met, this is an inpatient problem and I’d want an urgent flexible sigmoidoscopy; if it falls short and looks more mild to moderate, I’d lean toward outpatient therapy with close monitoring.\n\nOn endoscopy, I’m seeking an objective read on mucosal inflammation—loss of vascular pattern, spontaneous bleeding, and ulceration—so we can assign a meaningful severity label. If the endoscopic read is high and there’s no early improvement on steroids, I’d be quicker to prepare for rescue options. I also want the disease mapped clearly: confined to the rectum, left-sided, or more extensive. And I’d like the severity label in the chart to align with bedside criteria, because that informs long-term risk and maintenance strategy.\n\nAt admission, let’s do a quick nutrition screen. If it indicates medium or high risk, I’d like a more quantitative nutrition index later in the course to set calorie targets, decide on enteral versus parenteral feeding if needed, and plan micronutrient repletion; if the screen looks low risk, standard support is fine. From the outset, I want a standardized daily symptom score for UC so we have a baseline and can track change—please ensure quantitative stool frequency is captured, as those data feed into early risk checks.\n\nI’d also like to follow the neutrophil-to-lymphocyte ratio from the CBC as a quick read on systemic inflammation. If that ratio is very high or rising despite steroids, and the scope shows severe inflammation, that pushes me toward planning rescue therapy sooner and moving on to early prognostication without delay.\n\nEarly during IV steroid therapy, I want separate risk assessments: one that combines stool frequency with key labs to gauge the chance steroids will fail, and another that uses stool frequency alongside inflammatory markers to estimate the likelihood of needing colectomy during the inpatient course. If both point to high risk, let’s not delay—move toward rescue therapy (infliximab or cyclosporine depending on context) and get surgery involved early. If those checks look reassuring, continue steroids and keep monitoring with the symptom score and that blood count ratio. If the initial nutrition screen was concerning, this is also when I’d like the more detailed nutrition index to quantify malnutrition severity and guide feeding route and repletion.\n\nIf, initially, the threshold for an acute severe flare is not met, I’m comfortable with outpatient management while still using a standardized symptom score to anchor follow-up, ensuring the anatomic extent is clearly documented from scope reports, and running the quick nutrition screen—reserving the deeper nutrition index only if that screen shows risk.\n\nWhat’s your take on this case and how would you reason it through? I really need proper calculations—this can’t be based on gut feeling alone. Whatever approach you suggest, make sure it’s backed by solid calculations. This needs to hold up to scrutiny.", "required_calculators": ["Truelove and Witts Severity Index for Ulcerative Colitis", "Ulcerative Colitis Endoscopic Index of Severity (UCEIS)", "Montreal Classification for Inflammatory Bowel Disease (IBD)", "Malnutrition Universal Screening Tool (MUST)", "Mayo Score/Disease Activity Index (DAI) for Ulcerative Colitis", "Neutrophil-Lymphocyte Ratio (NLR) Calculator", "Ho Index", "Travis Criteria", "Nutritional Risk Index (NRI)"], "calculator_answers": [{"order": 1, "name": "Truelove and Witts Severity Index for Ulcerative Colitis", "inputs": [{"field": "Bowel movements per day", "value": "12 stools/day (category: ≥6)"}, {"field": "Blood in stool", "value": "Visible blood"}, {"field": "Pyrexia (≥37.8 °C)", "value": "Yes (38.2 °C / 100.8 °F)"}, {"field": "Pulse >90 bpm", "value": "Yes (112 bpm)"}, {"field": "Anemia (Hb ≤10.5 g/dL)", "value": "Yes (Hemoglobin 9.8 g/dL)"}, {"field": "ESR (mm/hr)", "value": "68 mm/hr (>30)"}], "final_answer": "Severe", "notes": "Severity of ulcerative colitis"}, {"order": 2, "name": "Ulcerative Colitis Endoscopic Index of Severity (UCEIS)", "inputs": [{"field": "Vascular pattern", "value": "Obliterated (+2)", "score": 2}, {"field": "Bleeding", "value": "Luminal moderate or severe (+3)", "score": 3}, {"field": "Erosions and ulcers", "value": "Deep ulcer (+3)", "score": 3}], "final_answer": 8, "notes": "Severe\nUlcerative colitis severity"}, {"order": 3, "name": "Montreal Classification for Inflammatory Bowel Disease (IBD)", "inputs": [{"field": "Type of IBD", "value": "Ulcerative colitis"}, {"field": "Extent (UC)", "value": "E2 – Left-sided UC (also known as distal UC): involvement limited to the portion of the colorectum distal to the splenic flexure"}, {"field": "Severity (UC)", "value": "S3 – Severe UC: ≥6 bloody stools daily, pulse ≥90 bpm, temperature ≥99.5°F (37.5°C), hemoglobin <10.5 g/dL (105 g/L), and erythrocyte sedimentation rate ≥30 mm/hr"}], "final_answer": "E2 S3", "notes": "Montreal Classification for UC"}, {"order": 4, "name": "Malnutrition Universal Screening Tool (MUST)", "inputs": [{"field": "BMI (kg/m²)", "value": "25.2 (score 0)", "score": 0}, {"field": "Unplanned weight loss in past 3–6 months", "value": "7% (score +1)", "score": 1}, {"field": "Acutely ill with no intake >5 days", "value": "No (score 0)", "score": 0}], "final_answer": 1, "notes": "Medium risk\nObserve; document dietary intake and if adequate/little concern, continue screening; if inadequate, improve and increase overall intake according to local policy"}, {"order": 5, "name": "Mayo Score/Disease Activity Index (DAI) for Ulcerative Colitis", "inputs": [{"field": "Stool frequency (vs normal)", "value": ">4 stools/day more than normal (+3)", "score": 3}, {"field": "Rectal bleeding", "value": "Passing blood alone (+3)", "score": 3}, {"field": "Mucosal appearance at endoscopy", "value": "Severe (spontaneous bleeding, ulceration) (+3)", "score": 3}, {"field": "Physician rating of disease activity", "value": "Severe (+3)", "score": 3}], "final_answer": 12, "notes": "Scores should be compared to previous scores taken for a patient.\nThe higher the score (maximum 12 points), the more severe the ulcerative colitis."}, {"order": 6, "name": "Neutrophil-Lymphocyte Ratio (NLR) Calculator", "inputs": [{"field": "Absolute neutrophil count", "value": "11.8 ×10^3/μL"}, {"field": "Absolute lymphocyte count", "value": "0.9 ×10^3/μL"}], "final_answer": 13, "notes": "13\nNeutrophil-Lymphocyte Ratio\nModerate\nPhysiologic stress level"}, {"order": 7, "name": "Ho Index", "inputs": [{"field": "Mean stool frequency (stools/24 h) on day 3", "value": "10 stools/24 h (category: >9, +4)", "score": 4}, {"field": "Colonic dilatation", "value": "Absent (0); cecal diameter 5.0 cm on AXR", "score": 0}, {"field": "Hypoalbuminemia (albumin ≤3.0 g/dL)", "value": "Yes (Albumin 2.8 g/dL, +1)", "score": 1}], "final_answer": 5, "notes": "85 %\nHigh risk of medical therapy failure"}, {"order": 8, "name": "Travis Criteria", "inputs": [{"field": "Number of stools on day 3", "value": ">8 (actual: 10 stools/24 h)"}, {"field": "CRP >45 mg/L on day 3", "value": "Yes (CRP 72 mg/L)"}], "final_answer": "High", "notes": "High risk\nRisk of needing a colectomy"}, {"order": 9, "name": "Nutritional Risk Index (NRI)", "inputs": [{"field": "Serum albumin", "value": "2.8 g/dL"}, {"field": "Present weight", "value": "176 lb (80 kg)"}, {"field": "Usual weight (last 6 months)", "value": "189 lb (86 kg)"}], "final_answer": 81.3, "notes": "81.3 points\nNRI Score\nSevere risk\nRisk of malnutrition"}]}
{"task_id": "medmcp-calc_013_e75c660d", "task_scenario": "Medication Side Effect Monitoring", "task_category": "Clinical Medicine / Neurology & Mental Health / Mental & Psychological Health", "patient_id": "P013_e75c660d", "task_description": "Clinical scenario: A hospitalized patient receiving antipsychotic therapy, a mood stabilizer, and opioids for pain has had recent dose changes and reports new or worsening side effects. The team must systematically triage symptoms, quantify movement disorders, rule out severe hypersensitivity, confirm opioid-related constipation, and evaluate cardiac risk before modifying the regimen. Workflow: 1) Begin with the Frequency, Intensity and Burden of Side Effects Rating Scale (FIBSER) Revised to capture overall side-effect frequency, intensity, and burden across the current psychotropic and analgesic regimen; use this as the triage step to prioritize which symptoms require immediate targeted assessments. 2) Conditional branches from FIBSER: If FIBSER flags clinically significant restlessness/inner agitation, apply the Barnes Akathisia Rating Scale (BARS) to confirm and grade akathisia; if FIBSER flags abnormal involuntary movements interfering with function, apply the Abnormal Involuntary Movement Scale (AIMS) to assess tardive dyskinesia severity; if FIBSER flags rash with systemic symptoms after a recently introduced agent, compute the RegiSCAR Score for Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) to evaluate for severe hypersensitivity; if FIBSER flags troublesome constipation in a patient using opioids, use the Rome IV Diagnostic Criteria for Opioid-Induced Constipation to confirm OIC. 3) Movement-disorder to cardiac-risk linkage: If BARS and/or AIMS indicate moderate-to-severe severity prompting antipsychotic dose change or switch, compute the Tisdale Risk Score for QT Prolongation before altering therapy or adding adjuncts; use the resulting risk category to guide selection of lower-risk agents and the intensity of cardiac monitoring. 4) Safety-critical branch: If RegiSCAR indicates probable or definite DRESS, immediately hold the suspected medication and prioritize management of hypersensitivity; defer other medication changes until the reaction is addressed; if RegiSCAR is unlikely, proceed with movement and cardiac risk-informed adjustments. 5) OIC management branch: If Rome IV confirms opioid-induced constipation, initiate targeted OIC treatment and consider opioid regimen adjustments; if criteria are not met, manage as nonspecific constipation. 6) Integrate outputs to finalize the plan: Combine FIBSER with BARS/AIMS severity and Tisdale risk to select antipsychotic dose adjustments, switches, or adjuncts while maintaining cardiac safety; address DRESS if present; treat OIC when confirmed; after interventions, re-administer FIBSER to document improvement and refine follow-up.", "fuzzy_question": "I'm reviewing a hospitalized patient receiving an antipsychotic, a mood stabilizer, and opioid therapy. After recent dose adjustments, there are new or worsening adverse effects: inner restlessness, abnormal movements interfering with basic tasks, a rash with possible systemic symptoms following a recent medication change, and significant constipation. Before modifying medications, I want a structured overview of how often these effects occur, how intense they are, and how much they disrupt day-to-day functioning across the psychiatric and pain regimen, to help prioritize what needs attention first.\n\nIf the global check suggests true inner restlessness, I would pursue a formal akathisia assessment to confirm it and grade severity. If it points to functionally impairing abnormal involuntary movements, I would perform a standardized tardive dyskinesia examination with graded severity rather than relying on a quick visual impression. If the rash follows a newly started or up-titrated medication and there are systemic features (fever, lymph nodes, eosinophils, or organ involvement), I would use a recognized framework to estimate the likelihood of a serious drug reaction such as DRESS. If probable or definite, stop the suspect agent promptly and prioritize managing the reaction; defer other medication changes until that is addressed. If unlikely, monitor the skin while proceeding with evaluation and management of the movement symptoms and constipation.\n\nFor constipation, given concurrent opioid therapy, I would confirm whether the pattern fits opioid-induced constipation: stool frequency and consistency, straining, a sense of incomplete evacuation, and onset or worsening in relation to opioids. If consistent, initiate targeted treatment for opioid-related constipation and consider adjustments to the opioid plan; if not, manage as nonspecific constipation.\n\nIf movement ratings are in the moderate-to-severe range and I'm considering reducing or switching the antipsychotic or adding an agent to mitigate movements, I want to avoid cardiac complications. Before changing therapy, I would obtain a quantified estimate of QT prolongation risk that accounts for baseline QTc from ECG, demographic and clinical factors, electrolytes, the overall burden of QT-prolonging medications, and other relevant risks. Depending on the risk category, select lower-risk antipsychotic options and set appropriate cardiac monitoring to avoid trading one harm for another.\n\nOverall, I would integrate the side-effect snapshot, movement severity ratings, and the QT-risk estimate to guide antipsychotic dose adjustments, switches, or adjuncts while keeping cardiac safety central. If a serious drug reaction is likely, address that first and hold other medication changes. If opioid-related constipation is confirmed, treat it specifically and revisit the opioid strategy; otherwise manage constipation generally. After interventions, repeat the global side-effect check to confirm improvement in frequency, intensity, and burden, and adjust follow-up accordingly.\n\nWhat's your take on this? How would you reason through it step by step? I need proper calculations to support the approach rather than relying on clinical intuition alone. Whatever you suggest, please back it with solid, defensible quantification so it holds up to scrutiny.", "required_calculators": ["Frequency, Intensity and Burden of Side Effects Rating Scale (FIBSER) Revised", "Barnes Akathisia Rating Scale (BARS)", "Abnormal Involuntary Movement Scale (AIMS)", "Tisdale Risk Score for QT Prolongation", "RegiSCAR Score for Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)", "Rome IV Diagnostic Criteria for Opioid-Induced Constipation"], "calculator_answers": [{"order": 1, "name": "Frequency, Intensity and Burden of Side Effects Rating Scale (FIBSER) Revised", "inputs": [{"field": "frequency_past_week", "value": "Most of the time (~70% of the time)"}, {"field": "intensity_past_week", "value": "Severe"}, {"field": "interference_past_week", "value": "Marked interference with day-to-day activities"}], "final_answer": 4, "notes": "FIBSER Score\n4\nInterpretation\nSide effects should be addressed"}, {"order": 2, "name": "Barnes Akathisia Rating Scale (BARS)", "inputs": [{"field": "objective", "value": "3 (Moderate): continuous fidgeting while seated and standing; cannot remain still >1 minute; occasional pacing"}, {"field": "subjective_awareness", "value": "3: Clear awareness of inner restlessness with strong urge to move"}, {"field": "subjective_distress", "value": "3: Severe distress related to restlessness"}, {"field": "global_akathisia", "value": "3 (Severe akathisia)"}], "final_answer": 12, "notes": "Score\n12"}, {"order": 3, "name": "Abnormal Involuntary Movement Scale (AIMS)", "inputs": [{"field": "facial_expression_movements", "value": "2 (Mild)", "score": 2}, {"field": "lips_perioral_movements", "value": "2 (Mild)", "score": 2}, {"field": "jaw_movements", "value": "1 (Minimal)", "score": 1}, {"field": "tongue_movements", "value": "1 (Minimal)", "score": 1}, {"field": "upper_extremity_movements", "value": "3 (Moderate)", "score": 3}, {"field": "lower_extremity_movements", "value": "2 (Mild)", "score": 2}, {"field": "trunk_movements", "value": "2 (Mild)", "score": 2}, {"field": "global_severity_overall", "value": "Moderate"}, {"field": "incapacitation_due_to_movements", "value": "Moderate: interferes with feeding/hygiene; requires assistance for fine motor tasks"}, {"field": "patient_awareness_of_movements", "value": "Aware, moderate distress"}, {"field": "dental_problems", "value": "No"}, {"field": "dentures_worn", "value": "No"}, {"field": "edentia", "value": "No"}, {"field": "movements_disappear_in_sleep", "value": "Yes"}], "final_answer": 13, "notes": "Strong\nEvidence of TD\nOverall severity: Moderate\nIncapacitation: Moderate\nAwareness: Aware, moderate distress\nProblems with teeth/dentures: No\nDentures: No\nEdentia: No\nMovements disappear in sleep: Yes"}, {"order": 4, "name": "RegiSCAR Score for Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)", "inputs": [{"field": "fever_greater_equal_38_5_c", "value": "No (38.2 °C recorded; low-grade)", "score": -1}, {"field": "enlarged_lymph_nodes_ge_2_sites_gt_1cm", "value": "Yes (cervical and axillary nodes ~1.5 cm)", "score": 1}, {"field": "atypical_lymphocytes", "value": "Yes (peripheral smear: atypical lymphocytes present)", "score": 1}, {"field": "eosinophilia_category", "value": "≥1,500 cells or ≥20% (absolute eosinophils 1,800 cells/µL; 22%)", "score": 2}, {"field": "skin_rash_extent_gt_50_percent_bsa", "value": "Yes (~60% BSA: trunk and limbs)", "score": 1}, {"field": "rash_morphology_at_least_two_features", "value": "Yes (edema, infiltration, scaling)", "score": 1}, {"field": "biopsy_suggesting_dress", "value": "Yes (interface dermatitis with eosinophils; consistent with drug eruption)", "score": 0}, {"field": "internal_organ_involvement_count", "value": "1 (hepatitis: ALT 176 U/L, AST 98 U/L; bilirubin 1.2 mg/dL)", "score": 1}, {"field": "resolution_in_ge_15_days", "value": "Unknown (rash onset 3 days ago)", "score": 0}, {"field": "alternative_diagnoses_excluded", "value": "Yes (negative hepatitis A/B/C serologies, EBV VCA IgM negative, CMV IgM negative; strep screen negative)", "score": 1}], "final_answer": 6, "notes": "Definite case\nLikelihood of DRESS diagnosis"}, {"order": 5, "name": "Rome IV Diagnostic Criteria for Opioid-Induced Constipation", "inputs": [{"field": "new_or_worsening_constipation_after_opioid_change", "value": "Yes (hydromorphone dose increased 5 days ago)"}, {"field": "straining_ge_25_percent_defecations", "value": "Yes (~80% of defecations)"}, {"field": "lumpy_or_hard_stools_bristol_1_2_ge_25_percent_defecations", "value": "Yes (Bristol type 1-2 ~70% of defecations)"}, {"field": "sensation_incomplete_evacuation_ge_25_percent_defecations", "value": "Yes (~70% of defecations)"}, {"field": "sensation_anorectal_obstruction_ge_25_percent_defecations", "value": "Yes (~50% of defecations)"}, {"field": "manual_maneuvers_ge_25_percent_defecations", "value": "No (0%)"}, {"field": "spontaneous_bowel_movements_per_week", "value": "2"}, {"field": "loose_stools_rare_without_laxatives", "value": "Yes"}], "final_answer": "Positive", "notes": "Diagnosis for opioid-induced constipation as per Rome IV criteria"}, {"order": 6, "name": "Tisdale Risk Score for QT Prolongation", "inputs": [{"field": "age_ge_68_years", "value": "No (Age: 59 years)", "score": 0}, {"field": "sex", "value": "Female", "score": 1}, {"field": "on_loop_diuretic", "value": "No", "score": 0}, {"field": "potassium_le_3_5_meq_l", "value": "Yes (K+ 3.3 mEq/L)", "score": 2}, {"field": "admission_qtc_ge_450_ms", "value": "Yes (QTc 462 ms, Bazett)", "score": 2}, {"field": "admitted_for_acute_myocardial_infarction", "value": "No", "score": 0}, {"field": "admitted_for_sepsis", "value": "No", "score": 0}, {"field": "admitted_for_heart_failure", "value": "No", "score": 0}, {"field": "number_qt_prolonging_drugs", "value": "≥2 (haloperidol; ondansetron)", "score": 6}], "final_answer": 11, "notes": "High risk\nHigh risk for QT prolongation; consider consultation with pharmacist, adjusting risk factors as much as possible, and using alternative medications if possible\nEKG should be repeated after 5 half-lives of QT prolonging drugs given to evaluate QTc"}]}
{"task_id": "medmcp-calc_014_073263ee", "task_scenario": "Infective Endocarditis Diagnostic Criteria", "task_category": "Clinical Medicine / Medicine & Organ Systems / Infectious Diseases", "patient_id": "P014_073263ee", "task_description": "Clinical scenario: A hospitalized patient presents with signs suggestive of infective endocarditis. The care team must triage the urgency of echocardiography and then establish a formal diagnostic classification to determine whether the patient has definite, possible, or no infective endocarditis.\n\nStep-by-step calculator sequence:\n1) Use the VIRSTA Score to estimate infective endocarditis risk and set the priority for echocardiography. If the score indicates high risk, proceed urgently with transesophageal echocardiography; if low risk, schedule transthoracic echocardiography at standard priority. This risk output determines the timing and intensity of imaging that will supply key inputs for diagnostic criteria.\n2) Apply the 2023 Duke-International Society for Cardiovascular Infectious Diseases (ISCVID) Criteria using the available imaging findings and clinical/microbiologic features to classify the case as definite, possible, or rejected infective endocarditis. This classification is the central diagnostic decision point.\n3) Conditional branch based on the 2023 ISCVID result:\n   - If \"definite,\" finalize the diagnosis and document per the 2023 criteria.\n   - If \"possible,\" apply the Duke Criteria for Infective Endocarditis to determine whether legacy criteria classify the case as \"definite.\" If classic Duke returns \"definite,\" heighten diagnostic suspicion and pursue additional evidence (e.g., repeat or advanced imaging) to satisfy the 2023 criteria; if not, maintain the \"possible\" classification while continuing the workup.\n   - If \"rejected,\" use the VIRSTA output to guide next steps: if VIRSTA was low risk, de-prioritize further echocardiography; if VIRSTA was high risk, still apply the Duke Criteria for Infective Endocarditis to ensure no missed classification and consider repeating imaging if clinical trajectory remains concerning.\n4) Integrate outputs for final documentation: use VIRSTA to justify imaging priority; use the 2023 ISCVID classification as the primary diagnostic label; use the classic Duke classification only to inform additional workup when the 2023 criteria are non-definitive or discordant with clinical risk.\n\nRationale: This workflow begins with risk triage to allocate resources efficiently, then applies the contemporary reference standard for diagnosis, with legacy criteria serving as a cross-check in borderline or discordant cases. Outputs from each step deterministically trigger subsequent steps and branches.", "fuzzy_question": "I'm evaluating a hospitalized patient with ongoing fevers and persistent bacteremia, plus clinical features suggestive of endocarditis (new murmur and embolic-appearing signs). I'm debating the intensity and timing of imaging. Can you start by risk-stratifying at the bedside to justify whether an urgent transesophageal echo is needed versus starting with a routine transthoracic echo and escalating as needed? I want that triage to incorporate the organism identity and culture dynamics (number of positive sets and whether they are persistent), any history of valve disease or implanted cardiac material, and clinical hints such as neurologic events, peripheral stigmata, or conduction changes, so the echo plan is not based on intuition alone.\n\nOnce you set the imaging priority from that risk assessment, please fold the echo findings back into the overall picture and use the most up-to-date international diagnostic framework to determine whether this is \"definite,\" \"possible,\" or \"rejected\" endocarditis. Base that on the echo interpretation (vegetations, abscess, new regurgitation, prosthetic involvement), the microbiology (pathogen and culture course), and the clinical features.\n\nDepending on where we land:\n- If it is \"definite,\" state it and document clearly which criteria are satisfied under the current standard.\n- If it is \"possible,\" add a second lens: check how the older framework many clinicians trained on would label the same case. If that older system would upgrade it to \"definite,\" raise the index of suspicion and pursue additional evidence (repeat or higher-yield imaging) to meet the modern bar. If the older system does not move it to \"definite,\" keep it as \"possible\" while continuing the work-up.\n- If the modern criteria say \"rejected,\" tie the next steps back to the initial bedside risk call. If the initial risk looks low, it is reasonable to de-prioritize more echo. If the initial risk looks high, still run the case through the older framework so nothing is missed, and consider repeating or escalating imaging if the clinical course remains worrisome over the next short interval.\n\nIn the final note, anchor the imaging priority to the bedside risk triage, use the updated criteria for the primary diagnostic label, and use the older framework only to justify more testing when there is a gray zone or when the risk picture and the modern label do not align.\n\nWhat is your take? Please walk through the reasoning step by step. I need proper quantitative risk estimates and defensible calculations so this decision is evidence-based, not just clinical intuition.", "required_calculators": ["VIRSTA Score", "2023 Duke-International Society for Cardiovascular Infectious Diseases (ISCVID) Criteria", "Duke Criteria for Infective Endocarditis"], "calculator_answers": [{"order": 1, "name": "VIRSTA Score", "inputs": [{"field": "Cerebral or peripheral emboli", "value": "Yes (MRI brain: multiple small embolic infarcts; Janeway lesions on palms)", "score": 5}, {"field": "Meningitis", "value": "No", "score": 0}, {"field": "Permanent intracardiac device or previous IE", "value": "No", "score": 0}, {"field": "Pre-existing native valve disease", "value": "Yes (mitral valve prolapse with mild MR on TTE 18 months ago)", "score": 3}, {"field": "Intravenous drug use", "value": "No", "score": 0}, {"field": "Persistent bacteremia", "value": "Yes (MSSA positive in 4/4 blood culture sets over 48 hours)", "score": 3}, {"field": "Vertebral osteomyelitis", "value": "No", "score": 0}, {"field": "Community or non-nosocomial health care associated acquisition", "value": "Yes (community-acquired)", "score": 2}, {"field": "Severe sepsis or shock", "value": "Yes (SBP 88 mmHg, lactate 3.2 mmol/L, improved after fluids)", "score": 1}, {"field": "C-reactive protein >190 mg/L", "value": "Yes (CRP 236 mg/L)", "score": 1}], "final_answer": 15, "notes": "High risk\nRisk of IE\nPhysicians are strongly encouraged to perform urgent echocardiography."}, {"order": 2, "name": "2023 Duke-International Society for Cardiovascular Infectious Diseases (ISCVID) Criteria", "inputs": [{"field": "Typical IE microorganism isolated from ≥2 separate blood culture sets", "value": "Yes (Staphylococcus aureus, MSSA; 4/4 sets positive over 48 hours)"}, {"field": "Nontypical microorganism isolated from ≥3 separate blood culture sets", "value": "No"}, {"field": "Positive blood PCR for Coxiella/Bartonella/T. whipplei", "value": "No"}, {"field": "Coxiella burnetii antiphase I IgG >1:800 or single blood culture", "value": "No"}, {"field": "Bartonella IFA IgG titer ≥1:800", "value": "No"}, {"field": "Echocardiography or cardiac CT shows vegetation/perforation/abscess/pseudoaneurysm/fistula", "value": "Yes (TEE: 11x6 mm mobile vegetation on anterior mitral leaflet with small leaflet perforation)"}, {"field": "Significant new valvular regurgitation on echocardiography vs prior imaging", "value": "Yes (new moderate-to-severe MR; prior TTE showed mild MR)"}, {"field": "New partial dehiscence of prosthetic valve", "value": "No (no prosthetic valve)"}, {"field": "[18F]FDG PET/CT abnormal valvular or lead activity", "value": "Not performed"}, {"field": "Surgical inspection evidence of IE without major imaging/histology/micro confirmation", "value": "No"}, {"field": "Fever >38.0°C", "value": "Yes (Tmax 39.1 C)"}, {"field": "Vascular phenomena (arterial emboli, septic pulmonary infarcts, splenic/cerebral abscess, mycotic aneurysm, ICH, conjunctival hemorrhages, Janeway lesions)", "value": "Yes (MRI: multiple small embolic cerebral infarcts; Janeway lesions)"}, {"field": "Immunologic phenomena (RF+, Osler nodes, Roth spots, immune complex GN)", "value": "No"}, {"field": "Predisposition (previous IE, prosthetic valve, previous repair, CHD, >mild regurg/stenosis, endovascular CIED, HOCM, IVDU)", "value": "No applicable predisposition"}, {"field": "Positive blood cultures for organism consistent with IE but not meeting major criterion", "value": "No (major microbiologic criterion already met)"}], "final_answer": "Definite endocarditis", "notes": "Definite endocarditis\nMeets clinical Duke-ISCVID criteria"}, {"order": 3, "name": "Duke Criteria for Infective Endocarditis", "inputs": [{"field": "Pathologic criteria (microorganisms in vegetation or histologic active endocarditis)", "value": "No (no surgery performed)"}, {"field": "Blood cultures positive for typical IE organism (major)", "value": "Yes (MSSA from 2 separate sets; persistent positives >12 h apart)"}, {"field": "Evidence of endocardial involvement (major)", "value": "Yes (TEE vegetation 11x6 mm; new moderate-to-severe MR)"}, {"field": "Predisposing heart condition or injection drug use (minor)", "value": "Yes (pre-existing mitral valve prolapse with mild MR)"}, {"field": "Fever ≥38.0°C (minor)", "value": "Yes (39.1 C)"}, {"field": "Vascular phenomena (minor)", "value": "Yes (embolic cerebral infarcts; Janeway lesions)"}, {"field": "Immunologic phenomena (minor)", "value": "No"}, {"field": "Microbiologic evidence not meeting major (minor)", "value": "No"}], "final_answer": "Definite", "notes": "Diagnostic Result\nDefinite\nSee Next Steps for full criteria."}]}
{"task_id": "medmcp-calc_015_d703b297", "task_scenario": "Pneumonia and Infection Severity", "task_category": "Clinical Medicine / Medicine & Organ Systems / Respiratory & Thoracic Medicine", "patient_id": "P015_d703b297", "task_description": "Clinical scenario: A patient presents with symptoms and imaging consistent with community-acquired pneumonia. You must rapidly triage illness severity, determine site-of-care (outpatient, general ward, or ICU), anticipate need for intensive respiratory or vasopressor support, screen for sepsis/organ failure, assess hypoxemia severity, and tailor empiric antibiotic coverage to local resistance risk.\n\nStep-by-step workflow using calculators:\n1) Initial triage: Use National Early Warning Score (NEWS) 2 to quantify overall acute illness and guide urgency of interventions.\n   - If NEWS2 is high, proceed immediately to oxygenation assessment (Step 6) and sepsis screen (Step 4) in parallel; otherwise continue with pneumonia risk stratification (Step 2).\n2) Rapid CAP severity without labs: Use CRB-65 Score for Pneumonia Severity for quick site-of-care estimation while comprehensive data are pending.\n   - If CRB-65 suggests low risk and NEWS2 is low, consider outpatient pathway; otherwise proceed to a lab-based CAP severity assessment (Step 3) and sepsis screen (Step 4).\n3) Definitive site-of-care for CAP: Use PSI/PORT Score: Pneumonia Severity Index for CAP to refine admission versus discharge decisions and to inform level of monitoring.\n4) Sepsis screen outside ICU: Use qSOFA (Quick SOFA) Score for Sepsis to identify high risk for poor outcomes from infection.\n   - If qSOFA is positive, immediately calculate the Sequential Organ Failure Assessment (SOFA) Score (Step 5) to quantify organ dysfunction and prioritize ICU consultation and resuscitation measures.\n5) Organ dysfunction and ICU mortality risk context: Use Sequential Organ Failure Assessment (SOFA) Score to gauge the severity of organ failure and support ICU disposition decisions.\n6) Oxygenation severity: Use SpO₂/FiO₂ Ratio to rapidly estimate hypoxemia severity at the bedside.\n   - If the SpO₂/FiO₂ Ratio indicates moderate-to-severe impairment, obtain and interpret an arterial blood gas using the Arterial Blood Gas (ABG) Analyzer (Step 7) to clarify oxygenation and acid–base status; if mild impairment and patient is otherwise stable, you may proceed directly to Step 8.\n7) ABG interpretation for decision support: Use the Arterial Blood Gas (ABG) Analyzer. The outputs supply the oxygenation and acid–base parameters required for SMART-COP in the next step and help adjudicate severity of respiratory failure.\n8) Predict need for intensive respiratory or vasopressor support: Use SMART-COP Score for Pneumonia Severity to estimate likelihood of requiring advanced respiratory support or vasopressors.\n   - If SMART-COP is high, prioritize ICU-level care and early escalation of respiratory support; if low, ward-level care may be appropriate if PSI/PORT and SOFA are also reassuring.\n9) Risk of drug-resistant pathogens: Use Drug Resistance in Pneumonia (DRIP) Score to estimate the likelihood of resistant organisms and to decide whether to broaden empiric coverage beyond standard CAP regimens.\n10) Specific MRSA risk: Use Shorr Score for MRSA Pneumonia to determine whether to add anti-MRSA therapy to empiric antibiotics.\n\nIntegration and decision points:\n- Low NEWS2 + low CRB-65 may support outpatient management; in such cases, DRIP and Shorr can still guide narrow versus broadened empiric therapy.\n- Moderate/high CRB-65 or elevated NEWS2 triggers PSI/PORT, qSOFA, and oxygenation assessment to finalize inpatient level of care.\n- Positive qSOFA deterministically triggers SOFA calculation, which, together with SMART-COP and oxygenation assessment (SpO₂/FiO₂ and ABG), guides ICU referral and escalation decisions.\n- ABG Analyzer outputs are used directly in SMART-COP inputs to refine prediction of intensive support needs.\n- DRIP and Shorr outputs determine whether to include resistant-pathogen coverage in the empiric regimen.", "fuzzy_question": "I’m evaluating a patient with fever, cough, dyspnea, and a focal infiltrate on imaging consistent with community-acquired pneumonia. I’m trying to determine the safest site of care (home, ward, or ICU), the risk of decompensation, and how broad the initial antibiotics should be.\n\nFirst, I want a rapid “how sick are they” snapshot from vital signs and mental status to gauge urgency. If that initial pass is concerning, don’t wait—check oxygenation immediately and perform a focused sepsis screen. If the first snapshot is reassuring, I still want a pneumonia-specific severity assessment while labs are pending to guide early disposition.\n\nWhile awaiting labs, provide a quick bedside sense of pneumonia severity that does not rely on bloodwork; if that and the early warning snapshot are both low risk, outpatient care may be considered. If either raises concern, proceed to a more definitive, lab-informed severity assessment to decide on admission versus discharge and the needed monitoring level.\n\nOutside the ICU, I also want a sepsis check based on mental status, blood pressure, and respiratory rate. If that screen is concerning, quantify organ dysfunction with standard labs and blood gases to prioritize early ICU input and resuscitation decisions, not just bed placement.\n\nFor oxygenation, interpret saturation in the context of the current oxygen delivery method. If this suggests at least moderate impairment, obtain an arterial blood gas and interpret both oxygenation and acid–base status; if impairment appears mild and the patient is otherwise stable, proceeding without an immediate gas is acceptable.\n\nUsing gas values when available—together with the clinical picture—estimate the near-term likelihood of needing high-flow oxygen, noninvasive ventilation, intubation, or vasopressors. If risk is high, favor ICU-level care and early escalation of respiratory support; if low and the pneumonia severity and organ-dysfunction context are reassuring, ward-level care may be appropriate.\n\nFor antibiotics, assess risk for resistant organisms based on recent exposures, healthcare contact, chronic care needs, prior microbiology, and underlying lung conditions to decide between standard community coverage versus broader therapy. Separately, evaluate MRSA risk to determine whether to add targeted coverage. Recommendations should reflect local resistance patterns.\n\nBringing this together: if both the early snapshot and the quick pneumonia check are low risk, outpatient treatment with appropriate antibiotics and safety-netting may be reasonable. If not, use the detailed, lab-informed severity assessment plus the sepsis/organ-dysfunction profile, oxygenation metrics (including ABG if performed), and the estimated need for advanced respiratory or vasopressor support to justify ward versus ICU placement and the initial respiratory plan. Then match the empiric regimen to the identified resistance and MRSA risk.\n\nWhat’s your take? Please show reasoning step by step with intermediate outputs supporting each decision. I need proper calculations—this decision should be evidence-based and able to withstand scrutiny.", "required_calculators": ["National Early Warning Score (NEWS) 2", "CRB-65 Score for Pneumonia Severity", "PSI/PORT Score: Pneumonia Severity Index for CAP", "qSOFA (Quick SOFA) Score for Sepsis", "Sequential Organ Failure Assessment (SOFA) Score", "SpO₂/FiO₂ Ratio", "Arterial Blood Gas (ABG) Analyzer", "SMART-COP Score for Pneumonia Severity", "Drug Resistance in Pneumonia (DRIP) Score", "Shorr Score for MRSA Pneumonia"], "calculator_answers": [{"order": 1, "name": "National Early Warning Score (NEWS) 2", "inputs": [{"field": "Respiratory rate, breaths per minute", "value": "24 breaths/min", "score": 2}, {"field": "Hypercapnic respiratory failure", "value": "No"}, {"field": "Room air or supplemental O₂", "value": "Supplemental O₂", "score": 2}, {"field": "SpO₂", "value": "90%", "score": 3}, {"field": "Temperature", "value": "38.5 °C", "score": 1}, {"field": "Systolic BP, mmHg", "value": "112 mmHg", "score": 0}, {"field": "Pulse, beats per minute", "value": "112 bpm", "score": 2}, {"field": "Consciousness", "value": "Alert", "score": 0}], "final_answer": 10, "notes": "10 points\nNational Early Warning Score\nHigh risk\nEmergent assessment by a clinical team or critical care team and usually transfer to higher level of care\nContinuous monitoring\nFrequency of monitoring"}, {"order": 2, "name": "CRB-65 Score for Pneumonia Severity", "inputs": [{"field": "Confusion", "value": "No", "score": 0}, {"field": "Respiratory rate ≥30/min", "value": "No", "score": 0}, {"field": "Blood pressure (SBP <90 mm Hg or DBP ≤60 mm Hg)", "value": "No", "score": 0}, {"field": "Age ≥65", "value": "Yes", "score": 0}], "final_answer": 1, "notes": "Intermediate risk\nMortality risk\nConsider hospital referral"}, {"order": 3, "name": "PSI/PORT Score: Pneumonia Severity Index for CAP", "inputs": [{"field": "Age", "value": "67 years"}, {"field": "Sex", "value": "Male", "score": 0}, {"field": "Nursing home resident", "value": "No", "score": 0}, {"field": "Neoplastic disease", "value": "No", "score": 0}, {"field": "Liver disease history", "value": "No", "score": 0}, {"field": "CHF history", "value": "No", "score": 0}, {"field": "Cerebrovascular disease history", "value": "No", "score": 0}, {"field": "Renal disease history", "value": "No", "score": 0}, {"field": "Altered mental status", "value": "No", "score": 0}, {"field": "Respiratory rate ≥30 breaths/min", "value": "No", "score": 0}, {"field": "Systolic blood pressure <90 mmHg", "value": "No", "score": 0}, {"field": "Temperature <35°C (95°F) or >39.9°C (103.8°F)", "value": "No", "score": 0}, {"field": "Pulse ≥125 beats/min", "value": "No", "score": 0}, {"field": "pH <7.35", "value": "No", "score": 0}, {"field": "BUN ≥30 mg/dL or ≥11 mmol/L", "value": "No", "score": 0}, {"field": "Sodium <130 mmol/L", "value": "No", "score": 0}, {"field": "Glucose ≥250 mg/dL or ≥14 mmol/L", "value": "No", "score": 0}, {"field": "Hematocrit <30%", "value": "No", "score": 0}, {"field": "Partial pressure of oxygen <60 mmHg or <8 kPa", "value": "Yes", "score": 10}, {"field": "Pleural effusion on x-ray", "value": "No", "score": 0}], "final_answer": 77, "notes": "Risk Class III, 0.9-2.8% mortality. Outpatient or inpatient treatment, depending on clinical judgment."}, {"order": 4, "name": "qSOFA (Quick SOFA) Score for Sepsis", "inputs": [{"field": "Altered mental status GCS  <15", "value": "No"}, {"field": "Respiratory rate ≥22", "value": "Yes"}, {"field": "Systolic BP ≤100", "value": "No"}], "final_answer": 1, "notes": "Not high risk\nIf sepsis is still suspected, continue to monitor, evaluate, and initiate treatment as appropriate, including serial qSOFA assessments."}, {"order": 5, "name": "Sequential Organ Failure Assessment (SOFA) Score", "inputs": [{"field": "PaO2 mm Hg", "value": "58 mmHg"}, {"field": "FiO2 %", "value": "40%"}, {"field": "On mechanical ventilation (Including CPAP)", "value": "No"}, {"field": "Platelets, ×10³/µL", "value": "180 ×10³/µL"}, {"field": "Glasgow Coma Scale", "value": "15"}, {"field": "Bilirubin, mg/dL", "value": "1.1 mg/dL"}, {"field": "Mean arterial pressure (MAP) mmHg", "value": "77 mmHg"}, {"field": "Vasoactive agents", "value": "None"}, {"field": "Creatinine, mg/dL", "value": "1.1 mg/dL"}], "final_answer": 2, "notes": "Initial SOFA Scores ≤9 predict ≤33.3% mortality (see Evidence for details)"}, {"order": 6, "name": "SpO₂/FiO₂ Ratio", "inputs": [{"field": "SpO2 %", "value": "90%"}, {"field": "FiO2 %", "value": "40%"}], "final_answer": 225.0, "notes": "S/F Ratio"}, {"order": 7, "name": "Arterial Blood Gas (ABG) Analyzer", "inputs": [{"field": "pH", "value": "7.46"}, {"field": "PaCO₂ mm Hg", "value": "33 mmHg"}, {"field": "HCO₃- mEq/L", "value": "24 mEq/L"}, {"field": "Sodium mEq/L", "value": "137 mEq/L"}, {"field": "Chloride mEq/L", "value": "102 mEq/L"}, {"field": "Albumin g/dL", "value": "3.4 g/dL"}, {"field": "If respiratory process present, chronicity", "value": "Acute"}], "final_answer": "Primary Respiratory Alkalosis, Acute, with: Appropriately Compensated by Metabolic Acidosis", "notes": "Primary Respiratory Alkalosis, Acute, with: Appropriately Compensated by Metabolic Acidosis"}, {"order": 8, "name": "SMART-COP Score for Pneumonia Severity", "inputs": [{"field": "Age (years)", "value": "67"}, {"field": "Multi-lobar involvement on chest x-ray", "value": "No", "score": 0}, {"field": "Albumin <3.5 g/dL (35 g/L)", "value": "Yes", "score": 1}, {"field": "Respiratory rate ≥30", "value": "No", "score": 0}, {"field": "Tachycardia ≥125", "value": "No", "score": 0}, {"field": "Confusion (new onset)", "value": "No", "score": 0}, {"field": "PaO₂ <60 mmHg, SaO₂ ≤90%, or PaO₂/FiO₂ <250", "value": "Yes", "score": 2}, {"field": "pH <7.35", "value": "No", "score": 0}, {"field": "sBP <90 mmHg", "value": "No", "score": 0}], "final_answer": 3, "notes": "Moderate risk\n1 in 8 risk of IRVS."}, {"order": 9, "name": "Drug Resistance in Pneumonia (DRIP) Score", "inputs": [{"field": "Antibiotic use within 60 days", "value": "No", "score": 0}, {"field": "Long term care resident", "value": "No", "score": 0}, {"field": "Tube feeding", "value": "No", "score": 0}, {"field": "Prior drug-resistant pneumonia diagnosis within 1 year", "value": "No", "score": 0}, {"field": "Hospitalization within 60 days", "value": "No", "score": 0}, {"field": "Chronic pulmonary disease", "value": "No", "score": 0}, {"field": "Poor functional status", "value": "No", "score": 0}, {"field": "H2 blocker or PPI within 14 days", "value": "Yes", "score": 1}, {"field": "Active wound care at time of admission", "value": "No", "score": 0}, {"field": "MRSA colonization within 1 year", "value": "No", "score": 0}], "final_answer": 1, "notes": "Low risk\nScores <4 were associated with lower risk of drug-resistant pneumonia. Consider treating without extended-spectrum antibiotics."}, {"order": 10, "name": "Shorr Score for MRSA Pneumonia", "inputs": [{"field": "Age 19-29 or >79 years", "value": "No", "score": 0}, {"field": "Nursing home, skilled nursing facility, or long term acute care exposure (Within 90 days)", "value": "No", "score": 0}, {"field": "Prior IV antibiotic therapy (Within 30 days)", "value": "No", "score": 0}, {"field": "Hospitalization for ≥2 days (Within 90 days)", "value": "No", "score": 0}, {"field": "ICU admission (On or before index culture)", "value": "No", "score": 0}, {"field": "Any cerebrovascular disease (Prior to admission)", "value": "No", "score": 0}, {"field": "Dementia", "value": "No", "score": 0}, {"field": "Female with diabetes mellitus", "value": "No", "score": 0}], "final_answer": 0, "notes": "Low risk\nConsider routine antibiotic coverage."}]}
{"task_id": "medmcp-calc_016_cf4bf811", "task_scenario": "Atrial Fibrillation Stroke Prevention (Neuro-Cardiology)", "task_category": "Clinical Medicine / Neurology & Mental Health / Neurosurgery & Neurology", "patient_id": "P016_cf4bf811", "task_description": "Clinical scenario: A patient with nonvalvular atrial fibrillation is evaluated in a neuro-cardiology clinic for secondary or primary stroke prevention. The team must determine whether to initiate or intensify anticoagulation, balance bleeding risk, and consider whether a concurrent patent foramen ovale (PFO) could have contributed to prior neurologic events.\nStep-by-step calculator use and rationale:\n1) Start with the CHA₂DS₂-VASc Score for Atrial Fibrillation Stroke Risk to establish baseline ischemic stroke risk. If the calculated risk is below guideline treatment thresholds, focus on risk-factor modification rather than anticoagulation; otherwise proceed to bleeding risk stratification.\n2) If sex categorization or sex-based weighting in CHA₂DS₂-VASc influences threshold decisions (for example, nonbinary or unknown sex, or borderline cases where sex points drive threshold crossing), recalculate with the CHA₂DS₂-VA Score for Atrial Fibrillation Stroke Risk to remove sex weighting and confirm whether the treatment threshold is truly met. The result deterministically triggers whether to continue to bleeding risk assessment.\n3) Use the HAS-BLED Score for Major Bleeding Risk to estimate bleeding hazard if anticoagulation is pursued. If bleeding risk is low, anticoagulation is favored; if moderate/high, proceed to an additional bleeding risk model to corroborate and refine.\n4) Apply the ORBIT Bleeding Risk Score for Atrial Fibrillation to corroborate HAS-BLED findings and assess bleeding risk on anticoagulation. If both scores indicate high bleeding risk—or if the two models are discordant—run integrated outcome modeling to weigh net clinical benefit before finalizing therapy.\n5) If warfarin is the anticipated agent (e.g., therapy-specific considerations favor warfarin), compute the ATRIA Bleeding Risk Score to quantify warfarin-specific bleeding risk. This result modifies the subsequent net-benefit analysis.\n6) Use GARFIELD-AF to estimate mortality, stroke, and bleeding with and without anticoagulation, integrating the prior stroke-risk classification (Steps 1–2) and bleeding-risk estimates (Steps 3–5). If GARFIELD-AF indicates a favorable net clinical benefit, proceed with anticoagulation and risk-mitigation strategies; if unfavorable, consider alternatives such as device-based stroke prevention alongside aggressive bleeding risk mitigation.\n7) If prior stroke was cryptogenic or echocardiography suggests a PFO, apply the PFO-Associated Stroke Causal Likelihood (PASCAL) Classification System to determine whether the PFO likely caused the stroke. If PASCAL indicates probable/definite PFO causality, coordinate PFO-focused management (e.g., closure) in addition to AF stroke prevention; if unlikely, continue AF-focused strategy.\n8) In borderline cases where the CHA₂DS₂-VASc or CHA₂DS₂-VA score sits near treatment thresholds, calculate the ATRIA Stroke Risk Score to cross-validate stroke risk and resolve uncertainty regarding anticoagulation initiation. The combined results drive the final individualized plan.", "fuzzy_question": "I'm evaluating a patient with nonvalvular atrial fibrillation for stroke prevention in a specialty clinic, possibly related to a prior transient neurologic episode of uncertain etiology, and I'm deciding whether to initiate or intensify anticoagulation. The goal is to prevent embolic events without provoking bleeding, and there is a possible patent foramen ovale on imaging that could be relevant. I would like a defensible plan for the next appointment.\n\nFirst, I want a clear, quantitative estimate of baseline thromboembolic risk based on age, hypertension, diabetes, heart failure, prior TIA/stroke, and vascular disease. If the estimate falls below the usual treatment threshold, I would favor optimizing risk factors over anticoagulation; if it meets or exceeds the treatment range, we then evaluate bleeding risk in detail. One wrinkle: sex can influence decisions in borderline cases or when the sex category is nonbinary or uncertain. If sex weighting appears to be the main factor crossing the threshold, please re-estimate without sex to confirm eligibility—if the patient still meets criteria, proceed; if not, hold off.\n\nIf the patient is in the treatment range, I want a careful assessment of bleeding risk on therapy incorporating recent blood pressure control, kidney and liver function, prior bleeding, anemia, labile INRs, alcohol use, and interacting medications such as antiplatelets or NSAIDs, using current labs and the medication list. If bleeding risk appears low, anticoagulation is favored. If it is moderate or high, please sanity-check with a second, independent bleeding-risk tool to see whether the concern persists.\n\nIf both views indicate high risk—or if they disagree—synthesize an outcomes view projecting annual stroke, major bleeding, and overall mortality with and without anticoagulation to judge net clinical benefit rather than relying on a single metric. If there are reasons to choose warfarin over a DOAC (cost, kidney disease, drug interactions), add a warfarin-specific hemorrhage estimate and incorporate it into the net-benefit assessment.\n\nIf the outcomes view shows a favorable net benefit, proceed with anticoagulation and document risk-mitigation steps (tight blood pressure control, avoid unnecessary antiplatelets/NSAIDs, consider a PPI if gastrointestinal risk, address falls/anemia, and set a monitoring plan). If the outlook is unfavorable, discuss alternatives such as device-based stroke prevention while aggressively optimizing modifiable bleeding risks.\n\nSeparately, if the prior event was cryptogenic or a PFO on imaging appears relevant, provide a reasoned assessment of the likelihood that the PFO caused the neurologic event. If likely causal or definite, add PFO-focused management—potentially closure—alongside the AF plan; if unlikely, keep the focus on AF-related prevention.\n\nIf thromboembolic risk sits at the treatment threshold—or if sex weighting is the main reason for crossing it—cross-check stroke risk with a different validated schema to resolve the gray zone before committing.\n\nPlease walk through the reasoning step by step, with intermediate numbers at each stage—baseline stroke risk (with and without sex weighting if relevant), bleeding risk on therapy (from both perspectives), and projected outcomes with versus without anticoagulation—and make the final recommendation explicit. The analysis should use proper calculations and be defensible.", "required_calculators": ["CHA₂DS₂-VASc Score for Atrial Fibrillation Stroke Risk", "CHA₂DS₂-VA Score for Atrial Fibrillation Stroke Risk", "HAS-BLED Score for Major Bleeding Risk", "ORBIT Bleeding Risk Score for Atrial Fibrillation", "ATRIA Bleeding Risk Score", "GARFIELD-AF", "PFO-Associated Stroke Causal Likelihood (PASCAL) Classification System", "ATRIA Stroke Risk Score"], "calculator_answers": [{"order": 1, "name": "CHA₂DS₂-VASc Score for Atrial Fibrillation Stroke Risk", "inputs": [{"field": "Age", "value": "65-74", "score": 1}, {"field": "Sex", "value": "Female", "score": 1}, {"field": "CHF history", "value": "No", "score": 0}, {"field": "Hypertension history", "value": "Yes", "score": 1}, {"field": "Stroke/TIA/thromboembolism history", "value": "No", "score": 0}, {"field": "Vascular disease history (prior MI, peripheral artery disease, or aortic plaque)", "value": "No", "score": 0}, {"field": "Diabetes history", "value": "No", "score": 0}], "final_answer": 3, "notes": "Stroke risk was 3.2% per year in >90,000 patients (the Swedish Atrial Fibrillation Cohort Study) and 4.6% risk of stroke/TIA/systemic embolism."}, {"order": 2, "name": "CHA₂DS₂-VA Score for Atrial Fibrillation Stroke Risk", "inputs": [{"field": "Age", "value": "65-74", "score": 1}, {"field": "Chronic heart failure", "value": "No", "score": 0}, {"field": "Hypertension", "value": "Yes", "score": 1}, {"field": "Prior stroke, TIA, or arterial thromboembolism", "value": "No", "score": 0}, {"field": "Vascular disease", "value": "No", "score": 0}, {"field": "Diabetes mellitus", "value": "No", "score": 0}], "final_answer": 2, "notes": "Anticoagulation should be recommended\nIschemic stroke incidence rate: 2.9 per 100 patient years"}, {"order": 3, "name": "HAS-BLED Score for Major Bleeding Risk", "inputs": [{"field": "Hypertension (Uncontrolled, >160 mmHg systolic)", "value": "No", "score": 0}, {"field": "Renal disease (Dialysis, transplant, Cr >2.26 mg/dL)", "value": "No", "score": 0}, {"field": "Liver disease (Cirrhosis or bilirubin >2x normal with AST/ALT/AP >3x normal)", "value": "No", "score": 0}, {"field": "Stroke history", "value": "No", "score": 0}, {"field": "Prior major bleeding or predisposition to bleeding", "value": "No", "score": 0}, {"field": "Labile INR (TTR <60%)", "value": "No", "score": 0}, {"field": "Age >65", "value": "Yes", "score": 1}, {"field": "Medication usage predisposing to bleeding (Aspirin, clopidogrel, NSAIDs)", "value": "Yes", "score": 1}, {"field": "Alcohol use (≥8 drinks/week)", "value": "No", "score": 0}], "final_answer": 2, "notes": "Risk was 4.1% in one validation study (Lip 2011) and 1.88 bleeds per 100 patient-years in another validation study (Pisters 2010).\nAnticoagulation can be considered, however patient does have moderate risk for major bleeding (~2/100 patient-years)."}, {"order": 4, "name": "ORBIT Bleeding Risk Score for Atrial Fibrillation", "inputs": [{"field": "Sex", "value": "Female"}, {"field": "Hemoglobin <12 g/dL or hematocrit <36%", "value": "No", "score": 0}, {"field": "Age >74 years", "value": "No", "score": 0}, {"field": "Bleeding history (GI bleed, intracranial bleed, or hemorrhagic stroke)", "value": "No", "score": 0}, {"field": "GFR <60 mL/min/1.73 m2", "value": "Yes", "score": 1}, {"field": "Treatment with antiplatelet agents", "value": "No", "score": 0}], "final_answer": 1, "notes": "1 points\nORBIT Score\nLow risk\nRisk group\n2.4 bleeds\nPer 100 patient-years"}, {"order": 5, "name": "ATRIA Bleeding Risk Score", "inputs": [{"field": "Anemia (Hemoglobin <13 g/dL male, <12 g/dL female)", "value": "No", "score": 0}, {"field": "Severe Renal Disease (GFR <30 mL/min or dialysis-dependent)", "value": "No", "score": 0}, {"field": "Age ≥ 75 years", "value": "No(67 yeas)", "score": 0}, {"field": "Any Prior Hemorrhage Diagnosis", "value": "No", "score": 0}, {"field": "Hypertension History", "value": "Yes", "score": 1}], "final_answer": 1, "notes": "Low Risk (<4 Points), 0.76% Annual Risk of Hemorrhage. Reasonable to start warfarin."}, {"order": 6, "name": "GARFIELD-AF", "inputs": [{"field": "Sex", "value": "Female"}, {"field": "Age", "value": "67 years"}, {"field": "Weight", "value": "168 lb"}, {"field": "Heart failure", "value": "No"}, {"field": "Vascular disease", "value": "No"}, {"field": "Prior stroke", "value": "No"}, {"field": "History of bleeding", "value": "No"}, {"field": "Carotid occlusive disease", "value": "No"}, {"field": "Diabetes", "value": "No"}, {"field": "Moderate-to-severe CKD", "value": "Yes"}, {"field": "Dementia", "value": "No"}, {"field": "Current smoker", "value": "No"}, {"field": "Antiplatelet treatment", "value": "No"}, {"field": "Ethnicity", "value": "Caucasian"}, {"field": "Pulse", "value": "88 beats/min"}, {"field": "Diastolic blood pressure", "value": "86 mm Hg"}, {"field": "OAC treatment", "value": "NOAC"}], "final_answer": "6 months\nAll-cause mortality: 0.8%\nIschemic stroke/SE: 0.4%\nMajor bleeding: 0.6%", "notes": "6 months\nAll-cause mortality: 0.8%\nIschemic stroke/SE: 0.4%\nMajor bleeding: 0.6%\n1 year\nAll-cause mortality: 1.3%\nIschemic stroke/SE: 0.7%\nMajor bleeding: 1.1%\n2 years\nAll-cause mortality: 2.4%\nIschemic stroke/SE: 1.2%\nMajor bleeding: 1.7%"}, {"order": 7, "name": "PFO-Associated Stroke Causal Likelihood (PASCAL) Classification System", "inputs": [{"field": "RoPE Score ≥7", "value": "No"}, {"field": "High-risk PFO feature (Large shunt and/or atrial septal aneurysm)", "value": "No"}], "final_answer": "Unlikely", "notes": "PFO-attributable stroke likelihood"}, {"order": 8, "name": "ATRIA Stroke Risk Score", "inputs": [{"field": "History of stroke", "value": "No"}, {"field": "Age", "value": "65-74 years"}, {"field": "Female", "value": "Yes", "score": 1}, {"field": "History of diabetes mellitus", "value": "No", "score": 0}, {"field": "History of congestive heart failure", "value": "No", "score": 0}, {"field": "History of hypertension", "value": "Yes", "score": 1}, {"field": "Proteinuria", "value": "No", "score": 0}, {"field": "eGFR <45 or end-stage renal disease", "value": "No", "score": 0}], "final_answer": 5, "notes": "Low risk (0-5 Points), <1% annual risk of ischemic stroke."}]}
{"task_id": "medmcp-calc_017_610d6c4d", "task_scenario": "Pulmonary Embolism and Venous Thromboembolism Risk", "task_category": "Clinical Medicine / Medicine & Organ Systems / Respiratory & Thoracic Medicine", "patient_id": "P017_610d6c4d", "task_description": "Scenario: A hemodynamically stable adult presents with acute pleuritic chest pain and dyspnea. The clinical team must evaluate for pulmonary embolism (PE), minimize unnecessary imaging, stratify severity if PE is confirmed, determine outpatient vs inpatient management, assess bleeding risk on anticoagulation, and plan therapy duration after the initial treatment period.\n\nStep-by-step calculator use and clinical reasoning:\n1) Wells' Criteria for Pulmonary Embolism: Estimate pre-test probability of PE at presentation.\n   - If low pre-test probability, proceed to Step 2.\n   - If intermediate probability, skip PERC and go to Step 3.\n   - If high probability, bypass D-dimer and proceed directly to definitive imaging; if PE is confirmed, continue with Step 4.\n\n2) PERC Rule for Pulmonary Embolism (applies only when pre-test probability is low):\n   - If all PERC criteria are negative, PE is ruled out; no further PE testing is needed and the workflow ends.\n   - If any PERC criterion is positive, proceed to Step 3.\n\n3) Age-Adjusted D-dimer for Venous Thromboembolism (VTE): Interpret D-dimer using age-adjusted threshold to steward imaging in low/intermediate-risk patients.\n   - If age-adjusted D-dimer is negative, PE is ruled out; the workflow ends.\n   - If positive, obtain definitive imaging for PE; if PE is confirmed, continue with Step 4.\n\n4) Simplified PESI (Pulmonary Embolism Severity Index): For confirmed PE, estimate 30-day mortality risk to guide disposition and intensity of care.\n   - If low-risk by Simplified PESI, continue with Step 5 to further refine early decompensation risk and validate outpatient suitability.\n   - If higher-risk by Simplified PESI, admission is favored; still continue with Step 5 to refine short-term complications risk and management.\n\n5) Bova Score for Pulmonary Embolism Complications (for hemodynamically stable PE): Quantify 30-day risk of PE-related complications.\n   - Low Bova class supports early discharge considerations.\n   - Higher Bova class supports inpatient monitoring and possible escalation.\n\n6) Hestia Criteria for Outpatient Pulmonary Embolism Treatment: Determine if the confirmed PE can be managed safely as an outpatient.\n   - All Hestia criteria negative plus low-risk by Simplified PESI/Bova supports outpatient DOAC-based treatment.\n   - Any Hestia criterion positive or higher-risk PESI/Bova mandates inpatient care.\n\n7) VTE-BLEED Score: Assess bleeding risk while on anticoagulation.\n   - Low bleeding risk supports standard outpatient anticoagulation.\n   - High bleeding risk favors inpatient initiation, closer follow-up, consideration of regimen choice, and mitigation strategies.\n\n8) Long-term anticoagulation decisions after completion of initial therapy:\n   - If this was a first unprovoked VTE and the patient is a woman, use HERDOO2 Rule for Discontinuing Anticoagulation in Unprovoked VTE: a low-risk HERDOO2 result supports discontinuation; higher risk supports extended therapy.\n   - Otherwise (e.g., men or not meeting HERDOO2 criteria), use DASH Prediction Score for Recurrent VTE: lower scores support stopping anticoagulation; higher scores support extended anticoagulation.\n\nThroughout, outputs from each calculator determine the next step: Wells' low-risk triggers PERC; PERC positivity triggers age-adjusted D-dimer; D-dimer positivity triggers imaging; confirmed PE risk on Simplified PESI and Bova guides Hestia and disposition; VTE-BLEED informs intensity and monitoring of anticoagulation; on follow-up, HERDOO2 or DASH guides therapy duration.", "fuzzy_question": "I’m evaluating a hemodynamically stable patient with acute pleuritic chest pain and shortness of breath. Vitals are acceptable—no hypotension and oxygenation adequate but not ideal—and I’m balancing the goal of ruling out a clot without unnecessary imaging against the risk of missing a serious diagnosis.\n\nFirst, I want to estimate the likelihood of a clot based on history, exam, and initial tests. If pretest probability appears low and a bedside PE rule-out screen is completely reassuring, I’d stop there. If any item is positive, I’d obtain a D‑dimer and apply an age-adjusted threshold rather than a single cut-off. If it’s below the age-adjusted threshold, I’d defer further workup; if elevated, I’d proceed to definitive imaging.\n\nIf a pulmonary embolus is confirmed, I want to assess short-term mortality risk to guide site of care (home vs admission, routine vs closer monitoring). I’d then refine the risk of early complications in otherwise stable PE—such as near-term decompensation—using imaging findings (e.g., right heart strain), biomarkers, and vitals. Next, I’d apply a practical outpatient eligibility checklist: no need for supplemental oxygen or IV analgesia, no concerning comorbidities or social barriers, and no anticipated need for close inpatient monitoring. If the checklist is favorable and short-term risk is low, I’m comfortable with an outpatient DOAC plan; if not, admission for monitoring and possible escalation is more appropriate.\n\nIn parallel, I need to estimate bleeding risk on anticoagulation—considering age, renal function, anemia, prior bleeding, cancer or other comorbidities, and interacting medications. If bleeding risk is low, standard outpatient anticoagulation is appropriate. If higher, I’d begin under closer supervision, choose and dose therapy carefully, mitigate bleeding risks (GI protection, blood pressure control, avoiding interacting drugs), and arrange tighter follow-up.\n\nFor duration beyond the initial treatment period, I want a defensible plan. If this is a first unprovoked event in a woman, I’d use a sex-specific decision aid to identify those who can safely stop after the initial course versus those who should continue. Otherwise—for men or for anyone not fitting that scenario—I’d use a validated recurrence-risk approach to balance the likelihood of another clot against bleeding risk and recommend stopping versus extended therapy accordingly.\n\nPlease walk through the clinical reasoning: estimate current PE likelihood, assess the bedside rule-out screen, interpret an age-adjusted D‑dimer, decide when to image, and, if PE is present, grade short-term mortality risk, early complication risk, outpatient suitability, and bleeding risk. Then outline the initial anticoagulation plan and the strategy for duration after the first treatment period, specifying how recommendations differ for provoked versus unprovoked events and by sex. I need this supported by explicit, defensible calculations; it must withstand scrutiny.", "required_calculators": ["Wells' Criteria for Pulmonary Embolism", "PERC Rule for Pulmonary Embolism", "Age-Adjusted D-dimer for Venous Thromboembolism (VTE)", "Simplified PESI (Pulmonary Embolism Severity Index)", "Bova Score for Pulmonary Embolism Complications", "Hestia Criteria for Outpatient Pulmonary Embolism Treatment", "VTE-BLEED Score", "HERDOO2 Rule for Discontinuing Anticoagulation in Unprovoked VTE", "DASH Prediction Score for Recurrent VTE"], "calculator_answers": [{"order": 1, "name": "Wells' Criteria for Pulmonary Embolism", "inputs": [{"field": "Clinical signs and symptoms of DVT", "value": "No", "score": 0}, {"field": "PE is #1 diagnosis OR equally likely", "value": "No", "score": 0}, {"field": "Heart rate >100", "value": "No (98 bpm)", "score": 0}, {"field": "Immobilization at least 3 days OR surgery in the previous 4 weeks", "value": "No", "score": 0}, {"field": "Previous, objectively diagnosed PE or DVT", "value": "No", "score": 0}, {"field": "Hemoptysis", "value": "No", "score": 0}, {"field": "Malignancy w/ treatment within 6 months or palliative", "value": "No", "score": 0}], "final_answer": 0, "notes": "0.0 points\nLow risk group: 1.3% chance of PE in an ED population.\nAnother study assigned scores ≤4 as “PE Unlikely” and had a 3% incidence of PE."}, {"order": 2, "name": "PERC Rule for Pulmonary Embolism", "inputs": [{"field": "Age ≥50", "value": "Yes (56 years)", "score": 1}, {"field": "HR ≥100", "value": "No (98 bpm)", "score": 0}, {"field": "O2 sat on room air <95%", "value": "No (95% on RA)", "score": 0}, {"field": "Unilateral leg swelling", "value": "No", "score": 0}, {"field": "Hemoptysis", "value": "No", "score": 0}, {"field": "Recent surgery or trauma", "value": "No", "score": 0}, {"field": "Prior PE or DVT", "value": "No", "score": 0}, {"field": "Hormone use", "value": "No", "score": 0}], "final_answer": 1, "notes": "If any criteria are positive, the PERC rule cannot be used to rule out PE in this patient."}, {"order": 3, "name": "Age-Adjusted D-dimer for Venous Thromboembolism (VTE)", "inputs": [{"field": "Age", "value": "56 years"}, {"field": "D-dimer level reported by lab", "value": "680 ug/L"}, {"field": "D-dimer unit type", "value": "FEU"}], "final_answer": 560, "notes": "560 µg/L\nAge-adjusted D-dimer cutoff, FEU\nVTE possible\nReported D-dimer is greater than cutoff; consider confirmatory testing with CTA or V/Q scan"}, {"order": 4, "name": "Simplified PESI (Pulmonary Embolism Severity Index)", "inputs": [{"field": "Age, years", "value": "56", "score": 0}, {"field": "History of cancer", "value": "No", "score": 0}, {"field": "History of chronic cardiopulmonary disease", "value": "No", "score": 0}, {"field": "Heart rate, bpm", "value": "98", "score": 0}, {"field": "Systolic BP, mmHg", "value": "126", "score": 0}, {"field": "O2 saturation", "value": "95%", "score": 0}], "final_answer": "Low", "notes": "Low risk\n1.1% risk of death in the “Low” risk group (0 points), with 1.5% having recurrent thromboembolism or non-fatal bleeding"}, {"order": 5, "name": "Bova Score for Pulmonary Embolism Complications", "inputs": [{"field": "Systolic BP", "value": "126 mmHg", "score": 0}, {"field": "Elevated cardiac troponin", "value": "No (troponin I 0.01 ng/mL; lab ULN 0.04)", "score": 0}, {"field": "RV dysfunction", "value": "No (CT RV/LV ratio 0.9; no dilation/hypokinesis)", "score": 0}, {"field": "Heart rate, beats/min", "value": "98", "score": 0}], "final_answer": 0, "notes": "0 points\nBova Score\nStage I\nLow risk\n4.4 %\nPE-related complications (death from PE, hemodynamic collapse, or recurrent nonfatal PE) at 30 days\n3.1% PE-related mortality at 30 days"}, {"order": 6, "name": "Hestia Criteria for Outpatient Pulmonary Embolism Treatment", "inputs": [{"field": "Hemodynamically unstable", "value": "No", "score": 0}, {"field": "Thrombolysis or embolectomy needed", "value": "No", "score": 0}, {"field": "Active bleeding or high risk for bleeding", "value": "No", "score": 0}, {"field": ">24 hrs on supplemental oxygen required to maintain SaO2 >90%", "value": "No", "score": 0}, {"field": "PE diagnosed while on anticoagulation", "value": "No", "score": 0}, {"field": "Severe pain needing IV pain medication required >24 hr", "value": "No", "score": 0}, {"field": "Medical or social reason for admission >24 hr (infection, malignancy, no support system)", "value": "No", "score": 0}, {"field": "Creatinine clearance <30 mL/min by Cockcroft-Gault", "value": "No", "score": 0}, {"field": "Severe liver impairment", "value": "No", "score": 0}, {"field": "Pregnant", "value": "No", "score": 0}, {"field": "Documented history of heparin-induced thrombocytopenia (HIT)", "value": "No", "score": 0}], "final_answer": 0, "notes": "Low risk\nPatient eligible for outpatient treatment (0% mortality, 2% VTE recurrence)."}, {"order": 7, "name": "VTE-BLEED Score", "inputs": [{"field": "Age ≥60 years", "value": "No (56 years)", "score": 0}, {"field": "Active cancer", "value": "No", "score": 0}, {"field": "Male patient with uncontrolled hypertension", "value": "No", "score": 0}, {"field": "Anemia", "value": "No (Hgb 13.0 g/dL)", "score": 0}, {"field": "History of bleeding", "value": "No", "score": 0}, {"field": "Renal dysfunction (creatinine clearance 30-60 mL/min)", "value": "No (CrCl ~88 mL/min)", "score": 0}], "final_answer": 0, "notes": "Low Bleeding risk"}, {"order": 8, "name": "HERDOO2 Rule for Discontinuing Anticoagulation in Unprovoked VTE", "inputs": [{"field": "Post-thrombotic signs", "value": "No", "score": 0}, {"field": "D-dimer level", "value": "230 ug/L FEU (measured at 5 months while on anticoagulation)", "score": 0}, {"field": "BMI, kg/m²", "value": "29.0", "score": 0}, {"field": "Age, years", "value": "56", "score": 0}], "final_answer": 0, "notes": "0 points\nHERDOO2 Score\n3.0 %\nRisk of recurrent major VTE per 100 patient years\nLow risk\nCan safely discontinue oral anticoagulation"}, {"order": 9, "name": "DASH Prediction Score for Recurrent VTE", "inputs": [{"field": "D-dimer abnormal", "value": "No (380 ug/L FEU at ~1 month after stopping; lab cutoff 500 FEU)", "score": 0}, {"field": "Age ≤50 years", "value": "No (56 years)", "score": 0}, {"field": "Male patient", "value": "No (female)", "score": 0}, {"field": "Hormone use at VTE onset (if female)", "value": "No", "score": 0}], "final_answer": 0, "notes": "2.4% annual risk of VTE recurrence.\nConsider discontinuing anticoagulation."}]}
{"task_id": "medmcp-calc_018_3aaad8b4", "task_scenario": "Diabetes and Insulin Management", "task_category": "Clinical Medicine / Medicine & Organ Systems / Endocrinology & Metabolism", "patient_id": "P018_3aaad8b4", "task_description": "Scenario: An adult living with type 2 diabetes has suboptimal glycemic control on basal insulin plus oral agents, intermittent hypoglycemia symptoms, and established cardiovascular risk factors. The clinical objective is to individualize glycemic targets, determine whether to adjust basal insulin or add prandial therapy, select cardioprotective medications when appropriate, and set safe monitoring and activity plans that minimize hypoglycemia. Workflow steps: 1) Use Individualizing Your Patient's A1c Target to set a patient-specific A1c goal based on age, comorbidities, hypoglycemia vulnerability, and life expectancy. This establishes the therapeutic target for subsequent decisions. 2) Apply Estimated Average Glucose (eAG) From HbA1C to translate the current A1c into an average glucose value. Decision trigger: if the eAG meaningfully exceeds the individualized target range, proceed to intensification steps; if the eAG is close to target, prioritize safety and maintenance rather than aggressive changes. 3) Calculate the BeAM Value (bedtime minus morning fasting glucose) to identify glycemic patterns. Branch: if BeAM is markedly positive (suggesting postprandial hyperglycemia), prioritize prandial interventions; if BeAM is negative or low (suggesting nocturnal lows or excess basal), favor reducing or retiming basal insulin versus adding bolus. 4) Use the Hypoglycemia Risk Score to quantify 12‑month hypoglycemia risk. Branch: if risk is high, revise or confirm a more conservative A1c target and prefer therapies with low hypoglycemia potential; if risk is low, more aggressive intensification (including prandial insulin) can be considered. The risk score also determines monitoring intensity later. 5) Assess endogenous insulin reserve via the C-Peptide to Glucose Ratio. Branch: if low (reduced beta-cell function), a basal‑bolus insulin strategy is more appropriate; if preserved, consider non‑insulin agents to address postprandial or overall hyperglycemia. 6) Estimate the 10‑year cardiovascular risk with Systematic Coronary Risk Evaluation 2‑Diabetes (SCORE2‑Diabetes). Branch: if risk is high, prioritize agents with cardiovascular benefit (e.g., GLP‑1 RA or SGLT2 inhibitor) and plan vascular protective therapy; if risk is lower, focus on glycemic efficacy and safety. 7) Use Pharmacotherapy for Type 2 Diabetes (2020 update to the Diabetes Canada guidelines) to integrate the above outputs—individualized A1c target and eAG (need for intensification), BeAM (basal vs prandial focus), Hypoglycemia Risk Score (safety), C‑peptide ratio (insulin vs non‑insulin), and SCORE2‑Diabetes (CV benefit)—into a concrete regimen: adjust basal dosing/timing, add prandial insulin or select GLP‑1 RA/SGLT2, and deprescribe agents increasing hypoglycemia risk when appropriate. 8) Apply Reducing Vascular Risk in Patients Living with Diabetes to determine statin, ACEi/ARB, and other vascular protective therapies, guided by the SCORE2‑Diabetes output and current glycemic status. 9) Determine Self‑Monitoring Blood Glucose (SMBG) frequency based on the chosen regimen and hypoglycemia risk. Branch: if prandial insulin is initiated or hypoglycemia risk is high, increase pre‑ and post‑meal checks and overnight testing; if using low‑risk non‑insulin agents and risk is low, set a less intensive schedule. 10) Use the Physical Activity Decision Tool for Patients Living with Diabetes to tailor a safe, practical exercise plan aligned with functional capacity and motivation. Branch: if on insulin or sulfonylureas, integrate SMBG timing and hypoglycemia mitigation strategies around activity; if on low‑risk regimens, progress intensity as tolerated. The sequence ensures that target setting and pattern analysis drive pharmacotherapy choices, which then inform vascular protection, monitoring intensity, and lifestyle planning.", "fuzzy_question": "I'm seeing an adult with type 2 diabetes who is on basal insulin plus oral agents. Glycemic control has been suboptimal in recent visits, and there are intermittent symptoms suggestive of hypoglycemia. The patient also has cardiovascular risk factors. I’m trying to figure out the safest and most effective way forward.\n\nFirst, before changing anything, I want to set a personalized A1c goal that fits the situation—considering overall health status, comorbidities, hypoglycemia vulnerability, and life expectancy. Once we have that target, help me interpret the current A1c in practical terms by translating it to estimated average glucose. If the average is clearly above where we’re aiming, we’ll need to intensify; if it’s close to the goal, we should favor safety and maintenance rather than pushing harder.\n\nNext, I want to look closely at patterns. There are bedtime and next-morning fasting readings from home. Can we compare those in a structured way? If bedtime is substantially higher than the morning, that suggests post-meal spikes are the main issue and we may need to focus on mealtime control. If the gap is small or flips the other way—suggesting overnight dips or too much basal—then I’d rather scale back or retime basal insulin instead of jumping straight to bolus doses.\n\nGiven the reported lows, I also want a formal estimate of annual hypoglycemia risk. If that risk is high, I’m inclined to confirm a more conservative A1c goal and prioritize options that don’t drive hypoglycemia. If it’s low, we can be more assertive, including considering prandial insulin if patterns warrant. This risk estimate should also guide how intensively we monitor sugars going forward.\n\nI’d like to understand endogenous insulin reserve. Can we use paired C-peptide with concurrent glucose to judge beta-cell function? If the reserve looks poor, a basal-bolus approach may be the right path. If it’s reasonably preserved, I’d favor non-insulin add-ons to tackle postprandial or overall hyperglycemia.\n\nOn the cardiovascular side, please give me a standardized long-term risk estimate appropriate for someone with diabetes. If they land in a higher-risk bucket, I want to prioritize agents with proven cardiovascular benefit (thinking GLP-1 receptor agonist or SGLT2 inhibitor) and make sure we’re on top of vascular protection. If risk is lower, we can focus more on glycemic efficacy and safety.\n\nPull all of this together into a concrete plan: should we adjust basal dose or timing, or pivot to adding mealtime coverage? If non-insulin is reasonable, which agent would you choose and why (especially with cardiovascular benefit in mind)? If we add prandial insulin, suggest practical starting doses and a titration approach. Also, if there are drugs on board that increase hypoglycemia risk without clear benefit, don’t hesitate to suggest deprescribing.\n\nPlease also address vascular prevention explicitly—confirm statin intensity, whether an ACE inhibitor or ARB is indicated, and any other vascular protective steps that fit the risk profile.\n\nBased on the final regimen and hypoglycemia risk, set a sensible home glucose monitoring schedule. If we go with prandial insulin or the risk of lows is high, I’d expect more frequent pre- and post-meal checks and some overnight checks until stable; if we’re using low-risk non-insulin options and risk is low, a lighter schedule is fine.\n\nLastly, propose a practical physical activity plan that accounts for current fitness and motivation. If the patient is on insulin or a sulfonylurea, build in glucose checks around exercise and strategies to avoid lows; if on lower-risk meds, we can progress the intensity more confidently.\n\nWhat’s your take on this? I’m torn between dialing back basal and adding prandial coverage versus introducing a GLP-1 RA or SGLT2 inhibitor given the cardiovascular profile. I really need proper calculations on this—can’t make this decision based on gut feeling alone. Whatever approach you suggest, make sure it’s backed by solid calculations. This needs to hold up to scrutiny.", "required_calculators": ["Individualizing Your Patient's A1c Target", "Estimated Average Glucose (eAG) From HbA1C", "BeAM Value", "Hypoglycemia Risk Score", "C-Peptide to Glucose Ratio", "Systematic Coronary Risk Evaluation 2-Diabetes (SCORE2-Diabetes)", "Pharmacotherapy for Type 2 Diabetes (2020 update to the Diabetes Canada guidelines)", "Reducing Vascular Risk in Patients Living with Diabetes", "Self-Monitoring Blood Glucose (SMBG)", "Physical Activity Decision Tool for Patients Living with Diabetes"], "calculator_answers": [{"order": 1, "name": "Individualizing Your Patient's A1c Target", "inputs": [{"field": "Age?", "value": "56 years"}, {"field": "Diabetes Type?", "value": "Type 2"}, {"field": "Gender?", "value": "Male"}, {"field": "Pregnant or Desiring Pregnancy?", "value": "No"}, {"field": "Level of Function?", "value": "Independent (no frailty)"}, {"field": "Current Therapy?", "value": "Basal insulin + metformin + sulfonylurea"}, {"field": "Recurrent Episodes of Severe Hypoglycemia or Hypoglycemic Unawareness?", "value": "No"}], "final_answer": "≤7.0%", "notes": "Patient specific A1c target recommendation\n≤7.0%"}, {"order": 2, "name": "Estimated Average Glucose (eAG) From HbA1C", "inputs": [{"field": "Hemoglobin A1C", "value": "8.2 %"}], "final_answer": 188.6, "notes": "188.6 mg/dL\nEquivalent to 10.5 mmol/L\nThis formula was calculated using a linear regression equation model, and did not change significantly by subgroup of age, sex, diabetes type, race/ethnicity, or smoking status."}, {"order": 3, "name": "BeAM Value", "inputs": [{"field": "Bedtime blood glucose", "value": "210 mg/dL"}, {"field": "Pre breakfast (AM) blood glucose", "value": "130 mg/dL"}], "final_answer": 80.0, "notes": "80.00 mg/dL\nHigh BeAM value"}, {"order": 4, "name": "Hypoglycemia Risk Score", "inputs": [{"field": "History of ED or hospital admission due to hypoglycemia", "value": "0"}, {"field": "ED visits, last 12 months", "value": "<2"}, {"field": "Insulin use", "value": "Yes"}, {"field": "Sulfonylurea use", "value": "Yes"}, {"field": "Severe or end-stage kidney disease\neGFR ≤29 by CKD-EPI Creatinine", "value": "No"}, {"field": "Age", "value": "<77 years"}], "final_answer": "Low", "notes": "Low risk\n<1% risk of hypoglycemia admission in 12 months"}, {"order": 5, "name": "C-Peptide to Glucose Ratio", "inputs": [{"field": "Serum C-peptide", "value": "5.8 ng/mL"}, {"field": "Plasma glucose", "value": "110 mg/dL"}], "final_answer": 5.3, "notes": "5.3\nC-peptide to glucose ratio\nPreserved\nEndogenous insulin secretory capacity"}, {"order": 6, "name": "Systematic Coronary Risk Evaluation 2-Diabetes (SCORE2-Diabetes)", "inputs": [{"field": "Sex", "value": "Male"}, {"field": "Age", "value": "56 years"}, {"field": "Smoking", "value": "Current"}, {"field": "SBP", "value": "138 mm Hg"}, {"field": "Diabetes", "value": "Yes"}, {"field": "Total cholesterol", "value": "198 mg/dL"}, {"field": "HDL cholesterol", "value": "42 mg/dL"}, {"field": "Age at diabetes diagnosis", "value": "44 years"}, {"field": "HbA1c", "value": "66 mmol/mol"}, {"field": "eGFR", "value": "68 mL/min/1.73 m²"}, {"field": "Risk region", "value": "High"}], "final_answer": "25.7 %", "notes": "25.7 %\n10-year risk of CVD"}, {"order": 7, "name": "Pharmacotherapy for Type 2 Diabetes (2020 update to the Diabetes Canada guidelines)", "inputs": [{"field": "Age?", "value": "56 years"}, {"field": "eGFR?", "value": "68 mL/min/1.73 m²"}, {"field": "Atherosclerotic cardiovascular disease (ASCVD)?", "value": "No"}, {"field": "History of heart failure (or ejection fraction <40)?", "value": "No"}], "final_answer": "basal insulin + metformin + sulfonylurea", "notes": "Currently on basal insulin + metformin + sulfonylurea."}, {"order": 8, "name": "Reducing Vascular Risk in Patients Living with Diabetes", "inputs": [{"field": "Cardiovascular Disease?", "value": "No"}, {"field": "Microvascular Disease?", "value": "Yes (albuminuria; urine ACR 45 mg/g)"}, {"field": "Diabetes Type?", "value": "Type 2"}, {"field": "Diabetes Duration >15 Years?", "value": "No (12 years)"}, {"field": "A1c Above Target (>7.0%)?", "value": "Yes (8.2%)"}, {"field": "Age?", "value": "56 years"}, {"field": "Does the Patient Have at Least One of These Risk Factors?", "value": "Yes (current smoker; hypertension; dyslipidemia; albuminuria)"}], "final_answer": "Statin Recommended\nYes\nACEi/ARB Recommended\nYes\nASA Recommended\nNot routinely recommended\nLiraglutide, Empagliflozin or Canagliflozin Recommended\nNo", "notes": "Statin Recommended\nYes\nRecommended even if the baseline blood pressure or LDL-C is at target. Dose adjustments or additional lipid therapy warranted if lipid target (LDL-C <2.0 mmol/L) not being met.\nCautions: Potentially embryopathic – discontinue prior to conception. Try to achieve targets in Canadian Cardiovascular Society guidelines, prescribe up to maximally tolerated and approved dose.\nACEi/ARB Recommended\nYes\nPrescribe at doses with demonstrated vascular protection [eg. perindopril 8 mg once daily (EUROPA trial), ramipril 10 mg once daily (HOPE trial), telmisartan 80 mg once daily (ONTARGET trial)].\nCautions: Potentially embryopathic – discontinue prior to conception (used to treat hypertension) or upon detection of pregnancy (used to treat CKD). Caution if hypotensive.\nASA Recommended\nNot routinely recommended\nLiraglutide, Empagliflozin or Canagliflozin Recommended\nNo"}, {"order": 9, "name": "Self-Monitoring Blood Glucose (SMBG)", "inputs": [{"field": "Diabetes Type?", "value": "Type 2"}, {"field": "Cardiovascular Disease?", "value": "No"}, {"field": "Recent Diabetes Diagnosis (<6 Months)?", "value": "No"}, {"field": "A1c Typically At Target (≤7.0%)?", "value": "No"}, {"field": "Treatment?", "value": "Basal insulin + sulfonylurea + metformin"}, {"field": "Is Patient Sick Or Starting A Steroid Drug?", "value": "No"}], "final_answer": "SMBG Frequency Recommendation\nRoutine SMBG is not recommended\nSMBG Pattern Recommendation\nThere is no SMBG pattern recommendation for prediabetes", "notes": "SMBG Frequency Recommendation\nRoutine SMBG is not recommended\nSMBG Pattern Recommendation\nThere is no SMBG pattern recommendation for prediabetes"}, {"order": 10, "name": "Physical Activity Decision Tool for Patients Living with Diabetes", "inputs": [{"field": "Does Your Patient Currently Have Symptoms of Angina That Would Limit Participation in Physical Activity?", "value": "No"}, {"field": "Diabetes Type?", "value": "Type 2"}, {"field": "Days/Week Of Moderate To Vigorous Intensity Activity?", "value": "2 days/week"}, {"field": "Minutes/Day Of Moderate To Vigorous Intensity Activity?", "value": "25 minutes/day"}, {"field": "Days/Week of Resistance Training?", "value": "0 days/week"}], "final_answer": "Advise patient of benefits of reducing sedentary behaviour for diabetes management.\nWork with patient to set an MVPA goal. If available, make referral to specific program, facility or qualified exercise professional to assist with their exercise prescription.\nResistance training needed\nAdvise patient of benefits of resistance activities for diabetes management and recommend the brochure:\nIntroductory Resistance Program\nConsult with patient\nAcknowledge barriers, identify potential sources of motivation and recommend the brochure:\nBenefits of Physical Activity.", "notes": "Advise patient of benefits of reducing sedentary behaviour for diabetes management.\nWork with patient to set an MVPA goal. If available, make referral to specific program, facility or qualified exercise professional to assist with their exercise prescription.\nResistance training needed\nAdvise patient of benefits of resistance activities for diabetes management and recommend the brochure:\nIntroductory Resistance Program\nConsult with patient\nAcknowledge barriers, identify potential sources of motivation and recommend the brochure:\nBenefits of Physical Activity."}]}
{"task_id": "medmcp-calc_019_87b15038", "task_scenario": "Acute Pancreatitis Severity", "task_category": "Clinical Medicine / Medicine & Organ Systems / Gastroenterology & Hepatology", "patient_id": "P019_87b15038", "task_description": "Clinical scenario: A patient presents with a first episode of acute pancreatitis. The clinical team must rapidly determine severity, appropriate level of care (ward versus intensive care), monitoring frequency, and whether to obtain contrast-enhanced CT to identify necrosis or complications. Stepwise calculator use: 1) Use the Harmless Acute Pancreatitis Score (HAPS) at presentation to identify a truly low-risk course. If HAPS indicates harmless and the patient is clinically stable with improving symptoms, continue standard supportive care and routine monitoring without immediate escalation to other severity calculators. If HAPS is not harmless or there is diagnostic/clinical uncertainty, proceed to the next step. 2) Apply the BISAP Score for Pancreatitis Mortality during the first 24 hours to estimate short-term mortality risk and guide level-of-care decisions. If BISAP is high risk, this triggers immediate organ failure assessment (next step). If BISAP is low risk but there are persistent concerns (e.g., systemic inflammation, pain not improving), proceed to NLR to refine risk. 3) Calculate the Neutrophil-Lymphocyte Ratio (NLR) as an adjunctive early inflammatory risk marker. If NLR is elevated or rising despite low BISAP, escalate monitoring and proceed to organ failure assessment with the Modified Marshall Score. If NLR is low and clinical trajectory is favorable, continue ward care and plan routine reassessment at 48 hours. 4) Use the Modified Marshall Score to define organ failure when prompted by high BISAP, elevated NLR, or any clinical deterioration. If organ failure is present or developing, escalate to higher-level care and plan for interval imaging; if no organ failure, continue close monitoring. 5) At 48 hours (or earlier if clinically warranted), complete Ranson's Criteria for Pancreatitis Mortality (initial elements at admission and full assessment at 48 hours). If Ranson's indicates severe disease, escalate level of care and plan for contrast-enhanced CT. 6) Also at approximately 48 hours, compute the Glasgow-Imrie Criteria for Severity of Acute Pancreatitis. If Glasgow-Imrie indicates severe disease, this similarly triggers escalation and supports the need for imaging. 7) Obtain contrast-enhanced CT and calculate the CT Severity Index (Pancreatitis) only if any of the following are present: organ failure by Modified Marshall, severe disease by Ranson's or Glasgow-Imrie, or persistent/worsening clinical course. Use the CT Severity Index to quantify morphological severity, anticipate complications, and guide the intensity of monitoring and need for invasive or step-up interventions. Branching logic summary: If HAPS is harmless and the patient improves, subsequent calculators may be deferred with continued observation; otherwise, BISAP guides early risk. High BISAP or elevated NLR triggers Modified Marshall organ failure assessment. Severe status by Ranson's or Glasgow-Imrie, or organ failure by Modified Marshall, triggers imaging and CT Severity Index. If none indicate severe disease and clinical status improves, avoid early CT and continue supportive management.", "fuzzy_question": "I’m reviewing a patient with acute pancreatitis and trying to determine illness severity and the appropriate level of care. On arrival, I want to verify whether this appears truly mild—stable vitals, a benign abdominal exam, and early labs without signs of hemoconcentration or kidney stress. If the bedside picture is reassuring and symptoms improve with fluids and analgesia, I’m comfortable with ward care and routine monitoring. If anything is atypical—uncertain diagnosis, concerning exam, or labs that don’t align with an uncomplicated mild course—I want an early risk assessment to guide disposition. If that early read suggests higher risk, I’d move directly to a structured evaluation for evolving organ failure. If it looks lower risk but clinical inflammation remains evident (fever, persistent tachycardia, pain not settling), I’d examine the neutrophil‑to‑lymphocyte pattern; if that signal is elevated or rising despite an initial low‑risk impression, I’d tighten monitoring and proceed with the organ failure assessment anyway. If the inflammatory signal stays low and the trajectory is favorable, we can continue ward care and plan a deliberate reassessment at a defined interval.\n\nFor the organ failure review, I’m thinking pragmatically across lungs, kidneys, and circulation—evidence of hypoxemia, renal dysfunction, or hemodynamic instability meeting organ failure criteria. If present, I’d escalate to a higher level of care with more frequent vitals, urine output tracking, and lab checks, and begin planning for interval imaging. If not, we continue close observation and supportive therapy. At the planned reassessment time point, I want a more complete severity review: revisiting admission features alongside follow‑up labs, plus a complementary check that leans on lab thresholds and clinical context. If either indicates a severe course, I’d escalate care and obtain contrast‑enhanced CT to assess for necrosis or local complications.\n\nIf imaging is performed, I’d like a structured CT interpretation that translates findings into a severity grade—extent of necrosis and peripancreatic inflammation or collections—to anticipate complications, set monitoring intensity, and consider step‑up interventions if needed. If no red flags emerge and the patient is steadily improving, I’d avoid early CT and continue supportive care with routine reassessment.\n\nWhat’s your take? I need evidence‑based risk stratification with clear calculations and explicit intermediate steps—this decision shouldn’t rely on clinical intuition alone.", "required_calculators": ["Harmless Acute Pancreatitis Score (HAPS)", "BISAP Score for Pancreatitis Mortality", "Neutrophil-Lymphocyte Ratio (NLR) Calculator", "Modified Marshall Score", "Ranson's Criteria for Pancreatitis Mortality", "Glasgow-Imrie Criteria for Severity of Acute Pancreatitis", "CT Severity Index (Pancreatitis)"], "calculator_answers": [{"order": 1, "name": "Harmless Acute Pancreatitis Score (HAPS)", "inputs": [{"field": "sex", "value": "male"}, {"field": "peritonitis (rebound tenderness/guarding)", "value": "absent", "score": 0}, {"field": "serum_creatinine", "value": "1.1 mg/dL", "score": 0}, {"field": "hematocrit", "value": "42 %", "score": 0}], "final_answer": 0, "notes": "0 points\nNon-severe pancreatitis.\nA score of 0 suggests no pancreatic necrosis, need for dialysis, artificial ventilation, or fatal outcome."}, {"order": 2, "name": "BISAP Score for Pancreatitis Mortality", "inputs": [{"field": "age", "value": "48 years", "score": 0}, {"field": "BUN", "value": "19 mg/dL", "score": 0}, {"field": "impaired_mental_status", "value": "no (alert and oriented x3)", "score": 0}, {"field": "SIRS_criteria_met_≥2", "value": "yes", "score": 1}, {"field": "temperature", "value": "38.3 °C"}, {"field": "heart_rate", "value": "102 bpm"}, {"field": "respiratory_rate", "value": "20 /min"}, {"field": "WBC", "value": "13.2 x10^3/μL"}, {"field": "pleural_effusion_present", "value": "no (CXR without effusion)", "score": 0}], "final_answer": 1, "notes": "1 points\nPatients with a BISAP Score >0 had an increasing risk of mortality, with mortality increasing significantly with a score of 3 or greater. A score of 5 had a mortality rate of 22%."}, {"order": 3, "name": "Neutrophil-Lymphocyte Ratio (NLR) Calculator", "inputs": [{"field": "absolute_neutrophil_count", "value": "9.4 x10^3/μL"}, {"field": "absolute_lymphocyte_count", "value": "2.0 x10^3/μL"}], "final_answer": 5, "notes": "Neutrophil-Lymphocyte Ratio"}, {"order": 4, "name": "Modified Marshall Score", "inputs": [{"field": "PaO2", "value": "89 mmHg"}, {"field": "FiO2", "value": "0.21 (room air, 21%)"}, {"field": "serum_creatinine", "value": "1.1 mg/dL"}, {"field": "systolic_blood_pressure", "value": "118 mmHg"}, {"field": "vasopressors_in_use", "value": "no"}], "final_answer": 0, "notes": "Modified Marshall Score\n0\nOrgan Failure Present?\nNo, as defined by 1 or more organ systems with 2 points"}, {"order": 5, "name": "Ranson's Criteria for Pancreatitis Mortality", "inputs": [{"field": "on_admission_age", "value": "48 years", "score": 0}, {"field": "on_admission_WBC", "value": "13.2 x10^3/μL", "score": 0}, {"field": "on_admission_glucose", "value": "142 mg/dL", "score": 0}, {"field": "on_admission_AST", "value": "68 U/L", "score": 0}, {"field": "on_admission_LDH", "value": "280 IU/L", "score": 0}, {"field": "admission_hematocrit", "value": "42 %"}, {"field": "48h_hematocrit", "value": "38 %"}, {"field": "Hct drop >10% from admission", "value": "No", "score": 0}, {"field": "admission_BUN", "value": "19 mg/dL"}, {"field": "48h_BUN", "value": "22 mg/dL"}, {"field": "BUN increase >5 mg/dL (>1.79 mmol/L) from admission", "value": "No", "score": 0}, {"field": "48h_calcium", "value": "8.6 mg/dL", "score": 0}, {"field": "48h_arterial_pO2", "value": "88 mmHg", "score": 0}, {"field": "48h_serum_bicarbonate (HCO3)", "value": "22 mEq/L"}, {"field": "base_deficit (24 - HCO3)", "value": "2", "score": 0}, {"field": "fluid_needs_first_48h", "value": "4.5 liters", "score": 0}], "final_answer": 0, "notes": "0 points\nRanson's Criteria (On Admission)\nSevere pancreatitis unlikely.\n0 points\nRanson's Criteria (Cumulative)\n1% predicted mortality."}, {"order": 6, "name": "Glasgow-Imrie Criteria for Severity of Acute Pancreatitis", "inputs": [{"field": "age", "value": "48 years", "score": 0}, {"field": "48h_PaO2", "value": "88 mmHg", "score": 0}, {"field": "48h_WBC", "value": "12.4 x10^3/μL", "score": 0}, {"field": "48h_calcium", "value": "8.6 mg/dL", "score": 0}, {"field": "48h_BUN (serum urea equivalent)", "value": "22 mg/dL", "score": 0}, {"field": "48h_LDH", "value": "280 IU/L", "score": 0}, {"field": "48h_albumin", "value": "3.6 g/dL", "score": 0}, {"field": "48h_glucose", "value": "138 mg/dL", "score": 0}], "final_answer": 0, "notes": "Low risk for severe pancreatitis."}, {"order": 7, "name": "CT Severity Index (Pancreatitis)", "inputs": [{"field": "CT_timing", "value": "day 3 from symptom onset (contrast-enhanced)"}, {"field": "Balthazar_grade_of_acute_pancreatitis", "value": "C (intrinsic pancreatic abnormalities with peripancreatic fat inflammation)"}, {"field": "degree_of_pancreatic_necrosis", "value": "0% (none)"}], "final_answer": 2, "notes": "CT Severity Index\n2\nEstimated Mortality Rate\n3 %\nEstimated Rate of Complications\n8 %"}]}
{"task_id": "medmcp-calc_020_53b7e451", "task_scenario": "Chest Pain & Acute Coronary Syndromes", "task_category": "Clinical Medicine / Emergency, Critical Care & Perioperative / Emergency Medicine & Trauma", "patient_id": "P020_53b7e451", "task_description": "Scenario: An emergency department patient presents with acute chest pain and indeterminate initial electrocardiogram findings. The clinical team must rapidly triage between safe early discharge and urgent reperfusion, while planning appropriate site-of-care and procedural risk mitigation.\nStep-by-step workflow:\n1) Begin with National Early Warning Score (NEWS) to gauge overall physiologic acuity and identify immediate resuscitation needs.\n2) If NEWS indicates moderate/high acuity, quantify hemodynamic instability using Shock Index and Mean Arterial Pressure (MAP). If Shock Index is elevated or MAP is low, bypass early-discharge steps and proceed directly to electrocardiographic MI evaluation (Step 5). If hemodynamics are stable, continue with risk stratification (Step 3).\n3) Apply HEART Pathway for Early Discharge in Acute Chest Pain to stratify short-term risk using clinical features, electrocardiographic assessment, and cardiac biomarkers. If the HEART Pathway identifies low-risk early discharge, go to Step 4. If not low risk, go to Step 5.\n4) Use Vancouver Chest Pain Rule to validate the safety of ED discharge among those flagged low risk by the HEART Pathway. If criteria are met, arrange expedited outpatient follow-up. If discharge criteria are not met, return to Step 5 for MI-focused evaluation.\n5) Determine the appropriate MI diagnostic tool based on the electrocardiogram:\n   - If left bundle branch block is present, use Modified Sgarbossa's Criteria for MI in Left Bundle Branch Block.\n   - If the anterior leads have subtle ST-elevation patterns without clear diagnostic criteria, use Subtle Anterior STEMI Calculator (4-Variable) to distinguish anterior STEMI from normal variants.\n6) Branch based on MI determination from Step 5:\n   - If STEMI is diagnosed: proceed to Step 7.\n   - If STEMI is not diagnosed but ACS remains likely (e.g., NSTEMI/UA), proceed to Step 8.\n7) For confirmed STEMI, use TIMI Risk Score for STEMI to estimate early mortality risk and guide urgency and intensity of therapy. Before urgent catheterization, apply Mehran Score for Post-PCI Contrast Nephropathy to forecast contrast-associated renal risk and plan prophylaxis and peri-procedural strategies.\n8) For suspected NSTEMI or unstable angina, use ACTION ICU Score for Intensive Care in NSTEMI to determine the need for ICU-level care versus monitored floor/telemetry.\nDeterministic triggers linking steps:\n- NEWS result dictates whether hemodynamic calculators (Shock Index, MAP) are required and whether early-discharge pathways are bypassed.\n- HEART Pathway output determines whether the Vancouver Chest Pain Rule is applied or whether the workflow advances to MI-focused EKG analysis.\n- EKG-based MI determination (Modified Sgarbossa or Subtle Anterior STEMI output) selects downstream risk tools: TIMI STEMI plus Mehran (STEMI branch) versus ACTION ICU Score (NSTEMI branch).", "fuzzy_question": "I’m evaluating a case in the emergency setting with acute chest pain and an initial EKG that isn’t clearly diagnostic. I’m weighing a safe early discharge versus moving quickly toward reperfusion, and I also need to determine the appropriate level of care if admission is needed and how to minimize procedure-related risks if we proceed to the lab.\n\nBefore focusing on the coronary question, I want an objective read on overall physiologic status from the current vital signs to catch any early deterioration or need for immediate resuscitation. If that snapshot suggests moderate-to-high acuity, I’d quantify circulatory stability—specifically, how heart rate relates to systolic pressure and whether average perfusion pressure appears adequate. If those elements are worrisome, I’d set aside early-discharge considerations and go straight to an infarct-focused EKG analysis.\n\nIf hemodynamics look steady, I’d shift to short-term chest pain risk using the history, risk factors, exam, the available EKG, and properly timed serial high-sensitivity troponins to determine whether the low-risk category for early discharge is appropriate. If they fit that, I still want a second safety check tailored to ED chest pain discharge to avoid missing someone who needs observation. If they don’t, I’d pivot back to an MI-centered evaluation.\n\nOn the MI-focused side, interpretation of the tracing matters. If there’s left bundle branch block, I need criteria tailored to that pattern to determine whether repolarization abnormalities are masking an occlusion. If there isn’t bundle branch block but the anterior leads show subtle, borderline ST changes that can resemble early repolarization, I’d rely on a nuanced comparison of ST segments to surrounding QRS and T-wave features to distinguish a true anterior occlusion from a normal variant.\n\nFrom there, if this proves to be STEMI, I want a quick estimate of early mortality risk to guide urgency and aggressiveness, and before heading to the cath lab I want to forecast the chance of contrast-associated kidney injury so we can plan fluids, adjust nephrotoxic medications, and limit contrast. If it’s not STEMI but still points to ACS—likely NSTEMI or unstable angina—then I’d base ICU versus a monitored floor/telemetry on an objective bedside assessment of the likelihood of clinical instability.\n\nTo be clear about the logic: the initial acuity check determines whether to fast-track to an infarct-focused EKG analysis; the early chest pain risk assessment determines whether rapid discharge is even on the table or whether we should circle back to MI evaluation; and the EKG conclusion then splits the downstream plan into either urgent reperfusion with renal-risk planning or a non–ST-elevation pathway with a level-of-care decision. Please walk through this step by step using the current vital signs, exam findings, EKG features, and serial troponins, and show the reasoning at each fork. I need explicit, calculation-based support—this can’t rest on clinical intuition alone and needs to hold up to scrutiny.", "required_calculators": ["National Early Warning Score (NEWS)", "Shock Index", "Mean Arterial Pressure (MAP)", "HEART Pathway for Early Discharge in Acute Chest Pain", "Vancouver Chest Pain Rule", "Modified Sgarbossa's Criteria for MI in Left Bundle Branch Block", "Subtle Anterior STEMI Calculator (4-Variable)", "TIMI Risk Score for STEMI", "Mehran Score for Post-PCI Contrast Nephropathy", "ACTION ICU Score for Intensive Care in NSTEMI"], "calculator_answers": [{"order": 1, "name": "National Early Warning Score (NEWS)", "inputs": [{"field": "Respiratory Rate", "value": "20 breaths/min", "score": 0}, {"field": "Oxygen Saturations", "value": "96%", "score": 0}, {"field": "Any Supplemental Oxygen", "value": "No", "score": 0}, {"field": "Temperature", "value": "37.3 °C", "score": 0}, {"field": "Systolic Blood Pressure", "value": "128 mm Hg", "score": 0}, {"field": "Heart Rate", "value": "92 bpm", "score": 1}, {"field": "AVPU Score", "value": "Alert", "score": 0}], "final_answer": 1, "notes": "Low score: Assessment by a competent registered nurse who should decide if a change to frequency of clinical monitoring or an escalation of clinical care is required."}, {"order": 2, "name": "Shock Index", "inputs": [{"field": "Heart Rate/Pulse", "value": "92 beats/min"}, {"field": "Systolic BP", "value": "128 mm Hg"}], "final_answer": 0.7, "notes": "0.5-0.7 is believed to be a normal shock index. Higher numbers have been shown to be more sensitive than vital signs alone in diagnosing occult shock, need for transfusion and/or operation."}, {"order": 3, "name": "Mean Arterial Pressure (MAP)", "inputs": [{"field": "Systolic BP", "value": "128 mm Hg"}, {"field": "Diastolic BP", "value": "78 mm Hg"}], "final_answer": 95, "notes": "95 mm Hg\nMean Arterial Pressure (MAP)"}, {"order": 4, "name": "HEART Pathway for Early Discharge in Acute Chest Pain", "inputs": [{"field": "History", "value": "Moderately suspicious (+1)", "score": 1}, {"field": "EKG", "value": "Non-specific repolarization disturbance (+1)", "score": 1}, {"field": "Age", "value": "45-64 (+1) [patient is 54]", "score": 1}, {"field": "Risk factors", "value": "1-2 risk factors (+1) [HTN, hyperlipidemia]", "score": 1}, {"field": "Initial troponin", "value": "≤ normal limit (0) [hs-cTnI 11 ng/L; local ULN 19 ng/L]", "score": 0}], "final_answer": 4, "notes": "High risk\n12-65% 30-day MACE\nAdmit to hospital or observation. Further testing indicated."}, {"order": 5, "name": "Vancouver Chest Pain Rule", "inputs": [{"field": "Abnormal initial EKG", "value": "Yes (borderline anterior STE ~1 mm in V2-V3)"}, {"field": "Positive troponin at 2 hours", "value": "Yes (hs-cTnI 146 ng/L; ULN 19 ng/L)"}, {"field": "Prior ACS or nitrate use", "value": "No"}, {"field": "Does palpation reproduce pain?", "value": "No"}, {"field": "Age 50 and above?", "value": "Yes (54 years)"}, {"field": "Does pain radiate to neck, jaw, or left arm?", "value": "Yes (left arm)"}], "final_answer": "Standard Evaluation", "notes": "This patient is not a candidate for early discharge and should receive a standard chest pain evaluation."}, {"order": 6, "name": "Modified Sgarbossa's Criteria for MI in Left Bundle Branch Block", "inputs": [{"field": "Concordant ST elevation ≥1 mm in leads with a positive QRS complex", "value": "No"}, {"field": "Concordant ST depression ≥1 mm in V1-V3", "value": "No"}, {"field": "ST Elevation at the J-point, relative to QRS onset, is at least 1 mm AND has an amplitude at least 25% of the preceding S-wave", "value": "No"}], "final_answer": "Negative", "notes": "Diagnosis by Modified Sgarbossa's Criteria\nModified Sgarbossa's Criteria are met if any criteria are positive."}, {"order": 7, "name": "Subtle Anterior STEMI Calculator (4-Variable)", "inputs": [{"field": "Bazett-corrected QT interval", "value": "445 ms"}, {"field": "QRS amplitude in lead V2", "value": "10 mm"}, {"field": "R wave amplitude in lead V4", "value": "7 mm"}, {"field": "ST segment elevation 60 ms after the J point in lead V3", "value": "1.5 mm"}], "final_answer": 21.3, "notes": "Likely anterior STEMI"}, {"order": 8, "name": "TIMI Risk Score for STEMI", "inputs": [{"field": "Age", "value": "< 65 years (0) [54 years]", "score": 0}, {"field": "Diabetes, Hypertension or Angina", "value": "Yes (+1) [Hypertension]", "score": 1}, {"field": "Systolic BP < 100 mmHg", "value": "No (0) [128 mm Hg]", "score": 0}, {"field": "Heart rate > 100", "value": "No (0) [92 bpm]", "score": 0}, {"field": "Killip Class II-IV", "value": "No (0) [no JVD or pulmonary edema]", "score": 0}, {"field": "Weight < 67kg (147.7 lbs)", "value": "No (0) [82 kg]", "score": 0}, {"field": "Anterior ST Elevation or LBBB", "value": "Yes (+1) [anterior STE present]", "score": 1}, {"field": "Time to treatment > 4 hours", "value": "No (0) [anticipated PCI within 120 minutes from ED arrival]", "score": 0}], "final_answer": 2, "notes": "2.2% risk of all-cause mortality at 30 days."}, {"order": 9, "name": "Mehran Score for Post-PCI Contrast Nephropathy", "inputs": [{"field": "Hypotension", "value": "No", "score": 0}, {"field": "Intra-aortic balloon pump", "value": "No", "score": 0}, {"field": "Congestive heart failure", "value": "No", "score": 0}, {"field": "Age >75 years", "value": "No (54 years)", "score": 0}, {"field": "Anemia", "value": "No [Hct 41% (male)]", "score": 0}, {"field": "Diabetes", "value": "No", "score": 0}, {"field": "Contrast media volume", "value": "130 mL"}, {"field": "eGFR, mL/min/1.73 m²", "value": "68 mL/min/1.73 m²", "score": 0}], "final_answer": 1, "notes": "1 points\nCIN Risk Score\n7.5 %\nRisk of any post-PCI CIN\n0.04 %\nRisk of post-PCI CIN requiring dialysis"}, {"order": 10, "name": "ACTION ICU Score for Intensive Care in NSTEMI", "inputs": [{"field": "Age, years", "value": "<70 (0) [54]", "score": 0}, {"field": "Serum creatinine, mg/dL", "value": "1.05 mg/dL (<1.1 = 0)", "score": 0}, {"field": "Heart rate, bpm", "value": "92 bpm (85-100 = +1)", "score": 1}, {"field": "Systolic blood pressure, mmHg", "value": "128 mmHg (125-145 = +1)", "score": 1}, {"field": "Ratio of initial troponin to upper limit of normal", "value": "0.58 (11/19) (<12 = 0)", "score": 0}, {"field": "Signs or symptoms of heart failure", "value": "No (0)", "score": 0}, {"field": "ST segment depression on EKG", "value": "No (0)", "score": 0}, {"field": "Prior revascularization", "value": "No (+1)", "score": 1}, {"field": "Chronic lung disease", "value": "No (0)", "score": 0}], "final_answer": 3, "notes": "5.5 %\nRisk of complications requiring ICU care among initially uncomplicated patients with NSTEMI (cardiac arrest, shock, high-grade AV block, respiratory failure, stroke, or death during index admission)"}]}
{"task_id": "medmcp-calc_021_a0e648df", "task_scenario": "PACU Discharge Criteria", "task_category": "Clinical Medicine / Emergency, Critical Care & Perioperative / Anesthesia & Perioperative Medicine", "patient_id": "P021_a0e648df", "task_description": "Scenario: A postoperative patient in the PACU is recovering from anesthesia. Nursing notes indicate fluctuating oxygen saturation and mild somnolence after airway instrumentation during surgery. The team must decide whether the patient is safe for discharge from the PACU. Workflow: 1) Calculate the Aldrete Score to perform a standardized assessment of recovery domains relevant to PACU discharge (activity, respiration, circulation, consciousness, and oxygen saturation). This establishes an objective baseline for readiness. Decision Point A: If the Aldrete Score meets the institutional discharge threshold and the clinical picture is stable, proceed to discharge without further testing. If the Aldrete Score is below threshold or the respiratory/oxygenation component is borderline, proceed to the next step. 2) Use the Arterial Blood Gas (ABG) Analyzer to clarify oxygenation, ventilation, and acid–base status when respiratory recovery is uncertain. The ABG interpretation provides a physiologic check that complements the Aldrete Score and explains ongoing desaturation or somnolence related to ventilation. Decision Point B: If ABG interpretation indicates adequate oxygenation/ventilation with stable acid–base status, perform a brief clinical optimization (e.g., titrate oxygen, ensure airway patency) and then reassess recovery. If ABG interpretation indicates impaired oxygenation/ventilation or acid–base derangement, initiate targeted interventions (e.g., airway support, respiratory therapy), continue monitoring, and delay discharge. 3) Recalculate the Aldrete Score after interventions or stabilization to confirm improvement in recovery domains. Decision Point C: If the repeat Aldrete Score now meets discharge criteria and ABG-related concerns have resolved clinically, discharge from PACU. If the score remains below threshold or respiratory concerns persist, continue observation or escalate care, deferring discharge.", "fuzzy_question": "I’m evaluating a postoperative patient in the PACU after general anesthesia with airway management. Recent checks show fluctuating oxygen saturation and more somnolence than expected. I need to determine whether the patient is ready for discharge from recovery or should remain for continued monitoring.\n\nBefore deciding, I want a standardized PACU recovery assessment that addresses: motor function, ventilation/respiratory effort, hemodynamic stability relative to baseline, level of consciousness/responsiveness, and the oxygen requirement needed to maintain adequate saturation. If this composite clearly meets discharge criteria and remains stable, discharge is reasonable. If the overall recovery score is subthreshold, or if the respiratory/oxygenation domain is borderline, I would obtain an arterial blood gas to clarify oxygenation, ventilation, and acid–base status as potential contributors to desaturation or decreased alertness.\n\nIf the ABG indicates adequate oxygenation/ventilation with no acid–base disorder, I’d proceed with bedside optimization: titrate oxygen, verify airway patency, encourage deep breathing and coughing, optimize analgesia if pain limits effort, and address likely atelectasis. Then reassess the same recovery domains.\n\nIf the ABG shows impaired oxygenation/ventilation or an acid–base disturbance, I’d escalate beyond minor adjustments: provide airway support, suction if secretions are present, consider CPAP/PEEP when appropriate, use bronchodilators if bronchospasm is suspected, and evaluate for residual sedative or opioid effects. Continue monitoring and defer discharge until stable.\n\nAfter interventions, re-evaluate the recovery domains against usual discharge criteria and proceed with discharge only if respiratory concerns have resolved clinically. If criteria are still not met, continue observation or escalate care.\n\nWhat’s your take? Please walk through this in sequence: provide the initial recovery assessment across each domain, ABG results with interpretation, recommended optimizations or interventions, and the follow-up recovery assessment supporting discharge versus continued care. Use appropriate calculations and clear reasoning to support the decision.", "required_calculators": ["Aldrete Score", "Arterial Blood Gas (ABG) Analyzer"], "calculator_answers": [{"order": 1, "name": "Aldrete Score", "inputs": [{"field": "Transition goal", "value": "MAS: Phase I to Phase II or inpatient care"}, {"field": "Activity", "value": "2 - Moves all extremities voluntarily or on command", "score": 2}, {"field": "Respiration", "value": "1 - Dyspnea/shallow or limited breathing", "score": 1}, {"field": "Circulation", "value": "2 - BP within 20% of preanesthetic level", "score": 2}, {"field": "Consciousness", "value": "1 - Arousable on calling", "score": 1}, {"field": "Oxygen Saturation", "value": "1 - Needs O2 to maintain SpO2 > 90%", "score": 1}], "final_answer": 7, "notes": "Aldrete Score\nNot ready for Phase II or inpatient transition\nSee Next Steps for details"}, {"order": 2, "name": "Arterial Blood Gas (ABG) Analyzer", "inputs": [{"field": "pH", "value": "7.33"}, {"field": "PaCO2 (mm Hg)", "value": "51"}, {"field": "HCO3- (mEq/L)", "value": "26"}, {"field": "Sodium (mEq/L)", "value": "140"}, {"field": "Chloride (mEq/L)", "value": "103"}, {"field": "Albumin (g/dL)", "value": "4.0"}, {"field": "Respiratory process chronicity", "value": "Acute"}], "final_answer": "Primary Respiratory Acidosis, Acute, with: Secondary Metabolic Alkalosis", "notes": "Primary Respiratory Acidosis, Acute, with: Secondary Metabolic Alkalosis"}, {"order": 3, "name": "Aldrete Score", "inputs": [{"field": "Transition goal", "value": "MAS: Phase I to Phase II or inpatient care"}, {"field": "Activity", "value": "2 - Moves all extremities voluntarily or on command", "score": 2}, {"field": "Respiration", "value": "2 - Able to breathe deeply and cough freely", "score": 2}, {"field": "Circulation", "value": "2 - BP within 20% of preanesthetic level", "score": 2}, {"field": "Consciousness", "value": "2 - Fully awake", "score": 2}, {"field": "Oxygen Saturation", "value": "2 - SpO2 > 92% on room air", "score": 2}], "final_answer": 10, "notes": "Aldrete Score\nReady for Phase II or inpatient transition\nSee Next Steps for details"}]}
{"task_id": "medmcp-calc_022_39dff296", "task_scenario": "Ascites SAAG Gradient", "task_category": "Clinical Medicine / Medicine & Organ Systems / Gastroenterology & Hepatology", "patient_id": "P022_39dff296", "task_description": "In a patient presenting with new or worsening ascites after diagnostic paracentesis, the clinical team must determine whether the fluid accumulation is due to portal hypertension, rule out infection, stage chronic liver disease, evaluate renal involvement, and plan safe therapeutic paracentesis with albumin support if needed. Step 1: Use the Serum Ascites Albumin Gradient (SAAG) calculator to categorize the ascites mechanism. If SAAG suggests portal hypertensive ascites, proceed to cirrhosis severity staging; if SAAG is low, consider non-portal etiologies while still screening for infection and assessing renal status. Step 2: Use an Absolute Neutrophil Count (ANC) calculator on the paracentesis sample to detect spontaneous bacterial peritonitis; if ANC meets SBP criteria, prioritize antibiotics and avoid immediate diuretic escalation, and plan early therapeutic paracentesis as indicated. Step 3 (portal hypertensive path): Calculate the Child-Pugh Score to determine hepatic functional class; if Child-Pugh class is moderate to severe, calculate the MELD-Na Score to quantify short-term mortality and inform transplant referral and procedural risk such as TIPS. Step 4: Estimate renal function with eGFR (CKD-EPI); if renal function is reduced or worsening, compute Fractional Excretion of Sodium (FENa) to differentiate hepatorenal physiology from intrinsic renal injury, guiding diuretic use versus albumin/vasoconstrictor strategies. Step 5: When therapeutic paracentesis is undertaken for tense or refractory ascites, use the Albumin Replacement After Large-Volume Paracentesis calculator to determine the albumin dose required to prevent post-paracentesis circulatory dysfunction. Step 6 (non-portal path): If SAAG suggests non-portal mechanisms, focus the workup on secondary causes while still applying the ANC to rule in/out SBP and using eGFR (and FENa when indicated) to safely manage volume and diuretics. Outputs from SAAG deterministically branch the pathway; Child-Pugh output triggers MELD-Na calculation only when hepatic dysfunction is substantial; eGFR results trigger FENa calculation when renal involvement is likely; ANC positivity triggers infection-first management and may defer nonurgent procedures. This sequencing mirrors real-world decision-making and ensures that each calculator’s output informs the next step in evaluation and treatment planning.", "fuzzy_question": "I'm evaluating a patient with cirrhosis presenting with new, worsening ascites soon after prior fluid sampling. I'm trying to determine whether the accumulation is primarily due to portal hypertension versus a secondary process, while also ensuring we are not missing infection, that hepatic reserve is adequately assessed, and that renal involvement is addressed.\n\nUsing the available serum and ascitic fluid albumin results, I want to determine whether the gradient is consistent with high-pressure ascites. If it is, I'll proceed to stage liver disease severity using standard bedside criteria (laboratory parameters and the presence of ascites/encephalopathy). If that staging indicates at least moderate compromise, I'd like a short-term mortality estimate that incorporates sodium, to inform timing of transplant referral and the risk profile for options such as TIPS.\n\nSeparately, I need to be sure we are not dealing with spontaneous bacterial peritonitis. Please assess the neutrophil count in the fluid; if it meets the typical criterion for SBP, antibiotics take priority, diuretics should be deferred initially, and timely therapeutic drainage should be planned if the abdomen is tense.\n\nI also want a clear assessment of kidney function based on the current creatinine and its trend. If the filtration estimate is reduced or worsening, we should obtain urine electrolytes to evaluate renal sodium handling, which helps distinguish a hepatorenal pattern from intrinsic injury and guides either diuretic adjustment or an albumin/vasoconstrictor strategy.\n\nIf large-volume paracentesis is planned for tense or refractory ascites, please calculate appropriate albumin replacement to reduce the risk of post-paracentesis circulatory dysfunction.\n\nConversely, if the albumin gradient is low and not consistent with portal-pressure ascites, I want to pivot to secondary causes (malignancy, pancreatic, cardiac, nephrotic, etc.), while maintaining the same discipline: confirm or exclude SBP from the fluid cell differential, and reassess renal function as above so we manage volume and diuretics safely.\n\nNext steps hinge on these results: the albumin gradient directs the diagnostic path; liver severity staging triggers short-term mortality estimation only if moderate or severe compromise is present; abnormalities in kidney function prompt urine electrolytes to refine the diagnosis; and if fluid neutrophils are elevated, antibiotics take precedence and nonurgent procedures are deferred. What's your take on this case, and how would you reason through it? I need evidence-based, calculation-driven support, not gut feeling. Whatever approach you suggest should be backed by solid calculations and able to withstand scrutiny.", "required_calculators": ["Serum Ascites Albumin Gradient (SAAG)", "Absolute Neutrophil Count (ANC)", "Child-Pugh Score", "MELDNa/MELD-Na Score for Liver Cirrhosis", "CKD-EPI Equations for Glomerular Filtration Rate (GFR)", "Fractional Excretion of Sodium (FENa)", "Albumin Replacement After Large-Volume Paracentesis"], "calculator_answers": [{"order": 1, "name": "Serum Ascites Albumin Gradient (SAAG)", "inputs": [{"field": "Albumin concentration of serum", "value": "2.4 g/dL"}, {"field": "Albumin concentration of ascitic fluid", "value": "0.8 g/dL"}], "final_answer": "1.6 g/dL", "notes": "Portal hypertension is likely the cause of ascites, with 97% accuracy."}, {"order": 2, "name": "Absolute Neutrophil Count (ANC)", "inputs": [{"field": "% neutrophils", "value": "68 %"}, {"field": "% bands", "value": "2 %"}, {"field": "WBC count", "value": "0.8 × 10^3 cells/µL (ascitic fluid total nucleated cells)"}], "final_answer": "560 cells/µL", "notes": "560 cells/µL\nAbsolute Neutrophil Count\nModerate neutropenia"}, {"order": 3, "name": "Child-Pugh Score", "inputs": [{"field": "Total bilirubin", "value": "3.2 mg/dL", "score": 3}, {"field": "Serum albumin", "value": "2.4 g/dL", "score": 3}, {"field": "INR", "value": "1.9", "score": 2}, {"field": "Ascites", "value": "Tense/refractory (requires therapeutic paracentesis)", "score": 3}, {"field": "Hepatic encephalopathy", "value": "Grade I–II (mild)", "score": 2}], "final_answer": 13, "notes": "Child Class C\nLife Expectancy : 1-3 years\nAbdominal surgery peri-operative mortality: 82%"}, {"order": 4, "name": "MELDNa/MELD-Na Score for Liver Cirrhosis", "inputs": [{"field": "Serum bilirubin", "value": "3.2 mg/dL"}, {"field": "INR", "value": "1.9"}, {"field": "Serum creatinine", "value": "1.8 mg/dL"}, {"field": "Serum sodium", "value": "129 mEq/L"}, {"field": "On dialysis in prior 7 days", "value": "No"}], "final_answer": 28, "notes": "28 points\nMELD-Na Score\n27 - 32%\nEstimated 90-Day Mortality"}, {"order": 5, "name": "CKD-EPI Equations for Glomerular Filtration Rate (GFR)", "inputs": [{"field": "Equation", "value": "2021 CKD-EPI Creatinine"}, {"field": "Age", "value": "54 years"}, {"field": "Sex", "value": "Male"}, {"field": "Serum creatinine", "value": "1.8 mg/dL"}], "final_answer": "44 ml/min/1.73 m²", "notes": "Estimated GFR by 2021 CKD-EPI Creatinine\nStageIIIB\nCKD stage by CKD-EPI Creatinine"}, {"order": 6, "name": "Fractional Excretion of Sodium (FENa)", "inputs": [{"field": "Serum sodium", "value": "129 mEq/L"}, {"field": "Serum creatinine", "value": "1.8 mg/dL"}, {"field": "Urine sodium", "value": "8 mEq/L"}, {"field": "Urine creatinine", "value": "74 mg/dL"}], "final_answer": "0.2%", "notes": "Prerenal\ne.g., Hypovolemia, heart failure, renal artery stenosis, sepsis (anything causing decreased effective renal perfusion). Remember, contrast-induced nephropathy will often look pre-renal."}, {"order": 7, "name": "Albumin Replacement After Large-Volume Paracentesis", "inputs": [{"field": "Volume of ascites removed", "value": "7.5 L"}, {"field": "Replacement dosing (guideline)", "value": "8 g of albumin per liter removed (for >5 L)"}], "final_answer": 60, "notes": "Planned albumin ≈ 60 g total (e.g., 25% albumin solution), to mitigate post-paracentesis circulatory dysfunction."}]}
{"task_id": "medmcp-calc_023_e08df28f", "task_scenario": "Hyperglycemic Emergencies (DKA/HHS) Fluid and Osmolarity Management", "task_category": "Clinical Medicine / Medicine & Organ Systems / Endocrinology & Metabolism", "patient_id": "P023_e08df28f", "task_description": "Clinical scenario: A patient presents with a hyperglycemic emergency (DKA/HHS) and significant dehydration. The clinical priority is to choose the appropriate crystalloid (isotonic vs hypotonic), establish a safe pace of tonicity correction, and monitor osmotic shifts to avoid complications such as cerebral edema or osmotic demyelination.\n\nStep-by-step calculator workflow:\n1) Initial tonicity check and fluid selection using Sodium Correction for Hyperglycemia:\n- Purpose: Hyperglycemia lowers measured sodium via osmotic water shifts; this calculator estimates the true sodium to guide fluid tonicity decisions.\n- Action: Calculate the corrected sodium to reflect extracellular tonicity.\n- Branch A (if/else):\n  • If corrected sodium is low: continue isotonic fluid resuscitation to restore extracellular volume and raise tonicity safely.\n  • If corrected sodium is normal or high: favor hypotonic saline for ongoing replacement to avoid worsening hypernatremia while correcting free water deficit.\n- Link to next step: Use the corrected sodium from this step as the sodium input for the subsequent osmolality calculation.\n\n2) Baseline osmolar burden and safety monitoring using Serum Osmolality/Osmolarity:\n- Purpose: Quantify the osmolar burden and assess for unmeasured osmoles by comparing calculated to measured osmolality.\n- Action: Calculate expected serum osmolality using the corrected sodium from step 1. Compare the calculated value with any measured osmolality (if available) to evaluate for an osmolal gap and to gauge severity of hyperosmolarity.\n- Branch B (if/else):\n  • If calculated osmolality is markedly elevated and/or the calculated-to-measured difference is unexpectedly large: use a more cautious fluid strategy and evaluate for additional osmoles.\n  • If calculated osmolality aligns with expectations and is improving with therapy: proceed with the chosen fluid plan.\n\n3) Serial reassessment loop to guide ongoing therapy:\n- Repeat Sodium Correction for Hyperglycemia at intervals as glucose falls, then re-run Serum Osmolality/Osmolarity using the updated corrected sodium.\n- Branch C (if/else):\n  • If corrected sodium rises despite therapy or becomes high: adjust to a lower sodium concentration fluid and consider adding dextrose when appropriate to prevent overly rapid tonicity shifts.\n  • If corrected sodium falls too quickly: increase sodium concentration of fluids to avoid rapid decreases in tonicity.\n- Branch D (if/else):\n  • If calculated osmolality is falling too rapidly: slow fluid rate and/or add dextrose to prevent excessive osmotic shifts.\n  • If calculated osmolality is not improving adequately: increase fluid rate within safety limits and reassess.\n- Ongoing safety check: Continue to compare calculated and measured osmolality when available; if the gap widens unexpectedly, reassess for other causes of osmolar load.\n\nRationale for the sequence: Corrected sodium first informs the tonicity of the chosen fluid, then feeds directly into the osmolality calculation to quantify severity and monitor for unsafe correction. Iterative use of both calculators creates a feedback loop that drives fluid-type and rate adjustments.", "fuzzy_question": "I’m evaluating an adult in hyperglycemic crisis (DKA/HHS) with clinical signs of volume depletion. I’m deciding between ongoing isotonic fluids versus a more hypotonic option. The measured sodium appears abnormal, but with significant hyperglycemia I suspect a glucose-associated water shift affecting the value rather than true extracellular tonicity. Before choosing a fluid strategy, I want an estimate of the corrected sodium/tonicity. If that proves truly low, I’d continue isotonic fluids to restore volume and raise tonicity at a controlled pace. If it’s actually normal or high, I’d favor hypotonic saline for ongoing replacement to avoid worsening hypernatremia while replacing free water. I’d use this corrected sodium as the anchor for judging osmotic status.\n\nI also want a baseline assessment of osmotic load. Using the corrected sodium together with concurrent glucose and BUN, I’d calculate an expected serum osmolality to compare with any measured osmolality. If it’s markedly elevated or the gap between calculated and measured exceeds what makes clinical sense, I’d slow the fluid strategy and look for additional osmolar contributors. If it aligns and improves steadily with therapy, I’m comfortable proceeding.\n\nAs glucose falls over time, I’ll repeatedly update the corrected sodium and recheck osmolality trends. If corrected sodium rises despite therapy or becomes high, I’d step down to a lower-sodium fluid and, once glucose is safer, consider adding dextrose to avoid an overly rapid fall in tonicity. If corrected sodium is dropping faster than desired, I’d increase the sodium concentration of fluids to prevent a rapid hypotonic shift. Similarly with osmolality: if it’s falling too quickly, I’d slow the rate and/or add dextrose; if it’s barely changing, I’d increase fluids within safety limits and reassess. Throughout, I’ll compare expected versus measured osmolality; if the gap widens unexpectedly, I’d pause and search for a new osmolar source.\n\nBig picture, I’m aiming to choose appropriate fluid tonicity upfront, set a safe pace for tonicity reduction, and monitor osmotic shifts to avoid complications like cerebral edema or osmotic demyelination. What’s the right approach here? I need this backed by solid calculations—not just clinical intuition—so the plan stands up to scrutiny.", "required_calculators": ["Sodium Correction for Hyperglycemia", "Serum Osmolality/Osmolarity"], "calculator_answers": [{"order": 1, "name": "Sodium Correction for Hyperglycemia", "inputs": [{"field": "Sodium", "value": "132 mEq/L"}, {"field": "Glucose", "value": "960 mg/dL"}], "final_answer": 153, "notes": "146 mEq/L\nCorrected Sodium\n(Katz, 1973)\n153 mEq/L\nCorrected Sodium\n(Hillier, 1999)"}, {"order": 2, "name": "Serum Osmolality/Osmolarity", "inputs": [{"field": "Sodium", "value": "152.6 mEq/L"}, {"field": "BUN", "value": "34 mg/dL"}, {"field": "Glucose", "value": "960 mg/dL"}, {"field": "Serum alcohol concentration", "value": "0 mg/dL"}, {"field": "Measured serum osm", "value": "372 mOsm/kg"}], "final_answer": 371, "notes": "371 mOsm/kg Calculated Serum Osm\nNormal serum osmolality = 285-295 mOsm/kg\n1.0 mOsm/kg Osm Gap\nNormal Serum Osm Gap (Measured-Calculated) is -14 to +10."}, {"order": 3, "name": "Sodium Correction for Hyperglycemia", "inputs": [{"field": "Sodium", "value": "134 mEq/L"}, {"field": "Glucose", "value": "820 mg/dL"}], "final_answer": 151, "notes": "146 mEq/L\nCorrected Sodium\n(Katz, 1973)\n151 mEq/L\nCorrected Sodium\n(Hillier, 1999)"}, {"order": 4, "name": "Serum Osmolality/Osmolarity", "inputs": [{"field": "Sodium", "value": "151.3 mEq/L"}, {"field": "BUN", "value": "33 mg/dL"}, {"field": "Glucose", "value": "820 mg/dL"}, {"field": "Serum alcohol concentration", "value": "0 mg/dL"}, {"field": "Measured serum osm", "value": "360 mOsm/kg"}], "final_answer": 360, "notes": "360 mOsm/kg Calculated Serum Osm\nNormal serum osmolality = 285-295 mOsm/kg\n0.0 mOsm/kg Osm Gap\nNormal Serum Osm Gap (Measured-Calculated) is -14 to +10."}, {"order": 5, "name": "Sodium Correction for Hyperglycemia", "inputs": [{"field": "Sodium", "value": "136 mEq/L"}, {"field": "Glucose", "value": "640 mg/dL"}], "final_answer": 149, "notes": "145 mEq/L\nCorrected Sodium\n(Katz, 1973)\n149 mEq/L\nCorrected Sodium\n(Hillier, 1999)"}, {"order": 6, "name": "Serum Osmolality/Osmolarity", "inputs": [{"field": "Sodium", "value": "149.0 mEq/L"}, {"field": "BUN", "value": "30 mg/dL"}, {"field": "Glucose", "value": "640 mg/dL"}, {"field": "Serum alcohol concentration", "value": "0 mg/dL"}, {"field": "Measured serum osm", "value": "345 mOsm/kg"}], "final_answer": 344, "notes": "344 mOsm/kg Calculated Serum Osm\nNormal serum osmolality = 285-295 mOsm/kg\n1.0 mOsm/kg Osm Gap\nNormal Serum Osm Gap (Measured-Calculated) is -14 to +10."}, {"order": 7, "name": "Sodium Correction for Hyperglycemia", "inputs": [{"field": "Sodium", "value": "140 mEq/L"}, {"field": "Glucose", "value": "460 mg/dL"}], "final_answer": 149, "notes": "146 mEq/L\nCorrected Sodium\n(Katz, 1973)\n149 mEq/L\nCorrected Sodium\n(Hillier, 1999)"}, {"order": 8, "name": "Serum Osmolality/Osmolarity", "inputs": [{"field": "Sodium", "value": "148.6 mEq/L"}, {"field": "BUN", "value": "28 mg/dL"}, {"field": "Glucose", "value": "460 mg/dL"}, {"field": "Serum alcohol concentration", "value": "0 mg/dL"}, {"field": "Measured serum osm", "value": "334 mOsm/kg"}], "final_answer": 333, "notes": "333 mOsm/kg Calculated Serum Osm\nNormal serum osmolality = 285-295 mOsm/kg\n1.0 mOsm/kg Osm Gap\nNormal Serum Osm Gap (Measured-Calculated) is -14 to +10."}, {"order": 9, "name": "Sodium Correction for Hyperglycemia", "inputs": [{"field": "Sodium", "value": "146 mEq/L"}, {"field": "Glucose", "value": "280 mg/dL"}], "final_answer": 150, "notes": "149 mEq/L\nCorrected Sodium\n(Katz, 1973)\n150 mEq/L\nCorrected Sodium\n(Hillier, 1999)"}, {"order": 10, "name": "Serum Osmolality/Osmolarity", "inputs": [{"field": "Sodium", "value": "150.3 mEq/L"}, {"field": "BUN", "value": "26 mg/dL"}, {"field": "Glucose", "value": "280 mg/dL"}, {"field": "Serum alcohol concentration", "value": "0 mg/dL"}, {"field": "Measured serum osm", "value": "326 mOsm/kg"}], "final_answer": 325, "notes": "325 mOsm/kg Calculated Serum Osm\nNormal serum osmolality = 285-295 mOsm/kg\n1.0 mOsm/kg Osm Gap\nNormal Serum Osm Gap (Measured-Calculated) is -14 to +10."}, {"order": 11, "name": "Sodium Correction for Hyperglycemia", "inputs": [{"field": "Sodium", "value": "144 mEq/L"}, {"field": "Glucose", "value": "210 mg/dL"}], "final_answer": 147, "notes": "146 mEq/L\nCorrected Sodium\n(Katz, 1973)\n147 mEq/L\nCorrected Sodium\n(Hillier, 1999)"}, {"order": 12, "name": "Serum Osmolality/Osmolarity", "inputs": [{"field": "Sodium", "value": "146.6 mEq/L"}, {"field": "BUN", "value": "24 mg/dL"}, {"field": "Glucose", "value": "210 mg/dL"}, {"field": "Serum alcohol concentration", "value": "0 mg/dL"}, {"field": "Measured serum osm", "value": "315 mOsm/kg"}], "final_answer": 313, "notes": "313 mOsm/kg Calculated Serum Osm\nNormal serum osmolality = 285-295 mOsm/kg\n2.0 mOsm/kg Osm Gap\nNormal Serum Osm Gap (Measured-Calculated) is -14 to +10."}, {"order": 13, "name": "Sodium Correction for Hyperglycemia", "inputs": [{"field": "Sodium", "value": "142 mEq/L"}, {"field": "Glucose", "value": "180 mg/dL"}], "final_answer": 144, "notes": "143 mEq/L\nCorrected Sodium\n(Katz, 1973)\n144 mEq/L\nCorrected Sodium\n(Hillier, 1999)"}, {"order": 14, "name": "Serum Osmolality/Osmolarity", "inputs": [{"field": "Sodium", "value": "143.9 mEq/L"}, {"field": "BUN", "value": "22 mg/dL"}, {"field": "Glucose", "value": "180 mg/dL"}, {"field": "Serum alcohol concentration", "value": "0 mg/dL"}, {"field": "Measured serum osm", "value": "306 mOsm/kg"}], "final_answer": 306, "notes": "306 mOsm/kg Calculated Serum Osm\nNormal serum osmolality = 285-295 mOsm/kg\n0.0 mOsm/kg Osm Gap\nNormal Serum Osm Gap (Measured-Calculated) is -14 to +10."}]}
{"task_id": "medmcp-calc_024_7e6a53f9", "task_scenario": "Malignancy Nutritional Status Assessment", "task_category": "Clinical Medicine / Medicine & Organ Systems / Comprehensive Oncology", "patient_id": "P024_7e6a53f9", "task_description": "Clinical scenario: A hospitalized patient with an active malignancy is being evaluated for treatment tolerance and supportive care planning. There is clinical concern for unintentional weight loss and reduced oral intake, and the team needs a structured, oncology-focused nutritional status assessment that integrates general, hospital-specific, geriatric, and inflammation-related factors to guide targeted nutrition interventions and multidisciplinary care.\n\nStep-by-step calculator use and rationale:\n1) BMI Calculator (Body Mass Index and BSA): Establish baseline anthropometrics by calculating BMI (for nutrition screening thresholds) and BSA (for treatment context). BMI category will be a direct input to subsequent malnutrition screening tools.\n2) Malnutrition Universal Screening Tool (MUST): Use the BMI from Step 1, recent weight change, and acute disease effect to classify malnutrition risk (low, medium, high). Decision branch: If MUST indicates low risk, continue routine monitoring and reassess at set intervals; if MUST indicates medium/high risk, proceed to hospital-specific screening (Step 4) and consider early dietitian referral.\n3) G8 Geriatric Screening Tool: Conditional branch: If the patient is elderly, apply the G8 to detect geriatric vulnerabilities that may compound malnutrition. Decision branch: If G8 is abnormal, trigger a comprehensive geriatric assessment (CGA) and integrate geriatric-informed nutrition goals (e.g., functional support, caregiver involvement); if G8 is normal, continue the standard pathway.\n4) Nutrition Risk Screening 2002 (NRS-2002): For hospitalized patients, incorporate BMI (from Step 1), recent weight loss, intake, and disease severity to determine hospital malnutrition risk. Decision branch: If NRS-2002 is below the intervention threshold, maintain enhanced monitoring and nutrition counseling; if NRS-2002 meets or exceeds the threshold, proceed to quantify severity with the NRI (Step 5) and initiate structured nutrition support.\n5) Nutritional Risk Index (NRI): Quantify the severity of malnutrition using serum protein status and weight-related parameters to stratify into no, mild, moderate, or severe risk. Decision branch: Use NRI category to determine the intensity and route of nutrition support (e.g., oral supplementation, enteral feeding, or parenteral nutrition), and set follow-up frequency for reassessment.\n6) Modified Glasgow Prognostic Score (mGPS) for Cancer Outcomes: Evaluate systemic inflammation and hypoalbuminemia related to cancer to understand catabolic burden and treatment tolerance. Decision branch: If mGPS is elevated, prioritize early, higher-intensity nutrition support, close monitoring, and consider palliative/supportive care involvement; if mGPS is low, proceed with standard nutrition support and routine reassessment.\n\nIntegration notes: The BMI result from Step 1 is a required input for MUST (Step 2) and NRS-2002 (Step 4). The MUST risk classification deterministically triggers whether to escalate to hospital-specific screening. NRS-2002 categorization triggers whether to quantify severity via the NRI (Step 5). The NRI and mGPS together inform the intensity and urgency of nutrition interventions and coordination with oncology and supportive care.", "fuzzy_question": "I’m seeing a hospitalized patient with active cancer who has reduced intake and appears to be losing weight recently. I’m trying to determine how robust they are for ongoing treatment and what level of nutrition support they can tolerate. Before making decisions, I want a clear sense of current body habitus—an approximate weight status—and an estimate of overall body size for oncology dosing. That starting point will anchor the rest of the nutrition risk thinking.\n\nFrom there, I’d like an initial nutrition risk look that leans on several elements: weight status, recent weight loss, and whether the acute illness has effectively shut down intake for a period. If that suggests low risk, I’m fine with routine check‑ins at sensible intervals. If it suggests medium or high risk, let’s move directly to the inpatient‑focused assessment and involve a dietitian early.\n\nIf geriatric vulnerabilities are suspected, I’m also concerned about factors that could amplify the problem—appetite, mobility, energy, cognition, mood, and medications. If that quick screen is concerning, I’d want a full geriatric workup and to shape nutrition goals around function and safety (including practical supports and caregiver involvement). If it’s reassuring, we can stay on the standard path.\n\nGiven admission for cancer, I want a hospital‑oriented nutrition risk view that considers the same weight status and recent weight loss, current intake, and the stress of the underlying disease. If that falls below the intervention threshold, let’s still upgrade monitoring and provide targeted counseling. If it meets or exceeds the action threshold, I’d like to determine malnutrition severity using serum proteins (e.g., albumin trends) alongside weight‑related parameters, classifying as none, mild, moderate, or severe.\n\nThat severity grade should guide the intensity and route of support: oral supplements if mild; enteral feeding if moderate or severe and the gut is usable; parenteral if the gut isn’t feasible—plus set the reassessment cadence during this admission and ahead of the next treatment cycle.\n\nIn parallel, I want an assessment of inflammatory burden related to the malignancy—systemic inflammation with low albumin shifts the picture on catabolism and tolerance. If inflammation is high, treat this as urgent: start earlier at higher intensity, monitor closely, and consider bringing in palliative/supportive care sooner. If the inflammatory signal is low, standard support with routine check‑ins should suffice.\n\nPlease tie this together coherently: the starting weight status should inform both the initial and inpatient risk assessments; the initial screen determines whether we escalate to the inpatient assessment; the inpatient result drives whether we formally grade severity with protein and weight data; and that severity, together with the inflammatory profile, should dictate how aggressive to be with nutrition support and who else to involve alongside oncology.\n\nI really need proper calculations on this—can’t make this decision based on gut feeling alone. Whatever approach you suggest, make sure it’s backed by solid calculations. This needs to hold up to scrutiny.", "required_calculators": ["BMI Calculator (Body Mass Index and BSA)", "Malnutrition Universal Screening Tool (MUST)", "G8 Geriatric Screening Tool", "Nutrition Risk Screening 2002 (NRS-2002)", "Nutritional Risk Index (NRI)", "Modified Glasgow Prognostic Score (mGPS) for Cancer Outcomes"], "calculator_answers": [{"order": 1, "name": "BMI Calculator (Body Mass Index and BSA)", "inputs": [{"field": "Weight", "value": "120 lb"}, {"field": "Height", "value": "67 in"}], "final_answer": 18.8, "notes": "18.8 kg/m²\nBody Mass Index (Normal weight)\n1.60 m²\nBody Surface Area"}, {"order": 2, "name": "Malnutrition Universal Screening Tool (MUST)", "inputs": [{"field": "BMI, kg/m2", "value": "18.8 kg/m²", "score": 1}, {"field": "Unplanned weight loss in past 3-6 months", "value": ">10% (from 148 lb to 120 lb over ~6 months; ~18.9% loss)", "score": 2}, {"field": "Acutely ill and no nutritional intake for >5 days", "value": "Yes (NPO ~6 days)", "score": 2}], "final_answer": 5, "notes": "High risk\nTreat (unless detrimental or no benefit is expected from nutritional support, e.g. imminent death); refer to dietitian, improve and increase overall intake, increase frequency of monitoring according to local policy"}, {"order": 3, "name": "G8 Geriatric Screening Tool", "inputs": [{"field": "Age, years", "value": "82 years", "score": 1}, {"field": "Food intake decline past 3 months", "value": "Severe decrease in food intake", "score": 0}, {"field": "Weight loss during the last 3 months, kg", "value": "5.2 kg (>3 kg category)", "score": 0}, {"field": "Mobility", "value": "Able to get out of bed/chair but does not go out", "score": 1}, {"field": "Neuropsychological conditions", "value": "Mild depression", "score": 1}, {"field": "Body mass index (BMI), kg/m2", "value": "18.8 kg/m² (<19 category)", "score": 0}, {"field": "Takes more than three prescription drugs per day", "value": "Yes", "score": 0}, {"field": "Self-rated health versus peers", "value": "Not as good", "score": 0}], "final_answer": 3, "notes": "Full geriatric evaluation recommended."}, {"order": 4, "name": "Nutrition Risk Screening 2002 (NRS-2002)", "inputs": [{"field": "BMI <20.5 kg/m²", "value": "Yes (BMI 18.8 kg/m²)"}, {"field": "Weight loss within 3 months", "value": "Yes (≈5.2 kg loss)"}, {"field": "Reduced dietary intake in the last week", "value": "Yes (severe reduction/NPO)"}, {"field": "ICU patient", "value": "No"}, {"field": "Nutritional impairment", "value": "Severe: weight loss >5% in 1 month (>15% in 3 months) or BMI <18.5 plus impaired general condition or food intake 0–25% of normal in past week", "score": 3}, {"field": "Severity of disease", "value": "Major abdominal surgery, stroke, severe pneumonia, hematologic malignancy", "score": 2}, {"field": "Age", "value": "≥70 years", "score": 1}], "final_answer": 6, "notes": "High risk\nInitiate early intervention nutritional care plan"}, {"order": 5, "name": "Nutritional Risk Index (NRI)", "inputs": [{"field": "Serum albumin", "value": "3.2 g/dL"}, {"field": "Present weight", "value": "120 lb"}, {"field": "Usual weight (stable ~6 months prior)", "value": "148 lb"}], "final_answer": 82.4, "notes": "Severe risk\nRisk of malnutrition"}, {"order": 6, "name": "Modified Glasgow Prognostic Score (mGPS) for Cancer Outcomes", "inputs": [{"field": "CRP", "value": "28 mg/L"}, {"field": "Albumin", "value": "3.2 g/dL"}], "final_answer": "mGPS 2", "notes": "mGPS 2\nPoor Prognosis"}]}
{"task_id": "medmcp-calc_025_c7aabb12", "task_scenario": "Chemotherapy Dosing and Body Surface Area", "task_category": "Clinical Medicine / Medicine & Organ Systems / Hematology & Oncology", "patient_id": "P025_c7aabb12", "task_description": "Scenario: A patient with a solid tumor is scheduled to begin a combination chemotherapy regimen that includes carboplatin and a BSA-based agent (e.g., paclitaxel). The clinical objective is to determine accurate, individualized dosing using body surface area and carboplatin AUC methodology while ensuring safety through conditional checks.\n\nWorkflow steps:\n1) Use the BMI Calculator (Body Mass Index and BSA) to compute BMI and body surface area from height and weight. Rationale: BMI informs obesity status and institutional policies on dose capping or weight selection; BSA is required for agents dosed by surface area.\n   - Conditional branch A: If BMI indicates obesity per institutional policy, cap BSA or plan to use adjusted weight in subsequent dosing decisions; otherwise, proceed with actual body weight and uncapped BSA.\n2) Use Carboplatin AUC Dosing (Calvert). Input the clinically available renal function (measured or previously estimated GFR per local lab reporting) and the regimen’s target AUC to calculate the carboplatin dose. Rationale: Carboplatin dosing is determined by the Calvert formula and must reflect renal function.\n   - Conditional branch B: If the calculated carboplatin dose is not clinically appropriate due to renal impairment or institutional maximums, adjust the target AUC or defer treatment per protocol; otherwise, proceed.\n3) Use Body Surface Area Based Dosing for the BSA-dosed agent(s). Input the BSA from Step 1 to determine the drug dose according to regimen standards.\n   - Conditional branch C: If BSA was capped in Step 1, ensure the dose reflects the capped value; if not capped, use the full calculated BSA. Apply any regimen-specific adjustments based on overall clinical assessment before finalizing doses.\n\nIntegration points: The BSA computed in Step 1 is a required input for Step 3. The BMI from Step 1 deterministically triggers whether BSA capping or adjusted weight policies are applied before proceeding to Steps 2 and 3. The carboplatin dose from Step 2 is finalized only after passing the renal safety check in the conditional branch.", "fuzzy_question": "I am seeing a patient with a solid tumor who is about to start carboplatin with a BSA-dosed partner (likely paclitaxel), and I want to ensure the initial doses are appropriate. The body habitus may meet institutional obesity criteria based on current anthropometrics. If that threshold is met, we may cap body size or use adjusted rather than actual weight; if not, proceed with actual weight and an uncapped body size. Dosing should be anchored to current height and weight, and whichever approach we choose for weight selection or capping should be applied consistently across the regimen.\n\nFor carboplatin, dosing needs to align with kidney function and the intended exposure (AUC). Laboratory data are available, and we should use the most reliable renal measure available for planning, whether a measured value or a reported estimate. If the resulting calculation appears excessive for renal status or approaches institutional limits, I would prefer adjusting the target exposure or deferring the start per protocol rather than proceeding and risking toxicity.\n\nFor the taxane, dosing should be tied to BSA derived from the initial height and weight. If a BSA cap is indicated due to obesity, the dose should reflect that cap; if not, use the full value. Before finalizing, incorporate the broader clinical context for regimen-specific adjustments (neuropathy risk, cytopenias, performance status) to avoid missing indications for modification.\n\nPlease walk me through the clinical approach: determining body habitus classification and its implications for weight selection or capping; how that informs the BSA used for the BSA-dosed agent; and, in parallel, deriving the carboplatin dose from kidney function and intended exposure, confirming renal safety before finalizing the carboplatin dose. I need proper, defensible calculations rather than judgment alone. Whatever approach you suggest, make sure it is backed by solid calculations. This needs to hold up to scrutiny.", "required_calculators": ["BMI Calculator (Body Mass Index and BSA)", "Carboplatin AUC Dosing (Calvert)", "Body Surface Area Based Dosing"], "calculator_answers": [{"order": 1, "name": "BMI Calculator (Body Mass Index and BSA)", "inputs": [{"field": "Weight", "value": "238 lb"}, {"field": "Height", "value": "65.8 in"}, {"field": "Target BMI", "value": "25 kg/m²"}], "final_answer": 38.6, "notes": "38.6 kg/m²\nBody Mass Index (Class 2 obesity)\n2.24 m²\nBody Surface Area\n154 lbs\nTarget weight for BMI 25 kg/m²"}, {"order": 2, "name": "Carboplatin AUC Dosing (Calvert)", "inputs": [{"field": "Age", "value": "58 years"}, {"field": "Weight", "value": "78.5 kg (adjusted body weight due to obesity)"}, {"field": "Creatinine", "value": "0.92 mg/dL"}, {"field": "Target AUC", "value": "5"}, {"field": "Gender", "value": "Female"}], "final_answer": 538, "notes": "Total Dose\n538 mg"}, {"order": 3, "name": "Body Surface Area Based Dosing", "inputs": [{"field": "BSA Based Dose", "value": "Paclitaxel 175 mg/m²"}, {"field": "Weight", "value": "107.95 kg"}, {"field": "Height", "value": "167.1 cm"}, {"field": "Select either", "value": "Mosteller formula"}, {"field": "Desired dose unit", "value": "mg"}], "final_answer": 391.73, "notes": "Dose\n391.73 mg"}]}
{"task_id": "medmcp-calc_026_61983b40", "task_scenario": "Combat Trauma ISS Scoring", "task_category": "Clinical Medicine / Emergency, Critical Care & Perioperative / Emergency Medicine & Trauma", "patient_id": "P026_61983b40", "task_description": "Scenario: A combat casualty with multi-system injuries arrives to a forward medical facility after blast and ballistic trauma. The team must quickly standardize injury severity, estimate survival probability, and make resuscitation and evacuation decisions under resource constraints.\n\nWorkflow steps:\n1) Calculate Injury Severity Score (ISS): Use identified injuries across body regions to generate a standardized severity score. Purpose: Establish whether the patient meets criteria for major trauma and provide an objective injury burden measure.\n   - Branch A (based on ISS):\n     • If ISS indicates major trauma classification, immediately activate advanced resuscitation resources, prepare for damage control surgery, and initiate expedited evacuation planning.\n     • Else, continue guideline-based resuscitation with close monitoring and plan for routine evacuation if stable.\n2) Calculate Trauma Score and Injury Severity Score (TRISS): Input the ISS result into TRISS along with standard trauma parameters to estimate probability of survival. Purpose: Quantify survival likelihood to refine triage priority and determine aggressiveness of interventions.\n   - Branch B (based on TRISS):\n     • If TRISS predicts low survival probability, prioritize damage control strategies, assign highest evacuation priority, and allocate critical resources to optimize survival chances.\n     • Else, when TRISS predicts high survival probability, proceed with definitive management and standard evacuation prioritization while conserving scarce resources.\n3) Integrate ISS and TRISS outputs: Use the ISS-driven major trauma classification and the TRISS survival estimate together to finalize triage category, resuscitation intensity, evacuation destination, and timing. Purpose: Align resource allocation with objective injury severity and survival probability to support mission and patient outcomes.", "fuzzy_question": "I’m working in a forward, resource-limited setting and we’ve received a trauma patient following combined blast and penetrating injury. The patient has injuries involving multiple regions—thoracic and abdominal concerns with a long-bone injury—along with borderline perfusion and depressed mental status on arrival. We have limited blood products and a constrained operative window before the next evacuation opportunity. I’m trying to determine, in a defensible way, how far to push damage control versus holding for definitive repair, and how aggressively to prioritize the patient for evacuation.\n\nBefore making those decisions, I want a formal method to quantify injury severity across involved body regions so we can assign an objective score indicating whether this meets major trauma criteria and how substantial the overall injury burden is. If a standardized rating clearly places the patient in major trauma, my inclination is to activate advanced resuscitation resources, prepare for damage control surgery, and fast-track evacuation. If the rating is lower, I would continue guideline-based resuscitation with close monitoring and plan routine evacuation if stabilization occurs.\n\nBuilding on that, I need a survival likelihood grounded in initial physiology—using the summarized injury burden together with variables such as GCS, blood pressure, respiratory status, age, and mechanism—to generate a percentage estimate of survival. If the probability is low, I would favor damage control strategies, assign the highest evacuation priority, and allocate scarce resources accordingly. If the probability is favorable, I would proceed with definitive management, conserve resources, and assign standard evacuation priority.\n\nMost importantly, I don’t want those elements considered in isolation. Please integrate the objective injury burden and the survival estimate to recommend triage category, intensity of resuscitation (damage control vs definitive), and evacuation destination and timing—i.e., whether immediate transfer to a higher-echelon surgical facility is needed now, or whether a more routine pathway is appropriate if stable.\n\nWe have a detailed injury inventory and initial vital signs available; I can share those as needed. Walk through the reasoning step by step: first determine injury severity across regions and whether this constitutes major trauma, then provide the survival probability using that severity plus physiology, and finally integrate both to set triage category, resuscitation intensity, and evacuation plan. I need proper calculations—this decision can’t rely on clinical intuition alone. Whatever approach you propose should be supported by solid calculations and able to withstand scrutiny.", "required_calculators": ["Injury Severity Score (ISS)", "Trauma Score and Injury Severity Score (TRISS)"], "calculator_answers": [{"order": 1, "name": "Injury Severity Score (ISS)", "inputs": [{"field": "Head and neck worst injury?", "value": "Serious"}, {"field": "Face worst injury?", "value": "Minor"}, {"field": "Chest worst injury?", "value": "Severe"}, {"field": "Abdomen worst injury?", "value": "Critical"}, {"field": "Extremity (including pelvis) worst injury?", "value": "Serious"}, {"field": "External worst injury?", "value": "Moderate"}], "final_answer": 50, "notes": "Out of a possible 75 points"}, {"order": 2, "name": "Trauma Score and Injury Severity Score (TRISS)", "inputs": [{"field": "Trauma type", "value": "Penetrating"}, {"field": "Revised Trauma Score (RTS) points", "value": "5.88"}, {"field": "Injury Severity Score (ISS) points", "value": "50"}, {"field": "Age, years", "value": "<=54(27 years)"}], "final_answer": "18.8 %", "notes": "18.8 %\nProbability of survival"}]}
{"task_id": "medmcp-calc_027_9769f3a4", "task_scenario": "Thyroid and Parathyroid (Calcium-Phosphate Metabolism)", "task_category": "Clinical Medicine / Medicine & Organ Systems / Endocrinology & Metabolism", "patient_id": "P027_9769f3a4", "task_description": "Clinical scenario: A patient presents with symptoms suggestive of a parathyroid-related disturbance in calcium-phosphate metabolism. Total serum calcium appears abnormal, but the patient’s albumin level is not within the typical range, making uncorrected calcium potentially misleading. The clinical objective is to accurately determine true calcium status and use that to triage urgency and direct diagnostic evaluation for parathyroid pathology.\n\nWorkflow steps using calculators:\n1) Pre-assessment: Recognize that abnormal albumin can distort total calcium interpretation; therefore, direct reliance on uncorrected calcium risks misclassification of hypo- or hypercalcemia.\n2) Calculator use: Apply the Calcium Correction for Hypoalbuminemia and Hyperalbuminemia to compute the albumin-corrected calcium value so that the physiologically relevant calcium status is established.\n3) Conditional branching based on corrected calcium:\n   - If corrected calcium indicates hypercalcemia: Use this corrected value (not the uncorrected value) to determine the urgency of intervention and to prioritize evaluation for parathyroid-mediated causes versus non–parathyroid causes. Initiate appropriate immediate support if symptomatic or severe, and proceed with targeted biochemical assessment to confirm or refute parathyroid-driven hypercalcemia and to guide subsequent management planning.\n   - If corrected calcium indicates hypocalcemia: Treat this as the primary trigger to investigate parathyroid insufficiency and other contributors to impaired calcium homeostasis. Initiate supportive care if symptomatic, and pursue targeted biochemical evaluation to differentiate hypoparathyroidism from alternative etiologies.\n   - If corrected calcium is within the reference range: Deprioritize emergent calcium-directed interventions and consider alternative explanations for symptoms, including normocalcemic parathyroid conditions. Plan follow-up assessment and ensure modifiable factors are addressed before repeating calcium status.\n4) Ongoing care planning: Reassess the patient’s status using the corrected calcium classification to inform monitoring frequency, need for urgent therapy, and the scope of subsequent diagnostic work-up.\n\nRationale for sequence: The corrected calcium result is the linchpin of decision-making in parathyroid disorders; it replaces the potentially misleading uncorrected value and deterministically drives the branching into hypercalcemia, hypocalcemia, or normocalcemia pathways, which in turn guides urgency, targeted testing, and initial management.", "fuzzy_question": "I’m reviewing a case with symptoms that could suggest either hyper- or hypocalcemia—fatigue, constipation, tingling, and muscle cramping. Laboratory results show abnormal total calcium with an abnormal albumin level, so I’m cautious about relying on the unadjusted value. For clinical decisions, I want to base management on calcium as it reflects physiology after adjusting for albumin to avoid misclassification.\n\nCan you walk through this by first interpreting the calcium in light of the abnormal albumin and then using that adjusted interpretation to guide next steps? I want to gauge urgency and assess parathyroid involvement without being misled by the uncorrected number.\n\nIf, after we account for the albumin issue, the calcium is truly elevated, I need your take on urgency (especially if symptoms are significant) and what immediate stabilization, if any, should be initiated. From there, I’d want a focused work-up anchored to the adjusted calcium to differentiate parathyroid-mediated hypercalcemia from other causes—considering PTH behavior relative to calcium, phosphate, kidney function, vitamin D status, urinary calcium, and, when indicated, markers that point away from parathyroid etiologies.\n\nIf the adjusted calcium is low, that should trigger evaluation for parathyroid insufficiency and other contributors to impaired calcium balance. I’d want guidance on symptom support as needed and a targeted assessment to distinguish hypoparathyroidism from alternatives such as vitamin D deficiency, magnesium disorders, or renal losses.\n\nIf the adjusted calcium falls within the reference range, I’d de-escalate emergent calcium-directed interventions and consider other explanations for the symptoms, including a possible normocalcemic parathyroid presentation. In that scenario, I’d like a plan to optimize modifiable factors (medications, hydration, vitamin D, magnesium), set expectations for timing, and recommend a reasonable interval for reassessment.\n\nUsing the adjusted calcium classification, I want to set monitoring intensity, determine whether urgent therapy is warranted, and define the scope of subsequent testing. Please lay out the step-by-step clinical reasoning, explicitly anchored to the adjusted calcium. I need this supported by proper calculations to ensure the approach holds up to scrutiny.", "required_calculators": ["Calcium Correction for Hypoalbuminemia and Hyperalbuminemia"], "calculator_answers": [{"order": 1, "name": "Calcium Correction for Hypoalbuminemia and Hyperalbuminemia", "inputs": [{"field": "Calcium (mg/dL)", "value": "11.2 mg/dL"}, {"field": "Albumin (g/dL)", "value": "2.8 g/dL"}, {"field": "Normal albumin: 4 g/dL or 40 g/L", "value": "4 g/dL"}], "final_answer": 12.2, "notes": "12.2 mg/dL\nCorrected Calcium\nEquivalent to 3.0 mmol/L"}]}
{"task_id": "medmcp-calc_028_01e56648", "task_scenario": "Pneumonia Severity Index", "task_category": "Clinical Medicine / Medicine & Organ Systems / Infectious Diseases", "patient_id": "P028_01e56648", "task_description": "Clinical scenario: An adult presents to the emergency setting with suspected community-acquired pneumonia. The clinician must rapidly determine the site of care (outpatient, inpatient ward, or ICU) and anticipate the need for intensive respiratory or vasopressor support while ED adverse risk is considered. The workflow uses multiple pneumonia severity calculators in a structured sequence to guide decisions as information becomes available.\nStep-by-step calculator use:\n1) Start with the CRB-65 Score for Pneumonia Severity for immediate, pre-laboratory triage. This quickly stratifies risk without needing laboratory data.\n2) Branch based on CRB-65:\n   - If CRB-65 indicates low risk consistent with potential outpatient care, apply the PSI/PORT Score: Pneumonia Severity Index for CAP to refine mortality risk and confirm site-of-care suitability.\n     • If PSI/PORT is low risk, proceed with outpatient management and targeted follow-up planning.\n     • If PSI/PORT is intermediate or high risk, use SMART-COP Score for Pneumonia Severity to determine the likelihood of needing intensive respiratory or vasopressor support; high SMART-COP risk prompts ICU-level planning, whereas low SMART-COP risk supports ward-level admission.\n     • For cases admitted or observed in the ED after PSI/PORT or SMART-COP suggests non-outpatient care, apply the Severe Community-Acquired Pneumonia (SCAP) Score to estimate near-term adverse outcomes and set monitoring frequency and early escalation thresholds.\n   - If CRB-65 indicates moderate to high severity requiring further evaluation, once initial labs are available, apply the CURB-65 Score for Pneumonia Severity to refine the inpatient versus ICU decision.\n     • If CURB-65 is high risk, use SMART-COP Score for Pneumonia Severity to assess the need for intensive respiratory or vasopressor support; high SMART-COP risk directs ICU admission, while lower SMART-COP risk supports ward admission.\n     • If CURB-65 is low to intermediate, apply PSI/PORT Score to estimate mortality risk and confirm the appropriate site of care (outpatient if very low risk, ward if higher risk).\n     • For all admitted or ED-observed patients after CURB-65/PSI/PORT decisions, use the Severe Community-Acquired Pneumonia (SCAP) Score to anticipate adverse outcomes in the ED and guide monitoring intensity and early interventions.\nRationale for sequence: CRB-65 enables immediate triage without labs. PSI/PORT provides a more granular mortality risk to confirm site-of-care decisions. CURB-65 refines risk once labs are available, especially for higher severity presentations. SMART-COP targets the specific need for intensive respiratory or vasopressor support that would mandate ICU. SCAP further informs ED adverse outcome risk and monitoring needs for those not discharged.", "fuzzy_question": "I’m evaluating a patient in the ED with likely community-acquired pneumonia—fever, cough, tachypnea, and shortness of breath—and need to quickly determine the appropriate site of care: home, the ward, or ICU. Before labs return, I want a rapid bedside assessment using age, vital signs, mental status, blood pressure, respiratory rate, and overall stability to judge severity and whether outpatient care is reasonable versus immediate admission.\n\nIf that initial assessment suggests low risk and home might be safe, I still want a formal estimate of pneumonia-related mortality to confirm discharge safety. If that estimate is not truly low—more in the intermediate or higher range—please help gauge the likelihood of needing high-level respiratory support (high-flow or ventilatory assistance) or vasopressors; if that appears likely, plan for ICU-level care, and if not, a ward bed would be appropriate. For anyone kept under ED observation or admitted on that basis, I need a short-term deterioration risk tailored to the ED course to set monitoring frequency and early thresholds for escalation.\n\nIf the bedside picture indicates moderate or higher severity and we’re leaning toward admission, then once the first labs are available, I want to revisit severity using pneumonia criteria that incorporate laboratory data to help choose ward versus ICU. If that updated severity is high, please estimate the likelihood of needing intensive respiratory support or vasopressors now—if that’s probable, ICU is appropriate. If the updated severity is low to intermediate, then provide a more granular mortality risk to confirm site of care (outpatient if it’s truly very low; otherwise the ward). For all patients admitted or continued in ED observation after that decision, again provide an ED-focused near-term adverse outcome risk to guide monitoring intensity and early intervention thresholds.\n\nIf outpatient care is appropriate at any point, please outline a practical follow-up plan: timing for re-evaluation, red flags that warrant immediate return, and how closely to monitor.\n\nI need proper calculations for all of this—no decisions based on gut feeling alone. Whatever approach you suggest should be backed by validated tools and solid calculations that can withstand scrutiny.", "required_calculators": ["CRB-65 Score for Pneumonia Severity", "PSI/PORT Score: Pneumonia Severity Index for CAP", "CURB-65 Score for Pneumonia Severity", "SMART-COP Score for Pneumonia Severity", "Severe Community-Acquired Pneumonia (SCAP) Score"], "calculator_answers": [{"order": 1, "name": "CRB-65 Score for Pneumonia Severity", "inputs": [{"field": "Age ≥65", "value": "Yes(72 years)", "score": 1}, {"field": "Confusion", "value": "No", "score": 0}, {"field": "Respiratory rate ≥30/min", "value": "Yes(32 breaths/min)", "score": 1}, {"field": "SBP <90 mmHg or DBP ≤60 mmHg", "value": "Yes(SBP 92 mmHg / DBP 56 mmHg)", "score": 1}], "final_answer": 3, "notes": "High risk\nMortality risk\nUrgent hospital admission"}, {"order": 2, "name": "PSI/PORT Score: Pneumonia Severity Index for CAP", "inputs": [{"field": "Age (years)", "value": 72}, {"field": "Sex", "value": "Male", "score": 0}, {"field": "Nursing home resident", "value": "No", "score": 0}, {"field": "Neoplastic disease history", "value": "No", "score": 0}, {"field": "Liver disease history", "value": "No", "score": 0}, {"field": "Congestive heart failure history", "value": "No", "score": 0}, {"field": "Cerebrovascular disease history", "value": "No", "score": 0}, {"field": "Renal disease history", "value": "No", "score": 0}, {"field": "Altered mental status", "value": "No", "score": 0}, {"field": "Respiratory rate ≥30 breaths/min", "value": "Yes (32/min)", "score": 20}, {"field": "Systolic blood pressure <90 mmHg", "value": "No (SBP 92 mmHg)", "score": 0}, {"field": "Temperature <35°C or >39.9°C", "value": "No (38.6°C)", "score": 0}, {"field": "Pulse ≥125 beats/min", "value": "Yes (128 bpm)", "score": 10}, {"field": "Arterial pH <7.35", "value": "No (pH 7.36)", "score": 0}, {"field": "BUN ≥30 mg/dL (≥11 mmol/L)", "value": "Yes (32 mg/dL)", "score": 20}, {"field": "Sodium <130 mmol/L", "value": "No (136 mmol/L)", "score": 0}, {"field": "Glucose ≥250 mg/dL (≥14 mmol/L)", "value": "No (138 mg/dL)", "score": 0}, {"field": "Hematocrit <30%", "value": "No (38%)", "score": 0}, {"field": "Partial pressure of oxygen <60 mmHg (<8 kPa)", "value": "Yes (PaO2 52 mmHg on room air)", "score": 10}, {"field": "Pleural effusion on chest x-ray", "value": "No(Right lower lobe consolidation; no effusion; single-lobe involvement)", "score": 0}], "final_answer": 132, "notes": "Risk Class V, 27.0-29.2% mortality. Hospitalization recommended based on risk."}, {"order": 3, "name": "CURB-65 Score for Pneumonia Severity", "inputs": [{"field": "Confusion", "value": "No", "score": 0}, {"field": "BUN >19 mg/dL (>7 mmol/L urea)", "value": "Yes(32 mg/dL)", "score": 1}, {"field": "Respiratory rate ≥30", "value": "Yes(32breaths/min)", "score": 1}, {"field": "Systolic BP <90 mmHg or Diastolic BP ≤60 mmHg", "value": "Yes (DBP 56 mmHg)", "score": 1}, {"field": "Age ≥65", "value": "Yes (72 years)", "score": 1}], "final_answer": 4, "notes": "Highest risk group: 27.8% 30-day mortality.\nConsider inpatient treatment with possible intensive care admission."}, {"order": 4, "name": "SMART-COP Score for Pneumonia Severity", "inputs": [{"field": "Age group", "value": ">50 years (72 years)"}, {"field": "Systolic blood pressure <90 mmHg", "value": "No (SBP 92 mmHg)", "score": 0}, {"field": "Multilobar involvement on chest x-ray", "value": "No (single lobe)", "score": 0}, {"field": "Albumin <3.5 g/dL", "value": "Yes", "score": 1}, {"field": "Respiratory rate high (≥30 if >50 yrs)", "value": "Yes", "score": 1}, {"field": "Tachycardia ≥125 bpm", "value": "Yes (HR 128 bpm)", "score": 0}, {"field": "Confusion", "value": "No", "score": 0}, {"field": "Oxygen threshold met (PaO2 <60 mmHg if >50 yrs or SpO2 ≤90%)", "value": "Yes(PaO2 52 mmHg; SpO2 88%; FiO2 0.21)", "score": 2}, {"field": "Arterial pH <7.35", "value": "No (pH 7.36)", "score": 0}], "final_answer": 5, "notes": "High risk\n1 in 3 risk of IRVS. Consider ICU admission."}, {"order": 5, "name": "Severe Community-Acquired Pneumonia (SCAP) Score", "inputs": [{"field": "Arterial pH <7.30", "value": "No(7.36)", "score": 0}, {"field": "Systolic pressure <90 mmHg", "value": "No (SBP 92 mmHg)", "score": 0}, {"field": "Respiratory rate >30 breaths/min", "value": "Yes", "score": 9}, {"field": "BUN >30 mg/dL", "value": "Yes(32 mg/dL)", "score": 5}, {"field": "Altered mental status (e.g., confusion)", "value": "No", "score": 0}, {"field": "PaO2 (mmHg)", "value": 52}, {"field": "FiO2", "value": 0.21}, {"field": "PaO2 <54 mmHg or PaO2/FiO2 <250 mmHg", "value": "Yes (PaO2 52; P/F ≈ 248)", "score": 6}, {"field": "Age ≥80 years", "value": "No (72 years)", "score": 0}, {"field": "Multilobar/bilateral X-ray", "value": "No (single lobe)", "score": 0}], "final_answer": 20, "notes": "36.62-41.82 %\nRisk of SCAP\nRecommended for ICU, monitored bed, and/or immediate intervention"}]}
{"task_id": "medmcp-calc_029_da5363df", "task_scenario": "Transient Ischemic Attack (TIA) Risk", "task_category": "Clinical Medicine / Neurology & Mental Health / Neurosurgery & Neurology", "patient_id": "P029_da5363df", "task_description": "Scenario: A patient presents with transient focal neurological symptoms that have resolved, raising concern for a transient ischemic attack (TIA). The clinical team must rapidly stratify the near-term stroke risk, determine the appropriate disposition (admission vs expedited outpatient pathway), and prioritize the urgency of vascular imaging and specialist involvement. Workflow: 1) Start with the ABCD² Score for TIA to perform immediate bedside risk stratification based on clinical features. The ABCD² risk tier (low/moderate/high) determines the initial pathway. If the ABCD² score indicates high risk, initiate the high-acuity pathway immediately; if low or moderate risk, proceed to confirm and refine risk with subsequent calculators. 2) Next, use the Canadian Transient Ischemic Attack (TIA) Score to estimate 7-day stroke risk. This complements the ABCD² by incorporating additional clinical elements and provides a near-term prognostic estimate. Branching logic: - If ABCD² is high risk, calculate the Canadian TIA Score and, if it also indicates high near-term risk, prioritize admission and urgent imaging; if it is not high, proceed to the Emory TIPSS to detect high-risk etiologic features that may still necessitate escalation. - If ABCD² is low or moderate, calculate the Canadian TIA Score; if the Canadian score indicates high near-term risk, escalate to admission and urgent imaging; if it indicates low or moderate risk, proceed to the Emory TIPSS to uncover high-risk etiologic predictors that could still warrant urgent evaluation. 3) Use the Emory Model (TIPSS) to identify high-risk etiologic features that refine triage decisions. Deterministic triggers: TIPSS is performed when earlier steps yield low or intermediate risk to ensure high-risk mechanisms are not missed; TIPSS is also performed when earlier steps show high risk to prioritize the level of urgency and resource allocation (e.g., immediate vascular imaging vs rapid outpatient work-up). Final actions: - If TIPSS indicates high-risk features, proceed with admission and urgent comprehensive vascular evaluation. - If TIPSS does not indicate high-risk features and prior scores are low or moderate, discharge with expedited TIA clinic follow-up and immediate initiation of secondary prevention plans. The sequence ensures early risk stratification, near-term prognostics, and etiologic prioritization, with each calculator’s output deterministically guiding subsequent steps and disposition.", "fuzzy_question": "I am seeing a patient with brief focal neurologic symptoms that are now completely resolved, consistent with a possible TIA. I am deciding between admission now versus a fast-track outpatient plan with expedited follow-up.\n\nFirst, I want a quick bedside read on immediate risk using basic presentation features: age group, initial blood pressure, whether there was unilateral weakness versus isolated speech disturbance, approximate episode duration, and presence of diabetes. Please classify early risk as low, moderate, or high. If this places the patient in a high-risk bucket, flag that and assume escalation to a higher-acuity track while you continue.\n\nNext, I would like a short-term outlook that goes beyond those basics and incorporates the broader clinical context from the chart and history. Provide a concrete estimate of near-term stroke risk along with a low, moderate, or high categorization. If this outlook is high, I am inclined to admit and prioritize urgent imaging; if not, I still want to be sure we are not missing a dangerous mechanism.\n\nThen, regardless of the early read, please perform a deliberate sweep for high-risk causes that would change urgency: significant carotid disease, atrial fibrillation or other cardioembolic sources, a pattern of crescendo spells, any early evidence of tissue injury if imaging is available, symptomatic intracranial stenosis, or other red flags that would push toward inpatient care. If anything concerning is present, specify which features are present and how that should escalate the plan - do we need head-and-neck vascular imaging and neurology involvement immediately, or can that occur first via a rapid pathway?\n\nIf that etiologic sweep does not reveal high-risk features and the earlier risk reads remain low to moderate, outline a safe discharge approach: expedited TIA clinic follow-up in the very near term, immediate initiation of secondary prevention (antiplatelet, statin, blood pressure and glucose optimization), return precautions, and recommended monitoring.\n\nPlease walk through the reasoning step by step - start with the bedside tier, then the short-term outlook, then the mechanism sweep - and end with a clear disposition and imaging plan. I am deciding between admission now versus using a rapid pathway, and I want to avoid missing someone who is about to declare a stroke.\n\nI need proper calculations rather than clinical intuition alone. Whatever approach you suggest, ensure it is supported by solid calculations and clearly justified. This needs to hold up to scrutiny.", "required_calculators": ["ABCD² Score for TIA", "Canadian Transient Ischemic Attack (TIA) Score", "Emory Model (TIPSS)"], "calculator_answers": [{"order": 1, "name": "ABCD² Score for TIA", "inputs": [{"field": "Age ≥60 years", "value": "Yes (68 years)", "score": 1}, {"field": "BP ≥140/90 mmHg", "value": "Yes (162/94 mmHg at triage)", "score": 1}, {"field": "Clinical features of the TIA", "value": "Speech disturbance without weakness (transient expressive aphasia)", "score": 1}, {"field": "Duration of symptoms", "value": "10-59 minutes (35 minutes)", "score": 1}, {"field": "History of diabetes", "value": "No", "score": 0}], "final_answer": 4, "notes": "Per the validation study, 4-5 points: Moderate Risk\n2-Day Stroke Risk: 4.1%\n7-Day Stroke Risk: 5.9%\n90-Day Stroke Risk: 9.8%"}, {"order": 2, "name": "Canadian Transient Ischemic Attack (TIA) Score", "inputs": [{"field": "First TIA in lifetime", "value": "Yes", "score": 2}, {"field": "Symptoms ≥10 mins", "value": "Yes (35 minutes)", "score": 2}, {"field": "History of carotid stenosis", "value": "No", "score": 0}, {"field": "Already on antiplatelet therapy", "value": "No", "score": 0}, {"field": "History of gait disturbance", "value": "No", "score": 0}, {"field": "History of unilateral weakness", "value": "No", "score": 0}, {"field": "History of vertigo", "value": "No", "score": 0}, {"field": "Initial triage diastolic blood pressure ≥110 mmHg", "value": "No (94 mmHg)", "score": 0}, {"field": "Dysarthria or aphasia (history or examination)", "value": "Yes (expressive aphasia)", "score": 1}, {"field": "Atrial fibrillation on ECG", "value": "No (sinus rhythm)", "score": 0}, {"field": "Infarction (new or old) on CT", "value": "No (non-contrast head CT: no acute or chronic infarct)", "score": 0}, {"field": "Platelet count ≥400×109/L", "value": "No (242×10^9/L)", "score": 0}, {"field": "Glucose ≥15 mmol/L (270 mg/dL)", "value": "No (108 mg/dL; 6.0 mmol/L)", "score": 0}], "final_answer": 5, "notes": "0.5 %\nMedium risk of stroke in the next 7 days"}, {"order": 3, "name": "Emory Model (TIPSS)", "inputs": [{"field": "Total Bilirubin?", "value": "0.7 mg/dL"}, {"field": "ALT?", "value": "22 U/L"}, {"field": "Pre-TIPSS Hepatic Encephalopathy?", "value": "No"}, {"field": "Urgency of TIPSS?", "value": "Elective"}], "final_answer": 0, "notes": "Score 0\nRisk Category\nLow Risk\nEstimated Mortality Rates after TIPSS:\nEstimated 3-month Mortality Rates after TIPSS\n10 %\nEstimated 12-month Mortality Rates after TIPSS\n30-33 %\nEstimated 36-month Mortality Rates after TIPSS\n30 %"}]}
{"task_id": "medmcp-calc_030_f9eb324e", "task_scenario": "Assessment of Inhalation Injury in Burns", "task_category": "Clinical Medicine / Emergency, Critical Care & Perioperative / Emergency Medicine & Trauma", "patient_id": "P030_f9eb324e", "task_description": "Scenario: A patient with thermal burns presents to the emergency department with signs suggestive of smoke inhalation (soot in the airway, facial burns, hoarseness, cough). The clinical team must rapidly determine inhalation injury severity, decide on airway and ventilatory support, and triage the patient to the appropriate level of care. Workflow using calculators: 1) Arterial Blood Gas (ABG) Analyzer: Immediately interpret oxygenation, ventilation, and acid–base status. This step determines whether there is critical hypoxemia, hypercapnia, or acidosis. Branch A (if ABG indicates severe derangement): prioritize airway control and proceed promptly to bronchoscopic evaluation; after bronchoscopy, classify severity with Abbreviated Injury Score (AIS) for Inhalation Injury, then obtain chest CT and score with RADS (Radiologist’s Score) for Smoke Inhalation Injury. Branch B (if ABG indicates only mild or moderate derangement): obtain chest CT early and calculate RADS first. 2) RADS (Radiologist’s Score) for Smoke Inhalation Injury: Score CT findings to stratify parenchymal and airway involvement. If RADS is moderate–severe, proceed to bronchoscopy and apply Abbreviated Injury Score (AIS) for Inhalation Injury; if RADS is mild, consider deferring invasive bronchoscopy unless clinical deterioration occurs. 3) Abbreviated Injury Score (AIS) for Inhalation Injury: Use bronchoscopic findings to grade airway injury (soot, edema, erythema, ulceration). AIS provides an objective airway injury severity linked to risks of obstruction and need for airway clearance. 4) A-HIPI: Integrate physiologic status (from ABG Analyzer), imaging severity (RADS category), and bronchoscopic severity (AIS grade) into a composite risk profile for smoke inhalation injury. Use this output to determine level of care (ICU vs monitored ward), frequency of re-assessment (repeat ABG/bronchoscopy), and the urgency of respiratory support escalation (e.g., ventilatory support, bronchoscopy for airway toilet). Decision chaining and conditional flow: ABG Analyzer results determine whether bronchoscopy precedes CT (Branch A) or CT precedes bronchoscopy (Branch B). RADS severity determines the necessity of bronchoscopy and AIS grading in Branch B. AIS grading, combined with ABG and RADS, is used as key inputs to A-HIPI to finalize disposition and monitoring intensity. The sequence ensures each calculator informs the next step and that intermediate results trigger different pathways tailored to the patient's physiologic and anatomic injury.", "fuzzy_question": "Evaluating a patient with burn injury and suspected smoke inhalation in the emergency setting: facial burns, soot in the oropharynx and nares, hoarseness, and a harsh cough. The patient is breathing spontaneously with increased work of breathing, and oxygen saturation is concerning. I need to determine how significant the inhalation component is, whether early airway protection is indicated, and the appropriate location for ongoing care.\n\nPlease walk through the arterial blood gas when available—oxygenation, ventilation, and acid-base—to distinguish clearly severe disturbance (true hypoxemia, rising CO2, acidemia) from a more modest abnormality. If findings are clearly severe, I am inclined to prioritize airway control and perform early bronchoscopic evaluation before advanced imaging; once stable and supported, we can proceed to imaging. If the gas shows only mild to moderate abnormalities, I would obtain a chest CT first to estimate the relative contributions of airway vs parenchymal involvement.\n\nFrom the CT, provide a structured, clinically meaningful read categorized as mild, moderate, or severe involvement to gauge the extent of smoke-related injury. If the appearance is moderate to severe, proceed with bronchoscopy to directly assess the mucosa and clear debris; if it appears truly mild, defer invasive evaluation unless clinical status worsens.\n\nWhen scoping, please use standardized descriptors—soot burden, degree of edema and erythema, and any ulceration—to assign an objective airway injury grade linked to obstruction risk and the likelihood of needing airway toilet.\n\nIntegrate the physiology from the gas, the CT severity category, and the bronchoscopic grade into an overall risk profile for smoke inhalation. Based on that, recommend disposition (ICU vs closely monitored bed), the frequency of reassessment over the next day (repeat gases and whether/when to repeat bronchoscopy), and the intensity of respiratory support (supplemental oxygen vs high-flow or noninvasive, thresholds for intubation, and the urgency of bronchoscopic airway toilet). Make it explicit how each data point informs the next decision to avoid missing critical steps.\n\nI need objective, calculation-based assessment and transparent reasoning so the approach stands up to scrutiny.", "required_calculators": ["Arterial Blood Gas (ABG) Analyzer", "RADS (Radiologist’s Score) for Smoke Inhalation Injury", "Abbreviated Injury Score (AIS) for Inhalation Injury", "A-HIPI"], "calculator_answers": [{"order": 1, "name": "Arterial Blood Gas (ABG) Analyzer", "inputs": [{"field": "pH", "value": 7.34}, {"field": "PaCO2", "value": "48 mm Hg"}, {"field": "HCO3-", "value": "25 mEq/L"}, {"field": "Sodium", "value": "140 mEq/L"}, {"field": "Chloride", "value": "104 mEq/L"}, {"field": "Albumin", "value": "3.5 g/dL"}, {"field": "If respiratory process present, chronicity", "value": "Acute"}], "final_answer": "Primary Respiratory Acidosis, Acute, with: Appropriately Compensated by Metabolic Alkalosis", "notes": "Primary Respiratory Acidosis, Acute, with: Appropriately Compensated by Metabolic Alkalosis."}, {"order": 2, "name": "RADS (Radiologist’s Score) for Smoke Inhalation Injury", "inputs": [{"field": "Worst finding, 1st quadrant left lung", "value": "Ground glass opacification", "score": 2}, {"field": "Worst finding, 2nd quadrant left lung", "value": "Increased interstitial markings", "score": 1}, {"field": "Worst finding, 3rd quadrant left lung", "value": "Ground glass opacification", "score": 2}, {"field": "Worst finding, 4th quadrant left lung", "value": "Normal", "score": 0}, {"field": "Worst finding, 1st quadrant right lung", "value": "Ground glass opacification", "score": 2}, {"field": "Worst finding, 2nd quadrant right lung", "value": "Increased interstitial markings", "score": 1}, {"field": "Worst finding, 3rd quadrant right lung", "value": "Ground glass opacification", "score": 2}, {"field": "Worst finding, 4th quadrant right lung", "value": "Increased interstitial markings", "score": 1}], "final_answer": 11, "notes": "RADS >8 associated with 12.7x increased risk of composite endpoint including pneumonia, acute lung injury/ARDS, and death."}, {"order": 3, "name": "Abbreviated Injury Score (AIS) for Inhalation Injury", "inputs": [{"field": "Bronchoscopic findings", "value": "Moderate erythema, carbonaceous deposits, bronchorrhea, or bronchial obstruction present"}], "final_answer": "Grade 2", "notes": "Grade 2\nAIS for inhalation injury\nModerate injury\n57% in-hospital survival"}, {"order": 4, "name": "A-HIPI", "inputs": [{"field": "Age", "value": "42 years"}, {"field": "Albumin", "value": "3.5 g/dL"}, {"field": "Bulk", "value": "No bulky disease"}, {"field": "Gender", "value": "Male"}, {"field": "Hemoglobin", "value": "14.2 g/dL"}, {"field": "Lymphocyte count", "value": "1.4 x10^9/L"}, {"field": "Stage", "value": "Stage IIB"}], "final_answer": "80.83%", "notes": "Progression Free Survival at 5 years\n80.83%\nOverall Survival at 5 years\n94.67%"}]}
{"task_id": "medmcp-calc_031_b61e1f6d", "task_scenario": "Substance Withdrawal Assessment", "task_category": "Clinical Medicine / Neurology & Mental Health / Mental & Psychological Health", "patient_id": "P031_b61e1f6d", "task_description": "Scenario: An adult presents to the emergency department with suspected alcohol and opioid withdrawal. The clinical team needs to rapidly characterize polysubstance use patterns, predict risk for severe alcohol withdrawal, quantify current withdrawal severity for each substance, select an appropriate monitoring approach, and determine readiness for ED-initiated buprenorphine if opioid withdrawal is confirmed. Workflow steps: 1) Use the Brief Addiction Monitor (BAM) to profile recent substance use behaviors, including alcohol and opioid exposure, to inform whether both alcohol and opioid withdrawal assessments are warranted. 2) If BAM indicates recent alcohol use with risk for withdrawal, apply the Prediction of Alcohol Withdrawal Severity Scale to estimate the likelihood of severe alcohol withdrawal during hospitalization; this risk estimate determines the monitoring strategy. 3) Alcohol branch—monitoring selection driven by the Prediction of Alcohol Withdrawal Severity Scale result: • If the risk is high, choose either the Glasgow Modified Alcohol Withdrawal Scale (GMAWS) for brief, frequent ED assessments when the patient can engage in symptom reporting, or the Modified Minnesota Detoxification Scale (mMINDS) when the patient has limited ability to self-report or requires higher-acuity monitoring. • If the risk is not high, use CIWA-Ar for Alcohol Withdrawal to conduct symptom-triggered assessments and guide medication titration. Scores from CIWA-Ar, GMAWS, or mMINDS then determine medication frequency, need for escalation of care, and disposition. 4) Opioid branch—if BAM indicates recent opioid use with probable withdrawal, apply the COWS Score for Opiate Withdrawal to quantify severity. 5) If COWS indicates moderate to severe withdrawal, use the Emergency Department-Initiated Buprenorphine for Opioid Use Disorder (EMBED) to confirm OUD, verify withdrawal and readiness, and guide ED-initiated buprenorphine and linkage to follow-up; if COWS is mild or not consistent with withdrawal, provide supportive care and reassess as needed. 6) Integrate findings from alcohol and opioid pathways to balance treatment decisions (e.g., ongoing benzodiazepine-based alcohol withdrawal management alongside appropriate buprenorphine initiation) and finalize monitoring frequency and disposition.", "fuzzy_question": "I’m evaluating a patient in the ED with suspected concurrent alcohol and opioid withdrawal. Clinical features include diaphoresis, anxiety, tremor, myalgias, and gastrointestinal symptoms. I’m not certain how much each substance is contributing. Before treatment, I want a brief, structured summary of recent alcohol and opioid use: quantity and frequency over the recent period, any binges or periods without use, overdoses, cravings, and any risky or protective behaviors. That should clarify whether we need to formally assess for both alcohol and opioid withdrawal now.\n\nIf the alcohol history suggests meaningful withdrawal risk, I’d like a solid bedside estimate of the likelihood of severe alcohol withdrawal during this ED visit or a possible admission. That estimate should determine how closely we monitor.\n\nDepending on that risk:\n- If it’s high, I’m choosing between a patient-reported, rapid, frequent symptom-based approach versus a more observational, objective approach that doesn’t rely on self-report and suits confusion, sedation, or higher-acuity needs.\n- If the severe-risk estimate isn’t high, I’m comfortable using a standard symptom-triggered alcohol withdrawal protocol where scale scores guide benzodiazepine dosing.\n\nIn all cases, I need objective scores to direct reassessment frequency and dosing, when to escalate to higher-acuity care, and when the patient is stable for discharge or floor placement.\n\nOn the opioid side, if recent use and exam suggest true withdrawal, please quantify current severity. If it is moderate to severe, I want to proceed via the ED buprenorphine pathway: confirm opioid use disorder, verify objective withdrawal and readiness to start, initiate appropriately, and arrange linkage to follow-up. If severity is mild or inconsistent with withdrawal, we should provide supportive care and reassess.\n\nFinally, please reconcile both tracks: how to safely run benzodiazepine-based alcohol withdrawal management while initiating buprenorphine, how to pace monitoring for each, and how to determine disposition. I’m particularly concerned about oversedation and respiratory compromise, so call out any factors that would push toward higher-acuity monitoring or delaying buprenorphine until safer.\n\nWhat’s your clinical thinking here? Please walk through it step by step with the objective numbers behind each decision point. I need proper calculations—not just clinical intuition—and an approach backed by solid calculations that will hold up to scrutiny.", "required_calculators": ["Brief Addiction Monitor (BAM)", "Prediction of Alcohol Withdrawal Severity Scale", "CIWA-Ar for Alcohol Withdrawal", "Glasgow Modified Alcohol Withdrawal Scale (GMAWS)", "Modified Minnesota Detoxification Scale (mMINDS)", "COWS Score for Opiate Withdrawal", "Emergency Department-Initiated Buprenorphine for Opioid Use Disorder (EMBED)"], "calculator_answers": [{"order": 1, "name": "Brief Addiction Monitor (BAM)", "inputs": [{"field": "physical_health_past_30_days", "value": "Fair (+3)", "score": 3}, {"field": "insomnia_nights_past_30_days", "value": "20 nights (16-30 category, +4)", "score": 4}, {"field": "days_depressed_anxious_angry_past_30_days", "value": "22 days (16-30 category, +4)", "score": 4}, {"field": "days_drink_any_alcohol_past_30_days", "value": "20 days (16-30 category, +4)", "score": 4}, {"field": "days_used_illegal_or_abused_rx_drugs_past_30_days", "value": "25 days (16-30 category, +4)", "score": 4}, {"field": "In the past 30 days, how many days did you have at least 5 drinks (if you are a man) or at least 4 drinks (if you are a woman)?", "value": "9-15", "score": 3}, {"field": "In the past 30 days, how many days did you use marijuana?", "value": "0", "score": 0}, {"field": "7B. In the past 30 days, how many days did you use sedatives/tranquilizers?\n“Benzos,” Valium, Xanax, Ativan, Ambien, “barbs,” phenobarbital, downers, etc.", "value": "4-8", "score": 2}, {"field": "In the past 30 days, how many days did you use cocaine/crack?", "value": "0", "score": 0}, {"field": "In the past 30 days, how many days did you use other stimulants?", "value": "0", "score": 0}, {"field": "In the past 30 days, how many days did you use opiates?", "value": "25", "score": 4}, {"field": "In the past 30 days, how many days did you use inhalants?", "value": "0", "score": 0}, {"field": "In the past 30 days, how many days did you use other drugs?", "value": "0", "score": 0}, {"field": "cravings_urges_intensity_past_30_days", "value": "Considerably (+3)", "score": 3}, {"field": "confidence_abstinence_next_30_days", "value": "Slightly (+1)", "score": 1}, {"field": "days_attended_self_help_meetings_past_30_days", "value": "0 days (+0)", "score": 0}, {"field": "days_in_risky_people_places_things_past_30_days", "value": "20 days (16-30 category, +4)", "score": 4}, {"field": "religion_spirituality_supports_recovery", "value": "Not at all (+0)", "score": 0}, {"field": "days_spent_much_of_time_at_work_school_volunteer_past_30_days", "value": "2 days (1-3 category, +1)", "score": 1}, {"field": "enough_legal_income_for_necessities", "value": "No (+0)", "score": 0}, {"field": "bothered_by_arguments_problems_with_family_friends_past_30_days", "value": "Moderately (+2)", "score": 2}, {"field": "days_in_contact_with_supportive_family_friends_past_30_days", "value": "6 days (4-8 category, +2)", "score": 2}, {"field": "satisfaction_progress_toward_recovery_goals", "value": "Slightly (+1)", "score": 1}], "final_answer": 42, "notes": "42 points\nUse factors: 11 points\nRisk factors: 20 points\nProtective factors: 4 points."}, {"order": 2, "name": "Prediction of Alcohol Withdrawal Severity Scale", "inputs": [{"field": "threshold_consumed_alcohol_last_30_days_or_positive_bal_on_admission", "value": "Yes (last drink 36 hours ago; BAL 0 mg/dL)", "score": 1}, {"field": "pawss_item_1_previous_alcohol_withdrawal_episodes", "value": "Yes (multiple prior mild-moderate AWS requiring benzodiazepines)", "score": 1}, {"field": "pawss_item_2_previous_withdrawal_seizures", "value": "Yes (single event ~11 months ago; no active seizure disorder)", "score": 1}, {"field": "pawss_item_3_previous_delirium_tremens", "value": "No", "score": 0}, {"field": "Have you ever experienced blackouts?", "value": "No", "score": 0}, {"field": "pawss_item_4_concurrent_sedative_hypnotic_use_past_90_days", "value": "Yes (intermittent non-prescribed alprazolam 0.5 mg 1-2×/week)", "score": 1}, {"field": "pawss_item_5_prior_inpatient_detox_or_rehab_for_alcohol", "value": "Yes (2 prior detox admissions last year)", "score": 1}, {"field": "pawss_item_6_current_intense_craving_for_alcohol", "value": "Yes (reports strong urge to drink today)", "score": 1}, {"field": "pawss_item_7_autonomic_hyperactivity_on_assessment", "value": "Yes (diaphoresis, tremor; pulse 108 bpm though <120)", "score": 1}, {"field": "pawss_item_8_positive_blood_alcohol_level_0_20_or_more_at_admission", "value": "No (BAL 0)", "score": 0}, {"field": "pawss_item_9_concomitant_cns_depressant_substance_use", "value": "Yes (daily opioid use; occasional benzodiazepines)", "score": 1}], "final_answer": 7, "notes": "7 points\nPAWSS\nHigh risk\nLikelihood ratio 174 for complicated AWS (withdrawal hallucinosis, withdrawal-related seizures, or delirium tremens)"}, {"order": 3, "name": "CIWA-Ar for Alcohol Withdrawal", "inputs": [{"field": "nausea_vomiting", "value": "Intermittent nausea with dry heaves (4)", "score": 4}, {"field": "tremor", "value": "Moderate, with patient's arms extended (4)", "score": 4}, {"field": "paroxysmal_sweats", "value": "Beads of sweat obvious on forehead (4)", "score": 4}, {"field": "anxiety", "value": "Moderately anxious (4)", "score": 4}, {"field": "agitation", "value": "Moderately fidgety and restless (4)", "score": 4}, {"field": "tactile_disturbances", "value": "Very mild itching/pins and needles (1)", "score": 1}, {"field": "auditory_disturbances", "value": "Very mild harshness, minimally frightening (1)", "score": 1}, {"field": "visual_disturbances", "value": "Very mild sensitivity to light (1)", "score": 1}, {"field": "headache_fullness_in_head", "value": "Moderate (3)", "score": 3}, {"field": "orientation_clouding_of_sensorium", "value": "Oriented, can do serial additions (0)", "score": 0}], "final_answer": 26, "notes": "26 points\nPatients with scores ≥20 frequently require medication for withdrawal, and may also require admission to the ICU for observation for seizures or development of delirium tremens, and more frequent medication dosing."}, {"order": 4, "name": "Glasgow Modified Alcohol Withdrawal Scale (GMAWS)", "inputs": [{"field": "tremor", "value": "Present with arms at rest (2)", "score": 2}, {"field": "sweating", "value": "Moist skin (1)", "score": 1}, {"field": "hallucinations", "value": "Uncertain or patient reports but not distressed (1)", "score": 1}, {"field": "orientation", "value": "Orientated (0)", "score": 0}, {"field": "agitation", "value": "Distressed or pacing (2)", "score": 2}], "final_answer": 6, "notes": "6 points\nGMAWS Score\nRecommended medication: Diazepam 20 mg PO/IV ×1\nAlt: Lorazepam 4 mg\nReassess in 1 hour"}, {"order": 5, "name": "Modified Minnesota Detoxification Scale (mMINDS)", "inputs": [{"field": "pulse_bpm", "value": "108 bpm (90-110 category, +1)", "score": 1}, {"field": "diastolic_bp_mmhg", "value": "98 mmHg (90-110 category, +1)", "score": 1}, {"field": "tremor", "value": "Moderate - noticeably visible with arms extended (+4)", "score": 4}, {"field": "sweat", "value": "Beads visible (+4)", "score": 4}, {"field": "hallucinations", "value": "Mild - mostly lucid, sporadic/rare (+1)", "score": 1}, {"field": "agitation_rass", "value": "RASS +2 (Moderately fidgety/restless, +6)", "score": 6}, {"field": "orientation", "value": "Oriented x3 (0)", "score": 0}, {"field": "delusions", "value": "Absent (0)", "score": 0}, {"field": "seizures", "value": "Not actively seizing (0)", "score": 0}], "final_answer": 17, "notes": "17 points\nmMINDS"}, {"order": 6, "name": "COWS Score for Opiate Withdrawal", "inputs": [{"field": "resting_pulse_rate_bpm", "value": "108 bpm (+2)", "score": 2}, {"field": "sweating", "value": "Beads of sweat on brow/face (+3)", "score": 3}, {"field": "restlessness", "value": "Frequent shifting/extraneous movements of legs/arms (+3)", "score": 3}, {"field": "pupil_size", "value": "Moderately dilated (+2)", "score": 2}, {"field": "bone_joint_aches", "value": "Rubbing joints/muscles and unable to sit still due to discomfort (+4)", "score": 4}, {"field": "runny_nose_tearing", "value": "Nose running or tearing (+2)", "score": 2}, {"field": "gi_upset", "value": "Vomiting or diarrhea (+3)", "score": 3}, {"field": "tremor", "value": "Slight tremor observable (+2)", "score": 2}, {"field": "yawning", "value": "Three or more times during assessment (+2)", "score": 2}, {"field": "anxiety_irritability", "value": "Obviously irritable/anxious (+2)", "score": 2}, {"field": "gooseflesh_skin", "value": "Piloerection felt/hairs standing up (+3)", "score": 3}], "final_answer": 28, "notes": "28 points\nModerately severe withdrawal"}, {"order": 7, "name": "Emergency Department-Initiated Buprenorphine for Opioid Use Disorder (EMBED)", "inputs": [{"field": "oud_present", "value": "Yes (DSM-5 history consistent: daily use, cravings, unsuccessful cut-down, tolerance/withdrawal, continued use despite harm)"}, {"field": "readiness_to_start_buprenorphine_today", "value": "Yes (Brief Negotiation Interview completed; patient agrees to start)"}, {"field": "assessed_cows_score_category", "value": ">12 (Moderate to Severe; actual COWS 28)"}, {"field": "patient_pregnant", "value": "No"}, {"field": "prescriber_buprenorphine_waiver_status", "value": "Yes (able to prescribe/dispense per ED protocol)"}], "final_answer": "Advice: Start 8mg BUP", "notes": "Advice: Start 8mg BUP\nI have used the MDCalc-EMBED Buprenorphine Initiation decision support calculator to assess this patient for opioid use disorder, opioid withdrawal, and readiness for treatment. Using this calculator, I determined that this patient has:\n(1) Opioid use disorder.\n(2) A clinical opioid withdrawal scale of greater than 12.\n(3) Has expressed readiness to begin treatment with buprenorphine.\nThe patient will receive:\n(1) Buprenorphine 8 mg in the ED today and then be observed for at least 30 minutes to ensure no side effects to the medication.\n(2) A prescription for buprenorphine 16mg sublingual daily for 3 days and for naloxone nasal spray.\n(3) Referral to treatment.\n(4) Education on opioid use disorder, naloxone use, this study and instructions to return to the emergency department in 24 hours for their next dose of buprenorphine if they are unable to schedule an appointment with a buprenorphine prescriber tomorrow."}]}
{"task_id": "medmcp-calc_032_174b5917", "task_scenario": "Streptococcal Pharyngitis Probability", "task_category": "Clinical Medicine / Medicine & Organ Systems / Sensory Systems (Ophthalmology / ENT / Dermatology)", "patient_id": "P032_174b5917", "task_description": "Scenario: In an ENT/primary care setting, a patient presents with acute sore throat. The clinician seeks to estimate the probability that the pharyngitis is caused by Group A Streptococcus (GAS) to guide management while promoting antibiotic stewardship. Workflow: Step 1—Initial risk stratification using the Centor Score (Modified/McIsaac) for Strep Pharyngitis. This provides an age-adjusted, widely adopted starting estimate of GAS probability and suggests an initial management category (low, intermediate, high risk). Decision Point A: If Centor indicates low risk, proceed with supportive care and no further calculators. If Centor indicates intermediate or high risk, advance to Step 2. Step 2—Secondary refinement using the FeverPAIN Score for Strep Pharyngitis. This parallel scoring system incorporates symptom characteristics that can recalibrate GAS probability. Decision Point B: If Centor and FeverPAIN both indicate high risk, empiric treatment is favored; if both indicate low risk, supportive care is favored. If the results are intermediate or discordant, advance to Step 3. Step 3—Adjudication using the Attia Criteria for Evaluation of Pharyngitis. This third validated tool serves as a tie-breaker when prior scores are borderline or conflicting. Decision Point C: If Attia is strongly suggestive of GAS, treat empirically; if Attia suggests low likelihood, favor supportive care; if Attia is equivocal, prioritize symptom management and consider confirmatory pathways rather than immediate antibiotics. Rationale: The sequence leverages an initial standard (Centor), refines with an alternative perspective (FeverPAIN), and resolves uncertainty with Attia, ensuring that each calculator’s output deterministically triggers whether subsequent calculators are used and what management path is chosen.", "fuzzy_question": "I’m evaluating an adult in clinic with an acute sore throat and trying to decide whether this is likely strep and whether to start antibiotics or focus on supportive care. The patient has no significant comorbidities. Symptoms began recently. There was a history of fever at home with improvement since then. The patient reports painful swallowing and tender anterior cervical lymph nodes. On exam, the tonsils are enlarged with patchy white exudates. There is faint palatal petechiae, no rash, no trismus or muffled voice, and the airway appears stable. The patient notes a mild dry cough and slight rhinorrhea, without lower respiratory symptoms. No penicillin allergy and not immunocompromised.\n\nI’d like to reason through this in a stepwise way rather than jump straight to treatment. First, can we look at the classic bedside features—fever history, tonsillar exudate, tender anterior cervical nodes, and whether there’s cough—and factor in age to get an initial feel for the likelihood of strep? Please translate that into a probability estimate and a clear risk band (low, intermediate, or high), and indicate whether that alone would argue for simple supportive care or for taking a closer look.\n\nIf that first take isn’t clearly low, I want a second pass using a symptom-focused lens that weighs factors such as fever, visible pus on the tonsils, early presentation after onset, the degree of tonsillar inflammation, and whether there’s no cough or cold-type symptoms. Show how that reshapes the probability and whether it pushes management toward or away from antibiotics. If both the first and second looks align strongly toward strep, I’m comfortable with empiric treatment; if they both lean away, I’d prefer supportive care and no antibiotics.\n\nIf those two views don’t agree or still sit in the middle, please adjudicate with the broader clinical picture that gives extra weight to findings like palatal petechiae and scarlatiniform rash alongside the usual sore throat signs. If that final pass comes out strongly in favor, treat empirically; if it points against, favor supportive care. And if it’s still uncertain after that, let’s prioritize symptom relief and consider a rapid swab or culture rather than starting antibiotics today.\n\nPlease provide quantitative probability estimates at each stage and be explicit about which risk band the patient is in at that point, so it’s clear why we’re proceeding or stopping. Tie each stage to a concrete management recommendation: when to stick with analgesics, fluids, and watchful waiting; when to test before treating; and when to go straight to a narrow-spectrum antibiotic—plus safety-net advice for the next few days and what would prompt re-evaluation.\n\nI really need proper calculations on this—can’t make this decision based on clinical intuition alone. Whatever approach you suggest, please ensure it’s backed by solid calculations that can stand up to scrutiny.", "required_calculators": ["Centor Score (Modified/McIsaac) for Strep Pharyngitis", "FeverPAIN Score for Strep Pharyngitis", "Attia Criteria for Evaluation of Pharyngitis"], "calculator_answers": [{"order": 1, "name": "Centor Score (Modified/McIsaac) for Strep Pharyngitis", "inputs": [{"field": "Age", "value": "15-44 years", "score": 0}, {"field": "Exudate or swelling on tonsils", "value": "Yes", "score": 1}, {"field": "Tender/swollen anterior cervical lymph nodes", "value": "Yes", "score": 1}, {"field": "Temp >38°C (100.4°F)", "value": "Yes", "score": 1}, {"field": "Cough", "value": "Cough present", "score": 0}], "final_answer": 3, "notes": "28% - 35%\nConsider rapid strep testing and/or culture."}, {"order": 2, "name": "FeverPAIN Score for Strep Pharyngitis", "inputs": [{"field": "Fever in past 24 hours", "value": "Yes", "score": 1}, {"field": "Absence of cough or coryza", "value": "No", "score": 0}, {"field": "Symptom onset ≤3 days", "value": "Yes", "score": 1}, {"field": "Purulent tonsils", "value": "Yes", "score": 1}, {"field": "Severe tonsil inflammation", "value": "Yes", "score": 1}], "final_answer": 4, "notes": "62-65% isolation of streptococcus.\nConsider antibiotics."}, {"order": 3, "name": "Attia Criteria for Evaluation of Pharyngitis", "inputs": [{"field": "Scarlatiniform rash present?", "value": "No"}, {"field": "Moderate to severe cervical node lymphadenopathy?", "value": "Yes"}, {"field": "Moderate to severe tonsillar swelling or exudate?", "value": "Yes"}, {"field": "Absence of coryza?", "value": "No"}], "final_answer": 2, "notes": "Intermediate likelihood of Streptococcal pharyngitis as per Attia criteria"}]}
{"task_id": "medmcp-calc_033_986a0e9c", "task_scenario": "Fall Risk Assessment", "task_category": "Clinical Medicine / Special Populations & General Tools / Geriatric Medicine", "patient_id": "P033_986a0e9c", "task_description": "Scenario: An older adult presents for a structured fall risk assessment to guide safety planning and targeted interventions. The clinic aims to quantify balance-related fall risk, then broaden risk profiling to include non-balance factors before choosing an intervention intensity. Workflow: 1) Begin with the Berg Balance Scale (BBS) to quantify balance impairment and baseline fall risk. The BBS serves as the primary standardized measure to stratify risk into low, moderate, or high categories. 2) Decision point: If the BBS indicates low fall risk, proceed with routine prevention recommendations and plan periodic re-evaluation; do not administer A-HIPI at this time. If the BBS indicates moderate or high fall risk, perform A-HIPI next to capture additional fall-related risk domains beyond balance. 3) Administer A-HIPI to refine risk stratification by integrating broader factors that influence falls. 4) Decision point: Combine the BBS and A-HIPI risk tiers to select an intervention pathway. If both tools indicate high risk, initiate a more intensive, multidisciplinary fall-prevention plan and closer follow-up. If A-HIPI moderates the risk estimate (e.g., high by BBS but not high by A-HIPI), tailor a medium-intensity plan emphasizing balance training and environmental modifications. If BBS was low and A-HIPI was skipped, proceed with standard fall-prevention education and routine monitoring. 5) Document the combined risk classification, implement the selected plan, and schedule follow-up reassessment using the BBS to monitor improvement and determine if A-HIPI is later warranted.", "fuzzy_question": "I’m evaluating a patient who’s feeling unsteady and had a near-fall. I’m determining the best approach to gauge concern and decide how aggressive to be with prevention. My plan is to start with a standard balance assessment to establish a baseline and categorize risk as low, moderate, or high. If that appears low, I’d stick with routine fall-prevention education and plan to recheck the same balance measure at a future visit rather than adding more screening that day. If it falls in the moderate or higher range, I’d follow up right away with a broader fall-risk review covering non-balance factors—medications with fall potential, vision, neuropathy or other neurologic issues, mood or cognitive changes, continence, home environment, and recent health changes—to determine whether the overall picture is truly higher risk.\n\nFrom there, I’d integrate both impressions to set intensity. If both the balance test and the broader profile indicate high risk, I’d proceed with a more intensive, team-based plan and closer follow-up. If the second look tempers the first (for example, the balance score is concerning but the broader profile doesn’t strongly suggest high risk), I’d favor a medium-intensity plan focused on targeted balance work and practical home modifications. If the initial balance result is reassuring and the broader review isn’t done that day, I’d continue with standard education and routine monitoring.\n\nIn all cases, I want the final risk determination documented clearly—what the balance assessment and broader factors showed—and the chosen plan implemented. I also want a follow-up scheduled to repeat the same balance measure to assess trajectory and decide then whether the broader review is necessary.\n\nWhat’s your take on walking this through step by step? I’m weighing simplicity versus escalation and want to prevent a fall. I need evidence-based risk quantification—not just clinical intuition. Whatever approach you suggest, please back it with appropriate calculations so it holds up to scrutiny.", "required_calculators": ["Berg Balance Scale (BBS)", "A-HIPI"], "calculator_answers": [{"order": 1, "name": "Berg Balance Scale (BBS)", "inputs": [{"field": "Sitting to standing", "value": "Able to stand independently using hands (+3)", "score": 3}, {"field": "Standing unsupported", "value": "Able to stand 2 minutes with supervision (+3)", "score": 3}, {"field": "Sitting with back unsupported", "value": "Able to sit safely and securely for 2 minutes (+4)", "score": 4}, {"field": "Standing to sitting", "value": "Controls descent by using hands (+3)", "score": 3}, {"field": "Transfers", "value": "Able to transfer safely with minor use of hands (+4)", "score": 4}, {"field": "Standing unsupported with eyes closed", "value": "Able to stand 10 seconds with supervision (+3)", "score": 3}, {"field": "Standing unsupported with feet together", "value": "Able to place feet together independently but unable to hold for 30 seconds (+2)", "score": 2}, {"field": "Reaching forward with outstretched arm while standing", "value": "Can reach forward 12 cm (5 inches) safely (+3)", "score": 3}, {"field": "Pick up object from the floor from a standing position", "value": "Able to pick up slipper but needs supervision (+3)", "score": 3}, {"field": "Turning to look behind over left and right shoulders", "value": "Looks behind one side only, other side shows less weight shift (+3)", "score": 3}, {"field": "Turn 360 degrees", "value": "Able to turn 360 degrees safely but slowly (+2)", "score": 2}, {"field": "Placing alternate foot on step or stool while standing unsupported", "value": "Able to stand independently, and complete 8 steps in >20 seconds (+3)", "score": 3}, {"field": "Standing unsupported one foot in front", "value": "Able to place foot ahead of other independently and hold 30 seconds (+3)", "score": 3}, {"field": "Standing on one leg", "value": "Able to lift leg independently and hold 5-10 seconds (+3)", "score": 3}], "final_answer": 42, "notes": "Increased\nFall risk"}, {"order": 2, "name": "A-HIPI", "inputs": [{"field": "Age", "value": "65 years"}, {"field": "Albumin", "value": "4.0 g/dL"}, {"field": "Bulk", "value": "No bulky disease"}, {"field": "Gender", "value": "Female"}, {"field": "Hemoglobin", "value": "12.8 g/dL"}, {"field": "Lymphocyte count", "value": "1.8 x10^9/L"}, {"field": "Stage", "value": "Stage IIB"}], "final_answer": "79.35%", "notes": "Progression Free Survival at 5 years\n79.35%\nOverall Survival at 5 years\n90.51%"}]}
{"task_id": "medmcp-calc_034_8254f7f5", "task_scenario": "Fracture Risk Assessment", "task_category": "Clinical Medicine / Medicine & Organ Systems / Orthopedics, Rheumatology & Immunology", "patient_id": "P034_8254f7f5", "task_description": "Scenario: A patient is being evaluated for overall fracture risk in an orthopedic/rheumatology clinic, with a focus on osteoporotic fractures and the possibility of pathologic fracture if a suspicious bone lesion is identified during workup. The care team needs to decide whether bone densitometry is warranted, quantify 10-year fracture risk, and plan treatment or preventive measures, while also addressing any red flags for pathologic fractures.\n\nStep-by-step workflow and rationale:\n1) Initial screening for osteoporosis risk using the Osteoporosis Self Assessment Tool (OST). Purpose: quickly classify baseline osteoporosis risk to guide whether further screening is needed. If OST indicates moderate/high risk, proceed directly to additional screening; if low risk, confirm with a second tool to avoid missed cases.\n2) Refine the screening decision with the Osteoporosis Risk Assessment Instrument (ORAI). Purpose: identify women at risk and whether bone densitometry (DXA) is recommended. Decision trigger: if ORAI recommends densitometry or aligns with a moderate/high risk classification from OST, proceed to densitometry; if ORAI suggests low risk and conflicts with OST, use a tie-breaker.\n3) Resolve discordance and finalize the densitometry referral plan using the Osteoporosis Index of Risk (OSIRIS). Purpose: a third validated tool to corroborate or overturn the initial triage. Conditional branches: \n   - If any of OST/ORAI/OSIRIS indicates moderate/high risk or densitometry is recommended, order DXA and proceed to BMD-based risk quantification.\n   - If all three indicate low risk, defer densitometry, implement lifestyle measures, and schedule routine reassessment.\n4) After DXA is obtained (if indicated), estimate fracture risk using Fracture Risk for Women with Known Bone Mineral Density (BMD). Purpose: leverage measured bone health to produce a risk estimate tailored to women where applicable. This output provides a quantitative risk that feeds into treatment decisions and further modeling.\n5) Complement and cross-validate the BMD-based estimate with the Canadian Association of Radiologists and Osteoporosis Canada (CAROC) System. Purpose: determine 10-year absolute fracture risk category using BMD and clinical risk factors. Conditional branches:\n   - If CAROC categorizes as high risk (or there is a prior fragility fracture), plan pharmacotherapy and fall prevention; proceed to step 7 for cross-check.\n   - If CAROC indicates moderate risk, refine the decision using another validated model in step 6.\n   - If CAROC indicates low risk, consider non-pharmacologic measures and routine follow-up, unless another model suggests otherwise.\n6) Apply the Dubbo Osteoporotic Fracture Risk model to refine the intermediate risk category. Purpose: add cohort-derived risk estimation to improve decision certainty in moderate-risk cases. Conditional branches:\n   - If Dubbo indicates high risk, escalate to pharmacotherapy and more frequent monitoring.\n   - If Dubbo indicates low risk, favor conservative measures and extended follow-up intervals.\n7) Use the FRACTURE Index to cross-check and stress-test the treatment decision for postmenopausal patients. Purpose: confirm consistency across models or identify discordance that warrants escalation or de-escalation. Conditional branches:\n   - If FRACTURE Index aligns with high-risk classification from CAROC/Dubbo/BMD-based estimate, proceed with pharmacotherapy.\n   - If FRACTURE Index is low when others are high, reassess secondary causes and risk factors before finalizing therapy.\n8) Separate branch: If imaging or clinical evaluation reveals a long bone lesion suspicious for metastasis, assess mechanical stability with Mirels’ Criteria for Prophylactic Fixation. Purpose: determine pathologic fracture risk and need for orthopedic prophylactic fixation. Conditional branches:\n   - If Mirels’ score suggests high risk, refer for prophylactic fixation and oncologic coordination.\n   - If Mirels’ score is low, manage conservatively with surveillance and symptom control.\n\nClinical rationale for sequence: Screening tools (OST, ORAI, OSIRIS) minimize unnecessary DXA while reducing missed cases. BMD-based models (Fracture Risk for Women with Known BMD and CAROC) anchor absolute risk and guide treatment thresholds. Dubbo offers refinement particularly in moderate-risk scenarios. FRACTURE Index provides cross-validation for postmenopausal patients to ensure robustness before finalizing therapy. Mirels’ adds a safety branch for pathologic fracture risk when metastatic disease is suspected, integrating orthopedic decision-making.", "fuzzy_question": "I’m seeing a postmenopausal patient in our ortho/rheum clinic whose overall fracture risk is unclear, and I’d like your help thinking this through in a stepwise way. The patient is small‑framed, with an inflammatory rheumatologic condition and intermittent glucocorticoid exposure. There is a history of a prior low‑trauma fracture. No recent falls, but the patient has new aching around the hip, and we’re trying to decide how aggressively to move on prevention versus treatment. At the same time, there’s a concern we might be dealing with a pathologic issue if a suspicious lesion is confirmed on imaging.\n\nHere’s how I’d like to approach it. First, I want a quick bedside triage using age and body weight to get a baseline sense of osteoporosis risk. If that comes back more than low, I’d go straight into a more refined screen; if it looks low, I still want a second pass to avoid missing a borderline case. And if those two don’t agree, let’s use a third validated screener to settle the triage rather than making a snap call. By the end of that initial look, please tell me whether you’d order a bone density test now or hold off—and if you’d hold off, I want to be confident that all three early screens are truly pointing low so we can focus on lifestyle measures and routine reassessment instead.\n\nIf we do proceed with a bone density test, I’d like you to turn the measured bone health into a 10‑year fracture outlook tailored for women. Give me the actual percentages and how you’d label the risk band, not just a general impression. Then cross‑check that estimate with a nationally endorsed approach that combines bone density and key clinical risk factors. If that framework places the patient high—or if a prior low‑trauma fracture or glucocorticoid exposure independently pushes the patient into the high band—let’s plan medication and fall‑prevention measures, but I still want to pressure‑test that decision before finalizing it. If the patient lands in the middle, use a cohort‑derived estimate to see whether we should lean toward treatment or stay conservative. And if the patient is clearly low, favor non‑pharmacologic measures and a routine follow‑up schedule.\n\nBefore we lock anything in, because the patient is postmenopausal, please stress‑test the plan with a postmenopausal fracture index. If that aligns with a high‑risk classification from the other looks, I’m comfortable proceeding with pharmacotherapy. If it’s notably lower when the others are higher, pause and walk back through possible secondary drivers (endocrine issues, vitamin D status, malabsorption, renal concerns, medications, etc.) and explain whether you’d still treat or de‑escalate.\n\nThere’s one more wrinkle. On recent hip imaging we see a lytic‑appearing lesion in the intertrochanteric region of the proximal femur, occupying a substantial portion of the bone diameter, and the patient has significant pain with weight‑bearing. I need you to judge fracture risk from a mechanical standpoint—considering lesion site, pain severity with function, pattern (lytic versus mixed/blastic), and size—and tell me whether you’d send the patient for prophylactic fixation versus watchful waiting, and loop in oncology if you think fixation is warranted. If your mechanical read is low, outline how you’d monitor and control symptoms; if it’s high, I don’t want to miss the window for preventing a catastrophic fracture.\n\nPlease walk me through each step and the intermediate judgments rather than jumping straight to a final plan: the initial age–weight screen result, how the second pass changes (or confirms) the picture, how you resolve any disagreement with the third screener, whether you’d order the bone density now, the 10‑year fracture percentages and category from the bone‑based estimate, the risk band from the clinical‑plus‑bone approach (including how prior fracture or steroids affect it), what happens when you apply the cohort‑derived estimate if the patient is in the middle, how the postmenopausal index either supports or challenges treatment, and then your mechanical fracture‑risk call and fixation plan for the femur lesion.\n\nI really need proper calculations on this—can’t make this decision based on gut feeling alone. Whatever approach you suggest, make sure it’s backed by solid calculations, okay? This needs to hold up to scrutiny.", "required_calculators": ["Osteoporosis Self Assessment Tool (OST)", "Osteoporosis Risk Assessment Instrument (ORAI)", "Osteoporosis Index of Risk (OSIRIS)", "Fracture Risk for Women with Known Bone Mineral Density (BMD)", "Canadian Association of Radiologists and Osteoporosis Canada (CAROC) System", "Dubbo Osteoporotic Fracture Risk", "FRACTURE Index", "Mirels’ Criteria for Prophylactic Fixation"], "calculator_answers": [{"order": 1, "name": "Osteoporosis Self Assessment Tool (OST)", "inputs": [{"field": "Age, years", "value": 68}, {"field": "Sex", "value": "Female"}, {"field": "Weight (lbs)", "value": 114.6}], "final_answer": -3, "notes": "Intermediate\nOsteoporosis risk"}, {"order": 2, "name": "Osteoporosis Risk Assessment Instrument (ORAI)", "inputs": [{"field": "Age, years", "value": 68, "score": 9}, {"field": "Weight (kg)", "value": 52, "score": 9}, {"field": "Current estrogen use", "value": "No", "score": 2}], "final_answer": 20, "notes": "Bone densitometry should be considered for this patient."}, {"order": 3, "name": "Osteoporosis Index of Risk (OSIRIS)", "inputs": [{"field": "Age, years", "value": 68}, {"field": "Weight (lbs)", "value": 114.6}, {"field": "Current HRT", "value": "No", "score": 0}, {"field": "Prior low impact fracture", "value": "Yes", "score": -2}], "final_answer": -5, "notes": "High\nOsteoporosis risk level"}, {"order": 4, "name": "Fracture Risk for Women with Known Bone Mineral Density (BMD)", "inputs": [{"field": "Patient age (years)", "value": 68}, {"field": "Patient Bone Mineral Density T-score (BMD)", "value": -2.6}, {"field": "Patient has had fractures after age 50?", "value": "Yes"}, {"field": "Patient’s mother has had a hip fracture after age 50?", "value": "No"}, {"field": "Patient body weight is less than 125 lbs or 56.6 kg?", "value": "Yes"}, {"field": "Patient is an active smoker?", "value": "No"}, {"field": "Patient requires arm assistance to stand from chair?", "value": "No"}], "final_answer": 7, "notes": "Risk Profile\n5 Year Non-Vertebral Fracture Risk: 19.8%\n5 Year Hip Fracture Risk: 3.9%\n5 Year Vertebral Fracture Risk: 7.1%"}, {"order": 5, "name": "Canadian Association of Radiologists and Osteoporosis Canada (CAROC) System", "inputs": [{"field": "Age, years (category)", "value": 70}, {"field": "Sex", "value": "Woman"}, {"field": "Fragility fractures after 40 years of age", "value": "Yes"}, {"field": "Current systemic glucocorticoid therapy for more than 3 months", "value": "Yes"}, {"field": "Femoral neck T-score", "value": -2.7}], "final_answer": "High", "notes": "High\n10-year absolute fracture risk"}, {"order": 6, "name": "Dubbo Osteoporotic Fracture Risk", "inputs": [{"field": "Gender", "value": "Female"}, {"field": "Age (years)", "value": 68}, {"field": "Is the T-Score Positive or Negative?", "value": "Negative"}, {"field": "T-Score Value", "value": -2.7}, {"field": "Number of Prior Fractures since the Age of 50 (excluding major trauma)", "value": 1}, {"field": "Number of Falls in Past 12 Months", "value": 0}], "final_answer": "0.1 %", "notes": "Estimated 5-Year Risk of Hip Fracture\n0.1 %\nEstimated 10-Year Risk of Hip Fracture\n0.2 %\nEstimated 5-Year Risk of Osteoporotic/Fragility Fracture\n2.2 %\nEstimated 10-Year Risk of Osteoporotic/Fragility Fracture\n4.7 %"}, {"order": 7, "name": "FRACTURE Index", "inputs": [{"field": "Age, years (category)", "value": "65-69", "score": 1}, {"field": "History of any fracture after age 50", "value": "Yes", "score": 1}, {"field": "Mother's history of a hip fracture after age 50", "value": "No/don’t know", "score": 0}, {"field": "Weight", "value": "≤125 lb (≤56.7 kg)", "score": 1}, {"field": "Current smoker", "value": "No", "score": 0}, {"field": "Need to use arms to assist in standing up from a chair", "value": "No/don’t know", "score": 0}, {"field": "BMD results: total hip T-score (numeric)", "value": -2.6}, {"field": "BMD category: total hip T-score", "value": "<-2.5"}], "final_answer": 7, "notes": "3.9 %\n5-year risk of hip fracture."}, {"order": 8, "name": "Mirels’ Criteria for Prophylactic Fixation", "inputs": [{"field": "Site of lesion", "value": "Trochanteric region", "score": 3}, {"field": "Size of lesion", "value": "1/3 to 2/3 of bone diameter", "score": 2}, {"field": "Nature of lesion", "value": "Lytic", "score": 3}, {"field": "Pain", "value": "Functional", "score": 3}], "final_answer": 11, "notes": "11 points\nProphylactic fixation indicated\n>33 %\nRisk of fracture at 6 months post-irradiation"}]}
{"task_id": "medmcp-calc_035_d529c9ec", "task_scenario": "Burn Size and Emergency Fluid Resuscitation", "task_category": "Clinical Medicine / Emergency, Critical Care & Perioperative / Emergency Medicine & Trauma", "patient_id": "P035_d529c9ec", "task_description": "In the emergency department, a patient presents after a thermal injury with mixed-depth burns and possible smoke exposure. The team must rapidly estimate burn size, determine whether formal fluid resuscitation is indicated, and plan initial fluids to prevent burn shock while arranging appropriate triage. Step 1: Use the Rule of Nines to map involved body regions and calculate total body surface area (TBSA) affected by partial- and full-thickness burns. This percentage quantifies injury severity and is the key variable for subsequent resuscitation planning. Decision Branch A (based on TBSA): If the TBSA meets major-burn criteria per local guidelines, proceed to formal fluid resuscitation; if it does not, prioritize analgesia, local wound care, and oral hydration, with frequent reassessment rather than formal large-volume resuscitation. Step 2: For major burns, use the Parkland Formula for Burns. Input the TBSA percentage obtained from the Rule of Nines (and other standard inputs required by the formula) to calculate the total 24-hour crystalloid requirement. Distribute the calculated volume according to standard early and subsequent phases from the time of injury. Decision Branch B (based on clinical modifiers after TBSA-driven Parkland planning): If presentation is delayed from time of injury or if inhalation injury is suspected, adjust the infusion plan to reflect remaining volume and potential increased fluid needs per institutional protocols. Continue bedside monitoring and titrate around physiologic endpoints, using the Parkland-calculated volume as the starting framework. This sequence ensures TBSA quantification drives whether and how formal fluid resuscitation is initiated, with further adjustments guided by real-time clinical factors.", "fuzzy_question": "I’m evaluating a patient who presented to the emergency department after a thermal injury with mixed‑depth burns and potential inhalation exposure. I need a clear, defensible estimate of burn size. Please review body regions systematically and determine the percentage of total body surface area with at least partial‑thickness involvement versus deeper injury, so we avoid over‑ or underestimation. That estimate will drive next steps.\n\nHere’s the dilemma: if the burn size meets major‑burn criteria for this setting, I’m inclined toward formal IV resuscitation to prevent burn shock; if it does not, I’d prioritize analgesia, local wound care, oral hydration, and frequent reassessment rather than large‑volume fluids. What is the clinical assessment of where this case fits?\n\nIf IV fluids are indicated, I want an initial plan linked to burn size and body weight, with the early resuscitation period front‑loaded from the time of injury rather than arrival. Please outline how to distribute fluids between the early phase and the later phase so bedside staff can implement it.\n\nComplications of concern: timing and airway. If there was a delay between injury and presentation, do not restart the clock—give only what remains due for the early phase. If the history or exam suggests inhalation injury (e.g., soot, voice changes, hypoxia), anticipate increased fluid needs; propose a thoughtful adjustment and a plan to titrate to bedside endpoints (urine output and overall perfusion) while avoiding over‑resuscitation.\n\nFinally, triage: based on burn size and airway risk, should this case be transferred to a burn center now, or can it be managed locally with close follow‑up and frequent checks?\n\nI need evidence‑based calculations rather than clinical intuition. Whatever approach you propose should be supported by solid, defensible calculations that will hold up to scrutiny.", "required_calculators": ["Rule of Nines", "Parkland Formula for Burns"], "calculator_answers": [{"order": 1, "name": "Rule of Nines", "inputs": [{"field": "Head and face", "value": "4.5%"}, {"field": "Torso", "value": "9%"}, {"field": "Back", "value": "0%"}, {"field": "Right arm", "value": "4.5%"}, {"field": "Left arm", "value": "0%"}, {"field": "Genital area", "value": "0%"}, {"field": "Right leg", "value": "0%"}, {"field": "Left leg", "value": "0%"}], "final_answer": "18%", "notes": "Rule of Nines\nTotal body surface area affected by burns"}, {"order": 2, "name": "Parkland Formula for Burns", "inputs": [{"field": "Weight", "value": "176 lb"}, {"field": "Estimated percentage body burned", "value": "18%"}], "final_answer": 5.7, "notes": "5.7 L\nFluid requirements, 1st 24 hours from time of burn\n2.9 L\nFluid requirements, 1st 8 hours (1/2 of Total) from time of burn"}]}
{"task_id": "medmcp-calc_036_bf4f9cc1", "task_scenario": "Pulmonary Embolism and Deep Vein Thrombosis (VTE)", "task_category": "Clinical Medicine / Emergency, Critical Care & Perioperative / Emergency Medicine & Trauma", "patient_id": "P036_bf4f9cc1", "task_description": "Clinical scenario: A hemodynamically stable adult presents to the emergency department with acute dyspnea and pleuritic chest pain, raising concern for venous thromboembolism (VTE), specifically pulmonary embolism (PE). The goal is to minimize unnecessary imaging while safely diagnosing or excluding PE, then stratify severity, determine site of care, and plan anticoagulation with attention to bleeding and recurrence risk.\n\nWorkflow steps and decision points:\n1) Initial low-risk exclusion: Use the PERC Rule for Pulmonary Embolism to determine if PE can be ruled out without testing. If all PERC criteria are negative and clinical pre-test probability is low, PE is ruled out and no further PE calculators are needed. If any criterion is positive or clinical suspicion remains, proceed.\n2) Formal clinical probability: Apply the 4-Level Pulmonary Embolism Clinical Probability Score (4PEPS) to categorize the patient into very low, low, intermediate, or high clinical probability. This classification will dictate the need for D-dimer testing and/or imaging.\n   - If 4PEPS is very low/low: proceed to D-dimer testing to potentially avoid imaging.\n   - If 4PEPS is intermediate: D-dimer testing can still gate imaging, but a lower threshold for imaging is maintained.\n   - If 4PEPS is high: skip D-dimer and proceed directly to imaging. If imaging confirms PE, continue to step 4.\n3) Gate testing with Age-Adjusted D-dimer for Venous Thromboembolism (VTE): For patients who require D-dimer based on step 2, interpret the D-dimer using age-adjusted thresholds to reduce unnecessary imaging in older adults.\n   - If age-adjusted D-dimer is negative: PE is ruled out; end the PE pathway.\n   - If age-adjusted D-dimer is positive: obtain imaging. If imaging is negative: PE ruled out. If imaging confirms PE: proceed to severity and management planning.\n4) Severity and mortality risk: Use Simplified PESI (Pulmonary Embolism Severity Index) to estimate 30-day mortality risk and identify low-risk patients who may be candidates for outpatient care.\n5) Outpatient eligibility: For patients classified as low risk by Simplified PESI, apply the Hestia Criteria for Outpatient Pulmonary Embolism Treatment. \n   - If Hestia criteria are met: patient is eligible for outpatient management. \n   - If Hestia criteria are not met: manage as inpatient.\n6) Early complication risk in stable PE: Use the Bova Score for Pulmonary Embolism Complications to identify hemodynamically stable patients at risk for early adverse events (e.g., hypotension, ICU needs). \n   - If Bova risk is intermediate/high: escalate monitoring and consider more intensive inpatient management.\n   - If Bova risk is low: standard monitoring and treatment protocols are appropriate.\n7) Early major bleeding risk: Use the Pulmonary Embolism Syncope-Anemia-Renal Dysfunction (PE-SARD) Score to estimate risk of early major bleeding in acute PE. \n   - If PE-SARD indicates high early bleeding risk: adjust anticoagulation strategy (agent selection, dosing, care setting) accordingly.\n   - If PE-SARD is low: proceed with standard anticoagulation.\n8) Bleeding risk during anticoagulation: Apply the VTE-BLEED Score to assess bleeding risk over the course of anticoagulation.\n   - If high risk: implement bleeding mitigation (agent choice, dose adjustments, monitoring, gastroprotection as clinically indicated).\n   - If low risk: standard anticoagulation monitoring.\n9) Recurrence risk after a first VTE: Use the DASH Prediction Score for Recurrent VTE to estimate recurrence risk and inform duration of therapy in the general population with a first unprovoked event.\n10) Discontinuation decision in women with unprovoked VTE: If the event was unprovoked and the patient is a woman, apply the HERDOO2 Rule for Discontinuing Anticoagulation in Unprovoked VTE.\n   - If HERDOO2 indicates low risk: consider safe discontinuation after a standard treatment course.\n   - If not low risk: continue anticoagulation as clinically appropriate.\n\nRationale: Outputs from PERC and 4PEPS determine whether D-dimer is needed and whether imaging can be avoided; the age-adjusted D-dimer result deterministically triggers imaging or rule-out. Confirmation of PE triggers severity stratification with Simplified PESI, which then requires Hestia to determine site of care. Bova identifies early complication risk, while PE-SARD and VTE-BLEED guide anticoagulation safety. Finally, DASH and HERDOO2 address recurrence risk and treatment duration.", "fuzzy_question": "I’m seeing a hemodynamically stable patient in the ED with acute shortness of breath and pleuritic chest pain. I want to minimize imaging but avoid missing a PE. First, I’m considering whether this could be a truly low-risk presentation that can be ruled out at the bedside without labs. If the history and exam are reassuring—normal vital signs, adequate oxygenation, no hemoptysis, no unilateral leg swelling, no exogenous hormone exposure, no recent procedures or trauma, and no prior venous thromboembolism—I’d be comfortable standing down. If any of that isn’t clearly reassuring or clinical suspicion remains, we proceed.\n\nIf we move forward, I want to assign a pretest likelihood (very low, low, intermediate, or high) to guide next steps. For the lower categories, I prefer using a D-dimer to gate further testing rather than going straight to imaging; for high likelihood, I would skip labs and proceed directly to imaging. When sending a D-dimer, I plan to interpret it using validated adjusted thresholds to reduce unnecessary scans. If it’s negative by appropriate cutoffs, we can stop; if it’s positive, we image. A negative scan closes the workup; if PE is confirmed, we pivot to severity assessment and management.\n\nOnce PE is proven, I want an early mortality risk estimate to identify who appears low risk over the short term and may be a candidate for outpatient care. Even when risk appears low, I’ll confirm practical discharge considerations: oxygen needs, bleeding concerns, renal or hepatic limitations, uncontrolled pain requiring parenteral therapy, pregnancy, social support and follow-up, or any other reasons necessitating admission. If those flags are present, we admit.\n\nFor stable PE, I’m also considering short-term deterioration risk: significant tachycardia, borderline blood pressure, right-heart strain on imaging or echocardiography, or biomarkers indicating myocardial stress. If that risk isn’t trivial, I’ll escalate monitoring and consider a higher level of care.\n\nRegarding anticoagulation, early bleeding risk in the initial phase matters: features such as syncope at presentation, anemia on recent labs, and impaired kidney function may influence choice of agent, dosing, and whether home treatment is appropriate. In the absence of these concerns, standard therapy is reasonable. For the remainder of therapy, I want a clear bleeding risk assessment to choose the drug, consider dose adjustments for extended treatment, determine monitoring intensity, and add gastroprotection when appropriate.\n\nLooking ahead, if this is a first event without a clear trigger, I want an evidence-based estimate of recurrence risk to guide treatment duration—considering post-treatment D-dimer, sex, and whether hormone exposure played a role. If the patient is female with an unprovoked event, please assess whether very-low-risk criteria for safe discontinuation after the usual course are met (based on clinical features and D-dimer characteristics); if not, we continue therapy.\n\nCan you walk through this reasoning chain step by step and make the call at each juncture? I need proper, validated calculations—not just clinical intuition. Whatever approach you suggest should be supported by solid calculations and able to withstand scrutiny.", "required_calculators": ["PERC Rule for Pulmonary Embolism", "4-Level Pulmonary Embolism Clinical Probability Score (4PEPS)", "Age-Adjusted D-dimer for Venous Thromboembolism (VTE)", "Simplified PESI (Pulmonary Embolism Severity Index)", "Hestia Criteria for Outpatient Pulmonary Embolism Treatment", "Bova Score for Pulmonary Embolism Complications", "Pulmonary Embolism Syncope-Anemia-Renal Dysfunction (PE-SARD) Score", "VTE-BLEED Score", "DASH Prediction Score for Recurrent VTE", "HERDOO2 Rule for Discontinuing Anticoagulation in Unprovoked VTE"], "calculator_answers": [{"order": 1, "name": "PERC Rule for Pulmonary Embolism", "inputs": [{"field": "Age >=50", "value": "Yes (50 years)", "score": 1}, {"field": "Heart rate >=100", "value": "Yes (104 bpm)", "score": 1}, {"field": "O2 sat on room air <95%", "value": "Yes (94% on room air)", "score": 1}, {"field": "Unilateral leg swelling", "value": "No", "score": 0}, {"field": "Hemoptysis", "value": "No", "score": 0}, {"field": "Recent surgery or trauma (<=4 weeks, GA)", "value": "No", "score": 0}, {"field": "Prior PE or DVT", "value": "No", "score": 0}, {"field": "Hormone use (estrogen)", "value": "No", "score": 0}], "final_answer": 3, "notes": "3 criteria\nIf any criteria are positive, the PERC rule cannot be used to rule out PE in this patient."}, {"order": 2, "name": "4-Level Pulmonary Embolism Clinical Probability Score (4PEPS)", "inputs": [{"field": "Age (years)", "value": "50"}, {"field": "Sex", "value": "Female", "score": 0}, {"field": "Chronic respiratory disease", "value": "No", "score": 0}, {"field": "Heart rate <80", "value": "No (104 bpm)", "score": 0}, {"field": "Chest pain AND acute dyspnea", "value": "Yes", "score": 1}, {"field": "Current estrogen use", "value": "No", "score": 0}, {"field": "Prior history of VTE", "value": "No", "score": 0}, {"field": "Syncope", "value": "No", "score": 0}, {"field": "Immobility within last 4 weeks", "value": "No", "score": 0}, {"field": "O2 saturation <95%", "value": "Yes (94%)", "score": 3}, {"field": "Calf pain and/or unilateral lower limb edema", "value": "Yes (calf pain only; no edema)", "score": 3}, {"field": "PE is the most likely diagnosis", "value": "Yes", "score": 5}], "final_answer": 11, "notes": "11 points\n4PEPS Score\n20-65 %\nModerate CPP\nPE can be ruled out if D-dimer level <0.5 µg/mL OR <(age x 0.01) µg/mL"}, {"order": 3, "name": "Age-Adjusted D-dimer for Venous Thromboembolism (VTE)", "inputs": [{"field": "Age (years)", "value": "50"}, {"field": "D-dimer level reported by lab", "value": "780 ug/L (0.78 ug/mL)"}, {"field": "D-dimer unit type", "value": "FEU"}], "final_answer": 0.5, "notes": "0.5 µg/mL\nAge-adjusted D-dimer cutoff, FEU\nVTE possible\nReported D-dimer is greater than cutoff; consider confirmatory testing with CTA or V/Q scan"}, {"order": 4, "name": "Simplified PESI (Pulmonary Embolism Severity Index)", "inputs": [{"field": "Age (years)", "value": "50", "score": 0}, {"field": "History of cancer", "value": "No", "score": 0}, {"field": "History of chronic cardiopulmonary disease", "value": "No", "score": 0}, {"field": "Heart rate (bpm)", "value": "104", "score": 0}, {"field": "Systolic BP (mmHg)", "value": "122", "score": 0}, {"field": "O2 saturation (%)", "value": "94", "score": 0}], "final_answer": "Low", "notes": "Low risk\n1.1% risk of death in the “Low” risk group (0 points), with 1.5% having recurrent thromboembolism or non-fatal bleeding"}, {"order": 5, "name": "Hestia Criteria for Outpatient Pulmonary Embolism Treatment", "inputs": [{"field": "Hemodynamically unstable (sBP <100 with HR >100 or ICU need)", "value": "No", "score": 0}, {"field": "Thrombolysis or embolectomy needed", "value": "No", "score": 0}, {"field": "Active bleeding or high bleeding risk", "value": "No", "score": 0}, {"field": ">24 hrs supplemental O2 required to keep SaO2 >90%", "value": "No (room air SaO2 94%)", "score": 0}, {"field": "PE diagnosed while on anticoagulation", "value": "No", "score": 0}, {"field": "Severe pain needing IV analgesia >24 hrs", "value": "No (oral analgesics adequate)", "score": 0}, {"field": "Medical or social reason for admission >24 hrs", "value": "No (reliable follow-up)", "score": 0}, {"field": "Creatinine clearance <30 mL/min (Cockcroft-Gault)", "value": "No (CrCl ~89 mL/min)", "score": 0}, {"field": "Severe liver impairment", "value": "No", "score": 0}, {"field": "Pregnant", "value": "No (urine hCG negative)", "score": 0}, {"field": "History of HIT", "value": "No", "score": 0}, {"field": "Weight", "value": "72 kg"}, {"field": "Height", "value": "1.63 m"}, {"field": "Serum creatinine", "value": "0.90 mg/dL"}], "final_answer": 0, "notes": "0 points\nHestia Criteria\nLow risk\nPatient eligible for outpatient treatment (0% mortality, 2% VTE recurrence)."}, {"order": 6, "name": "Bova Score for Pulmonary Embolism Complications", "inputs": [{"field": "Systolic BP category", "value": ">100 mmHg (122 mmHg)", "score": 0}, {"field": "Elevated cardiac troponin (per lab cutoff)", "value": "No (hs-cTnT 8 ng/L; ULN 14 ng/L)", "score": 0}, {"field": "RV dysfunction", "value": "No (CT RV/LV ratio 0.9; echo not required)", "score": 0}, {"field": "Heart rate category", "value": "<110 bpm (104 bpm)", "score": 0}], "final_answer": 0, "notes": "0 points\nBova Score\nStage I\nLow risk\n4.4 %\nPE-related complications (death from PE, hemodynamic collapse, or recurrent nonfatal PE) at 30 days\n3.1% PE-related mortality at 30 days"}, {"order": 7, "name": "Pulmonary Embolism Syncope-Anemia-Renal Dysfunction (PE-SARD) Score", "inputs": [{"field": "Anemia (Hgb <12 g/dL)", "value": "Absent (Hgb 13.1 g/dL)", "score": 0}, {"field": "Syncope", "value": "Absent", "score": 0}, {"field": "Renal dysfunction (eGFR <60 mL/min/1.73m2)", "value": "Absent (eGFR ~88 mL/min/1.73m2)", "score": 0}], "final_answer": 0, "notes": "Low risk\nRisk of early major bleeding"}, {"order": 8, "name": "VTE-BLEED Score", "inputs": [{"field": "Age >=60 years", "value": "No (50 years)", "score": 0}, {"field": "Active cancer", "value": "No", "score": 0}, {"field": "Male patient with uncontrolled hypertension", "value": "No (female; BP 122/76 mmHg)", "score": 0}, {"field": "Anemia", "value": "No (Hgb 13.1 g/dL)", "score": 0}, {"field": "History of bleeding", "value": "No", "score": 0}, {"field": "Renal dysfunction (CrCl 30-60 mL/min)", "value": "No (CrCl ~89 mL/min)", "score": 0}], "final_answer": 0, "notes": "Low\nBleeding risk"}, {"order": 9, "name": "DASH Prediction Score for Recurrent VTE", "inputs": [{"field": "D-dimer abnormal (~1 month after stopping anticoagulation)", "value": "No (220 ug/L FEU; lab ULN 500 ug/L FEU)", "score": 0}, {"field": "Age <=50 years", "value": "Yes (50 years)", "score": 1}, {"field": "Male patient", "value": "No (female)", "score": 0}, {"field": "Hormone use at VTE onset (if female)", "value": "No", "score": 0}], "final_answer": 1, "notes": "3.9% annual risk of VTE recurrence.\nConsider discontinuing anticoagulation."}, {"order": 10, "name": "HERDOO2 Rule for Discontinuing Anticoagulation in Unprovoked VTE", "inputs": [{"field": "Post-thrombotic signs (hyperpigmentation, edema, or redness)", "value": "No", "score": 0}, {"field": "D-dimer level (after stopping anticoagulation)", "value": "220 ug/L FEU (<250 ug/L threshold)", "score": 0}, {"field": "BMI (kg/m2)", "value": "27.1", "score": 0}, {"field": "Age (years)", "value": "50", "score": 0}], "final_answer": 0, "notes": "0 points\nHERDOO2 Score\n3.0 %\nRisk of recurrent major VTE per 100 patient years\nLow risk\nCan safely discontinue oral anticoagulation"}]}
{"task_id": "medmcp-calc_037_efed038e", "task_scenario": "Life Expectancy Estimation", "task_category": "Clinical Medicine / Special Populations & General Tools / Geriatric Medicine", "patient_id": "P037_efed038e", "task_description": "Scenario: A geriatric patient (≥70) is initiating dialysis and has portal hypertension with potential need for TIPSS. The care team needs to estimate life expectancy to guide transplant referral, TIPSS consideration, and overall treatment intensity. Workflow steps: 1) Start with the CSHA Clinical Frailty Scale (CFS) to categorize frailty and baseline physiologic reserve. The frailty category sets the context for subsequent risk calculations and determines whether aggressive interventions are likely appropriate. 2) Next, use the Guide Transplant Referral for Incident Dialysis Patients Over 70 to estimate near-term mortality after dialysis start. This quantifies survival expectations specific to elderly incident dialysis patients and informs transplant referral feasibility. If the CFS indicates severe frailty, the dialysis mortality estimate is still obtained but will be weighed more heavily towards conservative management. If the CFS indicates low-to-moderate frailty, proceed to transplant referral decisions using the dialysis mortality estimate. 3) If TIPSS is being considered (e.g., for variceal bleeding or refractory ascites), apply the Emory Model (TIPSS) to estimate post-TIPSS mortality risk. Use the dialysis mortality estimate and frailty category to determine whether to run the TIPSS risk calculation: if predicted dialysis mortality is high or frailty is severe, TIPSS may be avoided; if predicted dialysis mortality is lower and frailty is acceptable, TIPSS risk is calculated to refine overall life expectancy and procedural appropriateness. 4) Synthesize outputs: a) If frailty is severe OR dialysis mortality is high OR TIPSS risk is high, conclude shorter life expectancy and prioritize symptom-focused care, avoid transplant referral, and defer TIPSS. b) If frailty is low-to-moderate AND dialysis mortality is acceptable AND TIPSS risk is acceptable, conclude longer expected survival, proceed with transplant referral evaluation, and consider TIPSS if clinically indicated. The sequence ensures that frailty informs whether to pursue additional risk stratifications, dialysis mortality quantifies short-term survival critical to transplant consideration, and TIPSS risk refines hepatic procedural decisions—together yielding a patient-centered estimate of life expectancy and a matched care plan.", "fuzzy_question": "I’m seeing an older adult who has recently initiated dialysis and also has portal hypertension; we may need to consider a shunt if variceal bleeding or refractory ascites persists. I’m trying to determine the appropriate overall intensity of care—whether to move toward transplant referral, whether a shunt makes sense, or whether we should lean more toward symptom‑focused management.\n\nFirst, I want a clear sense of where the patient sits on the frailty spectrum using a standard bedside impression—day‑to‑day independence, mobility and energy, recovery from minor illnesses—because that frames what outcomes are realistic and whether aggressive options are appropriate.\n\nOnce frailty is established, I need a near‑term survival picture specific to older patients initiating dialysis—the early post‑initiation period matters most for planning. If the patient appears severely frail, I still want that early mortality estimate, but I’ll weigh it heavily toward conservative care. If frailty looks low to moderate, I’d use that short‑term dialysis outlook to decide whether a transplant referral is sensible at this point.\n\nOn the portal hypertension side, if we think a shunt could help with bleeding or ascites, I’d like a procedure‑focused mortality and early outcome estimate after the shunt that reflects current liver disease and overall reserve. But I only want to proceed if it’s justified by the broader picture: if the dialysis prognosis looks poor or frailty is severe, I’d be inclined to avoid the shunt; if the dialysis outlook is acceptable and frailty is manageable, then let’s quantify the shunt risk to see whether it actually improves life expectancy and symptom control in the near term.\n\nPlease pull this together and tell me, practically: if frailty is severe or early dialysis prognosis looks poor or shunt risk is high, we should assume a shorter life expectancy, prioritize symptom‑focused care, defer transplant workup for now, and hold off on the shunt. But if frailty is low to moderate, early dialysis survival looks acceptable, and shunt risk is reasonable, then we can assume a longer expected survival, move forward with transplant referral, and consider the shunt if clinically indicated.\n\nWhat’s your take? Please reason it through in that sequence—frailty context first, then the older incident‑dialysis survival picture, and shunt risk only if justified—and finish with a defensible estimate of life expectancy and a matched plan. I need proper calculations on this—can’t make this decision on gut feeling. Whatever approach you suggest, make sure it’s backed by solid calculations that will hold up to scrutiny.", "required_calculators": ["CSHA Clinical Frailty Scale (CFS)", "Guide Transplant Referral for Incident Dialysis Patients Over 70", "Emory Model (TIPSS)"], "calculator_answers": [{"order": 1, "name": "CSHA Clinical Frailty Scale (CFS)", "inputs": [{"field": "CFS Score (1-9)", "value": "With limited dependence on others for instrumental activities of daily living", "score": 5}, {"field": "Canadian Triage Acuity Scale (CTAS) available?", "value": "No"}], "final_answer": 5, "notes": "5 points\nMildly frail\n72 %\nApproximate probability of avoidance of institutional care at 30 months\nApproximate probability of mortality at 70 months: 58%\n68 %\nApproximate probability of survival at 30 months\nApproximate probability of survival at 70 months: 42%"}, {"order": 2, "name": "Guide Transplant Referral for Incident Dialysis Patients Over 70", "inputs": [{"field": "Sex", "value": "Male"}, {"field": "Age (years)", "value": 74}, {"field": "Ethnicity", "value": "White (non-Hispanic)"}, {"field": "Primary cause of kidney disease", "value": "Hypertensive nephrosclerosis"}, {"field": "Body Mass Index", "value": "27.2 kg/m^2"}, {"field": "Previous employment", "value": "Retired"}, {"field": "Previous renal care before dialysis initiation", "value": "Yes"}, {"field": "Access type or dialysis modality", "value": "Hemodialysis via tunneled catheter"}, {"field": "Comorbidities: CHF", "value": "No"}, {"field": "Comorbidities: Atherosclerotic heart disease", "value": "Yes"}, {"field": "Comorbidities: Other cardiac", "value": "No"}, {"field": "Comorbidities: CVA/TIA", "value": "No"}, {"field": "Comorbidities: PVD", "value": "No"}, {"field": "Comorbidities: HTN", "value": "Yes"}, {"field": "Comorbidities: Amputation", "value": "No"}, {"field": "Comorbidities: Insulin-dependent diabetes", "value": "No"}, {"field": "Comorbidities: COPD", "value": "No"}, {"field": "Comorbidities: Tobacco use", "value": "No"}, {"field": "Comorbidities: Cancer", "value": "No"}, {"field": "Comorbidities: Immobility", "value": "No"}, {"field": "Comorbidities: Needs assistance with ADLs", "value": "No"}, {"field": "Comorbidities: Institutionalized", "value": "No"}], "final_answer": -4, "notes": "Risk Score\n-4\nEstimated 5 Year Mortality\n60-61%"}, {"order": 3, "name": "Emory Model (TIPSS)", "inputs": [{"field": "Sex", "value": "Male"}, {"field": "Total Bilirubin", "value": "2.3 mg/dL"}, {"field": "ALT", "value": "38 U/L"}, {"field": "Pre-TIPSS Hepatic Encephalopathy", "value": "No"}, {"field": "Urgency of TIPSS", "value": "Elective"}], "final_answer": 2, "notes": "Score\n2\nRisk Category\nModerate Risk\nEstimated Mortality Rates after TIPSS:\nEstimated 3-month Mortality Rates after TIPSS\n25 %\nEstimated 12-month Mortality Rates after TIPSS\n51-57 %\nEstimated 36-month Mortality Rates after TIPSS\n>60 %"}]}
{"task_id": "medmcp-calc_038_1c1feffa", "task_scenario": "Sedation, Analgesia and Delirium", "task_category": "Clinical Medicine / Emergency, Critical Care & Perioperative / Critical Care", "patient_id": "P038_1c1feffa", "task_description": "Scenario: A mechanically ventilated adult in the ICU after traumatic brain injury with possible heavy alcohol use requires integrated sedation, analgesia, and delirium management while maintaining cerebral perfusion. The clinical task is to set an appropriate sedation target, quantify and treat pain, anticipate and manage alcohol withdrawal, screen for delirium, and ensure hemodynamics preserve brain perfusion.\n\nWorkflow steps using the selected calculators:\n1) Glasgow Coma Scale (GCS): Establish baseline neurologic responsiveness to guide how deeply to sedate and define goals for ongoing neuro checks.\n2) Cerebral Perfusion Pressure: Calculate CPP to determine hemodynamic constraints for sedative selection and depth; if CPP is low, favor agents with minimal cardiovascular depression and avoid deepening sedation.\n3) Richmond Agitation-Sedation Scale (RASS): Set and titrate to the sedation target; if the patient is more agitated than target, increase sedatives; if deeper than target, lighten sedation. RASS also gates whether delirium screening can be performed.\n4) AWOL Score for Delirium: On admission, estimate baseline delirium risk to determine the frequency of formal screening and intensity of early nonpharmacologic prevention.\n5) Prediction of Alcohol Withdrawal Severity Scale: Assess risk of severe alcohol withdrawal; if high, plan a benzodiazepine-based regimen as the sedative backbone.\n6) Benzodiazepine Conversion Calculator: If alcohol withdrawal risk is high or benzodiazepines are chosen, convert between benzodiazepines to achieve equivalent dosing when switching agents or routes.\n7) Critical Care Pain Observation Tool (CPOT): Assess pain in the intubated, nonverbal patient; if pain scores are elevated, escalate analgesia.\n8) Opiate Conversion Calculator: Based on CPOT and the analgesic plan, convert between opioids to achieve appropriate analgesia aligned with the sedation strategy.\n9) Morphine Milligram Equivalents (MME) Calculator: Sum the daily opioid burden to gauge oversedation and delirium risk; if MME is high, reduce opioid dose and add non-opioid adjuncts to limit delirium and respiratory depression.\n10) Confusion Assessment Method for the ICU (CAM-ICU): Before each CAM-ICU check, re-confirm RASS is not deeply sedated; if RASS indicates deep sedation, defer. If RASS allows assessment, perform CAM-ICU; a positive result triggers delirium management (nonpharmacologic measures, medication review) and reassessment of the sedation/analgesia plan.\n\nConditional branches and dependencies:\n- RASS result deterministically gates CAM-ICU administration (deep sedation defers CAM-ICU; adequate arousal permits CAM-ICU).\n- CPOT pain score triggers the need for Opiate Conversion and then MME calculation to ensure safe total opioid burden.\n- Prediction of Alcohol Withdrawal Severity Scale output deterministically triggers whether Benzodiazepine Conversion is used (high risk = benzodiazepine-based regimen planning).\n- CPP guides sedative choice and depth; low CPP leads to favoring hemodynamically neutral strategies and less deep sedation.\n- AWOL high-risk output increases the frequency of CAM-ICU checks and strengthens delirium prevention measures.", "fuzzy_question": "I'm looking after an intubated adult in the ICU after a traumatic brain injury with possible significant alcohol use, and I'm trying to balance sedation, pain control, and delirium prevention without compromising cerebral perfusion. I'm not entirely sure how light we can keep the patient, and I want to ensure our choices don't lower blood pressure or make neurologic checks unreliable.\n\nMy first step is to establish the patient's current neurologic responsiveness as a baseline so we can decide how light our sedation target can safely be while still allowing meaningful neuro exams at regular intervals. In parallel, given the patient's hemodynamics and intracranial pressure, I want to determine where cerebral perfusion stands and the minimum we must maintain. If it appears borderline, I'd prefer hemodynamically gentler agents and to avoid deepening sedation beyond what is necessary.\n\nFor day-to-day management, I'd like a clear target on an agitation-sedation scale and active titration toward it: if the patient is more agitated than our goal, we increase sedation; if deeper than intended, we reduce it so we can keep assessing neurologic status. We should only check for delirium when the patient is arousable enough—if too deeply sedated, defer and adjust the sedation first.\n\nOn admission, can we estimate baseline delirium risk to set how often we'll screen and how aggressive we'll be with nonpharmacologic prevention? If high risk, I'd want tighter surveillance and an early push on sleep optimization, reorientation, lights and eyeglasses/hearing aids during the day, minimizing nighttime disruptions, and avoiding restraints where possible.\n\nBecause alcohol withdrawal could be a significant factor in the near term, I'd like a structured estimate of the likelihood of severe withdrawal. If high risk, I'd prefer to anchor the plan with a benzodiazepine-forward approach rather than escalating other sedatives. And if we switch between benzodiazepines or routes (for example, IV to enteral), please ensure the doses are matched so the patient receives an equivalent exposure and we avoid stacking.\n\nThe patient can't self-report pain, so let's use behavioral cues to judge discomfort. If the patient appears to be in pain, I'd rather escalate analgesia first than simply deepen sedation. If we switch opioids—fentanyl to hydromorphone, or later to an enteral option—please ensure we're using truly equianalgesic doses and accounting for incomplete cross-tolerance.", "required_calculators": ["Glasgow Coma Scale (GCS)", "Cerebral Perfusion Pressure", "Richmond Agitation-Sedation Scale (RASS)", "AWOL Score for Delirium", "Prediction of Alcohol Withdrawal Severity Scale", "Benzodiazepine Conversion Calculator", "Critical Care Pain Observation Tool (CPOT)", "Opiate Conversion Calculator", "Morphine Milligram Equivalents (MME) Calculator", "Confusion Assessment Method for the ICU (CAM-ICU)"], "calculator_answers": [{"order": 1, "name": "Glasgow Coma Scale (GCS)", "inputs": [{"field": "Best eye response", "value": "To verbal command (+3)", "score": 3}, {"field": "Best verbal response", "value": "Not testable/intubated (NT)"}, {"field": "Best motor response", "value": "Localizes pain (+5)", "score": 5}], "final_answer": "E(3) V(NT) M(5)", "notes": "Glasgow Coma Score cannot be calculated (one or more components not testable)\nE(3) V(NT) M(5)\nGlasgow Coma Scale"}, {"order": 2, "name": "Cerebral Perfusion Pressure", "inputs": [{"field": "MAP", "value": "85 mm Hg"}, {"field": "ICP", "value": "18 mm Hg"}], "final_answer": 67, "notes": "67 mmHg\nWithin normal limits. Likely adequate perfusion."}, {"order": 3, "name": "Richmond Agitation-Sedation Scale (RASS)", "inputs": [{"field": "Patient description", "value": "Light sedation (-2)", "score": -2}], "final_answer": -2, "notes": "-2 points\nPatients with a RASS of -2 to 1 are properly sedated."}, {"order": 4, "name": "AWOL Score for Delirium", "inputs": [{"field": "Age", "value": "46 years (<80 years = 0)", "score": 0}, {"field": "Correctly spells “world” backward", "value": "No (+1)", "score": 1}, {"field": "Oriented to city, state, county, hospital name, and floor", "value": "No (+1)", "score": 1}, {"field": "Nursing illness severity assessment", "value": "Severely ill (+1)", "score": 1}], "final_answer": 3, "notes": "3 points\nAWOL Score\n20 %\nRisk of delirium during hospitalization"}, {"order": 5, "name": "Prediction of Alcohol Withdrawal Severity Scale", "inputs": [{"field": "Threshold criteria (any alcohol in last 30 days or positive BAL on admission)", "value": "Yes (last drink ~6 hours pre-admit; BAL 160 mg/dL on arrival)"}, {"field": "Alcohol intoxication at admission", "value": "Yes", "score": 1}, {"field": "Positive blood alcohol level on admission", "value": "Yes (160 mg/dL)", "score": 1}, {"field": "History of previous alcohol withdrawal", "value": "Yes", "score": 1}, {"field": "History of alcohol withdrawal seizures", "value": "Yes", "score": 1}, {"field": "History of delirium tremens", "value": "No", "score": 0}, {"field": "Combines alcohol with other downers (benzodiazepines/barbiturates) in last 90 days", "value": "Yes (intermittent non-prescribed alprazolam)", "score": 1}, {"field": "Have you combined alcohol with any other substance of abuse during the last 90 days?", "value": "No", "score": 0}, {"field": "Prior alcohol rehab/detox admission", "value": "No", "score": 0}, {"field": "Positive blood alcohol level (BAL) on presentation", "value": "No", "score": 0}, {"field": "PEvidence of increased autonomic activity (i.e., HR >120, tremor, sweating, agitation, nausea)", "value": "No", "score": 0}, {"field": "Blackouts in last 30 days", "value": "Yes", "score": 1}], "final_answer": 5, "notes": "5 points\nPAWSS\nHigh risk\nLikelihood ratio 174 for complicated AWS (withdrawal hallucinosis, withdrawal-related seizures, or delirium tremens)"}, {"order": 6, "name": "Benzodiazepine Conversion Calculator", "inputs": [{"field": "Converting from", "value": "LORazepam (Ativan)"}, {"field": "Total daily drug dosage (mg)", "value": "8 mg"}, {"field": "Converting to", "value": "DiazePAM (Valium)"}], "final_answer": 48.0, "notes": "48.0 mg\nValium dose equivalent to 8 mg Ativan\n20.0-80.0 mg\nRange of Valium dose equivalent to 8 mg Ativan"}, {"order": 7, "name": "Critical Care Pain Observation Tool (CPOT)", "inputs": [{"field": "Intubated?", "value": "Yes"}, {"field": "Compliance with ventilator", "value": "Coughing but tolerating", "score": 1}, {"field": "Facial expression", "value": "Grimacing (+2)", "score": 2}, {"field": "Body movements", "value": "Restlessness (+2)", "score": 2}, {"field": "Muscle tension", "value": "Tense, rigid (+1)", "score": 1}], "final_answer": 6, "notes": "6 points\nUnacceptable amount of pain. Consider further sedation or other analgesia."}, {"order": 8, "name": "Opiate Conversion Calculator", "inputs": [{"field": "Converting from", "value": "FentaNYL (parenteral)"}, {"field": "Total daily drug dosage (mg)", "value": "1.2 mg"}, {"field": "Converting to", "value": "HYDROmorphone (parenteral)"}], "final_answer": 16, "notes": "16 mg\nApproximate Hydromorphone (parenteral) equivalence to: 1.2mg of Fentanyl (parenteral)"}, {"order": 9, "name": "Morphine Milligram Equivalents (MME) Calculator", "inputs": [{"field": "Drug", "value": "OxyCODONE (oral)"}, {"field": "Dosage", "value": "5 mg/dose"}, {"field": "Doses per day", "value": "4"}, {"field": "Add another drug", "value": "No"}], "final_answer": 30.0, "notes": "30.0\nMME/day\n2x higher risk of overdose than <20 MME/day; there is no completely safe opioid dose; use caution when prescribing opioids at any dose and always prescribe the lowest effective dose\nDrug(s):\n20.0 mg oxycodone"}, {"order": 10, "name": "Confusion Assessment Method for the ICU (CAM-ICU)", "inputs": [{"field": "Level of Consciousness: RASS ≥ -3 (or sufficient arousal)", "value": "Yes (current RASS -2)"}, {"field": "Patient different than baseline, pre-hospital mental status", "value": "Yes"}, {"field": "Patient with fluctuating mental status in past 24 hours by fluctuation of level of consciousness/sedation", "value": "Yes"}, {"field": "Letters attention test with >2 errors", "value": "No"}], "final_answer": "CAM-ICU negative", "notes": "CAM-ICU negative\nDelirium absent."}]}
{"task_id": "medmcp-calc_039_5a48e2cb", "task_scenario": "Cancer Pain Management and Opioid Conversion", "task_category": "Clinical Medicine / Medicine & Organ Systems / Comprehensive Oncology", "patient_id": "P039_5a48e2cb", "task_description": "Clinical scenario: An oncology patient with cancer-related pain is on a mixed opioid regimen with suboptimal analgesia and bothersome adverse effects. A switch to a different opioid and possibly a different route is planned. The goal is to quantify opioid exposure, perform a safe equianalgesic conversion, and verify the safety of the new regimen. Workflow steps: 1) Use the Morphine Milligram Equivalents (MME) Calculator to calculate the total daily MME for the current regimen (including both scheduled and breakthrough opioids). This provides a quantitative risk and exposure baseline for decision-making. 2) Branch A (if MME indicates a high-dose exposure or heightened safety risk): plan a conservative opioid rotation strategy; choose a target opioid and route that match clinical needs (e.g., transdermal or parenteral if oral route is limited), and apply a larger cross-tolerance reduction during conversion. Branch B (if MME indicates a moderate exposure without specific safety flags): proceed with standard opioid rotation; choose the target opioid and route and apply a routine cross-tolerance reduction. 3) Use the Opiate Conversion Calculator to convert the current total daily opioid regimen to the target opioid and route, incorporating the cross-tolerance reduction approach determined in Step 2. If a breakthrough medication is needed, use the same calculator to convert to an appropriate short-acting opioid that complements the long-acting agent. 4) Re-run the Morphine Milligram Equivalents (MME) Calculator for the proposed new regimen (long-acting plus breakthrough) to verify the total daily MME is within an acceptable safety envelope. 5) Branch C (if the post-conversion MME remains high-risk or analgesia is anticipated to be inadequate): iterate using the Opiate Conversion Calculator to adjust opioid choice, route, or dose; then re-check with the MME Calculator. Branch D (if the post-conversion MME is acceptable and the plan meets analgesic goals): finalize the regimen and document the conversion assumptions and safety checks. Rationale: The initial MME quantifies exposure to guide how aggressive the cross-tolerance reduction should be; the equianalgesic conversion then translates that plan into a specific opioid and route; the final MME check confirms safety before implementation.", "fuzzy_question": "I'm reviewing a case of a patient with advanced cancer whose pain control has been inconsistent despite a combination of long-acting and short-acting opioids. Recently, the patient has required frequent rescue doses and is experiencing sedation and constipation that interfere with function. Oral intake has been unreliable at times due to treatment-related nausea and oral/GI symptoms, and renal function appears suboptimal. I'm looking to switch to a regimen that provides steadier relief with fewer side effects and am considering whether to change the route of administration.\n\nBefore making changes, I want an accurate picture of total daily opioid exposure based on actual use, including scheduled doses and all rescues, to establish a realistic risk baseline and determine where this falls in morphine equivalents.\n\nIf the exposure is high or safety concerns are present (sleepiness, falls risk, renal issues), I prefer a conservative rotation: select a target opioid and route that fit the situation (if oral intake is unreliable, consider transdermal or parenteral) and reduce more than usual to account for incomplete cross-tolerance. If exposure appears moderate without specific red flags, a standard rotation with the usual reduction seems reasonable.\n\nFrom there, translate the current total into a specific dose of the chosen opioid and route using that reduction strategy. If a rescue option is still needed, pair a compatible short-acting agent with an appropriate breakthrough dose and frequency that aligns with the long-acting plan.\n\nAfter proposing the regimen, I want to check what the overall daily opioid burden would look like on the new plan—long-acting plus likely rescues—to ensure it remains within a safe range and does not increase risk.\n\nIf the post-switch burden still looks high-risk, or if analgesia seems inadequate, please iterate by adjusting the drug, route, or dose and re-check until safety and pain control are balanced. If it looks acceptable and likely to meet the patient's goals, finalize it and clearly document the assumptions behind the conversion and the safety checks used so the team understands the rationale.\n\nWhat's your take on this? Am I missing anything important? I need explicit, defensible calculations—this cannot be based on intuition alone. Whatever approach you suggest, make sure it is backed by solid calculations; this needs to hold up to scrutiny.", "required_calculators": ["Morphine Milligram Equivalents (MME) Calculator", "Opiate Conversion Calculator"], "calculator_answers": [{"order": 1, "name": "Morphine Milligram Equivalents (MME) Calculator", "inputs": [{"field": "Drug 1", "value": "Morphine (oral)"}, {"field": "Dosage 1 (mg/dose)", "value": "60 mg"}, {"field": "Doses per day 1 (doses/day)", "value": "2"}, {"field": "Add another drug", "value": "Yes"}, {"field": "Drug 2", "value": "Oxycodone (oral)"}, {"field": "Dosage 2 (mg/dose)", "value": "10 mg"}, {"field": "Doses per day 2 (doses/day)", "value": "5"}], "final_answer": 195.0, "notes": "195.0\nMME/day\n8.9x higher risk of overdose; consult pain specialist to reassess pain regimen and decrease dosage and/or wean off opioids\nDrug(s):\n120.0 mg morphine\n50.0 mg oxycodone"}, {"order": 2, "name": "Opiate Conversion Calculator", "inputs": [{"field": "Converting from", "value": "Morphine (oral)"}, {"field": "Total daily drug dosage (mg)", "value": "120 mg"}, {"field": "Converting to", "value": "Hydromorphone (oral)"}], "final_answer": 24, "notes": "24 mg\nApproximate Hydromorphone (oral) equivalence to: 120mg of Morphine (oral)"}, {"order": 3, "name": "Opiate Conversion Calculator", "inputs": [{"field": "Converting from", "value": "Oxycodone (oral)"}, {"field": "Total daily drug dosage (mg)", "value": "50 mg"}, {"field": "Converting to", "value": "Hydromorphone (oral)"}], "final_answer": 13, "notes": "13 mg\nApproximate Hydromorphone (oral) equivalence to: 50mg of Oxycodone (oral)."}, {"order": 4, "name": "Morphine Milligram Equivalents (MME) Calculator", "inputs": [{"field": "Drug 1", "value": "Hydromorphone (oral) — extended release"}, {"field": "Dosage 1 (mg/dose)", "value": "16 mg"}, {"field": "Doses per day 1 (doses/day)", "value": "1"}, {"field": "Add another drug", "value": "Yes"}, {"field": "Drug 2", "value": "Hydromorphone (oral) — immediate release (breakthrough)"}, {"field": "Dosage 2 (mg/dose)", "value": "2 mg"}, {"field": "Doses per day 2 (doses/day)", "value": "3"}], "final_answer": 110.0, "notes": "110.0\nMME/day\n8.9x higher risk of overdose; consult pain specialist to reassess pain regimen and decrease dosage and/or wean off opioids\nDrug(s):\n16.0 mg hydromorphone\n6.0 mg hydromorphone"}]}
{"task_id": "medmcp-calc_040_6cdea9bd", "task_scenario": "Crohn's Disease Activity Index", "task_category": "Clinical Medicine / Medicine & Organ Systems / Gastroenterology & Hepatology", "patient_id": "P040_6cdea9bd", "task_description": "Clinical scenario: A patient with known Crohn’s disease presents with symptoms suggesting a possible flare. The clinician must rapidly stratify severity, select the appropriate activity index based on age, and use the results to guide immediate management and follow-up monitoring within the framework of Gastroenterology & Hepatology focused on Crohn’s Disease Activity Index.\nStep-by-step workflow:\n1) Initial triage with the Harvey-Bradshaw Index (HBI) for Crohn’s Disease to quickly estimate symptom-based severity at the point of care. The HBI category (e.g., mild, moderate, severe) serves as the immediate decision trigger.\n2) Conditional branch based on age and HBI severity:\n   - If the patient is an adult: proceed to the Crohn’s Disease Activity Index (CDAI) to formally quantify current disease activity for treatment decisions.\n   - If the patient is pediatric: proceed to the Pediatric Crohn’s Disease Activity Index (PCDAI) to formally quantify disease activity tailored to children.\n3) Use the CDAI or PCDAI category to determine management intensity and monitoring cadence:\n   - If low activity/remission: continue maintenance therapy and schedule routine monitoring. Use HBI at follow-up visits to detect early changes, and repeat CDAI/PCDAI only if HBI shows a concerning rise.\n   - If moderate activity: initiate/adjust therapy and set short-interval monitoring. Use HBI frequently to track symptom trends; if HBI worsens or fails to improve, repeat CDAI/PCDAI to reassess activity and escalate care as needed.\n   - If severe activity: escalate therapy urgently. Use HBI for near-term symptom tracking; once clinically stable, repeat CDAI/PCDAI to confirm improvement and guide de-escalation.\n4) Discordance handling branch: If HBI suggests severe activity but CDAI/PCDAI indicates mild (or vice versa), verify inputs (history/exam consistency) and repeat the appropriate index after a brief interval; management prioritizes the more conservative path (addressing higher indicated severity) until concordance is achieved.\n5) Ongoing monitoring: After any therapy change, use HBI at each interim visit to determine whether and when to repeat CDAI (adults) or PCDAI (pediatrics); improved HBI categories trigger a planned re-calculation of CDAI/PCDAI to document transition to lower activity/remission and to adjust long-term follow-up.", "fuzzy_question": "I’m evaluating a patient with established Crohn’s disease who presents with new abdominal pain and increased stool frequency—could represent a flare, but the current severity is uncertain. For immediate decision-making, I want a rapid bedside symptom check to gauge acuity and guide near-term steps.\n\nDepending on that snapshot—and whether the patient is an adult or a child—I plan to follow with a comprehensive, multi-component activity assessment (adult version for adults, pediatric‑tailored version for children) to anchor treatment choices. Recent visits have shown variable control, and recent labs suggest mild inflammatory activity, so I’d like to be systematic rather than rely on impression.\n\nIf the comprehensive assessment indicates low activity or near remission, I’m inclined to continue maintenance therapy and routine follow‑up, using the quick symptom check at subsequent visits to detect early changes, and repeating the comprehensive assessment only if bedside symptoms trend upward.\n\nIf results fall in a moderate range, I’d initiate or adjust therapy now and reassess at close intervals. I’d use the quick symptom check frequently to monitor trends; if there’s no improvement or worsening, I’d repeat the comprehensive assessment to reassess activity and determine whether to escalate.\n\nIf findings are clearly severe, I’d escalate urgently. In the near term I’d track with the simple symptom check; once clinically steadier, I’d repeat the comprehensive assessment to document improvement and guide safe step‑down.\n\nIf the bedside snapshot and the comprehensive assessment don’t align—symptoms suggesting severe activity but the composite indicating mild, or the reverse—I’d verify history and exam inputs, then repeat the measure that seems inconsistent after a brief interval. Until they agree, I’d prioritize safety and manage as if the higher activity level is present.\n\nAfter any therapy change, I’d plan to use the quick symptom check at each interim visit to determine whether and when to repeat the full assessment; if those quick categories improve, I’d schedule a formal reassessment to document transition to lower activity or remission and adjust long‑term follow‑up accordingly.\n\nWhat’s your view on working through it this way in the GI clinic? I need evidence‑based, quantitative scoring—decisions shouldn’t rely on intuition alone. Please outline an approach backed by solid calculations that can withstand scrutiny.", "required_calculators": ["Harvey-Bradshaw Index (HBI) for Crohn's Disease", "Crohn's Disease Activity Index (CDAI)", "Pediatric Crohn’s Disease Activity Index (PCDAI)"], "calculator_answers": [{"order": 1, "name": "Harvey-Bradshaw Index (HBI) for Crohn's Disease", "inputs": [{"field": "General well-being (previous day)", "value": "Poor (2 points)", "score": 2}, {"field": "Abdominal pain (previous day)", "value": "Moderate (2 points)", "score": 2}, {"field": "Number of liquid/soft stools (previous day)", "value": "7 stools"}, {"field": "Abdominal mass", "value": "None (0 points)", "score": 0}, {"field": "Complications - Arthralgia", "value": "Yes (+1)", "score": 1}, {"field": "Complications - Uveitis", "value": "No (0)", "score": 0}, {"field": "Complications - Erythema nodosum", "value": "No (0)", "score": 0}, {"field": "Complications - Aphthous ulcers", "value": "No (0)", "score": 0}, {"field": "Complications - Pyoderma gangrenosum", "value": "No (0)", "score": 0}, {"field": "Complications - Anal fissures", "value": "No (0)", "score": 0}, {"field": "Complications - New fistula", "value": "No (0)", "score": 0}, {"field": "Complications - Abscess", "value": "No (0)", "score": 0}], "final_answer": 12, "notes": "Moderate disease"}, {"order": 2, "name": "Crohn's Disease Activity Index (CDAI)", "inputs": [{"field": "Weight", "value": "160 lb"}, {"field": "Ideal body weight", "value": "175 lb"}, {"field": "Sex", "value": "Male"}, {"field": "Total number of soft/liquid stools in the last 7 days", "value": "49 stools"}, {"field": "Abdominal pain (average daily rating, past 7 days; 0–3)", "value": "2"}, {"field": "General well-being (average daily rating, past 7 days; 0–4)", "value": "2"}, {"field": "Anti-diarrhea drug use", "value": "Yes", "score": 1}, {"field": "Abdominal mass", "value": "No (0)", "score": 0}, {"field": "Hematocrit", "value": "38 %"}, {"field": "Extraintestinal - Arthritis/arthralgias", "value": "Yes", "score": 1}, {"field": "Extraintestinal - Iritis/uveitis", "value": "No", "score": 0}, {"field": "Extraintestinal - Erythema nodosum/pyoderma gangrenosum/aphthous stomatitis", "value": "No", "score": 0}, {"field": "Extraintestinal - Anal fissure, fistula, or abscess", "value": "No", "score": 0}, {"field": "Extraintestinal - Other fistula", "value": "No", "score": 0}, {"field": "Extraintestinal - Fever >100°F (37.8°C)", "value": "No", "score": 0}], "final_answer": 379, "notes": "CDAI of 150-450 is used as a marker of active Crohn's disease. The higher the score, the more severe the disease activity."}, {"order": 3, "name": "Pediatric Crohn’s Disease Activity Index (PCDAI)", "inputs": [{"field": "Sex", "value": "Male"}, {"field": "Age", "value": "18 years"}, {"field": "History - Abdominal pain", "value": "Moderate/Severe (10 points): daily, longer lasting, affects activities or nocturnal", "score": 10}, {"field": "History - Stools per day", "value": "≥6 liquid (10 points)", "score": 10}, {"field": "History - General well-being", "value": "Below par (5 points)", "score": 5}, {"field": "Examination - Weight (vs 4–6 months ago)", "value": "Weight voluntarily stable (0 points)", "score": 0}, {"field": "Examination - Height/height velocity", "value": "<1 channel decrease or velocity ≥ -1 SD (0 points)", "score": 0}, {"field": "Examination - Abdomen", "value": "No tenderness, no mass (0 points)", "score": 0}, {"field": "Examination - Peri-rectal disease", "value": "None or asymptomatic tags (0 points)", "score": 0}, {"field": "Extra-intestinal manifestations (fever/arthritis/uveitis/EN/PG)", "value": "1 present (5 points) — arthralgia", "score": 5}, {"field": "Laboratory - Hematocrit", "value": "38 %"}, {"field": "Laboratory - ESR", "value": "32 mm/hr"}, {"field": "Laboratory - Albumin", "value": "3.7 g/dL"}], "final_answer": 32.5, "notes": "Moderate Crohn's Disease Activity"}]}
{"task_id": "medmcp-calc_041_0f7a3ded", "task_scenario": "Pain Assessment Scales (VAS/NRS)", "task_category": "Clinical Medicine / Neurology & Mental Health / Neurosurgery & Neurology", "patient_id": "P041_0f7a3ded", "task_description": "Clinical scenario: A postoperative neurosurgical ICU patient is intermittently unable to self-report (standard VAS/NRS not feasible) due to intubation and fluctuating cognition. The team suspects a neuropathic component to the pain. The task is to quantify pain reliably, differentiate neuropathic features, and monitor response to interventions using validated observational and neuropathic scales.\n\nWorkflow steps:\n- Step 1 (Critical care baseline): Use the Critical Care Pain Observation Tool (CPOT) to establish an initial observational pain score in the ICU setting. Rationale: CPOT is broadly applicable to critically ill patients and provides a reproducible baseline for trend monitoring.\n- Decision A (triggered by CPOT output):\n  - If CPOT indicates minimal pain, continue routine CPOT monitoring at clinically appropriate intervals and proceed only if status changes.\n  - If CPOT indicates moderate/severe pain, branch by airway and communication status to refine quantification.\n- Step 2a (Intubated branch): If the patient is intubated, use the Behavioral Pain Scale (BPS) for Pain Assessment in Intubated Patients. Rationale: BPS adds intubation-specific behavioral indicators. The BPS result then guides immediate analgesic adjustments.\n  - Follow-up: After any intervention, recheck CPOT to confirm direction of change; use BPS for ongoing spot checks while intubated.\n- Step 2b (Nonverbal, not intubated): If the patient is not intubated but remains nonverbal, use the Nonverbal Pain Scale (NVPS) for Nonverbal Patients. Rationale: NVPS captures behaviors and physiological cues in nonverbal, non-intubated patients. NVPS output informs analgesic titration and triggers CPOT recheck to track ICU trends.\n- Step 3 (Cognitive branch): If dementia or advanced cognitive impairment is present, use the Pain Assessment in Advanced Dementia Scale (PAINAD) in parallel with the above. Rationale: PAINAD addresses dementia-specific behavioral expressions of pain.\n  - Decision B (triggered by PAINAD output): If PAINAD indicates moderate/severe pain, proceed to neuropathic characterization (Step 4) to tailor adjuvant therapy.\n- Step 4 (Neuropathic characterization): Use the Neuropathic Pain Scale (NPS) if any of CPOT/BPS/NVPS/PAINAD suggests persistent or significant pain or if neuropathic features are suspected clinically. Rationale: NPS distinguishes and quantifies neuropathic qualities to guide targeted adjuvant strategies.\n  - Decision C (triggered by NPS output): High neuropathic burden prompts prioritization of neuropathic-focused interventions; lower neuropathic burden emphasizes nociceptive-focused strategies and continued observational monitoring.\n- Step 5 (Monitoring loop): Trend CPOT as the primary ICU monitoring tool. If CPOT decreases to a mild/absent range, step down to less frequent BPS (if still intubated) or NVPS (if nonverbal) checks. If CPOT, BPS, or NVPS remain elevated despite interventions, repeat NPS to reassess neuropathic contribution and refine the plan.\n\nClinical rationale for sequence: CPOT first for ICU baseline; then conditionally add BPS or NVPS depending on airway/communication status; incorporate PAINAD when dementia is present; use NPS to characterize neuropathic components once observational scales confirm clinically meaningful pain. Outputs from CPOT, BPS, NVPS, and PAINAD deterministically trigger NPS and subsequent monitoring choices.", "fuzzy_question": "I’m evaluating a post-operative critical care patient with variable ability to report pain, intermittent mechanical ventilation, and fluctuating cognition, with concern for a neuropathic component. I want a reliable current pain assessment, clarification of any neuropathic contribution, and a way to monitor response to therapy.\n\nFirst, obtain an objective, behavior-based pain assessment appropriate for critical care to establish a baseline. If it indicates minimal pain, keep routine checks at reasonable intervals and defer additional steps unless the clinical picture changes. If it indicates moderate to severe pain, refine based on current communication status:\n- If intubated, use a ventilated-patient behavioral scale to guide immediate analgesic adjustments. After any intervention, recheck the original ICU observational measure to confirm directionally appropriate change, and keep spot checks with the ventilated-patient tool while intubation persists.\n- If extubated but nonverbal, use a nonverbal bedside assessment that combines behaviors and physiologic cues to guide titration, and again recheck the ICU observational measure to maintain the ICU trend.\n\nIf there is baseline dementia or clearly advanced cognitive impairment, add a dementia-focused pain behavior rating alongside the above. If that indicates at least moderate pain, proceed to a more formal characterization of neuropathic features.\n\nAt that point—or whenever bedside scores remain elevated or there are clues such as burning, shooting/electric sensations, pins-and-needles, or painful sensitivity to light touch—obtain a structured neuropathic pain profile that details qualities and intensity. If the neuropathic burden appears high, prioritize neuropathic-targeted adjuvants and supports; if low, emphasize nociceptive-focused strategies while continuing behavioral monitoring.\n\nOver the ensuing period, trend the ICU observational score as the primary tracker. If it decreases into a mild/absent range, space out the specialized checks (ventilated-specific or nonverbal-focused) according to status. If any bedside scores remain elevated despite adjustments, repeat the neuropathic profile to reassess its contribution and refine the plan.\n\nPlease document validated scale scores at each step to show trajectory, not impressions alone. What additional considerations should we weigh? I need an evidence-based, calculation-supported assessment—ground recommendations in validated scoring methods so the plan withstands scrutiny.", "required_calculators": ["Critical Care Pain Observation Tool (CPOT)", "Behavioral Pain Scale (BPS) for Pain Assessment in Intubated Patients", "Nonverbal Pain Scale (NVPS) for Nonverbal Patients", "Pain Assessment in Advanced Dementia Scale (PAINAD)", "Neuropathic Pain Scale (NPS)"], "calculator_answers": [{"order": 1, "name": "Critical Care Pain Observation Tool (CPOT)", "inputs": [{"field": "Intubated?", "value": "Yes"}, {"field": "Compliance with ventilator", "value": "Fighting ventilator", "score": 2}, {"field": "Facial expression", "value": "Grimacing", "score": 2}, {"field": "Body movements", "value": "Restlessness", "score": 2}, {"field": "Muscle tension", "value": "Very tense or rigid", "score": 2}], "final_answer": 8, "notes": "Unacceptable amount of pain. Consider further sedation or other analgesia."}, {"order": 2, "name": "Behavioral Pain Scale (BPS) for Pain Assessment in Intubated Patients", "inputs": [{"field": "Facial expression", "value": "Grimacing", "score": 4}, {"field": "Upper limb movements", "value": "Fully bent with finger flexion", "score": 3}, {"field": "Compliance with mechanical ventilation", "value": "Fighting ventilator", "score": 3}], "final_answer": 10, "notes": "Unacceptable amount of pain\nConsider further sedation or other analgesia."}, {"order": 3, "name": "Critical Care Pain Observation Tool (CPOT)", "inputs": [{"field": "Intubated?", "value": "Yes"}, {"field": "Compliance with ventilator", "value": "Coughing but tolerating", "score": 1}, {"field": "Facial expression", "value": "Tense", "score": 1}, {"field": "Body movements", "value": "Protection", "score": 1}, {"field": "Muscle tension", "value": "Tense, rigid", "score": 1}], "final_answer": 4, "notes": "Unacceptable amount of pain. Consider further sedation or other analgesia."}, {"order": 4, "name": "Pain Assessment in Advanced Dementia Scale (PAINAD)", "inputs": [{"field": "Breathing (independent of vocalization)", "value": "Occasional labored breathing or short periods of hyperventilation", "score": 1}, {"field": "Negative vocalization", "value": "Occasional moan/groan or low-level speech with negative quality", "score": 1}, {"field": "Facial expression", "value": "Facial grimacing", "score": 2}, {"field": "Body language", "value": "Tense, distressed pacing/fidgeting", "score": 1}, {"field": "Consolability", "value": "Distracted or reassured by voice/touch", "score": 1}], "final_answer": 6, "notes": "Moderate pain\nRanges are based on a standard 0-10 scale of pain, but the original tool only quantifies 0 as \"No pain\" and 10 as \"Severe pain\"."}, {"order": 5, "name": "Neuropathic Pain Scale (NPS)", "inputs": [{"field": "How intense is the pain?", "value": 7}, {"field": "How sharp is the pain?", "value": 6}, {"field": "How hot is the pain?", "value": 7}, {"field": "How dull is the pain?", "value": 3}, {"field": "How cold is the pain?", "value": 2}, {"field": "How sensitive is the skin to light touch?", "value": 8}, {"field": "How itchy is the pain?", "value": 1}, {"field": "How unpleasant is the pain?", "value": 8}, {"field": "If the pain is deep, how intense is the deep pain?", "value": 5}, {"field": "If the pain is on the surface, how intense is the surface pain?", "value": 7}, {"field": "What is the time quality of the pain?", "value": "Background pain present all the time, with occasional flare-ups (breakthrough pain)"}], "final_answer": 54.0, "notes": "The higher the score (maximum 100 points), the worse the neuropathic pain. Consider appropriate analgesia.\nTime quality of pain: background pain present all the time, with occasional flare-ups (breakthrough pain)"}, {"order": 6, "name": "Nonverbal Pain Scale (NVPS) for Nonverbal Patients", "inputs": [{"field": "Face", "value": "Occasional grimace, tearing, frowning, wrinkled forehead", "score": 1}, {"field": "Activity (movement)", "value": "Seeking attention through movement or slow, cautious movement", "score": 1}, {"field": "Guarding", "value": "Splinting areas of the body, tense", "score": 1}, {"field": "Physiology (vital signs)", "value": "Change in SBP>20 mmHg or HR>20 bpm", "score": 1}, {"field": "Respiratory", "value": "RR >10 bpm over baseline, 5% decrease SpO₂ or mild ventilator asynchrony", "score": 1}], "final_answer": 5, "notes": "Moderate pain\nConsider analgesia. Sepsis, hypovolemia, and hypoxia need to be resolved prior to interventions."}, {"order": 7, "name": "Critical Care Pain Observation Tool (CPOT)", "inputs": [{"field": "Intubated?", "value": "No"}, {"field": "Vocalization", "value": "Sighing, moaning", "score": 1}, {"field": "Facial expression", "value": "Relaxed, neutral", "score": 0}, {"field": "Body movements", "value": "Protection", "score": 1}, {"field": "Muscle tension", "value": "Relaxed", "score": 0}], "final_answer": 2, "notes": "Minimal or no pain present."}]}
{"task_id": "medmcp-calc_042_870ac5cd", "task_scenario": "Osmolality and Water Balance", "task_category": "Clinical Medicine / Medicine & Organ Systems / Nephrology & Electrolytes", "patient_id": "P042_870ac5cd", "task_description": "Scenario: An adult is admitted with confusion, suspected dysnatremia, and acute kidney injury. The clinical team must determine whether the sodium abnormality is true or pseudohyponatremia from hyperglycemia, quantify water and solute deficits, evaluate the AKI etiology (which influences fluid strategy), choose a safe correction plan, and monitor ongoing fluid balance to avoid overcorrection. Workflow steps: 1) Begin with the Serum Osmolality/Osmolarity calculator to estimate the expected serum osmolarity and compare it to the measured osmolality. If the osmolal gap is elevated, consider unmeasured osmoles and exercise caution with rapid correction; if the profile suggests hyperglycemia as a major contributor to osmolar load, proceed to correct the sodium for glucose. 2) Use Sodium Correction for Hyperglycemia to obtain the corrected serum sodium. This corrected value determines whether the patient truly has hyponatremia or hypernatremia and prevents misclassification that would misdirect therapy. 3) Calculate Total Body Water (Watson Formula) to provide the TBW input required for deficit calculations in later steps. 4) Branch based on corrected sodium: If hyponatremia, use Sodium Deficit in Hyponatremia to quantify the sodium deficit using TBW; if hypernatremia, use Free Water Deficit in Hypernatremia to quantify free water deficit based on TBW and corrected sodium. 5) Evaluate AKI etiology to guide fluid strategy: If the patient is not on diuretics, use Fractional Excretion of Sodium (FENa) to distinguish prerenal from intrinsic causes; if on diuretics, use Fractional Excretion of Urea (FEUrea) instead. A prerenal pattern supports volume repletion with isotonic fluids, whereas an intrinsic pattern prompts cautious fluid administration and closer monitoring. 6) Use Sodium Correction Rate in Hyponatremia and Hypernatremia to select the appropriate fluid type (e.g., hypertonic saline, isotonic saline, D5W) and set a safe correction rate and volume, informed by the quantified sodium or water deficit and the AKI classification. 7) Employ the Body Fluid Balance Calculator by Inputs and Outputs to track ongoing IV fluids, oral intake, urine output, and other losses, ensuring the net fluid balance aligns with the intended correction rate and adjusting the plan if correction is too rapid or too slow. This monitoring step closes the loop by informing recalculation of deficits and correction rate as the clinical status evolves.", "fuzzy_question": "I’m evaluating a patient with confusion, an abnormal sodium on the basic panel, and a rise in creatinine. Glucose is elevated. I’m trying to determine whether this represents a true sodium disorder versus a dilutional picture from hyperglycemia, and how much of the mental status change is osmotic versus another cause.\n\nFirst, I want to check whether the calculated serum osmolality based on routine contributors aligns with the measured value, and whether there is an osmolar gap suggesting unmeasured osmoles. If there’s a meaningful gap, I’d be cautious about rapid sodium shifts. If the osm load appears largely driven by hyperglycemia, I’d like the sodium adjusted for the hyperglycemia to clarify the underlying tonicity before labeling hypo- or hypernatremia.\n\nOnce the adjusted sodium is established, that will guide therapy. We’ll estimate total body water using standard demographic and anthropometric factors to anchor the plan. If the adjusted sodium is low, I want to translate that into a sodium deficit; if it’s high, then quantify the free water deficit. That will frame how aggressive we should be and over what timeframe.\n\nThe kidney injury will shape the fluid strategy. I’d like to characterize whether this looks more pre-renal or intrinsic. If diuretics are not in use, a sodium-based fractional excretion can help; if diuretics are in use, a urea-based approach is more reliable. A pre-renal pattern would push toward careful volume repletion with isotonic fluid; an intrinsic picture argues for a more conservative approach with close monitoring to avoid volume overload.\n\nBringing this together, help me select the appropriate fluid and a safe pace of correction over the next hours and during the initial day. If it’s truly low sodium with symptoms, hypertonic saline may be indicated; if low sodium from volume depletion, isotonic saline may be the right starting point; if the corrected sodium is high, we’ll likely need free water (e.g., a dextrose-containing solution). Whatever we choose, the plan should respect accepted hourly and daily limits to avoid overshooting and causing harm.\n\nAs we proceed, I want a running tally of inputs and outputs—intravenous fluids, oral intake, urine output, and other measurable losses—so we can match the net balance to the correction target. If sodium is moving faster than intended, we need to slow down; if it’s lagging, adjust the approach. As labs and clinical status evolve, let’s recalculate the remaining deficit and re-check that the current rate still makes sense.\n\nWhat’s your take on this case? Please walk through your reasoning, including the calculations behind each step, and update the plan as new data come in. I need this backed by solid calculations, not just clinical intuition. This needs to hold up to scrutiny.", "required_calculators": ["Serum Osmolality/Osmolarity", "Sodium Correction for Hyperglycemia", "Total Body Water (Watson Formula)", "Sodium Deficit in Hyponatremia", "Free Water Deficit in Hypernatremia", "Fractional Excretion of Sodium (FENa)", "Fractional Excretion of Urea (FEUrea)", "Sodium Correction Rate in Hyponatremia and Hypernatremia", "Body Fluid Balance Calculator by Inputs and Outputs"], "calculator_answers": [{"order": 1, "name": "Serum Osmolality/Osmolarity", "inputs": [{"field": "Sodium", "value": "130 mEq/L"}, {"field": "BUN", "value": "48 mg/dL"}, {"field": "Glucose", "value": "820 mg/dL"}, {"field": "Serum alcohol concentration", "value": "0 mg/dL"}, {"field": "Measured serum osm", "value": "325 mOsm/kg"}], "final_answer": 323, "notes": "323 mOsm/kg Calculated Serum Osm\nNormal serum osmolality = 285-295 mOsm/kg\n2.0 mOsm/kg Osm Gap\nNormal Serum Osm Gap (Measured-Calculated) is -14 to +10."}, {"order": 2, "name": "Sodium Correction for Hyperglycemia", "inputs": [{"field": "Sodium", "value": "130 mEq/L"}, {"field": "Glucose", "value": "820 mg/dL"}], "final_answer": 147, "notes": "142 mEq/L\nCorrected Sodium\n(Katz, 1973)\n147 mEq/L\nCorrected Sodium\n(Hillier, 1999)"}, {"order": 3, "name": "Total Body Water (Watson Formula)", "inputs": [{"field": "Height", "value": "178 cm"}, {"field": "Weight", "value": "82 kg"}, {"field": "Sex", "value": "Male"}, {"field": "Age", "value": "58 years"}], "final_answer": "43.61 L", "notes": "Total Body Water\n43.61 L"}, {"order": 4, "name": "Sodium Deficit in Hyponatremia", "inputs": [{"field": "Sex", "value": "Male"}, {"field": "Age range", "value": "Adult"}, {"field": "Age", "value": "58 years"}, {"field": "Height", "value": "178 cm"}, {"field": "Weight", "value": "181 lbs"}, {"field": "Sodium", "value": "130 mEq/L"}, {"field": "Desired sodium", "value": "135 mEq/L"}], "final_answer": 218.2, "notes": "218.2 mEq\nSodium Deficit"}, {"order": 5, "name": "Free Water Deficit in Hypernatremia", "inputs": [{"field": "Sex", "value": "Male"}, {"field": "Age range", "value": "Adult"}, {"field": "Weight", "value": "181 lbs"}, {"field": "Sodium", "value": "141.5 mEq/L"}, {"field": "Sodium desired", "value": "140 mEq/L"}], "final_answer": 0.5, "notes": "0.5 L\nFree Water Deficit"}, {"order": 6, "name": "Fractional Excretion of Sodium (FENa)", "inputs": [{"field": "Serum sodium", "value": "130 mEq/L"}, {"field": "Serum creatinine", "value": "2.2 mg/dL"}, {"field": "Urine sodium", "value": "14 mEq/L"}, {"field": "Urine creatinine", "value": "100 mg/dL"}], "final_answer": "0.2%", "notes": "0.2 %\nFENa\nPrerenal\ne.g., Hypovolemia, heart failure, renal artery stenosis, sepsis (anything causing decreased effective renal perfusion). Remember, contrast-induced nephropathy will often look pre-renal."}, {"order": 7, "name": "Fractional Excretion of Urea (FEUrea)", "inputs": [{"field": "BUN or serum urea", "value": "48 mg/dL"}, {"field": "Serum creatinine", "value": "2.2 mg/dL"}, {"field": "Urine urea", "value": "300 mg/dL"}, {"field": "Urine creatinine", "value": "100 mg/dL"}], "final_answer": "13.8%", "notes": "13.8 %\nFEUrea <35% suggests pre-renal disease"}, {"order": 8, "name": "Sodium Correction Rate in Hyponatremia and Hypernatremia", "inputs": [{"field": "Sex", "value": "Male"}, {"field": "Age range", "value": "Adult"}, {"field": "Weight", "value": "181 lbs"}, {"field": "Serum sodium", "value": "141.5 mEq/L"}, {"field": "Fluid type", "value": "0.45% saline (77 mmol/L Na)"}, {"field": "Rate of sodium correction", "value": "0.20 mEq/L/hr"}], "final_answer": 156, "notes": "156 mL/hr\nFluid rate to increase Na by 0.2 mmol/L/hr with 0.45% saline\nNOTE: Na is within normal. Confirm correction is needed."}, {"order": 9, "name": "Body Fluid Balance Calculator by Inputs and Outputs", "inputs": [{"field": "Urine", "value": "900 mL"}, {"field": "Insensible losses", "value": "300 mL"}, {"field": "0.9% saline", "value": "1000 mL"}, {"field": "0.45% saline", "value": "500 mL"}, {"field": "D5W", "value": "250 mL"}], "final_answer": 870, "notes": "870 mL\n0.9% saline (Net Gain)\n-320 mL\nFree H2O (Net Loss)"}]}
{"task_id": "medmcp-calc_043_86352306", "task_scenario": "Hepatocellular Carcinoma (HCC) Staging", "task_category": "Clinical Medicine / Medicine & Organ Systems / Gastroenterology & Hepatology", "patient_id": "P043_86352306", "task_description": "Clinical scenario: A patient with chronic liver disease is found to have a suspicious hepatic lesion on surveillance. The care team must confirm the likelihood of hepatocellular carcinoma (HCC), stage the tumor, assess hepatic reserve, choose a treatment pathway, and determine liver transplant eligibility. Workflow: Step 1 – Use the GALAD Model for Hepatocellular Carcinoma (HCC) to estimate the probability of HCC based on available serum biomarkers in the chronic liver disease setting. If the GALAD probability is low (not consistent with HCC), pause disease staging and continue routine surveillance. If the GALAD probability is high (consistent with HCC), proceed to formal staging. Step 2 – Apply Hepatocellular Carcinoma TNM Staging to define tumor burden (number/size), vascular invasion, nodal disease, and metastasis. The TNM output provides structured tumor features that will be used to drive treatment decisions and transplant eligibility checks. Step 3 – Calculate the ALBI (Albumin-Bilirubin) Grade for Hepatocellular Carcinoma (HCC) to quantify hepatic reserve. The ALBI result informs suitability for curative interventions (e.g., resection) versus locoregional or systemic therapies. Step 4 – Use the Barcelona-Clinic Liver Cancer (BCLC) Staging Classification and Treatment Guidelines, integrating tumor burden (from TNM), performance status, and hepatic function (guided by ALBI). Determine the BCLC stage and map to treatment: If BCLC 0/A and ALBI suggests good hepatic reserve, favor curative options (resection or ablation); if BCLC 0/A but ALBI indicates limited reserve or TNM shows features unfavorable for resection, prioritize transplant evaluation or ablation; if BCLC B, select locoregional therapy (e.g., TACE); if BCLC C, pursue systemic therapy; if BCLC D, provide best supportive care. Step 5 – For patients in early stages or those not ideal for resection, apply the Milan Criteria for Liver Transplantation using the TNM-derived lesion number/size and absence of extrahepatic spread/vascular invasion. If within Milan, proceed with transplant listing; if beyond Milan, consider BCLC-guided downstaging (e.g., TACE/ablation) and then re-evaluate with Milan Criteria to determine transplant eligibility versus continued non-transplant therapy. This sequence ensures that outputs from GALAD gate the need for staging, TNM and ALBI feed directly into BCLC decision-making, and TNM features deterministically trigger Milan assessments for transplant.", "fuzzy_question": "Got a patient with cirrhosis under surveillance who now has a new hepatic lesion that appears suspicious on imaging. I'm trying to determine how likely this is hepatocellular carcinoma, how advanced it may be, and what the liver can realistically tolerate so we avoid over- or under-treatment.\n\nBefore moving straight to staging, I'd like an objective estimate of the probability this lesion is HCC based on recent labs and basic demographics. We have AFP, the AFP-L3 fraction, and des-gamma-carboxy prothrombin (PIVKA-II). If that profile suggests a low likelihood, I'd prefer to hold off on an intensive work-up and stick with the usual surveillance schedule. If it suggests a high likelihood, let's proceed to fully characterize the disease.\n\nIf we proceed, I need the staging details laid out clearly because that drives everything: lesion count, maximal dimension, whether there is obvious vascular involvement (portal or hepatic vein), and whether there are regional nodes or distant spread. That snapshot will shape both treatment choices and whether we should open a transplant discussion.\n\nIn parallel, I want a clean, objective sense of hepatic reserve using albumin and bilirubin from the same labs. That read on liver function will tell us whether curative strategies like resection are realistic, or whether we should favor ablation, catheter-based therapies, or move straight to systemic treatment. Please factor in day-to-day functional status (activity level, limitations), since that will influence whether more aggressive approaches are tolerable.\n\nOnce we have the tumor details, functional status, and liver reserve, help place the patient along the usual spectrum from very early disease to end-stage, and match that to a sensible treatment plan. My bias is:\n- If it's very early or early and the liver looks strong, lean toward resection or ablation.\n- If it's early but liver reserve is marginal or the anatomy/features don't favor resection, prioritize a transplant evaluation or consider ablation.\n- If it's more in the intermediate range, locoregional therapy like TACE makes sense.\n- If there's clear vascular invasion or spread and the patient is still fit, consider systemic therapy.\n- If liver function and performance status are poor, best supportive care may be most appropriate.\n\nFor patients who look early or aren't ideal for resection, I also want a firm check on transplant candidacy using standard limited-tumor-burden criteria without macrovascular invasion or extrahepatic disease. If the patient fits within that, move toward listing. If outside those limits, outline a reasonable downstaging plan (e.g., TACE or ablation), then re-assess to see if criteria are met; if not, continue non-transplant therapy guided by stage.\n\nWhat's your clinical take as you work through this? I really need proper calculations on this—can't make this decision based on gut feeling alone. Whatever approach you suggest, make sure it's backed by solid calculations. This needs to hold up to scrutiny.", "required_calculators": ["GALAD Model for Hepatocellular Carcinoma (HCC)", "Hepatocellular Carcinoma TNM Staging", "ALBI (Albumin-Bilirubin) Grade for Hepatocellular Carcinoma (HCC)", "Barcelona-Clinic Liver Cancer (BCLC) Staging Classification and Treatment Guidelines", "Milan Criteria for Liver Transplantation"], "calculator_answers": [{"order": 1, "name": "GALAD Model for Hepatocellular Carcinoma (HCC)", "inputs": [{"field": "Gender", "value": "Male"}, {"field": "Age", "value": "62 years"}, {"field": "Alpha fetoprotein L3 (AFP-L3)", "value": "12 %"}, {"field": "Alpha fetoprotein (AFP)", "value": "75 ng/mL"}, {"field": "Des-carboxy-prothrombin (DCP)", "value": "85 ng/mL"}], "final_answer": 4.6, "notes": "99.01 %\nProbability of concurrent HCC in this CLD patient"}, {"order": 2, "name": "Hepatocellular Carcinoma TNM Staging", "inputs": [{"field": "Primary Tumour (T)", "value": "T1b (solitary tumor >2 cm, no vascular invasion)"}, {"field": "Regional Lymph Nodes (N)", "value": "N0 (no regional lymph node involvement)"}, {"field": "Distant Metastasis (M)", "value": "M0 (no distant metastasis)"}], "final_answer": "IB", "notes": "TNM Classification\nT1b N0 M0\nAJCC Prognostic Stage Group\nIB"}, {"order": 3, "name": "ALBI (Albumin-Bilirubin) Grade for Hepatocellular Carcinoma (HCC)", "inputs": [{"field": "Bilirubin", "value": "0.9 mg/dL"}, {"field": "Albumin", "value": "4.2 g/dL"}], "final_answer": -2.79, "notes": "-2.79 points\nALBI Score\nGrade 1\n18.5-85.6 months\nMedian survival"}, {"order": 4, "name": "Barcelona-Clinic Liver Cancer (BCLC) Staging Classification and Treatment Guidelines", "inputs": [{"field": "Nodule", "value": "Single, or ≤3 nodules each ≤3cm"}, {"field": "Liver function", "value": "Preserved liver function"}, {"field": "ECOG performance status", "value": "0"}, {"field": "Number of nodules", "value": "Single"}, {"field": "Portal pressure, bilirubin", "value": "Normal"}], "final_answer": "Stage A", "notes": "Stage A\nExpected survival: >5 years\nResection\n1st treatment option"}, {"order": 5, "name": "Milan Criteria for Liver Transplantation", "inputs": [{"field": "Single tumor with diameter ≤5 cm", "value": "Yes", "score": 1}, {"field": "Up to 3 tumors each with diameter ≤3 cm", "value": "No", "score": 0}, {"field": "Extra-hepatic involvement", "value": "No", "score": 1}, {"field": "Major vessel involvement", "value": "No", "score": 1}], "final_answer": "Criteria met", "notes": "Milan Criteria fulfilled. Patient is a viable transplant candidate."}]}
{"task_id": "medmcp-calc_044_ea460124", "task_scenario": "Pulmonary Hypertension Risk Stratification", "task_category": "Clinical Medicine / Medicine & Organ Systems / Cardiovascular Medicine", "patient_id": "P044_ea460124", "task_description": "Clinical scenario: In Clinical Medicine / Medicine & Organ Systems / Cardiovascular Medicine _ Pulmonary Hypertension Risk Stratification, a patient with suspected or newly confirmed pulmonary arterial hypertension (PAH) requires a structured, calculator-driven workflow to determine risk category and guide management intensity.\n\nStep-by-step workflow:\n1) Hemodynamics (Echo): Begin with noninvasive hemodynamic assessment to estimate the probability of pulmonary hypertension and characterize right ventricular size/function and estimated pressures. This sets the pre-test probability and identifies whether invasive confirmation is warranted.\n2) Decision branch based on echo findings:\n   - If echo suggests low probability of pulmonary hypertension, defer invasive testing and reassess clinically; end the calculator workflow here.\n   - If echo indicates intermediate/high probability, proceed to invasive evaluation and use the next calculator.\n3) Pulmonary Resistance: After right heart catheterization provides standard invasive hemodynamic variables, calculate pulmonary vascular resistance (PVR). This quantifies pulmonary vascular load and helps distinguish pre-capillary PAH physiology from other forms of pulmonary hypertension.\n4) Decision branch based on PVR result:\n   - If PVR is consistent with pre-capillary pulmonary vascular disease, proceed to formal PAH risk stratification using REVEAL 2.0.\n   - If PVR does not support pre-capillary physiology, do not apply PAH-specific risk scores; redirect care toward alternative etiologies of pulmonary hypertension and exit the workflow.\n5) REVEAL Registry Risk Score 2.0 for Pulmonary Arterial Hypertension (PAH): Enter clinical, functional, and hemodynamic data to generate a validated survival-based risk category. This provides a quantitative estimate of mortality risk and informs management intensity.\n6) Conditional refinement with A-HIPI:\n   - If the REVEAL 2.0 result is intermediate or borderline between risk tiers, apply A-HIPI to refine risk layering using available hemodynamic/imaging parameters, supporting a more granular decision on therapy escalation and follow-up cadence.\n   - If REVEAL 2.0 shows clearly low or high risk, A-HIPI is optional and may be skipped; proceed directly to management planning.\n7) Translate the final risk category into a care plan: Use the combined outputs to determine need for escalation (e.g., advanced therapies, expedited referral to a PH center), intensity of monitoring, and timing of reassessment (including repeat echo and potential re-evaluation of PVR and scores at follow-up).", "fuzzy_question": "Got a patient where we are worried about pulmonary arterial hypertension, but it is not crystal clear how aggressive to be right now. I would like to start by anchoring on a careful echo read: how likely does this look to be true pulmonary hypertension, and what do you make of the right ventricle’s size and function with the estimated pressures? If that picture feels low probability, I am inclined to hold off on invasive testing and just outline how you would follow clinically. But if the echo points to an intermediate or high chance, then we should move on to right-sided hemodynamics and get the usual measurements to understand the load on the pulmonary circulation.\n\nIf we do proceed with cath, please use those measurements to quantify the pulmonary vascular load and tell me whether the pattern fits a pre-capillary process versus post-capillary or mixed. If it does not look pre-capillary, let us not force a PAH framework - shift the workup toward alternative causes and stop the PAH-specific path there. But if it does look pre-capillary, I would like a formal, survival-oriented risk picture that pulls together the clinical factors (comorbidities, symptoms/functional class), functional data (walk distance or CPET), biomarkers (natriuretic peptides, renal function), and the invasive/imaging findings to land them in a clear risk tier. If that result sits in the gray zone or feels borderline between tiers, please layer in a hemodynamic/imaging-based refinement to sharpen the risk and guide whether we escalate now or watch more closely. If it is clearly low or clearly high risk, we can skip that extra layer and move straight to decisions.\n\nFrom there, translate the final risk into a practical care plan: whether we should step up therapy (including advanced options and early referral to a PH center), how tight the monitoring should be, and when to bring them back - with a concrete timeline for repeat echo and, if needed, a re-look at the invasive numbers and an updated risk picture. Recently there has been worsening dyspnea, rising biomarkers, and impaired renal function, so I am torn between pushing harder now versus staging this out. Walk me through your reasoning in that order, and please surface the intermediate conclusions at each step. I need proper calculations - this cannot rest on gut feeling. Whatever approach you suggest, make sure it is backed by solid calculations; this has to hold up to scrutiny.", "required_calculators": ["Hemodynamics (Echo)", "Pulmonary Resistance", "REVEAL Registry Risk Score 2.0 for Pulmonary Arterial Hypertension (PAH)", "A-HIPI"], "calculator_answers": [{"order": 1, "name": "Hemodynamics (Echo)", "inputs": [{"field": "LVOT Diameter?", "value": "19 mm"}, {"field": "LVOT Subvalvular Velocity Time Integral?", "value": "16 cm"}, {"field": "Heart Rate?", "value": "98 bpm"}, {"field": "Weight?", "value": "68 kg"}, {"field": "Height?", "value": "165 cm"}], "final_answer": "4.4 L/min", "notes": "Cardiac Output\n4.4 L/min\nCardiac Index\n2.52 L/min/m²\nStroke Volume\n45 mL/beat\nStroke Volume Index\n26 mL/beat/m²"}, {"order": 2, "name": "Pulmonary Resistance", "inputs": [{"field": "Mean Pulmonary Artery Pressure?", "value": "38 mmHg"}, {"field": "Pulmonary Capillary Wedge Pressure?", "value": "10 mmHg"}, {"field": "Pulmonary Flow?", "value": "4.6 L/min"}, {"field": "Units?", "value": "Wood Units"}], "final_answer": 6, "notes": "Pulmonary Vascular Resistance\n6 Wood Units\nTotal Pulmonary Resistance\n8 Wood Units"}, {"order": 3, "name": "REVEAL Registry Risk Score 2.0 for Pulmonary Arterial Hypertension (PAH)", "inputs": [{"field": "WHO group 1 subgroup", "value": "Other (idiopathic PAH)", "score": 0}, {"field": "Male age >60 years", "value": "No (female, 58 years)", "score": 0}, {"field": "eGFR <60 mL/min/1.73 m2 or renal insufficiency", "value": "Yes (eGFR 52 mL/min/1.73 m2)", "score": 1}, {"field": "NYHA/WHO functional class", "value": "III", "score": 1}, {"field": "Systolic BP, mmHg", "value": "108 mmHg", "score": 1}, {"field": "Heart rate, bpm", "value": "98 bpm", "score": 1}, {"field": "Any hospitalizations within 6 months", "value": "No", "score": 0}, {"field": "6-minute walk test", "value": "290 m", "score": 0}, {"field": "BNP, pg/mL", "value": "850 pg/mL", "score": 2}, {"field": "Pericardial effusion on echocardiogram", "value": "No", "score": 0}, {"field": "DLCO on pulmonary function test", "value": "38% predicted (<40%)", "score": 1}, {"field": "Mean right atrial pressure >20 mmHg within 1 year on right heart catheterization", "value": "No (RAP 14 mmHg)", "score": 0}, {"field": "Pulmonary vascular resistance <5 Wood units on right heart catheterization", "value": "No (PVR 6.1 WU)", "score": 0}], "final_answer": 13, "notes": "High risk\n<70 %\nPredicted 1-year survival"}, {"order": 4, "name": "A-HIPI", "inputs": [{"field": "Age?", "value": "58 years"}, {"field": "Albumin?", "value": "3.8 g/dL"}, {"field": "Bulk?", "value": "No bulky disease"}, {"field": "Gender?", "value": "Female"}, {"field": "Hemoglobin?", "value": "12.6 g/dL"}, {"field": "Lymphocyte count?", "value": "1.8 x10^9/L"}, {"field": "Stage?", "value": "Stage IIB"}], "final_answer": "80.13%", "notes": "Progression Free Survival at 5 years\n80.13%\nOverall Survival at 5 years\n92.31%"}]}
{"task_id": "medmcp-calc_045_d83878ce", "task_scenario": "Renal Function and Drug Metabolism", "task_category": "Clinical Medicine / Special Populations & General Tools / Clinical Pharmacology & Nursing", "patient_id": "P045_d83878ce", "task_description": "Clinical scenario: An adult oncology inpatient with chronic kidney disease develops an acute illness with fluctuating renal function while requiring empiric vancomycin and is scheduled for carboplatin-based chemotherapy. The care team must determine reliable renal function metrics under non–steady-state conditions, stage acute kidney injury (AKI), dose nephrotoxic/renally cleared medications safely, manage fluids, and plan continuous renal replacement therapy (CRRT) if needed. Workflow: 1) Establish the patient’s baseline kidney function using the CKD-EPI Equations for Glomerular Filtration Rate (GFR) to anchor dosing decisions if renal function appears stable. 2) Use KDIGO AKI Staging to classify the severity of AKI based on changes in kidney function and urine output; this stage determines whether creatinine is changing sufficiently to invalidate steady-state GFR estimators. 3) If KDIGO suggests non–steady-state or rapidly changing creatinine, calculate the Kinetic Estimated Glomerular Filtration Rate (keGFR) and treat this as the primary renal function input for drug dosing; otherwise continue with CKD-EPI eGFR. 4) Calculate Creatinine Clearance (Cockcroft-Gault Equation) to obtain CrCl, because some dosing references prefer CrCl over eGFR. 5) If CKD-EPI eGFR and Cockcroft-Gault CrCl differ substantially or clinical factors make either estimate unreliable, perform CrCl from 24h Urine to obtain a measured clearance; the measured value supersedes estimates for dosing if available. 6) With the selected renal function metric (keGFR if non–steady-state; otherwise measured 24h CrCl if available, or the most reliable of CKD-EPI/CrCl), enter it into Vancomycin Dosing Based on eGFR (creatinine-cystatin C) to select an appropriate loading dose and maintenance interval. 7) Using the same chosen renal function parameter, compute the carboplatin dose with Carboplatin AUC Dosing (Calvert), aligning the target AUC set by oncology and adjusting for renal impairment to avoid overdosing. 8) To refine the etiology of the AKI and guide fluid management, use Fractional Excretion of Urea (FEUrea); prerenal patterns support fluid resuscitation, while intrinsic patterns suggest a conservative fluid approach and closer drug monitoring. 9) Plan fluid therapy with the Body Fluid Balance Calculator by Inputs and Outputs to quantify net isotonic saline and free water needs; results help optimize perfusion, mitigate volume overload, and anticipate effects on drug distribution and clearance. 10) If KDIGO staging indicates severe AKI or persistent oliguria despite appropriate fluids, initiate CRRT planning and use the CRRT Dosing Calculator to set effluent dose targets; this informs ongoing antimicrobial dosing strategies and chemotherapy timing. Conditional branches: a) If KDIGO shows non–steady-state AKI, use keGFR for dosing; else use CKD-EPI. b) If CKD-EPI and Cockcroft-Gault disagree or are unreliable, confirm with 24h urine CrCl and use that for dosing. c) If FEUrea suggests prerenal physiology, proceed with liberal isotonic fluid planning; if intrinsic, use a conservative fluid plan and intensify drug monitoring. d) If AKI is severe or unresponsive, proceed to CRRT and apply CRRT dosing to guide supportive care and medication management.", "fuzzy_question": "I’m seeing an oncology inpatient with chronic kidney disease admitted with an acute illness; creatinine has been fluctuating recently and urine output is variable. The patient is receiving empiric vancomycin and is anticipated to receive carboplatin-based chemotherapy. I’m trying to identify the most reliable anchor for kidney function to guide safe dosing and day-to-day management.\n\nMy initial approach is to base decisions on baseline kidney function if current labs appear reasonably stable; if the clinical picture is not changing, I’m comfortable using the usual outpatient estimate as a starting point. If creatinine is changing or urine output suggests acute injury, I want to stage severity using both creatinine trajectory and urine output to judge how trustworthy steady-state estimates are.\n\nIf we’re not in steady state, I’d prefer a kinetic filtration approach that accounts for changing creatinine rather than a steady-state method. In parallel, I also want the creatinine-based clearance many drug references cite (age-weight-creatinine formula) because we may need to dose from that. If these approaches diverge meaningfully, or if body habitus or low muscle mass make either unreliable, I’d obtain a timed urine collection for measured creatinine clearance and let that guide dosing when available.\n\nUsing the most defensible kidney function input (kinetic when changing, otherwise the best available estimate or measured clearance), please set a vancomycin plan with an appropriate loading dose and maintenance interval; incorporate cystatin C if available. Given renal variability and nephrotoxicity risk, I’d like a monitoring strategy that keeps exposure on target without overshooting. Then, using the same kidney function, size carboplatin to the oncology team’s target exposure to avoid overdosing in the setting of renal impairment.\n\nTo help clarify the driver of acute kidney injury and guide fluids, I plan to assess the fractional excretion of urea; if findings are consistent with prerenal physiology, I’d favor more liberal isotonic fluids; if intrinsic, I’d be conservative with fluids and intensify drug monitoring. Please also lay out a clear fluid plan based on intake and output—how much net isotonic fluid versus free water is likely needed—to support perfusion without causing overload, and note how these shifts would affect drug distribution and clearance.\n\nIf the injury is severe or oliguria persists despite appropriate fluids, we should be prepared to initiate continuous dialysis. In that case, please propose an effluent rate target, how vancomycin dosing should be adjusted, and the safest timing for carboplatin.\n\nWhat’s your take on this approach? I’m balancing timely chemotherapy with maintaining therapeutic antibiotics while avoiding preventable kidney injury. I need solid calculations to support the plan so it stands up to scrutiny.", "required_calculators": ["CKD-EPI Equations for Glomerular Filtration Rate (GFR)", "KDIGO AKI Staging", "Kinetic Estimated Glomerular Filtration Rate (keGFR)", "Creatinine Clearance (Cockcroft-Gault Equation)", "CrCl from 24h Urine", "Vancomycin Dosing Based on eGFR (creatinine-cystatin C)", "Carboplatin AUC Dosing (Calvert)", "Fractional Excretion of Urea (FEUrea)", "Body Fluid Balance Calculator by Inputs and Outputs", "CRRT Dosing Calculator"], "calculator_answers": [{"order": 1, "name": "CKD-EPI Equations for Glomerular Filtration Rate (GFR)", "inputs": [{"field": "equation_version", "value": "2021 CKD-EPI Creatinine-Cystatin C"}, {"field": "sex", "value": "Male"}, {"field": "age_years", "value": "62 years"}, {"field": "serum_creatinine", "value": "1.8 mg/dL (baseline, stable outpatient value)"}, {"field": "serum_cystatin_c", "value": "1.6 mg/L (baseline)"}], "final_answer": 42, "notes": "42 ml/min/1.73 m²\nEstimated GFR by 2021 CKD-EPI Creatinine-Cystatin C\nStage IIIb\nCKD stage by CKD-EPI Creatinine"}, {"order": 2, "name": "KDIGO AKI Staging", "inputs": [{"field": "baseline_serum_creatinine", "value": "1.8 mg/dL"}, {"field": "current_serum_creatinine", "value": "3.0 mg/dL"}, {"field": "absolute_increase_in_creatinine", "value": "1.2 mg/dL"}, {"field": "multiple_of_baseline_creatinine", "value": "1.67 × baseline"}, {"field": "urine_output_last_12h", "value": "330 mL over 12 hours"}, {"field": "body_weight", "value": "78 kg"}, {"field": "urine_output_rate", "value": "0.35 mL/kg/h over 12 hours"}, {"field": "urine_output_last_24h", "value": "800 mL over 24 hours"}, {"field": "anuria_duration", "value": "0 hours"}], "final_answer": "Stage 2", "notes": "Serum creatinine 2.0–2.9 times baseline or <0.5 ml/kg/h for ≥12 hours"}, {"order": 3, "name": "Kinetic Estimated Glomerular Filtration Rate (keGFR)", "inputs": [{"field": "sex", "value": "Male"}, {"field": "age_years", "value": "62 years"}, {"field": "baseline_creatinine", "value": "1.8 mg/dL"}, {"field": "first_recorded_creatinine_Cr1", "value": "2.3 mg/dL"}, {"field": "second_recorded_creatinine_Cr2", "value": "3.0 mg/dL"}, {"field": "time_between_measurements", "value": "18 hours"}, {"field": "black_race", "value": "No"}], "final_answer": 9.9, "notes": "9.9 mL/min\nKeGFR of 30 mL/min is 90% specific (71% sensitive) for AKI, according to one small retrospective study (O'Sullivan 2017)"}, {"order": 4, "name": "Creatinine Clearance (Cockcroft-Gault Equation)", "inputs": [{"field": "sex", "value": "Male"}, {"field": "age_years", "value": "62 years"}, {"field": "weight", "value": "172 lb (78 kg)"}, {"field": "height", "value": "69 in (175 cm)"}, {"field": "serum_creatinine", "value": "3.0 mg/dL (current)"}], "final_answer": "28 mL/min", "notes": "28 mL/min\nCreatinine clearance, original Cockcroft-Gault\n27 mL/min\nCreatinine clearance modified for overweight patient, using adjusted body weight of 73 kg (162 lbs).\n25.4-26.5 mL/min\nNote: This range uses IBW and adjusted body weight. Controversy exists over which form of weight to use."}, {"order": 5, "name": "CrCl from 24h Urine", "inputs": [{"field": "urine_creatinine", "value": "150 mg/dL"}, {"field": "plasma_creatinine", "value": "3.0 mg/dL"}, {"field": "urine_volume", "value": "800 mL over 24 hours"}], "final_answer": "27.78 mL/min", "notes": "Creatinine Clearance\n27.78 mL/min"}, {"order": 6, "name": "Vancomycin Dosing Based on eGFR (creatinine-cystatin C)", "inputs": [{"field": "received_>1_dose_last_4_days", "value": "No"}, {"field": "rapidly_changing_renal_function_or_dialysis", "value": "NO"}, {"field": "age_<18_or_weight_>130kg_>286lb", "value": "No"}, {"field": "age_years", "value": "62 years"}, {"field": "sex", "value": "Male"}, {"field": "black", "value": "No"}, {"field": "height", "value": "69 in (175 cm)"}, {"field": "weight", "value": "172 lb (78 kg)"}, {"field": "serum_creatinine", "value": "3.0 mg/dL (current)"}, {"field": "serum_cystatin_c", "value": "2.1 mg/L (current)"}, {"field": "target_trough", "value": "15-20 mg/mL"}], "final_answer": 1300, "notes": "BSA (m²)\n1.94\neGFR (mL/min/1.73m²)\n27\nDose\nBased on the eGFRcr-cys C of 27 (mL/min), for a target trough range of 15-20 mg/mL, the recommended vancomycin dose and interval is:\n1300 mg every 24 hours"}, {"order": 7, "name": "Carboplatin AUC Dosing (Calvert)", "inputs": [{"field": "age", "value": "62 years"}, {"field": "weight", "value": "78 kg"}, {"field": "serum_creatinine", "value": "3.0 mg/dL (current)"}, {"field": "target_auc", "value": "5 mg·min/mL"}, {"field": "gender", "value": "Male"}], "final_answer": "265.8 mg", "notes": "Total Dose\n265.8 mg"}, {"order": 8, "name": "Fractional Excretion of Urea (FEUrea)", "inputs": [{"field": "bun", "value": "62 mg/dL"}, {"field": "serum_creatinine", "value": "3.0 mg/dL"}, {"field": "urine_urea", "value": "682 mg/dL"}, {"field": "urine_creatinine", "value": "150 mg/dL"}], "final_answer": "22.0 %", "notes": "FEUrea <35% suggests pre-renal disease"}, {"order": 9, "name": "Body Fluid Balance Calculator by Inputs and Outputs", "inputs": [{"field": "gastric_loss", "value": "0 mL"}, {"field": "biliary_loss", "value": "0 mL"}, {"field": "pancreatic_loss", "value": "0 mL"}, {"field": "small_bowel_loss", "value": "0 mL"}, {"field": "diarrhea_nonosmotic", "value": "0 mL"}, {"field": "sorbitol_osmotic_diarrhea", "value": "0 mL"}, {"field": "lactulose_osmotic_diarrhea", "value": "0 mL"}, {"field": "osmotic_diarrhea_PEG", "value": "0 mL"}, {"field": "pleural_or_peritoneal_fluid_loss", "value": "0 mL"}, {"field": "wound_drainage", "value": "0 mL"}, {"field": "dialysis_net_ultrafiltrate", "value": "0 mL"}, {"field": "urine_output", "value": "800 mL"}, {"field": "insensible_losses", "value": "600 mL"}, {"field": "other_body_fluid_loss", "value": "0 mL"}, {"field": "packed_rbcs_given", "value": "0 mL"}, {"field": "plasma_cryoprecipitate_platelets_ivig", "value": "0 mL"}, {"field": "albumin_5_20_25", "value": "0 mL"}, {"field": "normal_saline_0_9", "value": "1500 mL"}, {"field": "half_normal_saline_0_45", "value": "0 mL"}, {"field": "plasmalyte_A", "value": "0 mL"}, {"field": "ringers_lactate", "value": "0 mL"}, {"field": "d5w", "value": "250 mL"}, {"field": "nahco3_concentrate", "value": "0 mL"}, {"field": "100mEq_nahco3_in_1L_d5w", "value": "0 mL"}, {"field": "injectable_sodium_phosphates", "value": "0 mL"}, {"field": "tpn", "value": "0 mL"}, {"field": "enteral_pulmocare", "value": "0 mL"}, {"field": "enteral_nutren_2_0", "value": "0 mL"}, {"field": "enteral_fibersource_hn", "value": "0 mL"}, {"field": "enteral_impact_peptide_1_5", "value": "0 mL"}, {"field": "enteral_nutren_pulmonary", "value": "0 mL"}, {"field": "enteral_isosource_hn", "value": "0 mL"}, {"field": "enteral_diabetisource_ac", "value": "0 mL"}, {"field": "enteral_novasource_renal", "value": "0 mL"}, {"field": "enteral_osmolyte", "value": "0 mL"}, {"field": "enteral_jevyty", "value": "0 mL"}, {"field": "enteral_replete_fiber", "value": "0 mL"}, {"field": "enteral_ensure", "value": "0 mL"}, {"field": "enteral_nepro", "value": "0 mL"}, {"field": "enteral_peptamen", "value": "0 mL"}, {"field": "enteral_suplena", "value": "0 mL"}, {"field": "enteral_vivonex_rtf", "value": "0 mL"}, {"field": "enteral_twocal_hn", "value": "0 mL"}, {"field": "enteral_beneprotein", "value": "0 mL"}, {"field": "enteral_renalcal", "value": "0 mL"}, {"field": "other_enteral_solution", "value": "0 mL"}], "final_answer": 1162, "notes": "1162 mL\n0.9% saline (Net Gain)\n-812 mL\nFree H2O (Net Loss)"}, {"order": 10, "name": "CRRT Dosing Calculator", "inputs": [{"field": "patient_weight", "value": "78 kg"}, {"field": "desired_dialysis_dose", "value": "25 mL/kg/h (effluent dose target)"}], "final_answer": "1950 ml/hr", "notes": "Calculated Dialysis Dose\n1950 ml/hr"}]}
{"task_id": "medmcp-calc_046_e5543ab9", "task_scenario": "Glaucoma Risk Assessment", "task_category": "Clinical Medicine / Medicine & Organ Systems / Sensory Systems (Ophthalmology / ENT / Dermatology)", "patient_id": "P046_e5543ab9", "task_description": "Clinical scenario: In an ophthalmology clinic, a patient with ocular hypertension and optic nerve features raising concern for future glaucoma is being evaluated to determine the risk of developing primary open-angle glaucoma and whether to initiate intraocular pressure (IOP)-lowering therapy or pursue close observation. Workflow steps: 1) Begin with the Ocular Hypertension Treatment Study (OHTS) Calculator to estimate baseline 5-year risk of conversion to glaucoma using standard clinical inputs. The OHTS output (risk category) is used as the first deterministic decision point. 2) Branching logic based on OHTS: If the OHTS result indicates a low risk, proceed to A-HIPI to establish a baseline hazard profile and tailor surveillance intervals (the OHTS low-risk category triggers a conservative monitoring pathway). If the OHTS result indicates an intermediate or high risk, apply A-HIPI to refine the risk by integrating additional contributory factors into a composite hazard profile (the OHTS intermediate/high-risk category triggers a more intensive evaluation via A-HIPI). 3) Second branch driven by A-HIPI: If A-HIPI categorizes the patient as high hazard, initiate IOP-lowering therapy and schedule earlier follow-up; if A-HIPI indicates lower hazard than expected, defer therapy and set enhanced monitoring with targeted testing. 4) Reassessment cycle: After therapy initiation (or after a period of observation), repeat the OHTS Calculator to re-quantify risk under the new clinical conditions (e.g., post-therapy IOP stabilization), using the updated OHTS risk category to adjust subsequent follow-up intensity and determine whether to re-run A-HIPI for ongoing risk tracking. This sequence ensures that the OHTS output deterministically triggers use of A-HIPI, and the A-HIPI output deterministically triggers treatment vs observation planning, with iterative reassessment using OHTS to close the loop.", "fuzzy_question": "I’m evaluating a patient with ocular hypertension and optic nerve appearance that is concerning—larger cupping than expected, OCT with borderline findings, but visual fields without defects. IOP has been persistently elevated across recent visits, central corneal thickness is not increased, and there is a positive family history. I’m torn between starting topical therapy now versus close observation.\n\nWhat I need first is a structured, quantitative estimate of the 5-year chance of developing primary open-angle glaucoma based on standard clinical inputs (recent IOP measurements, age, central corneal thickness, optic disc cupping, baseline visual field indices, family history, race/ethnicity). Let’s use that initial risk category as the first decision point.\n\nIf that initial read suggests genuinely low risk, I’m inclined to observe—but I still want a clear baseline hazard profile that justifies how often to bring the patient back and which tests to prioritize (pressure checks, OCT RNFL, disc photos, visual fields), so the surveillance schedule isn’t guesswork. If they land in the intermediate or high-risk range, go deeper and refine the picture by incorporating additional contributors often missed on a first pass: corneal hysteresis if available, OCT trend rather than a single scan, disc hemorrhages ever documented, degree of myopia, ocular perfusion considerations (nocturnal systemic hypotension, sleep apnea), steroid exposure, migraines/vascular issues, and any other relevant factors. Provide a composite hazard profile that indicates the true risk after this fuller assessment.\n\nThen, depending on that refined hazard read: if it points to a high likelihood of progression, recommend starting IOP-lowering therapy now and set earlier follow-up with targeted testing; if the refined hazard ends up lower than the initial impression, explain why to hold off on treatment and spell out an enhanced monitoring plan—how frequently to see the patient, what specific changes would trigger treatment, and how to keep risk visible without overtesting.\n\nFinally, after therapy has stabilized pressure or after a defined period of observation, revisit the structured risk under the new clinical conditions to update the 5-year risk category and use that to recalibrate follow-up intensity. Based on that new category, indicate whether to repeat the refined hazard assessment to keep ongoing risk tracking accurate.\n\nWalk me through this step by step—give the initial risk category, the refined hazard classification, and the management plan that follows from each stage. I need proper calculations—this can’t rely on clinical intuition alone. Ensure the approach is backed by solid calculations and will hold up to scrutiny.", "required_calculators": ["Ocular Hypertension Treatment Study (OHTS) Calculator", "A-HIPI"], "calculator_answers": [{"order": 1, "name": "Ocular Hypertension Treatment Study (OHTS) Calculator", "inputs": [{"field": "Age, years", "value": "52", "score": 1}, {"field": "Mean intraocular pressure, mmHg", "value": "25.6 mmHg", "score": 2}, {"field": "Mean central corneal thickness, µm", "value": "540 µm", "score": 3}, {"field": "Mean vertical cup-to-disc ratio by contour", "value": "0.64", "score": 4}, {"field": "Mean pattern standard deviation, dB", "value": "1.9 dB", "score": 1}], "final_answer": 11, "notes": "11 points\nOHTS Score\nIntermediate risk\nRecommend counseling on risks/benefits of treatment versus close observation\n20 %\n5-year risk of developing primary open angle glaucoma"}, {"order": 2, "name": "A-HIPI", "inputs": [{"field": "Age", "value": "52 years"}, {"field": "Albumin", "value": "4.2 g/dL"}, {"field": "Bulk", "value": "No bulky disease"}, {"field": "Gender", "value": "Female"}, {"field": "Hemoglobin", "value": "13.6 g/dL"}, {"field": "Lymphocyte count", "value": "1.8 x10^9/L"}, {"field": "Stage", "value": "IIB"}], "final_answer": "83.31%", "notes": "Progression Free Survival at 5 years\n83.31%\nOverall Survival at 5 years\n95.44%"}, {"order": 3, "name": "Ocular Hypertension Treatment Study (OHTS) Calculator", "inputs": [{"field": "Age, years", "value": "52", "score": 1}, {"field": "Mean intraocular pressure, mmHg", "value": "16.5 mmHg", "score": 0}, {"field": "Mean central corneal thickness, µm", "value": "540 µm", "score": 3}, {"field": "Mean vertical cup-to-disc ratio by contour", "value": "0.64", "score": 4}, {"field": "Mean pattern standard deviation, dB", "value": "1.8 dB", "score": 1}], "final_answer": 9, "notes": "9 points\nOHTS Score\nIntermediate risk\nRecommend counseling on risks/benefits of treatment versus close observation\n15 %\n5-year risk of developing primary open angle glaucoma"}]}
{"task_id": "medmcp-calc_047_b697ad47", "task_scenario": "Atrial Fibrillation Management: Anticoagulation Decisions", "task_category": "Clinical Medicine / Medicine & Organ Systems / Cardiovascular Medicine", "patient_id": "P047_b697ad47", "task_description": "Clinical scenario: An adult with nonvalvular atrial fibrillation presents for a decision on whether to initiate anticoagulation and, if indicated, which agent to select. The clinician must balance thromboembolic risk against bleeding risk and tailor therapy choice (DOAC vs warfarin) based on predicted outcomes and patient-specific risk modifiers. The following stepwise workflow uses multiple calculators to quantify stroke risk, bleeding risk, net clinical benefit, and therapy-specific bleeding risk to arrive at a defensible, patient-centered plan.\n\nStepwise calculator sequence and rationale:\n1) Use the CHA₂DS₂-VASc Score for Atrial Fibrillation Stroke Risk to estimate baseline stroke risk and categorize it (e.g., low vs intermediate/high). This stratification is the primary trigger for whether anticoagulation is likely indicated.\n2) Conditional branch: If CHA₂DS₂-VASc suggests low or borderline risk, apply CHADS-65 (Canadian Society of Cardiology Guideline) as a pragmatic, guideline-oriented tie-breaker. If CHADS-65 supports anticoagulation, proceed; if it does not, defer anticoagulation and consider rhythm/rate control and surveillance.\n3) If anticoagulation is indicated after Steps 1–2, estimate baseline bleeding risk with the HAS-BLED Score for Major Bleeding Risk to identify modifiable risk factors and overall bleeding propensity.\n4) Conditional branch: If HAS-BLED is high or borderline, compute the ORBIT Bleeding Risk Score for Atrial Fibrillation to corroborate bleeding risk classification. Concordant high bleeding risk (HAS-BLED and ORBIT both high) triggers enhanced risk-mitigation planning (e.g., blood pressure control, fall prevention) before selecting an agent.\n5) Integrate the above risk profiles using GARFIELD-AF to compare predicted outcomes with and without anticoagulation (stroke, mortality, bleeding). Use GARFIELD-AF as a deterministic decision check: if predicted net clinical benefit favors anticoagulation, continue to agent selection; if it does not, revisit modifiable risks and shared decision-making before proceeding.\n6) If proceeding with anticoagulation and DOAC is a candidate option, apply the Direct-Acting Oral Anticoagulants (DOAC) Score to predict bleeding risk specifically on DOAC therapy.\n7) Conditional branch: If the DOAC Score indicates low/moderate bleeding risk, select a DOAC with risk-mitigation strategies aligned to HAS-BLED/ORBIT findings. If the DOAC Score indicates high bleeding risk, pivot to a warfarin pathway.\n8) On the warfarin pathway, calculate the ATRIA Bleeding Risk Score to quantify warfarin-associated bleeding risk and guide intensity of monitoring and mitigation.\n9) Conditional branch: If the patient is elderly (e.g., ≥65 years), add Warfarin Bleeding Risk - Elderly to refine short-term (e.g., 90-day) bleeding risk. If warfarin bleeding risk is unacceptable after ATRIA and the elderly model, reconsider DOAC with intensified mitigation or re-evaluate the overall plan with GARFIELD-AF to ensure net benefit.\n10) Finalize the plan by synthesizing stroke risk (CHA₂DS₂-VASc with CHADS-65), baseline bleeding risk (HAS-BLED/ORBIT), net outcome prediction (GARFIELD-AF), and therapy-specific bleeding risk (DOAC Score vs ATRIA/Warfarin Elderly), and document the selected agent or deferral with a risk-reduction strategy and follow-up plan.", "fuzzy_question": "I’m evaluating a patient with non‑valvular atrial fibrillation and I’m torn about starting anticoagulation now versus holding off. I want a careful, quantitative assessment of stroke risk based on age, prior cerebrovascular events, hypertension, diabetes, heart failure, and vascular history to determine whether they’re clearly in a higher‑risk group or more borderline. If that initial look suggests low or intermediate risk, I’d like a pragmatic, guideline‑informed rule‑of‑thumb based on age and comorbidities to break the tie—if that favors treatment, we proceed; if it doesn’t, I’m comfortable deferring anticoagulation for now and focusing on rate/rhythm strategy and close follow‑up.\n\nIf we lean toward anticoagulation, please also provide a baseline bleeding risk review using a standard atrial fibrillation–focused checklist that highlights modifiable issues—blood pressure control, renal/hepatic function from laboratory results, any prior bleeding, alcohol use, fall risk, concomitant antiplatelets/NSAIDs, and, if relevant, INR lability. If that picture looks high or borderline, double‑check it against an alternative bleeding framework. If both methods classify risk as high, let’s build in a stronger mitigation plan (optimized blood pressure targets, fall prevention, alcohol reduction, gastrointestinal protection if indicated, and avoidance of dual antithrombotic therapy) before choosing a drug.\n\nPlease bring the stroke and bleeding profiles together with a forecasting step that models expected stroke, major bleeding, and mortality with and without anticoagulation. This is a gut‑check on net clinical benefit; if the projection doesn’t clearly favor treatment, let’s pause, address modifiable factors, and use shared decision‑making before moving forward.\n\nIf we proceed and a direct oral anticoagulant is considered, please estimate bleeding risk specific to that therapy. If that therapy‑specific risk is low to moderate, recommend a DOAC and a dose appropriate for kidney function, drug interactions, and adherence considerations, aligned with the earlier risk‑reduction steps. If the DOAC‑specific risk looks high, pivot to a warfarin route.\n\nOn the warfarin pathway, please estimate bleeding risk specific to warfarin to guide monitoring intensity and the most important mitigation steps. In older adults, also provide a short‑term view during the initial treatment period, when bleeding risk can be higher. If, after both perspectives, the warfarin risk still appears unacceptable, consider whether a DOAC with tighter safeguards could be safer, or revisit the overall net‑benefit projection to ensure we’re not causing more harm than good.\n\nFor the next appointment, pull this together into a plan: where they land for stroke risk (and whether the simple age/comorbidity check changes the call), how the baseline bleeding assessment looked (and whether the second framework agreed), what the outcome modeling says about net benefit, the therapy‑specific bleeding picture, and your final recommendation—start anticoagulation with agent/dose plus concrete risk‑reduction and monitoring steps with a follow‑up timeline, or defer with a clear risk‑reduction and surveillance plan.\n\nI need proper, evidence‑based calculations and defensible assumptions; this decision should not rely on clinical intuition alone.", "required_calculators": ["CHA₂DS₂-VASc Score for Atrial Fibrillation Stroke Risk", "CHADS-65 (Canadian Society of Cardiology Guideline)", "HAS-BLED Score for Major Bleeding Risk", "ORBIT Bleeding Risk Score for Atrial Fibrillation", "GARFIELD-AF", "Direct-Acting Oral Anticoagulants (DOAC) Score", "ATRIA Bleeding Risk Score", "Warfarin Bleeding Risk - Elderly"], "calculator_answers": [{"order": 1, "name": "CHA₂DS₂-VASc Score for Atrial Fibrillation Stroke Risk", "inputs": [{"field": "Age", "value": "66 years (65-74 category)", "score": 1}, {"field": "Sex", "value": "Male", "score": 0}, {"field": "CHF history", "value": "No", "score": 0}, {"field": "Hypertension history", "value": "Yes", "score": 1}, {"field": "Stroke/TIA/thromboembolism history", "value": "No", "score": 0}, {"field": "Vascular disease history (prior MI, peripheral artery disease, or aortic plaque)", "value": "No", "score": 0}, {"field": "Diabetes history", "value": "No", "score": 0}], "final_answer": 2, "notes": "Stroke risk was 2.2% per year in >90,000 patients (the Swedish Atrial Fibrillation Cohort Study) and 2.9% risk of stroke/TIA/systemic embolism."}, {"order": 2, "name": "CHADS-65 (Canadian Society of Cardiology Guideline)", "inputs": [{"field": "Age ≥65 years", "value": "Yes"}], "final_answer": "OAC", "notes": "Therapy recommendation.\nDirect oral anticoagulants are preferred over warfarin."}, {"order": 3, "name": "HAS-BLED Score for Major Bleeding Risk", "inputs": [{"field": "Hypertension (Uncontrolled, >160 mmHg systolic)", "value": "No (recent SBP 138 mmHg)", "score": 0}, {"field": "Renal disease (dialysis, transplant, or Cr >2.26 mg/dL)", "value": "No (serum creatinine 1.45 mg/dL; eGFR 52 mL/min)", "score": 0}, {"field": "Liver disease (cirrhosis or bilirubin >2x normal with AST/ALT/AP >3x normal)", "value": "No (AST 28 U/L, ALT 31 U/L, ALP 85 U/L, bilirubin 0.8 mg/dL)", "score": 0}, {"field": "Stroke history", "value": "No", "score": 0}, {"field": "Prior major bleeding or predisposition to bleeding", "value": "No", "score": 0}, {"field": "Labile INR (TTR <60%)", "value": "No (not on warfarin)", "score": 0}, {"field": "Age >65", "value": "Yes", "score": 1}, {"field": "Medication usage predisposing to bleeding (aspirin, clopidogrel, NSAIDs)", "value": "No", "score": 0}, {"field": "Alcohol use ≥8 drinks/week", "value": "No (about 4 drinks/week)", "score": 0}], "final_answer": 1, "notes": "Risk was 3.4% in one validation study (Lip 2011) and 1.02 bleeds per 100 patient-years in another validation study (Pisters 2010).\nAnticoagulation should be considered: Patient has a relatively low risk for major bleeding (~1/100 patient-years)."}, {"order": 4, "name": "ORBIT Bleeding Risk Score for Atrial Fibrillation", "inputs": [{"field": "Sex", "value": "Male"}, {"field": "Hemoglobin <13 g/dL or hematocrit <40%", "value": "No", "score": 0}, {"field": "Age >74 years", "value": "No (66 years)", "score": 0}, {"field": "Bleeding history (GI bleed, intracranial bleed, or hemorrhagic stroke)", "value": "No", "score": 0}, {"field": "GFR <60 mL/min/1.73 m²", "value": "Yes (eGFR 52 mL/min/1.73 m²)", "score": 1}, {"field": "Treatment with antiplatelet agents", "value": "No", "score": 0}], "final_answer": 1, "notes": "1 points\nORBIT Score\nLow risk\nRisk group\n2.4 bleeds\nPer 100 patient-years"}, {"order": 5, "name": "GARFIELD-AF", "inputs": [{"field": "Sex", "value": "Male"}, {"field": "Age", "value": "66 years"}, {"field": "Weight", "value": "176 lbs"}, {"field": "Heart failure", "value": "No"}, {"field": "Vascular disease", "value": "No"}, {"field": "Prior stroke", "value": "No"}, {"field": "History of bleeding", "value": "No"}, {"field": "Carotid occlusive disease", "value": "No"}, {"field": "Diabetes", "value": "No"}, {"field": "Moderate-to-severe CKD", "value": "Yes (stage 3; eGFR ~52 mL/min)"}, {"field": "Dementia", "value": "No"}, {"field": "Current smoker", "value": "No"}, {"field": "Antiplatelet treatment", "value": "No"}, {"field": "Ethnicity", "value": "Caucasian"}, {"field": "Pulse", "value": "88 beats/min"}, {"field": "Diastolic blood pressure", "value": "82 mm Hg"}, {"field": "OAC treatment", "value": "No oral anticoagulant"}], "final_answer": "6 months\nAll-cause mortality: 1.5%\nIschemic stroke/SE: 0.7%\nMajor bleeding: 0.5%", "notes": "6 months\nAll-cause mortality: 1.5%\nIschemic stroke/SE: 0.7%\nMajor bleeding: 0.5%\n1 year\nAll-cause mortality: 2.5%\nIschemic stroke/SE: 1.1%\nMajor bleeding: 0.8%\n2 years\nAll-cause mortality: 4.6%\nIschemic stroke/SE: 1.9%\nMajor bleeding: 1.2%"}, {"order": 6, "name": "GARFIELD-AF", "inputs": [{"field": "Sex", "value": "Male"}, {"field": "Age", "value": "66 years"}, {"field": "Weight", "value": "176 lbs"}, {"field": "Heart failure", "value": "No"}, {"field": "Vascular disease", "value": "No"}, {"field": "Prior stroke", "value": "No"}, {"field": "History of bleeding", "value": "No"}, {"field": "Carotid occlusive disease", "value": "No"}, {"field": "Diabetes", "value": "No"}, {"field": "Moderate-to-severe CKD", "value": "Yes (stage 3; eGFR ~52 mL/min)"}, {"field": "Dementia", "value": "No"}, {"field": "Current smoker", "value": "No"}, {"field": "Antiplatelet treatment", "value": "No"}, {"field": "Ethnicity", "value": "Caucasian"}, {"field": "Pulse", "value": "88 beats/min"}, {"field": "Diastolic blood pressure", "value": "82 mm Hg"}, {"field": "OAC treatment", "value": "NOAC"}], "final_answer": "6 months\nAll-cause mortality: 1.0%\nIschemic stroke/SE: 0.4%\nMajor bleeding: 0.6%", "notes": "6 months\nAll-cause mortality: 1.0%\nIschemic stroke/SE: 0.4%\nMajor bleeding: 0.6%\n1 year\nAll-cause mortality: 1.7%\nIschemic stroke/SE: 0.6%\nMajor bleeding: 1.0%\n2 years\nAll-cause mortality: 3.0%\nIschemic stroke/SE: 1.1%\nMajor bleeding: 1.6%"}, {"order": 7, "name": "GARFIELD-AF", "inputs": [{"field": "Sex", "value": "Male"}, {"field": "Age", "value": "66 years"}, {"field": "Weight", "value": "176 lbs"}, {"field": "Heart failure", "value": "No"}, {"field": "Vascular disease", "value": "No"}, {"field": "Prior stroke", "value": "No"}, {"field": "History of bleeding", "value": "No"}, {"field": "Carotid occlusive disease", "value": "No"}, {"field": "Diabetes", "value": "No"}, {"field": "Moderate-to-severe CKD", "value": "Yes (stage 3; eGFR ~52 mL/min)"}, {"field": "Dementia", "value": "No"}, {"field": "Current smoker", "value": "No"}, {"field": "Antiplatelet treatment", "value": "No"}, {"field": "Ethnicity", "value": "Caucasian"}, {"field": "Pulse", "value": "88 beats/min"}, {"field": "Diastolic blood pressure", "value": "82 mm Hg"}, {"field": "OAC treatment", "value": "VKA"}], "final_answer": "6 months\nAll-cause mortality: 1.2%\nIschemic stroke/SE: 0.5%\nMajor bleeding: 0.9%", "notes": "6 months\nAll-cause mortality: 1.2%\nIschemic stroke/SE: 0.5%\nMajor bleeding: 0.9%\n1 year\nAll-cause mortality: 2.1%\nIschemic stroke/SE: 0.8%\nMajor bleeding: 1.5%\n2 years\nAll-cause mortality: 3.8%\nIschemic stroke/SE: 1.3%\nMajor bleeding: 2.3%"}, {"order": 8, "name": "Direct-Acting Oral Anticoagulants (DOAC) Score", "inputs": [{"field": "Age, years", "value": "66 (65-69 = +2)", "score": 2}, {"field": "Creatinine clearance/estimated glomerular filtration rate (mL/min)", "value": "52 mL/min (30-60 = +1)", "score": 1}, {"field": "Underweight (BMI <18.5 kg/m2)", "value": "No (BMI ~25.3 kg/m²; 176 lbs, 5 ft 10 in)", "score": 0}, {"field": "Stroke/transient ischemic attack/embolism history", "value": "No", "score": 0}, {"field": "Diabetes", "value": "No", "score": 0}, {"field": "Hypertension", "value": "Yes (+1)", "score": 1}, {"field": "Antiplatelet use", "value": "No (0)", "score": 0}, {"field": "Nonsteroidal anti-inflammatory (NSAID) use", "value": "No (0)", "score": 0}, {"field": "Bleeding history", "value": "No (0)", "score": 0}, {"field": "Liver disease", "value": "No (0)", "score": 0}], "final_answer": 4, "notes": "Low\n1-year major bleeding risk"}, {"order": 9, "name": "ATRIA Bleeding Risk Score", "inputs": [{"field": "Anemia (Hemoglobin <13 g/dL male)", "value": "No (Hemoglobin 14.0 g/dL)", "score": 0}, {"field": "Severe Renal Disease (GFR <30 mL/min or dialysis-dependent)", "value": "No (eGFR 52 mL/min)", "score": 0}, {"field": "Age ≥ 75 years", "value": "No (66 years)", "score": 0}, {"field": "Any Prior Hemorrhage Diagnosis", "value": "No", "score": 0}, {"field": "Hypertension History", "value": "Yes", "score": 1}], "final_answer": 1, "notes": "Low Risk (<4 Points), 0.76% Annual Risk of Hemorrhage. Reasonable to start warfarin."}, {"order": 10, "name": "Warfarin Bleeding Risk - Elderly", "inputs": [{"field": "Age", "value": "66 years"}, {"field": "Gender", "value": "Male"}, {"field": "Remote Bleeding Event", "value": "No"}, {"field": "Recent Bleeding Event", "value": "No"}, {"field": "Alcohol or Drug Abuse", "value": "No (drinks ~4/week, denies abuse)"}, {"field": "Diabetes", "value": "No"}, {"field": "Anemia (Hct <30%)", "value": "No (Hct 41%)"}, {"field": "Concurrent Antiplatelet Drug Use", "value": "No"}], "final_answer": "0.9 %", "notes": "Estimated Bleeding Risk\nLow Risk\nEstimated Rate of Major Bleeding Within 90 Days with Warfarin Therapy\n0.9 %"}]}
{"task_id": "medmcp-calc_048_f95deb14", "task_scenario": "Ankylosing Spondylitis Assessment", "task_category": "Clinical Medicine / Medicine & Organ Systems / Orthopedics, Rheumatology & Immunology", "patient_id": "P048_f95deb14", "task_description": "Clinical scenario: A patient presents with features suggestive of axial spondyloarthritis. The clinician needs to confirm classification, quantify disease activity from both patient-reported symptoms and objective inflammation, and use these results to guide treatment intensity and follow-up monitoring. Workflow: First, apply the ASAS Criteria for Axial Spondyloarthritis (SpA) to determine whether the patient meets classification for axial spondyloarthritis. If classification is not met, halt this ankylosing spondylitis assessment pathway and consider alternative etiologies. If classification is met, establish a baseline patient-reported disease activity using BASDAI to capture symptom burden and functional impact. Use the BASDAI result as a gate: if it indicates active disease per standard thresholds, proceed to an objective disease activity score; if it indicates low activity, defer immediate objective scoring and plan routine monitoring with future BASDAI reassessments. For objective stratification, choose the Ankylosing Spondylitis Disease Activity Score with CRP (ASDAS-CRP) when the CRP-based pathway is available; otherwise, use the Ankylosing Spondylitis Disease Activity Score with ESR (ASDAS-ESR). Interpret the ASDAS category (inactive/low/high/very high) to determine management intensity: high or very high activity should trigger escalation of therapy and closer follow-up, while low or inactive activity supports continuation of current therapy and standard monitoring. In follow-up, repeat BASDAI to track patient-reported response and, when indicated by persistent symptoms or prior high ASDAS, reassess with the appropriate ASDAS variant to confirm objective improvement. The outputs from ASAS classification gate the use of disease activity calculators, BASDAI guides whether to invoke ASDAS, and ASDAS severity categories deterministically drive treatment escalation and the need for more frequent calculator-based monitoring.", "fuzzy_question": "I’m evaluating a patient with chronic inflammatory back symptoms and some extra‑articular features, and I’m working out the best approach for diagnosis and monitoring. I’m not certain this truly fits axial spondyloarthritis versus mechanical back pain or another inflammatory mimic. Before committing to an ankylosing spondylitis management pathway, I want to confirm the accepted classification for axial disease; if not met, I’d pivot to alternative causes of back pain.\n\nIf criteria are met, I’d establish a baseline from the patient’s perspective using a standardized patient‑reported outcome that captures fatigue, spinal pain, stiffness over the day, and functional impact to quantify symptom burden. If that score appears low by usual clinical thresholds, I’d defer additional indices and continue routine monitoring with repeat symptom checks at future visits. If it indicates active disease, I’d proceed to an objective activity index that integrates symptoms with inflammatory markers.\n\nFor the objective index, I’d use the CRP‑based version when a recent CRP is available; otherwise, I’d use the ESR‑based variant. Where that objective index lands matters: if it’s in the high or very high range, I’d escalate therapy and shorten the follow‑up interval; if it’s inactive or low, I’d continue current treatment with standard monitoring. Over subsequent visits, I’d repeat the patient‑reported measure to track response, and if symptoms persist—or if an earlier objective score was high—I’d reassess with the same type of objective index (CRP‑based when possible, otherwise ESR‑based) to confirm improvement in inflammatory activity.\n\nI only want to pursue this formal activity‑tracking pathway if the presentation truly fits axial spondyloarthritis; the patient‑reported measure is my gatekeeper for adding the lab‑anchored index, and the objective index category should set treatment intensity and follow‑up cadence. What’s your view on this sequence? I need proper, evidence‑based calculations to support the approach so it holds up to scrutiny.", "required_calculators": ["ASAS Criteria for Axial Spondyloarthritis (SpA)", "BASDAI", "Ankylosing Spondylitis Disease Activity Score with CRP (ASDAS-CRP)", "Ankylosing Spondylitis Disease Activity Score with ESR (ASDAS-ESR)"], "calculator_answers": [{"order": 1, "name": "ASAS Criteria for Axial Spondyloarthritis (SpA)", "inputs": [{"field": "entry_criterion_back_pain_ge_3_months_and_age_at_onset_lt_45", "value": "Yes"}, {"field": "back_pain_duration", "value": "72 months"}, {"field": "age_at_back_pain_onset", "value": "28 years"}, {"field": "HLA_B27_status", "value": "Positive"}, {"field": "sacroiliitis_on_MRI", "value": "Present (bilateral SI joint BME consistent with active inflammation)"}, {"field": "sacroiliitis_on_plain_radiograph", "value": "No definite radiographic sacroiliitis"}, {"field": "inflammatory_back_pain_features", "value": "Yes (night pain, morning stiffness >60 min, improves with exercise)"}, {"field": "good_response_to_NSAIDs", "value": "Yes (marked improvement within 48 hours of full-dose NSAID)"}, {"field": "enthesitis", "value": "Yes (right Achilles insertional tenderness)"}, {"field": "acute_anterior_uveitis_history", "value": "Yes (1 episode in past year, responsive to topical steroids)"}, {"field": "dactylitis", "value": "No"}, {"field": "psoriasis", "value": "No"}, {"field": "inflammatory_bowel_disease", "value": "No"}, {"field": "family_history_SpA", "value": "Yes (father with ankylosing spondylitis)"}, {"field": "elevated_CRP_feature", "value": "Yes (12 mg/L)"}], "final_answer": "Axial SpA", "notes": "Meets ASAS criteria for axial SpA classification."}, {"order": 2, "name": "BASDAI", "inputs": [{"field": "Q1_fatigue", "value": "6.5/10"}, {"field": "Q2_spinal_pain", "value": "7.0/10"}, {"field": "Q3_peripheral_joint_pain_swelling", "value": "3.0/10"}, {"field": "Q4_tender_areas_to_touch_pressure", "value": "4.0/10"}, {"field": "Q5_morning_stiffness_severity", "value": "7.0/10"}, {"field": "Q6_morning_stiffness_duration", "value": "6.0/10 (~72 minutes)"}], "final_answer": 5.3, "notes": "BASDAI\n5.3"}, {"order": 3, "name": "Ankylosing Spondylitis Disease Activity Score with CRP (ASDAS-CRP)", "inputs": [{"field": "back_pain_VAS", "value": "7.0/10", "score": 7}, {"field": "duration_of_morning_stiffness_VAS", "value": "6.0/10", "score": 6}, {"field": "patient_global_disease_activity_VAS", "value": "6.0/10", "score": 6}, {"field": "peripheral_pain_swelling_VAS", "value": "3.0/10", "score": 3}, {"field": "CRP", "value": "12.0 mg/L"}], "final_answer": 3.6, "notes": "Very high\nDisease activity"}, {"order": 4, "name": "Ankylosing Spondylitis Disease Activity Score with ESR (ASDAS-ESR)", "inputs": [{"field": "back_pain_VAS", "value": "7.0/10", "score": 7}, {"field": "duration_of_morning_stiffness_VAS", "value": "6.0/10", "score": 6}, {"field": "patient_global_disease_activity_VAS", "value": "6.0/10", "score": 6}, {"field": "peripheral_pain_swelling_VAS", "value": "3.0/10", "score": 3}, {"field": "ESR", "value": "30 mm/hr"}], "final_answer": 3.5, "notes": "High\nDisease activity"}]}
{"task_id": "medmcp-calc_049_7772f399", "task_scenario": "Anemia and Iron Metabolism", "task_category": "Clinical Medicine / Medicine & Organ Systems / Hematology & Oncology", "patient_id": "P049_7772f399", "task_description": "A patient with known sickle cell disease presents with symptomatic anemia and red cell indices suggesting microcytosis. The clinical priority is to clarify whether the microcytosis represents iron deficiency or a thalassemia trait, determine the bone marrow’s compensatory response to anemia, and then plan either iron replacement or a red blood cell exchange if indicated by the hemolytic burden and clinical status. Step-by-step workflow: First, use the Mentzer Index to classify the microcytic pattern as more consistent with iron deficiency or thalassemia trait. This classification is used as a decision trigger for subsequent management. Next, use the Corrected Reticulocyte Percentage/Reticulocyte Production Index (RPI) to evaluate the bone marrow’s response to anemia; this helps distinguish a blunted production state from a robust hemolytic response typical of sickle cell disease. Conditional branches follow: If the Mentzer Index suggests iron deficiency and the RPI indicates a blunted response, proceed to the Ganzoni Equation for Iron Deficiency Anemia to calculate total iron deficit and plan iron replacement therapy. After initial iron therapy, recheck with the RPI to verify improving marrow response as a process quality check. Alternatively, if the Mentzer Index does not support iron deficiency and the RPI indicates a robust hemolytic response consistent with sickle cell–related anemia, and there is a clinical indication to rapidly lower sickled hemoglobin burden, use the Sickle Cell RBC Exchange Volume calculator to estimate donor red cell volume for an exchange transfusion. The overall sequence ensures classification of anemia type, assessment of erythropoietic activity, and targeted intervention planning aligned with iron metabolism and hemoglobinopathy management.", "fuzzy_question": "I’m evaluating a patient with sickle cell disease who is more symptomatic than baseline, with labs suggesting microcytosis. I’m weighing iron deficiency versus a coexisting thalassemia trait, and that distinction changes management. I plan to assess the relationship between red cell size and red cell count—small cells with a disproportionately low count would favor iron deficiency; small cells with a relatively preserved count would favor trait. That direction will guide next steps.\n\nI also need to determine whether marrow production is adequate. A raw reticulocyte percentage isn’t sufficient—I want it interpreted in the context of anemia severity and the prolonged reticulocyte lifespan seen in significant anemia. This will clarify whether erythropoiesis is blunted versus appropriately elevated in hemolysis, which is critical in sickle cell disease.\n\nIf findings support iron deficiency and the corrected reticulocyte response is sluggish, I’d plan full repletion by estimating the iron deficit with standard formulas based on body size, the hemoglobin deficit to a reasonable target, and an allowance to rebuild stores, then outline a regimen suited to the clinical context. After initial dosing, I’d look for an anemia‑adjusted reticulocyte response trending upward as a quick check that the marrow is responding.\n\nIf the microcytic pattern does not support iron deficiency and the marrow response appears brisk in a way consistent with hemolysis—and the clinical context indicates a need to lower sickled hemoglobin promptly (e.g., persistent symptoms, concerning laboratory trends, acute chest–type features, or higher‑risk peri‑procedural circumstances)—I’d favor exchange transfusion over simple transfusion. I’d estimate the donor red cell volume using starting hemoglobin, body size, and targets for total hemoglobin and a safer fraction of sickled hemoglobin to set an appropriate endpoint.\n\nWhat’s your take? Please walk through how you’d reason this case: where the microcytosis pattern points, whether the marrow is underperforming or appropriately revved, and—based on that—either a concrete iron repletion plan with an estimated deficit and follow‑up check on marrow response, or a thoughtful exchange plan with the donor volume you’d aim for. The approach should include solid, calculation‑based justification.", "required_calculators": ["Mentzer Index", "Corrected Reticulocyte Percentage/Reticulocyte Production Index (RPI)", "Ganzoni Equation for Iron Deficiency Anemia", "Sickle Cell RBC Exchange Volume"], "calculator_answers": [{"order": 1, "name": "Mentzer Index", "inputs": [{"field": "MCV", "value": "68 fL"}, {"field": "RBC count", "value": "3.0 ×10^6 cells/µL"}], "final_answer": 22.7, "notes": "22.7\nMentzer Index\nIDA\nProbable diagnosis"}, {"order": 2, "name": "Corrected Reticulocyte Percentage/Reticulocyte Production Index (RPI)", "inputs": [{"field": "% of reticulocytes", "value": "2.5 %"}, {"field": "Red blood cell count", "value": "3.0 ×10^6 cells/µL"}, {"field": "Measured hematocrit", "value": "21 %"}, {"field": "Normal hematocrit", "value": "40 %"}], "final_answer": 0.7, "notes": "0.7\nReticulocyte Production Index (RPI)\nCorrected Reticulocyte %: 1.31\nAbsolute Reticulocyte Count: 75,000 cells/μL\nInadequate response\nRPI <2 indicates inadequate response"}, {"order": 3, "name": "Ganzoni Equation for Iron Deficiency Anemia", "inputs": [{"field": "Weight", "value": "140 lbs"}, {"field": "Target hemoglobin", "value": "10 g/dL"}, {"field": "Actual hemoglobin", "value": "6.8 g/dL"}, {"field": "Iron stores", "value": "500 mg"}], "final_answer": 988, "notes": "988 mg\nTotal iron deficit"}, {"order": 4, "name": "Corrected Reticulocyte Percentage/Reticulocyte Production Index (RPI)", "inputs": [{"field": "% of reticulocytes", "value": "7 %"}, {"field": "Red blood cell count", "value": "3.6 ×10^6 cells/µL"}, {"field": "Measured hematocrit", "value": "24 %"}, {"field": "Normal hematocrit", "value": "40 %"}], "final_answer": 0.8, "notes": "Reticulocyte Production Index (RPI)\nCorrected Reticulocyte %: 1.50\nAbsolute Reticulocyte Count: 75,000 cells/μL\nInadequate response\nRPI <2 indicates inadequate response"}, {"order": 5, "name": "Sickle Cell RBC Exchange Volume", "inputs": [{"field": "Patient sex", "value": "Female"}, {"field": "Patient height", "value": "64 in"}, {"field": "Patient weight", "value": "140 lbs"}, {"field": "Patient hematocrit", "value": "21 %"}, {"field": "Patient's initial HgbS", "value": "88 %"}, {"field": "Goal HgbS", "value": "30 %"}, {"field": "Hematocrit of transfused RBCs", "value": "60 %"}], "final_answer": "1436 mL", "notes": "1436 mL\nRBC exchange replacement volume\n4 units\nApproximate number of units, assuming 350 mL RBCs per unit"}]}
{"task_id": "medmcp-calc_050_34ec1e8e", "task_scenario": "Difficult Airway Assessment", "task_category": "Clinical Medicine / Emergency, Critical Care & Perioperative / Anesthesia & Perioperative Medicine", "patient_id": "P050_34ec1e8e", "task_description": "Clinical scenario: A patient in a perioperative or ICU setting requires urgent endotracheal intubation, and the team suspects a potentially difficult airway. The goal is to rapidly stratify risk and construct a safe, staged airway plan using validated tools. Step 1: Perform the Modified Mallampati Classification during the pre-intubation airway exam to gauge oropharyngeal visibility; record the class. This result is a direct input variable for subsequent risk scores and anchors the anatomic assessment. Step 2: Calculate the MACOCHA Score to integrate ICU/emergency context factors (physiologic severity and operator/environment elements) alongside the Mallampati class from Step 1. Use the MACOCHA risk category to branch decisions: If MACOCHA predicts high difficulty, immediately escalate preparations (experienced assistance, advanced devices at bedside, backup strategies) and proceed to Step 3 to refine anatomical difficulty. If MACOCHA suggests low to moderate difficulty, proceed to Step 3 if the Mallampati class indicates limited oropharyngeal view or other anatomic concerns; otherwise, continue with a standard plan while keeping advanced backups available. Step 3: Calculate the El-Ganzouri Risk Index (EGRI) for Difficult Airway to quantify anatomical risk (incorporating Mallampati and other physical findings). Use the EGRI category to determine technique and device selection: If EGRI indicates high anatomical difficulty, favor awake or video-assisted intubation with adjuncts and a ready front‑of‑neck access plan; if moderate, plan video‑laryngoscopy with bougie and a second operator; if low, proceed with conventional laryngoscopy after optimization, maintaining rescue devices nearby. In this workflow, the Mallampati output is required input for both MACOCHA and EGRI; the MACOCHA result deterministically triggers escalation and whether EGRI is needed; the EGRI output directly guides the airway technique and backup strategy.", "fuzzy_question": "I am at the bedside with a patient who requires urgent airway management, and the airway appears potentially difficult given limited mouth opening, a bulky tongue, a short neck, and possible OSA. I want to select the safest plan quickly without skipping essential checks.\n\nFirst, please start with the standard bedside mouth/pharynx view used before intubation and provide the class. That grading anchors the anatomic picture and I will rely on it for the next steps, so record it clearly.\n\nThen, integrate that mouth view into an ICU/emergency snapshot of difficult airway risk that blends anatomy with current status: oxygenation, hemodynamics, level of consciousness, neck mobility, the degree of mouth-opening limitation, any OSA, and operator/environment factors (who is managing the airway, experience level, and immediately available resources). Provide an explicit risk category from that snapshot, not just impressions, because that result determines how aggressively we prepare. If the snapshot indicates high risk, escalate preparations immediately—get experienced help in the room, have advanced devices at the bedside, and lay out backup strategies—while simultaneously refining the anatomical difficulty. If the snapshot seems low to moderate risk, proceed to the more detailed anatomy review if the mouth view is limited or any other anatomic red flags are present; if the mouth view is reassuring and nothing else is concerning anatomically, proceed with a standard plan but keep advanced backups within arm’s reach.\n\nFor the more granular anatomical assessment, incorporate the mouth view together with bedside predictors of difficult laryngoscopy: true interincisor distance, thyromental distance, neck movement, ability to protrude the jaw, body habitus, and any history of prior difficult intubation. Provide a clear category from this anatomical index. Based on that:\n- If the anatomy appears high risk, consider an awake or video-assisted approach with adjuncts, maintain spontaneous ventilation if possible, and actively prepare for front-of-neck access.\n- If it is intermediate, use video-laryngoscopy with a bougie on the first pass, ramped positioning, and have a second operator at the bedside.\n- If it is reassuring, after optimizing preoxygenation and positioning, proceed with conventional laryngoscopy while keeping rescue devices (supraglottic options, bougie, fiberoptic) and a clear backup sequence readily available.\n\nPlease walk through your reasoning and share the outputs at each stage—the mouth view class, the ICU/emergency risk category, and the detailed anatomical risk category—because each one informs the next decision. Also specify the recommended technique for this patient and the backup plan you would have ready, including whether to actively prepare for front-of-neck access.\n\nI need this supported by formal calculations and validated tools rather than intuition. Whatever approach you propose, back it with solid calculations so it can withstand scrutiny.", "required_calculators": ["Modified Mallampati Classification", "MACOCHA Score", "El-Ganzouri Risk Index (EGRI) for Difficult Airway"], "calculator_answers": [{"order": 1, "name": "Modified Mallampati Classification", "inputs": [{"field": "oropharyngeal_visualization", "value": "Soft palate not visualized"}], "final_answer": "Class IV", "notes": "Class IV\nModified Mallampati Classification\nPredicted difficult airway by Mallampati. Consider supportive strategies (see Next Steps for details)."}, {"order": 2, "name": "MACOCHA Score", "inputs": [{"field": "mallampati_score_III_or_IV", "value": "Yes", "score": 5}, {"field": "obstructive_sleep_apnea_syndrome", "value": "Yes", "score": 2}, {"field": "reduced_cervical_spine_mobility", "value": "Yes", "score": 1}, {"field": "limited_mouth_opening_less_than_3_cm", "value": "Yes", "score": 1}, {"field": "coma", "value": "No", "score": 0}, {"field": "severe_hypoxemia_less_than_80_percent", "value": "Yes", "score": 1}, {"field": "nonanesthesiologist", "value": "Yes", "score": 1}], "final_answer": 11, "notes": "MACOCHA Score\nA higher score corresponds to a higher difficulty of intubation."}, {"order": 3, "name": "El-Ganzouri Risk Index (EGRI) for Difficult Airway", "inputs": [{"field": "mouth_opening_interincisor_distance_cm", "value": "2.5 cm", "score": 1}, {"field": "thyromental_distance_cm", "value": "5.5 cm", "score": 2}, {"field": "mallampati_class", "value": "IV", "score": 2}, {"field": "neck_movement_degrees", "value": "60°", "score": 2}, {"field": "ability_to_prognath", "value": "No", "score": 1}, {"field": "weight_kg", "value": "118 kg", "score": 2}, {"field": "history_of_difficult_intubation", "value": "None", "score": 0}], "final_answer": 10, "notes": "High risk\nRisk of difficult airway\n93.8% specificity"}]}
{"task_id": "medmcp-calc_051_a4f9642d", "task_scenario": "Delirium and Cognitive Impairment", "task_category": "Clinical Medicine / Neurology & Mental Health / Mental & Psychological Health", "patient_id": "P051_a4f9642d", "task_description": "Scenario: An inpatient develops acute confusion and fluctuating attention during hospitalization. The clinical team must rapidly detect delirium, differentiate it from pre-existing cognitive impairment, identify modifiable contributors (e.g., pain), and plan a safe discharge informed by frailty.\nStep-by-step workflow:\n1) Admission risk stratification: Use the AWOL Score for Delirium to estimate the patient's delirium risk on arrival. If risk is high, initiate a prevention bundle (orientation, sleep hygiene, mobilization) and schedule early/serial delirium screening. Regardless of risk, proceed to determine whether a bedside delirium test is feasible by assessing arousal.\n2) Sedation/agitation gate: Use the Richmond Agitation-Sedation Scale (RASS) to document current arousal. If RASS indicates calm or only light sedation, proceed to the 4 A’s Test for Delirium Screening. If RASS indicates moderate-to-severe agitation or deep sedation, pivot to the Confusion Assessment Method for the ICU (CAM-ICU), which is suitable for altered arousal states. The RASS output also triggers immediate safety measures when severe agitation is present.\n3) Primary delirium detection:\n   - If the 4 A’s Test for Delirium Screening is performed and positive, suspect delirium and use CAM-ICU to confirm and monitor, especially if arousal fluctuates or the patient is in a high-risk setting.\n   - If the 4 A’s Test is negative but cognitive concerns persist, proceed to the Montreal Cognitive Assessment (MoCA) to characterize non-delirium cognitive impairment.\n   - If CAM-ICU is the initial tool (due to RASS), a positive result establishes delirium; a negative result with ongoing cognitive complaints prompts MoCA.\n4) Evaluate pain as a contributor: For any delirium or agitation, use the Pain Assessment in Advanced Dementia Scale (PAINAD) to assess pain in potentially nonverbal patients. If PAINAD indicates significant pain, treat analgesia needs and then re-evaluate delirium with the previously chosen tool (4 A’s Test or CAM-ICU) after pain control.\n5) Distinguish delirium from baseline dementia: Obtain an Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) to determine whether there was cognitive decline prior to admission. If IQCODE suggests longstanding decline, proceed to the Clinical Dementia Rating (CDR) Scale to stage dementia, which informs capacity, goals of care, and follow-up needs.\n6) Characterize current cognitive impairment: Use the Montreal Cognitive Assessment (MoCA) once delirium has improved/cleared or when initial delirium screens are negative but deficits persist. MoCA helps determine mild cognitive impairment versus normal cognition and guides outpatient memory clinic referral.\n7) Disposition planning: Use the Edmonton Frail Scale to quantify frailty. Integrate frailty with delirium status (4 A’s Test or CAM-ICU), dementia staging (CDR), and current cognition (MoCA) to decide the level of supervision, rehabilitation, and services required for a safe discharge.\nConditional branches and triggers:\n- AWOL high risk → earlier screening cadence and prevention bundle.\n- RASS calm/light sedation → choose 4 A’s Test; RASS moderate/severe agitation or deep sedation → choose CAM-ICU.\n- 4 A’s Test positive → confirm/monitor with CAM-ICU; 4 A’s Test negative with concerns → MoCA.\n- CAM-ICU positive → delirium management; CAM-ICU negative with deficits → MoCA.\n- PAINAD elevated → treat pain and re-screen delirium.\n- IQCODE suggests chronic decline → CDR; IQCODE normal → interpret MoCA for MCI vs normal.\n- Frailty (Edmonton Frail Scale) integrates with cognition/delirium outputs to tailor discharge.", "fuzzy_question": "I’m evaluating a hospitalized patient with acute, fluctuating confusion and inattention. I’m assessing whether this represents delirium superimposed on baseline cognitive status, identifying contributors (pain may be one), and planning a discharge aligned with overall physiologic reserve.\n\nAt presentation and during hospitalization, I want to gauge delirium vulnerability to guide early prevention: if risk appears high, we’ll emphasize orientation cues, protect sleep, mobilize early, and increase monitoring frequency. Before selecting a bedside screen, I’d document arousal and agitation with a standard sedation–agitation rating to determine what testing is feasible. If the patient is calm or only lightly drowsy, I’d use a brief bedside screen focused on attention and alertness. If markedly agitated or deeply sedated, I’d switch to an ICU-validated approach appropriate to those arousal states. If agitation is dangerous, immediate safety measures are needed while proceeding.\n\nIf the brief bedside screen is positive, I’d treat this as delirium and then confirm and trend it with the arousal-tolerant approach, especially if wakefulness fluctuates or the care setting confers higher risk. If the brief screen is negative but collateral reports suggest a change, I’d escalate to a comprehensive cognitive assessment to evaluate non-delirium impairment. If we start with the ICU-style assessment because of arousal and it’s positive, that establishes delirium; if it’s negative but thinking still seems off, I’d proceed to the same comprehensive cognitive test.\n\nBecause pain can masquerade as agitation or cloud cognition, I’d use an observational pain measure suitable when self-report is limited. If it indicates significant pain, I’d treat it and then repeat the chosen delirium screen to assess for change after analgesia.\n\nIn parallel, I want collateral history from someone who knows the patient well regarding cognitive and functional trajectory prior to admission. If this suggests a longer-standing decline predating hospitalization, I’d follow with a structured dementia staging discussion to guide capacity, goals-of-care, and follow-up planning. If there’s no convincing story of prior decline, interpretation of the comprehensive cognitive assessment becomes key for distinguishing expected aging from mild impairment.\n\nOnce the acute confusion improves—or if delirium screens remain negative but deficits persist—I’d complete the comprehensive cognitive screen to clarify mild cognitive impairment versus expected aging and use it to determine whether specialty referral is warranted.\n\nFor discharge, I’d obtain a brief frailty assessment and integrate it with current delirium status, any dementia staging, and cognitive findings to determine supervision needs, the role for rehabilitation, and services required for a safe plan.\n\nWhat’s your take, and how would you reason through this at the bedside? Please walk me through what you’d do and what you’d expect to find at each stage. I need evidence-based risk stratification supported by calculations rather than clinical intuition, and the approach should withstand scrutiny.", "required_calculators": ["AWOL Score for Delirium", "Richmond Agitation-Sedation Scale (RASS)", "4 A’s Test for Delirium Screening", "Confusion Assessment Method for the ICU (CAM-ICU)", "Pain Assessment in Advanced Dementia Scale (PAINAD)", "Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE)", "Clinical Dementia Rating (CDR) Scale", "Montreal Cognitive Assessment (MoCA)", "Edmonton Frail Scale"], "calculator_answers": [{"order": 1, "name": "AWOL Score for Delirium", "inputs": [{"field": "Age", "value": "≥80 years", "score": 1}, {"field": "Correctly spells “world” backward", "value": "No", "score": 1}, {"field": "Oriented to city, state, county, hospital name, and floor", "value": "No", "score": 1}, {"field": "Nursing illness severity assessment", "value": "Moderately ill", "score": 1}], "final_answer": 4, "notes": "4 points\nAWOL Score\n64 %\nRisk of delirium during hospitalization"}, {"order": 2, "name": "Richmond Agitation-Sedation Scale (RASS)", "inputs": [{"field": "Patient description", "value": "Alert and calm (0)", "score": 0}], "final_answer": 0, "notes": "Patients with a RASS of -2 to 1 are properly sedated."}, {"order": 3, "name": "4 A’s Test for Delirium Screening", "inputs": [{"field": "Alertness", "value": "Normal (0)", "score": 0}, {"field": "AMT4 (Age, DOB, place, current year)", "value": "≥2 mistakes or untestable (+2)", "score": 2}, {"field": "Attention (months backward from December)", "value": "Untestable (+2) — unable to sustain attention", "score": 2}, {"field": "Acute change or fluctuating course (last 2 weeks, persisting in last 24h)", "value": "Yes (+4)", "score": 4}], "final_answer": 8, "notes": "Possible delirium and/or cognitive impairment"}, {"order": 4, "name": "Confusion Assessment Method for the ICU (CAM-ICU)", "inputs": [{"field": "Level of Consciousness (RASS ≥ -3 or sufficient arousal)", "value": "Yes (RASS 0)"}, {"field": "Feature 1: Acute onset or fluctuating course", "value": "Present"}, {"field": "Feature 2: Inattention", "value": "Present"}, {"field": "Feature 3: Altered level of consciousness", "value": "Absent (RASS 0)"}, {"field": "Feature 4: Disorganized thinking", "value": "Present"}], "final_answer": "CAM-ICU positive", "notes": "CAM-ICU positive\nDelirium present."}, {"order": 5, "name": "Pain Assessment in Advanced Dementia Scale (PAINAD)", "inputs": [{"field": "Breathing (independent of vocalization)", "value": "Normal (0)", "score": 0}, {"field": "Negative vocalization", "value": "Occasional moan/groan or low-level speech with negative quality (+1)", "score": 1}, {"field": "Facial expression", "value": "Sad/frightened/frown (+1)", "score": 1}, {"field": "Body language", "value": "Tense, distressed pacing/fidgeting (+1)", "score": 1}, {"field": "Consolability", "value": "Distracted or reassured by voice/touch (+1)", "score": 1}], "final_answer": 4, "notes": "Moderate pain\nRanges are based on a standard 0-10 scale of pain, but the original tool only quantifies 0 as \"No pain\" and 10 as \"Severe pain\"."}, {"order": 6, "name": "Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE)", "inputs": [{"field": "1. Remembering things about family and friends", "value": 3}, {"field": "2. Remembering things that have happened recently", "value": 4}, {"field": "3. Recalling conversations a few days later", "value": 4}, {"field": "4. Remembering address and telephone number", "value": 3}, {"field": "5. Remembering what day and month it is", "value": 4}, {"field": "6. Remembering where things are usually kept", "value": 3}, {"field": "7. Finding things put in a different place", "value": 4}, {"field": "8. Knowing how to work familiar machines around the house", "value": 3}, {"field": "9. Learning to use a new gadget or machine", "value": 4}, {"field": "10. Learning new things in general", "value": 4}, {"field": "11. Following a story in a book or on TV", "value": 4}, {"field": "12. Making decisions on everyday matters", "value": 4}, {"field": "13. Handling money for shopping", "value": 3}, {"field": "14. Handling financial matters (bank, pension)", "value": 4}, {"field": "15. Handling other everyday arithmetic problems", "value": 3}, {"field": "16. Using intelligence to understand/reason what's going on", "value": 3}], "final_answer": 3.4, "notes": "IQCODE Score\n3.4\nScreening Interpretation\nSignificant cognitive impairment likely"}, {"order": 7, "name": "Clinical Dementia Rating (CDR) Scale", "inputs": [{"field": "Memory (M)", "value": "Moderate memory loss; more marked for recent events; interferes with everyday activities (1)", "score": 1}, {"field": "Orientation (O)", "value": "Moderate difficulty with time relationships; oriented for place and person at examination (1)", "score": 1}, {"field": "Judgment and problem solving (JPS)", "value": "Moderate difficulty in handling complex problems; social judgment usually maintained (1)", "score": 1}, {"field": "Community affairs (CA)", "value": "Unable to function independently at these activities although may still be engaged in some (1)", "score": 1}, {"field": "Home and hobbies (HH)", "value": "Mild but definite impairment of function at home; more difficult chores/hobbies abandoned (1)", "score": 1}, {"field": "Personal care (PC)", "value": "Fully capable of self-care (0)", "score": 0}], "final_answer": 1, "notes": "1 points\nCDR\nMild dementia"}, {"order": 8, "name": "Montreal Cognitive Assessment (MoCA)", "inputs": [{"field": "Education >12 years", "value": "No (+1)", "score": 1}, {"field": "Visuospatial/executive: Trail making", "value": "Completed correctly (+1)", "score": 1}, {"field": "Visuospatial/executive: Cube copy", "value": "Completed correctly (+1)", "score": 1}, {"field": "Visuospatial/executive: Clock drawing", "value": "2 of 3 features correct (+2)", "score": 2}, {"field": "Naming: Lion", "value": "Correct (+1)", "score": 1}, {"field": "Naming: Rhinoceros", "value": "Correct (+1)", "score": 1}, {"field": "Naming: Camel", "value": "Correct (+1)", "score": 1}, {"field": "Read \"Face\", \"Velvet\", \"Church\", \"Daisy\", \"Red\", and ask patient to repeat (do two trials and a recall later in exam)", "value": "Completed both trials correctly"}, {"field": "Attention: Digit span forward (2-1-8-5-4)", "value": "Correct (+1)", "score": 1}, {"field": "Attention: Digit span backward (7-4-2)", "value": "Correct (+1)", "score": 1}, {"field": "Attention: Vigilance/tap at letter A (<2 errors)", "value": "Correct (+1)", "score": 1}, {"field": "Attention: Serial 7s", "value": "2 or 3 correct (+2)", "score": 2}, {"field": "Language: Repeat “I only know that John is the one to help today”", "value": "Correct (+1)", "score": 1}, {"field": "Language: Repeat “The cat always hid under the couch when dogs were in the room”", "value": "Correct (+1)", "score": 1}, {"field": "Language: Phonemic fluency (F-words)", "value": "Named <11 words (9 words) (0)", "score": 0}, {"field": "Abstraction: Train–bicycle", "value": "Correct (+1)", "score": 1}, {"field": "Abstraction: Watch–ruler", "value": "Incorrect (0)", "score": 0}, {"field": "Delayed recall (Face, Velvet, Church, Daisy, Red)", "value": "Recalled 2 words (+2)", "score": 2}, {"field": "Orientation (date, month, year, day, place, city)", "value": "5 correct (+5)", "score": 5}], "final_answer": 23, "notes": "23 points\nLower scores indicate more cognitive impairment; cutoff of <26 points is 90% sensitive for mild cognitive impairment.."}, {"order": 9, "name": "Edmonton Frail Scale", "inputs": [{"field": "Clock test (ten past eleven)", "value": "Incorrect"}, {"field": "Hospital admissions in the past year", "value": "2 admissions"}, {"field": "General health status", "value": "Fair"}, {"field": "Number of IADLs requiring help (out of 8)", "value": "3 (transportation, shopping, managing money)"}, {"field": "Social support available when needed", "value": "Yes (reliable caregiver support)"}, {"field": "Uses ≥5 prescription medications regularly", "value": "Yes"}, {"field": "Sometimes forgets to take prescription medications", "value": "Yes"}, {"field": "Recent unintentional weight loss", "value": "Yes (≈4 kg over 3 months)"}, {"field": "Often feels sad or depressed", "value": "Sometimes (several days in last 2 weeks)"}, {"field": "Urinary incontinence", "value": "Yes"}, {"field": "Timed Get Up and Go", "value": "18 seconds"}], "final_answer": 11, "notes": "Final output:\n11 out of 17\nInterpretation:\nModerate Frailty"}]}
{"task_id": "medmcp-calc_052_ca8378b0", "task_scenario": "Disease Severity & Prognosis", "task_category": "Clinical Medicine / Emergency, Critical Care & Perioperative / Critical Care", "patient_id": "P052_ca8378b0", "task_description": "Scenario: An adult patient is admitted to the ICU with community-acquired pneumonia (CAP), hypotension, tachypnea, and escalating oxygen needs. The team must quickly stage overall illness severity, confirm sepsis status, quantify organ dysfunction, determine pneumonia-specific need for intensive respiratory or vasopressor support, classify ARDS, and decide on escalation (HFNC vs intubation) and ECMO candidacy. Workflow steps: 1) Start with National Early Warning Score (NEWS) 2 to establish immediate physiological severity and trigger urgent escalation pathways if high. 2) Apply SIRS, Sepsis, and Septic Shock Criteria to categorize infection-related systemic response and shock status and guide resuscitation intensity. 3) Calculate Sequential Organ Failure Assessment (SOFA) Score to quantify acute organ dysfunction and baseline ICU mortality risk; trend over time for trajectory. 4) Use SMART-COP Score for Pneumonia Severity to estimate the need for intensive respiratory or vasopressor support (IRVS); a high score triggers proactive planning for advanced oxygenation and vasopressors. 5) Quantify oxygenation with either SpO₂/FiO₂ Ratio or Horowitz Index for Lung Function (P/F Ratio) based on available data: if an arterial blood gas is available, compute the P/F Ratio; otherwise compute the S/F Ratio and plan to confirm with ABG. 6) Classify ARDS using the Berlin Criteria for Acute Respiratory Distress Syndrome, leveraging the P/F Ratio (or interim S/F estimate) to stage mild/moderate/severe ARDS and standardize ventilatory strategy. 7) If managed initially with high-flow nasal cannula (HFNC), calculate the ROX Index for Intubation after HFNC; if the ROX Index is below failure threshold, proceed to intubation and lung-protective ventilation; if above threshold, continue HFNC with close monitoring. 8) In intubated patients with persistent moderate-severe ARDS despite optimal conventional strategies (e.g., proning and lung-protective ventilation), compute the Murray Score for Acute Lung Injury to quantify lung injury severity and help decide ECMO evaluation. 9) If the Murray Score indicates severe lung injury, calculate the RESP (Respiratory ECMO Survival Prediction) Score to estimate survival prospects on ECMO; integrate RESP with SOFA to inform ECMO candidacy and goals-of-care discussions. This sequence ties general critical illness severity and sepsis staging to pneumonia-specific IRVS needs, objective oxygenation metrics, ARDS classification, HFNC failure risk, and ECMO prognosis to support timely, data-driven escalation and prognostication.", "fuzzy_question": "I’m evaluating a patient in intensive care with community-acquired pneumonia, low blood pressure, rapid breathing, and increasing oxygen needs. I’m trying to determine how unstable the situation is right now and what level of escalation to prepare for.\n\nI want a quick bedside snapshot that consolidates current vital signs and observations into an overall sense of acuity. If this suggests high immediate risk, we should be ready to escalate urgently.\n\nI also want clarity on where this falls along the infection spectrum—systemic inflammatory response versus sepsis and whether this has progressed to shock—using standard bedside criteria (fever or hypothermia, tachycardia, tachypnea, white count), along with blood pressure response to fluids, vasopressor requirements, and lactate. If the picture indicates shock, we need aggressive resuscitation and support.\n\nI’d like a structured assessment of acute organ strain across respiratory, circulatory, renal, hepatic, hematologic, and neurologic systems to establish an objective ICU baseline and track trajectory over the next day or two. Please include a plan for reassessment so we’re not relying on a single snapshot.\n\nBecause the source is pneumonia, I want a pneumonia-focused bedside assessment estimating the likelihood of needing high-level oxygen delivery or vasopressors. If the estimate is high, we should proactively plan for advanced oxygenation strategies and vasopressor support rather than waiting for deterioration.\n\nFor oxygenation, let’s quantify impairment. If an arterial blood gas is available, base the oxygenation ratio on that; if not, use a saturation-to-inspired oxygen estimate as an interim measure and plan to confirm with a blood gas as soon as feasible. I want that value specified so we can compare cleanly over time.\n\nIf imaging and timing fit an acute respiratory distress picture, please stage ARDS (mild, moderate, or severe) from the oxygenation ratio under standard conditions to guide ventilatory targets and intensity.\n\nI’m weighing continued high-flow nasal cannula versus moving to intubation. If we start high-flow, let’s track the early bedside composite that combines oxygen saturation, delivered oxygen, and respiratory rate. If that composite falls into a “likely to fail” range in the first few hours, do not delay—proceed to intubation with lung-protective ventilation. If it remains in safer territory, continue high-flow with close monitoring and frequent reassessment.\n\nIf intubated and, despite best practices—low tidal volumes, appropriate pressures, and early proning—there is ongoing moderate-to-severe lung injury, I want a formal lung injury severity assessment that captures imaging extent, hypoxemia level, pressure requirements, and mechanics. If severity is high, we should seriously consider an ECMO evaluation.\n\nIf ECMO becomes a consideration, I need a realistic survival estimate on ECMO based on the clinical profile (age, time on ventilation, immune status, need for pressors, renal involvement, coinfections, and related factors), integrated with the overall organ dysfunction assessment. This should guide candidacy and inform goals-of-care discussions.\n\nWhat’s your take on this case, and how would you reason through it? Am I missing anything that would change the plan? I need the approach supported by proper calculations—this can’t rest on clinical intuition alone and must hold up to scrutiny.", "required_calculators": ["National Early Warning Score (NEWS) 2", "SIRS, Sepsis, and Septic Shock Criteria", "Sequential Organ Failure Assessment (SOFA) Score", "SMART-COP Score for Pneumonia Severity", "SpO₂/FiO₂ Ratio", "Horowitz Index for Lung Function (P/F Ratio)", "Berlin Criteria for Acute Respiratory Distress Syndrome", "ROX Index for Intubation after HFNC", "Murray Score for Acute Lung Injury", "RESP (Respiratory ECMO Survival Prediction) Score"], "calculator_answers": [{"order": 1, "name": "National Early Warning Score (NEWS) 2", "inputs": [{"field": "Respiratory rate (breaths/min)", "value": "34 breaths/min", "score": 3}, {"field": "Hypercapnic respiratory failure", "value": "No"}, {"field": "SpO2", "value": "90 %", "score": 3}, {"field": "Room air or supplemental O2", "value": "Supplemental O2 (HFNC)", "score": 2}, {"field": "Temperature", "value": "38.9 °C", "score": 1}, {"field": "Systolic BP", "value": "86 mmHg", "score": 3}, {"field": "Pulse", "value": "128 bpm", "score": 2}, {"field": "Consciousness", "value": "New-onset confusion", "score": 3}], "final_answer": 17, "notes": "17 points\nNational Early Warning Score\nHigh risk\nEmergent assessment by a clinical team or critical care team and usually transfer to higher level of care\nContinuous monitoring\nFrequency of monitoring"}, {"order": 2, "name": "SIRS, Sepsis, and Septic Shock Criteria", "inputs": [{"field": "Temp >38°C or <36°C", "value": "Yes (38.9 °C)"}, {"field": "Heart rate >90", "value": "Yes (128 bpm)"}, {"field": "Respiratory rate >20 or PaCO2 <32 mmHg", "value": "Yes (RR 34; PaCO2 32 mmHg)"}, {"field": "WBC >12,000/mm³, <4,000/mm³, or >10% bands", "value": "Yes (17,500 /mm³; bands 8%)"}, {"field": "Suspected or present source of infection", "value": "Yes (community-acquired pneumonia)"}, {"field": "Lactate (mmol/L)", "value": "4.2 mmol/L"}, {"field": "Systolic BP", "value": "86 mmHg"}, {"field": "Adequate fluid resuscitation given", "value": "Yes (30 mL/kg crystalloid; ~2.1 L for 70 kg)"}, {"field": "Persistent hypotension requiring vasopressors", "value": "Yes (norepinephrine 0.12 mcg/kg/min)"}, {"field": "Evidence of ≥2 organs failing", "value": "Yes (respiratory, circulatory, renal; plus encephalopathy)"}], "final_answer": "This patient meets multiple organ dysfunction syndrome. Follow your guidelines for sepsis, which typically include aggressive fluid resuscitation, early, broad-spectrum antibiotics, ICU consultation, CVP evaluation, and occasionally pressors and transfusion.", "notes": "This patient meets multiple organ dysfunction syndrome. Follow your guidelines for sepsis, which typically include aggressive fluid resuscitation, early, broad-spectrum antibiotics, ICU consultation, CVP evaluation, and occasionally pressors and transfusion."}, {"order": 3, "name": "Sequential Organ Failure Assessment (SOFA) Score", "inputs": [{"field": "PaO2", "value": "85 mmHg"}, {"field": "FiO2", "value": "100 %"}, {"field": "On mechanical ventilation (including CPAP)", "value": "Yes (intubated)"}, {"field": "Platelets", "value": "128 x10^3/µL", "score": 1}, {"field": "Glasgow Coma Scale (GCS)", "value": "14 (off sedation estimate)", "score": 1}, {"field": "Bilirubin", "value": "1.1 mg/dL", "score": 0}, {"field": "Mean arterial pressure (MAP)", "value": "63 mmHg"}, {"field": "Vasoactive agents (dose)", "value": "Norepinephrine 0.12 mcg/kg/min", "score": 4}, {"field": "Creatinine", "value": "2.1 mg/dL", "score": 2}, {"field": "Urine output (24h)", "value": "900 mL/day"}], "final_answer": 6, "notes": "6 points\nInitial SOFA Scores ≤9 predict ≤33.3% mortality (see Evidence for details)"}, {"order": 4, "name": "SMART-COP Score for Pneumonia Severity", "inputs": [{"field": "Age (years)", "value": "58 years"}, {"field": "Systolic BP <90 mmHg", "value": "Yes (SBP 86 mmHg)", "score": 2}, {"field": "Multilobar chest radiograph involvement", "value": "Yes (bilateral multilobar consolidation)", "score": 1}, {"field": "Albumin", "value": "2.8 g/dL", "score": 1}, {"field": "Respiratory rate (breaths/min)", "value": "34 breaths/min", "score": 1}, {"field": "Heart rate (bpm)", "value": "128 bpm", "score": 1}, {"field": "New confusion", "value": "Yes", "score": 1}, {"field": "PaO2 on room air (pre-oxygenation, ED)", "value": "58 mmHg", "score": 2}, {"field": "Arterial pH", "value": "7.31", "score": 2}], "final_answer": 11, "notes": "11 points\nSMART-COP Score\nVery high risk\n2 in 3 risk of IRVS. Consider ICU admission."}, {"order": 5, "name": "SpO₂/FiO₂ Ratio", "inputs": [{"field": "SpO2", "value": "90 %"}, {"field": "FiO2", "value": "70 %"}], "final_answer": 128.6, "notes": "128.6\nS/F Ratio"}, {"order": 6, "name": "Berlin Criteria for Acute Respiratory Distress Syndrome", "inputs": [{"field": "Timing within 1 week of clinical insult/new/worsening respiratory symptoms", "value": "Yes (symptom onset 5 days ago; ICU day 0)"}, {"field": "Chest imaging shows bilateral opacities not fully explained by effusions/lobar collapse/nodules", "value": "Yes (bilateral multilobar consolidation)"}, {"field": "Respiratory failure not fully explained by cardiac failure or fluid overload", "value": "Yes (no clinical/echo evidence of hydrostatic edema)"}, {"field": "Risk factor for ARDS present", "value": "Yes (pneumonia/sepsis)"}, {"field": "PaO2", "value": "85 mmHg"}, {"field": "FiO2", "value": "100 %"}, {"field": "PEEP/CPAP", "value": "12 cm H2O"}, {"field": "Oxygenation severity category", "value": "Severe: PaO2/FiO2 ≤100 mmHg with PEEP ≥5 cm H2O"}], "final_answer": "Positive", "notes": "Diagnostic Result\nPositive\nModerate ARDS"}, {"order": 7, "name": "ROX Index for Intubation after HFNC", "inputs": [{"field": "SpO2", "value": "90 %"}, {"field": "FiO2", "value": "70 %"}, {"field": "Respiratory rate", "value": "34 breaths/min"}], "final_answer": 3.78, "notes": "3.78 points\nROX Index\nRisk of HFNC failure is high; intubation should be considered"}, {"order": 8, "name": "Murray Score for Acute Lung Injury", "inputs": [{"field": "Consolidation on CXR", "value": "3 quadrants"}, {"field": "PaO2/FiO2 ratio", "value": "85"}, {"field": "PEEP", "value": "12 cm H2O"}, {"field": "Compliance (VT / (PIP – PEEP))", "value": "28 mL/cm H2O"}, {"field": "Vent details (context)", "value": "VT 420 mL (~6 mL/kg PBW), PIP 32, PEEP 12, plateau 27"}], "final_answer": 3.3, "notes": "3.3 points\nSevere lung injury. Consider referral to ECMO center."}, {"order": 9, "name": "RESP (Respiratory ECMO Survival Prediction) Score", "inputs": [{"field": "Age", "value": "58 years (50–59: -2 points)", "score": -2}, {"field": "Immunocompromised status at time of ECMO", "value": "No (0)", "score": 0}, {"field": "Mechanically ventilated before ECMO initiated", "value": "<48 hours (+3); current duration ~18 hours", "score": 3}, {"field": "Primary diagnosis", "value": "Bacterial pneumonia (+3)", "score": 3}, {"field": "History of CNS dysfunction", "value": "No (0)", "score": 0}, {"field": "Acute associated nonpulmonary infection", "value": "No (0)", "score": 0}, {"field": "Neuromuscular blockade before ECMO", "value": "Yes (+1)", "score": 1}, {"field": "Nitric oxide before ECMO", "value": "No (0)", "score": 0}, {"field": "Bicarbonate infusion before ECMO", "value": "No (0)", "score": 0}, {"field": "Cardiac arrest before ECMO", "value": "No (0)", "score": 0}, {"field": "PaCO2 ≥75 mmHg (≥10 kPa)", "value": "No (45 mmHg; 0)", "score": 0}, {"field": "Peak inspiratory pressure ≥42 cm H2O", "value": "No (PIP 32 cm H2O; 0)", "score": 0}], "final_answer": 5, "notes": "5 points\nRESP Score\nClass II\nRisk class\n76 %\nIn-hospital survival"}]}
{"task_id": "medmcp-calc_053_166f8db0", "task_scenario": "Depression and Anxiety Screening", "task_category": "Clinical Medicine / Neurology & Mental Health / Mental & Psychological Health", "patient_id": "P053_166f8db0", "task_description": "Scenario: An adult presents in primary care reporting low mood, worry, and decreased functioning. The clinician aims to efficiently screen for both depression and anxiety, confirm diagnoses, quantify symptom severity, and assess suicide risk to guide immediate safety needs and treatment planning.\n\nWorkflow steps and rationale:\n1) Begin with the Patient Health Questionnaire-4 (PHQ-4) to rapidly triage for both depressive and anxiety symptoms in a single, ultra-brief screen. This establishes whether either domain needs deeper assessment.\n2) Administer the Who Five Well Being Index (WHO-5) to contextualize overall well-being. Low well-being can signal clinically significant distress and prompts full assessment even if the PHQ-4 is not clearly positive.\n3) If the PHQ-4 indicates elevated depressive symptoms or the WHO-5 suggests poor well-being, proceed with the PHQ-9 (Patient Health Questionnaire-9) to objectify depressive symptom severity and functional impact.\n4) If the PHQ-4 indicates elevated anxiety symptoms or the WHO-5 suggests poor well-being, administer the GAD-7 (General Anxiety Disorder-7) to measure anxiety severity and guide the need for further clinician-rated severity assessment.\n5) If suicidality is endorsed on the PHQ-9 or depressive severity appears high, immediately complete the Modified SAD PERSONS Scale to stratify suicide risk and trigger urgent safety planning when indicated.\n6) Use the DSM-5 Criteria for Major Depressive Disorder to confirm a formal MDD diagnosis when PHQ-9 shows clinically significant depressive symptoms with impairment. If DSM-5 criteria are not met, consider alternative diagnoses or subthreshold conditions and adjust the care plan accordingly.\n7) If DSM-5 criteria for MDD are met or the PHQ-9 indicates at least moderate severity, administer the Quick Inventory of Depressive Symptomatology (QIDS) to establish a detailed baseline severity profile for treatment selection and progress monitoring.\n8) If GAD-7 shows severe anxiety, add the Hamilton Anxiety Scale for clinician-rated confirmation of severity, aiding decisions about treatment intensity, referral, or co-management.\n\nConditional branches illustrate how outputs drive the next steps: A positive depression or anxiety signal on PHQ-4, or low WHO-5, triggers full domain-specific scales (PHQ-9 and/or GAD-7). Suicidality indicated on PHQ-9 deterministically triggers the Modified SAD PERSONS Scale. PHQ-9 severity and impairment inform the DSM-5 MDD diagnostic check, which then determines whether QIDS is collected. Severe GAD-7 results deterministically prompt the Hamilton Anxiety Scale for clinician-rated severity. Integrated results direct urgency (safety planning vs. routine follow-up) and the intensity of interventions.", "fuzzy_question": "I’m seeing an adult in primary care who has been struggling recently with low mood, persistent worry, and a noticeable decline in functioning at work and at home. Sleep is disrupted, fatigue is increased, and concentration is harder. No clear history of mania so far, but it’s unclear whether this is primarily depression, anxiety, or a mix. I want to be efficient and thorough to avoid missing concerns or underestimating risk.\n\nMy first priority is to quickly gauge both tracks—sadness/anhedonia and nervousness/worry—without a lengthy evaluation upfront. Can we start with a very brief combined check that taps both domains with a small set of items and reports, separately, whether mood or anxiety is lighting up? I’d like both signals reported distinctly to guide the next steps.\n\nAlongside that, I want a brief snapshot of overall well-being over the standard screening period. Sometimes patients don’t score high on that first pass yet still appear genuinely unwell, and low well-being should prompt a fuller assessment even if the initial screen is borderline.\n\nIf the quick check points toward low mood—or if the well-being snapshot is clearly poor—let’s follow with the fuller depression questionnaire that covers the core symptom areas and asks about how much this is getting in the way of daily life. Please provide the total score, the usual severity band (minimal, mild, moderate, etc.), and whether there’s meaningful impairment in functioning.\n\nIf the quick check points toward anxiety—or if well-being is poor—add the standard worry/tension questionnaire to quantify anxiety severity. Again, I need the total score and how it falls on the severity scale, so we can judge whether the level of anxiety merits more intensive work-up.\n\nIf there’s any indication of thoughts of self-harm on the depression questionnaire—or the depression severity looks high—I don’t want to wait. Please immediately walk through a structured suicide risk checklist that considers sex, age, current mood state, any history of attempts, alcohol or drug use, loss of rational thinking, social supports, presence or absence of a plan, relationship context, and medical illness. I need a clear risk tier and guidance on whether we should move to urgent safety planning immediately.\n\nFrom there, based on the depression findings, I’d like you to line this up against formal criteria for a major depressive episode: count symptoms; confirm that either depressed mood or loss of interest is present; check that duration meets the typical diagnostic threshold; verify that there’s real distress or impairment; and make sure we’re not missing bipolar features or a medical/substance explanation. Tell me whether a formal diagnosis fits; if not, what alternative or subthreshold picture makes more sense (e.g., adjustment, mixed anxiety-depression), and how that should shift the plan.\n\nIf they meet those criteria—or even if they don’t but the depression severity lands at least in the moderate range—I’d like a brief, more granular inventory that captures sleep pattern disturbances, appetite/weight changes, energy, motor slowing or agitation, interest, mood, concentration, and self-critical thinking. I want a solid baseline to guide treatment selection and track progress over upcoming visits.\n\nAnd if the anxiety score is coming out severe, please add a clinician-rated anxiety assessment that covers both the psychic experience (tension, fears, worries) and the physical side (somatic symptoms). That clinician-based perspective helps decide whether we need higher-intensity treatment, referral, or co-management.\n\nFinally, please integrate all of this to answer the practical questions: do we need immediate safety steps or can we arrange routine follow-up; how intense should the initial treatment be; are we starting with therapy, medication, or both; and do we need specialty input right away. Call out any red flags that increase urgency. I need this grounded in solid, score-based reasoning at each stage—no gut calls. The interpretation and conclusions should hold up to scrutiny.", "required_calculators": ["Patient Health Questionnaire-4 (PHQ-4)", "Who Five Well Being Index (WHO-5)", "PHQ-9 (Patient Health Questionnaire-9)", "GAD-7 (General Anxiety Disorder-7)", "Modified SAD PERSONS Scale", "DSM-5 Criteria for Major Depressive Disorder", "Quick Inventory of Depressive Symptomatology (QIDS)", "Hamilton Anxiety Scale"], "calculator_answers": [{"order": 1, "name": "Patient Health Questionnaire-4 (PHQ-4)", "inputs": [{"field": "Over the last 2 weeks, how often have you been bothered by feeling nervous, anxious or on edge?", "value": "Nearly every day"}, {"field": "Over the last 2 weeks, how often have you been bothered by not being able to stop or control worrying?", "value": "Nearly every day"}, {"field": "Over the last 2 weeks, how often have you been bothered by little interest or pleasure in doing things?", "value": "Nearly every day"}, {"field": "Over the last 2 weeks, how often have you been bothered by feeling down, depressed, or hopeless?", "value": "Nearly every day"}], "final_answer": 12, "notes": "PHQ-4 Score\n12\nScreening Interpretation\nDepression and Anxiety likely"}, {"order": 2, "name": "Who Five Well Being Index (WHO-5)", "inputs": [{"field": "Over the last two weeks, I have felt cheerful and in good spirits?", "value": "At no time"}, {"field": "Over the last two weeks, I have felt calm and relaxed?", "value": "Some of the time"}, {"field": "Over the last two weeks, I have felt active and vigorous?", "value": "Some of the time"}, {"field": "Over the last two weeks, I woke up feeling fresh and rested?", "value": "At no time"}, {"field": "Over the last two weeks, My daily life has been filled with things that interest me?", "value": "Some of the time"}], "final_answer": 12, "notes": "WHO Score\n12\nScreening Interpretation\nLikely indicative of reduced well-being"}, {"order": 3, "name": "PHQ-9 (Patient Health Questionnaire-9)", "inputs": [{"field": "Little interest or pleasure in doing things?", "value": "Nearly every day", "score": 3}, {"field": "Feeling down, depressed, or hopeless?", "value": "Nearly every day", "score": 3}, {"field": "Trouble falling or staying asleep, or sleeping too much?", "value": "Nearly every day", "score": 3}, {"field": "Feeling tired or having little energy?", "value": "Nearly every day", "score": 3}, {"field": "Poor appetite or overeating?", "value": "Several days", "score": 1}, {"field": "Feeling bad about yourself - or that you are a failure or have let yourself or your family down?", "value": "More than half the days", "score": 2}, {"field": "Trouble concentrating on things, such as reading the newspaper or watching television?", "value": "More than half the days", "score": 2}, {"field": "Moving or speaking so slowly that other people could have noticed? Or so fidgety or restless that you have been moving a lot more than usual?", "value": "Several days", "score": 1}, {"field": "Thoughts that you would be better off dead, or thoughts of hurting yourself in some way?", "value": "Several days", "score": 1}, {"field": "If you checked any problems, how difficult have these made it for you to do your work, take care of things at home, or get along with other people?", "value": "Very difficult"}], "final_answer": 19, "notes": "19 points\nScores 15-19 suggest moderately severe depression; patients typically should have immediate initiation of pharmacotherapy and/or psychotherapy.\nFunctionally, the patient finds it is “very difficult” to perform life tasks due to their symptoms.\nWARNING: This patient is having thoughts concerning for suicidal ideation or self-harm, and should be probed further, referred, or transferred for emergency psychiatric evaluation as clinically appropriate and depending on clinician overall risk assessment."}, {"order": 4, "name": "GAD-7 (General Anxiety Disorder-7)", "inputs": [{"field": "Feeling nervous, anxious, or on edge", "value": "Nearly every day", "score": 3}, {"field": "Not being able to stop or control worrying", "value": "Nearly every day", "score": 3}, {"field": "Worrying too much about different things", "value": "Nearly every day", "score": 3}, {"field": "Trouble relaxing", "value": "Nearly every day", "score": 3}, {"field": "Being so restless that it's hard to sit still", "value": "More than half the days", "score": 2}, {"field": "Becoming easily annoyed or irritable", "value": "More than half the days", "score": 2}, {"field": "Feeling afraid as if something awful might happen", "value": "Several days", "score": 1}], "final_answer": 17, "notes": "17 points\nSevere anxiety disorder.\nFunctionally, the patient does not report limitations due to their symptoms."}, {"order": 5, "name": "Modified SAD PERSONS Scale", "inputs": [{"field": "Gender?", "value": "Female"}, {"field": "Age?", "value": 35}, {"field": "Depression or Hopelessness?", "value": "Yes"}, {"field": "Previous Suicide Attempts?", "value": "No"}, {"field": "Alcohol or Drug Use?", "value": "No"}, {"field": "Rational Thinking Loss/Psychosis?", "value": "No"}, {"field": "Separated, Divorced or Widowed?", "value": "No"}, {"field": "Organized Plan?", "value": "No"}, {"field": "Social Supports?", "value": "Adequate (supportive spouse and sibling)"}, {"field": "Stated Future Attempt to Harm Self?", "value": "No"}], "final_answer": 2, "notes": "SAD PERSONS Score\n2\nProbability of Requiring Hospital Admission\nLow Probability"}, {"order": 6, "name": "DSM-5 Criteria for Major Depressive Disorder", "inputs": [{"field": "Depressed mood (most of the day, nearly every day)", "value": "Present"}, {"field": "Loss of interest/pleasure (most of the day, nearly every day)", "value": "Present"}, {"field": "Weight loss or gain / appetite change (nearly every day)", "value": "Absent (mild decreased appetite, no significant weight change)"}, {"field": "Insomnia or hypersomnia (nearly every day)", "value": "Present (insomnia)"}, {"field": "Psychomotor agitation or retardation (observable by others, nearly every day)", "value": "Present (mild agitation/fidgeting)"}, {"field": "Fatigue or loss of energy (nearly every day)", "value": "Present"}, {"field": "Feelings of worthlessness or excessive/inappropriate guilt (nearly every day)", "value": "Present"}, {"field": "Diminished ability to think or concentrate, or indecisiveness (nearly every day)", "value": "Present"}, {"field": "Recurrent thoughts of death or suicidal ideation (with or without specific plan)", "value": "Present (passive SI, no plan)"}, {"field": "Duration of episode", "value": "3 weeks"}, {"field": "Clinically significant distress or impairment in functioning", "value": "Present"}, {"field": "Episode not attributable to substance/medical condition", "value": "True"}, {"field": "Not better explained by schizoaffective or other psychotic disorders", "value": "True"}, {"field": "No history of manic or hypomanic episode", "value": "True"}], "final_answer": "Positive", "notes": "Diagnostic Result\nPositive\nDiagnosis of MDD by DSM-5 Criteria"}, {"order": 7, "name": "Quick Inventory of Depressive Symptomatology (QIDS)", "inputs": [{"field": "1. Sleep onset insomnia", "value": "Takes more than 60 minutes to fall asleep, more than half the time (3)", "score": 3}, {"field": "2. Mid-nocturnal insomnia", "value": "Awakens more than once a night and stays awake for 20 minutes or more, more than half the time (3)", "score": 3}, {"field": "3. Early morning insomnia", "value": "More than half the time, awakens more than 30 minutes before need be (1)", "score": 1}, {"field": "4. Hypersomnia", "value": "Sleeps no longer than 7-8 hours/night, without naps (0)", "score": 0}, {"field": "5. Mood (sad)", "value": "Feels sad more than half the time (2)", "score": 2}, {"field": "6. Appetite (decreased)", "value": "Eats somewhat less often and/or lesser amounts than usual (1)", "score": 1}, {"field": "7. Appetite (increased)", "value": "No change from usual appetite (0)", "score": 0}, {"field": "8. Weight (decrease) within the last two weeks", "value": "Feels as if some slight weight loss occurred (1)", "score": 1}, {"field": "9. Weight (increase) within the last two weeks", "value": "Has experienced no weight change (0)", "score": 0}, {"field": "10. Concentration/decision making", "value": "Most of the time struggles to focus attention or make decisions (2)", "score": 2}, {"field": "11. Outlook (self)", "value": "Largely believes that he/she causes problems for others (2)", "score": 2}, {"field": "12. Suicidal ideation", "value": "Feels life is empty or is not worth living (1)", "score": 1}, {"field": "13. Involvement (interest)", "value": "Finds only one or two former interests remain (2)", "score": 2}, {"field": "14. Energy/fatigability", "value": "Makes significant personal effort to initiate or maintain usual daily activities (2)", "score": 2}, {"field": "15. Psychomotor slowing", "value": "Notes slowed thinking, and voice modulation is reduced (1)", "score": 1}, {"field": "16. Psychomotor agitation", "value": "Fidgets, wrings hands, and shifts positions often (1)", "score": 1}], "final_answer": 16, "notes": "16 points\nSevere depression"}, {"order": 8, "name": "Hamilton Anxiety Scale", "inputs": [{"field": "1. Anxious mood", "value": "Severe (3)", "score": 3}, {"field": "2. Tension", "value": "Severe (3)", "score": 3}, {"field": "3. Fears", "value": "Mild (1)", "score": 1}, {"field": "4. Insomnia", "value": "Moderate (2)", "score": 2}, {"field": "5. Intellectual (difficulty in concentration, poor memory)", "value": "Moderate (2)", "score": 2}, {"field": "6. Depressed mood", "value": "Moderate (2)", "score": 2}, {"field": "7. Somatic (muscular)", "value": "Moderate (2)", "score": 2}, {"field": "8. Somatic (sensory)", "value": "Mild (1)", "score": 1}, {"field": "9. Cardiovascular symptoms", "value": "Moderate (2)", "score": 2}, {"field": "10. Respiratory symptoms", "value": "Mild (1)", "score": 1}, {"field": "11. Gastrointestinal symptoms", "value": "Mild (1)", "score": 1}, {"field": "12. Genitourinary symptoms", "value": "Mild (1)", "score": 1}, {"field": "13. Autonomic symptoms", "value": "Moderate (2)", "score": 2}, {"field": "14. Behavior at interview", "value": "Moderate (2)", "score": 2}], "final_answer": 25, "notes": "25 points\nModerate to severe anxiety"}]}
{"task_id": "medmcp-calc_054_3681c004", "task_scenario": "Perinatal Risk Assessment", "task_category": "Clinical Medicine / Special Populations & General Tools / Obstetrics & Reproductive Health", "patient_id": "P054_3681c004", "task_description": "Scenario: A pregnant patient with a history of prior cesarean presents in late pregnancy with elevated blood pressures and plans for delivery. The care team must assess maternal and fetal/neonatal risks to choose the safest delivery route, anticipate intrapartum needs, and plan postpartum newborn and maternal care.\n\nWorkflow steps:\n1) Use Gestational Age to confirm current gestational timing. This determines whether delivery planning should proceed now versus short-term expectant management.\n2) If delivery is appropriate, use Vaginal Birth After Cesarean (MFMU) to estimate the probability of successful VBAC. This output deterministically guides the next step: high predicted success supports a trial of labor; low success suggests repeat cesarean.\n3) If VBAC is favored, apply the Modified Bishop Score for Vaginal Delivery and Induction of Labor to assess cervical readiness. A low score triggers cervical ripening before induction; a favorable score supports immediate induction/augmentation. If VBAC success is low or the cervix is unfavorable and clinical circumstances favor avoiding prolonged labor, plan a repeat cesarean.\n4) Quantify blood pressure via Mean Arterial Pressure (MAP). If MAP indicates severe or poorly controlled hypertension, this becomes a decision trigger to expedite delivery and may shift the plan away from a labor trial toward a more controlled delivery route.\n5) At birth, calculate the APGAR Score at 1 and 5 minutes to determine immediate neonatal stability and the intensity of resuscitation and observation needed.\n6) Use the Neonatal Early-Onset Sepsis Calculator to combine maternal intrapartum risk factors and newborn status for sepsis risk stratification. High risk triggers empiric antibiotics; intermediate risk triggers enhanced observation; low risk supports routine care.\n7) Before discharge, assess bilirubin risk with the Hour-Specific Risk for Neonatal Hyperbilirubinemia at the infant’s hour of life. If risk is high or near a treatment threshold, proceed to the next step.\n8) If indicated by Step 7, apply the Newborn Hyperbilirubinemia Rate of Rise to determine whether bilirubin is increasing rapidly enough to require phototherapy or closer follow-up.\n9) For Rh(D)-negative mothers, use Maternal-Fetal Hemorrhage Rh(D) Immune Globulin Dosage to calculate the appropriate postpartum RhIG dose. If the mother is Rh(D)-positive, this step is skipped.\n10) Prior to discharge, screen maternal mental health with the Edinburgh Postnatal Depression Scale (EPDS) to identify those needing urgent support, counseling, or follow-up.\n\nConditional branches and data flow:\n- Gestational Age determines whether to pursue delivery planning immediately or defer short-term.\n- VBAC probability (MFMU) deterministically triggers whether the Modified Bishop Score is used for induction planning versus proceeding directly to repeat cesarean.\n- MAP influences the delivery route and urgency (e.g., escalation away from TOLAC if severe hypertension is present).\n- Hour-Specific Risk for Neonatal Hyperbilirubinemia deterministically triggers using Newborn Hyperbilirubinemia Rate of Rise to confirm need for phototherapy.\n- RhIG dosing is performed only if the mother is Rh(D)-negative.", "fuzzy_question": "Evaluating a late-pregnancy patient with a prior low-transverse cesarean and progressively rising blood pressure. The patient prefers to avoid another surgery if safe, but I’m unsure whether to pursue a trial of labor after cesarean versus a repeat cesarean, and whether delivery should occur now or after brief expectant management.\n\nFirst, I want to confirm gestational age with as much accuracy as possible. If the timing supports delivery, that favors proceeding; if slightly earlier than ideal, very short-term expectant management may be reasonable if safe.\n\nIf delivery is appropriate, I want an evidence-based estimate of the likelihood of successful vaginal birth after cesarean based on individual factors (maternal characteristics, prior vaginal birth history, indication for the previous cesarean, and current presentation). A higher likelihood favors a labor trial; a lower likelihood favors a repeat cesarean.\n\nIf a labor trial is favored, I need an assessment of cervical favorability (Bishop score components: dilation, effacement, station, consistency, position). If unfavorable, plan cervical ripening before induction; if favorable, consider immediate induction or augmentation. If predicted success is low or the cervix is very unfavorable and prolonged labor would be risky, a repeat cesarean may be safer.\n\nBlood pressure trajectory is a key determinant. I need to understand average levels and whether they approach the severe range or are difficult to control. Severe or poorly controlled pressures would prompt expeditious delivery and may shift the plan toward a more controlled surgical approach rather than a labor trial.\n\nAt birth, assess newborn status at standard time points to guide the intensity of resuscitation and monitoring. Then, frame neonatal sepsis risk using the maternal intrapartum picture (fever or chorioamnionitis signs, GBS status, timing of membrane rupture, intrapartum antibiotics) together with the newborn exam and vital signs, to decide between empiric antibiotics, enhanced observation, or routine care.\n\nBefore discharge, interpret bilirubin relative to time since birth to gauge jaundice risk and proximity to treatment thresholds. If elevated or borderline, consider the rate of rise to decide on immediate phototherapy versus closer follow-up.\n\nFor the mother, if Rh-negative, estimate fetomaternal hemorrhage exposure at delivery and administer an appropriate dose of Rh immune globulin; if Rh-positive, this is not needed. Ensure a standard postpartum mood screen before discharge to identify those needing urgent support or early follow-up.\n\nPlease walk through this case step by step, linking each decision to relevant quantitative assessments and clinical reasoning. I’m weighing a labor trial versus repeat cesarean in the context of rising blood pressure and want to avoid maternal and neonatal complications. I need calculations and evidence-based risk stratification rather than intuition, with recommendations that can withstand scrutiny.", "required_calculators": ["Gestational Age", "Vaginal Birth After Cesarean (MFMU)", "Modified Bishop Score for Vaginal Delivery and Induction of Labor", "Mean Arterial Pressure (MAP)", "APGAR Score", "Neonatal Early-Onset Sepsis Calculator", "Hour-Specific Risk for Neonatal Hyperbilirubinemia", "Newborn Hyperbilirubinemia Rate of Rise", "Maternal-Fetal Hemorrhage Rh(D) Immune Globulin Dosage", "Edinburgh Postnatal Depression Scale (EPDS)"], "calculator_answers": [{"order": 1, "name": "Gestational Age", "inputs": [{"field": "Current Date?", "value": "2025-12-15"}, {"field": "Due Date?", "value": "2026-01-10"}], "final_answer": "36 Weeks 2 Days", "notes": "End of 1st Trimester\nJune 28, 2025\nCurrent Gestational Age\n36 Weeks 2 Days"}, {"order": 2, "name": "Vaginal Birth After Cesarean (MFMU)", "inputs": [{"field": "Age, years", "value": 31}, {"field": "Pre-pregnancy weight", "value": "165 lb"}, {"field": "Height", "value": "64 in"}, {"field": "Arrest disorder for previous cesarean delivery", "value": "No"}, {"field": "Obstetric history", "value": "No previous vaginal history"}, {"field": "Treated chronic hypertension", "value": "No"}], "final_answer": "65.5 %", "notes": "65.5 %\nChance of successful vaginal birth after cesarean delivery"}, {"order": 3, "name": "Modified Bishop Score for Vaginal Delivery and Induction of Labor", "inputs": [{"field": "Cervical Dilation", "value": "1-2 cm", "score": 2}, {"field": "Cervical Length", "value": "1 cm", "score": 2}, {"field": "Station", "value": "-1, 0", "score": 2}, {"field": "Position", "value": "Mid-position", "score": 1}, {"field": "Consistency", "value": "Soft", "score": 2}, {"field": "Prior vaginal deliveries", "value": "0"}, {"field": "Pre-eclampsia", "value": "No", "score": 0}, {"field": "Postdate pregnancy", "value": "No", "score": 0}, {"field": "Nulliparity", "value": "No", "score": 0}, {"field": "PPROM", "value": "No", "score": 0}], "final_answer": 9, "notes": "9 points\nScores ≥ 8 suggest spontaneous vaginal delivery is more likely and augmentation or induction may be unnecessary.\nNote: Success rates tend to vary based on indication for induction and weeks gestation."}, {"order": 4, "name": "Mean Arterial Pressure (MAP)", "inputs": [{"field": "Systolic BP", "value": "152 mm Hg"}, {"field": "Diastolic BP", "value": "96 mm Hg"}], "final_answer": 115, "notes": "115 mm Hg\nMean Arterial Pressure (MAP)"}, {"order": 5, "name": "APGAR Score", "inputs": [{"field": "Activity/muscle tone", "value": "Active", "score": 2}, {"field": "Pulse", "value": "≥100 BPM", "score": 2}, {"field": "Grimace", "value": "Sneeze/cough", "score": 2}, {"field": "Appearance/color", "value": "Blue extremities, pink body", "score": 1}, {"field": "Respirations", "value": "Good/crying", "score": 2}], "final_answer": 9, "notes": "9 points\nScores ≥7 are typically “normal” for neonates."}, {"order": 6, "name": "Neonatal Early-Onset Sepsis Calculator", "inputs": [{"field": "Gestational age", "value": "36w2d"}, {"field": "Highest maternal antepartum temperature", "value": "99.1 F"}, {"field": "Duration of rupture of membranes (ROM)", "value": "4.5 hours"}, {"field": "Maternal GBS status", "value": "Negative"}, {"field": "Type of intrapartum antibiotics", "value": "No antibiotics or any antibiotics <2 hrs prior to birth"}], "final_answer": 0.39, "notes": "0.39\nEOS risk per 1000/births\nEOS Risk after Clinical Exam (risk per 1000/births)\nWell appearing: 0.16\nEquivocal: 1.97\nClinical illness: 8.31\nClinical Recommendation\nAt birth: Routine vitals\nAfter Clinical Exam\nWell appearing: No additional care\nEquivocal: Blood culture and vitals every 4 hours for 24 hours\nClinical illness: Treat empirically with antibiotics"}, {"order": 7, "name": "Hour-Specific Risk for Neonatal Hyperbilirubinemia", "inputs": [{"field": "Age", "value": "36 hours"}, {"field": "Total serum bilirubin", "value": "7.1 mg/dL"}, {"field": "Gestational age, weeks", "value": "35 to <38"}, {"field": "Risk factors for neurotoxicity present", "value": "No"}], "final_answer": "Low-intermediate", "notes": "Low-intermediate\nHour-specific TSB risk zone\n2.2 %\nProbability of subsequent neonatal hyperbilirubinemia\nNo\nStart phototherapy?\nDo not need to start phototherapy as per AAP phototherapy guidelines"}, {"order": 8, "name": "Newborn Hyperbilirubinemia Rate of Rise", "inputs": [{"field": "Bilirubin #1 Value?", "value": "5.6 mg/dL"}, {"field": "Bilirubin #2 Value?", "value": "7.1 mg/dL"}, {"field": "Time Between Bilirubin Values?", "value": "24 hours"}], "final_answer": "1.07 μmol/L/hour Or 25.65 μmol/L/day", "notes": "Rate of Rise (SI)\n1.07 μmol/L/hour Or 25.65 μmol/L/day\nRate of Rise (US)\n0.06 mg/dL/hour Or 1.50 mg/dL/day\nInterpretation\nRate of TSB rise ≤ 3.4 μmol/L/hour (0.2 mg/dL/hour). This is not a risk factor for severe hyperbilirubinemia"}, {"order": 9, "name": "Maternal-Fetal Hemorrhage Rh(D) Immune Globulin Dosage", "inputs": [{"field": "Maternal blood volume", "value": "5200 mL"}, {"field": "Fetal cells in mother", "value": "0.20 %"}], "final_answer": 1, "notes": "1 vials\nRhIG to give (assumes each vial is 30 mL)"}, {"order": 10, "name": "Edinburgh Postnatal Depression Scale (EPDS)", "inputs": [{"field": "I have been able to laugh and see the funny side of things", "value": "As much as I always could", "score": 0}, {"field": "I have looked forward with enjoyment to things", "value": "Rather less than I used to", "score": 1}, {"field": "I have blamed myself unnecessarily when things went wrong", "value": "Not very often", "score": 1}, {"field": "I have been anxious or worried for no good reason", "value": "Yes, sometimes", "score": 2}, {"field": "I have felt scared or panicky for no very good reason", "value": "No, not much", "score": 1}, {"field": "Things have been getting on top of me", "value": "No, most of the time I have coped quite well", "score": 1}, {"field": "I have been so unhappy that I have had difficulty sleeping", "value": "Not very often", "score": 1}, {"field": "I have felt sad or miserable", "value": "Not very often", "score": 1}, {"field": "I have been so unhappy that I have been crying", "value": "Only occasionally", "score": 1}, {"field": "The thought of harming myself has occurred to me", "value": "Never", "score": 0}], "final_answer": 9, "notes": "9 points\nEPDS Score\nNegative\nScreening result for depression in postnatal period"}]}
{"task_id": "medmcp-calc_055_a7f6eca4", "task_scenario": "Pain Management and Opioid Use", "task_category": "Clinical Medicine / Emergency, Critical Care & Perioperative / Anesthesia & Perioperative Medicine", "patient_id": "P055_a7f6eca4", "task_description": "Clinical scenario: An intubated post-procedure patient in the ED/PACU has suspected opioid-related respiratory depression. After stabilization, the team must prevent recurrent toxicity, assess and treat opioid withdrawal appropriately, provide effective analgesia while minimizing further opioid exposure, and plan safe discharge. The workflow uses multiple calculators in sequence to guide these decisions.\n\nStep-by-step calculator use:\n1) Naloxone Drip Dosing: Use this to determine bolus and continuous infusion parameters to reverse opioid-induced respiratory depression and prevent renarcotization. Decision trigger: If adequate ventilation and consciousness are achieved and maintained without recurrent depression, proceed to withdrawal assessment. If respiratory depression persists or recurs, continue titrating the naloxone infusion and delay subsequent steps until the patient is stabilized.\n2) COWS Score for Opiate Withdrawal: Once the patient is stabilized and can be assessed for withdrawal, calculate the COWS to quantify severity. Decision trigger: If COWS indicates moderate to severe withdrawal, proceed to buprenorphine initiation; if mild or no withdrawal, defer buprenorphine and focus on non-opioid analgesia and supportive care.\n3) Emergency Department-Initiated Buprenorphine for Opioid Use Disorder (EMBED): Use EMBED to confirm OUD, assess treatment readiness, and guide ED initiation of buprenorphine. The COWS severity and patient readiness from EMBED determine whether to start buprenorphine and the initial dosing approach. Branch: If EMBED indicates the patient is ready and eligible, initiate buprenorphine; if not, do not initiate and plan non-opioid analgesia or limited, closely monitored opioid use as needed.\n4) Critical Care Pain Observation Tool (CPOT): Because the patient is intubated/nonverbal, use CPOT to quantify pain. Decision trigger: If CPOT is low, continue minimal analgesia; if CPOT is elevated, escalate analgesia while avoiding high-dose opioids.\n5) Local Anesthetic Dosing Calculator: If CPOT indicates significant pain and a regional nerve block or local infiltration is clinically appropriate, use this calculator to safely dose the selected local anesthetic to achieve opioid-sparing analgesia. Branch: If regional/local techniques are contraindicated, skip this step and plan systemic analgesia.\n6) Opiate Conversion Calculator: If systemic opioids are still required (e.g., while buprenorphine is initiated or if buprenorphine is deferred), convert existing/home regimens or planned agents to the desired opioid and route using equianalgesic dosing. CPOT results and any local anesthetic use inform the target opioid dose range.\n7) Morphine Milligram Equivalents (MME) Calculator: Calculate the total daily MME of the planned systemic opioid regimen derived from the conversion step. Decision trigger: If the calculated MME is high, reduce opioid dosing, re-emphasize non-opioid modalities (including the regional technique), and recalculate MME until acceptable; if MME is acceptable, proceed to risk stratification.\n8) Revised Opioid Risk Tool (ORT-OUD): Before discharge or ongoing prescribing, assess the patient’s risk for opioid-related aberrant behaviors. Decision trigger: If ORT-OUD indicates moderate/high risk, avoid or minimize outpatient opioid prescriptions, rely on buprenorphine/non-opioid strategies, and align follow-up accordingly; if risk is low, provide a restricted supply if necessary with clear safety guidance.\n\nRationale for sequence: Overdose reversal and stabilization must precede withdrawal assessment; withdrawal severity (COWS) directly informs buprenorphine initiation (EMBED). Pain must be measured in the nonverbal, critically ill patient (CPOT) to titrate analgesia. Opioid-sparing regional techniques are dosed safely via the Local Anesthetic Dosing Calculator. If opioids are needed, equianalgesic conversion (Opiate Conversion Calculator) ensures accurate planning, and total daily load (MME Calculator) provides a risk-based check that informs dose reduction. Finally, patient-level misuse risk (ORT-OUD) guides safer discharge prescribing.", "fuzzy_question": "I'm seeing an intubated post-procedure patient in the ED/PACU who likely had opioid-related respiratory depression. An initial reversal has been given and the patient's ventilation looks better, but I'm worried about rebound and do not want to under- or over-treat. I'm trying to figure out the best approach to keep the patient safely breathing, prevent recurrent toxicity, manage withdrawal if it emerges, and still provide good pain control without using more opioid than necessary.\n\nMy first concern is whether breathing is truly stabilized. If the patient has any dip in ventilation or mental status, we may need a small additional reversal dose and a carefully titrated infusion to keep things steady and avoid recurrent sedation. If the patient remains consistently alert enough and ventilating adequately over the next period, then I would feel comfortable moving on to the withdrawal question.\n\nOnce the patient is stable enough to assess, I do not want to rely on eyeballing withdrawal. I would like a structured bedside withdrawal assessment to grade severity. If that points to moderate to severe withdrawal, I am inclined to initiate buprenorphine in the ED. If it is mild or absent, I would hold off and focus on non-opioid analgesia and supportive care. In parallel, I want to confirm whether the patient meets criteria for opioid use disorder and is ready and eligible to begin treatment now; if so, I would want an initial buprenorphine plan that matches current discomfort and the interval since the last opioid. If the patient is not ready or not a good candidate, we will need an analgesic strategy that avoids triggering more toxicity.\n\nBecause the patient is intubated and cannot report pain, I would like to use a validated nonverbal pain scale for ventilated patients instead of guessing. If the score stays low, great - keep analgesia minimal. If it rises, we should escalate carefully, aiming to spare opioids as much as possible.\n\nIf the surgical site and overall status make a regional block or local infiltration reasonable, I would prefer that approach and dose the local anesthetic safely based on weight, maximum allowable limits, and whether epinephrine is used. If a block is not appropriate or is contraindicated, then we will need to rely on systemic options.\n\nIf some opioid is still needed - either briefly while starting buprenorphine or because we decided not to start it - please convert any home or current opioids to the agent and route we plan to use so we are working from true equianalgesic dosing. Let's set the target dose range in light of the nonverbal pain scores and whether a regional technique was used.\n\nFrom there, I want to know the total daily morphine equivalent for whatever regimen we are proposing. If the total looks high, let's dial it back, emphasize non-opioid strategies (including the regional block if used), and re-check the total until it is in a safer range. If it is reasonable, we can proceed.\n\nBefore discharge or ongoing prescribing, I want a quick, validated screen for risk of opioid-related aberrant use. If the patient is categorized as moderate or high risk, we should avoid or minimize any outpatient opioid prescription, rely on buprenorphine and non-opioid strategies, and set up close follow-up. If risk looks low, a very limited supply may be acceptable with clear safety instructions.\n\nWhat is your take on sequencing and decision-making here? I really need proper calculations on this - I cannot make this decision based on gut feeling alone. Whatever approach you suggest, make sure it is backed by solid calculations. This needs to hold up to scrutiny.", "required_calculators": ["Naloxone Drip Dosing", "COWS Score for Opiate Withdrawal", "Emergency Department-Initiated Buprenorphine for Opioid Use Disorder (EMBED)", "Critical Care Pain Observation Tool (CPOT)", "Local Anesthetic Dosing Calculator", "Opiate Conversion Calculator", "Morphine Milligram Equivalents (MME) Calculator", "Revised Opioid Risk Tool (ORT-OUD)"], "calculator_answers": [{"order": 1, "name": "Naloxone Drip Dosing", "inputs": [{"field": "Bolus dose", "value": "0.4 mg IV"}], "final_answer": 0.3, "notes": "0.3 mg/hr\nContinuous IV infusion starting rate\n0.2 mg\nMay give ½ bolus dose 15 mins after starting drip"}, {"order": 2, "name": "COWS Score for Opiate Withdrawal", "inputs": [{"field": "Resting Pulse Rate (BPM)", "value": "101-120 (measured 108 bpm)", "score": 2}, {"field": "Sweating", "value": "Flushed or observable moistness on face (+2)", "score": 2}, {"field": "Restlessness observation during assessment", "value": "Frequent shifting or extraneous movements of legs/arms (+3)", "score": 3}, {"field": "Pupil size", "value": "Pupils possibly larger than normal for room light (+1)", "score": 1}, {"field": "Bone or joint aches", "value": "Not present (0)", "score": 0}, {"field": "Runny nose or tearing", "value": "Nasal stuffiness or unusually moist eyes (+1)", "score": 1}, {"field": "GI Upset", "value": "Stomach cramps (+1)", "score": 1}, {"field": "Tremor observation of outstretched hands", "value": "Slight tremor observable (+2)", "score": 2}, {"field": "Yawning observation during assessment", "value": "No yawning (0)", "score": 0}, {"field": "Anxiety or irritability", "value": "Patient obviously irritable/anxious (+2)", "score": 2}, {"field": "Gooseflesh skin", "value": "Piloerection of skin can be felt or hairs standing up on arms (+3)", "score": 3}], "final_answer": 17, "notes": "17 points\nModerate withdrawal."}, {"order": 3, "name": "Emergency Department-Initiated Buprenorphine for Opioid Use Disorder (EMBED)", "inputs": [{"field": "OUD Present", "value": "Yes"}, {"field": "How ready is the patient to start treatment with Buprenorphine today?", "value": "Ready to start today"}, {"field": "Assessed COWS Score", "value": "17"}, {"field": "Withdraw Severity", "value": ">12 (Moderate to Severe)"}, {"field": "Is the patient pregnant?", "value": "No"}, {"field": "Do you have a waiver to prescribe Buprenorphine?", "value": "Yes"}], "final_answer": "Advice: Start 8mg BUP", "notes": "I have used the MDCalc-EMBED Buprenorphine Initiation decision support calculator to assess this patient for opioid use disorder, opioid withdrawal, and readiness for treatment. Using this calculator, I determined that this patient has:\n(1) Opioid use disorder.\n(2) A clinical opioid withdrawal scale of greater than 12.\n(3) Has expressed readiness to begin treatment with buprenorphine.\nThe patient will receive:\n(1) Buprenorphine 8 mg in the ED today and then be observed for at least 30 minutes to ensure no side effects to the medication.\n(2) A prescription for buprenorphine 16mg sublingual daily for 3 days and for naloxone nasal spray.\n(3) Referral to treatment.\n(4) Education on opioid use disorder, naloxone use, this study and instructions to return to the emergency department in 24 hours for their next dose of buprenorphine if they are unable to schedule an appointment with a buprenorphine prescriber tomorrow."}, {"order": 4, "name": "Critical Care Pain Observation Tool (CPOT)", "inputs": [{"field": "Intubated?", "value": "Yes"}, {"field": "Compliance with ventilator", "value": "Tolerating ventilator or movement", "score": 0}, {"field": "Facial expression", "value": "Tense (+1)", "score": 1}, {"field": "Body movements", "value": "Restlessness (+2)", "score": 2}, {"field": "Muscle tension", "value": "Very tense or rigid (+2)", "score": 2}], "final_answer": 5, "notes": "Unacceptable amount of pain. Consider further sedation or other analgesia."}, {"order": 5, "name": "Local Anesthetic Dosing Calculator", "inputs": [{"field": "Drug", "value": "Ropivacaine"}, {"field": "Weight", "value": "154 lb (70 kg)"}, {"field": "Concentration", "value": "0.5%"}], "final_answer": 42.0, "notes": "42.0 mL\nMax allowable subQ dose of 0.5% ropivacaine (without epi) in a 70-kg patient (210.0 mg ropivacaine)"}, {"order": 6, "name": "Opiate Conversion Calculator", "inputs": [{"field": "Converting from", "value": "HYDROmorphone (parenteral)"}, {"field": "Total daily drug dosage (mg)", "value": "2 mg"}, {"field": "Converting to", "value": "OxyCODONE (oral)"}], "final_answer": 20, "notes": "20 mg\nApproximate Oxycodone (oral) equivalence to: 2mg of Hydromorphone (parenteral)"}, {"order": 7, "name": "Morphine Milligram Equivalents (MME) Calculator", "inputs": [{"field": "Drug", "value": "Oxycodone (oral)"}, {"field": "Dosage (mg/dose)", "value": "5 mg"}, {"field": "Doses per day (doses/day)", "value": "4"}, {"field": "Add another drug", "value": "No"}], "final_answer": 30.0, "notes": "30.0\nMME/day\n2x higher risk of overdose than <20 MME/day; there is no completely safe opioid dose; use caution when prescribing opioids at any dose and always prescribe the lowest effective dose\nDrug(s):\n20.0 mg oxycodone"}, {"order": 8, "name": "Revised Opioid Risk Tool (ORT-OUD)", "inputs": [{"field": "Age 16-45", "value": "Yes (+1)", "score": 1}, {"field": "History of depression", "value": "Yes (+1)", "score": 1}, {"field": "History of ADD, OCD, bipolar disorder, or schizophrenia", "value": "No (0)", "score": 0}, {"field": "Personal history of alcohol abuse", "value": "No (0)", "score": 0}, {"field": "Personal history of illegal drug abuse", "value": "Yes (+1)", "score": 1}, {"field": "Personal history of prescription drug abuse", "value": "No (0)", "score": 0}, {"field": "Family history of alcohol abuse", "value": "Yes (+1)", "score": 1}, {"field": "Family history of illegal drug abuse", "value": "No (0)", "score": 0}, {"field": "Family history of prescription drug abuse", "value": "No (0)", "score": 0}], "final_answer": 4, "notes": "High risk\nRisk of opioid use disorder"}]}
{"task_id": "medmcp-calc_056_5d1c756e", "task_scenario": "Valvular Disease and Echocardiographic Parameters", "task_category": "Clinical Medicine / Medicine & Organ Systems / Cardiovascular Medicine", "patient_id": "P056_5d1c756e", "task_description": "Scenario: A hospitalized patient with suspected left-sided infective endocarditis (IE) develops a new diastolic murmur, acute heart failure symptoms, and echocardiographic signs consistent with aortic valve involvement. The clinical team must confirm IE, quantify the severity of resultant aortic regurgitation (AR), assess hemodynamic compromise using echocardiographic parameters, and determine the timing and risk of surgical intervention. Workflow steps: 1) Use the VIRSTA Score to triage the urgency for comprehensive echocardiographic evaluation (including TTE/TEE). If high risk, proceed immediately; if low risk, schedule expeditiously but after initial stabilization. 2) Apply the 2023 Duke-International Society for Cardiovascular Infectious Diseases (ISCVID) Criteria to classify IE (definite, possible, or rejected). If definite (or possible with high suspicion), proceed to valvular damage quantification; if rejected, pursue alternative diagnoses and halt the IE-focused workflow. 3) Use Hemodynamics (Echo) to compute core flow parameters (e.g., LV stroke volume and forward flow) that will feed subsequent valvular quantification. 4) Use AR: Quantification (Volumetric) to calculate regurgitant volume and regurgitant fraction. This step requires stroke volume derived in step 3; the volumetric results provide a severity grade that will trigger downstream decisions. 5) Use AR: Regurgitant Orifice (PISA) to estimate the effective regurgitant orifice area (EROA) as a complementary method to confirm AR severity. If EROA and regurgitant fraction indicate severe AR, advance to hemodynamic compromise assessment and surgical planning; if non-severe, continue medical therapy with close monitoring. 6) Use Cardiac Output (Fick’s Formula) to quantify cardiac output and index, capturing systemic flow under current physiological stress and antibiotic therapy. 7) Use Cardiac Power Output (CPO), with cardiac output from step 6 as input, to determine the presence of cardiogenic shock or severe cardiac power reduction. If CPO is below critical thresholds, prioritize urgent surgical intervention; if adequate, consider semi-urgent or elective timing. 8) Use RV Systolic Pressure (TR Jet) to estimate pulmonary pressures and evaluate secondary pulmonary hypertension due to volume overload. If markedly elevated, escalate urgency and optimize preoperative management; if normal/mild, proceed per standard planning. 9) Use PCWP (Echo) to estimate left-sided filling pressures, informing the degree of pulmonary congestion and perioperative risk. Elevation supports expedited surgery and aggressive diuresis/afterload reduction. 10) Use the RiskE Score for Cardiac Surgery in Active Infective Endocarditis to estimate perioperative mortality specific to IE. If risk is acceptable in the context of severe AR and hemodynamic compromise, proceed to valve surgery; if prohibitive, consider temporizing strategies (inotropes, vasodilators, advanced support) while reassessing infectious control and hemodynamics.", "fuzzy_question": "I'm looking for help thinking through a patient with suspected left-sided endocarditis who has developed a new early diastolic murmur, acute shortness of breath with pulmonary edema, and initial imaging suggesting aortic valve involvement. I want to determine how urgently to obtain comprehensive imaging and confirm that this is endocarditis versus another process, then quantify the severity of aortic regurgitation and the current hemodynamics, because that will guide whether to proceed directly to surgery or pursue stabilization with close monitoring.\n\nFirst, I want to gauge how aggressively to pursue TTE plus TEE. Considering the bacteremia pattern, likely source, comorbidities, clinical stability, and any stigmata (embolic or immunologic features), can we place the patient into a higher- versus lower-risk category for endocarditis to decide whether to obtain TEE immediately or stabilize first and perform it soon after?\n\nNext, I would like a formal classification using contemporary endocarditis criteria—integrating blood culture results, imaging signs of vegetation/abscess/new valve regurgitation, and clinical features—to label this as definite, possible, or unlikely. If it does not meet criteria, we should pivot away from an endocarditis-focused plan. If it is definite (or possible with high suspicion), then proceed to quantifying valve damage and current physiology.\n\nOn the echo side, I need quantitative hemodynamics rather than only a qualitative interpretation. Specifically, I want the forward stroke volume across the outflow tract and the total left ventricular stroke volume to determine net forward flow under the current loading conditions. Using those, please provide the regurgitant volume and regurgitant fraction for the aortic valve with a clear severity grade. For an independent check of severity, also use the proximal flow convergence method to estimate the effective regurgitant orifice area. If both the orifice estimate and the regurgitant fraction indicate severe aortic regurgitation, we should proceed to assessing hemodynamic compromise and mapping surgical timing; if not severe, favor continued medical therapy, close monitoring, and reassessment.\n\nIn parallel, I want to understand systemic flow under current stress and treatment. Please quantify the cardiac output and cardiac index based on oxygen content differences and saturations to assess actual peripheral delivery. Then translate that into cardiac power by combining pressure and flow to determine whether the patient is approaching a shock range that would favor urgent surgery versus having enough reserve for semi-urgent or elective timing.\n\nGiven the volume load on the left side, I also want to know what the pulmonary circulation is experiencing. From the tricuspid regurgitant signal, estimate pulmonary pressures to assess for secondary pulmonary hypertension; if markedly elevated, that raises urgency and affects preoperative management. Alongside that, provide an echo-based estimate of left-sided filling pressures (using standard surrogates) to quantify pulmonary congestion and guide diuresis/afterload reduction; if elevated, that supports expediting surgery.\n\nFinally, I need a risk estimate tailored to valve surgery in the setting of active endocarditis to understand perioperative mortality. If the operative risk is acceptable in the context of severe regurgitation and the hemodynamic picture, plan for valve surgery; if prohibitive, consider temporizing with inotropes, vasodilators, or advanced support while consolidating infection control and reassessing.\n\nWhat is your approach to structuring this? I need the underlying numbers for each component—forward flow, regurgitant volume/fraction, orifice area, output/index, power, pulmonary pressures, and filling pressures—so we are not making a high-stakes decision based solely on clinical impression.", "required_calculators": ["VIRSTA Score", "2023 Duke-International Society for Cardiovascular Infectious Diseases (ISCVID) Criteria", "Hemodynamics (Echo)", "AR: Quantification (Volumetric)", "AR: Regurgitant Orifice (PISA)", "Cardiac Output (Fick’s Formula)", "Cardiac Power Output (CPO)", "RV Systolic Pressure (TR Jet)", "PCWP (Echo)", "RiskE Score for Cardiac Surgery in Active Infective Endocarditis"], "calculator_answers": [{"order": 1, "name": "VIRSTA Score", "inputs": [{"field": "Cerebral or peripheral emboli", "value": "Yes (CT abdomen: splenic infarct)", "score": 5}, {"field": "Meningitis", "value": "No", "score": 0}, {"field": "Permanent intracardiac device or previous IE", "value": "No", "score": 0}, {"field": "Pre-existing native valve disease", "value": "Yes (bicuspid aortic valve, previously mild AS/AR)", "score": 3}, {"field": "Intravenous drug use", "value": "No", "score": 0}, {"field": "Persistent bacteremia", "value": "Yes (≥2 positive sets over 24 hours)", "score": 3}, {"field": "Vertebral osteomyelitis", "value": "No", "score": 0}, {"field": "Community or non-nosocomial health care associated acquisition", "value": "Yes (community-onset MSSA bacteremia)", "score": 2}, {"field": "Severe sepsis or shock", "value": "No", "score": 0}, {"field": "C-reactive protein >190 mg/L", "value": "Yes (CRP 210 mg/L)", "score": 1}], "final_answer": 14, "notes": "14 points\nVIRSTA Score\nHigh risk\nRisk of IE\nPhysicians are strongly encouraged to perform urgent echocardiography."}, {"order": 2, "name": "2023 Duke-International Society for Cardiovascular Infectious Diseases (ISCVID) Criteria", "inputs": [{"field": "Typical microorganisms from 2 or more separate blood culture sets", "value": "Yes (MSSA in 2/2 sets drawn 12 hours apart; persistent positives)"}, {"field": "Nontypical microorganisms from 3 or more separate blood culture sets", "value": "No"}, {"field": "Positive PCR for Coxiella/Bartonella/Whipple from blood", "value": "No"}, {"field": "Coxiella burnetii antiphase I IgG >1:800 or isolated from single blood culture", "value": "No"}, {"field": "Bartonella IFA IgG ≥1:800", "value": "No"}, {"field": "Echocardiography/cardiac CT showing vegetation/perforation/abscess/pseudoaneurysm/fistula", "value": "Yes (TEE: 1.0×0.8 cm vegetation on non-coronary cusp with leaflet perforation; small aortic root abscess)"}, {"field": "Significant new valvular regurgitation on echocardiography", "value": "Yes (new severe AR vs prior mild AR)"}, {"field": "New partial dehiscence of prosthetic valve", "value": "No (native valve)"}, {"field": "FDG-PET/CT abnormal metabolic activity involving valve/prosthesis", "value": "Not performed"}, {"field": "Fever >38.0°C (100.4°F)", "value": "Yes (38.5°C)"}, {"field": "Vascular phenomena", "value": "Yes (splenic infarct; Janeway lesions on soles)"}, {"field": "Injection drug use", "value": "No"}, {"field": "Congenital heart disease", "value": "Yes (bicuspid aortic valve)"}], "final_answer": "Definite endocarditis", "notes": "Diagnostic Result\nDefinite endocarditis\nMeets clinical Duke-ISCVID criteria"}, {"order": 3, "name": "Hemodynamics (Echo)", "inputs": [{"field": "LVOT Diameter", "value": "21 mm"}, {"field": "LVOT Subvalvular Velocity Time Integral", "value": "12 cm"}, {"field": "Heart Rate", "value": "110 beats/min"}, {"field": "Weight", "value": "85 kg"}, {"field": "Height", "value": "178 cm"}], "final_answer": "4.6 L/min", "notes": "Cardiac Output\n4.6 L/min\nCardiac Index\n2.23 L/min/m²\nStroke Volume\n42 mL/beat\nStroke Volume Index\n20 mL/beat/m²"}, {"order": 4, "name": "AR: Quantification (Volumetric)", "inputs": [{"field": "LV Outflow Tract Diameter", "value": "2.1 cm"}, {"field": "Maximal LV Outflow Tract VTI", "value": "12 cm"}, {"field": "MV Annulus Diameter", "value": "2.7 cm"}, {"field": "Maximal MV VTI", "value": "22 cm"}], "final_answer": "84 cm³", "notes": "Regurgitant Volume\n84 cm³\nRegurgitant Fraction\n67\nGradation of Severity of AR\n(ACC/AHA 2006)\nMild\nQualitative\n1+, Jet width <25% LV outflow tract, Doppler vena contracta width (<0.3 cm)\nQuantitative\nRegurgitant volume (<30 ml/beat), fraction (<30%), orifice area (<0.1 cm²)\nModerate\nQualitative\nJet width 25-64% LVOT, Doppler vena contracta width (0.3-0.6 cm)\nQuantitative\nRegurgitant volume (30-59 ml/beat), fraction (30-59%), orifice (0.1-0.3 cm²)\nSevere\nQualitative\n3+-4+, Jet width >65% LVOT, Doppler vena contracta width (>0.6 cm)\nQuantitative\nRegurgitant volume (>60 ml/beat), fraction (>50%), orifice (>0.3 cm²)"}, {"order": 5, "name": "AR: Regurgitant Orifice (PISA)", "inputs": [{"field": "Proximal Isovelocity Hemispheric Radius from the Orifice", "value": "0.9 cm"}, {"field": "Aliasing Velocity at Radial Distance r", "value": "40 cm/s"}, {"field": "Peak AR Velocity by CW Doppler", "value": "450 cm/s"}], "final_answer": "0.45 cm²", "notes": "Regurgitant Orifice\n0.45 cm²\nGradation of Severity of AR\n(ACC/AHA 2006)\nMild\nQualitative\n1+, Jet width <25% LV outflow tract, Doppler vena contracta width (<0.3 cm)\nQuantitative\nRegurgitant volume (<30 ml/beat), fraction (<30%), orifice area (<0.1 cm²)\nModerate\nQualitative\nJet width 25-64% LVOT, Doppler vena contracta width (0.3-0.6 cm)\nQuantitative\nRegurgitant volume (30-59 ml/beat), fraction (30-59%), orifice (0.1-0.3 cm²)\nSevere\nQualitative\n3+-4+, Jet width >65% LVOT, Doppler vena contracta width (>0.6 cm)\nQuantitative\nRegurgitant volume (>60 ml/beat), fraction (>50%), orifice (>0.3 cm²)"}, {"order": 6, "name": "Cardiac Output (Fick’s Formula)", "inputs": [{"field": "Weight", "value": "187 lb"}, {"field": "Height", "value": "70 in"}, {"field": "SaO₂ (ABG)", "value": "95 %"}, {"field": "SvO₂ (PA catheter)", "value": "55 %"}, {"field": "Hemoglobin", "value": "10.2 g/dL"}, {"field": "Heart rate", "value": "110 beats/min"}, {"field": "Age", "value": "<70 years"}], "final_answer": 4.7, "notes": "4.7 L/min\nCardiac output\n2.3 L/min/m²\nCardiac index\n43 mL/beat\nStroke volume"}, {"order": 7, "name": "Cardiac Power Output (CPO)", "inputs": [{"field": "Mean arterial pressure", "value": "68 mm Hg"}, {"field": "Cardiac output", "value": "4.6 L/min"}], "final_answer": 0.69, "notes": "0.69 W\nCardiac power output"}, {"order": 8, "name": "RV Systolic Pressure (TR Jet)", "inputs": [{"field": "TR Max Jet Velocity", "value": "3.5 m/s"}, {"field": "Right Atrial Pressure", "value": "IVC diameter 1.5-2.5 cm > 50% decrease in IVC diameter with respiration"}], "final_answer": 59, "notes": "RV Systolic Pressure\n59"}, {"order": 9, "name": "PCWP (Echo)", "inputs": [{"field": "Mitral Inflow E Velocity", "value": "120 cm/s"}, {"field": "Early Diastolic Lateral Mitral Annulus Velocity (E')", "value": "6 cm/s"}], "final_answer": 26.7, "notes": "PCWP\n26.7"}, {"order": 10, "name": "RiskE Score for Cardiac Surgery in Active Infective Endocarditis", "inputs": [{"field": "Age, years", "value": "58", "score": 9}, {"field": "Prosthetic endocarditis", "value": "No", "score": 0}, {"field": "Virulent microorganism (Staphylococcus aureus or fungi)", "value": "Yes (MSSA)", "score": 9}, {"field": "Septic shock", "value": "No", "score": 0}, {"field": "Thrombocytopenia (<150,000/mm³)", "value": "Yes (platelets 110,000/mm³)", "score": 7}, {"field": "Acute renal insufficiency", "value": "Yes (creatinine 2.1 mg/dL)", "score": 5}, {"field": "Cardiogenic shock", "value": "No", "score": 0}, {"field": "Periannular complications (abscess/pseudoaneurysm/fistula/prosthetic dehiscence)", "value": "Yes (aortic root abscess on TEE)", "score": 5}], "final_answer": 35, "notes": "35 points\nRiskE Score\n54.39 %\nPredicted in-hospital postop mortality"}]}
{"task_id": "medmcp-calc_057_7576dd51", "task_scenario": "Pediatric Drug Dosing Calculations", "task_category": "Clinical Medicine / Special Populations & General Tools / Pediatrics & Neonatology", "patient_id": "P057_7576dd51", "task_description": "Scenario: A pediatric patient presents after ingestion of an acetaminophen-containing product with possible opioid co-ingestion. The care team must determine appropriate antidote dosing and supportive medications while accounting for age-related pharmacokinetics and weight selection to minimize dosing errors.\n\nWorkflow steps:\n1) Gestational Age: Start by determining whether the patient is a neonate/preterm or an older pediatric patient. This distinction guides dosing strategies and intervals.\n   - If gestational age identifies a neonate/preterm, proceed using actual body weight for all subsequent dosing steps because neonatal dosing is not based on ideal body weight.\n   - If gestational age identifies an older pediatric patient, continue to the next step to determine dosing weight.\n2) Ideal Body Weight: For older pediatric patients where body habitus raises concern about under- or overdosing, calculate ideal body weight (IBW). Use IBW as the dosing weight when clinically appropriate for weight-based medications to avoid dose miscalculations.\n3) Acetaminophen Overdose and NAC Dosing: Use the nomogram within the calculator to determine whether the treatment threshold is met based on time since ingestion. If treatment is indicated, generate the NAC regimen (loading and maintenance), selecting dosing weight according to the prior step (actual weight in neonates; IBW or actual weight in older children, per clinical judgment).\n   - If the nomogram indicates no treatment is required, do not start NAC; proceed with observation and supportive care.\n   - If treatment is required, initiate NAC using the calculated regimen and dosing weight from Step 2 (or actual weight in neonates from Step 1).\n4) Naloxone Drip Dosing: Assess for clinical signs of opioid toxicity (e.g., persistent respiratory depression) that warrant ongoing reversal after initial bolus.\n   - If sustained toxicity is present, use this calculator to set the infusion, referencing the same dosing weight approach determined earlier (actual weight in neonates; IBW or actual weight in older children).\n   - If opioid toxicity is not present or resolves without infusion, do not start a naloxone drip.\n5) Weight-based liquid medication dosing: Plan supportive medications (e.g., agents to manage adverse effects associated with antidotes or symptomatic care) using weight-based dosing. Apply the dosing weight chosen in Steps 1–2 (actual weight for neonates; IBW or actual weight for older children) to maintain consistency and avoid dose errors across all medications.\n\nRationale for sequence: Gestational age first ensures a neonatal vs older pediatric pathway. IBW then establishes a safe dosing weight for older children when indicated. NAC dosing depends on the treatment decision triggered by the nomogram and uses the selected dosing weight. Naloxone dosing is conditionally added if opioid toxicity persists, and it uses the same weight approach. Supportive medications are calculated last and consistently apply the established dosing weight to reduce variability.", "fuzzy_question": "I’m evaluating a pediatric case involving possible ingestion of an acetaminophen-containing product with potential opioid co-exposure. I need to determine appropriate antidotes and supportive care without dosing errors, accounting for developmental differences and weight-based dosing.\n\nFirst, I need to clarify whether the patient falls into a neonatal/preterm versus older pediatric category, since this affects dosing and intervals. For neonatal/preterm patients, I would use actual body weight for all therapies. For older pediatric patients with atypical body habitus, I’m considering whether ideal or adjusted weight would be safer than actual weight. I want a clear recommendation on which weight basis to use and to apply it consistently across all therapies.\n\nFor the acetaminophen exposure, I need to decide whether treatment is indicated based on the concentration at the stated post-ingestion time. If treatment is indicated, I’d like a complete N‑acetylcysteine plan (loading and maintenance) using the selected weight approach. If it is not indicated, I’d prefer observation and supportive care rather than empiric treatment.\n\nOn the opioid side, if after initial reversal there is ongoing clinically meaningful respiratory depression or sedation, I’m inclined to use a continuous infusion to maintain effect, aligned with the same weight decision. If the patient improves and remains stable after boluses, a continuous infusion may not be necessary.\n\nWe also need to outline supportive medications—such as antiemetics if N‑acetylcysteine causes nausea and agents to manage infusion reactions—dosed by weight and aligned with the same weight choice to avoid inconsistency across orders.\n\nWhat is the best framework to reason through this? I need evidence-based, calculation-supported recommendations that can withstand scrutiny.", "required_calculators": ["Gestational Age", "Ideal Body Weight", "Acetaminophen Overdose and NAC Dosing", "Naloxone Drip Dosing", "Weight-based liquid medication dosing"], "calculator_answers": [{"order": 1, "name": "Gestational Age", "inputs": [{"field": "Current Date?", "value": "2015-08-15"}, {"field": "Due Date?", "value": "2015-09-12"}], "final_answer": "36 Weeks 0 Days", "notes": "End of 1st Trimester\nFebruary 28, 2015\nCurrent Gestational Age\n36 Weeks 0 Days"}, {"order": 2, "name": "Ideal Body Weight", "inputs": [{"field": "Gender?", "value": "Female"}, {"field": "Height?", "value": "142 cm"}], "final_answer": 36.1, "notes": "36.1 kg\nIdeal Body Weight\nEquivalent to 79.5 lbs\nFor people <60 inches (152.4 cm), a modification is needed (see Evidence for more details)"}, {"order": 3, "name": "Acetaminophen Overdose and NAC Dosing", "inputs": [{"field": "Route of N-Acetylcysteine (NAC)", "value": "IV"}, {"field": "Weight", "value": "92.6 lbs (IBW 42.0 kg)"}], "final_answer": "IV Dosing: 21-Hour Regimen, ‘3 Bag Dosing‘", "notes": "IV Dosing: 21-Hour Regimen, ‘3 Bag Dosing‘\nLoading Dose of: 6300 mg IV in 200 mL of diluent over 60 min, then\n2100 mg IV in 500 mL of diluent over 4 hr then\n4200 mg IV in 1000 mL of diluent over 16 hr."}, {"order": 4, "name": "Naloxone Drip Dosing", "inputs": [{"field": "Bolus dose", "value": "0.8 mg (effective wake-up dose)"}], "final_answer": "0.5 mg/hr", "notes": "Diagnostic Result\n0.5 mg/hr\nContinuous IV infusion starting rate\n0.4 mg\nMay give ½ bolus dose 15 mins after starting drip"}, {"order": 5, "name": "Weight-based liquid medication dosing", "inputs": [{"field": "Patient Weight?", "value": "42.0 kg (IBW dosing weight)"}, {"field": "Dosage (per day)?", "value": "0.45 mg/kg/day"}, {"field": "Frequency of dose? Once/Every", "value": "Every 8 hours"}, {"field": "Liquid Formulation - Medication amount:", "value": "4 mg"}, {"field": "Liquid Formulation - Per volume:", "value": "5 mL"}], "final_answer": "6.3 mg", "notes": "Calculated amount per single dose\n6.3 mg\nTotal daily dosage\n18.9 mg\nLiquid volume per single dose\n7.88 mL"}]}
{"task_id": "medmcp-calc_058_3048b8db", "task_scenario": "Mass Casualty Triage", "task_category": "Clinical Medicine / Emergency, Critical Care & Perioperative / Emergency Medicine & Trauma", "patient_id": "P058_3048b8db", "task_description": "Scenario: A mass casualty incident floods a triage area with victims across age groups, limited OR/ICU capacity, and constrained blood products. The trauma team must rapidly and consistently prioritize who receives immediate life-saving interventions, urgent operative care, or delayed/expectant management. The following stepwise calculator workflow supports fast physiologic sorting, pediatric-specific assessment, anatomic severity grading, and survival estimation to guide scarce resource allocation.\n\nStep 1 – Neurologic status: Use the Glasgow Coma Scale (GCS) to rapidly quantify mental status. Preserve this score specifically for later use in the Revised Trauma Score and pediatric risk tools.\n\nStep 2 – Circulatory risk: Calculate the Shock Index to screen for occult shock/hemorrhage and to triage urgency of resuscitation.\n\nDecision A (Shock Index): If critically elevated, escalate to immediate hemorrhage control/resuscitation and defer nonessential calculations until after initial stabilization; otherwise proceed directly to the next step.\n\nStep 3 – Global physiologic severity: Compute the Revised Trauma Score using the GCS from Step 1 and current physiologic findings to refine triage priority and anticipate need for urgent interventions.\n\nDecision B (Pediatric branch): For pediatric victims, calculate the Pediatric Trauma Score (PTS) to capture pediatric-specific injury severity nuances not reflected by adult-focused tools. If PTS suggests moderate-to-severe injury or if there is depressed GCS, then calculate the Pediatric Trauma BIG Score to estimate mortality risk and determine whether immediate transfer to the highest level of care is prioritized; otherwise continue with standard flow.\n\nStep 4 – Anatomic injury severity: After primary stabilization and rapid secondary survey, assign an Injury Severity Score (ISS) to quantify anatomic burden of injury across body regions.\n\nStep 5 – Survival estimation for resource allocation: Combine the physiologic severity (Revised Trauma Score) and anatomic severity (ISS) to compute the Trauma Score and Injury Severity Score (TRISS) for estimated probability of survival.\n\nDecision C (Allocation based on TRISS): If TRISS suggests high survivability with timely intervention, assign to immediate definitive management; if TRISS indicates extremely low probability of survival despite maximal resources, consider expectant management while maintaining comfort until resources free up; otherwise prioritize monitored stabilization and re-triage.\n\nRationale for sequence: The workflow progresses from fast, universally applicable physiologic checks (GCS, Shock Index), to a composite physiologic score (Revised Trauma Score), then branches to pediatric-specific risk stratification (PTS, Pediatric Trauma BIG Score), and finally incorporates anatomic severity (ISS) to enable survival prediction (TRISS) that informs ethically consistent resource allocation in a mass casualty context.", "fuzzy_question": "I’m working a triage bay during a mass-casualty surge—diverse ages, limited OR and ICU capacity, and constrained blood products. I’m trying to sort people quickly and consistently into who needs immediate life-saving care, who gets the next operative slot, and who can safely wait.\n\nOn arrival, I want to objectively quantify mental status with a standard bedside neurological assessment and document the score for later use when we assemble the broader physiologic picture. In parallel, I want a rapid read on perfusion risk by evaluating heart rate in relation to systolic pressure; if the pattern is concerning for occult hemorrhage, we should move directly to bleeding control and resuscitation and set aside non-essentials until the danger has passed. If not, we keep moving.\n\nFrom there, I’d like an integrated snapshot of physiology that blends the neurological score with breathing and perfusion to refine priority and anticipate who needs urgent interventions next. For pediatric patients, I do not want to miss age-specific nuances—let’s add a child-focused severity assessment that considers size, airway, circulation, and injury pattern. If that suggests more than a mild injury or the neurological score is depressed, I’d want a rapid pediatric mortality risk estimate that incorporates early labs (acid-base status and coagulation) alongside neurological status to decide whether to escalate to the highest level of care or prioritize immediate transfer.\n\nAfter initial stabilization and a quick head-to-toe, let’s tally injuries by body region to reflect the anatomic burden. Then combine that tally with the physiologic snapshot to generate a survival estimate we can actually use to allocate scarce OR time, ICU beds, and blood products. If the estimate suggests a high chance of survival with timely action, proceed to definitive management now. If it points to a very low chance even with maximal resources, focus on comfort while continuing reassessment as resources free up. Everyone else should receive monitored stabilization with planned re-triage.\n\nWhat’s your take on approaching the surge this way? I need proper calculations to support this—this cannot be based on gut feeling alone. Whatever approach you suggest should be backed by solid, defensible calculations that can withstand scrutiny.", "required_calculators": ["Glasgow Coma Scale (GCS)", "Shock Index", "Revised Trauma Score", "Pediatric Trauma Score (PTS)", "Pediatric Trauma BIG Score", "Injury Severity Score (ISS)", "Trauma Score and Injury Severity Score (TRISS)"], "calculator_answers": [{"order": 1, "name": "Glasgow Coma Scale (GCS)", "inputs": [{"field": "Best eye response", "value": "To verbal command (+3)", "score": 3}, {"field": "Best verbal response", "value": "Inappropriate words (+3)", "score": 3}, {"field": "Best motor response", "value": "Withdrawal from pain (+4)", "score": 4}], "final_answer": 10, "notes": "10 points\nGlasgow Coma Score\nE(3) V(3) M(4)\nGlasgow Coma Scale"}, {"order": 2, "name": "Shock Index", "inputs": [{"field": "Heart Rate/Pulse", "value": "106 beats/min"}, {"field": "Systolic BP", "value": "112 mm Hg"}], "final_answer": 0.9, "notes": "0.5-0.7 is believed to be a normal shock index. Higher numbers have been shown to be more sensitive than vital signs alone in diagnosing occult shock, need for transfusion and/or operation."}, {"order": 3, "name": "Revised Trauma Score", "inputs": [{"field": "Glasgow Coma Scale (GCS)", "value": "10 points"}, {"field": "Systolic BP", "value": "112 mm Hg"}, {"field": "Respiratory Rate", "value": "24 breaths/min"}], "final_answer": 7, "notes": "Some trauma protocols recommend patient treatment at a trauma center for a Revised Trauma Score <4, although other protocols use a higher number; the RTS correlates strongly with patient survival."}, {"order": 4, "name": "Pediatric Trauma Score (PTS)", "inputs": [{"field": "Weight", "value": ">20 kg (>44 lbs)", "score": 2}, {"field": "Airway status", "value": "Maintainable", "score": 1}, {"field": "Systolic BP", "value": ">90 mmHg (or pulse palpable at wrist)", "score": 2}, {"field": "Central nervous system", "value": "Obtunded/loss of consciousness", "score": 1}, {"field": "Skeletal injury", "value": "Open/multiple fractures", "score": -1}, {"field": "Cutaneous wounds", "value": "Major/penetrating", "score": -1}], "final_answer": 4, "notes": "Higher scores correlate with lower mortality (total scores range from -6 to 12 points); in the original and validation studies, no deaths were seen in patients with scores >8"}, {"order": 5, "name": "Pediatric Trauma BIG Score", "inputs": [{"field": "Base deficit", "value": "8 mEq/L"}, {"field": "INR", "value": "1.4"}, {"field": "GCS", "value": "10 points"}], "final_answer": 16.5, "notes": "16.50\nPediatric BIG Score\n12.9 %\nPredicted in-hospital mortality. Scores >16 were associated with the highest mortality."}, {"order": 6, "name": "Injury Severity Score (ISS)", "inputs": [{"field": "Head and neck worst injury", "value": "Moderate"}, {"field": "Face worst injury", "value": "Minor"}, {"field": "Chest worst injury", "value": "Serious"}, {"field": "Abdomen worst injury", "value": "Severe"}, {"field": "Extremity (including pelvis) worst injury", "value": "Serious"}, {"field": "External worst injury", "value": "Moderate"}], "final_answer": 34, "notes": "34 points\nOut of a possible 75 points"}, {"order": 7, "name": "Trauma Score and Injury Severity Score (TRISS)", "inputs": [{"field": "Trauma type", "value": "Blunt"}, {"field": "Revised Trauma Score (RTS)", "value": "6.904 points"}, {"field": "Injury Severity Score (ISS)", "value": "34 points"}, {"field": "Age, years", "value": "≤54"}], "final_answer": "93.9 %", "notes": "93.9 %\nProbability of survival"}]}
{"task_id": "medmcp-calc_059_f05a1a13", "task_scenario": "Early Sepsis Recognition", "task_category": "Clinical Medicine / Medicine & Organ Systems / Infectious Diseases", "patient_id": "P059_f05a1a13", "task_description": "Scenario: An adult presents to the emergency department with suspected infection and clinical instability. Early identification of sepsis and evolving organ dysfunction is essential before and after laboratory data become available. The clinician uses a structured series of calculators to rapidly triage, confirm sepsis, and gauge organ failure risk to guide escalation. Workflow: First, apply the National Early Warning Score (NEWS) 2 to gauge overall acute illness severity and trigger urgent review if high risk. Based on NEWS 2 and infection suspicion, calculate the qSOFA (Quick SOFA) Score for Sepsis to quickly identify patients at higher mortality risk outside the ICU. In parallel, compute the Shock Index to screen for occult hemodynamic compromise that may not be evident on routine vital signs. Decision branch: If NEWS 2 indicates high risk, or either qSOFA or Shock Index is elevated, immediately activate the sepsis pathway and proceed to formal criteria; otherwise, continue close monitoring but reassess frequently and move forward if the patient worsens. Next, use the SIRS, Sepsis, and Septic Shock Criteria to formally classify the patient’s condition based on combined clinical and laboratory parameters, confirming sepsis or septic shock when criteria are met. Following classification, interpret the Arterial Blood Gas (ABG) to assess oxygenation and acid–base status. The ABG interpretation directly informs the respiratory component of subsequent organ dysfunction scoring. When laboratory data are limited or delayed, calculate the Modified Sequential Organ Failure Assessment (mSOFA) Score to estimate organ dysfunction early using predominantly clinical variables (incorporating the ABG findings as relevant). Branch: If mSOFA suggests significant organ dysfunction, escalate care and proceed to full organ failure scoring as soon as labs are available; if mSOFA is lower risk, continue active surveillance while awaiting labs. Once laboratory data become available, calculate the Sequential Organ Failure Assessment (SOFA) Score to comprehensively quantify acute organ dysfunction (integrating ABG-derived respiratory status along with other laboratory and clinical data). If SOFA indicates moderate-to-severe organ failure, evaluate the risk of coagulopathy by calculating the Sepsis-Induced Coagulopathy (SIC) Score to identify patients at increased risk of sepsis-related coagulation abnormalities. This sequence ensures that results from earlier calculators deterministically trigger subsequent steps (e.g., elevated qSOFA/Shock Index prompting SIRS confirmation; ABG feeding into mSOFA and SOFA; high mSOFA prompting immediate full SOFA; elevated SOFA prompting SIC assessment), thereby enabling timely recognition and escalation.", "fuzzy_question": "I'm evaluating a patient in an acute care setting with suspected infection who appears unstable—fever, tachycardia, rapid breathing, low blood pressure, and altered mentation. I'm not certain whether this represents a severe infection or early sepsis with evolving organ involvement, and I want a rapid read on stability to decide whether to activate a sepsis pathway now versus close observation while additional data are gathered.\n\nMy first step is to assess global acuity from the current vital signs and mental status; if that snapshot looks high risk, I would seek urgent review and likely escalation. Given the infectious concern, I would also use a simple bedside triad—mental status, breathing rate, and blood pressure—to flag patients at higher risk outside the ICU. In parallel, I would watch for occult hemodynamic compromise by checking whether heart rate is disproportionately elevated relative to systolic pressure—the pulse-to-pressure relationship can reveal hidden shock even if the blood pressure has not fully declined. If any of these early screens raise concern, I would proceed directly into sepsis care and formal criteria; if they are reassuring, I would maintain close observation with frequent reassessment, ready to escalate at the first sign of deterioration.\n\nOnce that threshold is crossed, I want to determine where the patient sits on the spectrum: evidence of a systemic inflammatory response in the setting of infection, and whether this is progressing to more severe illness with persistent hypotension despite fluids and rising lactate. During this evaluation, I would obtain an arterial blood gas to clarify oxygenation and acid–base status—oxygenation relative to inspired oxygen, carbon dioxide, pH, bicarbonate, and whether there is a metabolic component—because this directly informs how I judge respiratory involvement in organ dysfunction.\n\nBecause laboratory studies can be delayed, while they are pending I still want an early read on organ dysfunction that leans heavily on clinical variables plus the blood gas. If that early estimate suggests meaningful organ involvement, I would escalate care now and be ready to move into a more complete assessment as soon as the labs return; if the early picture looks milder, I would continue active surveillance while the data mature. As soon as the labs are available, I want a comprehensive tally of acute organ dysfunction—lungs informed by the blood gas, kidneys from creatinine and urine output, liver from bilirubin, platelets for hematologic status, mentation for neurologic status, and cardiovascular status including any vasopressor needs—to judge severity. If that full assessment falls in the moderate-to-severe range, I would then specifically evaluate the risk of sepsis-associated coagulopathy—platelet trends and clotting times interpreted in the context of overall organ involvement—to avoid missing evolving coagulopathy.\n\nCan you walk me through this case in that sequence, making it clear how each step leads to the next, and show the quantitative reasoning at each decision point? I need proper calculations to support the decisions; this should hold up to scrutiny.", "required_calculators": ["National Early Warning Score (NEWS) 2", "qSOFA (Quick SOFA) Score for Sepsis", "Shock Index", "SIRS, Sepsis, and Septic Shock Criteria", "Arterial Blood Gas (ABG) Analyzer", "Modified Sequential Organ Failure Assessment (mSOFA) Score", "Sequential Organ Failure Assessment (SOFA) Score", "Sepsis-Induced Coagulopathy (SIC) Score"], "calculator_answers": [{"order": 1, "name": "National Early Warning Score (NEWS) 2", "inputs": [{"field": "Respiratory rate, breaths per minute", "value": "28 /min", "score": 3}, {"field": "Hypercapnic respiratory failure", "value": "No", "score": 0}, {"field": "SpO2", "value": "91%", "score": 3}, {"field": "Room air or supplemental O2", "value": "Supplemental O2 (nasal cannula 4 L/min; estimated FiO2 0.36)", "score": 2}, {"field": "Temperature", "value": "38.9 C", "score": 1}, {"field": "Systolic BP, mmHg", "value": "92 mmHg", "score": 2}, {"field": "Pulse, beats per minute", "value": "124 /min", "score": 2}, {"field": "Consciousness", "value": "New-onset confusion", "score": 3}], "final_answer": 16, "notes": "16 points\nNational Early Warning Score\nHigh risk\nEmergent assessment by a clinical team or critical care team and usually transfer to higher level of care\nContinuous monitoring\nFrequency of monitoring"}, {"order": 2, "name": "qSOFA (Quick SOFA) Score for Sepsis", "inputs": [{"field": "Altered mental status (GCS <15)", "value": "Yes (GCS 14)"}, {"field": "Respiratory rate ≥22", "value": "Yes (28 /min)"}, {"field": "Systolic BP ≤100", "value": "Yes (92 mmHg)"}], "final_answer": 3, "notes": "High risk\nqSOFA Scores 2-3 are associated with a 3- to 14-fold increase in in-hospital mortality. Assess for evidence of organ dysfunction with blood testing including serum lactate and calculation of the full SOFA Score.\nPatients meeting these qSOFA criteria should have infection considered even if it was previously not."}, {"order": 3, "name": "Shock Index", "inputs": [{"field": "Heart Rate/Pulse", "value": "124 /min"}, {"field": "Systolic BP", "value": "92 mmHg"}], "final_answer": 1.3, "notes": "1.3\n0.5-0.7 is believed to be a normal shock index. Higher numbers have been shown to be more sensitive than vital signs alone in diagnosing occult shock, need for transfusion and/or operation."}, {"order": 4, "name": "SIRS, Sepsis, and Septic Shock Criteria", "inputs": [{"field": "Temp >38 C or <36 C", "value": "Yes (38.9 C)"}, {"field": "Heart rate >90", "value": "Yes (124 /min)"}, {"field": "Respiratory rate >20 or PaCO2 <32 mmHg", "value": "Yes (RR 28 /min)"}, {"field": "WBC >12,000/mm3, <4,000/mm3, or >10% bands", "value": "Yes (WBC 15.8 x10^3/uL with 12% bands)"}, {"field": "Suspected or present source of infection", "value": "Yes (community-acquired pneumonia suspected; RLL infiltrate on CXR)"}, {"field": "Lactic acidosis, SBP <90 or SBP drop ≥40 mmHg of normal", "value": "Yes (lactate 4.2 mmol/L)"}, {"field": "Severe sepsis with hypotension, despite adequate fluid resuscitation", "value": "Yes (after ~2 L LR ~30 mL/kg, MAP remained 63 mmHg; started norepinephrine 0.08 mcg/kg/min)"}, {"field": "Evidence of ≥2 organs failing (MODS)", "value": "Yes (respiratory, cardiovascular, renal, hepatic, neuro)"}], "final_answer": "This patient meets multiple organ dysfunction syndrome. Follow your guidelines for sepsis, which typically include aggressive fluid resuscitation, early, broad-spectrum antibiotics, ICU consultation, CVP evaluation, and occasionally pressors and transfusion.", "notes": "This patient meets multiple organ dysfunction syndrome. Follow your guidelines for sepsis, which typically include aggressive fluid resuscitation, early, broad-spectrum antibiotics, ICU consultation, CVP evaluation, and occasionally pressors and transfusion."}, {"order": 5, "name": "Arterial Blood Gas (ABG) Analyzer", "inputs": [{"field": "pH", "value": "7.31"}, {"field": "PaCO2", "value": "33 mmHg"}, {"field": "HCO3-", "value": "16 mEq/L"}, {"field": "Sodium", "value": "140 mEq/L"}, {"field": "Chloride", "value": "104 mEq/L"}, {"field": "Albumin", "value": "3.0 g/dL"}, {"field": "If respiratory process present, chronicity", "value": "Acute"}], "final_answer": "This is an Anion Gap Metabolic Acidosis.\nPrimary Metabolic Acidosis, with: Appropriately Compensated by Respiratory Alkalosis and Additional Metabolic Alkalosis.", "notes": "This is an Anion Gap Metabolic Acidosis.\nPrimary Metabolic Acidosis, with: Appropriately Compensated by Respiratory Alkalosis and Additional Metabolic Alkalosis."}, {"order": 6, "name": "Modified Sequential Organ Failure Assessment (mSOFA) Score", "inputs": [{"field": "Respiratory (SpO2/FiO2)", "value": "253 (SpO2 91% on FiO2 0.36)", "score": 2}, {"field": "Liver (scleral icterus or jaundice present)", "value": "Yes", "score": 3}, {"field": "Cardiovascular (hypotension/vasopressors)", "value": "Norepinephrine 0.08 mcg/kg/min (MAP 63 mmHg prior to pressor)", "score": 3}, {"field": "CNS (GCS)", "value": "14", "score": 1}, {"field": "Renal (Creatinine)", "value": "2.1 mg/dL", "score": 2}], "final_answer": 11, "notes": "11 points\nmSOFA Score\n31 %\n30-day mortality"}, {"order": 7, "name": "Sequential Organ Failure Assessment (SOFA) Score", "inputs": [{"field": "PaO2", "value": "68 mmHg"}, {"field": "FiO2", "value": "36 %"}, {"field": "On mechanical ventilation (including CPAP)", "value": "No"}, {"field": "Platelets, x10^3/uL", "value": "110 x10^3/uL", "score": 1}, {"field": "Glasgow Coma Scale (GCS)", "value": "14", "score": 1}, {"field": "Bilirubin", "value": "3.2 mg/dL", "score": 2}, {"field": "Mean arterial pressure OR vasoactive agents", "value": "Norepinephrine 0.08 mcg/kg/min (worst MAP 63 mmHg pre-pressor)", "score": 3}, {"field": "Creatinine (or urine output)", "value": "2.1 mg/dL (UOP ~0.4 mL/kg/hr over 6 hr)", "score": 2}], "final_answer": 11, "notes": "Initial SOFA Scores of 10-11 predict 50.0% mortality (see Evidence for details)"}, {"order": 8, "name": "Sepsis-Induced Coagulopathy (SIC) Score", "inputs": [{"field": "INR", "value": "1.6", "score": 2}, {"field": "Platelet count, cells x10^9/L", "value": "110 x10^9/L", "score": 1}, {"field": "Total SOFA score (Respiratory + Cardiovascular + Hepatic + Renal components)", "value": "9 (Resp 2 + CV 3 + Hepatic 2 + Renal 2)", "score": 2}], "final_answer": 5, "notes": "5 points\n32% approximate 28-day mortality\nSIC likely\nDiagnosis of SIC"}]}
{"task_id": "medmcp-calc_060_3ce8cc0b", "task_scenario": "Gastrointestinal Bleeding & Acute Abdomen", "task_category": "Clinical Medicine / Emergency, Critical Care & Perioperative / Emergency Medicine & Trauma", "patient_id": "P060_3ce8cc0b", "task_description": "Scenario: In the emergency department, a patient presents with hematemesis/melena and acute epigastric abdominal pain. The clinical team must rapidly stabilize the patient, stratify bleeding risk before and after endoscopy, correct coagulopathy if present, and determine disposition and the need for advanced therapies, including potential TIPSS if variceal bleeding is suspected.\n\nWorkflow steps and rationale:\n1) Start with the Shock Index to quickly detect occult hemorrhagic shock and guide immediate resuscitation priorities. If the Shock Index is elevated, trigger urgent resuscitation and proceed immediately to both pre-endoscopy risk stratification and ABG assessment; if it is not elevated, continue with routine pre-endoscopy risk stratification.\n2) Use the Glasgow-Blatchford Bleeding Score (GBS) to determine pre-endoscopy risk and need for inpatient care. If GBS indicates very low risk, consider outpatient management and end the workflow; if not low risk, continue.\n3) Apply the AIMS65 Score for Upper GI Bleeding Mortality to estimate mortality risk and level of care. High AIMS65 prompts ICU-level monitoring and expedited endoscopy; lower scores allow monitored inpatient care.\n4) Calculate the Rockall Score for Upper GI Bleeding (Pre-Endoscopy) to refine early risk, transfusion thresholds, and endoscopy timing. High pre-endoscopy Rockall strengthens the decision for urgent endoscopy.\n5) Perform the Arterial Blood Gas (ABG) Analyzer to assess oxygenation and acid–base status during resuscitation. If ABG shows significant derangement, escalate airway/ventilation support and accelerate corrective measures.\n6) Use Plasma Dosage to determine appropriate plasma dosing when active bleeding coexists with suspected or known coagulopathy (e.g., anticoagulant use or liver disease), supporting hemostasis while endoscopy is prepared.\n7) After endoscopy, classify findings with the Forrest Classification of Upper GI Bleeding to determine the severity of stigmata of recent hemorrhage and immediate rebleeding risk. High-risk stigmata (e.g., active spurting or visible vessel) mandate endoscopic therapy and intensified monitoring.\n8) Compute the Rockall Score for Upper GI Bleeding (Complete). The Forrest Classification categories directly provide the “stigmata of recent hemorrhage” input into the complete Rockall, enabling comprehensive post-endoscopy risk and disposition planning.\n9) If endoscopy or history suggests portal hypertension or variceal bleeding, calculate MELD Na (UNOS/OPTN) to quantify underlying liver disease severity and inform the urgency of hepatology/transplant consultation.\n10) If bleeding is refractory or early rebleeding risk is high and MELD Na indicates significant liver disease burden, use the Emory Model (TIPSS) to evaluate risk/benefit for TIPSS as an advanced rescue/bridge therapy.\n\nConditional branches embedded in the sequence:\n- If GBS is low risk, consider outpatient management and stop the workflow; otherwise continue to AIMS65 and Rockall (Pre-Endoscopy).\n- If Shock Index is elevated, immediately perform ABG and expedite endoscopy; if not, proceed with standard pacing.\n- If Forrest Classification indicates high-risk stigmata, apply endoscopic therapy and compute Rockall (Complete) for disposition; if low-risk stigmata, consider expedited discharge after stabilization.\n- If MELD Na suggests significant liver disease, proceed to Emory Model (TIPSS); otherwise defer advanced interventions and finalize disposition with Rockall (Complete).", "fuzzy_question": "I'm evaluating a patient with hematemesis, melena, and acute epigastric pain. I'm trying to determine the likelihood of significant upper GI bleeding, the urgency of intervention, and the appropriate disposition after initial stabilization. I'm concerned about occult shock that may not yet be apparent and want to avoid missing a window to intervene early.\n\nFirst, I want an immediate bedside assessment of whether the pulse is disproportionately high relative to the systolic pressure as a quick screen for hidden hemorrhagic shock. If that is concerning, I would proceed directly to urgent resuscitation, obtain a blood gas to assess oxygenation and acid-base status, and move toward early endoscopy in parallel. If the initial hemodynamic snapshot is reassuring, I'm comfortable proceeding at a standard pace.\n\nBefore endoscopy, I need a practical pre-endoscopy bleeding risk assessment to decide whether outpatient management with close follow-up is reasonable versus the need for admission. If it indicates very low risk, I'm open to outpatient management and stopping additional inpatient steps. If it is anything other than clearly low risk, we should continue inpatient care.\n\nI also want a bedside estimate of short-term mortality risk in upper GI bleeding to determine the level of care. If high, that would support ICU-level monitoring and expedited endoscopy; if lower, a monitored inpatient bed may be appropriate.\n\nIn addition, I'd like an early, pre-endoscopy risk snapshot that integrates age, hemodynamics, comorbidity, and presentation to fine-tune transfusion thresholds and set the timing for endoscopy. If that assessment is high, it strengthens the case for urgent endoscopy and more intensive monitoring.\n\nWhile resuscitation is underway, please interpret the blood gas. If there is significant hypoxemia, metabolic acidosis, or other worrisome derangements, I want to escalate airway/ventilatory support and accelerate corrective measures immediately.\n\nIf there is ongoing bleeding and a suspected or known coagulation abnormality, whether from anticoagulants or underlying liver disease, I need a weight-based plan for plasma to support hemostasis while organizing the scope, guided by laboratory data and clinical context.\n\nAfter endoscopy, I need the findings framed in terms of stigmata of recent hemorrhage. If there are high-risk features such as active bleeding, a visible vessel, or similarly concerning signs, that should trigger immediate endoscopic therapy and a plan for intensified monitoring. If the stigmata appear low risk, we should consider earlier discharge once the patient is stabilized and safe.\n\nThen, integrate the endoscopic findings into a comprehensive post-endoscopy risk picture to settle disposition: who needs ICU versus a monitored floor bed versus who could be discharged, and why. The reasoning should combine endoscopic stigmata with the existing clinical factors.\n\nIf the history or endoscopic findings suggest portal hypertension or variceal bleeding, I want the severity of underlying liver disease quantified, including the role of serum sodium, to judge how urgently to involve hepatology and possibly the transplant team.\n\nFinally, if bleeding is refractory or early rebleeding risk remains high and the liver disease burden is substantial, help me consider whether urgent TIPS is appropriate as a rescue or bridge, using an established approach to balance benefits against procedure-related risk.\n\nPlease walk me through this step by step, with the concrete numbers and thresholds that would change management at each point, supported by solid quantitative reasoning that will hold up to scrutiny.", "required_calculators": ["Shock Index", "Glasgow-Blatchford Bleeding Score (GBS)", "AIMS65 Score for Upper GI Bleeding Mortality", "Rockall Score for Upper GI Bleeding (Pre-Endoscopy)", "Arterial Blood Gas (ABG) Analyzer", "Plasma Dosage", "Forrest Classification of Upper GI Bleeding", "Rockall Score for Upper GI Bleeding (Complete)", "MELD Na (UNOS/OPTN)", "Emory Model (TIPSS)"], "calculator_answers": [{"order": 1, "name": "Shock Index", "inputs": [{"field": "Heart Rate/Pulse", "value": "112 beats/min"}, {"field": "Systolic BP", "value": "102 mm Hg"}], "final_answer": 1.1, "notes": "1.1\n0.5-0.7 is believed to be a normal shock index. Higher numbers have been shown to be more sensitive than vital signs alone in diagnosing occult shock, need for transfusion and/or operation."}, {"order": 2, "name": "Glasgow-Blatchford Bleeding Score (GBS)", "inputs": [{"field": "Hemoglobin", "value": "7.9 g/dL"}, {"field": "BUN", "value": "48 mg/dL"}, {"field": "Initial systolic BP", "value": "102 mm Hg"}, {"field": "Sex", "value": "Male"}, {"field": "Heart rate ≥100", "value": "Yes", "score": 1}, {"field": "Melena present", "value": "Yes", "score": 1}, {"field": "Recent syncope", "value": "Yes", "score": 2}, {"field": "Hepatic disease history", "value": "Yes", "score": 2}, {"field": "Cardiac failure present", "value": "No", "score": 0}], "final_answer": 17, "notes": "17 points\nA GBS greater than zero suggests a “High Risk” GI bleed that is likely to require “medical intervention”: transfusion, endoscopy, or surgery. A higher GBS also correlated with a higher likelihood of needing intervention (scores ≥6 are associated with >50% risk of needing intervention)"}, {"order": 3, "name": "AIMS65 Score for Upper GI Bleeding Mortality", "inputs": [{"field": "Albumin <3 g/dL (30 g/L)", "value": "Yes (2.8 g/dL)", "score": 1}, {"field": "INR >1.5", "value": "Yes (1.8)", "score": 1}, {"field": "Alteration in mental status", "value": "No", "score": 0}, {"field": "sBP ≤90 mm Hg", "value": "No (102 mm Hg)", "score": 0}, {"field": "Age ≥65 years", "value": "No (58 years)", "score": 0}], "final_answer": 2, "notes": "5.3% In-hospital mortality."}, {"order": 4, "name": "Rockall Score for Upper GI Bleeding (Pre-Endoscopy)", "inputs": [{"field": "Age", "value": "<60 years", "score": 0}, {"field": "Shock", "value": "Tachycardia (SBP ≥100 AND HR ≥100)", "score": 1}, {"field": "Comorbidities", "value": "Renal failure, liver failure, and/or disseminated malignancy (liver failure/cirrhosis)", "score": 3}], "final_answer": 4, "notes": "24.6% mortality prior to endoscopy."}, {"order": 5, "name": "Arterial Blood Gas (ABG) Analyzer", "inputs": [{"field": "pH", "value": "7.33"}, {"field": "PaCO2", "value": "31 mm Hg"}, {"field": "HCO3-", "value": "17 mEq/L"}, {"field": "Sodium", "value": "128 mEq/L"}, {"field": "Chloride", "value": "96 mEq/L"}, {"field": "Albumin", "value": "2.8 g/dL"}, {"field": "If respiratory process present, chronicity", "value": "Acute"}], "final_answer": "This is an Anion Gap Metabolic Acidosis.\nPrimary Metabolic Acidosis, with: Appropriately Compensated by Respiratory Alkalosis and Additional Non-Gap Metabolic Acidosis.", "notes": "This is an Anion Gap Metabolic Acidosis.\nPrimary Metabolic Acidosis, with: Appropriately Compensated by Respiratory Alkalosis and Additional Non-Gap Metabolic Acidosis."}, {"order": 6, "name": "Plasma Dosage", "inputs": [{"field": "Patient weight", "value": "180 lbs"}, {"field": "Desired plasma dosage", "value": "15 mL/kg"}, {"field": "Unit volume", "value": "250 mL"}], "final_answer": 5, "notes": "5 units\nPlasma dose for transfusion\n1,225 mL\nPlasma dose for transfusion"}, {"order": 7, "name": "Forrest Classification of Upper GI Bleeding", "inputs": [{"field": "Endoscopy finding", "value": "Non-bleeding visible vessel"}], "final_answer": "2A", "notes": "2A\nForrest classification\n43 %\nRebleeding rate\n11 %\nMortality"}, {"order": 8, "name": "Rockall Score for Upper GI Bleeding (Complete)", "inputs": [{"field": "Age", "value": "<60 years", "score": 0}, {"field": "Shock", "value": "Tachycardia (SBP ≥100 AND HR ≥100)", "score": 1}, {"field": "Comorbidities", "value": "Renal failure, liver failure, and/or disseminated malignancy (liver failure/cirrhosis)", "score": 3}, {"field": "Diagnosis", "value": "All other diagnoses", "score": 1}, {"field": "Major stigmata of recent hemorrhage", "value": "Visible or spurting vessel", "score": 2}], "final_answer": 7, "notes": "7 points\nHigh Risk\n43.8% rebleeding risk.\n27% mortality.\nSee all mortality rates under Evidence > Facts & Figures."}, {"order": 9, "name": "MELD Na (UNOS/OPTN)", "inputs": [{"field": "Dialysis at least twice in the past week or CVVHD ≥24 hours", "value": "No"}, {"field": "Creatinine", "value": "1.2 mg/dL"}, {"field": "Bilirubin", "value": "3.2 mg/dL"}, {"field": "INR", "value": "1.8"}, {"field": "Sodium", "value": "128 mEq/L"}], "final_answer": 25, "notes": "25 points\nMELD Score (2016)*\n19.6%\nEstimated 3-Month Mortality"}, {"order": 10, "name": "Emory Model (TIPSS)", "inputs": [{"field": "Total Bilirubin", "value": "3.2 mg/dL"}, {"field": "ALT", "value": "48 U/L"}, {"field": "Pre-TIPSS Hepatic Encephalopathy", "value": "No"}, {"field": "Urgency of TIPSS", "value": "Elective"}], "final_answer": 1, "notes": "Score\n1\nRisk Category\nModerate Risk\nEstimated Mortality Rates after TIPSS:\nEstimated 3-month Mortality Rates after TIPSS\n25 %\nEstimated 12-month Mortality Rates after TIPSS\n51-57 %\nEstimated 36-month Mortality Rates after TIPSS\n>60 %"}]}
{"task_id": "medmcp-calc_061_8eaa65f7", "task_scenario": "Dermatologic Disease Severity", "task_category": "Clinical Medicine / Medicine & Organ Systems / Sensory Systems (Ophthalmology / ENT / Dermatology)", "patient_id": "P061_8eaa65f7", "task_description": "Clinical scenario: A patient presents with an acute, widespread cutaneous eruption after a recent exposure, with overlapping features (wheals, eczematous patches, and scaly plaques) and potential mucosal involvement. The clinical team must rapidly triage for life-threatening disease and then quantify severity across likely diagnoses to determine level of care and treatment intensity. Step-by-step calculator use: 1) Begin with the Severity-of-Illness Score for Toxic Epidermal Necrolysis (SCORTEN) when there is any concern for Stevens-Johnson syndrome/toxic epidermal necrolysis. Rationale: SCORTEN stratifies mortality risk and is the safety-first gatekeeper for urgent management. Decision branch: If SCORTEN is above a high-risk threshold, immediately prioritize intensive supportive care and specialty consultation; defer other chronic disease severity assessments until the patient is stabilized. If SCORTEN does not indicate high risk or the eruption is not consistent with SJS/TEN, proceed to disease-specific severity tools. 2) Use the Urticaria Activity Score (UAS) if the eruption includes wheals/hives and intense pruritus. Rationale: UAS quantifies urticaria activity and helps determine the need for escalation of antihistamines or adjunctive therapy. Decision branch: If UAS indicates high activity and morphology aligns with urticaria, initiate focused urticaria management and postpone eczema/psoriasis severity scoring until urticaria is controlled. If UAS is low or wheals are not predominant, continue to eczematous assessment. 3) Apply the Eczema Area and Severity Index (EASI) for eczematous patches. Rationale: EASI standardizes severity assessment to guide topical versus systemic therapy and follow-up frequency. Decision branch: If EASI categorizes disease as moderate-to-severe, prioritize eczema-directed escalation; consider deferring psoriasis scoring unless psoriatic plaques are clearly present and clinically relevant. If EASI is mild or eczema is not dominant, evaluate for psoriatic involvement. 4) Use the Psoriasis Area and Severity Index (PASI) when scaly plaques consistent with psoriasis are present. Rationale: PASI quantifies psoriasis severity and informs decisions on topical versus systemic therapy, phototherapy, and monitoring intervals. Final synthesis: Integrate SCORTEN (gatekeeper for urgent care), UAS (urticaria activity), EASI (eczema severity), and PASI (psoriasis severity) to determine the dominant disease process, appropriate level of care (outpatient versus inpatient), treatment intensity (topicals versus systemic agents), and follow-up cadence. Outputs from earlier calculators deterministically trigger whether subsequent assessments are performed and which condition receives priority in management.", "fuzzy_question": "I’m reviewing a case involving a patient who developed a dramatic, widespread rash after an exposure. The eruption is mixed: there are clear wheals with intense itch in some areas, eczematous patches with excoriations elsewhere, and a few thicker, scaly plaques with a psoriasiform appearance. The patient reports oral soreness with some lip involvement, and it’s unclear whether the eyes or other mucosal surfaces are involved.\n\nMy first concern is whether this could be a severe drug reaction with skin detachment that can be life‑threatening. I want to rapidly estimate immediate risk and obtain a realistic mortality risk estimate, not just a gut call, to decide whether to treat this as an emergency. If that early assessment suggests high risk, we should stop there and proceed directly to intensive supportive care and urgent specialty input (dermatology, ophthalmology, and possibly burn/ICU), and only return to the more chronic rash questions once the patient is stabilized.\n\nIf the initial screen doesn’t point strongly toward the emergency picture, I’d like to clarify how active the hive component is: how many wheals have occurred, how severe the itch has been, and how much this has disrupted sleep or required rescue medications. I need a practical, quantified sense of activity to decide whether to step up antihistamines or add adjuncts. If activity is high and the morphology clearly fits hives, center the plan on urticaria for now and defer the eczema/psoriasis deep dive until the hives settle.\n\nIf wheals aren’t the main issue, shift attention to the eczematous patches. Provide a clear, standardized picture across body regions—how red, thick/lichenified, and scratched these areas are, and roughly what proportion of skin is involved—so we can decide if topical care will suffice or if escalation to systemic options is needed, and how tight the follow‑up should be. If the numbers indicate moderate‑to‑severe disease, prioritize eczema management; address plaques afterward only if they’re clearly present and clinically relevant.\n\nIf eczema is mild or not the driver, focus on the scaly plaques. Provide a region‑by‑region sense of how red, thick, and scaly they are and the percentage of skin they occupy, because that will guide whether topical therapy alone is reasonable versus phototherapy or systemic agents, and how closely to monitor.\n\nAt the end, please synthesize these strands: what’s the dominant process in this mixed eruption, whether admission is needed or outpatient management is appropriate, how aggressive therapy should be, and how often to schedule follow‑up. The early risk assessment should determine whether to proceed to the hive/eczema/psoriasis deep dive, and a strong signal in one condition should appropriately bump the others down the priority list rather than treating everything at once. If there’s mucosal involvement—especially eyes—flag that clearly, since it changes urgency.\n\nI need proper calculations on this—decisions shouldn’t rely on gut feeling alone. Whatever approach you suggest, make sure it’s backed by solid, defensible numbers so the level of care and treatment intensity will hold up to scrutiny.", "required_calculators": ["Severity-of-Illness Score for Toxic Epidermal Necrolysis (SCORTEN)", "Urticaria Activity Score (UAS)", "Eczema Area and Severity Index (EASI)", "Psoriasis Area and Severity Index (PASI)"], "calculator_answers": [{"order": 1, "name": "Severity-of-Illness Score for Toxic Epidermal Necrolysis (SCORTEN)", "inputs": [{"field": "Age, years", "value": "48 years", "score": 1}, {"field": "Heart rate, per min", "value": "102 bpm", "score": 0}, {"field": "Cancer/hematologic malignancy", "value": "No", "score": 0}, {"field": "BSA detached", "value": "0%", "score": 0}, {"field": "Serum urea level", "value": "22 mg/dL", "score": 0}, {"field": "Serum bicarbonate level", "value": "23 mmol/L", "score": 0}, {"field": "Serum glucose level", "value": "118 mg/dL", "score": 0}, {"field": "RDW", "value": "12.8%"}, {"field": "Hb", "value": "13.4 g/dL"}], "final_answer": 1, "notes": "1 points\nRe-SCORTEN\n~4.3 %\nMortality rate"}, {"order": 2, "name": "Urticaria Activity Score (UAS)", "inputs": [{"field": "Wheals", "value": "Intense (>50 wheals/24 hrs or large confluent areas of wheals)", "score": 3}, {"field": "Pruritus", "value": "Intense (severe, interferes with normal daily activity or sleep)", "score": 3}], "final_answer": 6, "notes": "A cutoff of 11 points for UAS7 (sum of daily UAS scores over 7 consecutive days) showed sensitivity and specificity of 74% and 86% for change in score, respectively (Hawro 2018)."}, {"order": 3, "name": "Eczema Area and Severity Index (EASI)", "inputs": [{"field": "Head/neck - Redness", "value": "Moderate (obvious) [+2]", "score": 2}, {"field": "Head/neck - Thickness", "value": "Mild (just perceptible) [+1]", "score": 1}, {"field": "Head/neck - Scratching (excoriation)", "value": "Moderate (obvious) [+2]", "score": 2}, {"field": "Head/neck - Lichenification", "value": "Mild (just perceptible) [+1]", "score": 1}, {"field": "Head/neck - Percentage of region affected", "value": "10-29% [+2]", "score": 2}, {"field": "Upper limbs - Redness", "value": "Moderate (obvious) [+2]", "score": 2}, {"field": "Upper limbs - Thickness", "value": "Mild (just perceptible) [+1]", "score": 1}, {"field": "Upper limbs - Scratching (excoriation)", "value": "Moderate (obvious) [+2]", "score": 2}, {"field": "Upper limbs - Lichenification", "value": "Mild (just perceptible) [+1]", "score": 1}, {"field": "Upper limbs - Percentage of region affected", "value": "30-49% [+3]", "score": 3}, {"field": "Trunk - Redness", "value": "Moderate (obvious) [+2]", "score": 2}, {"field": "Trunk - Thickness", "value": "Mild (just perceptible) [+1]", "score": 1}, {"field": "Trunk - Scratching (excoriation)", "value": "Moderate (obvious) [+2]", "score": 2}, {"field": "Trunk - Lichenification", "value": "Mild (just perceptible) [+1]", "score": 1}, {"field": "Trunk - Percentage of region affected", "value": "30-49% [+3]", "score": 3}, {"field": "Lower limbs - Redness", "value": "Moderate (obvious) [+2]", "score": 2}, {"field": "Lower limbs - Thickness", "value": "Mild (just perceptible) [+1]", "score": 1}, {"field": "Lower limbs - Scratching (excoriation)", "value": "Moderate (obvious) [+2]", "score": 2}, {"field": "Lower limbs - Lichenification", "value": "Mild (just perceptible) [+1]", "score": 1}, {"field": "Lower limbs - Percentage of region affected", "value": "10-29% [+2]", "score": 2}], "final_answer": 15, "notes": "15.0 points\nTotal Eczema Area and Severity Index (EASI)\nHead/neck EASI: 1.2 points\nUpper limbs EASI: 3.6 points\nTrunk EASI: 5.4 points\nLower limbs EASI: 4.8 points"}, {"order": 4, "name": "Psoriasis Area and Severity Index (PASI)", "inputs": [{"field": "Head/neck - Erythema", "value": "Slight"}, {"field": "Head/neck - Induration/thickness", "value": "Slight"}, {"field": "Head/neck - Desquamation/scaling", "value": "Slight"}, {"field": "Head/neck - Percentage of region affected", "value": "1-9%"}, {"field": "Upper limbs - Erythema", "value": "Moderate"}, {"field": "Upper limbs - Induration/thickness", "value": "Moderate"}, {"field": "Upper limbs - Desquamation/scaling", "value": "Moderate"}, {"field": "Upper limbs - Percentage of region affected", "value": "1-9%"}, {"field": "Trunk - Erythema", "value": "Slight"}, {"field": "Trunk - Induration/thickness", "value": "Slight"}, {"field": "Trunk - Desquamation/scaling", "value": "Slight"}, {"field": "Trunk - Percentage of region affected", "value": "1-9%"}, {"field": "Lower limbs - Erythema", "value": "Moderate"}, {"field": "Lower limbs - Induration/thickness", "value": "Moderate"}, {"field": "Lower limbs - Desquamation/scaling", "value": "Moderate"}, {"field": "Lower limbs - Percentage of region affected", "value": "1-9%"}], "final_answer": 4.8, "notes": "4.8 points\nHigher PASI scores indicate higher severity of psoriasis; scores range from 0 (no disease) to 72 (maximal disease severity)\nHead/neck: 0.3\nUpper limbs: 1.2\nTrunk: 0.9\nLower limbs: 2.4"}]}
{"task_id": "medmcp-calc_062_ca857c24", "task_scenario": "Alcoholic Hepatitis Assessment", "task_category": "Clinical Medicine / Medicine & Organ Systems / Gastroenterology & Hepatology", "patient_id": "P062_ca857c24", "task_description": "Clinical scenario: A patient presents with suspected alcoholic hepatitis characterized by recent heavy alcohol use and clinical features of acute hepatic inflammation. The care team must rapidly determine disease severity, whether to initiate corticosteroid therapy, estimate short-term mortality, identify acute-on-chronic liver failure, and plan for transplant while addressing alcohol use disorder.\n\nStep-by-step use of calculators:\n1) Alcohol Use Disorders Identification Test (AUDIT): Begin by quantifying the pattern and severity of alcohol use to guide integrated addiction treatment planning, relapse prevention, and discharge coordination.\n2) Maddrey's Discriminant Function for Alcoholic Hepatitis: Enter the required baseline clinical and laboratory inputs to assess initial disease severity and potential benefit from corticosteroids.\n3) Glasgow Alcoholic Hepatitis Score: Use this complementary severity score to corroborate the steroid decision. If either this score or the previous one crosses a high-risk treatment threshold, proceed with a therapeutic steroid trial; if both are below threshold, pursue supportive care without steroids.\n4) MELD Score (Original, Pre-2016, Model for End-Stage Liver Disease): Calculate baseline hepatic severity. This standardized value will be needed as a direct input for downstream prognostication.\n5) Prognosis in Alcoholic Hepatitis: Feed the MELD value from step 4 into this tool to estimate short-term mortality specific to alcoholic hepatitis and refine counseling and level-of-care decisions.\n6) ABIC Score for Alcoholic Hepatitis: Perform additional survival risk stratification to guide monitoring intensity and the need for early escalation of care. If high risk, arrange more frequent reassessment and consider higher-acuity settings.\n7) MELD Na (UNOS/OPTN): Calculate the sodium-adjusted severity estimate to inform transplant prioritization. If above referral thresholds, expedite transplant center notification; if not, continue medical optimization and re-evaluate.\n8) CLIF-C ACLF (Acute-on-Chronic Liver Failure): Evaluate for acute-on-chronic liver failure. If the score indicates high risk, escalate to intensive care and fast-track transplant evaluation; if low or intermediate risk, continue standard ward-level management.\n9) Lille Model for Alcoholic Hepatitis: Only if steroids were started based on steps 2–3, reassess after a short treatment interval using this model to determine response. If poor response, discontinue steroids and intensify alternative therapies and transplant planning; if good response, continue steroids with close monitoring. Update overall disposition and follow-up intensity integrating results from steps 5–8.\n\nConditional branches embedded in the workflow:\n- If either initial severity score (steps 2–3) exceeds treatment thresholds → initiate steroids and schedule Lille assessment (step 9). Else → supportive care and skip Lille.\n- If ABIC (step 6) is high risk → increase monitoring intensity and consider higher-acuity care; else → standard monitoring.\n- If MELD Na (step 7) is high → expedite transplant referral; else → continue medical optimization and recheck.\n- If CLIF-C ACLF (step 8) is high → ICU-level care and transplant fast-track; else → ward-level care.\n- MELD (step 4) is a required input for Prognosis in Alcoholic Hepatitis (step 5), ensuring a direct dependency and coherent progression.", "fuzzy_question": "I am evaluating a patient with recent high-level alcohol use and a presentation consistent with alcoholic hepatitis (jaundice, liver tenderness, systemic inflammation). I need to gauge current severity, decide whether a corticosteroid trial is justified, estimate short-term prognosis, assess for possible acute-on-chronic liver failure, and determine the urgency of transplant discussions, while also addressing alcohol use disorder to reduce relapse risk after discharge.\n\nBefore committing to liver-directed therapy, I want a clear assessment of the alcohol use pattern and dependence severity—quantity and frequency, timing of last drink, prior withdrawals, cravings, prior attempts to cut down, and consequences—to tailor addiction support, consider medications for alcohol use disorder, outline relapse-prevention strategies, and plan a safe discharge with appropriate follow-up.\n\nFor hepatitis severity, please walk me through the standard bedside assessments used in alcoholic hepatitis using available labs (e.g., PT/INR, bilirubin, creatinine, urea, white count, and age). I would like a second, complementary tool to corroborate the decision. If either suggests high risk with likely steroid benefit—and there are no contraindications such as uncontrolled infection or gastrointestinal bleeding—plan to start steroids; if both indicate lower risk, proceed with supportive care and defer steroids.\n\nI also want a baseline liver disease severity estimate using the classic lab-based index that incorporates bilirubin, INR, and creatinine (without sodium), because I will use that value to feed directly into an alcoholic-hepatitis–specific short-term mortality estimate. Please use that to frame short-term risk for counseling and level-of-care decisions.\n\nSeparately, please perform survival risk stratification with the composite measure that combines age with bilirubin, INR, and creatinine commonly used in alcoholic hepatitis. If this places the patient in a high-risk category, plan tighter monitoring and a lower threshold for higher-acuity care; if not, routine ward-level reassessment is reasonable.\n\nFor transplant planning, obtain the sodium-adjusted version of the liver severity estimate used for listing and prioritization. If that score exceeds typical referral thresholds, alert the transplant center now; if not, continue medical optimization and recheck as labs evolve.\n\nI am also concerned about possible acute-on-chronic liver failure. Please evaluate with the organ-failure–based framework across liver, kidney, brain, coagulation, circulation, and lungs. If it indicates high-risk ACLF, escalate to ICU-level care and fast-track transplant evaluation; if low or intermediate, ward-level care is appropriate.\n\nIf steroids are started based on initial assessments, check early treatment response after several days using the usual bilirubin-trajectory approach. If the response is poor, stop steroids and intensify alternative therapies and transplant planning; if the response is good, continue with close monitoring. Whether or not steroids are used, integrate the short-term mortality estimate, survival risk stratification, sodium-adjusted severity, and organ-failure assessment to update disposition and follow-up intensity.\n\nWhat is your take? I am weighing early steroids versus supportive care and do not want to miss the window for transplant referral. I need properly calculated, evidence-based guidance that will withstand scrutiny.", "required_calculators": ["Alcohol Use Disorders Identification Test (AUDIT)", "Maddrey's Discriminant Function for Alcoholic Hepatitis", "Glasgow Alcoholic Hepatitis Score", "MELD Score (Original, Pre-2016, Model for End-Stage Liver Disease)", "Prognosis in Alcoholic Hepatitis", "ABIC Score for Alcoholic Hepatitis", "MELD Na (UNOS/OPTN)", "CLIF-C ACLF (Acute-on-Chronic Liver Failure)", "Lille Model for Alcoholic Hepatitis"], "calculator_answers": [{"order": 1, "name": "Alcohol Use Disorders Identification Test (AUDIT)", "inputs": [{"field": "Q1. Drinking frequency (past year)", "value": "4 or more times a week"}, {"field": "Q2. Typical drinks per drinking day", "value": "10 or more standard drinks"}, {"field": "Q3. Six or more drinks on one occasion", "value": "Daily or almost daily"}, {"field": "Q4. Unable to stop once started (past year)", "value": "Daily or almost daily"}, {"field": "Q5. Failed responsibilities due to drinking (past year)", "value": "Weekly"}, {"field": "Q6. Morning drink after heavy session (past year)", "value": "Daily or almost daily"}, {"field": "Q7. Guilt or remorse after drinking (past year)", "value": "Weekly"}, {"field": "Q8. Blackouts/unable to remember (past year)", "value": "Monthly"}, {"field": "Q9. You or someone else injured due to drinking", "value": "Yes, during the last year"}, {"field": "Q10. Others concerned or suggested cutting down", "value": "Yes, during the last year"}], "final_answer": 36, "notes": "AUDIT Score\n36\nInterpretation\nLikely alcohol dependence\nIntervention\nReferral to Specialist for Diagnostic Evaluation and Treatment"}, {"order": 2, "name": "Maddrey's Discriminant Function for Alcoholic Hepatitis", "inputs": [{"field": "PT", "value": "20.5 sec"}, {"field": "PT control/reference level", "value": "12.0 sec"}, {"field": "Total bilirubin", "value": "22.0 mg/dL"}], "final_answer": 61.1, "notes": "61.1 points\nPoor prognosis\nDiscriminant Function\n>32 points indicates poor prognosis and patient may benefit from glucocorticoid therapy."}, {"order": 3, "name": "Glasgow Alcoholic Hepatitis Score", "inputs": [{"field": "Age", "value": "52 years"}, {"field": "White blood cell count", "value": "17.2 × 10^3 cells/µL"}, {"field": "BUN", "value": "24 mg/dL"}, {"field": "Bilirubin", "value": "22.0 mg/dL"}, {"field": "PT", "value": "20.5 sec"}, {"field": "PT lab normal", "value": "12.0 sec"}], "final_answer": 11, "notes": "Scores of greater than or equal to 9 portended a much poorer 28- and 84-day survival than scores less than 9 (46%/40% vs. 87%/79%). The score was less sensitive but more accurate than the Modified Discriminant Function or MELD scores."}, {"order": 4, "name": "MELD Score (Original, Pre-2016, Model for End-Stage Liver Disease)", "inputs": [{"field": "Dialysis at least twice in the past week", "value": "No"}, {"field": "Creatinine", "value": "1.8 mg/dL"}, {"field": "Bilirubin", "value": "22.0 mg/dL"}, {"field": "INR", "value": "1.9"}], "final_answer": 31, "notes": "31 points\nOriginal MELD Score (Pre-2016)*\n52.6%\nEstimated 3-Month Mortality"}, {"order": 5, "name": "Prognosis in Alcoholic Hepatitis", "inputs": [{"field": "Creatinine", "value": "1.8 mg/dL"}, {"field": "Bilirubin", "value": "22.0 mg/dL"}, {"field": "INR", "value": "1.9"}], "final_answer": 31, "notes": "MELD Score\n31\nEstimated 3-month Mortality Rate\n65.7 %"}, {"order": 6, "name": "ABIC Score for Alcoholic Hepatitis", "inputs": [{"field": "Age", "value": "52 years"}, {"field": "Serum bilirubin", "value": "22.0 mg/dL"}, {"field": "INR", "value": "1.9"}, {"field": "Serum creatinine", "value": "1.8 mg/dL"}], "final_answer": 9.02, "notes": "9.02 points\nABIC Score\nHigh risk\n25% survival at 90 days\n33.3% survival at 1 year"}, {"order": 7, "name": "MELD Na (UNOS/OPTN)", "inputs": [{"field": "Dialysis at least twice in the past week", "value": "No"}, {"field": "Creatinine", "value": "1.8 mg/dL"}, {"field": "Bilirubin", "value": "22.0 mg/dL"}, {"field": "INR", "value": "1.9"}, {"field": "Sodium", "value": "130 mEq/L"}], "final_answer": 33, "notes": "33 points\nMELD Score (2016)*\n52.6%\nEstimated 3-Month Mortality"}, {"order": 8, "name": "CLIF-C ACLF (Acute-on-Chronic Liver Failure)", "inputs": [{"field": "Age", "value": "52 years"}, {"field": "WBC count", "value": "17.2 × 10^3 cells/µL"}, {"field": "Liver (Bilirubin)", "value": "22.0 mg/dL (category: ≥12 mg/dL → +3)", "score": 3}, {"field": "Kidney (Creatinine)", "value": "1.8 mg/dL (category: <2 mg/dL → +1)", "score": 1}, {"field": "Brain (West-Haven HE grade)", "value": "Grade 2 (category: 1–2 → +2)", "score": 2}, {"field": "Coagulation (INR)", "value": "1.9 (category: <2.0 → +1)", "score": 1}, {"field": "Circulatory (MAP)", "value": "82 mmHg (category: ≥70 mmHg → +1)", "score": 1}, {"field": "Respiratory - Information available", "value": "PaO2/FiO2 ratio"}, {"field": "Respiratory (PaO2/FiO2 ratio)", "value": "320 (category: >300 → +1)", "score": 1}], "final_answer": 48, "notes": "48 points\nCLIF-C ACLF Score\n23.8% probability of death at 1 month\n41.2% probability of death at 3 months\n46.3% probability of death at 6 months\n54.9% probability of death at 1 year"}, {"order": 9, "name": "Lille Model for Alcoholic Hepatitis", "inputs": [{"field": "Age", "value": "52 years"}, {"field": "Albumin", "value": "2.6 g/dL"}, {"field": "Bilirubin (initial)", "value": "22.0 mg/dL"}, {"field": "Bilirubin (day 7)", "value": "16.0 mg/dL"}, {"field": "Creatinine", "value": "1.8 mg/dL"}, {"field": "PT", "value": "20.5 sec"}], "final_answer": 0.353, "notes": "0.353 points\nGood prognosis. Scores <0.45 predict a 6-month survival of 85%."}]}
{"task_id": "medmcp-calc_063_e2dc319d", "task_scenario": "Corrected Age for Premature Infants", "task_category": "Clinical Medicine / Special Populations & General Tools / Pediatrics & Neonatology", "patient_id": "P063_e2dc319d", "task_description": "Clinical scenario: A premature infant presents for outpatient follow-up after NICU discharge. The care team needs to determine corrected age to accurately interpret growth percentiles and developmental expectations, and to select the appropriate growth standard based on maturity status. Workflow steps: First, use the Gestational Age calculator to confirm the gestational age at birth from obstetric data. Next, compute the current postmenstrual age using the Postmenstrual Age Calculator; this combines gestational age with chronological age and indicates whether the infant is still within the preterm growth window. Then, calculate the corrected age with Corrected Age (Prematurity) to adjust developmental and growth interpretation for prematurity. Conditional branching: If postmenstrual age indicates the infant is still within the preterm window, proceed to Fenton Growth Chart Percentiles to generate weight/length/head circumference percentiles using postmenstrual age. Otherwise, if the infant is beyond the preterm window but under 24 months, use WHO Child Growth Percentiles with corrected age; beyond 24 months, use WHO Child Growth Percentiles with chronological age (no correction). Management triggers: Percentile outputs guide decisions—if there is growth faltering (e.g., markedly low percentiles or downward crossing of major percentiles), plan intensified nutrition and closer follow-up; if percentiles are appropriate, continue routine monitoring. The sequence ensures each calculator output informs the next decision (gestational age feeds PMA and corrected age; PMA/ corrected age determine the growth chart choice), achieving clinically coherent age correction and growth interpretation.", "fuzzy_question": "I’m evaluating a former preterm infant in clinic following a NICU discharge and want to ensure growth and development are interpreted correctly for the current visit and upcoming visits. Before selecting any chart, I want to confirm the degree of prematurity at birth using objective obstetric dating (early ultrasound versus last menstrual period), rather than recollection.\n\nFrom there, I need to determine the current equivalent gestational age if the pregnancy had continued—combining the degree of prematurity with the time elapsed since birth. I’m unsure whether the infant still falls within a preterm frame of reference for growth; that decision determines which chart to use. In parallel, I also want the prematurity‑adjusted (corrected) age for interpreting milestones and growth once outside the preterm window.\n\nI’m torn: part of me thinks plotting by gestational age is still appropriate; part of me suspects the infant has transitioned to standard infant curves. If still within the preterm range now, plot weight, length, and head circumference against an appropriate preterm reference using the current equivalent gestational age. If beyond the preterm range but still within the typical correction window, use standard infant curves with prematurity adjustment. Once beyond the correction window, stop correcting and use chronological age.\n\nPlease provide percentiles for weight, length, and head circumference based on the applicable approach at the current visit, and comment on the pattern over prior visits—whether values are very low for age/gestation or crossing down major centile lines. If there is growth faltering, I would consider escalating nutrition and shortening follow‑up intervals; if tracking appropriately, continue routine monitoring and reassess at the next appointment.\n\nWhat’s your take? Walk me through the reasoning step by step—how you confirmed prematurity from obstetric details, how you translated that into the current status, how that guided chart choice, and the resulting percentile outputs. I need transparent calculations—not clinical intuition—so the approach holds up to scrutiny.", "required_calculators": ["Gestational Age", "Postmenstrual Age Calculator", "Corrected Age (Prematurity)"], "calculator_answers": [{"order": 1, "name": "Gestational Age", "inputs": [{"field": "current_date", "value": "2025-09-20 (date of birth; used as 'current date' to compute GA at birth)"}, {"field": "due_date", "value": "2025-11-21 (EDD from first-trimester ultrasound)"}], "final_answer": "31 Weeks 1 Day", "notes": "End of 1st Trimester\nMay 9, 2025\nCurrent Gestational Age\n31 Weeks 1 Day"}, {"order": 2, "name": "Postmenstrual Age Calculator", "inputs": [{"field": "date_of_birth", "value": "2025-09-20"}, {"field": "gestational_age_at_birth", "value": "31 weeks 1 days"}, {"field": "current_date", "value": "2025-12-15"}, {"field": "chronological_age_days", "value": 86}], "final_answer": "43 weeks 3 days", "notes": "PMA = GA at birth (31w1d) + chronological age (12w2d) = 43 weeks 3 days; within preterm window (Fenton up to ~50 weeks PMA)."}, {"order": 3, "name": "Corrected Age (Prematurity)", "inputs": [{"field": "date_of_birth", "value": "2025-09-20"}, {"field": "current_date", "value": "2025-12-15"}, {"field": "gestational_age_at_birth", "value": "31 weeks 1 days"}, {"field": "term_gestation_reference", "value": "40 weeks 0 days"}], "final_answer": "3 weeks 3 days", "notes": "Corrected age = chronological age − (40w0d − GA at birth) = 12w2d − 8w6d = 3 weeks 3 days (24 days)."}]}
{"task_id": "medmcp-calc_064_e9696af6", "task_scenario": "Sleep Apnea Screening", "task_category": "Clinical Medicine / Medicine & Organ Systems / Sensory Systems (Ophthalmology / ENT / Dermatology)", "patient_id": "P064_e9696af6", "task_description": "Clinical scenario: In an ENT-focused evaluation for suspected obstructive sleep apnea (OSA), the clinician needs a structured screening process that stratifies OSA risk and quantifies daytime sleepiness to determine the urgency and pathway for diagnostic sleep testing and counseling. Workflow steps: 1) Begin with the STOP-BANG Score for Obstructive Sleep Apnea to establish pretest probability based on history and examination findings. This yields a categorical risk level (low, intermediate, or high). 2) If STOP-BANG indicates intermediate or high risk, administer the Epworth Sleepiness Scale (ESS) to quantify symptom burden. Use ESS output to guide urgency: elevated ESS prompts expedited referral for diagnostic testing and immediate safety counseling (for example regarding drowsy driving), while normal ESS supports standard referral given elevated STOP-BANG risk. 3) If STOP-BANG indicates low risk, use a conditional approach to ESS: if the patient reports daytime sleepiness symptoms, administer ESS to confirm severity and consider targeted counseling and possible testing; if sleepiness is not reported and ESS is not performed, provide education and plan routine re-screening. 4) In follow-up, re-administer the ESS to monitor response after initial interventions (such as sleep hygiene or airway-related measures) and to track changes in symptom burden over time, particularly for those proceeding to diagnostic testing. This sequence leverages STOP-BANG to determine whether ESS is required and how its results direct next steps.", "fuzzy_question": "I’m seeing an adult patient in clinic with loud snoring, possible witnessed apneas, increased neck circumference, and elevated blood pressure. The patient has excess body weight and is unsure about the degree of daytime sleepiness. Airway findings suggest nasal obstruction and enlarged tonsils. I’m trying to estimate the likelihood of obstructive sleep apnea and decide whether to move quickly toward a sleep study or take a more routine path, as well as what safety counseling is needed now.\n\nMy plan is to start with a brief snoring/sleep-apnea screening tool that integrates history and exam features and categorizes likelihood as lower, moderate, or higher. Based on the result:\n- If the likelihood is moderate to higher, I’d formally assess daytime sleepiness using a standard patient questionnaire. If that indicates marked sleepiness, I’d expedite diagnostic testing and provide immediate guidance about drowsy driving and related safety risks. If daytime sleepiness appears minimal despite other risk factors, I’d still pursue testing, but on a standard timeline.\n- If the initial screen suggests lower likelihood, I’d use the daytime sleepiness questionnaire only if the patient reports dozing, difficulty staying awake, or near-misses while driving. If present, I’d quantify severity, offer targeted counseling, and consider testing anyway. If there’s no reported daytime sleepiness and the questionnaire isn’t administered, I’d focus on education (weight management, nasal care, sleep habits, avoiding sedatives) and plan to re-screen during routine visits.\n\nLooking ahead to follow-up—whether after sleep hygiene or airway measures, or as the patient moves toward a sleep study—I’d repeat the daytime sleepiness questionnaire to track changes over time and adjust the plan accordingly. Over the next visits, that trend will matter as much as the baseline.\n\nWhat’s your take on this approach and how you’d reason through the steps? I need evidence-based risk stratification with proper calculations—this can’t rely on clinical intuition alone. Whatever approach you suggest should be backed by solid calculations and able to withstand scrutiny.", "required_calculators": ["STOP-BANG Score for Obstructive Sleep Apnea", "Epworth Sleepiness Scale"], "calculator_answers": [{"order": 1, "name": "STOP-BANG Score for Obstructive Sleep Apnea", "inputs": [{"field": "Do you snore loudly?", "value": "Yes", "score": 1}, {"field": "Do you often feel tired, fatigued, or sleepy during the daytime?", "value": "No", "score": 0}, {"field": "Has anyone observed you stop breathing during sleep?", "value": "Yes", "score": 1}, {"field": "Do you have (or are you being treated for) high blood pressure?", "value": "No", "score": 0}, {"field": "BMI (kg/m²)", "value": 31.2}, {"field": "BMI >35 kg/m²", "value": "No", "score": 0}, {"field": "Age (years)", "value": 54}, {"field": "Age >50 years", "value": "Yes", "score": 1}, {"field": "Neck circumference (cm)", "value": 43}, {"field": "Neck circumference >40 cm", "value": "Yes", "score": 1}, {"field": "Gender", "value": "Male", "score": 1}], "final_answer": 5, "notes": "5 points\nSTOP-BANG\nHigh risk of OSA"}, {"order": 2, "name": "Epworth Sleepiness Scale", "inputs": [{"field": "Chance of dozing off while sitting and reading", "value": 1}, {"field": "Chance of dozing off while watching TV", "value": 2}, {"field": "Chance of dozing off while sitting inactive in a public place", "value": 1}, {"field": "Chance of dozing off as a passenger in a car for an hour without a break", "value": 2}, {"field": "Chance of dozing off while lying down to rest in the afternoon when circumstances permit", "value": 3}, {"field": "Chance of dozing off while sitting and talking to someone", "value": 0}, {"field": "Chance of dozing off while sitting quietly after lunch without alcohol", "value": 2}, {"field": "Chance of dozing off while in a car, while stopped for a few minutes in traffic", "value": 1}], "final_answer": 12, "notes": "Epworth Sleepiness Scale\n12\nCategory\nAbnormal Sleepiness"}, {"order": 3, "name": "Epworth Sleepiness Scale", "inputs": [{"field": "Chance of dozing off while sitting and reading", "value": 1}, {"field": "Chance of dozing off while watching TV", "value": 1}, {"field": "Chance of dozing off while sitting inactive in a public place", "value": 0}, {"field": "Chance of dozing off as a passenger in a car for an hour without a break", "value": 1}, {"field": "Chance of dozing off while lying down to rest in the afternoon when circumstances permit", "value": 2}, {"field": "Chance of dozing off while sitting and talking to someone", "value": 0}, {"field": "Chance of dozing off while sitting quietly after lunch without alcohol", "value": 1}, {"field": "Chance of dozing off while in a car, while stopped for a few minutes in traffic", "value": 0}], "final_answer": 6, "notes": "Epworth Sleepiness Scale\n6\nCategory\nAverage Sleepiness"}]}
{"task_id": "medmcp-calc_065_13cae948", "task_scenario": "Kidney Stone Burden and Recurrence Risk", "task_category": "Clinical Medicine / Medicine & Organ Systems / Urology & Reproductive System", "patient_id": "P065_13cae948", "task_description": "Clinical scenario: A patient presents to urology after a symptomatic kidney stone event. The team must estimate the patient’s future recurrence risk and quantify the current stone burden to decide on preventive intensity, follow-up intervals, and whether to escalate to intervention.\nStep-by-step workflow using calculators:\n1) Start with “ROKS - Recurrence Of Kidney Stone (2014)” to estimate the likelihood of stone recurrence. This risk stratification anchors how aggressively to pursue prevention and surveillance.\n2) Branch (deterministic trigger):\n   - If ROKS indicates low recurrence risk, proceed to the next step only if a stone is currently visible on imaging or symptoms persist; otherwise, defer further stone-burden scoring and adopt conservative follow-up.\n   - If ROKS indicates intermediate/high recurrence risk, immediately proceed to stone-burden quantification.\n3) Use “STONE Nephrolithometry Score for Renal Calculi” to quantify radiologic stone burden/complexity. This characterizes the current stone(s) and predicts the likelihood of persistent disease and the need for procedural management.\n4) Branch based on STONE severity:\n   - If STONE score indicates low complexity, favor conservative management and routine surveillance while reinforcing preventive measures.\n   - If STONE score indicates moderate/high complexity, consider earlier specialist intervention planning and tighter surveillance.\n5) Integration for planning: Combine ROKS (recurrence risk category) with STONE (burden/complexity category) to tailor the intensity of prevention (behavioral/pharmacologic), the cadence of follow-up imaging/visits, and thresholds for procedural intervention. High ROKS + high STONE supports a more aggressive plan; low ROKS + low STONE supports a minimal approach.", "fuzzy_question": "I’m seeing an adult patient with a recent episode of renal colic. A small stone passed in the emergency department, symptoms resolved, and a recent non‑contrast CT shows a left lower‑pole stone and a small contralateral calyceal stone. The patient is overweight, has a family history of nephrolithiasis, and kidney function appears normal on recent labs. Stone analysis and a timed urine collection are pending.\n\nI’m trying to determine how intensively to pursue prevention and how closely to follow the patient. I’d like a quantified estimate of the patient’s risk of another symptomatic stone over the coming years based on the clinical profile, not just a gestalt. That estimate will guide prevention and surveillance intensity.\n\nDepending on that risk: if it appears low and there are no residual stones or ongoing symptoms, I’d be comfortable keeping management simple and spacing out follow‑up. If the risk is intermediate or higher—or even if it’s low but the CT shows residual stone(s) or intermittent symptoms—then please use the CT features to translate the current stone situation into a practical “management complexity” category. Consider the scan features: largest stone size, qualitative stone density, presence or absence of hydronephrosis, involvement of multiple calyces, and the skin‑to‑stone distance. For reference, the scan describes a left lower‑pole stone of small‑to‑moderate size with relatively high density, mild ipsilateral hydronephrosis, a moderate skin‑to‑stone distance, an additional small ipsilateral calyceal stone, and a small contralateral calyceal stone without obstruction. Please convert that into a clear sense of burden/complexity and what it implies about the likelihood of persistent disease and the chances we’ll need a procedure versus being safe to observe.\n\nIf that burden assessment is “mild,” I’m inclined toward conservative management and routine surveillance while we strengthen preventive counseling. If it is moderate or high, I’d like a case for earlier intervention planning and a tighter follow‑up cadence.\n\nMost importantly, pull both pieces together—recurrence risk and current stone complexity—to provide a tailored plan: intensity of prevention (dietary measures alone versus adding medications), frequency of follow‑up and re‑imaging, and thresholds for moving from observation to procedural management. If the profile is “low risk + low burden,” I’m comfortable with a light touch; if it is “high risk + high burden,” I’d prefer a more assertive approach. Please state where you think the patient actually falls based on the available data and how that translates into concrete follow‑up timing over the next few visits and imaging intervals, plus what would prompt earlier action.\n\nWhat’s your take? Am I missing anything you’d want before committing to a plan? I need proper calculations—this can’t be based on gut feeling alone. Whatever approach you suggest, please back it with solid calculations; this needs to hold up to scrutiny.", "required_calculators": ["ROKS - Recurrence Of Kidney Stone (2014)", "STONE Nephrolithometry Score for Renal Calculi"], "calculator_answers": [{"order": 1, "name": "ROKS - Recurrence Of Kidney Stone (2014)", "inputs": [{"field": "First Symptomatic Stone?", "value": "Yes"}, {"field": "Age?", "value": "49 years"}, {"field": "Gender?", "value": "Male"}, {"field": "Race?", "value": "White"}, {"field": "Family History of Kidney Stones?", "value": "Yes (father)"}, {"field": "Gross Hematuria?", "value": "Yes"}, {"field": "Brushite, struvite, or uric acid composition?", "value": "No (composition unknown; not brushite/struvite/uric acid confirmed)"}, {"field": "Imaging Performed?", "value": "Yes (non-contrast CT)"}, {"field": "Symptomatic Ureterovesical Junction Stone?", "value": "Yes (passed in ED)"}, {"field": "Symptomatic Renal Pelvic or Lower Pole Stone?", "value": "No"}, {"field": "Concurrent Asymptomatic Stone?", "value": "Yes (residual left and contralateral right calyceal stones on CT)"}, {"field": "Prior Incidental (Asymptomatic) Stone?", "value": "No"}, {"field": "Prior Suspected Kidney Stone Event (No Stone Seen)?", "value": "No"}], "final_answer": "14.5%", "notes": "Risk of a Second Symptomatic Kidney Stone Event at 2-Years\n14.5 %\nRisk of a Second Symptomatic Kidney Stone Event at 5-Years\n27.8 %\nRisk of a Second Symptomatic Kidney Stone Event at 10-Years\n43.5 %"}, {"order": 2, "name": "STONE Nephrolithometry Score for Renal Calculi", "inputs": [{"field": "Stone size (length × width in mm)", "value": "9 mm × 6 mm (largest left lower-pole stone)"}, {"field": "Calculated area (mm²)", "value": "54 mm²", "score": 1}, {"field": "Tract length (mm)", "value": "105 mm (>100 mm category)", "score": 2}, {"field": "Obstruction (hydronephrosis)", "value": "No/mild hydronephrosis (mild on left)", "score": 1}, {"field": "Number of calyces with calculi (affected kidney)", "value": "2 (left kidney)", "score": 1}, {"field": "Essence (stone density in Hounsfield units)", "value": "950 HU (≤950 category)", "score": 1}], "final_answer": 6, "notes": "6 points\n88% chance of patient being stone free after first procedure."}]}
{"task_id": "medmcp-calc_066_408a42c1", "task_scenario": "Peripheral Neuropathy Scoring", "task_category": "Clinical Medicine / Neurology & Mental Health / Neurosurgery & Neurology", "patient_id": "P066_408a42c1", "task_description": "Scenario: A patient with suspected peripheral neuropathy presents with hand dysfunction and gait instability affecting daily activities. The neurology team needs an objective, reproducible way to quantify functional limitations, triage rehabilitation focus, and monitor response to treatment or disease progression over time for Clinical Medicine / Neurology & Mental Health / Neurosurgery & Neurology _ Peripheral Neuropathy Scoring. Workflow using calculators: 1) Baseline measurement: Use Overall Neuropathy Limitations Scale (ONLS) to obtain total score and domain subscores (upper limb, lower limb), establishing functional severity and dominant limb involvement. 2) Branch by domain dominance (decision based on ONLS outputs): If upper-limb subscore exceeds lower-limb subscore, prioritize fine-motor/hand function interventions and schedule an early repeat ONLS upper-limb check; else if lower-limb subscore exceeds upper-limb subscore, prioritize gait/fall-prevention strategies and schedule an early repeat ONLS lower-limb check. 3) Severity-stratified cadence (decision based on ONLS total severity category): Use the baseline ONLS total score to assign follow-up timing for the next ONLS (shorter interval for higher severity; routine interval for lower severity) and to determine need for expedited specialty rehabilitation referral. 4) Follow-up reassessment: Recalculate ONLS at the planned interval to generate a new total score and domain subscores; compute change from baseline conceptually (improved, stable, or worsened) to quantify response. 5) Response-based branching (decision based on ONLS change): If ONLS shows clinically meaningful improvement in the targeted domain(s) and total score, maintain the current plan and lengthen the next ONLS interval; if ONLS is unchanged or worsened, escalate the care plan and shorten the interval to the next ONLS to closely monitor progression. Throughout, ONLS outputs (domain subscores, total severity band, and change over time) deterministically trigger the timing and focus of subsequent ONLS recalculations and follow-up actions.", "fuzzy_question": "I’m seeing a patient with suspected peripheral neuropathy who has clumsy hands and an unsteady gait affecting daily activities. There has been difficulty with fine-motor tasks and near-falls. I want an objective, reproducible way to quantify current functional limitation, identify which area is primarily driving the disability, and determine whether the dominant hand is involved, so we can establish a clear baseline and track changes over time.\n\nI’m considering anchoring this to a structured functional measure that provides an overall severity rating with separate domain scores for arms/hands and legs/feet. If the hands are more impaired than the legs, I’d prioritize fine-motor and hand-focused therapy with an earlier follow-up centered on hand function. If the legs are the main issue, I’d emphasize gait training and fall prevention with an earlier reassessment focused on walking and balance. The overall severity at baseline should also guide the cadence: a higher global burden would prompt tighter follow-up and an expedited rehabilitation referral; a milder burden would support a routine schedule.\n\nAt follow-up, I plan to repeat the same structured assessment to enable like-for-like comparison—overall and by arm/leg domains—and classify status as improved, stable, or worse relative to baseline. If we see meaningful gains where therapy is targeted (and in the overall picture), we would continue the plan and consider lengthening the interval. If findings are flat or declining, we would escalate the care plan and shorten the monitoring interval to watch for progression. I want measured results to drive timing and focus rather than relying on clinical intuition.\n\nWhat’s your view on implementing this in clinic? I need a framework supported by proper calculations—no decisions based on gut feeling. Whatever approach you recommend should be backed by solid calculations and able to withstand scrutiny.", "required_calculators": ["Overall Neuropathy Limitations Scale (ONLS)"], "calculator_answers": [{"order": 1, "name": "Overall Neuropathy Limitations Scale (ONLS)", "inputs": [{"field": "Does the patient have any symptoms in their hands or arms?", "value": "Yes"}, {"field": "Wash and brush their hair", "value": "Affected but not prevented"}, {"field": "Turn a key in a lock", "value": "Affected but not prevented"}, {"field": "Use a knife and fork together", "value": "Affected but not prevented"}, {"field": "Do or undo buttons or zips", "value": "Affected but not prevented"}, {"field": "Dress the upper part of their body", "value": "Affected but not prevented"}, {"field": "Does the patient have difficulty running or climbing stairs?", "value": "Yes"}, {"field": "Does the patient have difficulty with walking?", "value": "Yes"}, {"field": "Does their gait look abnormal?", "value": "Yes"}, {"field": "How do they mobilize for about 10 m (33 ft)?", "value": "Without aid"}, {"field": "Does the patient use ankle foot orthoses/braces?", "value": "No"}], "final_answer": 4, "notes": "Overall Neuropathy Limitations Scale (ONLS)\nArms grade score: 2 points\nLegs grade score: 2 points"}, {"order": 2, "name": "Overall Neuropathy Limitations Scale (ONLS)", "inputs": [{"field": "Does the patient have any symptoms in their hands or arms?", "value": "Yes"}, {"field": "Wash and brush their hair", "value": "Affected but not prevented"}, {"field": "Turn a key in a lock", "value": "Affected but not prevented"}, {"field": "Use a knife and fork together", "value": "Affected but not prevented"}, {"field": "Do or undo buttons or zips", "value": "Affected but not prevented"}, {"field": "Dress the upper part of their body", "value": "Affected but not prevented"}, {"field": "Does the patient have difficulty running or climbing stairs?", "value": "Yes"}, {"field": "Does the patient have difficulty with walking?", "value": "No"}, {"field": "Does their gait look abnormal?", "value": "No"}, {"field": "How do they mobilize for about 10 m (33 ft)?", "value": "Without aid"}, {"field": "Does the patient use ankle foot orthoses/braces?", "value": "No"}], "final_answer": 2, "notes": "Overall Neuropathy Limitations Scale (ONLS)\nArms grade score: 2 points\nLegs grade score: 0 points"}]}
{"task_id": "medmcp-calc_067_4a049fa3", "task_scenario": "Coagulation and Bleeding Risk", "task_category": "Clinical Medicine / Medicine & Organ Systems / Hematology & Oncology", "patient_id": "P067_4a049fa3", "task_description": "Scenario: A hospitalized patient with established atrial fibrillation is admitted for an acute medical illness with reduced mobility. The team must prevent hospital-acquired VTE, evaluate a later episode suggestive of acute VTE, safely initiate/adjust anticoagulation, and screen for heparin-induced thrombocytopenia, then plan long-term AF anticoagulation prior to discharge. The workflow below sequences calculators to balance thrombosis prevention/treatment against bleeding risk while incorporating HIT safety checks and AF-specific long-term planning. Steps: 1) Use IMPROVE Risk Score for Venous Thromboembolism (VTE) at admission to stratify risk of hospital-acquired VTE and determine whether pharmacologic prophylaxis is indicated. 2) If prophylaxis is considered, immediately apply IMPROVE Bleeding Risk Score to gauge bleeding risk at admission and choose prophylaxis modality: if VTE risk is high and bleeding risk low, favor pharmacologic prophylaxis; if bleeding risk is high, pivot to mechanical prophylaxis or delay pharmacologic dosing until modifiable risks are mitigated. 3) If signs suggest acute VTE during hospitalization, use Age-Adjusted D-dimer for Venous Thromboembolism (VTE) to determine whether VTE can be ruled out. If negative by age-adjusted threshold, revert to the previously selected prophylaxis plan and monitoring; if not ruled out, proceed with therapeutic anticoagulation while awaiting confirmatory evaluation. 4) Once therapeutic anticoagulation is initiated for suspected/confirmed VTE, apply VTE-BLEED Score to stratify bleeding risk on anticoagulation; if high risk, intensify bleeding precautions, monitoring frequency, and consider the lowest effective intensity; if low risk, continue standard therapeutic anticoagulation. 5) Because the patient has atrial fibrillation, use HAS-BLED Score for Major Bleeding Risk to quantify AF-specific bleeding risk that will inform chronic anticoagulation planning. 6) If considering a DOAC for AF, use Direct-Acting Oral Anticoagulants (DOAC) Score to estimate bleeding risk on a DOAC and refine the choice of agent and intensity based on the HAS-BLED profile. 7) Apply GARFIELD-AF to integrate stroke, bleeding, and mortality predictions with and without anticoagulation, guiding the net clinical benefit decision for long-term AF management. If GARFIELD-AF indicates clear net benefit with anticoagulation, finalize the regimen aligned with HAS-BLED and DOAC Score; if net benefit is marginal, escalate risk mitigation strategies or reconsider intensity. 8) If new-onset thrombocytopenia occurs after heparin exposure, use 4Ts Score for Heparin-Induced Thrombocytopenia to stratify HIT probability: if low, continue heparin with routine surveillance; if intermediate/high, proceed to the next step and alter anticoagulation safety measures. 9) For intermediate/high 4Ts results, apply HIT Expert Probability (HEP) Score for Heparin-Induced Thrombocytopenia to refine pre-test probability and determine whether to stop heparin and transition to a non-heparin anticoagulant while arranging definitive testing and ongoing bleeding/thrombosis risk management.", "fuzzy_question": "I’m evaluating a hospitalized patient with atrial fibrillation, admitted for an acute condition and currently limited in mobility. On admission, I want to assess the risk of hospital-acquired venous thromboembolism and decide between immediate pharmacologic prophylaxis versus mechanical compression alone. In parallel, I need a careful assessment of near-term bleeding risk to guide that choice: if bleeding risk appears low, I would favor medication; if high, I would rely on mechanical prevention or briefly defer while correcting modifiable factors (hemodynamics, anemia, platelet count, recent procedures), then reconsider medication.\n\nEarly in the hospitalization, new symptoms raised concern for possible thromboembolism. If a D-dimer is obtained, please interpret it using an age-adjusted threshold rather than a single universal cutoff. If that adequately rules out clot, I would return to the original prevention plan and ongoing monitoring. If clot cannot be ruled out, I would begin treatment-dose anticoagulation while arranging confirmatory imaging, rather than waiting.\n\nOnce treatment dosing is underway, I want a focused assessment of bleeding risk specifically during full-dose anticoagulation, to determine the intensity of precautions and laboratory monitoring and whether to choose the lowest effective intensity versus standard dosing.\n\nGiven the atrial fibrillation, I also need a clear view of longer-term bleeding risk to guide the chronic plan before discharge. If a direct oral anticoagulant is considered, I would like an estimate of bleeding risk on those agents to help select the agent and dose that fit the clinical profile and kidney function. For discharge planning, I want an integrated assessment balancing stroke prevention against bleeding and overall prognosis with and without anticoagulation; if the net benefit is clearly favorable, we should finalize the regimen accordingly, and if marginal, outline risk-reduction steps or alternative intensities.\n\nAdditionally, if platelet counts decline after heparin exposure, I want a bedside probability estimate that considers timing, degree of fall, any new thrombosis, and alternative causes. If the probability is low, continue heparin with routine surveillance. If intermediate or high, refine the estimate with a more detailed clinical approach, stop heparin, transition to a non-heparin option, and send confirmatory testing, while actively managing both bleeding and thrombosis risks during the evaluation.\n\nWhat’s your take? I need this grounded in validated calculations and risk models rather than clinical intuition, with a defensible, evidence-based approach.", "required_calculators": ["IMPROVE Risk Score for Venous Thromboembolism (VTE)", "IMPROVE Bleeding Risk Score", "Age-Adjusted D-dimer for Venous Thromboembolism (VTE)", "VTE-BLEED Score", "HAS-BLED Score for Major Bleeding Risk", "Direct-Acting Oral Anticoagulants (DOAC) Score", "GARFIELD-AF", "4Ts Score for Heparin-Induced Thrombocytopenia", "HIT Expert Probability (HEP) Score for Heparin-Induced Thrombocytopenia"], "calculator_answers": [{"order": 1, "name": "IMPROVE Risk Score for Venous Thromboembolism (VTE)", "inputs": [{"field": "Previous VTE", "value": "No", "score": 0}, {"field": "Known thrombophilia", "value": "No", "score": 0}, {"field": "Current lower-limb paralysis", "value": "No", "score": 0}, {"field": "Current cancer", "value": "No", "score": 0}, {"field": "Immobilized ≥7 days (immediately prior to and during hospital admission)", "value": "Yes", "score": 1}, {"field": "ICU/CCU stay", "value": "No", "score": 0}, {"field": "Age >60 years", "value": "Yes (78 years)", "score": 1}], "final_answer": 2, "notes": "2 points\nIMPROVE Score\n1.0 %\n3-month risk of VTE"}, {"order": 2, "name": "IMPROVE Bleeding Risk Score", "inputs": [{"field": "Age, years", "value": "78", "score": 1.5}, {"field": "Gender", "value": "Male", "score": 1}, {"field": "Renal function (GFR), mL/min/m2", "value": "48 mL/min/1.73 m2", "score": 1}, {"field": "Current cancer", "value": "No", "score": 0}, {"field": "Rheumatic disease", "value": "No", "score": 0}, {"field": "Central venous catheter", "value": "No", "score": 0}, {"field": "ICU/CCU", "value": "No", "score": 0}, {"field": "Evidence of hepatic failure (INR >1.5)", "value": "No (INR 1.1)", "score": 0}, {"field": "Platelet count, cells/L", "value": "220 x10^9/L (at admission)", "score": 0}, {"field": "Bleeding in 3 months before admission", "value": "No", "score": 0}, {"field": "Active gastroduodenal ulcer", "value": "No", "score": 0}], "final_answer": 3.5, "notes": "IMPROVE Bleeding Risk Score\nNo increased risk of bleeding."}, {"order": 3, "name": "Age-Adjusted D-dimer for Venous Thromboembolism (VTE)", "inputs": [{"field": "Age", "value": "78 years"}, {"field": "D-dimer level reported by lab", "value": "1100 ug/L"}, {"field": "D-dimer unit type", "value": "FEU"}], "final_answer": "780 µg/L", "notes": "780 µg/L\nAge-adjusted D-dimer cutoff, FEU\nVTE possible\nReported D-dimer is greater than cutoff; consider confirmatory testing with CTA or V/Q scan"}, {"order": 4, "name": "VTE-BLEED Score", "inputs": [{"field": "Age ≥60 years", "value": "Yes (78 years)", "score": 1.5}, {"field": "Active cancer", "value": "No", "score": 0}, {"field": "Male patient with uncontrolled hypertension", "value": "Yes (SBP 168 mmHg)", "score": 1}, {"field": "Anemia", "value": "Yes (Hb 10.8 g/dL)", "score": 1.5}, {"field": "History of bleeding", "value": "No", "score": 0}, {"field": "Renal dysfunction (creatinine clearance 30-60 mL/min)", "value": "Yes (CrCl 48 mL/min)", "score": 1.5}], "final_answer": 4, "notes": "4 points\nVTE-BLEED Score\nElevated\nBleeding risk"}, {"order": 5, "name": "HAS-BLED Score for Major Bleeding Risk", "inputs": [{"field": "Hypertension (uncontrolled, >160 mmHg systolic)", "value": "Yes (SBP 168 mmHg)", "score": 1}, {"field": "Renal disease", "value": "No (Cr 1.6 mg/dL; eGFR 48 mL/min/1.73 m2; not dialysis/transplant or Cr >2.26)", "score": 0}, {"field": "Liver disease", "value": "No", "score": 0}, {"field": "Stroke history", "value": "No", "score": 0}, {"field": "Prior major bleeding or predisposition to bleeding", "value": "No", "score": 0}, {"field": "Labile INR", "value": "No (not on VKA)", "score": 0}, {"field": "Age >65", "value": "Yes (78 years)", "score": 1}, {"field": "Medication usage predisposing to bleeding (ASA, clopidogrel, NSAIDs)", "value": "No", "score": 0}, {"field": "Alcohol use (≥8 drinks/week)", "value": "No", "score": 0}], "final_answer": 2, "notes": "Risk was 4.1% in one validation study (Lip 2011) and 1.88 bleeds per 100 patient-years in another validation study (Pisters 2010).\nAnticoagulation can be considered, however patient does have moderate risk for major bleeding (~2/100 patient-years)."}, {"order": 6, "name": "Direct-Acting Oral Anticoagulants (DOAC) Score", "inputs": [{"field": "Age, years", "value": "78", "score": 4}, {"field": "Creatinine clearance / eGFR (mL/min)", "value": "48 mL/min", "score": 1}, {"field": "Underweight (BMI <18.5 kg/m2)", "value": "No (BMI 27 kg/m2)", "score": 0}, {"field": "Stroke/TIA/embolism history", "value": "No", "score": 0}, {"field": "Diabetes", "value": "Yes (type 2 diabetes)", "score": 1}, {"field": "Hypertension", "value": "Yes", "score": 1}, {"field": "Antiplatelet use", "value": "No", "score": 0}, {"field": "Nonsteroidal anti-inflammatory (NSAID) use", "value": "No", "score": 0}, {"field": "Bleeding history", "value": "No", "score": 0}, {"field": "Liver disease", "value": "No", "score": 0}], "final_answer": 7, "notes": "Moderate\n1-year major bleeding risk"}, {"order": 7, "name": "GARFIELD-AF", "inputs": [{"field": "Sex", "value": "Male"}, {"field": "Age", "value": "78 years"}, {"field": "Weight", "value": "176 lbs (80 kg)"}, {"field": "Heart failure", "value": "No"}, {"field": "Vascular disease", "value": "No"}, {"field": "Prior stroke", "value": "No"}, {"field": "History of bleeding", "value": "No"}, {"field": "Carotid occlusive disease", "value": "No"}, {"field": "Diabetes", "value": "Yes"}, {"field": "Moderate-to-severe CKD", "value": "Yes (eGFR 48 mL/min/1.73 m2)"}, {"field": "Dementia", "value": "No"}, {"field": "Current smoker", "value": "No"}, {"field": "Antiplatelet treatment", "value": "No"}, {"field": "Ethnicity", "value": "Caucasian"}, {"field": "Pulse", "value": "98 beats/min"}, {"field": "Diastolic blood pressure", "value": "94 mm Hg"}, {"field": "OAC treatment", "value": "NOAC"}], "final_answer": "6 months\nAll-cause mortality: 3.0%\nIschemic stroke/SE: 0.9%\nMajor bleeding: 1.3%\n1 year\nAll-cause mortality: 5.1%\nIschemic stroke/SE: 1.5%\nMajor bleeding: 2.1%\n2 years\nAll-cause mortality: 9.1%\nIschemic stroke/SE: 2.5%\nMajor bleeding: 3.3%", "notes": "6 months\nAll-cause mortality: 3.0%\nIschemic stroke/SE: 0.9%\nMajor bleeding: 1.3%\n1 year\nAll-cause mortality: 5.1%\nIschemic stroke/SE: 1.5%\nMajor bleeding: 2.1%\n2 years\nAll-cause mortality: 9.1%\nIschemic stroke/SE: 2.5%\nMajor bleeding: 3.3%"}, {"order": 8, "name": "4Ts Score for Heparin-Induced Thrombocytopenia", "inputs": [{"field": "Thrombocytopenia", "value": "Platelet count fall >50% AND platelet nadir ≥20 (220 → 110 x10^9/L)", "score": 2}, {"field": "Timing of platelet count fall", "value": "Clear onset between days 5–10 after heparin start (nadir on day 7)", "score": 2}, {"field": "Thrombosis or other sequelae", "value": "None", "score": 0}, {"field": "Other causes for thrombocytopenia", "value": "None apparent", "score": 2}], "final_answer": 6, "notes": "High Probability of HIT (~64%)"}, {"order": 9, "name": "HIT Expert Probability (HEP) Score for Heparin-Induced Thrombocytopenia", "inputs": [{"field": "Type of HIT onset suspected", "value": "Typical (day 5–10)"}, {"field": "Magnitude of platelet count fall (peak to nadir)", "value": ">50% (220 → 110 x10^9/L)", "score": 3}, {"field": "Timing of platelet count fall", "value": "Fall begins 5-10 days after heparin exposure", "score": 3}, {"field": "Nadir platelet count", "value": ">20 x10^9/L (110 x10^9/L)", "score": 2}, {"field": "Thrombosis", "value": "None", "score": 0}, {"field": "Skin necrosis at subcutaneous heparin injection sites", "value": "No", "score": 0}, {"field": "Acute systemic reaction after IV heparin bolus", "value": "No", "score": 0}, {"field": "Presence of bleeding, petechiae or extensive bruising", "value": "No", "score": 0}, {"field": "Presence of chronic thrombocytopenic disorder", "value": "No", "score": 0}, {"field": "Newly initiated non-heparin medication known to cause thrombocytopenia", "value": "No", "score": 0}, {"field": "Severe infection", "value": "No", "score": 0}, {"field": "Severe DIC (fibrinogen <100 mg/dL and D-dimer >5 ug/mL)", "value": "No", "score": 0}, {"field": "Indwelling intra-arterial device (IABP, VAD, ECMO)", "value": "No", "score": 0}, {"field": "Cardiopulmonary bypass within previous 96 hours", "value": "No", "score": 0}, {"field": "No other apparent cause", "value": "Yes", "score": 3}], "final_answer": 11, "notes": "Scores ≥2 are 100% sensitive for HIT."}]}
{"task_id": "medmcp-calc_068_1fb6b272", "task_scenario": "Erectile Dysfunction Scores", "task_category": "Clinical Medicine / Medicine & Organ Systems / Urology & Reproductive System", "patient_id": "P068_1fb6b272", "task_description": "Clinical scenario: A patient presents with erectile dysfunction symptoms and has known advanced liver disease being evaluated for a transjugular intrahepatic portosystemic shunt (TIPS). The clinician needs to quantify ED severity, determine whether to initiate ED therapies now or defer them around the timing of hepatic intervention, and plan follow-up assessment. Workflow steps: 1) Use the International Index of Erectile Function (IIEF-5) to quantify baseline ED severity and categorize the condition (e.g., mild vs moderate/severe). This score frames the initial management pathway. 2) Conditional branch: If IIEF-5 indicates mild ED, pursue conservative measures and schedule follow-up IIEF-5 to monitor response; do not proceed to the next calculator. If IIEF-5 indicates moderate/severe ED and the patient is concurrently being considered for TIPS due to portal hypertension, proceed to Emory Model (TIPSS) to estimate procedural risk. 3) Apply Emory Model (TIPSS) to risk-stratify the planned TIPS. The output deterministically informs ED management timing: • If TIPSS indicates high procedural risk, avoid invasive ED interventions (e.g., procedures or therapies requiring sedation) and favor non-invasive options until hepatic status is optimized; schedule reassessment with IIEF-5 after stabilization. • If TIPSS indicates low procedural risk, proceed with TIPS scheduling and plan ED interventions after post-TIPS stabilization; repeat IIEF-5 at follow-up to gauge improvement and guide therapy escalation. 4) Post-intervention or medical optimization, repeat IIEF-5 to quantify changes in erectile function and adjust the treatment plan accordingly. This sequence ensures ED care is aligned with the risk profile of an imminent hepatic procedure, using calculator outputs to trigger and time subsequent steps.", "fuzzy_question": "I'm reviewing a patient with cirrhosis and portal hypertension who is under evaluation for a TIPS. The patient has had bothersome erectile difficulties for a period of time, and I'm trying to determine the best way to time and tailor ED care in the context of liver disease.\n\nFirst, I want to anchor current status using a brief, validated erectile function questionnaire to determine whether severity appears mild versus more substantial. That initial read will guide everything else.\n\nIf it appears mild, my plan is to stay conservative: counseling, noninvasive measures, and a cautious medication trial if appropriate, then recheck the same questionnaire at follow-up to see whether symptoms are trending in the right direction, without tying ED decisions to the shunt evaluation.\n\nIf it falls in the moderate or worse range, given active consideration for a TIPS, I would review predicted periprocedural risk using a standard pre-procedure risk model. That would directly influence the timing and intensity of ED therapy:\n- If expected risk is high, avoid interventions that require sedation or invasive steps and stick to safer, noninvasive options until hepatic status is better stabilized; then reassess with the same questionnaire and adjust.\n- If expected risk is relatively low, proceed with the TIPS as planned, allow a period for post-procedure stabilization, then revisit ED options after that window, again repeating the questionnaire to gauge what has changed and whether to escalate therapy.\n\nIn either case, after the intervention or after optimizing medical status, I want to repeat the same symptom survey to quantify change and guide next steps.\n\nWhat's your take on this sequencing? Please walk me through it using standard tools: how to categorize the brief ED survey, how you interpret shunt risk, and how you would plan the timing of repeat assessment and therapy adjustments. I need evidence-based risk stratification supported by proper calculations rather than clinical intuition alone. Whatever approach you suggest, make sure it's backed by solid calculations that can withstand scrutiny.", "required_calculators": ["International Index of Erectile Function (IIEF-5)", "Emory Model (TIPSS)"], "calculator_answers": [{"order": 1, "name": "International Index of Erectile Function (IIEF-5)", "inputs": [{"field": "1. How do you rate your confidence that you could get and keep an erection?", "value": "2 (low confidence)"}, {"field": "2. When you had erections with sexual stimulation, how often were your erections hard enough for penetration?", "value": "2 (a few times)"}, {"field": "3. During sexual intercourse, how often were you able to maintain your erection after you had penetrated (entered) your partner?", "value": "2 (a few times)"}, {"field": "4. During sexual intercourse, how difficult was it to maintain your erection to completion of intercourse?", "value": "2 (very difficult)"}, {"field": "5. When you attempted sexual intercourse, how often was it satisfactory for you?", "value": "2 (a few times)"}], "final_answer": 8, "notes": "IEFF-5 Score\n8\nInterpretation\nModerate erectile dysfunction"}, {"order": 2, "name": "Emory Model (TIPSS)", "inputs": [{"field": "Total Bilirubin?", "value": "3.8 mg/dL"}, {"field": "ALT?", "value": "46 U/L"}, {"field": "Pre-TIPSS Hepatic Encephalopathy?", "value": "Yes"}, {"field": "Urgency of TIPSS?", "value": "Elective"}], "final_answer": 2, "notes": "Score\n2\nRisk Category\nModerate Risk\nEstimated Mortality Rates after TIPSS:\nEstimated 3-month Mortality Rates after TIPSS\n25 %\nEstimated 12-month Mortality Rates after TIPSS\n51-57 %\nEstimated 36-month Mortality Rates after TIPSS\n>60 %"}]}
{"task_id": "medmcp-calc_069_e1fcfd1c", "task_scenario": "Perioperative Thromboprophylaxis", "task_category": "Clinical Medicine / Emergency, Critical Care & Perioperative / Anesthesia & Perioperative Medicine", "patient_id": "P069_e1fcfd1", "task_description": "Clinical scenario: A patient on chronic anticoagulation is scheduled for elective cardiac surgery. The perioperative team must design a thromboprophylaxis plan that balances venous thromboembolism risk against bleeding and transfusion risk, while managing interruption and resumption of long-term anticoagulation. The following stepwise workflow uses multiple calculators to structure risk assessment, decision-making, and postoperative reassessment.\nStep 1: Use the Caprini Score for Venous Thromboembolism (2005) preoperatively to stratify baseline surgical VTE risk. This sets the initial intensity of prophylaxis planning (e.g., low vs moderate/high risk categories).\nStep 2: If Caprini indicates moderate/high VTE risk or if pharmacologic prophylaxis is being considered, apply the VTE-BLEED Score to estimate bleeding risk while on anticoagulation. The VTE-BLEED category informs how aggressively pharmacologic prophylaxis or bridging should be pursued.\nStep 3: Calculate the PORT score for PeriOperative Risk of blood Transfusion in cardiac surgery by ACTA to quantify transfusion risk specific to cardiac surgery. A high PORT category signals increased perioperative bleeding/transfusion risk and prompts more cautious anticoagulation timing and intensity.\nStep 4: Use the Perioperative Anticoagulation Management Algorithm to determine hold times, bridging strategy (if any), and resumption timing for chronic anticoagulation. Inputs from Steps 1–3 guide this: for example, high Caprini with low VTE-BLEED and low PORT favors earlier or more intensive pharmacologic strategies; high VTE-BLEED or high PORT favors initial mechanical prophylaxis and delayed pharmacologic resumption.\nStep 5: Postoperatively (in the ICU/ward), reassess in-hospital prophylaxis using the Geneva Risk Score for Venous Thromboembolism (VTE) Prophylaxis. A high Geneva category supports continuing or escalating pharmacologic VTE prophylaxis; a low category supports mechanical measures alone if bleeding risk remains elevated.\nStep 6: Conditional refinement with IMPROVEDD Risk Score for Venous Thromboembolism (VTE): If Geneva is intermediate or there is discordance (e.g., high Caprini but high bleeding/transfusion risk), use IMPROVEDD to integrate D-dimer into the inpatient risk assessment. A high IMPROVEDD category deterministically triggers escalation to pharmacologic prophylaxis once hemostasis is acceptable; a low IMPROVEDD category supports de-escalation or continued mechanical prophylaxis.\nKey decision branches: (a) If Caprini is low, prioritize mechanical prophylaxis and proceed to Step 4 only if chronic anticoagulation needs interruption/resumption; otherwise skip to Step 5 for routine inpatient assessment. (b) If VTE-BLEED or PORT is high, the Perioperative Anticoagulation Management Algorithm will favor delaying pharmacologic measures and avoiding therapeutic bridging, using mechanical methods first. (c) If Geneva is high and IMPROVEDD is low, continue standard-dose prophylaxis; if Geneva is intermediate and IMPROVEDD is high, escalate prophylaxis once surgical bleeding risk is controlled.", "fuzzy_question": "I’m reviewing a case of a patient on chronic anticoagulation who is scheduled for elective cardiac surgery, and I’m developing a perioperative plan that prevents clots without causing bleeding or transfusions.\n\nFirst, I need a clear estimate of baseline clotting risk around this surgery based on patient-specific factors and the nature of the cardiac procedure. I want to categorize this as low versus moderate/high, since that sets the initial intensity of prophylaxis. If low, I would prioritize mechanical measures and manage interruption and restart of the chronic anticoagulant. If moderate/high, we likely need more deliberate pharmacologic prophylaxis and possibly bridging, provided the bleeding profile allows it.\n\nIf any anticoagulation is used around the operation, I also want a structured estimate of bleeding risk while on anticoagulation. Factors such as older age, prior bleeding, anemia, blood pressure, renal function, active cancer, and recent bleeding-prone events are relevant. That bleeding tendency should directly shape decisions about bridging or early resumption versus leaning on mechanical measures first.\n\nBecause this is cardiac surgery, I also want a cardiac-surgery-specific estimate of transfusion risk. If that appears high, it pushes toward more cautious timing and lower-intensity anticoagulation early on, favoring mechanical methods at first and delaying pharmacologic measures until hemostasis is secure.\n\nPulling these together, I need a concrete, medication-specific plan for:\n- how long to hold the current anticoagulant before surgery (taking into account warfarin vs a DOAC and renal function),\n- whether to bridge at all (and at what intensity), and\n- exactly when and at what dose to restart after surgery, once chest tube output and overall hemostasis are acceptable.\n\nIf baseline surgical clot risk is high while bleeding and transfusion risks are reassuring, I would favor earlier or more intensive pharmacologic strategies. If bleeding or transfusion concern is high, I would avoid therapeutic bridging, start with mechanical measures, and delay pharmacologic resumption until it is safe.\n\nOnce in the ICU or on the ward, I want a fresh inpatient read on clot risk based on evolving status (age, immobility, infection, heart failure, prior clots, cancer, limb weakness, central lines, etc.). A high inpatient risk would support continuing or stepping up pharmacologic prophylaxis; a low inpatient risk might support sticking to mechanical methods if bleeding risk remains elevated.\n\nIf that inpatient reassessment is borderline or discordant with the pre-op impression (for example, high pre-op clot risk but also high bleeding/transfusion risk), I would incorporate D-dimer to help tip the balance. If that marker points to ongoing high clot risk, I would plan to escalate to pharmacologic prophylaxis as soon as hemostasis is acceptable. If it suggests low risk, I would be more comfortable de-escalating or staying with mechanical measures. Specifically: if inpatient risk looks high but D-dimer is not elevated, I would continue standard-dose prophylaxis rather than escalate; if inpatient risk is intermediate but D-dimer is clearly elevated, I would escalate once bleeding is under control.\n\nPlease walk through the reasoning along these lines and provide the categories for surgical clot risk, bleeding while anticoagulated, and cardiac-surgery transfusion risk, then translate that into specific hold times, whether or not to bridge, and when/how to restart. After surgery, include the inpatient risk assessment and, if it is borderline or discordant, how D-dimer would shift the plan. This should be supported by solid calculations and able to withstand scrutiny.", "required_calculators": ["Caprini Score for Venous Thromboembolism (2005)", "VTE-BLEED Score", "PORT score for PeriOperative Risk of blood Transfusion in cardiac surgery by ACTA", "Perioperative Anticoagulation Management Algorithm", "Geneva Risk Score for Venous Thromboembolism (VTE) Prophylaxis", "IMPROVEDD Risk Score for Venous Thromboembolism (VTE)"], "calculator_answers": [{"order": 1, "name": "Caprini Score for Venous Thromboembolism (2005)", "inputs": [{"field": "Age, years", "value": "72", "score": 2}, {"field": "Sex", "value": "Male"}, {"field": "Type of surgery", "value": "Major >45 min", "score": 2}, {"field": "Recent (<1 month) major surgery", "value": "No", "score": 0}, {"field": "CHF", "value": "Yes", "score": 1}, {"field": "Sepsis", "value": "No", "score": 0}, {"field": "Pneumonia", "value": "No", "score": 0}, {"field": "Immobilizing plaster cast", "value": "No", "score": 0}, {"field": "Hip, pelvis, or leg fracture", "value": "No", "score": 0}, {"field": "Stroke", "value": "No", "score": 0}, {"field": "Multiple trauma", "value": "No", "score": 0}, {"field": "Acute spinal cord injury causing paralysis", "value": "No", "score": 0}, {"field": "Varicose veins", "value": "No", "score": 0}, {"field": "Current swollen legs", "value": "Yes", "score": 1}, {"field": "Current central venous access", "value": "No", "score": 0}, {"field": "History of DVT/PE", "value": "No", "score": 0}, {"field": "Family history of thrombosis", "value": "No", "score": 0}, {"field": "Positive Factor V Leiden", "value": "No", "score": 0}, {"field": "Positive prothrombin 20210A", "value": "No", "score": 0}, {"field": "Elevated serum homocysteine", "value": "No", "score": 0}, {"field": "Positive lupus anticoagulant", "value": "No", "score": 0}, {"field": "Elevated anticardiolipin antibody", "value": "No", "score": 0}, {"field": "Heparin-induced thrombocytopenia", "value": "No", "score": 0}, {"field": "Other congenital or acquired thrombophilia", "value": "No", "score": 0}, {"field": "Mobility", "value": "Normal, out of bed", "score": 0}, {"field": "History of inflammatory bowel disease", "value": "No", "score": 0}, {"field": "BMI >25 kg/m²", "value": "Yes (BMI 32.6 kg/m²)", "score": 1}, {"field": "Acute MI", "value": "No", "score": 0}, {"field": "COPD", "value": "Yes (mild COPD)", "score": 1}, {"field": "Present or previous malignancy", "value": "No", "score": 0}, {"field": "Other risk factors", "value": "No", "score": 0}], "final_answer": 8, "notes": "8 points\nCaprini VTE Score\nHigh risk\nRecommended prophylaxis: Pneumatic compression devices AND low dose heparin OR low molecular weight heparin\n4.0% VTE risk\n7-10 days total for duration of chemoprophylaxis"}, {"order": 2, "name": "VTE-BLEED Score", "inputs": [{"field": "Age ≥60 years", "value": "Yes (72 years)", "score": 1.5}, {"field": "Active cancer", "value": "No", "score": 0}, {"field": "Male patient with uncontrolled hypertension", "value": "Yes (BP 165/94 mmHg on clinic check despite therapy)", "score": 1}, {"field": "Anemia", "value": "Yes (Hemoglobin 11.2 g/dL)", "score": 1.5}, {"field": "History of bleeding", "value": "Yes (upper GI bleed 2 years ago treated endoscopically)", "score": 1.5}, {"field": "Renal dysfunction (creatinine clearance 30-60 mL/min)", "value": "Yes (CrCl 54 mL/min)", "score": 1.5}], "final_answer": 7, "notes": "7 points\nVTE-BLEED Score\nElevated\nBleeding risk"}, {"order": 3, "name": "PORT score for PeriOperative Risk of blood Transfusion in cardiac surgery by ACTA", "inputs": [{"field": "Age ≥70?", "value": "Yes (72 years)"}, {"field": "Gender", "value": "Male"}, {"field": "Hemoglobin", "value": "11.2 g/dL"}, {"field": "Body Surface Area", "value": "2.07 m²"}, {"field": "Euroscore (logistic)", "value": "8 %"}, {"field": "Creatinine", "value": "1.6 mg/dL"}, {"field": "Type of operation", "value": "Combined valve and CABG (elective combined CABG + mitral valve repair)"}], "final_answer": 21, "notes": "ACTA-PORT Score\n21\nEstimated Risk of Peri-Operative Blood Transfusion\n76.9 %"}, {"order": 4, "name": "Perioperative Anticoagulation Management Algorithm", "inputs": [{"field": "Medication", "value": "Warfarin"}, {"field": "Surgery/procedure bleeding risk", "value": "High"}, {"field": "Date of the planned surgery/procedure", "value": "2026-01-20"}], "final_answer": "Last dose on Tuesday, Jan 13, 2026", "notes": "Last dose on Tuesday, Jan 13, 2026\nSee Next Steps for more details on LMWH bridging"}, {"order": 5, "name": "Geneva Risk Score for Venous Thromboembolism (VTE) Prophylaxis", "inputs": [{"field": "Cardiac failure", "value": "Yes (LVEF 35%)", "score": 2}, {"field": "Respiratory failure", "value": "No", "score": 0}, {"field": "Recent stroke (<3 months ago)", "value": "No", "score": 0}, {"field": "Recent myocardial infarction (<4 weeks ago)", "value": "No", "score": 0}, {"field": "Acute infectious disease (including sepsis)", "value": "No", "score": 0}, {"field": "Acute rheumatic disease", "value": "No", "score": 0}, {"field": "Active malignancy", "value": "No", "score": 0}, {"field": "Myeloproliferative syndrome", "value": "No", "score": 0}, {"field": "Nephrotic syndrome", "value": "No", "score": 0}, {"field": "Any prior VTE", "value": "No", "score": 0}, {"field": "Known hypercoagulable state", "value": "No", "score": 0}, {"field": "Immobilization for ≥3 days (<30 min walking/day)", "value": "Yes (early postoperative period expected ≥3 days limited ambulation)", "score": 1}, {"field": "Recent travel for >6 hrs", "value": "No", "score": 0}, {"field": "Age >60 years", "value": "Yes (72 years)", "score": 1}, {"field": "BMI >30 kg/m²", "value": "Yes (BMI 32.6 kg/m²)", "score": 1}, {"field": "Chronic venous insufficiency", "value": "No", "score": 0}, {"field": "Pregnancy", "value": "No", "score": 0}, {"field": "Hormonal therapy (contraceptive or replacement)", "value": "No", "score": 0}, {"field": "Dehydration", "value": "No", "score": 0}], "final_answer": 5, "notes": "5 points\nGeneva Risk Score for VTE Prophylaxis\n3.2 %\nVTE risk (composite of symptomatic VTE or 90-day VTE mortality)\nHigh risk\nVTE prophylaxis indicated (presuming no contraindications)"}, {"order": 6, "name": "IMPROVEDD Risk Score for Venous Thromboembolism (VTE)", "inputs": [{"field": "Previous VTE", "value": "No", "score": 0}, {"field": "Known thrombophilia", "value": "No", "score": 0}, {"field": "Current lower-limb paralysis", "value": "No", "score": 0}, {"field": "Current cancer", "value": "No", "score": 0}, {"field": "Immobilized ≥7 days", "value": "No", "score": 0}, {"field": "ICU/CCU stay", "value": "Yes (postoperative ICU)", "score": 1}, {"field": "Age >60 years", "value": "Yes (72 years)", "score": 1}, {"field": "D-dimer ≥2x ULN", "value": "Yes (D-dimer 1.2 mg/L FEU; ULN 0.5 mg/L; ~2.4× ULN on POD2)", "score": 2}], "final_answer": 4, "notes": "4 points\nIMPROVEDD Score\n1.6 %\n42-day VTE risk\n1.9 %\n77-day VTE risk"}]}
{"task_id": "medmcp-calc_070_8d2dbda3", "task_scenario": "Preoperative Cardiac/Systemic Risk Assessment", "task_category": "Clinical Medicine / Emergency, Critical Care & Perioperative / Anesthesia & Perioperative Medicine", "patient_id": "P070_8d2dbda3", "task_description": "Scenario: A patient is scheduled for major noncardiac surgery and presents with multiple comorbidities and uncertain functional capacity. The anesthesia team must quantify perioperative cardiac risk, decide whether additional testing or enhanced monitoring is needed, and align perioperative plans (optimization, surveillance, and level of care) accordingly. Workflow: 1) Use the Duke Activity Status Index (DASI) to estimate functional capacity based on everyday activities; treat the result as a first-pass measure of METs. 2) Use Exercise Capacity (METs) to confirm or refine functional capacity classification when the DASI result is borderline or inconsistent; the functional capacity category (adequate vs poor) determines whether additional cardiac risk stratification is needed. 3) Establish global systemic baseline using the ASA Physical Status/ASA Classification to contextualize comorbid burden for anesthesia planning. 4) Estimate perioperative cardiac complication risk with the Revised Cardiac Risk Index for Pre-Operative Risk (RCRI). Decision branch: If functional capacity is adequate and RCRI is low, proceed with standard perioperative planning; if functional capacity is poor and/or RCRI is intermediate to high, further stratify. 5) Apply the Gupta Perioperative Risk for Myocardial Infarction or Cardiac Arrest (MICA) to refine immediate perioperative MI/cardiac arrest risk; use this output to guide perioperative hemodynamic goals and postoperative telemetry needs. 6) If biomarkers are available and the patient’s functional capacity is poor or RCRI/MICA indicate elevated risk, use the VISION perioperative risk using NT-proBNP to integrate biomarker-informed risk for perioperative MI, vascular death, and all-cause death; a higher VISION risk triggers planning for troponin surveillance and higher-acuity postoperative monitoring. 7) If the patient is an older adult, use the Geriatric-Sensitive Perioperative Cardiac Risk Index | GSCRI to account for age-related cardiac vulnerability; elevated GSCRI risk prompts geriatric co-management and conservative hemodynamic targets. 8) Assess frailty using the CSHA Clinical Frailty Scale (CFS); moderate-to-severe frailty informs postoperative disposition (e.g., step-down/ICU), multimodal analgesia strategies to reduce delirium risk, and more cautious fluid management. The sequence moves from functional capacity and global health status to layered cardiac risk quantification, with calculator outputs deterministically triggering subsequent tools and management steps.", "fuzzy_question": "I’m evaluating a patient scheduled for major noncardiac surgery with multiple comorbidities, and I’m uncertain about activity tolerance. I want to develop the safest plan while avoiding unnecessary testing. First, I need a real-world assessment of functional capacity based on typical daily activities and moderate exertion tasks. If that information is unclear or inconsistent, translate it into an exercise-equivalent estimate to determine whether capacity is clearly adequate or likely limited, since that judgment will guide how much additional cardiac risk evaluation is needed.\n\nIn parallel, I need an overall anesthesia fitness classification to contextualize comorbidity burden for perioperative planning. After that, provide a structured estimate of perioperative cardiac complication risk for the planned procedure that incorporates comorbid conditions and surgical risk. If day-to-day capacity appears adequate and predicted event risk is low, I’d proceed with routine planning. If capacity seems limited or the predicted risk isn’t clearly low, I’d want to refine the estimate.\n\nI’m especially looking for a focused prediction of immediate risk of myocardial infarction or cardiac arrest around the time of surgery—something we can use to set hemodynamic targets, decide whether to add invasive monitoring, and determine whether postoperative telemetry is warranted. If natriuretic peptide results (NT-proBNP) are available or can reasonably be obtained—and if capacity is limited or earlier risk signals are elevated—please integrate that biomarker into risk estimates for perioperative MI, vascular death, and all-cause death. If the biomarker-informed risk looks high, I’d plan on postoperative troponin surveillance and a higher-acuity recovery location.\n\nWith age-related considerations in mind, I also want a geriatric-sensitive view of cardiac vulnerability; if that suggests higher risk, let’s involve geriatrics for co-management and keep hemodynamic targets conservative. Lastly, I’d like a bedside frailty assessment; if the result indicates at least moderate frailty, that should push us toward step-down/ICU disposition right after surgery, emphasize multimodal analgesia to reduce delirium risk, and a more cautious fluid strategy.\n\nPlease walk me through this chain of reasoning and show intermediate estimates before committing to recommendations. I’m looking for a final plan that ties quantitative estimates to actions: whether we need any additional preoperative testing, the intraoperative monitoring approach and hemodynamic goals, postoperative telemetry versus step-down/ICU, and whether to institute troponin surveillance. This needs to be backed by solid calculations suitable for scrutiny.", "required_calculators": ["Duke Activity Status Index (DASI)", "Exercise Capacity (METs)", "ASA Physical Status/ASA Classification", "Revised Cardiac Risk Index for Pre-Operative Risk", "Gupta Perioperative Risk for Myocardial Infarction or Cardiac Arrest (MICA)", "VISION perioperative risk using NT-proBNP", "Geriatric-Sensitive Perioperative Cardiac Risk Index | GSCRI", "CSHA Clinical Frailty Scale (CFS)"], "calculator_answers": [{"order": 1, "name": "Duke Activity Status Index (DASI)", "inputs": [{"field": "Take care of self (eating, dressing, bathing, using the toilet)", "value": "Yes", "score": 2.75}, {"field": "Walk indoors", "value": "Yes", "score": 1.75}, {"field": "Walk 1–2 blocks on level ground", "value": "Yes", "score": 2.75}, {"field": "Climb a flight of stairs or walk up a hill", "value": "Yes", "score": 5.5}, {"field": "Run a short distance", "value": "No", "score": 0}, {"field": "Do light work around the house (dusting, washing dishes)", "value": "Yes", "score": 2.7}, {"field": "Do moderate work around the house (vacuuming, sweeping floors, carrying in groceries)", "value": "Yes", "score": 3.5}, {"field": "Do heavy work around the house (scrubbing floors, lifting/moving heavy furniture)", "value": "No", "score": 0}, {"field": "Do yardwork (raking leaves, weeding, pushing a power mower)", "value": "No", "score": 0}, {"field": "Have sexual relations", "value": "Yes", "score": 5.25}, {"field": "Participate in moderate recreational activities (golf, bowling, dancing, doubles tennis)", "value": "Yes", "score": 6}, {"field": "Participate in strenuous sports (swimming, singles tennis, basketball, skiing)", "value": "No", "score": 0}], "final_answer": 30.2, "notes": "30.2 points\nThe higher the score (maximum 58.2), the higher the functional status.\n6.45 METs"}, {"order": 2, "name": "Exercise Capacity (METs)", "inputs": [{"field": "Gender", "value": "Female"}, {"field": "Age", "value": 76}, {"field": "Treadmill Speed", "value": "1.5 mph"}, {"field": "Treadmill Grade", "value": "5 %"}], "final_answer": "3.18 mL/kg/min METs", "notes": "Exercise Capacity\n3.18 mL/kg/min METs\nPredicted Exercise Capacity\n4.82 mL/kg/min METs"}, {"order": 3, "name": "ASA Physical Status/ASA Classification", "inputs": [{"field": "ASA Class", "value": "III - Patient with severe systemic disease"}, {"field": "Emergency surgery", "value": "No"}], "final_answer": "ASA 3", "notes": "ASA 3\nASA Physical Status"}, {"order": 4, "name": "Revised Cardiac Risk Index for Pre-Operative Risk", "inputs": [{"field": "High-risk surgery (intraperitoneal, intrathoracic, suprainguinal vascular)", "value": "Yes", "score": 1}, {"field": "History of ischemic heart disease", "value": "Yes (NSTEMI with DES 5 years ago; no angina currently)", "score": 1}, {"field": "History of congestive heart failure", "value": "No", "score": 0}, {"field": "History of cerebrovascular disease (TIA/stroke)", "value": "No", "score": 0}, {"field": "Pre-operative treatment with insulin", "value": "No (on metformin and GLP-1 RA)", "score": 0}, {"field": "Pre-operative creatinine >2 mg/dL (176.8 µmol/L)", "value": "No (1.6 mg/dL; 141 µmol/L)", "score": 0}], "final_answer": 2, "notes": "2 points\nRCRI Score\n5 %\nRisk of major cardiac event"}, {"order": 5, "name": "Gupta Perioperative Risk for Myocardial Infarction or Cardiac Arrest (MICA)", "inputs": [{"field": "Age (years)", "value": 76}, {"field": "Functional status", "value": "Independent (independent in basic ADLs)"}, {"field": "ASA class", "value": "3"}, {"field": "Creatinine category", "value": "Elevated (>1.5 mg/dL)"}, {"field": "Creatinine value", "value": "1.6 mg/dL (141 µmol/L)"}, {"field": "Type of procedure", "value": "Open intraperitoneal colon resection (colectomy)"}], "final_answer": "0.5 %", "notes": "Risk of myocardial infarction or cardiac arrest, intraoperatively or up to 30 days post-op"}, {"order": 6, "name": "VISION perioperative risk using NT-proBNP", "inputs": [{"field": "High risk surgery (intraperitoneal, intrathoracic, suprainguinal vascular)", "value": "Yes"}, {"field": "History of ischemic heart disease", "value": "Yes"}, {"field": "History of congestive heart failure", "value": "No"}, {"field": "History of cerebrovascular disease", "value": "No"}, {"field": "Diabetes treated with insulin before surgery", "value": "No"}, {"field": "Preoperative serum creatinine >177 µmol/L (>2 mg/dL)", "value": "No (141 µmol/L; 1.6 mg/dL)"}, {"field": "Preoperative NT-proBNP", "value": "720 ng/L"}, {"field": "Timing of NT-proBNP", "value": "Measured 7 days pre-op"}], "final_answer": "28.7% (24.4-33.4%)", "notes": "Risk of Myocardial injury after noncardiac surgery (MINS) and/or vascular death\n28.7% (24.4-33.4%)\nRisk of MI and/or death\n10.1% (7.5-13.5%)\nRisk of MI\n8.5% (6.1-11.7%)\nRisk of death\n1.8 (0.9-3.7%)"}, {"order": 7, "name": "Geriatric-Sensitive Perioperative Cardiac Risk Index | GSCRI", "inputs": [{"field": "History of Stroke", "value": "No"}, {"field": "ASA Class", "value": "III"}, {"field": "Surgery Type", "value": "Intraperitoneal general surgery (open colorectal resection)"}, {"field": "Functional Status", "value": "Independent"}, {"field": "Creatinine", "value": "1.6 mg/dL"}, {"field": "History of Heart Failure", "value": "No"}, {"field": "Diabetes", "value": "Yes (type 2, non-insulin)"}], "final_answer": "2.3%", "notes": "Probability of Perioperative Myocardial Infarction or Cardiac Arrest\n2.3%"}, {"order": 8, "name": "CSHA Clinical Frailty Scale (CFS)", "inputs": [{"field": "Canadian Triage Acuity Scale (5 level ED triage) available?", "value": "No"}, {"field": "Descriptor", "value": "With limited dependence on others for instrumental activities of daily living", "score": 5}], "final_answer": 5, "notes": "5 points\nMildly frail\n72 %\nApproximate probability of avoidance of institutional care at 30 months\nApproximate probability of mortality at 70 months: 58%\n68 %\nApproximate probability of survival at 30 months\nApproximate probability of survival at 70 months: 42%"}]}
{"task_id": "medmcp-calc_071_8f81080c", "task_scenario": "Airway Diseases and Functional Assessment", "task_category": "Clinical Medicine / Medicine & Organ Systems / Respiratory & Thoracic Medicine", "patient_id": "P071_8f81080c", "task_description": "Scenario: An adult with severe viral pneumonia presents with acute hypoxemic respiratory failure requiring high-flow nasal cannula (HFNC). The clinical team must decide whether HFNC is likely to fail and intubation is needed, confirm or refute ARDS once intubated, and personalize ventilator settings to optimize oxygenation while minimizing ventilator-induced lung injury. They also need a pathway to detect ventilator-associated pneumonia (VAP) if oxygenation deteriorates later.\nStep-by-step workflow:\n1) SpO₂/FiO₂ Ratio: Quantify oxygenation on HFNC as a baseline metric of gas exchange. This ratio will be used directly in the ROX Index.\n2) ROX Index for Intubation after HFNC: Input the SpO₂/FiO₂ ratio from step 1 and the patient’s respiratory rate to estimate the likelihood of HFNC failure and need for intubation.\n   - If ROX is reassuring (suggests HFNC success), continue HFNC, monitor, and reassess with step 1 and 2 as needed.\n   - If ROX is low (suggests HFNC failure), proceed to intubation and advance to step 3.\n3) Arterial Blood Gas (ABG) Analyzer: After intubation, interpret the ABG to obtain PaO₂ and PaCO₂. These ABG-derived values feed into subsequent oxygenation assessments.\n4) Horowitz Index for Lung Function (P/F Ratio): Use PaO₂ from the ABG (step 3) and the ventilator FiO₂ to calculate the P/F ratio, stratifying severity of hypoxemia.\n5) Berlin Criteria for Acute Respiratory Distress Syndrome: Apply diagnostic criteria for ARDS using timing, imaging, origin of edema, and severity classification informed by the P/F ratio from step 4.\n   - If ARDS criteria are not met, adjust ventilator strategy for non-ARDS pneumonia and skip to step 8 for gas exchange evaluation as needed.\n   - If ARDS criteria are met (mild/moderate/severe), proceed to recruitability assessment.\n6) Recruitment to Inflation Ratio: Characterize lung recruitability to personalize PEEP. Use this to decide whether higher PEEP will likely open additional lung units.\n   - If R/I shows high recruitability, favor higher PEEP with careful monitoring.\n   - If R/I shows low recruitability, avoid high PEEP to limit overdistension.\n7) Static Lung Compliance (Cstat) Calculation: Calculate lung compliance to support lung-protective ventilation (low tidal volumes, constrained driving pressures). Very low compliance reinforces the need for conservative tidal volumes and may prompt re-evaluation of PEEP from step 6.\n8) A-a O₂ Gradient: Quantify the degree of shunt/V/Q mismatch using ABG data (from step 3) and FiO₂, especially if oxygenation remains poor despite optimized PEEP. A markedly elevated gradient supports investigating additional causes of refractory hypoxemia (e.g., atelectasis, fluid overload, or infectious complications).\n9) Clinical Pulmonary Infection Score (CPIS) for Ventilator-Associated Pneumonia (VAP): If new fever, leukocytosis, secretions, or radiographic changes emerge, compute CPIS. The P/F ratio from step 4 is an input to CPIS. A high CPIS supports obtaining cultures and initiating/adjusting antibiotics; a low CPIS supports observation and continued ventilatory optimization.\nRationale for sequence: Early noninvasive oxygenation assessment (steps 1–2) informs the intubation decision. Post-intubation ABG analysis (step 3) supplies PaO₂ for the P/F ratio (step 4), which feeds into ARDS classification (step 5). Recruitability (step 6) and compliance (step 7) co-direct PEEP and tidal volume strategies. Persistent hypoxemia prompts gas-exchange analysis (step 8). Deterioration or new infectious signs trigger VAP assessment (step 9), which uses the P/F ratio from step 4.", "fuzzy_question": "I'm managing a patient with severe viral pneumonia on high-flow nasal cannula who is significantly hypoxemic and tachypneic. I'm weighing continued high-flow versus intubation and want the decision anchored in objective gas exchange and work of breathing. Please assess how oxygen saturation relates to the delivered oxygen concentration on high-flow, and consider that together with the respiratory rate to judge whether high-flow is likely to succeed or fail. If these indicators support safe continuation, I'm comfortable maintaining high-flow with close monitoring and repeating the same assessment at regular intervals. If they are unfavorable, I would proceed to intubation without delay.\n\nIf intubation is performed, I want an early arterial blood gas to define oxygen and carbon dioxide levels, and to interpret the oxygen value in the context of the fraction of inspired oxygen on the ventilator to quantify hypoxemia severity. Using that, help determine whether the picture fits acute lung injury from pneumonia (ARDS): timing relative to symptom onset, chest imaging findings, noncardiogenic edema versus heart failure, and the degree of oxygenation impairment. If criteria for ARDS are not met, shape the ventilator plan for non-ARDS pneumonia while tracking gas exchange. If ARDS is present—mild, moderate, or severe—tailor PEEP to estimated recruitability: consider higher PEEP with careful surveillance if recruitable, and avoid unnecessary increases if not to reduce overdistension risk.\n\nThroughout, track lung compliance. Very low compliance supports strictly lung-protective settings with small tidal volumes and limited driving pressures, and may prompt revisiting PEEP if benefits are not evident. If oxygenation remains refractory despite optimization, compare expected alveolar oxygen to measured arterial oxygen to quantify mismatch or shunt and guide evaluation for dependent atelectasis, fluid overload, or infectious complications.\n\nIf the patient later develops new fever, leukocytosis, more purulent secretions, or new/worsening opacities with deteriorating oxygenation, use a structured approach to estimate the likelihood of ventilator-associated pneumonia that incorporates those features and the degree of hypoxemia. If the score suggests infection, obtain cultures promptly and initiate or adjust antibiotics; if likelihood is low, continue close observation while optimizing ventilation.\n\nPlease walk through the reasoning in that sequence, and base each step on actual measurements rather than impressions. The recommendations should include explicit calculations and quantitative thresholds to support the decisions.", "required_calculators": ["SpO₂/FiO₂ Ratio", "ROX Index for Intubation after HFNC", "Arterial Blood Gas (ABG) Analyzer", "Horowitz Index for Lung Function (P/F Ratio)", "Berlin Criteria for Acute Respiratory Distress Syndrome", "Recruitment to Inflation Ratio", "Static Lung Compliance (Cstat) Calculation", "A-a O₂ Gradient", "Clinical Pulmonary Infection Score (CPIS) for Ventilator-Associated Pneumonia (VAP)"], "calculator_answers": [{"order": 1, "name": "SpO₂/FiO₂ Ratio", "inputs": [{"field": "SpO2 (%)", "value": "90 %"}, {"field": "FiO2 (%)", "value": "80 %"}], "final_answer": 112.5, "notes": "112.5\nS/F Ratio"}, {"order": 2, "name": "ROX Index for Intubation after HFNC", "inputs": [{"field": "SpO2 (%)", "value": "90 %"}, {"field": "FiO2 (%)", "value": "80 %"}, {"field": "Respiratory rate (breaths/min)", "value": "34 breaths/min"}], "final_answer": 3.31, "notes": "3.31 points\nROX Index\nRisk of HFNC failure is high; intubation should be considered"}, {"order": 3, "name": "Arterial Blood Gas (ABG) Analyzer", "inputs": [{"field": "pH", "value": "7.34"}, {"field": "PaCO2 (mm Hg)", "value": "48 mm Hg"}, {"field": "HCO3- (mEq/L)", "value": "25 mEq/L"}, {"field": "Sodium (mEq/L)", "value": "138 mEq/L"}, {"field": "Chloride (mEq/L)", "value": "102 mEq/L"}, {"field": "Albumin (g/dL)", "value": "3.2 g/dL"}, {"field": "If respiratory process present, chronicity", "value": "Acute"}], "final_answer": "Primary Respiratory Acidosis, Acute, with: Appropriately Compensated by Metabolic Alkalosis", "notes": "Primary Respiratory Acidosis, Acute, with: Appropriately Compensated by Metabolic Alkalosis"}, {"order": 4, "name": "Horowitz Index for Lung Function (P/F Ratio)", "inputs": [{"field": "PaO2 (mm Hg)", "value": "54 mm Hg"}, {"field": "FiO2 (%)", "value": "60 %"}], "final_answer": "90.0 mmHg", "notes": "90.0 mmHg\nHorowitz Index (P/F ratio)\nSevere\nSeverity of ARDS\n45 %\nMortality"}, {"order": 5, "name": "Berlin Criteria for Acute Respiratory Distress Syndrome", "inputs": [{"field": "Timing within 1 week of clinical insult or new/worsening respiratory symptoms", "value": "Yes (day 5 of viral pneumonia symptoms)"}, {"field": "Chest XR shows bilateral opacities not fully explained by effusions, lobar/lung collapse, or nodules", "value": "Yes (bilateral patchy opacities)"}, {"field": "Respiratory failure not fully explained by cardiac failure/fluid overload", "value": "Yes (no clinical volume overload; normal bedside echo)"}, {"field": "Risk factor", "value": "Risk factor for ARDS present (pneumonia)"}, {"field": "Severity (based on oxygenation)", "value": "Severe: PaO2/FiO2 ≤100 mmHg with PEEP ≥5 cm H2O"}], "final_answer": "Positive", "notes": "Diagnostic Result\nPositive\nSevere ARDS"}, {"order": 6, "name": "Recruitment to Inflation Ratio", "inputs": [{"field": "Airway Opening Pressure (cmH2O)", "value": "5 cm H2O"}, {"field": "High PEEP (cmH2O)", "value": "16 cm H2O"}, {"field": "Set Tidal Volume (VT) (mL)", "value": "360 mL"}, {"field": "VT exhaled @ high PEEP (mL)", "value": "340 mL"}, {"field": "Low PEEP (cmH2O)", "value": "8 cm H2O"}, {"field": "VT exhaled from high to low PEEP (mL)", "value": "220 mL"}, {"field": "Plateau Pressure at low PEEP (cmH2O)", "value": "26 cm H2O"}], "final_answer": 0, "notes": "Recruitment to Inflation Ratio\n0\nThis value represents the ratio between the compliance of the recruited lung to that of the respiratory system. Values ≥ 0.5 suggest more potential for lung recruitment with respect to lung inflation.\nLung Recruitability\nLow Recruiter"}, {"order": 7, "name": "Static Lung Compliance (Cstat) Calculation", "inputs": [{"field": "Corrected/delivered tidal volume (ΔV) (mL)", "value": "360 mL"}, {"field": "Plateau pressure (Pplat) (cm H2O)", "value": "28 cm H2O"}, {"field": "PEEP (cm H2O)", "value": "10 cm H2O"}], "final_answer": "20.0 mL/cm H₂O", "notes": "20.0 mL/cm H₂O\nStatic Lung Compliance (Cstat)\nNormal static lung compliance is 50-100 mL/cm H₂O"}, {"order": 8, "name": "A-a O₂ Gradient", "inputs": [{"field": "Atmospheric pressure (mm Hg)", "value": "760 mm Hg"}, {"field": "PaO2 (mm Hg)", "value": "54 mm Hg"}, {"field": "FiO2 (%)", "value": "60 %"}, {"field": "PaCO2 (mm Hg)", "value": "48 mm Hg"}, {"field": "Age (years)", "value": "58 years"}], "final_answer": "313.8 mm Hg", "notes": "313.8 mm Hg\nA-a Gradient\n18.5 mm Hg\nExpected A-a Gradient for Age"}, {"order": 9, "name": "Clinical Pulmonary Infection Score (CPIS) for Ventilator-Associated Pneumonia (VAP)", "inputs": [{"field": "Temperature (°C)", "value": "38.8 °C (category 38.5–38.9 = +1)", "score": 1}, {"field": "White blood cell count", "value": "15.4 x10^9/L (category <4 or >11; no bandemia)", "score": 2}, {"field": "Tracheal secretions", "value": "≥14+ plus purulent secretions (+2)", "score": 2}, {"field": "Oxygenation, PaO2/FiO2 (mm Hg)", "value": "90 mm Hg with ARDS present (0 points per CPIS rule)", "score": 0}, {"field": "Pulmonary radiography", "value": "Localized infiltrate (+2)", "score": 2}, {"field": "Culture of tracheal aspirate specimen", "value": "Pathogenic bacteria cultured >1+ plus same pathogen on gram stain >1+ (+2); e.g., Pseudomonas aeruginosa 3+, Gram stain 3+ GNR", "score": 2}], "final_answer": 9, "notes": "Perform bronchoalveolar lavage (BAL) or mini-BAL."}]}
{"task_id": "medmcp-calc_072_feacb853", "task_scenario": "Psychotic Symptoms and Mania", "task_category": "Clinical Medicine / Neurology & Mental Health / Mental & Psychological Health", "patient_id": "P072_feacb853", "task_description": "Clinical scenario: A patient presents to emergency psychiatric care with marked agitation, decreased need for sleep, pressured speech, grandiosity, and active psychotic symptoms. The clinical team must rapidly ensure safety, differentiate bipolar mania with psychotic features from a primary psychotic disorder, quantify symptom domains, and document a diagnosis and baseline severity for monitoring.\n\nStep 1: Behavioral Activity Rating Scale (BARS). Use BARS immediately to stage agitation and determine safety needs. If BARS indicates severe agitation, prioritize de-escalation and defer self-report tools until the patient is calm enough to participate. If BARS indicates low/moderate agitation, proceed with self-report instruments in Step 2.\n\nStep 2 (self-report pathway if BARS permits): Mood Disorder Questionnaire (MDQ). Screen for a lifetime pattern consistent with bipolar spectrum. A positive screen suggests a bipolar trajectory and raises pretest probability for DSM-5 bipolar criteria in Step 6.\n\nStep 3 (self-report pathway if BARS permits): Bipolar Spectrum Diagnostic Scale (BSDS). Complement MDQ by better detecting bipolar II/cyclothymic presentations. Combine MDQ and BSDS results to strengthen the diagnostic signal for the bipolar pathway in Step 6.\n\nStep 4 (self-report pathway if BARS permits): Altman Self-Rating Mania Scale (ASRM). Obtain the patient’s self-rated current manic symptom severity. If the patient cannot reliably self-report (based on BARS), skip ASRM and proceed to clinician rating in Step 5.\n\nStep 5: Young Mania Rating Scale (YMRS). Clinician-rate the current severity of mania. YMRS establishes whether the presentation meets mild, moderate, or severe mania and acts as a decision trigger for diagnostic confirmation in Step 6.\n\nStep 6 (conditional diagnostic branch): Apply DSM-5 Criteria for Bipolar Disorder if MDQ and/or BSDS are positive OR if YMRS indicates at least moderate current mania. If these screens are negative and YMRS is low, bypass DSM-5 bipolar criteria and prioritize the primary psychosis pathway.\n\nStep 7: Positive and Negative Syndrome Scale (PANSS) for Schizophrenia. Quantify psychotic symptom domains (positive, negative, general psychopathology). Use PANSS whether DSM-5 bipolar criteria are met or not, as psychotic features require domain-level profiling. In bipolar mania with psychotic features, PANSS helps characterize the psychosis within the mood episode; if DSM-5 bipolar criteria are not met, PANSS supports characterization of a primary psychotic disorder.\n\nStep 8: Brief Psychiatric Rating Scale (BPRS). Capture overall psychiatric symptom burden across affective and psychotic domains to establish a global baseline for monitoring trajectory and level-of-care decisions.\n\nStep 9: Clinician-Rated Dimensions of Psychosis Symptom Severity (CRDPSS). Document dimensional aspects of psychosis (hallucinations, delusions, negative symptoms, cognitive symptoms, depression, mania) to align the care plan with the predominant symptom clusters identified by PANSS/BPRS and YMRS.\n\nSafety reassessment: After initial interventions, re-check BARS to confirm that agitation has decreased enough for ongoing engagement and serial monitoring. YMRS, PANSS, and BPRS scores serve as quantitative baselines for follow-up reassessment.", "fuzzy_question": "I’m evaluating a patient in an acute psychiatric setting who appears highly activated—minimal sleep, pressured speech, grandiosity, and active psychosis. I’m weighing an acute manic episode with psychotic features versus a primary psychotic disorder. My goals are safety, clarifying the intensity of mood and psychotic symptoms, and establishing a defensible diagnosis and baseline for follow-up across upcoming shifts.\n\nRight now, my first question is the level of activation in the room—do we need immediate de-escalation and containment, or is there agitation with capacity to participate? If engagement is unreliable, prioritize calming measures and defer self-report until responses are dependable. If agitation is present but manageable, proceed with patient-completed screening.\n\nAssuming participation is possible, I want a brief lifetime screen for bipolarity to identify distinct elevated periods with functional impact, paired with a tool sensitive to subtler bipolar spectrum presentations (including bipolar II/cyclothymic patterns). I don’t want either in isolation; I want to consider them together to clarify the bipolar trajectory before committing diagnostically.\n\nI also want the patient’s self-assessment of current elevation—sleep, energy, thought/speech speed, goal-directed drive, and irritability—to capture the present state from their perspective. If insight or agitation limits reliability, skip self-rating and rely on clinician observation.\n\nEither way, I need a clinician-rated measure of mania severity that places the presentation in a mild vs moderate vs severe range today. That anchors decision-making and serves as the trigger for whether to move toward confirming a bipolar diagnosis now.\n\nDepending on lifetime screens and current severity: if the bipolar signal is present or the clinician rating indicates at least moderate severity, walk through formal diagnostic criteria for bipolar disorder to confirm a manic episode with psychotic features. If screens are quiet and clinician rating is low, favor the primary psychosis track for the moment.\n\nBecause psychotic symptoms are active, obtain a structured psychosis profile—positive, negative, and general domains—regardless of diagnostic direction. In mania with psychotic features, it clarifies psychosis within the mood episode; if mood criteria aren’t met, it supports a schizophrenia-spectrum formulation and guides treatment targets.\n\nIn addition, capture an overall snapshot of psychiatric symptom burden that integrates affective and psychotic features to establish a global baseline for level-of-care decisions and to monitor trajectory over time.\n\nAlso document the dimensional picture clearly—hallucinations, delusions, negative symptoms, cognitive difficulties, and mood elements (depressive and manic)—so the care plan aligns with the domains driving impairment and matches what is seen on the psychosis and mania ratings.\n\nAfter initial interventions, reassess agitation to ensure sufficient reduction to continue collaborative work. Treat the mania rating, psychosis domain profile, and global psychiatric burden as quantitative baselines for follow-up reassessments.\n\nCan you walk through this sequence, explain reasoning at each step, and provide concrete ratings and a defensible diagnostic conclusion? I need proper calculations and standardized scoring—this decision can’t rest on clinical intuition alone and should withstand scrutiny.", "required_calculators": ["Behavioral Activity Rating Scale (BARS)", "Mood Disorder Questionnaire (MDQ)", "Bipolar Spectrum Diagnostic Scale (BSDS)", "Altman Self-Rating Mania Scale (ASRM)", "Young Mania Rating Scale (YMRS)", "DSM-5 Criteria for Bipolar Disorder", "Positive and Negative Syndrome Scale (PANSS) for Schizophrenia", "Brief Psychiatric Rating Scale (BPRS)", "Clinician-Rated Dimensions of Psychosis Symptom Severity (CRDPSS)"], "calculator_answers": [{"order": 1, "name": "Behavioral Activity Rating Scale (BARS)", "inputs": [{"field": "observation_category", "value": "Extremely or continuously active, not requiring restraint"}], "final_answer": 6, "notes": "6 points\nBehavioral Activity Rating Scale\nExtremely or continuously active, not requiring restraint\nPatient activity assessment"}, {"order": 2, "name": "Mood Disorder Questionnaire (MDQ)", "inputs": [{"field": "Q1_so_good_or_hyper", "value": "Yes"}, {"field": "Q2_so_irritable_shouted_or_started_fights", "value": "Yes"}, {"field": "Q3_much_more_self_confident", "value": "Yes"}, {"field": "Q4_much_less_sleep_didnt_miss_it", "value": "Yes"}, {"field": "Q5_much_more_talkative_or_spoke_faster", "value": "Yes"}, {"field": "Q6_racing_thoughts", "value": "Yes"}, {"field": "Q7_easily_distracted_trouble_concentrating", "value": "Yes"}, {"field": "Q8_much_more_energy", "value": "Yes"}, {"field": "Q9_much_more_active_did_many_more_things", "value": "Yes"}, {"field": "Q10_much_more_social_or_outgoing", "value": "Yes"}, {"field": "Q11_much_more_interested_in_sex", "value": "Yes"}, {"field": "Q12_did_unusual_excessive_foolish_or_risky_things", "value": "Yes"}, {"field": "Q13_spending_money_caused_trouble", "value": "Yes"}, {"field": "Q14_symptoms_occurred_during_same_period", "value": "Yes"}, {"field": "Q15_severity_of_problems_caused", "value": "Serious problem"}], "final_answer": "Positive Screening for Bipolar I Disorder", "notes": "Screening Interpretation\nPositive Screening for Bipolar I Disorder"}, {"order": 3, "name": "Bipolar Spectrum Diagnostic Scale (BSDS)", "inputs": [{"field": "S1_mood_energy_shifts_drastic", "value": "Yes"}, {"field": "S2_low_then_high_phases", "value": "Yes"}, {"field": "S3_low_phase_lack_energy_excess_sleep_low_motivation", "value": "Yes"}, {"field": "S4_weight_gain_during_lows", "value": "No"}, {"field": "S5_low_phase_feel_blue_sad_depressed", "value": "Yes"}, {"field": "S6_low_phase_helpless_or_suicidal", "value": "No"}, {"field": "S7_function_impairment_work_social", "value": "Yes"}, {"field": "S8_low_phase_typically_last_days_weeks", "value": "Yes"}, {"field": "S9_periods_of_normal_between_swings", "value": "Yes"}, {"field": "S10_marked_shift_switch_in_feelings", "value": "Yes"}, {"field": "S11_energy_above_normal_get_many_things_done", "value": "Yes"}, {"field": "S12_high_periods_feel_too_much_energy_hyper", "value": "Yes"}, {"field": "S13_high_periods_irritable_on_edge_aggressive", "value": "Yes"}, {"field": "S14_high_periods_too_many_activities", "value": "Yes"}, {"field": "S15_high_periods_spend_money_cause_trouble", "value": "Yes"}, {"field": "S16_more_talkative_outgoing_or_sexual", "value": "Yes"}, {"field": "S17_behavior_seems_strange_or_annoying_to_others", "value": "Yes"}, {"field": "S18_difficulty_with_coworkers_or_police_during_highs", "value": "Yes"}, {"field": "S19_increase_alcohol_or_nonprescription_drug_use_during_highs", "value": "No"}, {"field": "S20_overall_fit", "value": "Fits very well"}], "final_answer": 22, "notes": "Score\n22\nScreening Interpretation\nBipolar spectrum disorder high probability\nStatistical Measures\nSensitivity 26.7% Specificity 93.5%"}, {"order": 4, "name": "Altman Self-Rating Mania Scale (ASRM)", "inputs": [{"field": "timeframe", "value": "Past 7 days"}, {"field": "Mood_score_0to4", "value": 4}, {"field": "Self_confidence_score_0to4", "value": 4}, {"field": "Sleep_score_0to4", "value": 4}, {"field": "Speech_score_0to4", "value": 3}, {"field": "Activity_level_score_0to4", "value": 3}], "final_answer": 18, "notes": "ASRM Score\n18\nInterpretation\nHigh probability of hypomania or mania\nStatistical Measures\nSensitivity 87.3% Specificity 85.5%"}, {"order": 5, "name": "Young Mania Rating Scale (YMRS)", "inputs": [{"field": "1_Elevated_Mood_0to4", "value": 4}, {"field": "2_Increased_Motor_Activity_Energy_0to4", "value": 4}, {"field": "3_Sexual_Interest_0to4", "value": 3}, {"field": "4_Sleep_0to4", "value": 4}, {"field": "5_Irritability_0to8", "value": 6}, {"field": "6_Speech_rate_amount_0to8", "value": 6}, {"field": "7_Language_Thought_Disorder_0to4", "value": 3}, {"field": "8_Content_0to8", "value": 6}, {"field": "9_Disruptive_Aggressive_Behavior_0to8", "value": 4}, {"field": "10_Appearance_0to4", "value": 3}, {"field": "11_Insight_0to4", "value": 4}], "final_answer": 45, "notes": "Clinician-rated during initial assessment; score consistent with severe mania."}, {"order": 6, "name": "DSM-5 Criteria for Bipolar Disorder", "inputs": [{"field": "distinct_period_elevated_expansive_or_irritable_mood_and_increased_energy", "value": "Yes"}, {"field": "duration_manic_episode", "value": "10 days (present most of the day, nearly every day)"}, {"field": "manic_symptoms_grandiosity", "value": "Yes"}, {"field": "manic_symptoms_decreased_need_for_sleep", "value": "Yes"}, {"field": "manic_symptoms_more_talkative_pressured_speech", "value": "Yes"}, {"field": "manic_symptoms_flight_of_ideas_racing_thoughts", "value": "Yes"}, {"field": "manic_symptoms_distractibility", "value": "Yes"}, {"field": "manic_symptoms_increase_goal_directed_activity_or_psychomotor_agitation", "value": "Yes"}, {"field": "manic_symptoms_risky_activities", "value": "Yes"}, {"field": "psychotic_features_present", "value": "Yes (grandiose delusions; intermittent auditory hallucinations)"}, {"field": "impairment_or_hospitalization", "value": "Yes (marked impairment requiring inpatient care for safety)"}, {"field": "episode_not_attributable_to_substance_or_medical_condition", "value": "Yes (no substance intoxication; no medical cause identified)"}, {"field": "schizoaffective_or_schizophrenia_ruled_out", "value": "Yes (psychotic symptoms occur in the context of a full manic syndrome; lifetime history supports bipolar trajectory)"}], "final_answer": "Positive", "notes": "Diagnostic Result\nPositive\nPositive for bipolar I disorder by DSM-5 Criteria"}, {"order": 7, "name": "Positive and Negative Syndrome Scale (PANSS) for Schizophrenia", "inputs": [{"field": "P1_Delusions_1to7", "value": "Severe", "score": 6}, {"field": "P2_Conceptual_disorganization_1to7", "value": "Moderate", "score": 4}, {"field": "P3_Hallucinatory_behavior_1to7", "value": "Moderate-severe", "score": 5}, {"field": "P4_Excitement_1to7", "value": "Severe", "score": 6}, {"field": "P5_Grandiosity_1to7", "value": "Severe", "score": 6}, {"field": "P6_Suspiciousness_persecution_1to7", "value": "Moderate-severe", "score": 5}, {"field": "P7_Hostility_1to7", "value": "Moderate", "score": 4}, {"field": "N1_Blunted_affect_1to7", "value": "Minimal", "score": 2}, {"field": "N2_Emotional_withdrawal_1to7", "value": "Minimal", "score": 2}, {"field": "N3_Poor_rapport_1to7", "value": "Minimal", "score": 2}, {"field": "N4_Passive_apathetic_social_withdrawal_1to7", "value": "Minimal", "score": 2}, {"field": "N5_Difficulty_in_abstract_thinking_1to7", "value": "Mild", "score": 3}, {"field": "N6_Lack_of_spontaneity_flow_of_conversation_1to7", "value": "Mild", "score": 3}, {"field": "N7_Stereotyped_thinking_1to7", "value": "Minimal", "score": 2}, {"field": "G1_Somatic_concern_1to7", "value": "Absent", "score": 1}, {"field": "G2_Anxiety_1to7", "value": "Mild", "score": 3}, {"field": "G3_Guilt_feelings_1to7", "value": "Absent", "score": 1}, {"field": "G4_Tension_1to7", "value": "Moderate-severe", "score": 5}, {"field": "G5_Mannerisms_posturing_1to7", "value": "Minimal", "score": 2}, {"field": "G6_Depression_1to7", "value": "Absent", "score": 1}, {"field": "G7_Motor_retardation_1to7", "value": "Absent", "score": 1}, {"field": "G8_Uncooperativeness_1to7", "value": "Moderate", "score": 4}, {"field": "G9_Unusual_thought_content_1to7", "value": "Moderate-severe", "score": 5}, {"field": "G10_Disorientation_1to7", "value": "Absent", "score": 1}, {"field": "G11_Poor_attention_1to7", "value": "Moderate-severe", "score": 5}, {"field": "G12_Lack_of_judgement_and_insight_1to7", "value": "Severe", "score": 6}, {"field": "G13_Disturbance_of_volition_1to7", "value": "Mild", "score": 3}, {"field": "G14_Poor_impulse_control_1to7", "value": "Moderate-severe", "score": 5}, {"field": "G15_Preoccupation_1to7", "value": "Moderate-severe", "score": 5}, {"field": "G16_Active_social_avoidance_1to7", "value": "Minimal", "score": 5}], "final_answer": 101, "notes": "101 points\nPANSS Score\nPositive Scale: 36 points\nNegative Scale: 16 points\nGeneral Psychopathology Scale: 49 points\nMarkedly ill\nSchizophrenia severity"}, {"order": 8, "name": "Brief Psychiatric Rating Scale (BPRS)", "inputs": [{"field": "1_Somatic_Concern_1to7", "value": 2}, {"field": "2_Anxiety_1to7", "value": 3}, {"field": "3_Emotional_Withdrawal_1to7", "value": 2}, {"field": "4_Conceptual_Disorganization_1to7", "value": 5}, {"field": "5_Guilt_1to7", "value": 1}, {"field": "6_Tension_1to7", "value": 6}, {"field": "7_Mannerisms_Posturing_1to7", "value": 2}, {"field": "8_Grandiosity_1to7", "value": 6}, {"field": "9_Depression_1to7", "value": 1}, {"field": "10_Hostility_1to7", "value": 4}, {"field": "11_Suspiciousness_1to7", "value": 5}, {"field": "12_Hallucinations_1to7", "value": 5}, {"field": "13_Motor_Retardation_1to7", "value": 1}, {"field": "14_Uncooperativeness_1to7", "value": 4}, {"field": "15_Unusual_Thought_Content_1to7", "value": 5}, {"field": "16_Blunted_Affect_1to7", "value": 2}, {"field": "17_Excitement_1to7", "value": 6}, {"field": "18_Disorientation_1to7", "value": 1}], "final_answer": 61, "notes": "BPRS Score\n61"}, {"order": 9, "name": "Clinician-Rated Dimensions of Psychosis Symptom Severity (CRDPSS)", "inputs": [{"field": "I_Hallucinations_0to4", "value": 2}, {"field": "II_Delusions_0to4", "value": 3}, {"field": "III_Disorganized_speech_0to4", "value": 2}, {"field": "IV_Abnormal_psychomotor_behavior_0to4", "value": 3}, {"field": "V_Negative_symptoms_0to4", "value": 1}, {"field": "VI_Impaired_cognition_0to4", "value": 2}, {"field": "VII_Depression_0to4", "value": 0}, {"field": "VIII_Mania_0to4", "value": 4}], "final_answer": 17, "notes": "CRDPSS Score\n17"}]}
{"task_id": "medmcp-calc_073_b7696abc", "task_scenario": "Neuro-oncology and Functional Status", "task_category": "Clinical Medicine / Neurology & Mental Health / Neurosurgery & Neurology", "patient_id": "P073_b7696abc", "task_description": "Clinical scenario: An older patient with known systemic malignancy presents with symptomatic brain metastases and fluctuating consciousness. The care team must triage acuity, estimate neuro-oncologic prognosis, assess functional and cognitive status, and plan radiation and systemic therapy while mitigating treatment toxicity. Step-by-step calculator use: 1) GCS-Pupils Score: Perform immediate bedside neurologic triage to determine severity. If the score indicates severe impairment, proceed to step 2 before any oncologic decisions; if not severe, skip to step 3. 2) Cerebral Perfusion Pressure: If the patient is critically ill per GCS-Pupils, calculate cerebral perfusion pressure to decide on urgent intracranial pressure and hemodynamic optimization. If perfusion is inadequate, initiate neurocritical stabilization and defer oncology planning; re-assess with GCS-Pupils after stabilization, then proceed. If adequate, move forward. 3) Karnofsky Performance Status Scale: Establish baseline functional capacity. This score is then used as a required input for the next step’s prognostic assessment. 4) Brain Metastases Prognostic Index: Use the graded prognostic assessment, incorporating the Karnofsky result, to estimate survival and treatment benefit. If the index suggests poor prognosis, pivot toward comfort-focused care; otherwise proceed to treatment planning steps while still documenting functional needs. 5) ECOG Performance Status: Determine therapy tolerance in parallel with Karnofsky, and use ECOG as a required input for chemotherapy toxicity prediction later. If ECOG suggests poor performance, emphasize supportive care and avoid aggressive systemic therapy; if acceptable, continue. 6) Montreal Cognitive Assessment (MoCA): Screen for cognitive impairment to guide consent capacity, caregiver support, and the suitability of neurotoxic regimens. If impairment is present, plan enhanced support and consider less cognitively taxing therapies; otherwise continue without modification. 7) Barthel Index for Activities of Daily Living (ADL): Quantify independence to inform discharge planning and whether intensive therapy is feasible. If low independence, integrate rehabilitation or palliative supports; if high independence, aggressive therapy may remain appropriate. 8) Brain Metastasis Velocity (BMV) Model: If the patient previously underwent or is planned for stereotactic radiosurgery, estimate the rate of distant brain failure. High velocity prompts consideration of whole-brain approaches or closer surveillance; low velocity supports focal therapy and routine follow-up. 9) Cancer and Aging Research Group Chemotherapy Toxicity Tool (CARG-TT): For an older candidate for systemic therapy, use ECOG from step 5 as a required input to estimate severe toxicity risk. High risk directs toward dose attenuation or alternative regimens; lower risk supports standard protocols. The sequence ensures acute stabilization precedes oncologic decisions, prognosis and performance status drive intensity of therapy, cognitive and ADL assessments tailor support needs, and radiotherapy plus chemotherapy plans are refined by risk modeling.", "fuzzy_question": "I’m seeing a patient with systemic cancer who has symptomatic brain lesions and fluctuating alertness. I’m trying to figure out the best approach that balances urgency, prognosis, and treatment intensity while avoiding avoidable toxicity.\n\nRight now I need a quick bedside sense of neurological status—how awake the patient is and what the pupils are doing. If that looks severe, I’d press pause on oncology choices and first make sure the brain is being perfused adequately given overall hemodynamics and intracranial pressure. If clinical parameters suggest the brain isn’t getting enough flow, I’d prioritize ICP and hemodynamic stabilization and only come back to cancer planning after stabilization and a rechecked neuro exam. If the bedside picture isn’t that dire or improves with stabilization, I’m comfortable moving forward.\n\nFrom there, I want a clear read on day-to-day function—whether the patient is mostly independent or spending much of the day in bed. That functional baseline should feed directly into a realistic survival estimate for brain metastases so we can judge whether radiation or systemic therapy is likely to meaningfully help. If the outlook is very limited, I’d lean toward comfort-focused care; if more favorable, we can proceed with treatment planning while documenting needed supports.\n\nIn parallel, I’d like a simple therapy-tolerance rating; if it’s on the poor end, I’d avoid aggressive systemic therapy and emphasize supportive care, but if it’s acceptable we can consider standard options. Given the fluctuating mentation, a brief cognitive screen would help assess decision-making capacity, caregiver needs, and how risky neurotoxic regimens might be—if impaired, we’ll plan extra support and choose less cognitively taxing treatments. I also want a feel for basic activities of daily living—feeding, bathing, transfers—so we can plan discharge and judge how intensive we can be; low independence pushes me toward integrating rehab or palliative supports, while higher independence keeps more aggressive therapy on the table.\n\nIf the patient has already had, or we’re planning, focal radiosurgery, I’d like to gauge how fast new brain lesions are likely to appear over time. If intracranial disease tends to appear quickly, that nudges us toward whole-brain approaches or very close surveillance; if it’s slower, focal therapy with routine follow-up is reasonable. Because age-related factors may influence systemic therapy candidacy, I want a geriatric toxicity risk estimate that incorporates the therapy-tolerance rating; if risk is high, we should consider dose attenuation or alternate regimens, and if lower, standard dosing may be fine.\n\nWhat’s your take on this sequence? Anything you’d weigh differently? I really need proper calculations on this; I can’t make this decision based on gut feeling alone. Whatever approach you suggest, make sure it’s backed by solid calculations, okay? This needs to hold up to scrutiny.", "required_calculators": ["GCS-Pupils Score", "Cerebral Perfusion Pressure", "Karnofsky Performance Status Scale", "Brain Metastases Prognostic Index", "Eastern Cooperative Oncology Group (ECOG) Performance Status", "Montreal Cognitive Assessment (MoCA)", "Barthel Index for Activities of Daily Living (ADL)", "Brain Metastasis Velocity (BMV) Model", "Cancer and Aging Research Group Chemotherapy Toxicity Tool (CARG-TT)"], "calculator_answers": [{"order": 1, "name": "GCS-Pupils Score", "inputs": [{"field": "Eye response", "value": "Eye opening to pain (+2)", "score": 2}, {"field": "Verbal response", "value": "Incomprehensible sounds (+2)", "score": 2}, {"field": "Motor response", "value": "Withdrawal from pain (+4)", "score": 4}, {"field": "Pupil response", "value": "One pupil unreactive to light (-1)", "score": -1}], "final_answer": 7, "notes": "7 points\nGCS-Pupils Score\n19.17 %\nMortality at 6 months post-injury\n37.20 %\nUnfavorable outcome (vegetative state or severe disability) at 6 months post-injury"}, {"order": 2, "name": "Cerebral Perfusion Pressure", "inputs": [{"field": "MAP", "value": "70 mm Hg"}, {"field": "ICP", "value": "25 mm Hg"}], "final_answer": 45, "notes": "45 mmHg\nLow CPP. Consider interventions to increase MAP or decrease ICP (see Next Steps for details)."}, {"order": 3, "name": "Karnofsky Performance Status Scale", "inputs": [{"field": "Patient description", "value": "Requires considerable assistance and frequent medical care"}], "final_answer": 50, "notes": "50 points\nUnable to work; able to live at home and care for most personal needs; varying amount of assistance needed.\nCorrelates to an ECOG Performance Status of 2.\nSee definitions of the Karnofsky Scale on the About section."}, {"order": 4, "name": "Brain Metastases Prognostic Index", "inputs": [{"field": "Tumor Type", "value": "Non-small cell lung cancer"}, {"field": "Karnofsky Performance Score (KPS)", "value": "50"}, {"field": "Extracranial Metastases", "value": "Yes"}, {"field": "Number of Brain Metastases", "value": "5"}, {"field": "Age", "value": "76 years"}, {"field": "Breast Cancer subtype (if applicable)", "value": "Not applicable"}], "final_answer": 0, "notes": "Diagnosis-Specific Graded Prognostic Assessment Index\n0\nMedian Survival (Months)\n3 Months"}, {"order": 5, "name": "Eastern Cooperative Oncology Group (ECOG) Performance Status", "inputs": [{"field": "Patient description", "value": "Symptomatic, <50% in bed during the day"}], "final_answer": 2, "notes": "2 points\nCapable of all self care, but no work activities, out of bed >50% of day.\nSee definitions of the ECOG/Zubrod Score in the About section."}, {"order": 6, "name": "Montreal Cognitive Assessment (MoCA)", "inputs": [{"field": "More than 12 years of education", "value": "No (+1)", "score": 1}, {"field": "Trail making (trace diagram in order)", "value": "Did not complete correctly (0)", "score": 0}, {"field": "Copy cube", "value": "Did not complete correctly (0)", "score": 1}, {"field": "Clock drawing", "value": "Correctly drew two out of three features (+2)", "score": 2}, {"field": "Naming - lion", "value": "Named lion (+1)", "score": 1}, {"field": "Naming - rhinoceros", "value": "Did not name rhinoceros (0)", "score": 0}, {"field": "Naming - camel", "value": "Named camel (+1)", "score": 1}, {"field": "Forward digit span (2,1,8,5,4)", "value": "Repeated correctly (+1)", "score": 1}, {"field": "Backward digit span (7,4,2)", "value": "Did not repeat correctly (0)", "score": 0}, {"field": "Letter A tapping", "value": "≥2 errors (0)", "score": 0}, {"field": "Serial 7s", "value": "2 or 3 correct (+2)", "score": 2}, {"field": "Sentence repetition 1", "value": "Repeated correctly (+1)", "score": 1}, {"field": "Sentence repetition 2", "value": "Did not repeat correctly (0)", "score": 0}, {"field": "Letter fluency (words beginning with F in 1 minute)", "value": "Named <11 words (0)", "score": 0}, {"field": "Abstraction - train and bicycle", "value": "Answered correctly (+1)", "score": 1}, {"field": "Abstraction - watch and ruler", "value": "Did not answer correctly (0)", "score": 0}, {"field": "Delayed recall (Face, Velvet, Church, Daisy, Red)", "value": "Recalled 2 words (+2)", "score": 2}, {"field": "Orientation (date, month, year, day, place, city)", "value": "4 correct (+4)", "score": 4}], "final_answer": 16, "notes": "Lower scores indicate more cognitive impairment; cutoff of <26 points is 90% sensitive for mild cognitive impairment."}, {"order": 7, "name": "Barthel Index for Activities of Daily Living (ADL)", "inputs": [{"field": "Feeding", "value": "Needs help (+5)", "score": 5}, {"field": "Bathing", "value": "Unable (0)", "score": 0}, {"field": "Grooming", "value": "Unable (0)", "score": 0}, {"field": "Dressing", "value": "Needs help (+5)", "score": 5}, {"field": "Bowel control", "value": "Occasional accident (+5)", "score": 5}, {"field": "Bladder control", "value": "Occasional accident (+5)", "score": 5}, {"field": "Toilet use", "value": "Needs help (+5)", "score": 5}, {"field": "Transfers (bed to chair and back)", "value": "Needs major help (1-2 people), can sit (+5)", "score": 5}, {"field": "Mobility on level surfaces", "value": "Walks with help of one person >50 yards (+10)", "score": 10}, {"field": "Stairs", "value": "Needs help (+5)", "score": 5}], "final_answer": 45, "notes": "45 points\nPartially dependent"}, {"order": 8, "name": "Brain Metastasis Velocity (BMV) Model", "inputs": [{"field": "Number of new brain metastases since initial SRS", "value": "4 metastases"}, {"field": "Time interval between initial SRS and appearance of new brain metastases", "value": "0.75 years"}], "final_answer": 5.3, "notes": "Diagnostic Result\n5.3 per year\nBMV\nIntermediate risk\nRisk group\n8.2 months\nMedian overall survival"}, {"order": 9, "name": "Cancer and Aging Research Group Chemotherapy Toxicity Tool (CARG-TT)", "inputs": [{"field": "Sex", "value": "Male"}, {"field": "Age, years", "value": "76", "score": 2}, {"field": "Cancer type", "value": "Other", "score": 0}, {"field": "Dosage (first dose of chemotherapy)", "value": "Standard dose", "score": 2}, {"field": "Number of chemotherapy drugs", "value": "1", "score": 0}, {"field": "Hemoglobin, g/dL", "value": "≥11 g/dL", "score": 0}, {"field": "Creatinine clearance, mL/min", "value": "48 mL/min", "score": 0}, {"field": "Hearing", "value": "Fair", "score": 2}, {"field": "Number of falls in the past six months", "value": "1", "score": 3}, {"field": "Needs help taking meds", "value": "Yes", "score": 1}, {"field": "Walking ability within one block", "value": "Limited", "score": 2}, {"field": "Social activity decreased due to health", "value": "Yes", "score": 1}], "final_answer": 13, "notes": "13 points\nCARG-TT Score\n83 %\nHigh risk of Grade 3 or greater toxicity"}]}
{"task_id": "medmcp-calc_074_a26c3ebe", "task_scenario": "Cancer Prognosis and Performance Status", "task_category": "Clinical Medicine / Medicine & Organ Systems / Hematology & Oncology", "patient_id": "P074_a26c3ebe", "task_description": "Scenario: An older adult is newly diagnosed with diffuse large B‑cell lymphoma (DLBCL). The clinical team needs to integrate cancer prognosis with performance status to tailor initial therapy intensity, determine the need for CNS prophylaxis, anticipate toxicity, plan supportive care, and prepare contingency pathways for relapse and potential transplantation. Workflow: First, establish baseline disease risk using the International Prognostic Index for Diffuse Large B-cell Lymphoma (IPI and R-IPI). If the R‑IPI places the patient in an intermediate‑to‑high risk category, refine risk stratification with the National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI) to better estimate overall and progression-free survival. Based on high NCCN‑IPI risk or other high‑risk features, assess CNS relapse risk using the Central Nervous System International Prognostic Index (CNS-IPI) to decide whether CNS prophylaxis is warranted in the initial treatment plan. Next, determine the patient’s ability to tolerate systemic therapy using the Eastern Cooperative Oncology Group (ECOG) Performance Status. If performance status is poor, consider dose-attenuated or palliative approaches; if acceptable, proceed to geriatric vulnerability screening with the G8 Geriatric Screening Tool. If the G8 screening is abnormal, estimate severe chemotherapy toxicity risk with the Cancer and Aging Research Group Chemotherapy Toxicity Tool (CARG‑TT) to guide regimen intensity, supportive measures, and care setting. Quantify comorbidity burden using the Charlson Comorbidity Index (CCI), and integrate these results with ECOG and CARG‑TT to finalize initial regimen selection and need for prophylactic growth factor support or enhanced monitoring. During treatment, if the patient presents with febrile neutropenia, use the MASCC Risk Index for Febrile Neutropenia to triage outpatient versus inpatient management. If the disease fails to respond or relapses, estimate survival and guide salvage strategies using the Prognosis Calculator for Relapsed/Refractory DLBCL. For patients selected for autologous or allogeneic hematopoietic cell transplantation based on salvage planning, evaluate transplant risk with the Hematopoietic Cell Transplantation-specific Comorbidity Index (HCT‑CI) to inform eligibility and peri-transplant risk mitigation.", "fuzzy_question": "I am evaluating an older adult newly diagnosed with DLBCL and planning an initial approach that aims for cure while remaining safe. Recent labs and staging are being finalized, and energy levels have been variable. I want an objective baseline disease risk using standard DLBCL clinical factors (age category, stage, LDH status, extent of involvement, and day-to-day functioning). If that places the patient anywhere above very low risk, I would like a more granular contemporary model to refine overall and progression-free outlook for accurate counseling.\n\nIf the refined assessment suggests higher risk—or if there are features associated with possible CNS sanctuary involvement (such as multiple extranodal sites or high-risk organ involvement)—I would appreciate a structured estimate of CNS relapse risk to guide whether CNS prophylaxis (intrathecal or systemic) should be included upfront.\n\nIn parallel, I need a clear assessment of treatment tolerance. First, determine performance status; if poor, consider a dose-attenuated or palliative approach. If acceptable, perform a brief frailty screen; if concerning, follow with a detailed older-adult chemotherapy toxicity prediction to quantify the risk of severe toxicity. Use this to recommend regimen intensity, whether to start as an outpatient versus with closer inpatient/observation for the first cycle, and what supportive measures to put in place upfront.\n\nI also want a formal, weighted comorbidity assessment—not just a list—integrated with functional status and the older-adult toxicity estimate to finalize the initial regimen and decide on primary growth-factor support and tighter monitoring from the start.\n\nDuring treatment, if febrile neutropenia occurs, please use a bedside risk approach to decide who can be safely managed at home versus who requires admission, so the triage is clear rather than improvised overnight.\n\nIf the disease is refractory or relapses, I would like an evidence-based survival outlook at that point and a reasoned salvage pathway tailored to fitness, including when to pursue consolidation strategies. If proceeding to autologous or allogeneic transplant, please quantify transplant risk with a transplant-specific comorbidity framework to judge eligibility and plan peri-transplant risk mitigation.\n\nWhat is your approach to this sequence, and how would you reason through it? Please base recommendations on validated calculations—this decision-making needs to withstand scrutiny.", "required_calculators": ["International Prognostic Index for Diffuse Large B-cell Lymphoma (IPI and R-IPI)", "National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI)", "Central Nervous System International Prognostic Index (CNS-IPI)", "Eastern Cooperative Oncology Group (ECOG) Performance Status", "G8 Geriatric Screening Tool", "Cancer and Aging Research Group Chemotherapy Toxicity Tool (CARG-TT)", "Charlson Comorbidity Index (CCI)", "MASCC Risk Index for Febrile Neutropenia", "Prognosis Calculator for Relapsed/Refractory DLBCL", "Hematopoietic Cell Transplantation-specific Comorbidity Index (HCT-CI)"], "calculator_answers": [{"order": 1, "name": "International Prognostic Index for Diffuse Large B-cell Lymphoma (IPI and R-IPI)", "inputs": [{"field": "age_years", "value": 72}, {"field": "age_category", "value": ">60 years", "score": 1}, {"field": "ann_arbor_stage", "value": "IV"}, {"field": "ann_arbor_stage_iii_iv", "value": "Yes", "score": 1}, {"field": "ecog_performance_status_≥2", "value": "No", "score": 0}, {"field": "serum_ldh_>1×_normal", "value": "Yes (LDH 780 U/L; ULN 240 U/L)", "score": 1}, {"field": ">1_extranodal_site", "value": "Yes (bone marrow, left kidney, stomach)", "score": 1}], "final_answer": 4, "notes": "4 points\nPoor prognosis (R-IPI)\nHigh risk group (IPI)\n55 %\nOverall survival (R-IPI)\n59% overall survival (IPI)\n53 %\nProgression-free survival (R-IPI)\n51% progression-free survival (IPI)"}, {"order": 2, "name": "National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI)", "inputs": [{"field": "age_years", "value": 72}, {"field": "age_group", "value": "61-75", "score": 2}, {"field": "ldh_ratio", "value": 3.25}, {"field": "ldh_ratio_category", "value": ">3", "score": 2}, {"field": "ecog_performance_status_≥2", "value": "No", "score": 0}, {"field": "ann_arbor_stage_iii_iv", "value": "Yes (IV)", "score": 1}, {"field": ">1_extranodal_disease_site", "value": "Yes (bone marrow and GI tract involvement; kidney involvement noted)", "score": 1}], "final_answer": 6, "notes": "6 points\nHigh risk\n30 %\n5-year progression-free survival\n33 %\n5-year overall survival"}, {"order": 3, "name": "Central Nervous System International Prognostic Index (CNS-IPI)", "inputs": [{"field": "age_>60_years", "value": "Yes (72 years)", "score": 1}, {"field": "ldh_>normal", "value": "Yes (LDH 780 U/L; ULN 240 U/L)", "score": 1}, {"field": "ecog_performance_status_>1", "value": "No (ECOG 1)", "score": 0}, {"field": "ann_arbor_stages_iii_or_iv", "value": "Yes (IV)", "score": 1}, {"field": ">1_extranodal_disease_site", "value": "Yes (bone marrow, stomach/GI, kidney)", "score": 1}, {"field": "kidney_and/or_adrenal_involvement", "value": "Yes (left kidney)", "score": 1}], "final_answer": 5, "notes": "5 points\nCNS-IPI\n10.2 %\nHigh risk of CNS relapse"}, {"order": 4, "name": "Eastern Cooperative Oncology Group (ECOG) Performance Status", "inputs": [{"field": "patient_description", "value": "Symptomatic but completely ambulatory"}], "final_answer": 1, "notes": "Restricted in strenuous activity, ambulatory and able to do light work.\nSee definitions of the ECOG/Zubrod Score in the About section."}, {"order": 5, "name": "G8 Geriatric Screening Tool", "inputs": [{"field": "age_years", "value": 72}, {"field": "age_category", "value": "<80", "score": 2}, {"field": "food_intake_declined_past_3_months", "value": "Moderate decrease", "score": 1}, {"field": "weight_loss_last_3_months_kg", "value": 2, "score": 2}, {"field": "mobility", "value": "Goes out", "score": 2}, {"field": "neuropsychological_conditions", "value": "No psychological conditions", "score": 2}, {"field": "bmi_kg/m2", "value": 27.5, "score": 3}, {"field": "takes_more_than_three_prescription_drugs_per_day", "value": "Yes (6 medications daily)", "score": 0}, {"field": "self-rated_health_vs_peers", "value": "As good", "score": 1}], "final_answer": 13, "notes": "Full geriatric evaluation recommended."}, {"order": 6, "name": "Cancer and Aging Research Group Chemotherapy Toxicity Tool (CARG-TT)", "inputs": [{"field": "sex", "value": "Male"}, {"field": "age_years", "value": 72, "score": 2}, {"field": "cancer_type", "value": "Other (DLBCL)", "score": 0}, {"field": "first_chemotherapy_dose", "value": "Standard dose (R-CHOP)", "score": 2}, {"field": "number_of_chemotherapy_drugs", "value": ">1 (combination regimen)", "score": 2}, {"field": "Hemoglobin, g/dL", "value": "≥11 g/dL", "score": 0}, {"field": "creatinine_clearance_ml/min", "value": 56, "score": 0}, {"field": "hearing", "value": "Fair", "score": 2}, {"field": "number_of_falls_in_past_6_months", "value": 1, "score": 3}, {"field": "needs_help_taking_medications", "value": "No", "score": 0}, {"field": "walking_ability_within_one_block", "value": "Limited", "score": 2}, {"field": "social_activity_decreased_due_to_health", "value": "Yes", "score": 1}], "final_answer": 14, "notes": "14 points\nCARG-TT Score\n83 %\nHigh risk of Grade 3 or greater toxicity"}, {"order": 7, "name": "Charlson Comorbidity Index (CCI)", "inputs": [{"field": "age_years", "value": 72}, {"field": "age_category", "value": "70–79 years", "score": 3}, {"field": "myocardial_infarction", "value": "No", "score": 0}, {"field": "congestive_heart_failure", "value": "No", "score": 0}, {"field": "peripheral_vascular_disease", "value": "No", "score": 0}, {"field": "cva_or_tia", "value": "No", "score": 0}, {"field": "dementia", "value": "No", "score": 0}, {"field": "chronic_pulmonary_disease", "value": "No", "score": 0}, {"field": "connective_tissue_disease", "value": "No", "score": 0}, {"field": "peptic_ulcer_disease", "value": "No", "score": 0}, {"field": "liver_disease", "value": "None", "score": 0}, {"field": "diabetes_mellitus", "value": "Uncomplicated (oral agents)", "score": 1}, {"field": "hemiplegia", "value": "No", "score": 0}, {"field": "moderate_to_severe_ckd", "value": "No (serum Cr 1.3 mg/dL)", "score": 0}, {"field": "solid_tumor", "value": "None", "score": 0}, {"field": "leukemia", "value": "No", "score": 0}, {"field": "lymphoma", "value": "Yes (DLBCL)", "score": 2}, {"field": "aids", "value": "No", "score": 0}], "final_answer": 6, "notes": "6 points\nCharlson Comorbidity Index\n2 %\nEstimated 10-year survival"}, {"order": 8, "name": "MASCC Risk Index for Febrile Neutropenia", "inputs": [{"field": "burden_of_illness_symptom_severity", "value": "None or mild", "score": 5}, {"field": "hypotension_sbp_<90_mmHg", "value": "No", "score": 5}, {"field": "active_copd", "value": "No", "score": 4}, {"field": "type_of_cancer", "value": "Hematologic, no prior fungal infection", "score": 4}, {"field": "dehydration_requiring_iv_fluids", "value": "No", "score": 3}, {"field": "status_at_onset_of_fever", "value": "Outpatient", "score": 3}, {"field": "age_years", "value": 72, "score": 0}], "final_answer": 24, "notes": "Low risk for poor outcome. Consider oral and/or outpatient empiric antibiotic therapy after discussion with oncology."}, {"order": 9, "name": "Prognosis Calculator for Relapsed/Refractory DLBCL", "inputs": [{"field": "age_at_first_progression_or_relapse_years", "value": 73}, {"field": "time_to_progression_on_frontline_immunochemotherapy_months", "value": 10}], "final_answer": "22%", "notes": "Predicted 2-year survival from progression:\n22%\nInterpretation:\nThis prognostic tool was developed to provide prognostic information on survival at the time of first progression or relapse for patients with DLBCL who were treated with frontline R-CHOP or like anthracycline based immunochemotherapy. Therapy selection may impact the risk estimates obtained in the model."}, {"order": 10, "name": "Hematopoietic Cell Transplantation-specific Comorbidity Index (HCT-CI)", "inputs": [{"field": "type_of_transplant", "value": "ASCT (autologous stem cell transplant)"}, {"field": "history_of_arrhythmia", "value": "None", "score": 0}, {"field": "cardiac_disease", "value": "None (no CAD/CHF/MI; EF >50%)", "score": 0}, {"field": "heart_valve_disease", "value": "None", "score": 0}, {"field": "inflammatory_bowel_disease", "value": "None", "score": 0}, {"field": "diabetes", "value": "Treated with oral hypoglycemics", "score": 1}, {"field": "cerebrovascular_disease", "value": "None", "score": 0}, {"field": "psychiatric_disturbance", "value": "None", "score": 0}, {"field": "hepatic_dysfunction", "value": "None (bilirubin and AST/ALT ≤ ULN)", "score": 0}, {"field": "obesity_bmi_≥35_kg/m2", "value": "No (BMI 27.5 kg/m2)", "score": 0}, {"field": "infection_requiring_continuation_of_abx_after_day_0", "value": "None", "score": 0}, {"field": "rheumatologic_disease", "value": "None", "score": 0}, {"field": "peptic_ulcer_requiring_treatment", "value": "No", "score": 0}, {"field": "renal_dysfunction", "value": "None (serum Cr ≤2 mg/dL, not on dialysis)", "score": 0}, {"field": "pulmonary_dysfunction", "value": "None or mild (FEV1/DLco >80%, no dyspnea)", "score": 0}, {"field": "prior_solid_tumor", "value": "None", "score": 0}], "final_answer": 1, "notes": "1 points\nHCT-CI Score\n3 %\nNRM at 1 year\n1-year OS: 88%\n3-year NRM: 6%\n3-year OS: 73%"}]}
{"task_id": "medmcp-calc_075_eba0fd37", "task_scenario": "Intracerebral Hemorrhage and Subarachnoid Hemorrhage", "task_category": "Clinical Medicine / Neurology & Mental Health / Neurosurgery & Neurology", "patient_id": "P075_eba0fd37", "task_description": "Scenario: An emergency department patient presents with a sudden severe headache, decreased level of consciousness, and focal neurological deficits. Imaging is pending. The clinical team must rapidly distinguish subarachnoid hemorrhage (SAH) from intracerebral hemorrhage (ICH), stabilize cerebral perfusion, and use CT-based grading to guide early neurosurgical and neurocritical care decisions. The following workflow uses multiple calculators in sequence, with outputs informing subsequent steps and branching into SAH and ICH pathways.\n\nStep-by-step workflow:\n- Step 1 (Initial triage for SAH suspicion): Apply the Ottawa Subarachnoid Hemorrhage (SAH) Rule for Headache Evaluation to determine pre-test probability of SAH in the context of thunderclap headache.\n  - If Ottawa SAH Rule suggests SAH: prioritize SAH diagnostic pathway and proceed to early CT and SAH grading (see SAH branch below).\n  - If Ottawa SAH Rule does not suggest SAH: continue evaluation with stroke mimic screening.\n\n- Step 2 (Differentiate stroke from mimics): Use the Recognition of Stroke in the Emergency Room (ROSIER) Scale to support whether an acute cerebrovascular event is likely.\n  - If ROSIER supports stroke: proceed to neuroimaging and the hemorrhage-specific branches below.\n  - If ROSIER does not support stroke: re-evaluate for non-neurological causes; pause the hemorrhage-specific pathway unless new evidence emerges.\n\n- Step 3 (Coma severity and airway/ICP posture): Calculate the GCS-Pupils Score to integrate level of consciousness and pupil reactivity for early airway protection and ICP strategy.\n  - The GCS component from the GCS-Pupils Score will be used later to compute the WFNS SAH Scale if SAH is present.\n\n- Step 4 (Hemodynamic stabilization—inputs for cerebral perfusion): Compute Mean Arterial Pressure (MAP) from the patient’s vital signs.\n\n- Step 5 (Cerebral perfusion assessment): Use the Cerebral Perfusion Pressure calculator, taking the MAP output from Step 4 and the clinically measured intracranial pressure to estimate cerebral perfusion.\n  - If CPP is low: escalate neurocritical interventions (e.g., adjust blood pressure targets, osmotherapy, CSF diversion if available).\n  - If CPP is adequate: maintain current strategy and proceed to imaging-based hemorrhage grading.\n\nImaging-based branching after CT:\n- SAH branch (if CT reveals subarachnoid blood):\n  - Step 6A (Vasospasm risk from CT): Apply the Modified Fisher Grading Scale for Subarachnoid Hemorrhage (SAH) to quantify the amount/type of blood and associated vasospasm risk.\n    - If high-grade Modified Fisher: increase frequency of vasospasm surveillance and consider prophylactic measures.\n  - Step 7A (Clinical SAH severity using consciousness and deficits): Calculate the WFNS SAH Scale, using the GCS component obtained in Step 3 and the presence of focal deficits.\n    - If severe WFNS: prioritize early definitive aneurysm management consideration and intensive neurocritical monitoring.\n\n- ICH branch (if CT reveals intraparenchymal hemorrhage):\n  - Step 6B (CT volumetrics): Use the ABC/2 Formula for Intracerebral Hemorrhage Volume to quantify hematoma size.\n  - Step 7B (Mortality risk): Calculate the Intracerebral Hemorrhage (ICH) Score, incorporating the volume output from Step 6B and other CT/clinical features to estimate mortality risk.\n    - If high ICH Score: initiate early goals-of-care discussions and consider surgical vs. medical management pathways.\n  - Step 8B (Etiologic suspicion for vascular lesion): Apply the Secondary Intracerebral Hemorrhage (sICH) Score to estimate the likelihood of an underlying vascular etiology.\n    - If high sICH Score: expedite advanced vascular imaging and neurosurgical consultation to evaluate for aneurysm/AVM or other lesions.\n\nRationale for the sequence: The workflow begins with pre-test probability tools (Ottawa SAH Rule and ROSIER) to efficiently channel care into appropriate hemorrhage pathways. Severity scoring (GCS-Pupils) informs immediate airway and ICP strategies and supplies the GCS input needed later by WFNS. Hemodynamic calculators (MAP feeding into Cerebral Perfusion Pressure) ensure perfusion targets are addressed before definitive imaging-based grading. The CT-based SAH (Modified Fisher, WFNS) and ICH (ABC/2 feeding into ICH Score, sICH Score) calculators then drive risk stratification, prognosis, and decisions about definitive management and advanced etiologic workup.", "fuzzy_question": "I’m seeing a patient in the ED with a thunderclap headache, now more somnolent with focal deficits. Imaging is pending, and I’m weighing subarachnoid bleeding versus intraparenchymal hemorrhage while protecting cerebral perfusion during the evaluation.\n\nFirst, in the context of this sudden severe headache, I want to sanity-check how concerned we should be about subarachnoid bleeding based on classic bedside features that increase pretest probability. If the history and exam point that way, we’ll pursue an SAH-focused workup and be ready to grade the initial head CT. If not, I still want to screen for an acute cerebrovascular event versus a mimic; if bedside screening doesn’t support a vascular cause, we should pause the hemorrhage pathway and reconsider non-neurologic explanations.\n\nWhile we’re waiting, I need a clear assessment of coma severity that integrates the standard consciousness exam and pupillary reactivity. That will guide airway posture and early ICP strategy, and I want a standardized Glasgow Coma Scale assessment documented for ongoing decision-making, especially if this is SAH.\n\nOn hemodynamics, calculate mean arterial pressure from available vitals and consider intracranial pressure (if measured) to assess whether cerebral perfusion is adequate. If it appears low, escalate—optimize blood pressure targets, consider osmotherapy, and evaluate cerebrospinal fluid diversion when appropriate. If adequate, maintain the current approach while moving to imaging-based risk stratification.\n\nOnce the CT is back:\n- If it shows subarachnoid blood, characterize the extent and distribution and note any intraventricular blood to gauge vasospasm risk; if that risk appears high, tighten surveillance and consider prophylaxis. In parallel, stage clinical severity using level of consciousness and any focal deficits; if severe, prioritize early definitive aneurysm management discussions and close neurocritical monitoring.\n- If it shows an intraparenchymal hemorrhage, obtain a quick, standardized estimate of hematoma volume from CT diameters. Using that, plus location, intraventricular extension, level of consciousness, and relevant patient factors, estimate early mortality risk to guide goals-of-care and the choice between surgical and medical management. Also assess the likelihood of an underlying structural cause (aneurysm, AVM, other lesions) based on the pattern, clinical context, and medications; if suspicion is high, proceed to advanced vascular imaging and involve neurosurgery.\n\nWhat’s your take on the sequence here? If there’s a better pathway, say so—but I need evidence-based, standardized calculations and scoring to support decisions. This needs to hold up to scrutiny.", "required_calculators": ["Ottawa Subarachnoid Hemorrhage (SAH) Rule for Headache Evaluation", "Recognition of Stroke in the Emergency Room (ROSIER) Scale", "GCS-Pupils Score", "Mean Arterial Pressure (MAP)", "Cerebral Perfusion Pressure", "Modified Fisher Grading Scale for Subarachnoid Hemorrhage (SAH)", "WFNS SAH Scale", "ABC/2 Formula for Intracerebral Hemorrhage Volume", "Intracerebral Hemorrhage (ICH) Score", "Secondary Intracerebral Hemorrhage (sICH) Score"], "calculator_answers": [{"order": 1, "name": "Ottawa Subarachnoid Hemorrhage (SAH) Rule for Headache Evaluation", "inputs": [{"field": "Age ≥40", "value": "Yes (56 years)", "score": 1}, {"field": "Neck pain or stiffness", "value": "Yes (meningismus present)", "score": 1}, {"field": "Witnessed loss of consciousness", "value": "Yes (brief LOC at onset)", "score": 1}, {"field": "Onset during exertion", "value": "Yes (exertional onset)", "score": 1}, {"field": "Thunderclap headache (instantly peaking pain)", "value": "Yes", "score": 1}, {"field": "Limited neck flexion on examination", "value": "Yes", "score": 1}], "final_answer": "Cannot Rule Out", "notes": "Cannot Rule Out\nThis patient cannot be ruled out for subarachnoid hemorrhage by the Ottawa SAH Rule (the rule was 100% sensitive for SAH but only 15% specific for SAH)."}, {"order": 2, "name": "Recognition of Stroke in the Emergency Room (ROSIER) Scale", "inputs": [{"field": "Loss of consciousness or syncope", "value": "Yes (-1)", "score": -1}, {"field": "Seizure activity", "value": "No (0)", "score": 0}, {"field": "Asymmetric facial weakness", "value": "Yes (+1)", "score": 1}, {"field": "Asymmetric arm weakness", "value": "Yes (+1)", "score": 1}, {"field": "Asymmetric leg weakness", "value": "No (0)", "score": 0}, {"field": "Speech disturbance", "value": "Yes (+1)", "score": 1}, {"field": "Visual field defect", "value": "Yes (+1)", "score": 1}], "final_answer": 3, "notes": "3 points\nROSIER Score\nStroke possible"}, {"order": 3, "name": "GCS-Pupils Score", "inputs": [{"field": "Eye response", "value": "Eye opening to pain (+2)", "score": 2}, {"field": "Verbal response", "value": "Inappropriate words (+3); not intubated", "score": 3}, {"field": "Motor response", "value": "Localizes pain (+5)", "score": 5}, {"field": "Pupil response", "value": "Both pupils reactive to light (0)", "score": 0}], "final_answer": 10, "notes": "10 points\nGCS-Pupils Score\n17.35 %\nMortality at 6 months post-injury\n28.88 %\nUnfavorable outcome (vegetative state or severe disability) at 6 months post-injury"}, {"order": 4, "name": "Mean Arterial Pressure (MAP)", "inputs": [{"field": "Systolic BP", "value": "178 mm Hg"}, {"field": "Diastolic BP", "value": "98 mm Hg"}], "final_answer": 125, "notes": "125 mm Hg\nMean Arterial Pressure (MAP)"}, {"order": 5, "name": "Cerebral Perfusion Pressure", "inputs": [{"field": "MAP", "value": "125 mm Hg (from Step 4)"}, {"field": "ICP", "value": "24 mm Hg (EVD monitoring)"}], "final_answer": 101, "notes": "101 mmHg\nHigh CPP. Consider weaning pressors if MAP is adequate (see Next Steps for details)."}, {"order": 6, "name": "Modified Fisher Grading Scale for Subarachnoid Hemorrhage (SAH)", "inputs": [{"field": "SAH pattern on CT", "value": "Diffuse thick SAH (≥1 mm) in basal cisterns/sylvian fissures"}, {"field": "Intraventricular hemorrhage (IVH) present", "value": "Yes (blood layering in lateral ventricles)"}], "final_answer": "Grade IV", "notes": "Grade IV\n34-40% probability of symptomatic vasospasm."}, {"order": 7, "name": "WFNS SAH Scale", "inputs": [{"field": "Glasgow Coma Score", "value": "10 (from Step 3)"}, {"field": "Motor Deficit", "value": "Yes (right facial/arm weakness)"}], "final_answer": 4, "notes": "WFNS SAH Scale\n4"}, {"order": 8, "name": "ABC/2 Formula for Intracerebral Hemorrhage Volume", "inputs": [{"field": "Hemorrhage Shape", "value": "Round or Ellipsoid"}, {"field": "Hemorrhage Length (A)", "value": "5.6 cm"}, {"field": "Hemorrhage Width (B)", "value": "3.8 cm"}, {"field": "Number of CT Slices with hemorrhage (C component)", "value": "5 slices total (4 full + 2 half-slices counted as 5)"}, {"field": "CT Slice Thickness", "value": "5 mm"}], "final_answer": 26.6, "notes": "26.6 mL (cm³)\nEstimated Hemorrhage Volume"}, {"order": 9, "name": "Intracerebral Hemorrhage (ICH) Score", "inputs": [{"field": "Glasgow Coma Score category", "value": "5–12 (+1) (GCS = 10)", "score": 1}, {"field": "Age ≥80 years", "value": "No (56 years; 0)", "score": 0}, {"field": "ICH volume ≥30 mL", "value": "No (26.6 mL; 0)", "score": 0}, {"field": "Intraventricular hemorrhage", "value": "Yes (+1)", "score": 1}, {"field": "Infratentorial origin of hemorrhage", "value": "No (0)", "score": 0}], "final_answer": 2, "notes": "26% mortality\nPlease note that the ICH score is primarily used as a clinical grading scale and communication tool. It is not meant to provide prognostic information, and should not be used as a primary means to predict the outcomes of patients with ICH."}, {"order": 10, "name": "Secondary Intracerebral Hemorrhage (sICH) Score", "inputs": [{"field": "Probability of vascular cause on NCCT", "value": "High (+2) (concurrent diffuse SAH and lobar ICH)", "score": 2}, {"field": "Age category", "value": "46–70 years (+1) (age 56)", "score": 1}, {"field": "Sex", "value": "Female (+1)", "score": 1}, {"field": "Absence of both hypertension AND impaired coagulation", "value": "Yes (+1); no known HTN history; INR 1.0, aPTT 31 s, platelets 230,000/µL; not on antiplatelet/anticoagulant therapy", "score": 1}], "final_answer": 5, "notes": "80% of CTA positive for vascular cause of ICH"}]}
{"task_id": "medmcp-calc_076_6b94301c", "task_scenario": "Solid Tumor TNM Staging", "task_category": "Clinical Medicine / Medicine & Organ Systems / Comprehensive Oncology", "patient_id": "P076_6b94301c", "task_description": "Clinical scenario: A patient presents to a head and neck oncology clinic with progressive voice changes and a firm parotid-region mass. Imaging and panendoscopy suggest a laryngeal mucosal malignancy with uncertain subsite (supraglottic vs glottic). The parotid lesion is suspicious for a primary major salivary gland tumor. The goal is comprehensive, site-appropriate AJCC 2017 TNM staging at baseline and, if resection is performed, final pathological staging for both primaries to coordinate definitive therapy and adjuvant planning. Workflow steps: Step 1 (larynx—clinical): If endoscopy indicates a supraglottic primary, use Laryngeal Cancer: Supraglottis (Clinical) to determine cT, cN, cM and stage group. Step 2 (larynx—clinical subsite branch): If instead the lesion is glottic at presentation, use Laryngeal Cancer: Glottis (Clinical) to define cTNM and stage; this replaces Step 1 and ensures subsite-accurate staging. Decision A (triggered by laryngeal clinical stage): If the laryngeal clinical stage is resectable with acceptable functional outcomes, plan surgery and proceed to pathological staging of the same subsite; if locally advanced and managed non-operatively, skip laryngeal pathological staging and base decisions on clinical stage and treatment response. Step 3 (parotid—clinical): Independently, stage the salivary gland tumor using Major Salivary Gland Cancer (Clinical) to determine cTNM and resectability. Decision B (triggered by salivary clinical stage): If the salivary tumor is operable, perform resection with appropriate neck management and proceed to pathological staging; if not, skip salivary pathological staging. Step 4 (larynx—pathological, supraglottic branch): If a supraglottic laryngectomy or total laryngectomy was performed, use Laryngeal Cancer: Supraglottis (Pathological) to finalize pT, pN, pM and stage group, informing adjuvant therapy indications. Step 5 (larynx—pathological, glottic branch): If instead a glottic primary was resected, use Laryngeal Cancer: Glottis (Pathological) to finalize pTNM and stage; use this in place of Step 4. Step 6 (parotid—pathological): After parotidectomy and neck dissection (when performed), use Major Salivary Gland Cancer TNM Staging (Pathological) to finalize pTNM and stage group. Integration: Combine the available pTNM outputs to determine adjuvant radiation fields, need for concurrent systemic therapy, and sequencing across both primaries; if pathological staging is unavailable due to non-operative management, rely on the corresponding clinical stage to guide definitive chemoradiation or systemic therapy. The laryngeal and salivary clinical stages serve as deterministic triggers for whether their respective pathological calculators are used, ensuring a coherent, decision-driven staging workflow.", "fuzzy_question": "I’m seeing a patient with voice changes and a mass in the parotid region. Imaging and endoscopic evaluation suggest a laryngeal mucosal cancer, but it’s unclear whether the primary is in the supraglottis or the glottis. That distinction will change staging and treatment, so before finalizing a plan I want subsite-accurate baseline staging for the larynx. If the findings fit supraglottic disease, walk me through how you’d frame the tumor’s local extent, neck node involvement, and any distant spread, and where that leaves us in terms of overall stage. If the features match a glottic primary instead, do the same using the glottic rules to avoid mis-staging.\n\nDepending on the laryngeal clinical stage, I need a practical call on whether it’s genuinely resectable with acceptable airway, voice, and swallowing outcomes. If you’d lean toward surgery, then I’ll want the final pathology-based staging for that same subsite after resection to guide adjuvant decisions. If it looks locally advanced and better managed non-operatively, recommendations should hinge on the clinical stage and subsequent treatment response.\n\nSeparately, the parotid lesion appears more consistent with a primary salivary gland tumor than a nodal metastasis. I’d like a thorough clinical staging for the parotid disease—tumor extent, possible facial nerve involvement, deep lobe or parapharyngeal space extension, nodal disease, and any distant spread—and an honest assessment of operability. If surgery is appropriate, assume a parotidectomy with the right neck management is done, then provide the final pathologic staging afterward. If it isn’t operable, stick with the clinical stage to steer therapy.\n\nIf laryngeal surgery proceeds, please match the pathologic staging to the actual subsite—use supraglottic criteria if that’s where it originates, and glottic criteria if that’s the case. For the parotid, after parotidectomy and any neck dissection, finalize the pathologic stage so we can determine indications for adjuvant treatment.\n\nOnce the clinical and, when available, pathological outputs for both primaries are established, help me integrate them. I’m looking for a clear plan on adjuvant radiation fields, whether concurrent systemic therapy is warranted, and how to sequence treatment across both sites. If one or both sites are managed non-operatively, base those recommendations on the clinical stage. In other words, let the baseline clinical staging drive whether we move to surgery and thus have pathology to refine the plan for each site.\n\nWhat’s your clinical thinking on this? Am I missing anything that would change how we stage or treat? I need evidence-based risk stratification with solid calculations and reasoning so these decisions hold up to scrutiny.", "required_calculators": ["Laryngeal Cancer: Supraglottis (Clinical)", "Laryngeal Cancer: Glottis (Clinical)", "Major Salivary Gland Cancer (Clinical)", "Laryngeal Cancer: Supraglottis (Pathological)", "Laryngeal Cancer: Glottis (Pathological)", "Major Salivary Gland Cancer TNM Staging (Pathological)"], "calculator_answers": [{"order": 1, "name": "Laryngeal Cancer: Supraglottis (Clinical)", "inputs": [{"field": "Primary Tumour (T)", "value": "T3: supraglottic mass involving epiglottis/AE fold with paraglottic and pre-epiglottic space invasion; right vocal cord fixation; estimated mucosal extent ~3.0 cm"}, {"field": "Regional Lymph Nodes (cN)", "value": "cN2b: multiple ipsilateral nodes ≤6 cm; 2 right level II nodes measuring 2.5 cm and 3.2 cm; no clinical ENE; contralateral neck negative"}, {"field": "Distant Metastasis (M)", "value": "M0: no distant metastasis on CT chest and PET-CT"}], "final_answer": "IVA", "notes": "TNM Classification\nT3 cN2b M0\nAJCC Prognostic Stage Group\nIVA"}, {"order": 2, "name": "Laryngeal Cancer: Glottis (Clinical)", "inputs": [{"field": "Primary Tumour (T)", "value": "T3: right glottic lesion crossing anterior commissure with vocal cord fixation and paraglottic space invasion; size ~1.8 cm mucosal component"}, {"field": "Regional Lymph Nodes (cN)", "value": "cN1: single ipsilateral level III node 2.1 cm; no clinical ENE"}, {"field": "Distant Metastasis (M)", "value": "M0: no distant disease on imaging"}], "final_answer": "III", "notes": "TNM Classification\nT3 cN1 M0\nAJCC Prognostic Stage Group\nIII"}, {"order": 3, "name": "Major Salivary Gland Cancer (Clinical)", "inputs": [{"field": "Primary Tumour (T)", "value": "T4a: 3.8 cm right parotid mass with clinical facial nerve weakness (House-Brackmann grade III) indicating nerve involvement; superficial+deep lobe involvement; no skin, mandible, or parapharyngeal space invasion clinically"}, {"field": "Regional Lymph Nodes (cN)", "value": "cN0: no suspicious cervical lymphadenopathy on ultrasound/contrast CT"}, {"field": "Distant Metastasis (M)", "value": "M0: no distant metastasis on PET-CT"}], "final_answer": "IVA", "notes": "TNM Classification\nT4a cN0 M0\nAJCC Prognostic Stage Group\nIVA"}, {"order": 4, "name": "Laryngeal Cancer: Supraglottis (Pathological)", "inputs": [{"field": "Primary Tumour (T)", "value": "pT3: supraglottic SCC with paraglottic and pre-epiglottic space invasion and vocal cord fixation; thyroid cartilage intact (no transmural invasion)"}, {"field": "Regional Lymph Nodes (pN)", "value": "pN2b: two ipsilateral (levels II/III) metastatic nodes, 1.9 cm and 3.2 cm; extranodal extension negative"}, {"field": "Distant Metastasis (M)", "value": "M0: no distant metastasis"}], "final_answer": "IVA", "notes": "TNM Classification\nT3 pN2b M0\nAJCC Prognostic Stage Group\nIVA"}, {"order": 5, "name": "Laryngeal Cancer: Glottis (Pathological)", "inputs": [{"field": "Primary Tumour (T)", "value": "pTX: primary tumor for glottic subsite not assessed/pathologically staged because definitive pathology confirmed supraglottic origin"}, {"field": "Regional Lymph Nodes (pN)", "value": "pNX: nodes not assigned for glottic primary (neck pathology attributed to supraglottic primary)"}, {"field": "Distant Metastasis (M)", "value": "M0: no distant metastasis"}], "final_answer": "Unable to stage for this combination", "notes": "TNM Classification\nTX pNX M0\nAJCC Prognostic Stage Group\nUnable to stage for this combination"}, {"order": 6, "name": "Major Salivary Gland Cancer TNM Staging (Pathological)", "inputs": [{"field": "Primary Tumour (T)", "value": "pT4a: 3.8 cm high-grade carcinoma of right parotid with facial nerve invasion (nerve sacrificed); no skin/mandible/ear canal involvement; deep lobe involvement present"}, {"field": "Regional Lymph Nodes (pN)", "value": "pN2b: two ipsilateral cervical nodes positive (levels II and III), 1.6 cm and 2.3 cm; extranodal extension negative"}, {"field": "Distant Metastasis (M)", "value": "M0: no distant metastasis"}], "final_answer": "IVA", "notes": "TNM Classification\nT4a pN2b M0\nAJCC Prognostic Stage Group\nIVA"}]}
{"task_id": "medmcp-calc_077_ac79114e", "task_scenario": "Organ Failure Scoring", "task_category": "Clinical Medicine / Emergency, Critical Care & Perioperative / Critical Care", "patient_id": "P077_ac79114e", "task_description": "Scenario: An intubated adult in the ICU with septic shock from pneumonia has worsening hypoxemia and evolving multi-organ dysfunction. The team must stage organ failure, confirm ARDS severity, and determine whether to escalate to ECMO while concurrently evaluating renal injury and sepsis-related coagulopathy to ensure safe advanced support. Step-by-step workflow: 1) Use SIRS, Sepsis, and Septic Shock Criteria to establish sepsis severity and shock status, triggering immediate resuscitative care and the need for comprehensive organ failure assessment. 2) Apply the Sequential Organ Failure Assessment (SOFA) Score to quantify global acute organ dysfunction and set a baseline for trajectory monitoring. 3) Calculate the Horowitz Index for Lung Function (P/F Ratio) to objectively measure oxygenation impairment under current ventilatory settings. 4) Use the Berlin Criteria for Acute Respiratory Distress Syndrome, incorporating the P/F Ratio, to confirm ARDS and grade severity; if ARDS is moderate to severe, proceed to advanced respiratory severity assessment. 5) Compute the Oxygenation Index to refine respiratory failure severity and ventilatory mechanics; if the index indicates refractory hypoxemia, move to ECMO viability assessment. 6) Evaluate Respiratory ECMO survival likelihood with the RESP (Respiratory ECMO Survival Prediction) Score; if the predicted survival is acceptable, cross-check to reduce selection bias. 7) Confirm and refine ECMO candidacy using the PREdiction of Survival on ECMO Therapy (PRESET) Score; if both ECMO scores support favorable outcomes, initiate ECMO consultation and planning, otherwise continue maximal conventional support and revisit goals of care. 8) In parallel, stage renal involvement using KDIGO AKI Staging to guide fluid, nephrotoxic exposure, and renal replacement therapy decisions; severe staging may influence ECMO cannulation strategy and integration of CRRT. 9) Screen for sepsis-associated coagulopathy using the Sepsis-Induced Coagulopathy (SIC) Score; if the screen suggests coagulopathy, proceed to definitive diagnostic criteria. 10) Apply the ISTH Criteria for Disseminated Intravascular Coagulation (DIC) to confirm overt DIC and tailor anticoagulation, transfusion, and procedural risk management, including considerations for ECMO circuit safety.", "fuzzy_question": "I’m seeing an intubated patient in the ICU with pneumonia, on vasopressors, with worsening oxygenation and emerging signs of multiorgan dysfunction. I’m trying to figure out the best approach for escalation, including whether we’re at the point of considering venovenous ECMO, but I want the decision anchored in a clear picture of how sick the patient is right now.\n\nFirst, I want to be sure we’re labeling infection‑driven shock correctly. If this is persistent hypotension despite adequate fluids with a concerning lactate and ongoing vasopressor needs, that pushes us into full shock physiology and sets the urgency for resuscitation while we map out organ failures more systematically.\n\nI also want a single, structured snapshot of global organ dysfunction across the usual systems—lungs, platelets/coagulation, liver, kidneys, blood pressure/vasopressors, and mental status—so we can set a firm baseline now and then track the trajectory over time. Recent labs and bedside assessments should feed into that, not just impressions.\n\nOn the lung side, I need a clear read on oxygenation under the current ventilator settings: how the arterial oxygen level stacks up against the delivered oxygen fraction right now, not a rough estimate. Then, please confirm we really meet the clinical picture of ARDS—timing with the pneumonia, bilateral opacities on imaging, and not simply hydrostatic edema—and grade how severe it is based on the oxygenation deficit with the current PEEP. If this shakes out as moderate to severe, go a level deeper and factor in how much mean airway pressure we’re using to maintain that oxygenation. That will tell us whether this is drifting into refractory territory despite lung‑protective ventilation (and, if relevant, whether proning/paralysis has already been attempted).\n\nIf it does look refractory, I’m wondering what a realistic survival expectation would be with venovenous ECMO for a case like this—taking into account patient demographics, primary diagnosis (pneumonia), duration of intubation, acid–base status, any immunosuppression or CNS issues, and similar clinical features. And I don’t want to rely on a single lens—please cross‑check that prognosis using a different framework that puts more weight on shock severity, lactate, pH, and vasopressor intensity so we’re not anchoring or introducing selection bias. If both perspectives suggest a reasonable shot, we should lean into an ECMO consult and planning; if they point the other way, let’s stay maximal on conventional therapy and revisit goals of care with the family.\n\nIn parallel, I’m worried the kidneys are getting involved. Recent labs show a trend that could be moving the wrong way, and urine output over the recent period hasn’t been great. Please stage the kidney injury based on creatinine change and urine output so we can guide fluids, avoid nephrotoxins, and decide on the timing of renal replacement therapy. If the staging is on the severe end, that may change how we think about cannulation and whether we integrate continuous dialysis with ECMO if we go there.\n\nI’m also concerned about sepsis‑related clotting issues. Do a focused screen for early sepsis‑associated coagulopathy using what we’re seeing with platelets, PT/INR, and overall organ dysfunction. If that screen raises concern, then go on to confirm or refute overt DIC using the standard criteria that look at platelets, PT prolongation, fibrinogen, and D‑dimer. That result needs to directly shape how aggressive we are with anticoagulation, what transfusions we plan, and our procedural risk management—especially if we’re contemplating large‑bore cannulation and the safety of an extracorporeal circuit.\n\nWhat’s your take on this? Walk me through your clinical reasoning in that order, showing how each piece informs the next decision. I really need proper calculations on this—can’t make this decision based on gut feeling alone. Whatever approach you suggest, make sure it’s backed by solid calculations, okay? This needs to hold up to scrutiny.", "required_calculators": ["SIRS, Sepsis, and Septic Shock Criteria", "Sequential Organ Failure Assessment (SOFA) Score", "Horowitz Index for Lung Function (P/F Ratio)", "Berlin Criteria for Acute Respiratory Distress Syndrome", "Oxygenation Index", "RESP (Respiratory ECMO Survival Prediction) Score", "PREdiction of Survival on ECMO Therapy (PRESET) Score", "KDIGO AKI Staging", "Sepsis-Induced Coagulopathy (SIC) Score", "ISTH Criteria for Disseminated Intravascular Coagulation (DIC)"], "calculator_answers": [{"order": 1, "name": "SIRS, Sepsis, and Septic Shock Criteria", "inputs": [{"field": "temperature_c", "value": "38.7 °C"}, {"field": "heart_rate_bpm", "value": "118 bpm"}, {"field": "respiratory_rate_bpm", "value": "28 breaths/min"}, {"field": "paCO2_mmHg", "value": "60 mmHg"}, {"field": "wbc_count_per_uL", "value": "18,500 /µL"}, {"field": "sirs_temp_criterion", "value": "Yes (>38°C)"}, {"field": "sirs_hr_criterion", "value": "Yes (>90 bpm)"}, {"field": "sirs_rr_or_paco2_criterion", "value": "Yes (RR >20/min)"}, {"field": "sirs_wbc_criterion", "value": "Yes (>12,000/µL)"}, {"field": "suspected_or_confirmed_infection", "value": "Yes (community-acquired bacterial pneumonia)"}, {"field": "lactate_mmol_L", "value": "3.8 mmol/L"}, {"field": "systolic_bp_mmHg", "value": "84 mmHg (pre-pressor, after fluids)"}, {"field": "adequate_fluid_resuscitation", "value": "Yes (30 mL/kg balanced crystalloid within 3 hours)"}, {"field": "vasopressor_support", "value": "Yes (norepinephrine 0.18 mcg/kg/min)"}, {"field": "severe_sepsis_criterion", "value": "Yes (hypotension and elevated lactate)"}, {"field": "septic_shock_criterion", "value": "Yes (hypotension requiring vasopressors despite adequate fluids)"}, {"field": "multiple_organ_dysfunction", "value": "Yes (respiratory, cardiovascular, renal, hepatic)"}], "final_answer": "This patient meets multiple organ dysfunction syndrome. Follow your guidelines for sepsis, which typically include aggressive fluid resuscitation, early, broad-spectrum antibiotics, ICU consultation, CVP evaluation, and occasionally pressors and transfusion.", "notes": "This patient meets multiple organ dysfunction syndrome. Follow your guidelines for sepsis, which typically include aggressive fluid resuscitation, early, broad-spectrum antibiotics, ICU consultation, CVP evaluation, and occasionally pressors and transfusion."}, {"order": 2, "name": "Sequential Organ Failure Assessment (SOFA) Score", "inputs": [{"field": "paO2_mmHg", "value": "55 mmHg (worst in last 24h)"}, {"field": "FiO2_percent", "value": "100 %"}, {"field": "on_mechanical_ventilation", "value": "Yes (volume-controlled ventilation)"}, {"field": "platelets_x10e3_per_uL", "value": "85 x10^3/µL", "score": 2}, {"field": "glasgow_coma_scale", "value": "12 (estimated off sedation)", "score": 2}, {"field": "bilirubin_mg_dL", "value": "2.8 mg/dL", "score": 2}, {"field": "mean_arterial_pressure_mmHg", "value": "76 mmHg (on pressors)", "score": 0}, {"field": "vasoactive_agents", "value": "Norepinephrine 0.18 mcg/kg/min", "score": 0}, {"field": "serum_creatinine_mg_dL", "value": "2.4 mg/dL", "score": 2}, {"field": "urine_output_mL_24hr", "value": "800 mL/24h"}], "final_answer": 12, "notes": "12 points\nInitial SOFA Scores ≥12 predict ≥95.2% mortality (see Evidence for details)"}, {"order": 3, "name": "Horowitz Index for Lung Function (P/F Ratio)", "inputs": [{"field": "paO2_mmHg", "value": "55 mmHg"}, {"field": "FiO2_percent", "value": "100 %"}], "final_answer": "55.0 mmHg", "notes": "55.0 mmHg\nHorowitz Index (P/F ratio)\nSevere\nSeverity of ARDS\n45 %\nMortality"}, {"order": 4, "name": "Berlin Criteria for Acute Respiratory Distress Syndrome", "inputs": [{"field": "timing_within_1_week", "value": "Yes (5 days from pneumonia onset)"}, {"field": "chest_imaging_bilateral_opacities", "value": "Yes (bilateral diffuse opacities on CXR)"}, {"field": "resp_failure_not_explained_by_cardiac_or_fluid_overload", "value": "Yes (no clinical/echo evidence of hydrostatic edema)"}, {"field": "risk_factor_present", "value": "Yes (pneumonia/sepsis)"}, {"field": "severity_category", "value": "Severe (PaO2/FiO2 ≤100 with PEEP ≥5)"}], "final_answer": "Positive", "notes": "Diagnostic Result\nPositive\nSevere ARDS"}, {"order": 5, "name": "Oxygenation Index", "inputs": [{"field": "FiO2_percent", "value": "100 %"}, {"field": "mean_airway_pressure_cmH2O", "value": "24 cm H2O"}, {"field": "paO2_mmHg", "value": "55 mmHg"}], "final_answer": 44, "notes": "Diagnostic Result\n44\nOxygenation Index"}, {"order": 6, "name": "RESP (Respiratory ECMO Survival Prediction) Score", "inputs": [{"field": "age_years", "value": "46", "score": 0}, {"field": "immunocompromised", "value": "No", "score": 0}, {"field": "mechanically_ventilated_before_ecmo", "value": "<48 hours", "score": 3}, {"field": "hours_on_mechanical_ventilation_pre_ecmo", "value": "36 hours"}, {"field": "primary_diagnosis", "value": "Bacterial pneumonia", "score": 3}, {"field": "history_of_cns_dysfunction", "value": "No", "score": 0}, {"field": "acute_associated_nonpulmonary_infection", "value": "No", "score": 0}, {"field": "neuromuscular_blockade_before_ecmo", "value": "Yes", "score": 1}, {"field": "nitric_oxide_before_ecmo", "value": "Yes", "score": -1}, {"field": "bicarbonate_infusion_before_ecmo", "value": "No", "score": 0}, {"field": "cardiac_arrest_before_ecmo", "value": "No", "score": 0}, {"field": "paCO2_ge_75mmHg", "value": "No (PaCO2 60 mmHg)", "score": 0}, {"field": "peak_inspiratory_pressure_ge_42_cmH2O", "value": "No (PIP 38 cm H2O)", "score": 0}], "final_answer": 6, "notes": "6 points\nRESP Score\nClass I\nRisk class\n92 %\nIn-hospital survival"}, {"order": 7, "name": "PREdiction of Survival on ECMO Therapy (PRESET) Score", "inputs": [{"field": "mean_arterial_pressure_mmHg", "value": "76 mmHg (71–80 bracket)", "score": 3}, {"field": "lactate_mmol_L", "value": "3.8 mmol/L (3.01–6.00 bracket)", "score": 2}, {"field": "arterial_pH", "value": "7.28 (7.201–7.300 bracket)", "score": 1}, {"field": "platelet_count_x10e3_per_uL", "value": "85 x10^3/µL (≤100 bracket)", "score": 2}, {"field": "hospital_days_pre_ecmo", "value": "2 days (≤2 bracket)", "score": 0}], "final_answer": 8, "notes": "8 points\nPRESET Score\nClass II\nRisk class\n68 %\nICU mortality"}, {"order": 8, "name": "KDIGO AKI Staging", "inputs": [{"field": "baseline_serum_creatinine_mg_dL", "value": "0.9 mg/dL (from admission)"}, {"field": "current_serum_creatinine_mg_dL", "value": "2.4 mg/dL"}, {"field": "creatinine_times_baseline", "value": "2.67× baseline"}, {"field": "weight_kg", "value": "82 kg"}, {"field": "urine_output_mL_24hr", "value": "800 mL/24h"}, {"field": "urine_output_mL_per_kg_per_hr", "value": "0.41 mL/kg/h over 24h"}, {"field": "duration_of_reduced_uop_hours", "value": "≥12 hours"}], "final_answer": "Stage 2", "notes": "Serum creatinine 2.0–2.9 times baseline or <0.5 ml/kg/h for ≥12 hours"}, {"order": 9, "name": "Sepsis-Induced Coagulopathy (SIC) Score", "inputs": [{"field": "inr", "value": "1.6 (>1.4)", "score": 2}, {"field": "platelet_count_x10e9_per_L", "value": "85 x10^9/L", "score": 2}, {"field": "total_sofa_subscore_resp_cardio_hepatic_renal", "value": "12 (Resp 4 + Cardio 4 + Hepatic 2 + Renal 2)", "score": 2}], "final_answer": 6, "notes": "6 points\n46% approximate 28-day mortality\nSIC likely\nDiagnosis of SIC"}, {"order": 10, "name": "ISTH Criteria for Disseminated Intravascular Coagulation (DIC)", "inputs": [{"field": "platelet_count_x10e9_per_L", "value": "85 x10^9/L (50–<100 bracket)", "score": 1}, {"field": "fibrin_related_marker_increase", "value": "Moderate increase (D-dimer 2,000 ng/mL FEU; lab ULN 500)", "score": 2}, {"field": "pt_prolongation_seconds_above_uln", "value": "4.5 seconds", "score": 1}, {"field": "fibrinogen_g_per_L", "value": "1.2 g/L (≥1.0)", "score": 0}], "final_answer": 4, "notes": "Not suggestive of overt DIC, may be non-overt DIC; repeat within next 1-2 days and manage clinically as appropriate"}]}
{"task_id": "medmcp-calc_078_bda4bbb8", "task_scenario": "Prognostic Scoring", "task_category": "Clinical Medicine / Medicine & Organ Systems / Comprehensive Oncology", "patient_id": "P078_bda4bbb8", "task_description": "Scenario: A patient is newly diagnosed with diffuse large B-cell lymphoma (DLBCL). The oncology team needs a comprehensive, stepwise prognostic assessment to guide intensity of first-line therapy, decide on CNS prophylaxis, and plan for contingencies if the disease becomes relapsed/refractory. This workflow uses multiple validated calculators to integrate performance status, disease-specific prognostic indices, systemic inflammation, and comorbidity. Step-by-step workflow: 1) Start with Eastern Cooperative Oncology Group (ECOG) Performance Status to quantify functional status. 2) Use the International Prognostic Index for Diffuse Large B-cell Lymphoma (IPI and R-IPI) to assign baseline disease risk; include the ECOG result as the performance status input within the IPI. 3) If the IPI shows intermediate or high risk, proceed to the National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI) to refine risk stratification using more granular factors; if IPI is low, NCCN-IPI can still be applied to confirm low-risk status and improve discrimination. 4) Apply the Modified Glasgow Prognostic Score (mGPS) for Cancer Outcomes to incorporate systemic inflammatory status into overall prognosis and expected survival, supporting counseling on supportive care needs. 5) Calculate the Charlson Comorbidity Index (CCI) to quantify competing comorbidity burden and inform whether standard-intensity therapy is tolerable or if de-escalation may be necessary. 6) Decision branch for CNS risk and prophylaxis: If combined results suggest higher systemic risk (e.g., intermediate/high IPI or NCCN-IPI with poor systemic profile by mGPS/CCI), use the Central Nervous System International Prognostic Index (CNS-IPI) to estimate risk of CNS relapse and to deterministically decide whether to plan CNS-directed prophylaxis; if systemic risk remains low, CNS-IPI may be deferred and CNS prophylaxis would not be pursued. 7) Post–first-line contingency: If the disease later proves relapsed/refractory, use the Prognosis Calculator for Relapsed/Refractory DLBCL to inform survival expectations and to support decisions around salvage strategies versus alternative approaches. Rationale: ECOG informs IPI directly; IPI then determines whether NCCN-IPI and CNS-IPI are needed. mGPS and CCI contextualize systemic resilience, sharpening decisions on therapy intensity and CNS prophylaxis. The R/R DLBCL calculator is reserved for the relapse branch.", "fuzzy_question": "I’m evaluating a patient diagnosed with DLBCL and I’m determining how aggressive to be up front, whether to include CNS protection, and how to plan if response is suboptimal. Day-to-day functional status is acceptable but not fully preserved, and routine staging labs are available, including LDH, albumin, and CRP. I’m uncertain whether the overall profile supports standard‑intensity therapy or a more cautious approach.\n\nFirst, I want a clear assessment of daily activity limitations using a standard performance scale, to incorporate into the baseline lymphoma risk picture. From there, can we place the patient on the standard front‑line DLBCL risk framework that uses age, anatomic stage, LDH, extranodal involvement, and performance, and cross‑check with the contemporary rituximab‑era version to determine low vs intermediate vs high risk?\n\nIf the picture is anything other than clearly low risk, I’d like to re‑stratify with a more granular model that tiers age and LDH and gives extra weight to certain organ sites; even if low risk, I’d still prefer that more granular lens to confirm. In parallel, I want the systemic inflammatory state (CRP and albumin) translated into a prognostic signal to support counseling and supportive care planning. I also need a structured assessment of comorbidity burden with a standard comorbidity index to determine whether full‑intensity treatment is realistic or if de‑escalation should be considered up front.\n\nDepending on how these elements align: if the overall picture suggests higher risk or the systemic profile appears unfavorable, I’d want a quantified estimate of CNS relapse risk using the DLBCL‑specific tool that incorporates age, stage, LDH, and organ involvement (including kidney/adrenal), to make a yes/no decision on CNS‑directed prophylaxis now. If the global risk appears convincingly low, I’m comfortable deferring CNS planning.\n\nLooking ahead, if relapse or refractory disease occurs after first‑line therapy, I’d want a structured survival estimate at that point to guide whether to pursue salvage strategies (with or without cellular therapy paths) versus alternative approaches or trials.\n\nWhat’s your take on this? Please lay out the intermediate outputs explicitly—day‑to‑day function category; initial risk bucket; refined granular risk; inflammation signal; comorbidity burden; and, if indicated, the CNS relapse risk with a clear recommendation on CNS prophylaxis—so the treatment‑intensity decision is well supported. The approach should include explicit, defensible calculations, as this needs to hold up to scrutiny.", "required_calculators": ["Eastern Cooperative Oncology Group (ECOG) Performance Status", "International Prognostic Index for Diffuse Large B-cell Lymphoma (IPI and R-IPI)", "National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI)", "Modified Glasgow Prognostic Score (mGPS) for Cancer Outcomes", "Charlson Comorbidity Index (CCI)", "Central Nervous System International Prognostic Index (CNS-IPI)", "Prognosis Calculator for Relapsed/Refractory DLBCL"], "calculator_answers": [{"order": 1, "name": "Eastern Cooperative Oncology Group (ECOG) Performance Status", "inputs": [{"field": "patient_description", "value": "Symptomatic but completely ambulatory"}], "final_answer": 1, "notes": "1 points\nRestricted in strenuous activity, ambulatory and able to do light work.\nSee definitions of the ECOG/Zubrod Score in the About section."}, {"order": 2, "name": "International Prognostic Index for Diffuse Large B-cell Lymphoma (IPI and R-IPI)", "inputs": [{"field": "Age_years", "value": 68, "score": 1}, {"field": "Ann_Arbor_stage", "value": "III"}, {"field": "Ann_Arbor_stage_III_IV", "value": "Yes", "score": 1}, {"field": "ECOG_performance_status_≥2", "value": "No", "score": 0}, {"field": "Serum_LDH_value", "value": "560 U/L"}, {"field": "LDH_upper_limit_of_normal", "value": "250 U/L"}, {"field": "Serum_LDH_level_>1×_normal", "value": "Yes", "score": 1}, {"field": "Extranodal_sites_count", "value": 1}, {"field": ">1_extranodal_site", "value": "No", "score": 0}], "final_answer": 3, "notes": "3 points\nPoor prognosis (R-IPI)\nHigh-intermediate risk group (IPI)\n55 %\nOverall survival (R-IPI)\n49% overall survival (IPI)\n53 %\nProgression-free survival (R-IPI)\n57% progression-free survival (IPI)"}, {"order": 3, "name": "National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI)", "inputs": [{"field": "Age_years", "value": 68}, {"field": "Age_category", "value": "61-75", "score": 2}, {"field": "LDH_value", "value": "560 U/L"}, {"field": "LDH_ULN", "value": "250 U/L"}, {"field": "LDH_ratio", "value": 2.24}, {"field": "LDH_ratio_category", "value": ">1-3", "score": 1}, {"field": "ECOG_≥2", "value": "No", "score": 0}, {"field": "Ann_Arbor_stage_III_or_IV", "value": "Yes", "score": 1}, {"field": "Stage_detail", "value": "III"}, {"field": ">1_extranodal_disease_site", "value": "No", "score": 0}], "final_answer": 4, "notes": "4 points\nHigh-intermediate risk\n51 %\n5-year progression-free survival\n64 %\n5-year overall survival"}, {"order": 4, "name": "Modified Glasgow Prognostic Score (mGPS) for Cancer Outcomes", "inputs": [{"field": "CRP_mg_L", "value": 22}, {"field": "Albumin_g_dL", "value": 3.3}], "final_answer": "mGPS 2", "notes": "mGPS 2\nPoor Prognosis\nSee Evidence for more info."}, {"order": 5, "name": "Charlson Comorbidity Index (CCI)", "inputs": [{"field": "Age_years", "value": 68}, {"field": "Age_category", "value": "60–69", "score": 2}, {"field": "Myocardial_infarction", "value": "No", "score": 0}, {"field": "Congestive_heart_failure", "value": "No", "score": 0}, {"field": "Peripheral_vascular_disease", "value": "No", "score": 0}, {"field": "CVA_TIA", "value": "No", "score": 0}, {"field": "Dementia", "value": "No", "score": 0}, {"field": "Chronic_pulmonary_disease", "value": "No", "score": 0}, {"field": "Connective_tissue_disease", "value": "No", "score": 0}, {"field": "Peptic_ulcer_disease", "value": "No", "score": 0}, {"field": "Liver_disease", "value": "None", "score": 0}, {"field": "Diabetes_mellitus", "value": "Uncomplicated", "score": 1}, {"field": "Hemiplegia", "value": "No", "score": 0}, {"field": "Moderate_to_severe_CKD", "value": "No", "score": 0}, {"field": "Solid_tumor", "value": "None", "score": 0}, {"field": "Leukemia", "value": "No", "score": 0}, {"field": "Lymphoma", "value": "Yes", "score": 2}, {"field": "AIDS", "value": "No", "score": 0}], "final_answer": 5, "notes": "5 points\nCharlson Comorbidity Index\n21 %\nEstimated 10-year survival"}, {"order": 6, "name": "Central Nervous System International Prognostic Index (CNS-IPI)", "inputs": [{"field": "Age_>60_years", "value": "Yes", "score": 1}, {"field": "LDH_>normal", "value": "Yes", "score": 1}, {"field": "ECOG_>1", "value": "No", "score": 0}, {"field": "Ann_Arbor_stage_III_or_IV", "value": "Yes", "score": 1}, {"field": ">1_extranodal_disease_site", "value": "No", "score": 0}, {"field": "Kidney_or_adrenal_involvement", "value": "No", "score": 0}], "final_answer": 3, "notes": "3 points\nCNS-IPI\n3.4 %\nIntermediate risk of CNS relapse"}, {"order": 7, "name": "Prognosis Calculator for Relapsed/Refractory DLBCL", "inputs": [{"field": "Age_at_first_progression_or_relapse_years", "value": 69}, {"field": "Time_to_progression_on_frontline_immunochemotherapy_months", "value": 9}], "final_answer": "21%", "notes": "Predicted 2-year survival from progression:\n21%\nInterpretation:\nThis prognostic tool was developed to provide prognostic information on survival at the time of first progression or relapse for patients with DLBCL who were treated with frontline R-CHOP or like anthracycline based immunochemotherapy. Therapy selection may impact the risk estimates obtained in the model."}]}
{"task_id": "medmcp-calc_079_93de714f", "task_scenario": "Basic Electrophysiology and Hemodynamics", "task_category": "Clinical Medicine / Medicine & Organ Systems / Cardiovascular Medicine", "patient_id": "P079_93de714f", "task_description": "Clinical scenario (Cardiovascular Medicine _ Basic Electrophysiology and Hemodynamics): An acutely ill patient presents with hypotension, tachycardia, dyspnea, and possible new systolic murmur. Differential includes cardiogenic shock from left ventricular pump failure versus obstructive shock from critical aortic stenosis, with concurrent need to evaluate arrhythmic risk before initiating vasoactive or antiarrhythmic therapy. The goal is to quantify global hemodynamics, classify heart failure severity, identify valvular obstruction, and ensure electrophysiologic safety in therapy selection. Step-by-step workflow: 1) Use Mean Arterial Pressure (MAP) to establish the baseline perfusion pressure, which will be required downstream for power and resistance calculations. 2) Apply Shock Index to rapidly screen for occult shock; if the Shock Index is elevated or MAP is low, prioritize immediate hemodynamic quantification and stabilization; if not elevated, continue the workflow but with lower urgency. 3) Calculate Cardiac Output (Fick’s Formula) to obtain cardiac output and cardiac index; these values will be used directly in subsequent calculations. 4) Compute Cardiac Power Output (CPO) using MAP (Step 1) and cardiac output (Step 3) to quantify the heart’s mechanical power; low CPO deterministically supports cardiogenic shock. 5) Estimate Systemic Vascular Resistance using MAP (Step 1) and cardiac output (Step 3). Branch: elevated SVR suggests significant afterload (consider vasodilators if perfusion permits), while low SVR suggests a distributive component (consider vasopressors). 6) Classify the patient with Forrester HF Class using cardiac index (from Step 3) and filling pressures (e.g., wedge when available) to determine cold/warm and wet/dry status, guiding the balance of diuresis, vasodilation, and inotropy. 7) Perform Hemodynamics (Echo) to derive LVOT diameter and VTI and aortic valve flow velocities—foundation measurements for valve calculations and stroke volume estimation when needed. 8) Use AS: Aortic Valve Area (Cont) with the echo-derived LVOT and aortic flow measurements (from Step 7) to quantify the aortic valve area. Branch: severe aortic stenosis deterministically indicates an obstructive valvular cause; prioritize valve-directed management and avoid aggressive vasodilators; if not severe, proceed to assess pump function. 9) Apply Ejection Fraction (Simplified) to quantify LV systolic function. Decision: reduced EF combined with low CPO supports inotropic therapy and advanced support consideration; preserved EF with high SVR shifts focus to afterload reduction; preserved EF with low SVR favors vasopressors and evaluation for distributive causes. 10) Calculate Corrected QT Interval (QTc) to assess repolarization and arrhythmic risk before starting agents that may prolong QT; if QTc is prolonged, avoid QT-prolonging medications and adjust therapy accordingly; if QTc is normal, standard vasoactive/antiarrhythmic options can be used with routine monitoring. This sequence integrates rapid triage, quantitative hemodynamics, structural valve assessment, pump function evaluation, and electrophysiologic safety to guide urgent management.", "fuzzy_question": "I’m reviewing a case of an acutely ill patient with hypotension, tachycardia, dyspnea, and a systolic murmur. I’m weighing pump failure causing cardiogenic shock versus an obstructive process from severe aortic stenosis, and I don’t want to miss arrhythmic risk before initiating vasoactive or antiarrhythmic therapy.\n\nTo ground the plan, I want to anchor on mean perfusion pressure rather than just peaks or troughs, and assess how the heart rate relates to the systolic pressure to gauge whether shock is present. If that relationship is worrisome or the mean pressure is low, prioritize rapid, precise hemodynamic quantification and stabilization; if it’s less concerning, proceed without the same urgency.\n\nBefore choosing medications, I need a firm sense of forward flow. Using oxygen uptake and the arterial-venous oxygen content difference (or appropriate surrogates), I want to estimate overall cardiac output and the output normalized to body size. Paired with the mean pressure, this can inform the heart’s mechanical power; if clearly depressed, that would support a pump problem. From the same data, I also want to understand systemic vascular resistance. If resistance is high, consider careful afterload reduction as tolerated; if low, that suggests a distributive component and supports pressure augmentation.\n\nIn parallel, place the patient within the warm vs cold and wet vs dry framework using flow and filling pressures—wedge if available, or reasonable echo-based surrogates—to balance diuresis, vasodilation, and inotropy appropriately.\n\nEcho-wise, I need measurements of the LV outflow tract diameter and VTI, plus aortic valve velocities. That will help determine whether there is significant valve obstruction and also provide a reliable stroke volume estimate if needed. Using these echo data, size the aortic valve. If it falls in the severe range, that would point toward an obstructive valvular cause; prioritize valve-directed management and be cautious with vasodilators. If it’s not severe, focus more on pump function.\n\nI also want a straightforward look at left ventricular systolic function. If the ejection fraction is reduced and the heart’s power is low, that supports inotropes and possibly advanced support. If the ejection fraction is preserved but afterload is high, afterload reduction is the main lever. If the ejection fraction is preserved with low afterload, favor vasopressors and evaluate for a distributive process.\n\nLastly, before starting any vasoactive or rhythm agents, obtain a corrected QT. If it’s prolonged, avoid QT-prolonging drugs and select safer options; if it’s normal, standard choices with routine monitoring are reasonable.\n\nWhat’s your take on this sequence for this case? I need proper calculations to support the plan—this cannot rest on clinical intuition alone, and the approach should hold up to scrutiny.", "required_calculators": ["Mean Arterial Pressure (MAP)", "Shock Index", "Cardiac Output (Fick’s Formula)", "Cardiac Power Output (CPO)", "Systemic Vascular Resistance", "Forrester HF Class", "Hemodynamics (Echo)", "AS: Aortic Valve Area (Cont)", "Ejection Fraction (Simplified)", "Corrected QT Interval (QTc)"], "calculator_answers": [{"order": 1, "name": "Mean Arterial Pressure (MAP)", "inputs": [{"field": "Systolic BP", "value": "78 mm Hg"}, {"field": "Diastolic BP", "value": "44 mm Hg"}], "final_answer": 55, "notes": "55 mm Hg\nMean Arterial Pressure (MAP)"}, {"order": 2, "name": "Shock Index", "inputs": [{"field": "Heart Rate/Pulse", "value": "120 beats/min"}, {"field": "Systolic BP", "value": "78 mm Hg"}], "final_answer": 1.5, "notes": "0.5-0.7 is believed to be a normal shock index. Higher numbers have been shown to be more sensitive than vital signs alone in diagnosing occult shock, need for transfusion and/or operation."}, {"order": 3, "name": "Cardiac Output (Fick’s Formula)", "inputs": [{"field": "Weight", "value": "176 lb"}, {"field": "Height", "value": "70 in"}, {"field": "SaO₂", "value": "95 %"}, {"field": "SvO₂", "value": "45 %"}, {"field": "Hemoglobin", "value": "12.8 g/dL"}, {"field": "Heart rate", "value": "120 beats/min"}, {"field": "Age", "value": "≥70 years"}], "final_answer": "2.5 L/min", "notes": "2.5 L/min\nCardiac output\n1.3 L/min/m²\nCardiac index\n21 mL/beat\nStroke volume"}, {"order": 4, "name": "Cardiac Power Output (CPO)", "inputs": [{"field": "Mean arterial pressure", "value": "55 mm Hg"}, {"field": "Cardiac output", "value": "2.58 L/min"}], "final_answer": "0.31 W", "notes": "0.31 W\nCardiac power output"}, {"order": 5, "name": "Systemic Vascular Resistance", "inputs": [{"field": "Mean Arterial Pressure", "value": "55 mmHg"}, {"field": "Central Venous Pressure", "value": "12 mmHg"}, {"field": "Cardiac Output", "value": "2.58 L/min"}, {"field": "Units", "value": "dynes·sec·cm^-5"}], "final_answer": 1333, "notes": "Systemic Vascular Resistance\n1333 Dynes·sec·cm⁻⁵"}, {"order": 6, "name": "Forrester HF Class", "inputs": [{"field": "PCWP", "value": "24 mmHg"}, {"field": "Cardiac Index", "value": "1.30 L/min/m^2"}], "final_answer": 4, "notes": "Forrester Class\n4\nAnticipated In-Hospital Mortality\n54 %"}, {"order": 7, "name": "Hemodynamics (Echo)", "inputs": [{"field": "LVOT Diameter", "value": "19 mm"}, {"field": "LVOT Subvalvular Velocity Time Integral", "value": "8.4 cm"}, {"field": "Heart Rate", "value": "120 beats/min"}, {"field": "Weight", "value": "80 kg"}, {"field": "Height", "value": "178 cm"}], "final_answer": "2.9 L/min", "notes": "Cardiac Output\n2.9 L/min\nCardiac Index\n1.44 L/min/m²\nStroke Volume\n24 mL/beat\nStroke Volume Index\n12 mL/beat/m²"}, {"order": 8, "name": "AS: Aortic Valve Area (Cont)", "inputs": [{"field": "Maximal Aortic Valve VTI", "value": "80 cm"}, {"field": "LV Outflow Tract Diameter", "value": "19 mm"}, {"field": "Maximal LV Outflow Tract VTI", "value": "8.4 cm"}], "final_answer": "29.76 cm²", "notes": "Estimated Aortic Valve Area\n29.76 cm²\nGradation of Severity of Aortic Stenosis\n(ACC/AHA 2006)\nMild\nAVA >1.5 cm², Mean pressure gradient <25 mmHg, Peak systolic flow velocity <3 m/s\nModerate\nAVA 1.0-1.5 cm², Mean pressure gradient 25-40 mmHg; Peak systolic flow velocity 3-4 m/s\nSevere\nAVA ≤1.0 cm², Mean pressure gradient >40 mmHg; Peak systolic flow velocity >4 m/s"}, {"order": 9, "name": "Ejection Fraction (Simplified)", "inputs": [{"field": "LV End Diastolic Dimension", "value": "52 mm"}, {"field": "LV End Systolic Dimension", "value": "40 mm"}, {"field": "Apical Contraction", "value": "Normal"}], "final_answer": "50 %", "notes": "Ejection Fraction\n50 %\nCategory\nMidly Abnormal"}, {"order": 10, "name": "Corrected QT Interval (QTc)", "inputs": [{"field": "Formula", "value": "Bazett"}, {"field": "Heart rate/pulse", "value": "120 beats/min"}, {"field": "Paper speed, mm/sec", "value": "25"}, {"field": "QT interval", "value": "9 small boxes"}], "final_answer": "509 msec", "notes": "509 msec\nCorrected QT Interval (QTc)"}]}
{"task_id": "medmcp-calc_080_a19d8670", "task_scenario": "Neonatal Hyperbilirubinemia", "task_category": "Clinical Medicine / Special Populations & General Tools / Pediatrics & Neonatology", "patient_id": "P080_a19d8670", "task_description": "Inpatient newborn with jaundice during birth hospitalization; clinician must decide on observation vs phototherapy and follow-up. Step 1: Use Hour-Specific Risk to stratify risk; if low, plan follow-up; if high, proceed to compute Rate of Rise. Step 2: Using Rate of Rise, if rapid, treat; if slow, observe. Step 3: If therapy initiated, compute Rebound Risk Score for follow-up. Only patients who received phototherapy proceed to Rebound risk.", "fuzzy_question": "I’m evaluating a newborn in the birth unit with visible jaundice. The infant is clinically stable, and feeding has been initiated. A bilirubin result is available, with a repeat level planned. I’m deciding between continued observation with scheduled follow-up versus initiating phototherapy.\n\nFirst, I want to determine where the bilirubin falls on the standard age-specific nomogram for this postnatal period. If it’s comfortably below treatment thresholds, I’d favor observation with a defined interval for the next check and appropriate outpatient follow-up after discharge. If it’s high for age or close to treatment thresholds, the trend between recent sequential measurements becomes critical. A rapid rate of rise would favor starting phototherapy; a slow rise that remains below thresholds would support continued observation with another level before discharge.\n\nIf phototherapy is started, before discontinuation and discharge I want an estimate of rebound risk for this infant and a plan for timing of recheck and post-discharge follow-up. If phototherapy is not used, we can omit rebound monitoring and arrange routine follow-up.\n\nWhat’s your recommendation? Please walk through the reasoning in that sequence using guideline-based thresholds and rate-of-rise calculations rather than clinical intuition, with calculations clearly shown to support the decision. This needs to hold up to scrutiny.", "required_calculators": ["Hour-Specific Risk for Neonatal Hyperbilirubinemia", "Newborn Hyperbilirubinemia Rate of Rise", "Rebound Hyperbilirubinemia Risk Score"], "calculator_answers": [{"order": 1, "name": "Hour-Specific Risk for Neonatal Hyperbilirubinemia", "inputs": [{"field": "Age", "value": "54 hours"}, {"field": "Total serum bilirubin", "value": "13.2 mg/dL"}, {"field": "Gestational age, weeks", "value": ">=38"}, {"field": "Risk factors for neurotoxicity present", "value": "No"}], "final_answer": "High-intermediate", "notes": "High-intermediate\nHour-specific TSB risk zone\n12.9 %\nProbability of subsequent neonatal hyperbilirubinemia\nNo\nStart phototherapy?\nDo not need to start phototherapy as per AAP phototherapy guidelines"}, {"order": 2, "name": "Newborn Hyperbilirubinemia Rate of Rise", "inputs": [{"field": "Bilirubin #1 Value", "value": "13.2 mg/dL"}, {"field": "Bilirubin #2 Value", "value": "15.0 mg/dL"}, {"field": "Time Between Bilirubin Values", "value": "8 hours"}], "final_answer": "3.85 μmol/L/hour Or 92.34 μmol/L/day", "notes": "Rate of Rise (SI)\n3.85 μmol/L/hour Or 92.34 μmol/L/day\nRate of Rise (US)\n0.23 mg/dL/hour Or 5.40 mg/dL/day\nInterpretation\nRate of TSB rise > 3.4 μmol/L/hour (0.2 mg/dL/hour) is a risk factor for severe hyperbilirubinemia"}, {"order": 3, "name": "Rebound Hyperbilirubinemia Risk Score", "inputs": [{"field": "Gestational age (GA)", "value": ">=38 weeks"}, {"field": "Age at phototherapy initiation, hours", "value": "62 hours"}, {"field": "Total serum bilirubin (TSB)", "value": "12.0 mg/dL"}], "final_answer": 7.9, "notes": "7.9 points\nRebound hyperbilirubinemia risk score\n0.3 %\nRisk of rebound hyperbilirubinemia"}]}
{"task_id": "medmcp-calc_081_959af1bf", "task_scenario": "Trauma Assessment & Spine Clearance", "task_category": "Clinical Medicine / Emergency, Critical Care & Perioperative / Emergency Medicine & Trauma", "patient_id": "P081_959af1bf", "task_description": "Scenario: An adult with high-energy blunt trauma arrives immobilized with suspected spinal injury. The team must rapidly assess hemodynamic and neurologic status, decide on cervical spine clearance versus imaging, classify any discovered spinal injuries, and determine overall trauma severity and survival probability to guide disposition and operative planning. Workflow steps using calculators: Step 1 — Shock Index: Immediately calculate the Shock Index to screen for occult hemorrhagic shock. This determines urgency of resuscitation and whether the patient is stable enough for clinical cervical spine clearance. Step 2 — Focused Assessment with Sonography for Trauma (FAST): If Shock Index is elevated or there is clinical concern for torso hemorrhage, perform FAST to rapidly detect pericardial or intra-abdominal injury. If FAST is positive (or clinical instability persists), prioritize hemorrhage control and definitive imaging while maintaining full spinal precautions. Step 3 — Glasgow Coma Scale (GCS): Assess baseline neurologic status. The GCS result will be used later as a required component of the Revised Trauma Score. Branch A (if GCS is depressed or unreliable): Calculate the GCS-Pupils Score to refine neurologic severity and prognosis; this situation precludes clinical cervical spine clearance and mandates imaging with continued immobilization. Branch B (if GCS is adequate and the patient is cooperative): Proceed to clinical cervical spine clearance decision in Step 4 if hemodynamics are stable (acceptable Shock Index). Step 4 — Canadian C-Spine Rule: In an alert, stable patient without distracting injuries per protocol, apply the rule to determine whether cervical spine imaging is required. If the rule indicates no imaging, the cervical spine can be clinically cleared. If imaging is indicated (or if earlier steps showed instability or low GCS), maintain precautions and image the cervical spine. Step 5 — Subaxial Injury Classification and Severity Scale (SLICS): If cervical imaging reveals a subaxial cervical spine injury, use SLICS to classify morphology, integrity of the disco-ligamentous complex, and neurologic status to guide operative versus non-operative management. Step 6 — Thoracolumbar Injury Classification and Severity Scale (TLICS): If thoracolumbar injury is suspected or confirmed on imaging (e.g., back pain, tenderness, or mechanism), use TLICS to classify and guide management for thoracolumbar injuries. Step 7 — Revised Trauma Score (RTS): Quantify physiologic severity using GCS (from Step 3) together with vital signs; this creates a standardized physiologic severity metric that will be used in TRISS. Step 8 — Injury Severity Score (ISS): After imaging and classification (including any injuries identified by SLICS/TLICS), aggregate all injuries to compute the ISS, reflecting anatomic injury burden. Step 9 — Trauma Score and Injury Severity Score (TRISS): Combine RTS (Step 7) and ISS (Step 8) to estimate probability of survival, supporting decisions about level of care (ICU/OR), transfer to a trauma center, and urgency of specialty consultations. Conditional logic summary: If Shock Index is elevated and/or FAST positive, prioritize hemorrhage control and imaging; defer clinical C-spine clearance. If GCS is low, use GCS-Pupils and mandate imaging; do not apply Canadian C-Spine Rule. If Canadian C-Spine Rule indicates imaging, proceed and apply SLICS if cervical injury is found; consider TLICS for thoracolumbar injury. RTS uses GCS from Step 3; TRISS requires both RTS and ISS, so outputs of Steps 7 and 8 are mandatory inputs for Step 9.", "fuzzy_question": "I’m reviewing a case of a patient who presented after a high‑energy blunt mechanism with full spinal precautions and a suspected spine injury. I need to quickly determine whether there is significant occult hemorrhage and how reliable the neurologic examination is, as this will guide whether to attempt bedside cervical clearance or proceed directly to imaging and hemorrhage control.\n\nUp front, I want a rapid screen from the vital signs to assess risk of occult shock—integrating heart rate and blood pressure to judge resuscitation urgency and whether the patient is stable enough to consider clinical neck clearance. If that screen is concerning or there is any suggestion of torso bleeding, I would obtain a focused bedside ultrasound to look for pericardial or intraperitoneal fluid. If fluid is detected, or instability persists, I would prioritize hemorrhage control and definitive imaging while maintaining full spinal precautions, deferring any attempt at clinical neck clearance.\n\nIn parallel, I need a baseline neurologic assessment using the standard eye/verbal/motor scoring. If that is depressed or unreliable, I will incorporate pupillary findings to gauge severity of brain injury; in that situation, I would not attempt bedside clearance—maintain immobilization and obtain imaging. If the neurologic status appears adequate and the patient can cooperate, and if the initial hemodynamic screen is acceptable, then I am comfortable applying established clinical criteria to decide whether the cervical spine can be cleared without imaging. If those criteria are not met—or earlier concerns about instability persist—I would obtain cervical imaging.\n\nIf imaging identifies a cervical injury, I want it characterized by morphology (compression/burst vs distraction/translation), integrity of the disco‑ligamentous complex, and the neurologic status to guide operative versus non‑operative management. If thoracic or lumbar involvement is suspected clinically or seen on imaging, please provide a similar structured assessment—morphology, posterior ligament complex integrity, and neurologic findings—to guide management.\n\nAfter obtaining the initial neurologic score and vital signs, I want a standard physiology‑based trauma severity measure calculated using the documented neurologic score. Once imaging confirms all injuries, please calculate the customary anatomic injury burden score. Then combine the physiologic and anatomic measures to estimate probability of survival; use that estimate to inform disposition (ICU versus operating room), potential need for transfer to a higher level of care, and the urgency of subspecialty involvement.\n\nFlow summary: if the early vital‑sign screen indicates concern or the bedside ultrasound suggests bleeding, defer bedside cervical clearance and focus on hemorrhage control and imaging. If the neurologic status is low, adjust the assessment using pupils and do not attempt clinical clearance—image the neck. If bedside criteria do not support clearance, obtain imaging; and if injuries are identified, classify cervical and thoracolumbar findings as above to guide management decisions.\n\nWhat’s the clinical reasoning here? Please walk through it step by step and provide quantitative, evidence‑based calculations at each decision point to justify the recommendations. The approach should be supported by validated measures and hold up to scrutiny.", "required_calculators": ["Shock Index", "Focused Assessment with Sonography for Trauma (FAST)", "Glasgow Coma Scale (GCS)", "GCS-Pupils Score", "Canadian C-Spine Rule", "Subaxial Injury Classification and Severity Scale (SLICS)", "Thoracolumbar Injury Classification and Severity Scale (TLICS)", "Revised Trauma Score", "Injury Severity Score (ISS)", "Trauma Score and Injury Severity Score (TRISS)"], "calculator_answers": [{"order": 1, "name": "Shock Index", "inputs": [{"field": "Heart Rate/Pulse", "value": "118 beats/min"}, {"field": "Systolic BP", "value": "96 mm Hg"}], "final_answer": 1.2, "notes": "0.5-0.7 is believed to be a normal shock index. Higher numbers have been shown to be more sensitive than vital signs alone in diagnosing occult shock, need for transfusion and/or operation."}, {"order": 2, "name": "Focused Assessment with Sonography for Trauma (FAST)", "inputs": [{"field": "Pericardial fluid", "value": "Absent"}, {"field": "Right upper quadrant (Morison's pouch) fluid", "value": "Present"}, {"field": "Left upper quadrant (splenorenal recess) fluid", "value": "Absent"}, {"field": "Suprapubic fluid", "value": "Present"}], "final_answer": "Positive FAST", "notes": "Suspected hemoperitoneum\nEmergent ex lap indicated for hemoperitoneum in unstable patients. Use clinical judgment; see Next Steps for details."}, {"order": 3, "name": "Glasgow Coma Scale (GCS)", "inputs": [{"field": "Best eye response", "value": "To verbal command (+3)", "score": 3}, {"field": "Best verbal response", "value": "Inappropriate words (+3)", "score": 3}, {"field": "Best motor response", "value": "Withdrawal from pain (+4)", "score": 4}], "final_answer": 10, "notes": "10 points\nGlasgow Coma Score\nE(3) V(3) M(4)\nGlasgow Coma Scale"}, {"order": 4, "name": "GCS-Pupils Score", "inputs": [{"field": "Eye response", "value": "Eye opening to verbal command (+3)", "score": 3}, {"field": "Verbal response", "value": "Inappropriate words (+3)", "score": 3}, {"field": "Motor response", "value": "Withdrawal from pain (+4)", "score": 3}, {"field": "Pupil response", "value": "Both pupils reactive to light (normal) (0)", "score": 0}], "final_answer": 10, "notes": "10 points\nGCS-Pupils Score\n17.35 %\nMortality at 6 months post-injury\n28.88 %\nUnfavorable outcome (vegetative state or severe disability) at 6 months post-injury"}, {"order": 5, "name": "Canadian C-Spine Rule", "inputs": [{"field": "Age ≥65 years, extremity paresthesias, or dangerous mechanism", "value": "Yes"}], "final_answer": "High", "notes": "High risk\nHigh risk patient. C-spine cannot be cleared clinically by these criteria. Imaging is recommended."}, {"order": 6, "name": "Subaxial Injury Classification and Severity Scale (SLICS)", "inputs": [{"field": "Morphology", "value": "Rotation/translation (+4)", "score": 4}, {"field": "Discoligamentous complex (DLC)", "value": "Disrupted (+2)", "score": 2}, {"field": "Neurological status", "value": "Incomplete cord injury (+3)", "score": 3}, {"field": "Continuous cord compression (signal change within cord on MRI) in setting of neuro deficit", "value": "Yes", "score": 1}], "final_answer": 10, "notes": "10 points\nSLICS Score\nOperative treatment\nMay consist of realignment, neurological decompression (if indicated), and stabilization"}, {"order": 7, "name": "Thoracolumbar Injury Classification and Severity Scale (TLICS)", "inputs": [{"field": "Morphology", "value": "Burst fracture (+2)", "score": 2}, {"field": "Neurologic involvement", "value": "Intact (0)", "score": 0}, {"field": "Posterior ligamentous complex", "value": "Injured (+3)", "score": 3}], "final_answer": 5, "notes": "5 points\nTLICS\nOperative\nStabilization with or without fracture reduction as appropriate"}, {"order": 8, "name": "Revised Trauma Score", "inputs": [{"field": "Glasgow Coma Scale", "value": "10 points"}, {"field": "Systolic BP", "value": "96 mm Hg"}, {"field": "Respiratory Rate", "value": "24 breaths/min"}], "final_answer": 7, "notes": "Some trauma protocols recommend patient treatment at a trauma center for a Revised Trauma Score <4, although other protocols use a higher number; the RTS correlates strongly with patient survival."}, {"order": 9, "name": "Injury Severity Score (ISS)", "inputs": [{"field": "Head and neck worst injury?", "value": "Severe"}, {"field": "Face worst injury?", "value": "No injury"}, {"field": "Chest worst injury?", "value": "Moderate"}, {"field": "Abdomen worst injury?", "value": "Severe"}, {"field": "Extremity (including pelvis) worst injury?", "value": "Serious"}, {"field": "External worst injury?", "value": "Minor"}], "final_answer": 41, "notes": "41 points\nOut of a possible 75 points"}, {"order": 10, "name": "Trauma Score and Injury Severity Score (TRISS)", "inputs": [{"field": "Trauma type", "value": "Blunt"}, {"field": "Revised Trauma Score (RTS)", "value": "6.90 points"}, {"field": "Injury Severity Score (ISS)", "value": "41 points"}, {"field": "Age, years", "value": "≤54"}], "final_answer": "89.9 %", "notes": "89.9 %\nProbability of survival"}]}
{"task_id": "medmcp-calc_082_70c18f58", "task_scenario": "Toxicology & Metabolic Emergencies", "task_category": "Clinical Medicine / Emergency, Critical Care & Perioperative / Emergency Medicine & Trauma", "patient_id": "P082_70c18f58", "task_description": "Scenario: A patient presents to the emergency department with altered mental status and severe metabolic derangements after a suspected ingestion. The clinical picture suggests toxic alcohol exposure (methanol or ethylene glycol) with high anion-gap metabolic acidosis and evolving kidney injury. The workflow below uses a sequence of calculators to rapidly confirm the diagnosis, initiate antidotal therapy, and plan renal replacement therapy.\nStep 1 — Identify high anion-gap metabolic acidosis: Use Serum Anion Gap to confirm a high anion gap, which raises suspicion for toxic alcohols among other causes. If the anion gap is not elevated, consider alternative etiologies and proceed to Step 3 only if clinical suspicion for toxic alcohols remains high.\nStep 2 — Assess respiratory compensation: If a high anion-gap metabolic acidosis is present, apply Winters' Formula for Metabolic Acidosis Compensation to determine whether respiratory compensation is appropriate. If compensation is inadequate (suggesting impending respiratory failure), escalate airway/ventilation support and proceed urgently with Steps 3–7.\nStep 3 — Evaluate osmolar gap to support toxic alcohol diagnosis: Use Serum Osmolality/Osmolarity to estimate expected osmolarity and compare to measured osmolality to determine the osmolar gap. A clearly elevated osmolar gap strengthens suspicion for methanol/ethylene glycol. If the osmolar gap is not elevated, reassess for non–toxic alcohol causes and defer antidotal/dialysis planning.\nStep 4 — Estimate initial toxin concentration if measured levels are delayed: Use Estimated Ethanol (and Toxic Alcohol) Serum Concentration Based on Ingestion to approximate the starting methanol or ethylene glycol concentration from history. This estimate will serve as the initial concentration input for the dialysis duration calculators in Steps 8–9 if lab confirmation is delayed.\nStep 5 — Initiate antidotal therapy: Use Fomepizole Dosing to dose and schedule the antidote to block alcohol dehydrogenase, minimizing toxic metabolite formation. Start treatment promptly once toxic alcohol ingestion is suspected from Steps 1–3.\nStep 6 — Stage kidney injury: Use KDIGO AKI Staging to classify acute kidney injury severity and trajectory. Higher stages or rapidly worsening injury strengthen the indication for renal replacement therapy planning in Steps 8–10.\nStep 7 — Determine hemodynamic stability to choose dialysis modality: Use Mean Arterial Pressure (MAP) to assess stability. If unstable (e.g., requiring vasopressors), plan for continuous renal replacement therapy; if stable, plan for intermittent hemodialysis.\nStep 8 — If methanol is suspected/confirmed and the patient is hemodynamically stable: Use Dialysis Duration Needed for Methanol Ingestion to estimate the time needed on dialysis to reduce methanol concentration to a safe level, using either the measured level or the estimated level from Step 4.\nStep 9 — If ethylene glycol is suspected/confirmed and the patient is hemodynamically stable: Use Dialysis Duration Needed for Ethylene Glycol Ingestion to estimate the time needed on dialysis to reach a safe level, again using measured or estimated initial concentration from Step 4.\nStep 10 — If the patient is hemodynamically unstable: Use CRRT Dosing Calculator to determine appropriate continuous renal replacement therapy dose to correct acid-base disturbances and remove toxins safely. Reassess periodically, and if stability improves, re-evaluate the need for intermittent dialysis using Steps 8–9.\nConditional branches occur at multiple points: (a) If the Serum Anion Gap is normal, proceed with osmolar gap (Step 3) only if clinical suspicion persists; otherwise pivot away from toxic alcohol workflow. (b) A significantly elevated osmolar gap in Step 3 is a deterministic trigger for initiating Step 5 (Fomepizole). (c) KDIGO stage from Step 6 and compensation assessment from Step 2 determine urgency and likelihood of proceeding to dialysis planning. (d) MAP from Step 7 is the trigger that routes to either the CRRT Dosing Calculator (Step 10) or the appropriate dialysis duration calculator (Steps 8–9). (e) The estimated toxin concentration from Step 4 is used as an input for the dialysis duration calculators in Steps 8–9 when measured levels are not yet available. The sequence prioritizes rapid diagnosis, antidote initiation, and tailored renal support to mitigate morbidity.", "fuzzy_question": "I’m evaluating a patient with altered mental status after a suspected ingestion, with significant metabolic abnormalities and worsening kidney function. Toxic alcohol exposure is a concern, but I want to avoid anchoring. First, I want to confirm whether this is truly a high anion gap metabolic acidosis based on the available electrolytes rather than a normal-gap process that would point elsewhere. If the gap isn’t elevated but the exposure history remains concerning, I’d still keep toxic alcohols in the differential rather than abandon that line entirely.\n\nIf it does appear to be a high-gap acidosis, I want to assess whether ventilation is appropriately compensating for the acid load. If there’s undercompensation, that would push me toward early airway and ventilatory support while proceeding with the rest of the plan.\n\nTo strengthen the diagnosis, I’d compare measured and calculated serum tonicity. If that difference is clearly abnormal, I’d treat this as a toxic alcohol exposure until proven otherwise. If it isn’t, I’d step back to reconsider alternative causes and hold on any dialysis planning until there’s a stronger signal.\n\nIf specific toxin levels will be delayed, I’d use the exposure history (timing, amount, substance type, co‑ingestants) to approximate a starting level so we can model clearance and plan therapy in the meantime.\n\nFor treatment, I’d start an alcohol dehydrogenase inhibitor promptly once the clinical story and labs point that way, using an appropriate loading strategy and scheduled maintenance, and adjust around any dialysis.\n\nGiven worsening kidney function and urine output changes, please stage the kidney injury to clarify severity and trajectory, as that will influence how aggressive we need to be with renal support. In parallel, I need a read on hemodynamic stability (vasopressor needs and blood pressure profile) to decide between intermittent treatments and a continuous approach.\n\nIf the patient is stable and methanol is the likely culprit, I want a plan for how long intermittent dialysis is needed to bring the level down to a safe range, using either a lab result when available or an estimate from the exposure history if the level isn’t back yet. Do the same if ethylene glycol is more likely. If the patient isn’t stable, then set an appropriate continuous therapy dose to steadily correct the acid–base disturbance and clear the toxin safely; reassess frequently, and if blood pressure improves, re‑evaluate a switch to an intermittent plan and its duration based on the measured or estimated level.\n\nKey pivot points: if the gap isn’t high, I only want to keep pursuing toxic alcohols when the clinical story remains compelling; a clearly abnormal tonicity difference should trigger antidote therapy right away; the combination of compensation status and kidney injury stage sets urgency; and the blood pressure profile guides continuous versus intermittent modalities. If we start with a history‑based level, carry that forward into dialysis planning and update it once the actual number returns.\n\nWhat’s your take on this? Please walk me through a stepwise approach and show the intermediate reasoning at each decision point. I need proper calculations to support this—clinical judgment alone isn’t enough. The plan should be defensible.", "required_calculators": ["Serum Anion Gap", "Winters' Formula for Metabolic Acidosis Compensation", "Serum Osmolality/Osmolarity", "Estimated Ethanol (and Toxic Alcohol) Serum Concentration Based on Ingestion", "Fomepizole Dosing", "KDIGO AKI Staging", "Mean Arterial Pressure (MAP)", "Dialysis Duration Needed for Methanol Ingestion", "Dialysis Duration Needed for Ethylene Glycol Ingestion", "CRRT Dosing Calculator"], "calculator_answers": [{"order": 1, "name": "Serum Anion Gap", "inputs": [{"field": "Sodium", "value": "140 mEq/L"}, {"field": "Chloride", "value": "96 mEq/L"}, {"field": "Bicarbonate", "value": "10 mEq/L"}, {"field": "Albumin", "value": "3.2 g/dL"}], "final_answer": "34.0 mEq/L", "notes": "34.0 mEq/L\nAnion gap\nDelta gap: 22.0 mEq/L\nDelta ratio: 1.6; Pure anion gap acidosis\n36.0 mEq/L\nAlbumin corrected anion gap; suggests high anion gap acidosis\nAlbumin corrected delta gap: 24.0 mEq/L\nAlbumin corrected delta ratio: 1.7"}, {"order": 2, "name": "Winters' Formula for Metabolic Acidosis Compensation", "inputs": [{"field": "Bicarbonate", "value": "10 mEq/L"}], "final_answer": "23 mm Hg", "notes": "Expected pCO2 ≈ 1.5 × 10 + 8 = 23 mm Hg (±2). ABG in chart: pH 7.12, PaCO2 25 mm Hg (near-appropriate compensation)."}, {"order": 3, "name": "Serum Osmolality/Osmolarity", "inputs": [{"field": "Sodium", "value": "140 mEq/L"}, {"field": "BUN", "value": "48 mg/dL"}, {"field": "Glucose", "value": "120 mg/dL"}, {"field": "Serum alcohol concentration", "value": "40 mg/dL"}, {"field": "Measured serum osm", "value": "350 mOsm/kg"}], "final_answer": "313-315 mOsm/kg", "notes": "313-315 mOsm/kg Calculated Serum Osm\nNormal serum osmolality = 285-295 mOsm/kg\n35.4 mOsm/kg Osm Gap\nThis is a significant Osm Gap; if there is also an anion gap acidosis, you should strongly consider methanol or ethylene glycol intoxication.\nOther causes of Osmolal Gap include other alcohols (acetone, isopropyl alcohol, polyethylene or propylene glycol), sugars (mannitol, sorbitol), lipids (hypertriglyceridemia) or proteins (hypergammaglobulinemia)."}, {"order": 4, "name": "Estimated Ethanol (and Toxic Alcohol) Serum Concentration Based on Ingestion", "inputs": [{"field": "Weight", "value": "176 lbs"}, {"field": "% alcohol", "value": "50 %"}, {"field": "Amount ingested", "value": "100 mL"}, {"field": "Type of alcohol", "value": "Ethylene glycol"}], "final_answer": "104 mg/dL", "notes": "104 mg/dL\nEstimated serum concentration\n(16.8 mmol/L). Treatment with fomepizole recommended at ethylene glycol concentration ≥20 mg/dL (3.2 mmol/L). See Next Steps for details.\n50 g\nDose of ethylene glycol"}, {"order": 5, "name": "Fomepizole Dosing", "inputs": [{"field": "Patient body weight", "value": "176 lbs"}], "final_answer": "1197 mg", "notes": "Diagnostic Result\n1197 mg\nIV loading dose\n798 mg\nGive 798 mg every 12 hrs for the next 4 doses, starting 12 hrs post loading dose\n1197 mg\nAfter 5th dose, give 1197 mg every 12 hrs until patient asymptomatic and serum alcohol levels undetectable"}, {"order": 6, "name": "KDIGO AKI Staging", "inputs": [{"field": "Baseline serum creatinine", "value": "0.9 mg/dL"}, {"field": "Current serum creatinine", "value": "4.2 mg/dL"}, {"field": "Time since baseline", "value": "24 hours"}, {"field": "Urine output total (last 24h)", "value": "400 mL"}, {"field": "Body weight for UO indexing", "value": "80 kg"}], "final_answer": "Stage 3", "notes": "Serum creatinine 3.0 times baseline or Increase in serum creatinine to ≥4.0 mg/dl (≥353.6 mmol/l) or Initiation of renal replacement therapy or in patients <18 years, decrease in eGFR to <35 ml/min per 1.73 m² or Urine output <0.3 ml/kg/h for ≥24 hours or anuria for ≥12 hours"}, {"order": 7, "name": "Mean Arterial Pressure (MAP)", "inputs": [{"field": "Systolic BP", "value": "98 mm Hg"}, {"field": "Diastolic BP", "value": "58 mm Hg"}], "final_answer": "71 mm Hg", "notes": "71 mm Hg\nMean Arterial Pressure (MAP)"}, {"order": 8, "name": "Dialysis Duration Needed for Methanol Ingestion", "inputs": [{"field": "Total Body Water?", "value": "48 L"}, {"field": "Initial Methanol Concentration?", "value": "30.9 mmol/L"}, {"field": "Dialyzer Urea Clearance?", "value": "220 mL/min"}], "final_answer": "8.28 hours", "notes": "Estimated Dialysis Duration Required to Achieve Methanol level of ≤5 mmol/L\n8.28 hours"}, {"order": 9, "name": "Dialysis Duration Needed for Ethylene Glycol Ingestion", "inputs": [{"field": "Total Body Water?", "value": "48 L"}, {"field": "Initial Ethylene Glycol Concentration?", "value": "18.7 mmol/L"}, {"field": "Dialyzer Urea Clearance?", "value": "220 mL/min"}], "final_answer": "6 hours", "notes": "Estimated Dialysis Duration Required to Achieve Ethylene Glycol level of ≤5 mmol/L\n6 hours"}, {"order": 10, "name": "CRRT Dosing Calculator", "inputs": [{"field": "Patient Weight?", "value": "80 kg"}, {"field": "Desired Dialysis Dose?", "value": "25 mL/kg/h"}], "final_answer": "2000 ml/hr", "notes": "Calculated Dialysis Dose\n2000 ml/hr"}]}
{"task_id": "medmcp-calc_083_e255090e", "task_scenario": "Immunotherapy Adverse Event Grading", "task_category": "Clinical Medicine / Medicine & Organ Systems / Comprehensive Oncology", "patient_id": "P083_e255090e", "task_description": "Scenario: An oncology patient receiving modern immunotherapy presents with acute multisystem symptoms after recent treatment. The care team must rapidly and systematically grade potential immune-related adverse events (irAEs) across organ systems to guide immediate triage, therapy holds, and coordinated specialty input. This workflow uses established grading tools tailored to immunotherapy to capture systemic reactions and organ-specific toxicities in a structured sequence. Step-by-step calculator use: 1) Begin with Cytokine Release Syndrome (CRS) Grading to determine whether a systemic inflammatory reaction is present and its severity. This step sets the immediate triage pathway. If CRS is Grade 2 or higher, proceed immediately to Step 2; if Grade 1 or lower, skip Step 2 and move to organ-specific assessments (Step 3 onward). 2) If CRS is moderate or higher, use Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Consensus Grading for Adults to evaluate and grade neurotoxicity, as neurocognitive changes are commonly linked with systemic immune activation. ICANS grading informs the priority of neurologic monitoring and influences the timing of further organ-specific assessments. 3) Assess respiratory complaints with Immune-Related Adverse Events for Lung Toxicity - Pneumonitis to grade pulmonary involvement. If pneumonitis is Grade 2 or higher, trigger a comprehensive safety response and immediately add Immune-Related Adverse Events for Renal Toxicities - Nephritis (Step 5) to screen for concurrent renal irAE, reflecting the increased likelihood of multisystem toxicity when any organ reaches moderate severity. If pneumonitis is Grade 1 or lower, proceed to GI assessment (Step 4) before renal screening. 4) Evaluate gastrointestinal symptoms using Immune-Related Adverse Events for GI Toxicity - Colitis to determine GI irAE severity. If colitis is Grade 2 or higher, immediately run Immune-Related Adverse Events for GI Toxicity - Hepatitis (Step 6) to grade hepatic involvement, recognizing that moderate GI irAEs may co-occur with hepatotoxicity and that joint grading supports safe therapy holds and coordinated management. If colitis is Grade 1 or lower, defer hepatitis grading unless clinical suspicion remains high, and continue to endocrine evaluation (Step 7). 5) Immune-Related Adverse Events for Renal Toxicities - Nephritis is used when any prior organ-specific irAE reached Grade 2 or higher (from Steps 3 or 4) or when renal irAE is suspected. This captures concurrent kidney involvement and informs the risk of systemic escalation. 6) Immune-Related Adverse Events for GI Toxicity - Hepatitis is applied when colitis reached Grade 2 or higher or hepatic toxicity is suspected. Grading hepatic involvement clarifies the breadth of GI-related irAEs and supports decisions about immunotherapy holds and multidisciplinary input. 7) Use Immune-Related Adverse Events for Endocrine Toxicities - Diabetes Mellitus to grade hyperglycemia as an endocrine irAE. If diabetes is Grade 2 or higher, proceed to Step 8 to evaluate for coexisting endocrine dysfunction, aligning with polyglandular irAE patterns. If Grade 1 or lower, endocrine screening can be limited to current symptoms and routine follow-up. 8) Apply Immune-Related Adverse Events for Endocrine Toxicities - Hypothyroidism to grade thyroid-related irAE, especially when diabetes grading reached Grade 2 or higher or hypothyroid symptoms are suspected. Final synthesis: Aggregate the grades from CRS, ICANS, and each organ-specific calculator to produce a consolidated multisystem irAE profile. This profile informs deterministic decisions about holding or continuing immunotherapy, prioritizing monitoring intensity, sequencing consults, and establishing follow-up plans. The sequence and branching ensure that moderate or worse findings automatically trigger broader multisystem screening and neuro assessment where appropriate.", "fuzzy_question": "I’m evaluating a patient who recently received immunotherapy and now appears multisystem: fevers, shortness of breath, gastrointestinal symptoms, and subtle cognitive changes. I need to determine, quickly but carefully, whether this represents a systemic immune-related reaction versus multiple isolated organ toxicities, because that will drive immediate triage and whether to hold treatment.\n\nFirst, I want to establish whether there is a genuine systemic inflammatory picture related to immunotherapy and how advanced it is. That will determine urgency and the level of care needed. If it’s more than mild, I’ll prioritize an early, structured neurologic assessment—objective grading of mental status and neurologic changes—since neuro dysfunction often accompanies systemic immune activation and can influence the timing of other evaluations. If systemic involvement is only minimal, I’m comfortable moving straight into organ-specific assessments.\n\nOn the respiratory side, the patient reports cough and dyspnea. Please characterize the severity of lung involvement in the context of immune-related pneumonitis. If the pulmonary picture is moderate or worse, that’s a safety trigger: stabilize breathing/oxygenation and, at the same time, evaluate renal function promptly, because once any organ crosses into moderate territory the risk of broader multisystem involvement rises. If lung findings are only mild, proceed to the gastrointestinal tract before circling back to the kidneys.\n\nFor the gastrointestinal tract, I’d like a clear sense of whether this suggests immune-related colitis and where it falls severity-wise. If bowel involvement is at least moderate, check the liver immediately for possible accompanying hepatitis—these often co-occur, and knowing both severities informs decisions about holding therapy and engaging GI/hepatology. If GI symptoms are mild and there isn’t strong laboratory or clinical concern for liver injury, a detailed hepatic work-up can be deferred.\n\nI don’t want to miss endocrine toxicities either. Please quantify elevated glucose as an immune-related diabetes picture and classify it as mild, moderate, or worse. If glucose dysregulation is beyond mild, assess thyroid function promptly—these endocrine events can cluster, and it’s important to know if both are present. If hyperglycemia is only mild, a focused endocrine check with routine follow-up may suffice for now.\n\nAfter reviewing those domains, pull everything together into a unified snapshot—systemic inflammatory reaction, neuro status if relevant, lungs, kidneys, gut, liver, and endocrine. Based on the combined picture, advise whether to hold immunotherapy immediately or continue with close observation, determine the appropriate monitoring intensity (floor versus step-up/ICU), identify which specialty consults to prioritize and in what sequence, and outline the follow-up cadence. As a rule of thumb, whenever one organ’s involvement is moderate or worse, broader screening should be initiated; if there’s a significant systemic reaction, neuro evaluation gets early priority.\n\nI need this grounded in evidence-based calculations—no reliance on clinical intuition alone. Please support the approach with solid calculations that can withstand scrutiny.", "required_calculators": ["Cytokine Release Syndrome (CRS) Grading", "Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Consensus Grading for Adults", "Immune-Related Adverse Events for Lung Toxicity - Pneumonitis", "Immune-Related Adverse Events for GI Toxicity - Colitis", "Immune-Related Adverse Events for GI Toxicity - Hepatitis", "Immune-Related Adverse Events for Renal Toxicities - Nephritis", "Immune-Related Adverse Events for Endocrine Toxicities - Diabetes Mellitus", "Immune-Related Adverse Events for Endocrine Toxicities - Hypothyroidism"], "calculator_answers": [{"order": 1, "name": "Cytokine Release Syndrome (CRS) Grading", "inputs": [{"field": "Toxicity", "value": "Moderate intervention required for response: oxygen requirement <40%, hypotension responsive to fluids, low dose of one pressor, or grade 2 organ toxicity"}, {"field": "Extensive comorbidities or older age", "value": "No"}], "final_answer": "Grade 2 CRS", "notes": "Vigilant supportive care (monitor cardiac and other organ function closely)"}, {"order": 2, "name": "Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Consensus Grading for Adults", "inputs": [{"field": "ICE_score_0_to_10", "value": "8"}, {"field": "ICE_score_category", "value": "7-9"}, {"field": "depressed_level_of_consciousness", "value": "Alert"}, {"field": "seizure", "value": "No seizure"}, {"field": "motor_findings", "value": "No deep focal motor weakness"}, {"field": "elevated_intracranial_pressure_cerebral_edema", "value": "No evidence of ICP/cerebral edema"}, {"field": "Death", "value": "Not applicable"}], "final_answer": "Grade 1", "notes": "Grade 1\nICANS Consensus Grading"}, {"order": 3, "name": "Immune-Related Adverse Events for Lung Toxicity - Pneumonitis", "inputs": [{"field": "symptom_status", "value": "Symptomatic (cough, dyspnea on exertion)"}, {"field": "ct_involvement_extent", "value": "Bilateral ground-glass opacities involving ~30% of lung parenchyma; >1 lobe"}, {"field": "oxygen_indicated", "value": "Yes; 2 L/min nasal cannula to maintain SpO2 95% (91% on room air)"}, {"field": "adl_limitation", "value": "Limiting instrumental ADLs (unable to perform usual work/household tasks due to dyspnea)"}, {"field": "hospitalization_required", "value": "No for respiratory status alone"}, {"field": "intubation_urgent_intervention", "value": "No"}, {"field": "Criteria", "value": "Symptomatic, involves more than one lobe of the lung or 25-50% of lung parenchyma, medical intervention indicated, limiting instrumental ADL"}], "final_answer": "G2", "notes": "Pneumonitis grade\nHold ICPi until resolution to Grade ≤ 1; start prednisone 1-2 mg/kg ; consider bronchoscopy with BAL; consider empirical antibiotics; monitor every 3 days with H&P, pulse oximetry and optional CXR; treat as Grade 3 if no improvement in 48-72 hours; see Next Steps for details"}, {"order": 4, "name": "Immune-Related Adverse Events for GI Toxicity - Colitis", "inputs": [{"field": "baseline_stools_per_day", "value": "1"}, {"field": "current_stools_per_day", "value": "6"}, {"field": "increase_in_stools_over_baseline", "value": "5"}, {"field": "incontinence", "value": "No"}, {"field": "hospitalization_indicated", "value": "No (for diarrhea alone)"}, {"field": "limitation_self_care_ADL", "value": "No"}, {"field": "CTCAE for diarrhea", "value": "Increase of 4-6 stools per day over baseline; moderate increase in ostomy output compared with baseline", "score": 2}], "final_answer": "G2", "notes": "Colitis grade\nHold ICPi until pt recovers to grade 1; consider permanently d/c CTLA-4; may restart PD-1, PD-L1 if pt recovers to grade ≤1; consider steroids; consider loperamide if infection is ruled out; If diarrhea is not transient, start steroids, then taper if symptoms improve to grade ≤1; GI consult; consider EGD/colonoscopy; see Next Steps for details"}, {"order": 5, "name": "Immune-Related Adverse Events for Renal Toxicities - Nephritis", "inputs": [{"field": "baseline_creatinine_mg_dl", "value": "0.9 mg/dL"}, {"field": "current_creatinine_mg_dl", "value": "1.6 mg/dL"}, {"field": "absolute_increase_mg_dl", "value": "0.7 mg/dL"}, {"field": "fold_increase_over_baseline", "value": "1.78x baseline"}, {"field": "dialysis_indicated", "value": "No"}, {"field": "Criteria", "value": "Creatinine level increase of >0.3 mg/dL; creatinine 1.5-2.0x over baseline"}], "final_answer": "G1", "notes": "Nephritis grade\nConsider temporarily holding ICPi, pending consideration of alternative etiologies and baseline renal function; monitor creatinine weekly; see Next Steps for details"}, {"order": 6, "name": "Immune-Related Adverse Events for GI Toxicity - Hepatitis", "inputs": [{"field": "AST_value_U_L", "value": "145 U/L"}, {"field": "ALT_value_U_L", "value": "168 U/L"}, {"field": "total_bilirubin_mg_dl", "value": "2.4 mg/dL"}, {"field": "AST_ULN_U_L", "value": "40 U/L"}, {"field": "ALT_ULN_U_L", "value": "40 U/L"}, {"field": "total_bilirubin_ULN_mg_dl", "value": "1.2 mg/dL"}, {"field": "hepatic_symptoms", "value": "None (no RUQ pain/jaundice); GI symptoms from colitis present"}, {"field": "Criteria", "value": "Asymptomatic (AST or ALT > ULN to 3.0 to 5 x ULN and/or total bilirubin >1.5 to ≤3 x ULN)"}], "final_answer": "G2", "notes": "Hepatitis grade\nHold ICPi temporarily; consider prednisone ≤10 mg/d; consider resuming ICPi if pt recovers to Grade 1; consider d/c other hepatotoxic meds; if symptomatic and persistent consider 0.5–1 mg/kg/d prednisone or equivalent; monitor every 3 days; see Next Steps for details"}, {"order": 7, "name": "Immune-Related Adverse Events for Endocrine Toxicities - Diabetes Mellitus", "inputs": [{"field": "fasting_glucose_mg_dl", "value": "238 mg/dL"}, {"field": "symptoms", "value": "Polyuria, polydipsia; able to perform ADLs"}, {"field": "ketosis_or_T1DM_evidence", "value": "No ketosis; urine ketones negative; no DKA features"}, {"field": "Criteria", "value": "Moderate symptoms, able to perform ADLs, fasting glucose value >160-250 mg/dL (>8.9-13.9 mmol/L), ketosis or evidence of T1DM at any glucose level"}], "final_answer": "G2", "notes": "Hyperglycemia grade\nMay hold ICPi until serum glucose is controlled; titrate oral therapy or add insulin if worsening of preexisting T2DM; initiate insulin if T1DM is diagnosed or suspected; consult endocrinology if T1DM; consider hospital admission if T1DM and DKA or immediate outpatient evaluation is not available; see Next Steps for details"}, {"order": 8, "name": "Immune-Related Adverse Events for Endocrine Toxicities - Hypothyroidism", "inputs": [{"field": "TSH_mIU_L", "value": "16.2 mIU/L"}, {"field": "free_T4_ng_dl", "value": "0.6 ng/dL"}, {"field": "symptoms", "value": "Fatigue, cold intolerance; able to perform ADLs"}, {"field": "Criteria", "value": "Moderate symptoms; able to perform ADLs; TSH persistently >10 mIU/L"}], "final_answer": "G2", "notes": "Hypothyroidism grade\nMay hold ICPi until symptoms resolve; consult endocrinology; start thyroid hormone supplementation if symptomatic, or asymptomatic with TSH is persistently > 10 mIU/L; monitor TSH every 6-8 weeks; see Next Steps for details"}]}
{"task_id": "medmcp-calc_084_a50a4f05", "task_scenario": "Liver Failure and Coagulation", "task_category": "Clinical Medicine / Emergency, Critical Care & Perioperative / Critical Care", "patient_id": "P084_a50a4f05", "task_description": "Scenario: In the ICU, a patient with chronic liver disease develops acute decompensation with suspected infection, respiratory compromise, and active bleeding. Coagulation is severely deranged with thrombocytopenia, and microangiopathic features raise concern for disseminated intravascular coagulation versus thrombotic thrombocytopenic purpura. The team must stabilize, correctly classify the coagulopathy, treat bleeding, and assess short-term prognosis and transplant urgency. Workflow: First, use the Arterial Blood Gas (ABG) Analyzer to interpret oxygenation and acid–base status. The ABG-derived oxygenation index is then incorporated into the Sequential Organ Failure Assessment (SOFA) Score to quantify acute organ dysfunction. If SOFA suggests sepsis-associated organ dysfunction, proceed to the Sepsis-Induced Coagulopathy (SIC) Score to screen for sepsis-related coagulation disorder. Branch A (DIC pathway): If the SIC Score meets or exceeds the typical threshold for coagulopathy, apply the ISTH Criteria for Disseminated Intravascular Coagulation (DIC) to confirm overt DIC. If ISTH DIC is overt and there is active bleeding or an imminent invasive procedure, calculate transfusion therapy using Plasma Dosage (for plasma/FFP) and Cryoprecipitate Dosing for Fibrinogen Replacement (for fibrinogen repletion). If ISTH DIC is not overt, continue supportive care and re-evaluate; proceed to Branch B if microangiopathy remains strongly suspected. Branch B (TTP pathway): If the SIC Score is low but profound thrombocytopenia with microangiopathic features persists, calculate the PLASMIC Score for TTP. If PLASMIC indicates high likelihood of TTP, plan therapeutic plasma exchange using the Therapeutic Plasmapheresis Calculator to estimate intravascular reduction after each exchange and to guide the number of exchanges. Concurrently, for transplant prioritization and short-term prognosis, calculate the MELDNa/MELD-Na Score for Liver Cirrhosis to quantify baseline liver disease severity, then compute the CLIF-C ACLF (Acute-on-Chronic Liver Failure) score to estimate mortality risk. The prior SOFA-derived organ dysfunction details inform the organ failure profile considered in ACLF assessment. Outputs from MELD-Na and CLIF-C ACLF help determine escalation of supportive therapies, candidacy for transfer to a transplant-capable center, and discussions about goals of care.", "fuzzy_question": "I'm looking after a patient with cirrhosis in the ICU who has acutely worsened - feverish, requiring more oxygen than earlier, and actively bleeding. Recent labs show marked thrombocytopenia, prolonged clotting times, low fibrinogen, and hemolysis with schistocytes. I'm torn between this being a sepsis-driven coagulopathy heading toward DIC versus an atypical presentation of TTP, and I don't want to miss either.\n\nMy plan is to clarify the patient's current physiology first: review the blood gas for oxygenation and acid-base status, then integrate oxygenation, hemodynamics, kidney and liver indices, platelets, and mental status into the usual ICU organ-failure snapshot to gauge the extent of organ dysfunction. If that profile is consistent with sepsis-related organ injury, I'd proceed with a bedside screen for sepsis-associated coagulopathy using platelets, clotting times, and fibrin markers.\n\nIf that screen flags a coagulopathy, I'd check the patient against international criteria for overt disseminated intravascular coagulation, looking at platelet trend, degree of clotting time prolongation, fibrinogen, and fibrin degradation products. If overt DIC is present and given active bleeding and potential need for urgent procedures (lines, scopes), I need product support mapped out precisely: how much plasma to replete clotting factors and how many pools of cryo to bring fibrinogen back to a safe target. If overt DIC is not met, I'd continue supportive care and reassess; but if the microangiopathic picture remains strong, I don't want to let TTP slip past.\n\nAlternatively, if the sepsis-coagulopathy screen is low yet thrombocytopenia is profound with ongoing hemolysis and schistocytes, I'd use a validated bedside tool to estimate the likelihood of TTP from clinical and laboratory features. If the likelihood is high, I'd plan to start plasma exchange urgently and map out the course - expected intravascular reduction after successive sessions and an estimate of sessions needed before durable improvement.\n\nIn parallel, for the underlying liver disease and short-term outlook, I need an updated severity estimate that incorporates sodium, and a current acute-on-chronic liver failure mortality estimate, ensuring the earlier-identified organ failures are reflected accurately. Those numbers should guide how far to escalate supports, whether to push for transfer to a transplant-capable center, and how to frame immediate goals-of-care discussions with family.\n\nWhat's your take on this? Am I missing a key angle? I need proper calculations - I can't make these calls on gut feeling alone. Whatever approach you suggest, please back it with solid, transparent math that will stand up to scrutiny.", "required_calculators": ["Arterial Blood Gas (ABG) Analyzer", "Sequential Organ Failure Assessment (SOFA) Score", "Sepsis-Induced Coagulopathy (SIC) Score", "ISTH Criteria for Disseminated Intravascular Coagulation (DIC)", "Plasma Dosage", "Cryoprecipitate Dosing for Fibrinogen Replacement", "PLASMIC Score for TTP", "Therapeutic Plasmapheresis Calculator", "MELDNa/MELD-Na Score for Liver Cirrhosis", "CLIF-C ACLF (Acute-on-Chronic Liver Failure)"], "calculator_answers": [{"order": 1, "name": "Arterial Blood Gas (ABG) Analyzer", "inputs": [{"field": "pH", "value": "7.31"}, {"field": "PₐCO₂", "value": "30 mm Hg"}, {"field": "HCO₃-", "value": "15 mEq/L"}, {"field": "Sodium", "value": "128 mEq/L"}, {"field": "Chloride", "value": "98 mEq/L"}, {"field": "Albumin", "value": "2.0 g/dL"}, {"field": "If respiratory process present, chronicity", "value": "Acute"}], "final_answer": "This is an Anion Gap Metabolic Acidosis.\nPrimary Metabolic Acidosis, with: Appropriately Compensated by Respiratory Alkalosis and Additional Non-Gap Metabolic Acidosis.", "notes": "This is an Anion Gap Metabolic Acidosis.\nPrimary Metabolic Acidosis, with: Appropriately Compensated by Respiratory Alkalosis and Additional Non-Gap Metabolic Acidosis."}, {"order": 2, "name": "Sequential Organ Failure Assessment (SOFA) Score", "inputs": [{"field": "PaO₂", "value": "65 mm Hg"}, {"field": "FiO₂", "value": "60 %"}, {"field": "On mechanical ventilation", "value": "Yes (CPAP)"}, {"field": "Platelets, ×10³/µL", "value": "24", "score": 3}, {"field": "Glasgow Coma Scale", "value": "13", "score": 1}, {"field": "Bilirubin, mg/dL (μmol/L)", "value": "6.8 mg/dL", "score": 3}, {"field": "Mean arterial pressure OR administration of vasoactive agents required", "value": "Norepinephrine 0.08 mcg/kg/min", "score": 3}, {"field": "Creatinine, mg/dL (μmol/L) (or urine output)", "value": "2.6 mg/dL", "score": 2}], "final_answer": 15, "notes": "Initial SOFA Scores ≥12 predict ≥95.2% mortality (see Evidence for details)"}, {"order": 3, "name": "Sepsis-Induced Coagulopathy (SIC) Score", "inputs": [{"field": "INR", "value": "2.3", "score": 2}, {"field": "Platelet count, cells x 10^9/L", "value": "24", "score": 2}, {"field": "Total SOFA score (sum of respiratory, cardiovascular, hepatic, renal components)", "value": "11", "score": 2}], "final_answer": 6, "notes": "6 points\n46% approximate 28-day mortality\nSIC likely\nDiagnosis of SIC"}, {"order": 4, "name": "ISTH Criteria for Disseminated Intravascular Coagulation (DIC)", "inputs": [{"field": "Platelet count, cells x 10^9/L", "value": "24", "score": 2}, {"field": "Elevated levels of a fibrin-related marker (e.g. D-dimer, fibrin degradation products)", "value": "Severe increase", "score": 3}, {"field": "Prolonged PT, seconds", "value": "7.2 seconds above ULN", "score": 2}, {"field": "Fibrinogen level, g/L", "value": "0.8 g/L", "score": 1}], "final_answer": 8, "notes": "Compatible with overt DIC; treat for DIC as appropriate and repeat scoring daily"}, {"order": 5, "name": "Plasma Dosage", "inputs": [{"field": "Patient weight", "value": "154 lb"}, {"field": "Desired plasma dosage", "value": "15 mL/kg"}, {"field": "Unit volume", "value": "250 mL"}], "final_answer": 4, "notes": "4 units\nPlasma dose for transfusion\n1,048 mL\nPlasma dose for transfusion"}, {"order": 6, "name": "Cryoprecipitate Dosing for Fibrinogen Replacement", "inputs": [{"field": "Plasma volume", "value": "3400 mL"}, {"field": "Initial fibrinogen", "value": "80 mg/dL"}, {"field": "Goal fibrinogen", "value": "150 mg/dL"}, {"field": "Fibrinogen content of unit", "value": "200 mg per unit"}], "final_answer": 12, "notes": "12 units\nCryoprecipitate dose"}, {"order": 7, "name": "PLASMIC Score for TTP", "inputs": [{"field": "Platelet count <30 x 10^9/L", "value": "Yes", "score": 1}, {"field": "Hemolysis", "value": "Yes", "score": 1}, {"field": "Active cancer", "value": "No", "score": 1}, {"field": "History of solid-organ or stem-cell transplant", "value": "No", "score": 1}, {"field": "MCV <90 fL", "value": "Yes (MCV 88 fL)", "score": 1}, {"field": "INR <1.5", "value": "No (INR 2.3)", "score": 0}, {"field": "Creatinine <2.0 mg/dL (176.8 μmol/L)", "value": "No (2.6 mg/dL)", "score": 0}], "final_answer": 5, "notes": "5 points\nPLASMIC Score\nIntermediate risk\nRisk group\n6 %\nRisk of severe ADAMTS13 deficiency"}, {"order": 8, "name": "Therapeutic Plasmapheresis Calculator", "inputs": [{"field": "Total blood volume", "value": "4550 mL"}, {"field": "Plasma volume", "value": "3400 mL"}, {"field": "Number of plasma volumes to be exchanged", "value": "1.0"}], "final_answer": "47.4 %", "notes": "47.4 %\nResidual relative concentration"}, {"order": 9, "name": "MELDNa/MELD-Na Score for Liver Cirrhosis", "inputs": [{"field": "Dialysis at least twice in the past week", "value": "No"}, {"field": "Creatinine", "value": "2.6 mg/dL"}, {"field": "Bilirubin", "value": "6.8 mg/dL"}, {"field": "INR", "value": "2.3"}, {"field": "Sodium", "value": "128 mEq/L"}], "final_answer": 35, "notes": "35 points\nMELD-Na Score\n65 - 66%\nEstimated 90-Day Mortality"}, {"order": 10, "name": "CLIF-C ACLF (Acute-on-Chronic Liver Failure)", "inputs": [{"field": "Age", "value": "54 years"}, {"field": "WBC count", "value": "18.2 ×10³/µL"}, {"field": "Liver (Bilirubin)", "value": "6.8 mg/dL (6 to <12 mg/dL) → +2", "score": 2}, {"field": "Kidney (Creatinine)", "value": "2.6 mg/dL (2 to <3.5 mg/dL) → +2", "score": 2}, {"field": "Brain (West-Haven Grade for Hepatic Encephalopathy)", "value": "Grade 2 → +2", "score": 2}, {"field": "Coagulation (INR)", "value": "2.3 (2.0 to <2.5) → +2", "score": 2}, {"field": "Circulatory (MAP/vasopressors)", "value": "Any MAP with vasopressors (norepinephrine 0.08 mcg/kg/min) → +3", "score": 3}, {"field": "Respiratory (PaO2/FiO2 ratio or SpO2/FiO2 ratio)", "value": "PaO2/FiO2 = 65/0.60 ≈ 108 (≤200) → +3", "score": 3}], "final_answer": 66, "notes": "66 points\nCLIF-C ACLF Score\n79.3% probability of death at 1 month\n91.5% probability of death at 3 months\n93.0% probability of death at 6 months\n94.5% probability of death at 1 year"}]}
{"task_id": "medmcp-calc_085_857eb2ac", "task_scenario": "Antenatal Monitoring and Due Date Calculation", "task_category": "Clinical Medicine / Special Populations & General Tools / Obstetrics & Reproductive Health", "patient_id": "P085_857eb2ac", "task_description": "Scenario: A pregnant patient presents late in prenatal care with uncertain last menstrual period and intermittent symptoms prompting antenatal monitoring. The clinical objective is to reconcile the estimated due date (EDD), determine current gestational age (GA), assess fetal well-being, and decide on timing and method of delivery with appropriate maternal preparation.\n\nStep-by-step calculator workflow:\n1) Establish an LMP-based EDD using the Pregnancy Due Dates Calculator. Purpose: Create an initial dating framework when history is available.\n2) Independently compute an ultrasound-based EDD using the Due Date by Ultrasound. Purpose: Provide an objective EDD based on biometric dating.\n3) Reconcile dating: Compare the LMP-based EDD (Step 1) with the ultrasound-based EDD (Step 2). If the discrepancy is clinically significant for the gestational age at time of the ultrasound, adopt the ultrasound EDD; otherwise, retain the LMP-based EDD. The resulting final EDD becomes the required input for the next step.\n4) Determine the current GA using the Gestational Age calculator, entering the final EDD from Step 3. Purpose: Anchor all subsequent surveillance and delivery timing decisions to an accurate GA.\n5) Fetal well-being: If GA is at or near term, or if there are symptoms/conditions warranting evaluation, perform the Fetal Biophysical Profile (BPP) Score. Purpose: Integrate ultrasound and nonstress testing to guide urgency of delivery.\n   - If/Else Branch A: If the BPP is non-reassuring or if GA is post-term based on Step 4, plan delivery now.\n   - If/Else Branch B: If the BPP is reassuring and GA is not post-term, continue expectant management with interval surveillance; re-check GA later with the Gestational Age calculator as needed to time follow-up testing and delivery.\n6) If proceeding to induction of labor (for post-term pregnancy or other indications), calculate the Bishop Score for Vaginal Delivery and Induction of Labor. Purpose: Determine cervical favorability and tailor the induction method.\n   - If/Else Branch C: If the Bishop Score indicates an unfavorable cervix, plan cervical ripening before induction. If favorable, proceed with standard induction methods.\n7) If GA from Step 4 is at or beyond the late third trimester and delivery is planned (urgent or elective), use the Maternal blood volume estimator. Purpose: Anticipate intrapartum/postpartum hemodynamic needs and guide preparation (e.g., IV access, blood product readiness) as part of safe delivery planning.\n\nRationale for sequence: The EDD reconciliation (Steps 1–3) is foundational; GA (Step 4) directly informs whether to test and how to interpret results. BPP (Step 5) determines immediate delivery versus expectant management. If delivering, the Bishop Score (Step 6) refines induction strategy. Finally, maternal blood volume estimation (Step 7) ensures readiness for potential obstetric hemorrhage as delivery proceeds.", "fuzzy_question": "I’m seeing a pregnant patient who is late to care with an uncertain last menstrual period. Recently there have been intermittent symptoms leading to antenatal monitoring—nothing clearly alarming, but enough that I don’t want to miss a window to act. I need accurate dating so subsequent decisions rest on solid ground.\n\nMy plan is to establish an estimated due date from clinical history and, separately, from fetal measurements on a dating ultrasound. Then I will assess the discrepancy between these estimates; given the gestational age at the time of the scan, if the difference exceeds accepted thresholds for that stage, I’ll adopt the ultrasound-based date, and if not, I’ll keep the history-based one. Once we commit to a single due date, determine the precise current gestational age and use that as the basis for everything that follows.\n\nBecause the pregnancy is advanced and symptoms have been intermittent, I’d like a comprehensive fetal assessment that combines ultrasound parameters with a nonstress test. If that evaluation is not reassuring, or if by our dating the pregnancy is already post-term, I’d move toward delivery. If it’s reassuring and not post-term, I’d prefer expectant management with interval surveillance, updating the gestational age to time the next assessment and guide delivery.\n\nIf we proceed with induction, please assess cervical favorability; if it appears unfavorable, plan cervical ripening first, and if favorable, proceed with a standard induction approach.\n\nIf we are nearing delivery—urgent or elective—in late pregnancy, I want to assess maternal intravascular volume status and prepare for bleeding risk with adequate IV access and blood product readiness.\n\nWhat’s your clinical thinking here, step by step? I need solid numbers behind this—please back recommendations with clear, defensible calculations so the plan stands up to scrutiny.", "required_calculators": ["Pregnancy Due Dates Calculator", "Due Date by Ultrasound", "Gestational Age", "Fetal Biophysical Profile (BPP) Score", "Bishop Score for Vaginal Delivery and Induction of Labor", "Maternal blood volume estimator"], "calculator_answers": [{"order": 1, "name": "Pregnancy Due Dates Calculator", "inputs": [{"field": "Cycle length", "value": "31 days"}, {"field": "Last menstrual period", "value": "2025-03-18"}], "final_answer": "39 weeks & 3 days", "notes": "Gestational age\n39 weeks & 3 days\nDue date\nThursday, Dec 25, 2025\nDate of conception\nMonday, Mar 31, 2025"}, {"order": 2, "name": "Due Date by Ultrasound", "inputs": [{"field": "Current Date?", "value": "2025-12-15"}, {"field": "Ultrasound Date?", "value": "2025-08-25"}, {"field": "Gestational Age by Ultrasound?", "value": "23 weeks 1 day"}], "final_answer": "December 21, 2025", "notes": "End of 1st Trimester\nJune 8, 2025\nEstimated Due Date\nDecember 21, 2025\nCurrent Gestational Age\n39 Weeks\n1 Day"}, {"order": 3, "name": "Gestational Age", "inputs": [{"field": "Current Date?", "value": "2025-12-15"}, {"field": "Due Date?", "value": "2025-12-26"}], "final_answer": "38 Weeks 3 Days", "notes": "End of 1st Trimester\nJune 13, 2025\nCurrent Gestational Age\n38 Weeks 3 Days"}, {"order": 4, "name": "Fetal Biophysical Profile (BPP) Score", "inputs": [{"field": "Fetal breathing", "value": "≥1 episode of rhythmic breathing lasting ≥30 sec within 30 min", "score": 2}, {"field": "Fetal movement", "value": "≥3 discrete body or limb movements within 30 min", "score": 2}, {"field": "Fetal tone", "value": "≥1 episode of extremity extension and subsequent return to flexion", "score": 2}, {"field": "Amniotic fluid volume (AFV)", "value": "A pocket of amniotic fluid ≥2 cm in 2 perpendicular planes (2x2 cm pocket)", "score": 2}, {"field": "Nonstress test (NST)", "value": "NST not done"}], "final_answer": 8, "notes": "8 points\nNormal, non-asphyxiated fetus (normal AFV)\nNo fetal indication for intervention; repeat testing per protocol"}, {"order": 5, "name": "Bishop Score for Vaginal Delivery and Induction of Labor", "inputs": [{"field": "Dilation", "value": "1-2 cm", "score": 1}, {"field": "Effacement", "value": "40-50%", "score": 1}, {"field": "Station", "value": "-2", "score": 1}, {"field": "Position", "value": "Posterior", "score": 0}, {"field": "Consistency", "value": "Firm", "score": 0}], "final_answer": 3, "notes": "Scores ≤ 5 suggest an unfavorable cervix, and that induction may be necessary for successful vaginal delivery.\nNote: Success rates tend to vary based on indication for induction and weeks gestation."}, {"order": 6, "name": "Maternal blood volume estimator", "inputs": [{"field": "Weeks gestation?", "value": "38 weeks 3 days"}, {"field": "Height?", "value": "165 cm"}, {"field": "Weight?", "value": "84 kg"}], "final_answer": 30.8, "notes": "BMI (Body Mass Index)\n30.9\nEBV (Estimated Blood Volume)\n7358.8 mL or 87.6 mL/kg"}]}
{"task_id": "medmcp-calc_086_9930111c", "task_scenario": "Nursing Risk Assessment Scales", "task_category": "Clinical Medicine / Special Populations & General Tools / Clinical Pharmacology & Nursing", "patient_id": "P086_9930111c", "task_description": "Scenario: An older adult is admitted to a medical-surgical ward with a complex, multi-morbidity profile. A bedside nurse leads a structured, multi-domain risk assessment to anticipate and prevent common inpatient complications (clinical deterioration, delirium, respiratory compromise from undiagnosed OSA, unrecognized pain in nonverbal states, pressure injuries, malnutrition, venous thromboembolism) and to plan safe transition of care.\n\nWorkflow steps and rationale:\n1) Use the National Early Warning Score (NEWS) to establish current physiologic acuity and monitoring frequency. If NEWS is high, escalate observation and notify the team; proceed with the rest of the risk assessment once stabilized.\n2) Apply the AWOL Score for Delirium to identify baseline risk of developing delirium during hospitalization.\n3) If AWOL risk is elevated or confusion is suspected, use the 4 A’s Test for Delirium Screening to confirm or refute active delirium. If 4 A’s is negative, continue routine delirium precautions; if positive, initiate delirium prevention/management bundle.\n4) Screen for Obstructive Sleep Apnea using the STOP-BANG Score for Obstructive Sleep Apnea to identify patients at risk for sedation-related respiratory events.\n5) Monitor level of agitation/sedation with the Richmond Agitation-Sedation Scale (RASS). If 4 A’s is positive or STOP-BANG is high, increase frequency of RASS assessments and aim for a safe target (e.g., avoid oversedation). Adjust sedatives/analgesics accordingly.\n6) If the patient is delirious or otherwise unable to self-report pain, use the Nonverbal Pain Scale (NVPS) for Nonverbal Patients to guide analgesia. If the patient is communicative and 4 A’s is negative, use standard self-report methods and document pain routinely.\n7) Calculate the Braden Score for Pressure Ulcers to determine skin integrity risk and inform repositioning schedules, support surfaces, and moisture management.\n8) If Braden indicates moderate/high risk (or if there is observed poor intake), use Nutrition Risk Screening 2002 (NRS-2002) to assess malnutrition risk and trigger timely dietitian referral and nutrition interventions. If NRS-2002 is low risk, continue routine nutrition monitoring.\n9) Use the Geneva Risk Score for Venous Thromboembolism (VTE) Prophylaxis to determine need for pharmacologic and/or mechanical VTE prevention. If Geneva risk is high—especially when Braden suggests immobility—prioritize appropriate prophylaxis and mobilization plans.\n10) Estimate readmission risk with the LACE Index for Readmission. If LACE is high, initiate early discharge planning (e.g., multidisciplinary coordination, expedited education, home supports), schedule closer follow-up, and reinforce delirium and falls prevention strategies for transition.\n\nKey decision branches:\n- If AWOL is high → then perform the 4 A’s Test for Delirium Screening. If 4 A’s is positive → increase RASS monitoring and use NVPS for pain; if 4 A’s is negative → proceed with routine monitoring.\n- If STOP-BANG is high → then increase vigilance with RASS to avoid oversedation and adjust analgesia and nighttime monitoring; if STOP-BANG is low → standard sedation monitoring.\n- If Braden is moderate/high → then perform NRS-2002; if Braden is low → nutrition screening may be deferred to routine diet assessment.\n- If Geneva VTE risk is high (especially with immobility indicated by Braden) → implement pharmacologic/mechanical prophylaxis; if risk is low → mechanical mobilization-focused approach.\n- If LACE is high → initiate intensified discharge planning; if LACE is low → standard discharge planning.", "fuzzy_question": "I’m looking after a patient who just came onto our med-surg floor with multiple chronic issues, and I’m trying to get ahead of the usual inpatient pitfalls while also setting us up for a safe discharge. Can I run my thinking by you and have you walk this through in a structured way?\n\nFirst, before we get too far into prevention planning, I want an objective sense of how sick they are right now so we can set how often the bedside team needs to check in. If that quick snapshot of their vitals/oxygenation points to a higher chance of tipping into deterioration, I’d rather escalate observation and loop in the team right away, then come back to the rest of the risk sweep once they’re settled.\n\nAfter that, I’m worried about delirium during the stay. I’d like an estimate of their baseline risk of becoming confused while hospitalized. If that comes back on the higher side—or if we’re already catching signs of inattention or fluctuating alertness—please do a brief bedside check to decide whether they’re actually delirious right now. If that check is negative, let’s keep routine prevention going. If it’s positive, I want the full non-pharmacologic bundle started and a search for triggers (infection, meds, retention, constipation, uncontrolled pain), with the team adjusting as needed.\n\nI’m also thinking about undiagnosed sleep apnea. Can we screen for that with the usual questions (loud snoring, daytime sleepiness, witnessed apneas, hypertension) and basic risk factors like body habitus, neck size, and relevant demographic characteristics? If they look high-risk, I’d like us to be more conservative with opioids and sedatives—especially overnight—and step up respiratory vigilance.\n\nOn that note, let’s track their level of arousal and agitation with the unit’s standard bedside tool. If they’re delirious or look likely to have sleep-disordered breathing, I’d increase how often we check this and aim for calm and easily arousable rather than oversedated, adjusting analgesia and sedatives to hit that target safely.\n\nFor pain, when they’re lucid I’m fine using a standard self-report pain scale and documenting regularly. But if they’re confused or can’t reliably report, please switch to an observational approach (facial expression, body movements, muscle tension, and associated vital sign changes) so we’re not undertreating or overshooting with opioids.\n\nSkin integrity is another big one. I want a structured look at their risk for pressure injuries—sensation, moisture, activity, mobility, nutrition, friction/shear—so we can set the turning schedule, choose the right support surface, and manage moisture. If that assessment suggests at least a moderate risk, or if their intake has been poor or there’s recent weight loss, please do a quick nutrition risk check that accounts for disease burden and recent weight change. If nutrition risk is meaningful, let’s bring in a dietitian early and start interventions; if it’s low, routine monitoring is fine.\n\nWe should also systematically size up their risk for clots during this admission. Consider age, prior clots, cancer, immobility, recent surgery, tachycardia, and bleeding risk, and pair that with how mobile they actually are from the skin/mobility assessment. If clot risk is high—especially if they’re not moving much—I’d prioritize appropriate chemical prophylaxis alongside mechanical measures and early mobilization; if it’s low, focus on mobilization and mechanical methods.\n\nLastly, looking ahead to discharge, I’d like a reasoned estimate of their short-term readmission risk using the intensity of this admission, how long they’re likely to stay, recent emergency visits, and multimorbidity. If that looks high, let’s start the heavier-lift discharge plan now: earlier case management, caregiver engagement, medication teaching and reconciliation, clear return-precautions, home safety plus delirium and falls prevention education, and tighter follow-up. If it’s low, standard planning should be enough.\n\nWhat’s your take? Please walk me through your reasoning in this order—starting with current stability and monitoring frequency, then delirium risk and status, breathing/sedation safety, pain assessment strategy, skin and nutrition planning, clot prevention, and finally the discharge plan. For each piece, I need the quantitative thresholds or standardized categories you’re using and how they change what we do at the bedside. I can’t make these calls on gut feeling alone—please anchor your recommendations in solid, defensible calculations so this stands up to scrutiny.", "required_calculators": ["National Early Warning Score (NEWS)", "AWOL Score for Delirium", "4 A’s Test for Delirium Screening", "STOP-BANG Score for Obstructive Sleep Apnea", "Richmond Agitation-Sedation Scale (RASS)", "Nonverbal Pain Scale (NVPS) for Nonverbal Patients", "Braden Score for Pressure Ulcers", "Nutrition Risk Screening 2002 (NRS-2002)", "Geneva Risk Score for Venous Thromboembolism (VTE) Prophylaxis", "LACE Index for Readmission"], "calculator_answers": [{"order": 1, "name": "National Early Warning Score (NEWS)", "inputs": [{"field": "respiratory_rate", "value": "22 breaths/min", "score": 2}, {"field": "oxygen_saturations", "value": "94 %", "score": 1}, {"field": "any_supplemental_oxygen", "value": "Yes (2 L/min nasal cannula)", "score": 2}, {"field": "temperature", "value": "37.6 C", "score": 0}, {"field": "systolic_blood_pressure", "value": "108 mmHg", "score": 1}, {"field": "heart_rate", "value": "96 bpm", "score": 1}, {"field": "AVPU_score", "value": "Alert (A)", "score": 0}], "final_answer": 7, "notes": "High score: Emergency assessment by a clinical/critical care outreach team with critical-care competencies and usually transfer of the patient to a higher dependency care area."}, {"order": 2, "name": "AWOL Score for Delirium", "inputs": [{"field": "age", "value": "82 years (≥80 = +1)", "score": 1}, {"field": "spells_world_backward_correctly", "value": "No (+1)", "score": 1}, {"field": "oriented_city_state_county_hospital_floor", "value": "No (+1)", "score": 1}, {"field": "nursing_illness_severity", "value": "Moderately ill (+1)", "score": 1}], "final_answer": 4, "notes": "4 points\nAWOL Score\n64 %\nRisk of delirium during hospitalization"}, {"order": 3, "name": "4 A’s Test for Delirium Screening", "inputs": [{"field": "alertness", "value": "Mild sleepiness <10 seconds after waking, then normal (0)", "score": 0}, {"field": "AMT4_orientation", "value": "≥2 mistakes (2)", "score": 2}, {"field": "attention_months_reverse", "value": "Starts but lists <7 months (1)", "score": 1}, {"field": "acute_change_or_fluctuating_course", "value": "Yes (4)", "score": 4}], "final_answer": 7, "notes": "Possible delirium and/or cognitive impairment"}, {"order": 4, "name": "STOP-BANG Score for Obstructive Sleep Apnea", "inputs": [{"field": "snoring_loudly", "value": "Yes (+1)", "score": 1}, {"field": "daytime_tiredness", "value": "Yes (+1)", "score": 1}, {"field": "observed_apneas", "value": "Yes (+1)", "score": 1}, {"field": "hypertension_treated", "value": "Yes (+1)", "score": 1}, {"field": "BMI", "value": "36.1 kg/m^2 (>35 = +1)", "score": 1}, {"field": "age", "value": "82 years (>50 = +1)", "score": 1}, {"field": "neck_circumference", "value": "42 cm (>40 = +1)", "score": 1}, {"field": "gender", "value": "Male (+1)", "score": 1}], "final_answer": 8, "notes": "8 points\nSTOP-BANG\nHigh risk of OSA"}, {"order": 5, "name": "Richmond Agitation-Sedation Scale (RASS)", "inputs": [{"field": "patient_description", "value": "Restless (+1)", "score": 1}], "final_answer": 1, "notes": "Patients with a RASS of -2 to 1 are properly sedated."}, {"order": 6, "name": "Nonverbal Pain Scale (NVPS) for Nonverbal Patients", "inputs": [{"field": "face", "value": "Occasional grimace/tearing/frown (+1)", "score": 1}, {"field": "activity_movement", "value": "Slow, cautious movement (+1)", "score": 1}, {"field": "guarding", "value": "Splinting/tense (+1)", "score": 1}, {"field": "physiology_vitals", "value": "Change in SBP >20 mmHg or HR >20 bpm (+1)", "score": 1}, {"field": "respiratory", "value": "RR >10 over baseline or 5% decrease in SpO2 (+1)", "score": 1}], "final_answer": 5, "notes": "Moderate pain\nConsider analgesia. Sepsis, hypovolemia, and hypoxia need to be resolved prior to interventions."}, {"order": 7, "name": "Braden Score for Pressure Ulcers", "inputs": [{"field": "sensory_perception", "value": "Slightly limited (3)", "score": 3}, {"field": "moisture", "value": "Occasionally moist (3)", "score": 3}, {"field": "activity", "value": "Chairfast (2)", "score": 2}, {"field": "mobility", "value": "Very limited (2)", "score": 2}, {"field": "nutrition", "value": "Probably inadequate (2)", "score": 2}, {"field": "friction_and_shear", "value": "Potential problem (2)", "score": 2}], "final_answer": 14, "notes": "Braden Score\nModerate risk"}, {"order": 8, "name": "Nutrition Risk Screening 2002 (NRS-2002)", "inputs": [{"field": "initial_BMI_less_than_20_5", "value": "No (BMI 36.1)"}, {"field": "initial_weight_loss_within_3_months", "value": "Yes (~5% over 2 months)"}, {"field": "initial_reduced_dietary_intake_last_week", "value": "Yes (~50% of usual)"}, {"field": "initial_ICU_patient", "value": "No"}, {"field": "final_nutritional_status_score_0_to_3", "value": "2 (5–10% weight loss and/or intake 50–75%)", "score": 2}, {"field": "final_disease_severity_score_0_to_3", "value": "2 (moderate disease burden: CHF exacerbation/pneumonia)", "score": 2}, {"field": "age_adjustment_70_or_more", "value": "Yes (+1)", "score": 1}], "final_answer": 5, "notes": "NRS-2002\nHigh risk\nInitiate early intervention nutritional care plan"}, {"order": 9, "name": "Geneva Risk Score for Venous Thromboembolism (VTE) Prophylaxis", "inputs": [{"field": "cardiac_failure", "value": "Yes (+2)", "score": 2}, {"field": "respiratory_failure", "value": "No (0)", "score": 0}, {"field": "recent_stroke_less_than_3_months", "value": "No (0)", "score": 0}, {"field": "recent_myocardial_infarction_less_than_4_weeks", "value": "No (0)", "score": 0}, {"field": "acute_infectious_disease_including_sepsis", "value": "Yes (suspected pneumonia) (+2)", "score": 2}, {"field": "acute_rheumatic_disease", "value": "No (0)", "score": 0}, {"field": "active_malignancy", "value": "No (0)", "score": 0}, {"field": "myeloproliferative_syndrome", "value": "No (0)", "score": 0}, {"field": "nephrotic_syndrome", "value": "No (0)", "score": 0}, {"field": "any_prior_VTE", "value": "No (0)", "score": 0}, {"field": "known_hypercoagulable_state", "value": "No (0)", "score": 0}, {"field": "immobilization_for_3_or_more_days", "value": "No (0)", "score": 0}, {"field": "recent_travel_more_than_6_hours", "value": "No (0)", "score": 0}, {"field": "age_over_60_years", "value": "Yes (+1)", "score": 1}, {"field": "BMI_over_30", "value": "Yes (+1)", "score": 1}, {"field": "chronic_venous_insufficiency", "value": "Yes (+1)", "score": 1}, {"field": "pregnancy", "value": "No (0)", "score": 0}, {"field": "hormonal_therapy", "value": "No (0)", "score": 0}, {"field": "dehydration", "value": "No (0)", "score": 0}], "final_answer": 7, "notes": "Geneva Risk Score for VTE Prophylaxis\n3.2 %\nVTE risk (composite of symptomatic VTE or 90-day VTE mortality)\nHigh risk\nVTE prophylaxis indicated (presuming no contraindications)"}, {"order": 10, "name": "LACE Index for Readmission", "inputs": [{"field": "length_of_stay_days", "value": "5 days", "score": 4}, {"field": "acute_emergent_admission", "value": "Yes (+3)", "score": 3}, {"field": "charlson_comorbidity_index_points", "value": "4 points (CHF, COPD, DM2, CKD stage 3) (+5)", "score": 5}, {"field": "number_of_ED_visits_within_6_months", "value": "2 (+2)", "score": 2}], "final_answer": 14, "notes": "High risk of readmission."}]}
{"task_id": "medmcp-calc_087_f66a5399", "task_scenario": "Pediatric Asthma Control Scores", "task_category": "Clinical Medicine / Special Populations & General Tools / Pediatrics & Neonatology", "patient_id": "P087_f66a5399", "task_description": "Clinical scenario: A child presents to urgent care with wheeze and increased work of breathing. The team aims to standardize acute severity assessment, guide treatment and disposition, and plan outpatient control and risk mitigation using validated pediatric asthma tools. Step-by-step workflow: 1) At triage, quantify baseline airway obstruction with the Pediatric Respiratory Assessment Measure (PRAM) for Asthma Exacerbation Severity to classify the episode as mild, moderate, or severe and set initial treatment intensity. 2) If PRAM indicates moderate or severe exacerbation, immediately calculate the Pediatric Asthma Score (PAS) to corroborate severity and ensure treatment aligns with the higher risk category; if PRAM indicates mild severity, skip directly to chronic control assessment later in the workflow. 3) If PRAM and PAS are discordant or the classification sits at a threshold where escalation decisions are uncertain, use the Respiratory Score for Asthma to adjudicate severity and adopt the highest resulting category to standardize the initial management plan. 4) After initial bronchodilator/systemic therapy and reassessment period, calculate the Pediatric Asthma Severity Score (PASS) for Asthma Exacerbation Severity to measure response; this post-treatment score informs disposition decisions. 5) Branch based on PASS: if PASS remains moderate or severe, proceed to the Risk Score for Asthma Exacerbation (RSE) to estimate the likelihood of an exacerbation within 6 months and intensify follow-up and controller strategy accordingly; if PASS improves to mild, proceed to chronic control assessment. 6) Measure chronic impairment and risk with the Asthma Impairment and Risk Questionnaire (AIRQ) to determine ongoing symptom burden and risk features; if AIRQ indicates moderate/high impairment or ongoing risk, compute RSE to refine near-term risk and adjust outpatient plan (e.g., closer follow-up, action plan emphasis, controller step-up). 7) If the child is preschool-aged with recurrent wheeze or diagnostic uncertainty regarding persistent asthma, use the Modified Asthma Predictive Index (mAPI) to estimate future asthma risk and inform early controller therapy decisions or referral. Throughout, earlier severity outputs (PRAM/PAS/Respiratory Score) deterministically trigger whether and when subsequent tools (PASS, RSE, AIRQ, mAPI) are applied, ensuring a cohesive progression from acute care to longitudinal control planning.", "fuzzy_question": "I'm evaluating a pediatric patient in an acute care setting with wheeze and increased work of breathing, with concerning findings on exam. I want to be deliberate about assessing illness severity at initial presentation so therapy intensity matches risk and disposition decisions are sound. My initial step is to quantify airway obstruction and classify severity (mild, moderate, or severe) using a standardized bedside approach, so initial bronchodilator dosing and early systemic therapy are appropriate.\n\nIf the initial assessment suggests more than mild severity, I'd add a follow-up objective bedside measure to corroborate severity and ensure treatment intensity is adequate. If it appears truly mild, I'm comfortable foregoing additional acute severity checks and focusing later on longer-term control once stabilized.\n\nI worry about situations where initial assessments don't agree or the patient sits on the cusp where escalation is unclear. In those cases, I'd add another structured respiratory assessment to break the tie and, when in doubt, lean toward the higher-risk classification so the initial management plan remains consistent and safe.\n\nAfter initial bronchodilators and systemic corticosteroids, with a brief reassessment period, I want a structured post-treatment gauge of response. That result should drive disposition - who can be discharged versus who needs prolonged observation or admission.\n\nIf, despite therapy, they remain in the moderate-to-severe range, I want an estimate of near-term exacerbation risk to guide tighter follow-up, potential step-up of controller therapy, and reinforcement of a written action plan. If they've moved into a mild range by the post-treatment check, I'd pivot to chronic control: recent symptoms, nighttime awakenings, reliever use, activity limitations, and other risk features. If that review suggests moderate or high impairment or ongoing risk, I'd still want a near-term risk estimate to calibrate outpatient intensity.\n\nAnother consideration: if this is a pediatric patient with recurrent wheeze and persistent asthma remains uncertain, I'd apply a validated pediatric risk framework to estimate the probability of developing asthma, to inform early initiation of controller therapy or referral to pulmonology/allergy.\n\nCan you walk me through this case the way I've laid it out - tie each step to the next based on what you find, and make sure decisions about treatment intensity, disposition, and longer-term planning are anchored in objective, standardized measures rather than gut feel? I really need proper calculations on this - can't make this decision based on gut feeling alone. Whatever approach you suggest, make sure it's backed by solid calculations, okay? This needs to hold up to scrutiny.", "required_calculators": ["Pediatric Respiratory Assessment Measure (PRAM) for Asthma Exacerbation Severity", "Pediatric Asthma Score (PAS)", "Respiratory Score for Asthma", "Pediatric Asthma Severity Score (PASS) for Asthma Exacerbation Severity", "Asthma Impairment and Risk Questionnaire (AIRQ)", "Risk Score for Asthma Exacerbation (RSE)", "Modified Asthma Predictive Index (mAPI)"], "calculator_answers": [{"order": 1, "name": "Pediatric Respiratory Assessment Measure (PRAM) for Asthma Exacerbation Severity", "inputs": [{"field": "O2 saturation (room air, %)", "value": "93%", "score": 1}, {"field": "Suprasternal retractions present", "value": "Yes", "score": 2}, {"field": "Scalene muscle contractions present", "value": "No", "score": 0}, {"field": "Air entry", "value": "Decreased at the apex and the base", "score": 2}, {"field": "Wheezing", "value": "Expiratory only", "score": 1}], "final_answer": 6, "notes": "6 points\nModerate asthma"}, {"order": 2, "name": "Pediatric Asthma Score (PAS)", "inputs": [{"field": "Respiratory rate (breaths/min)", "value": "48"}, {"field": "Age (years)", "value": "3"}, {"field": "Oxygen requirements", "value": "90-95% on room air", "score": 2}, {"field": "Auscultation", "value": "Expiratory wheezing", "score": 2}, {"field": "Retractions", "value": "Intercostal and substernal", "score": 2}, {"field": "Dyspnea", "value": "Speaks partial sentences (short cry)", "score": 2}], "final_answer": 11, "notes": "11 points\nPediatric Asthma Score\nModerate\nExacerbation\n50-70 %\nPercent of peak flow (personal best or predicted)"}, {"order": 3, "name": "Respiratory Score for Asthma", "inputs": [{"field": "Age category", "value": "2 to 3 years"}, {"field": "Respiratory rate (breaths/min)", "value": "48", "score": 3}, {"field": "Retractions", "value": "Intercostal and substernal", "score": 2}, {"field": "Dyspnea", "value": "1 of the following: difficulty feeding, decreased vocalization, or agitated", "score": 1}, {"field": "Wheezing", "value": "Inspiratory and expiratory wheeze and/or diminished breath sounds", "score": 3}], "final_answer": 9, "notes": "9 points\nHigh risk"}, {"order": 4, "name": "Pediatric Asthma Severity Score (PASS) for Asthma Exacerbation Severity", "inputs": [{"field": "Wheezing", "value": "None or mild", "score": 0}, {"field": "Work of breathing (accessory muscles, retractions)", "value": "Normal or mildly diminished", "score": 0}, {"field": "Prolongation of expiration (E:I ratio)", "value": "Moderately prolonged", "score": 1}], "final_answer": 1, "notes": "1 points\nPASS suggests asthma may be treatable as outpatient."}, {"order": 5, "name": "Asthma Impairment and Risk Questionnaire (AIRQ)", "inputs": [{"field": "Daytime symptoms on more than 4 days in past 2 weeks", "value": "Yes", "score": 1}, {"field": "Night awakenings more than 1 time in past 2 weeks", "value": "Yes", "score": 1}, {"field": "Activities limited every day in past 2 weeks", "value": "No", "score": 0}, {"field": "Rescue inhaler/nebulizer used every day in past 2 weeks", "value": "Yes", "score": 1}, {"field": "Limited social activities in past 2 weeks", "value": "Yes", "score": 1}, {"field": "Exercise limited in past 2 weeks", "value": "Yes", "score": 1}, {"field": "Felt asthma difficult to control in past 2 weeks", "value": "Yes", "score": 1}, {"field": "Steroid pills/shots in past 12 months", "value": "Yes", "score": 1}, {"field": "ER or unplanned visits in past 12 months", "value": "Yes", "score": 1}, {"field": "Hospital overnight in past 12 months", "value": "No", "score": 0}], "final_answer": 8, "notes": "8 points\nAIRQ Score\nVery poorly controlled\nAsthma severity"}, {"order": 6, "name": "Risk Score for Asthma Exacerbation (RSE)", "inputs": [{"field": "BMI ≥30 kg/m²", "value": "No", "score": 0}, {"field": "ACQ-5 Score", "value": "2.0", "score": 7}, {"field": "Postbronchodilator FEV1 (% predicted)", "value": "85%", "score": 13}, {"field": "Rescue inhaler usage per day", "value": "2", "score": 11}, {"field": "GINA treatment step 4 or higher (medium-high ICS/LABA)", "value": "No", "score": 0}], "final_answer": 31, "notes": "10-12% Likelihood of asthma exacerbation within 6 months."}, {"order": 7, "name": "Modified Asthma Predictive Index (mAPI)", "inputs": [{"field": "≥4 wheezing episodes/year", "value": "Yes"}, {"field": "Major: Parent with asthma", "value": "Yes"}, {"field": "Major: Patient has atopic dermatitis", "value": "Yes"}, {"field": "Major: Aeroallergen sensitivity", "value": "No"}, {"field": "Minor: Wheezing unrelated to colds", "value": "Yes"}, {"field": "Minor: Eosinophils ≥4% on CBC", "value": "Yes"}, {"field": "Minor: Allergy to milk, egg, or peanuts", "value": "Yes"}], "final_answer": "Positive", "notes": ">98% specific for asthma diagnosis by age 11.\nSee sensitivity and specificity information in the About section."}]}
{"task_id": "medmcp-calc_088_d6212f13", "task_scenario": "Acute Coronary Syndrome (ACS) Prognosis", "task_category": "Clinical Medicine / Medicine & Organ Systems / Cardiovascular Medicine", "patient_id": "P088_d6212f13", "task_description": "Clinical scenario: In Clinical Medicine / Medicine & Organ Systems / Cardiovascular Medicine _ Acute Coronary Syndrome (ACS) Prognosis, an adult presents to the emergency department with chest pain concerning for ACS. The team must rapidly decide whether ACS can be safely ruled out and, if not, forecast short-term mortality and complications to guide intensity of care, invasive strategy, and disposition.\n\nStep-by-step workflow and clinical rationale:\n1) Emergency Department Assessment of Chest Pain Score (EDACS): Use EDACS for initial triage to identify patients who are low risk for major adverse cardiac events.\n   - If EDACS classifies the patient as low risk, proceed to T-MACS (Step 2) to attempt rule-out of ACS.\n   - If EDACS is not low risk, skip to Killip classification (Step 4) and proceed on an ACS management pathway.\n2) Troponin-only Manchester Acute Coronary Syndromes (T-MACS) Decision Aid: Apply T-MACS to determine whether ACS can be ruled out using troponin-based decision support.\n   - If T-MACS rules out ACS, proceed to HEART Pathway (Step 3) to finalize early discharge planning.\n   - If T-MACS does not rule out ACS, skip to Killip classification (Step 4).\n3) HEART Pathway for Early Discharge in Acute Chest Pain: For patients identified as low risk by EDACS and ruled out by T-MACS, use the HEART Pathway to confirm safe early discharge and end the workflow for this branch.\n4) Killip Classification for Heart Failure: For patients on the ACS pathway, quantify heart failure severity from I–IV. The Killip class derived here is a required input for GRACE.\n5) GRACE ACS Risk and Mortality Calculator: Estimate in-hospital to 6-month mortality using GRACE, incorporating the Killip class from Step 4 as an input. Use GRACE risk categories to determine monitoring intensity and urgency of intervention.\n   - If GRACE indicates high risk, assess shock risk (Step 8) before proceeding to invasive decisions.\n6) Branch by ACS type:\n   - If STEMI is diagnosed, compute TIMI Risk Score for STEMI (Step 6a).\n   - If UA/NSTEMI is diagnosed, compute TIMI Risk Score for UA/NSTEMI (Step 6b).\n6a) TIMI Risk Score for STEMI: Estimate early mortality in STEMI. Use the TIMI risk category to drive urgency and level of care.\n   - If moderate/high TIMI risk and reperfusion/PCI is planned, proceed to British Columbia PCI risk score (Step 9) for 30-day post-PCI mortality.\n6b) TIMI Risk Score for UA/NSTEMI: Estimate event risk in UA/NSTEMI. Use the TIMI category to plan invasive vs conservative strategy and level of monitoring.\n   - If moderate/high TIMI risk, compute ACTION ICU Score for Intensive Care in NSTEMI (Step 7) to determine ICU-level care.\n   - If an early invasive strategy is planned, proceed to British Columbia PCI risk score (Step 9) for expected post-PCI mortality.\n7) ACTION ICU Score for Intensive Care in NSTEMI: For UA/NSTEMI patients at moderate/high risk by TIMI, estimate the likelihood of complications warranting ICU-level care to guide placement and monitoring.\n8) SEX-SHOCK Risk Score for the Development of Cardiogenic Shock: If GRACE is high or there are clinical signs of hemodynamic compromise, estimate in-hospital cardiogenic shock risk. A high SEX-SHOCK score deterministically triggers escalation of hemodynamic support and highest-acuity monitoring while proceeding to reperfusion decisions.\n9) British Columbia PCI risk score: For patients proceeding to PCI (either STEMI or high-risk UA/NSTEMI), estimate 30-day mortality post-PCI to inform consent, post-procedural monitoring, and resource planning.\n\nThe workflow connects outputs between tools: Killip class is a required input to GRACE; EDACS and T-MACS outputs deterministically trigger use of the HEART Pathway (early discharge) or continued ACS risk pathways; TIMI (STEMI or UA/NSTEMI) outputs drive whether to use ACTION ICU Score and whether to apply the British Columbia PCI risk score; GRACE output triggers shock risk assessment via SEX-SHOCK. This creates a coherent, branching pathway from ED triage through definitive ACS prognosis and management.", "fuzzy_question": "Evaluating an adult in the emergency department with pressure-like chest pain concerning for acute coronary syndrome. The goal is to decide whether early discharge is safe or whether full ACS management is required, and, if so, how intensively to monitor and how urgent invasive management should be.\n\nFirst, perform an ED chest pain triage to determine whether the patient meets low-risk criteria for major adverse cardiac events. If they appear low risk, pair that assessment with a troponin-guided rapid rule-out to determine whether ACS can be confidently excluded. If both indicate safety, proceed with early discharge using a structured low-risk chest pain pathway. If either raises concern, continue on the ACS pathway.\n\nIf on the ACS pathway, establish the current degree of heart failure using the usual bedside functional class, as this informs overall risk. Then generate a comprehensive ACS mortality estimate that integrates age, vital signs, kidney function, ECG findings, troponin, and heart failure class to provide in-hospital and short- to intermediate-term risk, categorized to guide care level (telemetry versus intensive care) and the urgency of catheterization. If global risk is high or there are signs of hemodynamic compromise, also estimate the likelihood of developing cardiogenic shock during this admission to guide escalation of hemodynamic support and highest-acuity monitoring while moving toward reperfusion.\n\nNext, branch by diagnosis. If the presentation is ST-elevation myocardial infarction, obtain an early mortality risk estimate specific to that condition to set how aggressive and fast to proceed. If the presentation is unstable angina or non–ST-elevation myocardial infarction, estimate short-term event risk to decide on invasive versus more conservative timing and the level of monitoring. For those in the moderate or high range, also estimate the likelihood of requiring intensive care because of anticipated complications such as arrhythmia, worsening heart failure, or shock, to guide bed placement and monitoring intensity.\n\nFor anyone proceeding to percutaneous coronary intervention—whether as reperfusion for ST-elevation myocardial infarction or as part of an early invasive strategy for higher-risk unstable angina or non–ST-elevation myocardial infarction—obtain a pre-procedural estimate of short-term mortality after the procedure to inform consent, post-procedure surveillance, and resource planning.\n\nPlease walk through this step by step, and at each checkpoint provide actual risk estimates and categories rather than a generalized impression, supported by validated calculations. The approach should be defensible and suitable for scrutiny.", "required_calculators": ["Emergency Department Assessment of Chest Pain Score (EDACS)", "Troponin-only Manchester Acute Coronary Syndromes (T-MACS) Decision Aid", "HEART Pathway for Early Discharge in Acute Chest Pain", "Killip Classification for Heart Failure", "GRACE ACS Risk and Mortality Calculator", "TIMI Risk Score for STEMI", "TIMI Risk Score for UA/NSTEMI", "ACTION ICU Score for Intensive Care in NSTEMI", "SEX-SHOCK Risk Score for the Development of Cardiogenic Shock", "British Columbia PCI risk score"], "calculator_answers": [{"order": 1, "name": "Emergency Department Assessment of Chest Pain Score (EDACS)", "inputs": [{"field": "Age", "value": "62 years"}, {"field": "Sex", "value": "Male", "score": 6}, {"field": "Diaphoresis", "value": "Yes", "score": 3}, {"field": "Pain radiates to arm, shoulder, neck, or jaw", "value": "Yes", "score": 5}, {"field": "Pain occurred or worsened with inspiration", "value": "No", "score": 0}, {"field": "Pain is reproduced by palpation", "value": "No", "score": 0}], "final_answer": 24, "notes": "Not low risk. This patient is not a candidate for early discharge and should receive a standard chest pain evaluation with delayed troponin testing."}, {"order": 2, "name": "Troponin-only Manchester Acute Coronary Syndromes (T-MACS) Decision Aid", "inputs": [{"field": "EKG ischemia", "value": "Yes", "score": 1}, {"field": "Worsening or crescendo angina", "value": "Yes", "score": 1}, {"field": "Pain radiating to right arm or shoulder", "value": "No", "score": 0}, {"field": "Pain associated with vomiting", "value": "No", "score": 0}, {"field": "Sweating observed", "value": "Yes", "score": 1}, {"field": "Hypotension", "value": "No", "score": 0}, {"field": "hs-cTnT concentration on arrival", "value": "0.032 ug/L"}], "final_answer": "Moderate risk", "notes": "Moderate risk\nSerial troponin in general ward, consider stress testing and/or CT coronary angiography.\n94 %\nRisk of ACS or MACE in 30 days"}, {"order": 3, "name": "HEART Pathway for Early Discharge in Acute Chest Pain", "inputs": [{"field": "History", "value": "Moderately suspicious", "score": 1}, {"field": "EKG", "value": "Significant ST depression", "score": 2}, {"field": "Age", "value": "45-64", "score": 1}, {"field": "Risk factors", "value": ">=3 risk factors or history of atherosclerotic disease", "score": 2}, {"field": "Initial troponin", "value": "1-3x normal limit", "score": 1}], "final_answer": 7, "notes": "HEART Pathway Score\nHigh risk\n12-65% 30-day MACE\nCardiology consultation and admission recommended. Further testing indicated."}, {"order": 4, "name": "Killip Classification for Heart Failure", "inputs": [{"field": "Classification", "value": "S3 and basal rales on auscultation"}], "final_answer": "Class II", "notes": "Class II\nKillip Classification\n5-12 %\n30-day mortality"}, {"order": 5, "name": "GRACE ACS Risk and Mortality Calculator", "inputs": [{"field": "Age", "value": "62 years"}, {"field": "Heart rate/pulse", "value": "96 beats/min"}, {"field": "Systolic BP", "value": "132 mm Hg"}, {"field": "Creatinine", "value": "1.2 mg/dL"}, {"field": "Cardiac arrest at admission", "value": "No"}, {"field": "ST segment deviation on EKG?", "value": "Yes"}, {"field": "Abnormal cardiac enzymes", "value": "Yes"}, {"field": "Killip class (signs/symptoms)", "value": "Rales and/or JVD"}], "final_answer": 132, "notes": "132 points\nGRACE Score\n11 %\nProbability of death from admission to 6 months"}, {"order": 6, "name": "TIMI Risk Score for STEMI", "inputs": [{"field": "Age", "value": "< 65 years", "score": 0}, {"field": "Diabetes, Hypertension or Angina", "value": "Yes", "score": 1}, {"field": "Systolic BP < 100 mmHg", "value": "No", "score": 0}, {"field": "Heart rate > 100", "value": "No", "score": 0}, {"field": "Killip Class II-IV", "value": "Yes", "score": 2}, {"field": "Weight < 67kg (147.7 lbs)", "value": "No", "score": 0}, {"field": "Anterior ST Elevation or LBBB", "value": "No", "score": 0}, {"field": "Time to treatment > 4 hours", "value": "No", "score": 0}], "final_answer": 3, "notes": "4.4% risk of all-cause mortality at 30 days."}, {"order": 7, "name": "TIMI Risk Score for UA/NSTEMI", "inputs": [{"field": "Age ≥65", "value": "No", "score": 0}, {"field": "≥3 CAD risk factors", "value": "Yes", "score": 1}, {"field": "Known CAD (stenosis ≥50%)", "value": "No", "score": 0}, {"field": "ASA use in past 7 days", "value": "No", "score": 0}, {"field": "Severe angina (≥2 episodes in 24 hrs)", "value": "Yes", "score": 1}, {"field": "EKG ST changes ≥0.5mm", "value": "Yes", "score": 1}, {"field": "Positive cardiac marker", "value": "Yes", "score": 1}], "final_answer": 4, "notes": "20% risk at 14 days of: all-cause mortality, new or recurrent MI, or severe recurrent ischemia requiring urgent revascularization."}, {"order": 8, "name": "ACTION ICU Score for Intensive Care in NSTEMI", "inputs": [{"field": "Age, years", "value": "62 (<70)", "score": 0}, {"field": "Serum creatinine, mg/dL", "value": "1.2 (≥1.1)", "score": 1}, {"field": "Heart rate, bpm", "value": "96 (85-100)", "score": 1}, {"field": "Systolic blood pressure, mmHg", "value": "132 (125-145)", "score": 1}, {"field": "Ratio of initial troponin to upper limit of normal", "value": "2.3 (<12)", "score": 0}, {"field": "Signs or symptoms of heart failure", "value": "Yes", "score": 5}, {"field": "ST segment depression on EKG", "value": "Yes", "score": 1}, {"field": "Prior revascularization", "value": "No", "score": 1}, {"field": "Chronic lung disease", "value": "No", "score": 0}], "final_answer": 10, "notes": "ACTION ICU Score\n23.3 %\nRisk of complications requiring ICU care among initially uncomplicated patients with NSTEMI (cardiac arrest, shock, high-grade AV block, respiratory failure, stroke, or death during index admission)"}, {"order": 9, "name": "SEX-SHOCK Risk Score for the Development of Cardiogenic Shock", "inputs": [{"field": "Age >70 years", "value": "No"}, {"field": "Sex", "value": "Male"}, {"field": "Received PCI", "value": "No"}, {"field": "Glycemia >10 mmol/L", "value": "No"}, {"field": "SBP <125 and PP <45 mmHg", "value": "No"}, {"field": "Heart rate >90/min", "value": "Yes"}, {"field": "Killip Classification class III", "value": "No"}, {"field": "Presentation as cardiac arrest", "value": "No"}, {"field": "Left-ventricular ejection fraction (%)", "value": "35-50"}, {"field": "ST-segment elevation", "value": "No"}, {"field": "Creatinine", "value": "1.2 mg/dL"}, {"field": "C-reactive protein", "value": "8 mg/L"}], "final_answer": "1.3 %", "notes": "Risk of in-hospital cardiogenic shock by SEX-SHOCKlight score"}, {"order": 10, "name": "British Columbia PCI risk score", "inputs": [{"field": "Age", "value": "62 years"}, {"field": "Gender", "value": "Male"}, {"field": "Emergency", "value": "Yes"}, {"field": "Left Main Disease", "value": "No"}, {"field": "Triple-vessel Disease", "value": "Yes"}, {"field": "Left Ventricular Ejection Fraction", "value": "40 %"}, {"field": "NYHA Class", "value": "II"}, {"field": "Critical Pre-procedural State", "value": "No"}, {"field": "Indication", "value": "NSTEMI (urgent/early invasive)(Other ACS)"}, {"field": "Dialysis or Creatinine >2.2 mg/dL, or >200 µmol/L", "value": "No"}], "final_answer": "2.1 %", "notes": "Predicted 30-day Mortality\n2.1 %"}]}
{"task_id": "medmcp-calc_089_fe4a60ec", "task_scenario": "Drug Interaction Assessment", "task_category": "Clinical Medicine / Special Populations & General Tools / Clinical Pharmacology & Nursing", "patient_id": "P089_fe4a60ec", "task_description": "Scenario: An older adult with multimorbidity is being considered for a new prescription NSAID to manage chronic musculoskeletal pain. The patient is already on multiple chronic therapies commonly implicated in the so-called “triple whammy” interaction (e.g., renin–angiotensin system agents and diuretics), making renal and electrolyte safety a primary concern. The care team (clinical pharmacology and nursing) must assess interaction risk, decide whether and how to proceed, and design monitoring and mitigation steps. Workflow: 1) Perform a baseline risk estimation using the NSAID risk of AKI or hyperkalemia calculator to quantify near-term safety risk after NSAID initiation. 2) Branching based on the output: • If the predicted risk is high, pause NSAID initiation and implement mitigation strategies (e.g., optimize the concurrent regimen and supportive measures), then re-run the same NSAID risk of AKI or hyperkalemia calculator to reassess residual risk after changes. • If the predicted risk is moderate, consider a conservative analgesic strategy (e.g., topical formulations or shortest feasible systemic course) and establish enhanced safety monitoring; optionally re-run the calculator if minor regimen adjustments are made to confirm acceptable residual risk before proceeding. • If the predicted risk is low, proceed with the planned NSAID while instituting routine safety monitoring appropriate for renal and electrolyte safety. 3) Use the second (post-mitigation) calculator output as a deterministic decision trigger: • If risk remains high, avoid systemic NSAIDs and pivot to alternative pain management strategies. • If risk improves to acceptable levels, proceed with a limited NSAID plan and finalize monitoring frequency and safety checkpoints. Rationale: Iterative application of the same risk tool ensures decisions are data-driven both before and after mitigation, aligning nursing and pharmacology actions with the predicted interaction risk.", "fuzzy_question": "I’m seeing an older adult with a lot going on, and I’m wrestling with how to manage their chronic musculoskeletal pain without worsening kidney function. They have knee osteoarthritis and degenerative lumbar spine disease, are overweight, and their kidney function is chronically impaired with stable labs showing mildly elevated creatinine, moderately reduced eGFR, and potassium near the upper end of normal. Blood pressure is well controlled. Medications include a renin-angiotensin system inhibitor, a loop diuretic, and a potassium-sparing diuretic; they are also on standard cardiometabolic therapy for diabetes and dyslipidemia. There was a prior episode of prerenal AKI after a gastrointestinal illness, and they tend to become volume depleted without hydration guidance. No active infection or edema at present. We’re considering adding an NSAID to improve function, ideally for flares, and possibly intermittently for a limited period.\n\nMy worry is the classic triple whammy setup with a renin-angiotensin system inhibitor and diuretics on board. I’d like to approach this with a clear, number-backed sense of the near-term risk of kidney injury and potassium disturbances if we proceed with an oral NSAID, and to let that risk guide whether we start, adjust other meds first, or avoid systemic NSAIDs altogether.\n\nHere’s what I need help with:\n\n- First, using their current meds and recent labs, can you give me a quantitative read on their short-horizon risk of kidney trouble and hyperkalemia if we start a low-dose oral NSAID (i.e., in the early period after initiation)? I want real numbers here—not just “higher” or “lower”—so we can share them with the team and the patient.\n\n- If those numbers look high, my instinct is to hold off on starting the NSAID and see what we can do to bring the risk down—things like tightening up hydration counseling, sick-day rules, avoiding any hidden OTC NSAID use, reconsidering whether the diuretic intensity and/or the renin-angiotensin system inhibitor dose can be temporarily eased, and whether the potassium-sparing component should be adjusted. We could also steer toward topical options or non-NSAID analgesics while we shore things up. If you think that kind of medication and supportive adjustment makes sense here, please lay out exactly what you’d change and for how long—and then use the same approach to give me a new, post-adjustment risk estimate so we can see if we’ve meaningfully lowered the chance of AKI or hyperkalemia.\n\n- If the initial risk lands in a middle ground where it’s not clearly prohibitive but not trivial either, I’m leaning toward a very conservative analgesic plan—topical therapy as first line and, if needed, the smallest reasonable oral dose for the shortest feasible time—paired with tighter monitoring. In that circumstance, if you’re suggesting minor tweaks to the current regimen (for example, small diuretic adjustments or brief holds around the NSAID exposure), please also check how those tweaks affect the risk using the same method so we know the residual risk before we proceed.\n\n- If the initial risk is genuinely low, I’m comfortable moving ahead with the planned NSAID, but I still want a sensible monitoring plan.\n\nEither way, once you’ve walked through your baseline numbers and any proposed changes, please make a clear recommendation based on the second set of numbers: either avoid systemic NSAIDs and pivot to alternatives (e.g., topical NSAID, acetaminophen, duloxetine, physical therapy, injections), or proceed with a limited NSAID plan. If you recommend proceeding, I need a concrete safety plan we can implement with nursing: when to recheck creatinine and potassium (and how often thereafter), what thresholds would make you stop or back down (e.g., percent rise in creatinine, potassium cut-offs), what symptoms should trigger urgent labs or cessation, and explicit sick-day guidance if they get dehydrated or unwell. Please also note any medication counseling points that are especially important in this context (hydration, avoiding OTC NSAIDs, what to do with their renin-angiotensin system inhibitor/diuretics during an intercurrent illness).\n\nI’m torn here because the pain is limiting their mobility, but I really want to avoid preventable kidney or potassium complications. What’s your clinical take, step by step? Start with the initial risk numbers, then your proposed mitigation strategy if needed with an updated risk estimate, and finish with a go/no-go call and a monitoring/checkpoint plan. I really need proper calculations on this—can’t make this decision based on gut feeling alone. Whatever approach you suggest, make sure it’s backed by solid numbers that will hold up to scrutiny.", "required_calculators": ["NSAID risk of AKI or hyperkalemia"], "calculator_answers": [{"order": 1, "name": "NSAID risk of AKI or hyperkalemia", "inputs": [{"field": "Age", "value": "78 years"}, {"field": "Sex", "value": "Male"}, {"field": "eGFR", "value": "42 mL/min/1.73 m2"}, {"field": "Serum potassium", "value": "4.8 mmol/L"}, {"field": "Any diuretics?", "value": "Yes"}, {"field": "Any ACEi/ARB?", "value": "Yes"}], "final_answer": "7%", "notes": "Risk of AKI or hyperkalemia within 30 days of NSAID initiation\nAKI: a serum creatinine increase of 50% or more, or an absolute increase of at least 0.3 mg/dL (26.5 µmol/L). Hyperkalemia: K at least 5.5 mmol/L\n7 %"}, {"order": 2, "name": "NSAID risk of AKI or hyperkalemia", "inputs": [{"field": "Age", "value": "78 years"}, {"field": "Sex", "value": "Male"}, {"field": "eGFR", "value": "45 mL/min/1.73 m2"}, {"field": "Serum potassium", "value": "4.5 mmol/L"}, {"field": "Any diuretics?", "value": "Yes"}, {"field": "Any ACEi/ARB?", "value": "No"}], "final_answer": "4%", "notes": "Risk of AKI or hyperkalemia within 30 days of NSAID initiation\nAKI: a serum creatinine increase of 50% or more, or an absolute increase of at least 0.3 mg/dL (26.5 µmol/L). Hyperkalemia: K at least 5.5 mmol/L\n4 %"}]}
{"task_id": "medmcp-calc_090_2987a54f", "task_scenario": "Heart Failure Staging and Prognosis", "task_category": "Clinical Medicine / Medicine & Organ Systems / Cardiovascular Medicine", "patient_id": "P090_2987a54f", "task_description": "Clinical scenario: A patient presents to the emergency setting with symptoms and signs concerning for acute decompensated heart failure. The clinical team must confirm the diagnosis, stage disease severity, distinguish phenotype (reduced vs preserved ejection fraction), profile hemodynamics, estimate near-term mortality risk for disposition, and project longer-term prognosis to guide therapy and device considerations. Workflow steps and rationale: 1) Use the Framingham Heart Failure Diagnostic Criteria to confirm the presence of heart failure; if not confirmed, halt this workflow and reassess the differential. If confirmed, proceed. 2) Apply ACC/AHA Heart Failure Staging to categorize the patient’s HF stage (e.g., structural heart disease with symptoms vs advanced disease). This stage will later act as a decision trigger for device therapy consideration. 3) Determine left ventricular systolic function using Ejection Fraction (Simplified). This EF output is used to phenotype the patient and will be an input for subsequent risk models. 4) Conditional branch: If EF is preserved, calculate the H2FPEF Score for Heart Failure with Preserved Ejection Fraction to estimate the probability that symptoms are due to HFpEF; if the probability is low, re-evaluate for alternative causes; if intermediate/high, continue staging/prognosis steps. If EF is reduced, skip H2FPEF and proceed directly to hemodynamic profiling. 5) Classify hemodynamic profile using Stevenson HF Class (warm/cold, wet/dry) to determine the degree of congestion and perfusion. This profile influences the immediate risk assessment and disposition planning. 6) Based on clinical stability and the Stevenson profile, estimate short-term risk using the Emergency Heart Failure Mortality Risk Grade (EHMRG) to guide ED disposition. Conditional branch: If EHMRG indicates high 7-day risk or the Stevenson profile suggests hypoperfusion/congestion, prioritize admission and intensive therapy; if low risk and clinically stable, consider safe discharge with close follow-up. 7) Assign New York Heart Association (NYHA) Functional Classification for Heart Failure to quantify symptom burden; this output is also used as an input for subsequent prognostic models. 8) Estimate 1- and 3-year mortality using the MAGGIC Risk Calculator for Heart Failure, incorporating EF and NYHA outputs from prior steps to contextualize longer-term prognosis. 9) Cross-check longer-term survival projections with the Seattle Heart Failure Model, again leveraging EF and NYHA class; use concordance or divergence between MAGGIC and Seattle outputs to refine discussions on prognosis and follow-up intensity. 10) Conditional branch for device planning: If the patient has reduced EF and ACC/AHA stage indicates persistent symptomatic structural disease despite guideline-directed therapy, compute the MADIT-ICD Benefit Score to estimate the benefit of a primary-prevention ICD; if EF is preserved or stage is not appropriate, skip device scoring. This integrated sequence ties diagnostic confirmation, staging, short-term disposition, and long-term prognosis together, with multiple outputs serving as inputs or decision triggers for subsequent steps.", "fuzzy_question": "I’m seeing a patient in the ED with acute shortness of breath, orthopnea, leg swelling, and crackles on exam. There is elevated body weight, chronic hypertension, and kidney impairment. Natriuretic peptides are elevated, but there is also fever and troponin elevation, so I’m not completely certain we should anchor on heart failure without being systematic. This could be pneumonia, COPD exacerbation, pulmonary embolism, or a noncardiac cause.\n\nBefore we commit to a treatment pathway, I want to be confident the overall picture genuinely meets accepted bedside criteria for heart failure. If it doesn’t meet that threshold, let’s reopen the differential rather than forcing a heart failure track. If it does, then I’d like you to place the patient along the heart failure spectrum—does this look like structural disease with current symptoms or something more advanced? That placement will matter later when we’re considering device therapy.\n\nNext, I need a quick sense of left ventricular systolic function—just a reasonable estimate of EF from the bedside echo or recent imaging is fine—so we can phenotype this as reduced versus preserved function and carry that forward into risk discussions. If EF appears preserved, I’m specifically wondering how likely the symptoms are truly due to HFpEF versus comorbid contributors (lung disease, deconditioning, excess weight, anemia, renal issues). If that likelihood is low, I’d want to pivot away from a heart failure explanation; if it’s intermediate or high, we should proceed with staging and prognosis.\n\nAt the bedside, please characterize the hemodynamics: is the patient congested or not, and are they well perfused or borderline “cold”? That profile will drive immediate therapy and the appropriate care setting. Given the ED context, I’d also like a structured estimate of very short-term risk using readily available vitals, labs, and history to guide disposition. If they appear hypoperfused and/or markedly congested—or if the short-horizon risk is high—let’s favor admission and more intensive therapy. If they look stable and the short-horizon risk is reassuring, I’d consider discharge with very close follow-up.\n\nFor day-to-day living, please grade the symptom burden with ordinary activity so we have a functional anchor to track over time. We’ll use that, along with EF, for longer-term planning. Looking ahead, I want a reasoned estimate of short- and intermediate-term mortality that incorporates the phenotype and symptom level, so we can set expectations and calibrate follow-up intensity. Please cross-check that with a second, widely used survival model as a reality check; if the two paint different pictures, explain why and how you’d reconcile that in counseling and care planning.\n\nFinally, if this truly turns out to be systolic dysfunction and the patient remains symptomatic despite guideline-based medical therapy appropriate for their disease stage, I’d like to understand the expected benefit of a preventive defibrillator. If EF is preserved or they’re not at a stage where a device would be appropriate, let’s skip that.\n\nPlease walk me through this in that sequence—confirming it’s really heart failure before all else, then placing the patient along the disease spectrum, giving your best read on EF, judging the likelihood of HFpEF when EF is preserved, describing the bedside hemodynamics, advising on disposition with a short-horizon risk estimate, assigning functional status, projecting short- and intermediate-term outcomes, checking those against a second model, and, if applicable, weighing potential device benefit. I need proper calculations—this can’t be based on clinical intuition alone and must hold up to scrutiny.", "required_calculators": ["Framingham Heart Failure Diagnostic Criteria", "ACC/AHA Heart Failure Staging", "Ejection Fraction (Simplified)", "H2FPEF Score for Heart Failure with Preserved Ejection Fraction", "Stevenson HF Class", "Emergency Heart Failure Mortality Risk Grade (EHMRG)", "New York Heart Association (NYHA) Functional Classification for Heart Failure", "MAGGIC Risk Calculator for Heart Failure", "Seattle Heart Failure Model", "MADIT-ICD Benefit Score"], "calculator_answers": [{"order": 1, "name": "Framingham Heart Failure Diagnostic Criteria", "inputs": [{"field": "Acute pulmonary edema", "value": "No"}, {"field": "Cardiomegaly", "value": "Yes (CXR: mild enlargement)"}, {"field": "Hepatojugular reflux", "value": "No"}, {"field": "Neck vein distention", "value": "Yes (JVP ~12 cm H2O)"}, {"field": "Paroxysmal nocturnal dyspnea or orthopnea", "value": "Yes (orthopnea, needs 3 pillows)"}, {"field": "Pulmonary rales", "value": "Yes (bilateral basal crackles)"}, {"field": "Third heart sound (S3)", "value": "No"}, {"field": "Weight loss >4.5 kg in 5 days in response to treatment", "value": "No (pre-treatment)"}, {"field": "Ankle edema", "value": "Yes (2+ pitting to mid-shin)"}, {"field": "Dyspnea on exertion", "value": "Yes"}, {"field": "Hepatomegaly", "value": "No"}, {"field": "Nocturnal cough", "value": "Yes"}, {"field": "Pleural effusion", "value": "Yes (small right-sided on CXR)"}, {"field": "Tachycardia (HR >120)", "value": "No (HR 98 bpm)"}], "final_answer": "Positive", "notes": "Diagnostic Result\nPositive\nDiagnosis of Heart Failure"}, {"order": 2, "name": "ACC/AHA Heart Failure Staging", "inputs": [{"field": "Patient with history of hypertension, cardiovascular disease, diabetes, or obesity", "value": "Yes (HTN, obesity)"}, {"field": "Patient using cardiotoxins", "value": "No"}, {"field": "Patient with genetic variant for cardiomyopathy or family history of cardiomyopathy", "value": "No"}, {"field": "Patient with structural heart disease", "value": "Yes"}, {"field": "Patient with evidence of increased filling pressures", "value": "Yes"}, {"field": "Patient with increased natriuretic peptide levels or persistently elevated cardiac troponin (in the absence of competing diagnoses)", "value": "Yes"}, {"field": "Patient with current or previous signs/symptoms of heart failure", "value": "Yes"}, {"field": "Patient with marked heart failure symptoms that intefere with daily life and with recurrent hospitalizations despite attempts to optimize guideline-directed medical therapy", "value": "No"}], "final_answer": "Stage: C", "notes": "Symptomatic heart failure: structural heart disease with current or previous signs/symptoms of HF.\nTherapy considerations:\nAll measures under stage A and B\nGDMT, such as ARNI, ACEi, or ARB, beta-blocker, SGLT2i, MRA, and diuretics\nDietary sodium restriction\nExercise training\nCardiac rehabilitation"}, {"order": 3, "name": "Ejection Fraction (Simplified)", "inputs": [{"field": "LV End Diastolic Dimension", "value": "50 mm"}, {"field": "LV End Systolic Dimension", "value": "32 mm"}, {"field": "Apical Contraction", "value": "Normal"}], "final_answer": "65 %", "notes": "Ejection Fraction\n65 %\nCategory\nNormal"}, {"order": 4, "name": "H2FPEF Score for Heart Failure with Preserved Ejection Fraction", "inputs": [{"field": "Age", "value": "74 years"}, {"field": "BMI", "value": "32 kg/m²"}, {"field": "Early mitral inflow velocity/mitral annular early diastolic velocity (E/e') ratio", "value": "16"}, {"field": "Pulmonary artery systolic pressure", "value": "45 mm Hg"}, {"field": "Atrial fibrillation", "value": "No"}], "final_answer": "88.5 %", "notes": "Probability of heart failure with preserved EF"}, {"order": 5, "name": "Stevenson HF Class", "inputs": [{"field": "Evidence of Congestion?", "value": "Yes (orthopnea, JVP elevated, rales, 2+ edema)"}, {"field": "Evidence of Low Perfusion?", "value": "No (warm extremities, SBP 152 mm Hg, normal mentation)"}], "final_answer": "Warm and Wet", "notes": "Clinical Class\nWarm and Wet\nAnticipated In-Hospital Mortality\n10 %"}, {"order": 6, "name": "Emergency Heart Failure Mortality Risk Grade (EHMRG)", "inputs": [{"field": "Age", "value": "74 years"}, {"field": "Transported by EMS", "value": "Yes", "score": 60}, {"field": "Systolic blood pressure", "value": "152 mm Hg"}, {"field": "Heart rate", "value": "98 beats/min"}, {"field": "Oxygen saturation (lowest initial/triage)", "value": "89 %"}, {"field": "Creatinine", "value": "1.6 mg/dL"}, {"field": "Potassium", "value": "4.7 mmol/L (≥4.6 category)", "score": 30}, {"field": "Troponin >ULN", "value": "Yes (mild elevation)", "score": 60}, {"field": "Active cancer", "value": "No", "score": 0}, {"field": "Metolazone use at home", "value": "No", "score": 0}], "final_answer": 110.0, "notes": "110.0 points\nEHMRG Score\n8.5 %\n7-day mortality rate (risk group: 5b)"}, {"order": 7, "name": "New York Heart Association (NYHA) Functional Classification for Heart Failure", "inputs": [{"field": "Physical ability", "value": "Marked limitation of physical activity; comfortable at rest; less than ordinary activity causes fatigue, palpitation, or dyspnea"}], "final_answer": "Class III", "notes": "Class III\nNYHA Heart Failure Classification"}, {"order": 8, "name": "MAGGIC Risk Calculator for Heart Failure", "inputs": [{"field": "Age", "value": "74 years"}, {"field": "Ejection Fraction", "value": "58 %"}, {"field": "sBP", "value": "152 mm Hg"}, {"field": "BMI", "value": "32 kg/m²"}, {"field": "Creatinine", "value": "1.6 mg/dL"}, {"field": "NYHA Class", "value": "Class III", "score": 6}, {"field": "Gender", "value": "Male", "score": 1}, {"field": "Current smoker", "value": "No", "score": 0}, {"field": "Diabetes", "value": "No", "score": 0}, {"field": "COPD", "value": "No", "score": 0}, {"field": "Heart failure first diagnosed ≥18 months ago", "value": "No", "score": 0}, {"field": "Beta blocker", "value": "Yes", "score": 0}, {"field": "ACEi/ARB", "value": "Yes", "score": 0}], "final_answer": 19, "notes": "9.3 %\n1-year mortality\n22.7 %\n3-year mortality"}, {"order": 9, "name": "Seattle Heart Failure Model", "inputs": [{"field": "Age", "value": "74 years"}, {"field": "Gender", "value": "Male"}, {"field": "NYHA class", "value": "Class III"}, {"field": "Ejection fraction", "value": "58 %"}, {"field": "Ischemic etiology", "value": "No"}, {"field": "SBP", "value": "152 mm Hg"}, {"field": "Furosemide (daily dose)", "value": "20 mg"}, {"field": "Torsemide (daily dose)", "value": "0 mg"}, {"field": "Bumetanide (daily dose)", "value": "0 mg"}, {"field": "Metolazone (daily dose)", "value": "0 mg"}, {"field": "Hydrochlorothiazide (daily dose)", "value": "12.5 mg"}, {"field": "Weight", "value": "210 lb"}, {"field": "Using allopurinol", "value": "No"}, {"field": "Using statins", "value": "Yes"}, {"field": "Using ACE inhibitors", "value": "Yes"}, {"field": "Using beta-blockers", "value": "Yes"}, {"field": "Using angiotensin receptor blockers", "value": "No"}, {"field": "Using K-sparing diuretics", "value": "No"}, {"field": "Devices", "value": "None"}, {"field": "Sodium", "value": "137 mEq/L"}, {"field": "Total cholesterol", "value": "165 mg/dL"}, {"field": "Hemoglobin", "value": "12.8 g/dL"}, {"field": "Lymphocytes", "value": "18 %"}, {"field": "Uric acid", "value": "7.2 mg/dL"}], "final_answer": 0.11, "notes": "0.11 points\nSeattle Heart Failure Score\n96 %\nPredicted 1-year survival\n80 %\nPredicted 5-year survival"}, {"order": 10, "name": "MADIT-ICD Benefit Score", "inputs": [{"field": "LVEF ≤ 25%?", "value": "No (EF 58%)"}, {"field": "Atrial arrhythmia?", "value": "No"}, {"field": "Age < 75 yrs?", "value": "Yes (74 years)"}, {"field": "Heart Rate > 75 bpm?", "value": "Yes (98 bpm)"}, {"field": "SBP < 140 mmHg?", "value": "No (152 mm Hg)"}, {"field": "Myocardial Infarction?", "value": "No"}, {"field": "Male?", "value": "Yes"}, {"field": "Prior NSVT?", "value": "No"}, {"field": "CRT-D?", "value": "No"}, {"field": "NYHA ≥II?", "value": "Yes (NYHA III)"}, {"field": "Diabetes?", "value": "No"}, {"field": "BMI < 23 kg/m²?", "value": "No (BMI 32 kg/m²)"}], "final_answer": 45, "notes": "VT/VF Score\n5\nNon-arrhythmic Mortality Score\n1\nBenefit Score\n45\nBenefit Group\nIntermediate\nResult\nThe patient has an ICD Benefit Score of 45 (from a range of 0 to 100)\nPredicted risk of experiencing Life-threatening VT/VF at 3-years after ICD = 15%(13-17%)\nPredicated risk of death 3-years after ICD (not as a result of VT/VF) 9%(8-10%)"}]}
{"task_id": "medmcp-calc_091_24d8027d", "task_scenario": "Sepsis Screening (ED perspective)", "task_category": "Clinical Medicine / Emergency, Critical Care & Perioperative / Emergency Medicine & Trauma", "patient_id": "P091_24d8027d", "task_description": "Scenario: In the emergency department, a patient presents with suspected infection and concerning vital signs. The clinician must rapidly screen for sepsis, stratify risk, determine the need for blood cultures, and identify organ dysfunction and coagulopathy to guide level of care and early interventions. Use the following calculators in sequence, with explicit decision points linking one step to the next.\nStep 1: National Early Warning Score (NEWS) 2: Perform initial triage severity assessment to detect early physiological deterioration and prompt a sepsis screen. If NEWS2 is moderate/high, immediately activate a sepsis pathway and proceed to Step 2 and Step 4 without delay; if low, continue but maintain vigilance.\nStep 2: Shock Index: Screen for occult shock that may not be obvious on single vital signs. If the Shock Index is elevated, prioritize resuscitation and proceed directly to Step 4 even if NEWS2 is borderline; if not elevated, continue with standard progression.\nStep 3: Glasgow Coma Scale (GCS): Quantify mentation. The GCS result will feed the mentation component of qSOFA in the next step, ensuring an objective assessment of altered mental status.\nStep 4: qSOFA (Quick SOFA) Score for Sepsis: Rapidly risk-stratify for poor outcomes outside the ICU. If qSOFA is high (or if NEWS2 and/or Shock Index were elevated), deterministically trigger immediate diagnostic work-up and obtain labs to enable SOFA calculation (Step 7). If qSOFA is low and earlier screens were not concerning, proceed to Step 5 to evaluate for inflammatory criteria before escalation.\nStep 5: SIRS, Sepsis, and Septic Shock Criteria: Confirm systemic inflammation and categorize sepsis severity. If SIRS criteria are met with suspected infection, treat as possible sepsis and proceed to Step 6 to determine whether to draw blood cultures. If criteria for septic shock are met here, escalate level of care and continue to Step 7 as soon as labs are available.\nStep 6: Shapiro Rule: Decide whether blood cultures are indicated prior to antibiotics. If the Shapiro Rule suggests cultures are warranted, obtain cultures promptly; if not, and no other indications exist, cultures may be deferred per local policy.\nStep 7: Sequential Organ Failure Assessment (SOFA) Score: Once initial lab results are available, quantify organ dysfunction. If SOFA indicates an increase consistent with sepsis, confirm diagnosis and use the magnitude and trajectory to guide disposition (ED observation vs. admission vs. ICU). If SOFA is low and clinical status is stable, maintain close monitoring and reassess.\nStep 8: Sepsis-Induced Coagulopathy (SIC) Score: If SOFA shows significant organ dysfunction or there are clinical concerns for coagulopathy, calculate the SIC Score. A positive SIC Score indicates higher risk of sepsis-associated coagulopathy and prompts intensified monitoring and coagulopathy-focused management; if negative, continue standard monitoring.\nLinkages and deterministic triggers: GCS directly informs the mentation component of qSOFA. Elevated qSOFA and/or high NEWS2 and/or elevated Shock Index deterministically trigger early labs and subsequent SOFA calculation. SIRS positivity deterministically triggers the Shapiro Rule to decide on blood cultures. SOFA scoring feeds into the SIC Score, which uses organ dysfunction to refine coagulopathy risk.", "fuzzy_question": "I'm evaluating a patient in an acute care setting with a likely infection and worrisome vital signs: fever, tachycardia, relative hypotension, rapid breathing, increasing oxygen requirement, and decreased alertness. I'm deciding how aggressively to initiate a sepsis pathway versus a more measured approach, and I want this done promptly but thoughtfully.\n\nFirst, based on the initial vital signs and oxygen requirement, help me judge the risk of early physiological deterioration. If that overall triage picture is in the moderate-to-high range, don't wait: treat as sepsis, proceed with early resuscitation principles, and move directly to a rapid sepsis risk screen and early labs. If it is only mildly concerning, continue cautiously while keeping suspected infection high on the differential.\n\nI'm also interested in whether the balance of heart rate to systolic blood pressure suggests occult shock. If that hemodynamic balance appears worrisome, prioritize resuscitation and advance to the early sepsis risk screen and labs even if the initial triage impression felt borderline. If that balance is not notably abnormal, continue with the usual flow.\n\nFor mentation, I need an objective read on eye opening, verbal response, and motor response, because that will feed directly into the quick bedside sepsis risk check. Please make that mental status assessment explicit rather than using vague terms.\n\nNext, perform a quick bedside screen used outside the ICU to flag patients with suspected sepsis who might decompensate. If that screen is high — or if the initial triage picture and the heart-rate-to-blood-pressure balance are already concerning — go straight to a full diagnostic work-up and order labs to quantify organ dysfunction. If that bedside screen is low and earlier checks aren't raising red flags, pause and look for a classic systemic inflammatory pattern (temperature, pulse, breathing, white count) before escalating.\n\nIf the inflammatory picture fits and infection is suspected, treat as possible sepsis and, before starting antibiotics, use a structured pre-test approach to decide whether blood cultures are warranted. If that decision aid supports cultures, obtain them promptly; if not, and absent other indications, it is reasonable to defer per local practice. If at this point a shock phenotype is present, escalate level of care and be ready to assess organ dysfunction as soon as labs return.\n\nOnce labs are available — kidney and liver function, platelets, oxygenation/ABG, need for blood pressure support, lactate, and other relevant tests — provide a clear, objective picture of organ dysfunction and whether there is an acute change that would clinch sepsis. Use the magnitude and trend of dysfunction to guide disposition recommendations: observation, general admission, or ICU.\n\nIf organ dysfunction is significant or there are hints of bleeding/bruising or abnormal coagulation studies, check for sepsis-associated coagulation abnormalities using platelets, clotting times, and the organ dysfunction context. If positive, escalate monitoring and apply clotting-focused management; if negative, continue standard monitoring.\n\nAs you work through this, connect the dots: show how mental status feeds the bedside sepsis risk screen; how a worrisome early screen (or concerning triage picture or heart-rate-to-blood-pressure imbalance) triggers labs; how the inflammatory pattern influences the blood culture decision before antibiotics; and how the organ dysfunction assessment informs the coagulation risk check and level-of-care decisions. Don't just give a final label — walk through each checkpoint with the objective measures you're using. Use standardized calculations and scoring rather than clinical intuition alone; this needs to withstand scrutiny.", "required_calculators": ["National Early Warning Score (NEWS) 2", "Shock Index", "Glasgow Coma Scale (GCS)", "qSOFA (Quick SOFA) Score for Sepsis", "SIRS, Sepsis, and Septic Shock Criteria", "Shapiro Rule", "Sequential Organ Failure Assessment (SOFA) Score", "Sepsis-Induced Coagulopathy (SIC) Score"], "calculator_answers": [{"order": 1, "name": "National Early Warning Score (NEWS) 2", "inputs": [{"field": "respiratory_rate_breaths_per_min", "value": "28 breaths/min", "score": 3}, {"field": "hypercapnic_respiratory_failure", "value": "No"}, {"field": "SpO₂", "value": "92-93%", "score": 2}, {"field": "oxygen_supplementation", "value": "Yes (3 L/min via nasal cannula)", "score": 2}, {"field": "temperature_C", "value": "39.2 °C", "score": 2}, {"field": "systolic_bp_mmHg", "value": "96 mmHg", "score": 2}, {"field": "pulse_beats_per_min", "value": "122 bpm", "score": 2}, {"field": "consciousness", "value": "New-onset confusion/responds to voice", "score": 3}], "final_answer": 16, "notes": "16 points\nNational Early Warning Score\nHigh risk\nEmergent assessment by a clinical team or critical care team and usually transfer to higher level of care\nContinuous monitoring\nFrequency of monitoring"}, {"order": 2, "name": "Shock Index", "inputs": [{"field": "heart_rate_beats_per_min", "value": "122 bpm"}, {"field": "systolic_bp_mmHg", "value": "96 mmHg"}], "final_answer": 1.3, "notes": "0.5-0.7 is believed to be a normal shock index. Higher numbers have been shown to be more sensitive than vital signs alone in diagnosing occult shock, need for transfusion and/or operation."}, {"order": 3, "name": "Glasgow Coma Scale (GCS)", "inputs": [{"field": "best_eye_response", "value": "To verbal command (+3)", "score": 3}, {"field": "best_verbal_response", "value": "Confused (+4)", "score": 4}, {"field": "best_motor_response", "value": "Obeys commands (+6)", "score": 6}], "final_answer": 13, "notes": "13 points\nGlasgow Coma Score\nE(3) V(4) M(6)\nGlasgow Coma Scale"}, {"order": 4, "name": "qSOFA (Quick SOFA) Score for Sepsis", "inputs": [{"field": "altered_mental_status_GCS_less_than_15", "value": "Yes (GCS 13)"}, {"field": "respiratory_rate_≥22_per_min", "value": "Yes (28)"}, {"field": "systolic_bp_≤100_mmHg", "value": "Yes (96)"}], "final_answer": 3, "notes": "3 points\nqSOFA Score\nHigh risk\nqSOFA Scores 2-3 are associated with a 3- to 14-fold increase in in-hospital mortality. Assess for evidence of organ dysfunction with blood testing including serum lactate and calculation of the full SOFA Score.\nPatients meeting these qSOFA criteria should have infection considered even if it was previously not."}, {"order": 5, "name": "SIRS, Sepsis, and Septic Shock Criteria", "inputs": [{"field": "temp_gt_38C_or_lt_36C", "value": "Yes (39.2 °C)"}, {"field": "heart_rate_gt_90_bpm", "value": "Yes (122 bpm)"}, {"field": "resp_rate_gt_20_per_min_or_PaCO2_lt_32_mmHg", "value": "Yes (RR 28)"}, {"field": "WBC_gt_12000_lt_4000_or_bands_gt_10_percent", "value": "Yes (WBC 16.7 x10^3/µL with 12% bands)"}, {"field": "suspected_or_confirmed_infection", "value": "Yes (community-acquired pneumonia suspected)"}, {"field": "severe_sepsis_criteria_lactate_or_hypotension", "value": "Yes (initial lactate 3.6 mmol/L)"}, {"field": "septic_shock_persistent_hypotension_despite_fluids", "value": "No (SBP improved with fluids; no vasopressors initially)"}, {"field": "multiple_organ_dysfunction_≥2_organs", "value": "Yes (respiratory, renal, hepatic, cardiovascular)"}], "final_answer": "This patient meets multiple organ dysfunction syndrome. Follow your guidelines for sepsis, which typically include aggressive fluid resuscitation, early, broad-spectrum antibiotics, ICU consultation, CVP evaluation, and occasionally pressors and transfusion.", "notes": "This patient meets multiple organ dysfunction syndrome. Follow your guidelines for sepsis, which typically include aggressive fluid resuscitation, early, broad-spectrum antibiotics, ICU consultation, CVP evaluation, and occasionally pressors and transfusion."}, {"order": 6, "name": "Shapiro Rule", "inputs": [{"field": "age_years", "value": "68", "score": 1}, {"field": "temperature_C", "value": "39.2 °C", "score": 1}, {"field": "suspect_endocarditis", "value": "No", "score": 0}, {"field": "indwelling_vascular_catheter", "value": "No", "score": 0}, {"field": "chills", "value": "Yes (rigors reported)", "score": 1}, {"field": "vomiting", "value": "Yes", "score": 1}, {"field": "hypotension_SBP_lt_90_mmHg", "value": "No (SBP 96 mmHg)", "score": 0}, {"field": "WBC_gt_18000_per_mm3", "value": "No (16,700/mm³)", "score": 0}, {"field": "bands_gt_5_percent", "value": "Yes (12%)", "score": 1}, {"field": "platelets_lt_150000_per_mm3", "value": "Yes (135,000/mm³)", "score": 1}, {"field": "creatinine_gt_2_0_mg_per_dL", "value": "Yes (2.1 mg/dL)", "score": 1}], "final_answer": 7, "notes": "Major criteria: 0\nMinor criteria: 7\nBy the Shapiro Rule, a blood culture is indicated."}, {"order": 7, "name": "Sequential Organ Failure Assessment (SOFA) Score", "inputs": [{"field": "PaO2_mmHg", "value": "65 mmHg (ABG on O2)"}, {"field": "FiO2_percent", "value": "32%"}, {"field": "on_mechanical_ventilation_including_CPAP", "value": "No"}, {"field": "platelets_x10^3_per_uL", "value": "135 x10^3/µL", "score": 1}, {"field": "Glasgow_Coma_Scale_total", "value": "13", "score": 1}, {"field": "bilirubin_mg_per_dL", "value": "2.6 mg/dL", "score": 2}, {"field": "mean_arterial_pressure_mmHg", "value": "66 mmHg", "score": 1}, {"field": "vasoactive_agents_administered", "value": "None"}, {"field": "creatinine_mg_per_dL", "value": "2.1 mg/dL", "score": 2}], "final_answer": 9, "notes": "Initial SOFA Scores ≤9 predict ≤33.3% mortality (see Evidence for details)"}, {"order": 8, "name": "Sepsis-Induced Coagulopathy (SIC) Score", "inputs": [{"field": "INR", "value": "1.5", "score": 2}, {"field": "platelet_count_x10^9_per_L", "value": "135 x10^9/L", "score": 1}, {"field": "total_SOFA_resp_plus_cardio_plus_hepatic_plus_renal", "value": "7", "score": 2}], "final_answer": 5, "notes": "32% approximate 28-day mortality\nSIC likely\nDiagnosis of SIC"}]}
{"task_id": "medmcp-calc_092_e9b5945f", "task_scenario": "Fluid Therapy and Electrolytes", "task_category": "Clinical Medicine / Special Populations & General Tools / Pediatrics & Neonatology", "patient_id": "P092_e9b5945f", "task_description": "Scenario: A child under five presents with acute diarrhea, reduced intake, and clinical signs of dehydration. The care team must assess severity, identify tonicity and acid–base disturbances, quantify electrolyte and fluid deficits, plan safe correction rates, provide maintenance fluids with adequate dextrose, and monitor ongoing losses. The workflow uses multiple calculators to structure decisions and ensure safety.\n\nStep-by-step use of calculators:\n1) Dehydration: Assessing Kids Accurately (DHAKA) Score: Classify dehydration (none/mild/moderate/severe) at triage. This determines the initial route and urgency of rehydration. If mild, proceed with oral rehydration and close monitoring; if moderate to severe, proceed with IV therapy and the subsequent calculators below.\n2) Serum Osmolality/Osmolarity: Estimate expected serum osmolarity to classify the tonicity of the presentation and confirm true dysnatremia versus pseudodisturbances. This step triggers the branch to either hyponatremia or hypernatremia pathways.\n3) Serum Anion Gap: Evaluate for metabolic acidosis due to diarrheal bicarbonate losses (typically non-gap) versus other causes (gap). This determines whether bicarbonate replacement should be considered later.\n4) Conditional branch A (true hyponatremia based on tonicity assessment): Use Sodium Deficit in Hyponatremia to quantify the sodium deficit to be corrected.\n5) Conditional branch B (hypernatremia based on tonicity assessment): Use Free Water Deficit in Hypernatremia to quantify the free water deficit to be replaced.\n6) Sodium Correction Rate in Hyponatremia and Hypernatremia: Using the quantified deficit from step 4 or 5 and the desired safe correction rate, determine the recommended IV fluid type, rate, and volume. This output provides the infusion parameters that will be combined with maintenance needs and checked for dextrose delivery safety.\n7) Conditional branch from step 3 (non-gap acidosis consistent with diarrheal losses): Use Bicarbonate Deficit to estimate the amount of bicarbonate needed if clinically indicated, and integrate that into the fluid plan. If a gap acidosis is present, defer bicarbonate replacement and focus on underlying cause while continuing fluid/electrolyte correction.\n8) Maintenance Fluids Calculations: Calculate the baseline maintenance fluid requirement by weight. Combine this with the deficit replacement plan from step 6 (and bicarbonate plan from step 7 if used) to finalize the total infusion plan.\n9) Glucose Infusion Rate (GIR): Using the selected fluid composition and total infusion rate, verify that the dextrose delivery is appropriate for the child's age and clinical status. If the GIR is outside the target range, adjust the fluid composition or rate and re-check.\n10) Pediatric Ins and Outs: Monitor intake and output over time in volume per weight and per time to assess response. If ongoing losses are substantial or urine output is inadequate, update the plan: revisit deficit calculations (steps 4–6) and adjust maintenance (step 8) and GIR (step 9) accordingly. If the child stabilizes with adequate urine output and improving balance, taper deficit replacement and transition toward maintenance and oral rehydration.\n\nThis sequence ensures initial severity assessment, appropriate tonicity and acid–base classification, precise deficit quantification, safe correction rate planning, maintenance support, dextrose safety, and continuous monitoring with iterative adjustments.", "fuzzy_question": "I’m seeing a pediatric patient with acute watery diarrhea, poor intake, dry mucosa, and tachycardia. I’m trying to determine the safest way to rehydrate and at what pace. At the bedside I’m not confident if this is only mild dehydration or drifting into moderate/severe, and that call will decide whether we push oral rehydration with close observation or move straight to IV in a more urgent way. What’s your take on how to make that severity call up front and choose the initial route?\n\nRecent labs suggest the sodium may be off, but I want to confirm the tonicity first—does the overall picture (sodium with glucose and urea) fit with true dysnatremia, or could this be a pseudo issue? That branch matters: if it’s truly low sodium, I’d want to know how much sodium the patient is actually short and plan replacement around that; if it’s truly high sodium, I’d want to work out the free water deficit to replace. Either way, I’m keen to set a safe pace for how quickly the sodium changes over the next hours to day, and translate that into a concrete fluid choice, rate, and total volume that also covers maintenance—spelled out so we’re not moving sodium too fast.\n\nBicarbonate is low, which could reflect diarrheal loss. I’m wondering whether this looks like a non-gap picture where we might thoughtfully include some bicarbonate, or if there’s a gap that should steer us away from giving bicarb and toward finding the underlying cause while we keep correcting fluids and electrolytes. For day-to-day management, I’d like maintenance based on weight folded into the deficit plan so the total infusion makes sense for a pediatric patient. Given pediatric considerations, I also want reassurance that the dextrose content is appropriate—specifically that the actual sugar delivery per kilogram per minute stays in the right range; if it’s off, tweak the composition or rate and re-check.\n\nFinally, I want a practical plan to track intake and output in mL/kg/hr—stool, emesis, and urine—and use that to adjust. If ongoing losses stay heavy or urine lags, circle back and update the deficits, maintenance, and dextrose delivery; if urine picks up and the balance improves, start tapering the deficit replacement and move toward maintenance and oral rehydration. I want to avoid complications from over- or under-correction. What’s your clinical reasoning and plan? I need proper calculations on this—can’t make this decision based on gut feeling alone. Whatever approach you suggest, make sure it’s backed by solid calculations. This needs to hold up to scrutiny.", "required_calculators": ["Dehydration: Assessing Kids Accurately (DHAKA) Score", "Serum Osmolality/Osmolarity", "Serum Anion Gap", "Sodium Deficit in Hyponatremia", "Free Water Deficit in Hypernatremia", "Sodium Correction Rate in Hyponatremia and Hypernatremia", "Bicarbonate Deficit", "Maintenance Fluids Calculations", "Glucose Infusion Rate (GIR)", "Pediatric Ins and Outs"], "calculator_answers": [{"order": 1, "name": "Dehydration: Assessing Kids Accurately (DHAKA) Score", "inputs": [{"field": "General appearance", "value": "Restless/irritable (+2)", "score": 2}, {"field": "Respirations", "value": "Normal (0)", "score": 0}, {"field": "Skin pinch", "value": "Slow (+2)", "score": 2}, {"field": "Tears", "value": "Decreased (+1)", "score": 1}], "final_answer": 5, "notes": "5 points\nDHAKA Score\nSevere dehydration\nDehydration category"}, {"order": 2, "name": "Serum Osmolality/Osmolarity", "inputs": [{"field": "Sodium", "value": "152 mEq/L"}, {"field": "BUN", "value": "22 mg/dL"}, {"field": "Glucose", "value": "72 mg/dL"}, {"field": "Serum alcohol concentration", "value": "0 mg/dL"}, {"field": "Measured serum osm", "value": "316 mOsm/kg"}], "final_answer": 316, "notes": "316 mOsm/kg Calculated Serum Osm\nNormal serum osmolality = 285-295 mOsm/kg\n0.0 mOsm/kg Osm Gap\nNormal Serum Osm Gap (Measured-Calculated) is -14 to +10."}, {"order": 3, "name": "Serum Anion Gap", "inputs": [{"field": "Sodium", "value": "152 mEq/L"}, {"field": "Chloride", "value": "124 mEq/L"}, {"field": "Bicarbonate", "value": "16 mEq/L"}, {"field": "Albumin", "value": "4.2 g/dL"}], "final_answer": "12.0 mEq/L", "notes": "12.0 mEq/L\nAnion gap\nDelta gap: 0.0 mEq/L\nDelta ratio: 0.0; Pure normal anion gap acidosis\n11.5 mEq/L\nAlbumin corrected anion gap; suggests non-anion gap acidosis\nAlbumin corrected delta gap: -0.5 mEq/L\nAlbumin corrected delta ratio: -0.1"}, {"order": 4, "name": "Sodium Deficit in Hyponatremia", "inputs": [{"field": "Sex", "value": "Male"}, {"field": "Age range", "value": "Child"}, {"field": "Weight", "value": "27.6 lbs"}, {"field": "Sodium", "value": "152 mEq/L"}, {"field": "Desired sodium", "value": "140"}], "final_answer": "-75.1 mEq", "notes": "-75.1 mEq\nSodium Deficit"}, {"order": 5, "name": "Free Water Deficit in Hypernatremia", "inputs": [{"field": "Sex", "value": "Male"}, {"field": "Age range", "value": "Child"}, {"field": "Weight", "value": "27.6 lbs"}, {"field": "Sodium", "value": "152 mEq/L"}, {"field": "Sodium desired", "value": "142 mEq/L"}], "final_answer": "0.5L", "notes": "0.5 L\nFree Water Deficit"}, {"order": 6, "name": "Sodium Correction Rate in Hyponatremia and Hypernatremia", "inputs": [{"field": "Sex", "value": "Male"}, {"field": "Age range", "value": "Child"}, {"field": "Weight", "value": "27.6 lbs"}, {"field": "Serum sodium", "value": "152 mEq/L"}, {"field": "Fluid type", "value": "0.45% saline (77 mmol/L Na)"}, {"field": "Rate of sodium correction", "value": "0.4 mEq/L/hr"}], "final_answer": "45 mL/hr", "notes": "45 mL/hr\nFluid rate to decrease Na by 0.4 mmol/L/hr with 0.45% saline"}, {"order": 7, "name": "Bicarbonate Deficit", "inputs": [{"field": "Weight", "value": "27.6 lbs"}, {"field": "Bicarbonate", "value": "16 mEq/L"}], "final_answer": "40.1 mEq", "notes": "40.1 mEq\nBicarbonate Deficit"}, {"order": 8, "name": "Maintenance Fluids Calculations", "inputs": [{"field": "Weight", "value": "27.6 lbs"}], "final_answer": "45 mL/hr", "notes": "45 mL/hr\nMaintenance fluids\n68 mL/hr\nMaintenance fluids x 1.5\n251 mL\nFluid bolus (20 mL/kg)"}, {"order": 9, "name": "Glucose Infusion Rate (GIR)", "inputs": [{"field": "Dextrose concentration", "value": "5 g/dL (D5)"}, {"field": "Infusion rate", "value": "60 mL/hr"}, {"field": "Weight", "value": "27.6 lbs"}], "final_answer": "4.0 mg/kg/min", "notes": "4.0 mg/kg/min\nGIR"}, {"order": 10, "name": "Pediatric Ins and Outs", "inputs": [{"field": "Weight", "value": "27.6 lbs"}, {"field": "Volume to be calculated", "value": "180 mL"}, {"field": "Period of time", "value": "4 hours"}], "final_answer": "3.6 mL/kg/hour", "notes": "14.4 mL/kg\nVolume Per Weight\n3.6 mL/kg/hour\nVolume Per Weight Per Hour"}]}
{"task_id": "medmcp-calc_093_839d283f", "task_scenario": "Consciousness and Coma Assessment", "task_category": "Clinical Medicine / Neurology & Mental Health / Neurosurgery & Neurology", "patient_id": "P093_839d283f", "task_description": "Scenario: An adult ICU patient is admitted after a sudden collapse and is now unresponsive with airway secured and sedation recently administered. The care team must objectively grade coma severity, identify the most likely neurologic etiology (traumatic brain injury, ischemic stroke, or subarachnoid hemorrhage), optimize cerebral perfusion, monitor for delirium during recovery, and set functional goals for disposition.\n\nStep-by-step workflow using calculators:\n1) Start with the Richmond Agitation-Sedation Scale (RASS) to determine whether current sedation or agitation will confound the neurologic exam and whether an intubated/nonverbal condition exists.\n2) Branch based on RASS: If sedation or intubation limits verbal testing, use the FOUR (Full Outline of UnResponsiveness) Score to grade coma without reliance on verbal response; otherwise, use the Glasgow Coma Scale (GCS) for the initial coma severity.\n3) If the initial coma scale (FOUR or GCS) indicates severe coma, compute the GCS-Pupils Score to incorporate pupil reactivity and refine severity/prognostic understanding at low levels of consciousness.\n4) If the GCS-Pupils Score and/or the initial coma scale suggest a risk of intracranial hypertension or impaired perfusion, begin hemodynamic optimization guided by the Cerebral Perfusion Pressure calculator to ensure adequate cerebral blood flow during acute management.\n5) Etiology triage after imaging and clinical context:\n   - If traumatic brain injury is present, use the IMPACT Score for Outcomes in Head Injury to estimate 6‑month mortality/unfavorable outcome and inform family counseling and neurocritical care intensity.\n   - If findings indicate ischemic stroke or focal deficits are evident, calculate the NIH Stroke Scale/Score (NIHSS) to quantify stroke severity, guide monitoring frequency, and trajectory.\n   - If subarachnoid hemorrhage is identified, apply the Modified Fisher Grading Scale for Subarachnoid Hemorrhage (SAH) to grade hemorrhage burden and anticipate vasospasm risk, shaping surveillance and perfusion strategy.\n6) As sedation is minimized and the patient becomes more interactive, use the Confusion Assessment Method for the ICU (CAM-ICU) to detect delirium; a positive result prompts targeted delirium management and re-titration of sedation while maintaining an appropriate RASS target.\n7) Prior to transition of care, assess global functional status with the Modified Rankin Score-9Q (mRS-9Q) to quantify disability for discharge planning and rehabilitation needs; earlier etiologic severity scores (IMPACT, NIHSS, Modified Fisher) guide expectations and goals for mRS improvement.\n\nClinical rationale for sequence: RASS prevents misinterpretation of coma from sedation. FOUR or GCS provide the primary severity estimate, with GCS-Pupils enhancing accuracy when responses are minimal. CPP calculation operationalizes physiologic management in severe cases. Etiology-specific scores (IMPACT, NIHSS, Modified Fisher) direct prognostication and complication surveillance. CAM-ICU distinguishes delirium during recovery. mRS-9Q standardizes the functional endpoint for disposition decisions.", "fuzzy_question": "I’m evaluating a patient in a critical care setting after an acute collapse. The airway is secured with endotracheal intubation, sedation is in place, and there is no meaningful responsiveness. I’m trying to distinguish medication effects from true neurologic injury and get an honest, objective read on coma depth.\n\nFirst, I need a quick sense of current arousal and agitation, with an explicit target for where we want the patient to be. Are the current medications likely to mask the exam, and to what extent? Given intubation, clarify whether any attempt at command following or purposeful movement is possible so we don’t misinterpret lack of speech as impaired brainstem or cortical function.\n\nDepending on whether verbal participation is feasible, please grade coma using an approach that does not rely on verbal output if needed; if verbal participation is possible, use the usual eye–verbal–motor framework. Provide the objective grade along with the component bedside findings used to derive it. If the grade is very low, please include pupil size and reactivity to refine how severe this is and what that implies in the near term.\n\nIf that combination raises concern for elevated intracranial pressure or marginal cerebral perfusion, I want to actively manage the pressure driving blood into the brain. Walk me through the targets you’d set using arterial pressure and either measured or best‑estimated intracranial pressure, how you’d adjust fluids, vasopressors, and sedation in real time, and how you’d recheck and retune those targets while keeping arousal where we want it.\n\nOnce imaging and the clinical context clarify the cause, help me triage it. If this is trauma, I’m looking for a structured estimate of medium‑term mortality and the likelihood of an unfavorable outcome to guide family conversations and the intensity of neurocritical care. If it’s an ischemic stroke or the exam shows clear focal deficits, I want a quantified severity that informs monitoring frequency and anticipated trajectory. If it’s a subarachnoid hemorrhage, please grade the hemorrhage burden—including whether blood is layering in the ventricles—so we can anticipate vasospasm risk and tailor both surveillance and our perfusion strategy.\n\nAs sedation is lightened and interaction improves, please screen for ICU delirium. If it’s positive, retune sedation and address modifiable contributors, while keeping the arousal target appropriate for safe neurologic monitoring.\n\nBefore transition of care, I want a simple, global functional disability grade based on independence in daily activities to anchor discharge planning and rehabilitation needs. Use the earlier severity assessments (whether trauma, stroke, or subarachnoid hemorrhage) to set realistic goals for target functional status.\n\nWhat’s your take and how would you reason through this? I need proper, validated calculations—this can’t rest on clinical impression alone. Whatever approach you suggest, please back it with solid calculations so it holds up to scrutiny.", "required_calculators": ["Richmond Agitation-Sedation Scale (RASS)", "FOUR (Full Outline of UnResponsiveness) Score", "Glasgow Coma Scale (GCS)", "GCS-Pupils Score", "Cerebral Perfusion Pressure", "IMPACT Score for Outcomes in Head Injury", "NIH Stroke Scale/Score (NIHSS)", "Modified Fisher Grading Scale for Subarachnoid Hemorrhage (SAH)", "Confusion Assessment Method for the ICU (CAM-ICU)", "Modified Rankin Score-9Q (mRS-9Q)"], "calculator_answers": [{"order": 1, "name": "Richmond Agitation-Sedation Scale (RASS)", "inputs": [{"field": "Patient description", "value": "Deep sedation (-4)", "score": -4}], "final_answer": -4, "notes": "-4 points\nPatients with a RASS of ≤-3 should have their sedation decreased or modified in order to achieve a RASS of -2 to 0."}, {"order": 2, "name": "FOUR (Full Outline of UnResponsiveness) Score", "inputs": [{"field": "Eye response", "value": "Eyelids closed but open to pain (+1)", "score": 1}, {"field": "Motor response (upper extremities)", "value": "Flexion response to pain (+2)", "score": 2}, {"field": "Brainstem reflexes", "value": "One pupil wide and fixed (+3)", "score": 3}, {"field": "Respiration pattern", "value": "Breathes at ventilator rate or apnea (0)", "score": 0}], "final_answer": 6, "notes": "6 points\nE1 M2 B3 R0\nLower scores indicate higher coma severity."}, {"order": 3, "name": "Glasgow Coma Scale (GCS)", "inputs": [{"field": "Best eye response", "value": "To pain (+2)", "score": 2}, {"field": "Best verbal response", "value": "Not testable/intubated (NT)"}, {"field": "Best motor response", "value": "Flexion to pain (+3)", "score": 3}], "final_answer": "E(2) V(NT) M(3)", "notes": "Glasgow Coma Score cannot be calculated (one or more components not testable)\nE(2) V(NT) M(3)\nGlasgow Coma Scale"}, {"order": 4, "name": "GCS-Pupils Score", "inputs": [{"field": "Eye response", "value": "Eye opening to pain (+2)", "score": 2}, {"field": "Verbal response", "value": "Intubated (+1)", "score": 1}, {"field": "Motor response", "value": "Flexion to pain (+3)", "score": 3}, {"field": "Pupil response", "value": "One pupil unreactive to light (-1)", "score": -1}], "final_answer": 5, "notes": "5 points\nGCS-Pupils Score\n32.57 %\nMortality at 6 months post-injury\n57.75 %\nUnfavorable outcome (vegetative state or severe disability) at 6 months post-injury"}, {"order": 5, "name": "Cerebral Perfusion Pressure", "inputs": [{"field": "MAP", "value": "85 mm Hg"}, {"field": "ICP", "value": "28 mm Hg"}], "final_answer": "57 mmHg", "notes": "57 mmHg\nLow CPP. Consider interventions to increase MAP or decrease ICP (see Next Steps for details)."}, {"order": 6, "name": "IMPACT Score for Outcomes in Head Injury", "inputs": [{"field": "Information available", "value": "H&P, CT, and labs (lab model)"}, {"field": "Age (years)", "value": 56}, {"field": "Motor score (GCS M)", "value": "M3 (flexion to pain)", "score": 3}, {"field": "Pupillary reactivity", "value": "One pupil unreactive"}, {"field": "Hypotension at presentation (SBP <90 mm Hg)", "value": "No"}, {"field": "Hypoxia at presentation (SpO2 <90% or PaO2 <60 mm Hg)", "value": "No"}, {"field": "CT: Marshall classification", "value": "Diffuse injury II (cisterns present, midline shift 0–5 mm, no mass lesion)"}, {"field": "CT: Traumatic subarachnoid hemorrhage", "value": "No"}, {"field": "CT: Epidural hematoma", "value": "No"}, {"field": "CT: Non-evacuated mass lesion", "value": "No"}, {"field": "Lab: Hemoglobin", "value": "13.2 g/dL"}, {"field": "Lab: Glucose", "value": "148 mg/dL"}], "final_answer": "52.9 %", "notes": "52.9 %\nProbability of 6-month mortality (core model)\nProbability of 6-month unfavorable outcome: 78.9% (core model)\n28.7 %\nProbability of 6-month mortality (extended model)\nProbability of 6-month unfavorable outcome: 61.3% (extended model)\n18.1 %\nProbability of 6-month mortality (lab model)\nProbability of 6-month unfavorable outcome: 50.5% (lab model)"}, {"order": 7, "name": "NIH Stroke Scale/Score (NIHSS)", "inputs": [{"field": "1A: Level of consciousness", "value": "Postures or unresponsive (+3)", "score": 3}, {"field": "1B: Ask month and age", "value": "Dysarthric/intubated/trauma/language barrier (+1)", "score": 1}, {"field": "1C: 'Blink eyes' & 'squeeze hands'", "value": "Performs 0 tasks (+2)", "score": 2}, {"field": "2: Horizontal extraocular movements", "value": "Partial gaze palsy: corrects with oculocephalic reflex (+1)", "score": 1}, {"field": "3: Visual fields", "value": "Complete hemianopia (+2)", "score": 2}, {"field": "4: Facial palsy", "value": "Partial paralysis (lower face) (+2)", "score": 2}, {"field": "5A: Left arm motor drift", "value": "Some effort against gravity (+2)", "score": 2}, {"field": "5B: Right arm motor drift", "value": "No movement (+4)", "score": 4}, {"field": "6A: Left leg motor drift", "value": "Some effort against gravity (+2)", "score": 2}, {"field": "6B: Right leg motor drift", "value": "No movement (+4)", "score": 4}, {"field": "7: Limb ataxia", "value": "Does not understand (0)", "score": 0}, {"field": "8: Sensation", "value": "Coma/unresponsive (+2)", "score": 2}, {"field": "9: Language/aphasia", "value": "Coma/unresponsive (+3)", "score": 3}, {"field": "10: Dysarthria", "value": "Intubated/unable to test (0)", "score": 0}, {"field": "11: Extinction/inattention", "value": "Extinction to >1 modality (+2)", "score": 2}], "final_answer": 30, "notes": "30 points\nNIH Stroke Scale"}, {"order": 8, "name": "Modified Fisher Grading Scale for Subarachnoid Hemorrhage (SAH)", "inputs": [{"field": "SAH pattern on CT", "value": "Focal or diffuse thick SAH (≥1 mm)"}, {"field": "Intraventricular hemorrhage (IVH) present", "value": "Yes"}], "final_answer": "Grade IV", "notes": "Grade IV\n34-40% probability of symptomatic vasospasm."}, {"order": 9, "name": "Confusion Assessment Method for the ICU (CAM-ICU)", "inputs": [{"field": "Level of Consciousness: RASS ≥ -3 (sufficient to assess)", "value": "Yes"}, {"field": "Patient different than baseline, pre-hospital mental status", "value": "Yes"}, {"field": "Patient with fluctuating mental status in past 24 hours by fluctuation of level of consciousness/sedation", "value": "No"}], "final_answer": "CAM-ICU negative", "notes": "CAM-ICU negative\nDelirium absent."}, {"order": 10, "name": "Modified Rankin Score-9Q (mRS-9Q)", "inputs": [{"field": "Q1: Any symptoms bothering you?", "value": "Yes"}, {"field": "Q2: Able to do the same work as before?", "value": "No"}, {"field": "Q3: Able to keep up with hobbies?", "value": "No"}, {"field": "Q4: Maintained ties to friends and family?", "value": "Yes"}, {"field": "Q5: Need help making a simple meal/household chores/checkbook?", "value": "Yes"}, {"field": "Q6: Need help with shopping or traveling close to home?", "value": "Yes"}, {"field": "Q7: Need another person to help you walk?", "value": "Yes"}, {"field": "Q8: Need help with eating, going to the toilet, or bathing?", "value": "Yes"}, {"field": "Q9: Stay in bed most of the day and need constant nursing care?", "value": "No"}], "final_answer": 4, "notes": "mRS = 4\nModified Rankin Scale\nModerately severe disability\nUnable to attend to own bodily needs without assistance, and unable to walk unassisted."}]}
{"task_id": "medmcp-calc_094_92247846", "task_scenario": "Glomerular Filtration Rate (GFR) Assessment", "task_category": "Clinical Medicine / Medicine & Organ Systems / Nephrology & Electrolytes", "patient_id": "P094_92247846", "task_description": "Scenario: An adult with known chronic kidney disease (CKD) presents after a recent illness with fluctuating creatinine. You must determine the most accurate current kidney function to guide immediate medication dosing, confirm CKD staging, counsel on prognosis if kidney function is severely reduced, and implement guideline-based management.\n\nStep-by-step calculator sequence and decision points:\n1) Establish current filtration in the setting of possible dynamic kidney function:\n   - If creatinine has been changing over a short interval (suggesting non–steady state), use the Kinetic Estimated Glomerular Filtration Rate (keGFR) to approximate current GFR in real time.\n   - Else (creatinine stable), use the CKD-EPI Equations for Glomerular Filtration Rate (GFR) as the primary estimate for staging and baseline comparison.\n2) Refine accuracy at low GFR: If the initial eGFR suggests moderately to severely decreased function or is borderline for key thresholds, compute the Mayo Quadratic eGFR to cross-validate accuracy in CKD.\n   - Branch A (concordant estimates): If CKD-EPI and Mayo Quadratic are in close agreement, proceed with this consensus as the working GFR.\n   - Branch B (discordant or borderline): If these estimators diverge meaningfully or straddle critical thresholds (staging or dosing), plan to adjudicate with a measured clearance in Step 4.\n3) Determine drug-dosing clearance: Calculate Creatinine Clearance (Cockcroft-Gault Equation) because many prescribing references use CrCl-based cutoffs.\n   - If the Cockcroft-Gault result clearly falls within an unambiguous dosing category, proceed with dosing.\n   - If the Cockcroft-Gault CrCl is near a dosing breakpoint or conflicts with the eGFR estimates from Steps 1–2, confirm with a measured clearance in Step 4.\n4) Resolve uncertainty with a measured clearance: Use CrCl from 24h Urine to adjudicate when estimates are discordant or near critical cut points. Use this measured result to finalize medication dosing and CKD staging decisions.\n5) Prognostication for severe CKD: If the final best estimate of GFR (from keGFR/CKD-EPI/Mayo and, if used, measured CrCl) indicates severely decreased kidney function, use Clinical outcomes in CKD with severely decreased GFR to estimate risks and timing of adverse outcomes. This output informs urgency of nephrology referral, education about kidney replacement therapy, and advance care planning.\n6) Guideline-based care plan: Apply Chronic Kidney Disease Management: BC Guidelines to construct a stage-appropriate management plan (e.g., blood pressure targets, RAAS blockade considerations, SGLT2 use where appropriate, monitoring frequency, vaccination, mineral bone disease screening, and referral criteria) based on the finalized GFR and risk profile.\n7) Dialysis-related branch: If the outcomes model and clinical trajectory indicate imminent kidney replacement therapy or the patient is already on dialysis with ongoing urine output, use Residual Kidney Function to quantify remaining native clearance for dialysis adequacy targets and fluid management. Reassess periodically as guided by risk trajectory and clinical status.", "fuzzy_question": "I’m evaluating a patient with chronic kidney disease who recently recovered from an intercurrent illness and now has fluctuating creatinine on serial labs. I need to determine current kidney function to dose renally cleared medications safely, ensure accurate CKD staging, and set expectations if function is drifting into a very low range.\n\nI’m concerned the usual estimating formulas may lag during non–steady state when creatinine is changing. If creatinine is still shifting over short intervals, I’d like a near–real-time assessment of filtration that accounts for the direction and speed of change and the time between draws, so immediate dosing isn’t off. If results appear stable and we’re back at steady state, I’m comfortable using the standard approach for CKD staging and comparing with historical baseline.\n\nIf the estimate falls in the moderate-to-severely reduced range or near thresholds that would alter stage or medication dosing, I want a second estimate that performs better at lower kidney function. If the results align reasonably, we’ll use that consensus as the working value. If they diverge or straddle decision-changing thresholds, we should reconcile with a direct measurement using a timed urine collection to finalize both staging and dosing.\n\nFor prescribing now, I also need a creatinine clearance estimate commonly used in medication references. Please estimate it thoughtfully, selecting an appropriate weight approach given body size, recent weight changes, and potential muscle loss. If that clearance clearly fits a single dosing bracket, we can proceed. If it hovers near a breakpoint or conflicts with other kidney function estimates, that’s another scenario to confirm with a timed urine collection and dose based on the measured result.\n\nIf the best estimate indicates severely reduced function, I’d like a clear, numbers-based sense of prognosis—risk of progression to kidney failure, cardiovascular events, and mortality over the coming months to years—to guide how urgent a nephrology referral should be and to start education about dialysis and transplant options and advance care planning if appropriate.\n\nThen, based on the finalized stage and risk (including the albumin-to-creatinine ratio), I’d like a practical, guideline-driven care plan: blood pressure targets and agent choices (including when an ACE inhibitor or ARB is appropriate if albuminuria is present, with potassium monitoring and mitigation strategies), candidacy for an SGLT2 inhibitor, diuretic strategy, statin and antiplatelet considerations, glycemic targets if diabetes is present, anemia evaluation and when to consider ESAs, bone–mineral disorder screening (calcium, phosphate, PTH, vitamin D) and how to act on it, screening for metabolic acidosis and whether to use alkali therapy, tailored dietary advice (sodium, protein, potassium as appropriate), avoidance of nephrotoxins, vaccinations to update, and a monitoring schedule tied to stage and albumin category. Please also flag clear triggers for earlier nephrology input—such as a rapid decline in kidney function, heavy albuminuria, refractory hypertension or hyperkalemia, persistent acidosis, or diagnostic uncertainty.\n\nIf the patient is approaching kidney replacement therapy—or is already on dialysis with residual urine output—I’d like to quantify residual native function and incorporate that into dialysis dosing and fluid removal targets, with a plan for periodic reassessment as the condition evolves.\n\nWhat’s your clinical approach here? Walk me through the reasoning in sequence, and show the calculations at each step and how they drive the next decision. The proposal should be rigorous enough to withstand pharmacy and nephrology scrutiny.", "required_calculators": ["Kinetic Estimated Glomerular Filtration Rate (keGFR)", "CKD-EPI Equations for Glomerular Filtration Rate (GFR)", "Mayo Quadratic eGFR", "Creatinine Clearance (Cockcroft-Gault Equation)", "CrCl from 24h Urine", "Clinical outcomes in CKD with severely decreased GFR", "Chronic Kidney Disease Management: BC Guidelines", "Residual Kidney Function"], "calculator_answers": [{"order": 1, "name": "Kinetic Estimated Glomerular Filtration Rate (keGFR)", "inputs": [{"field": "Sex", "value": "Male"}, {"field": "Age", "value": "62 years"}, {"field": "Baseline creatinine", "value": "2.0 mg/dL"}, {"field": "First recorded creatinine (Cr1)", "value": "3.1 mg/dL"}, {"field": "Second recorded creatinine (Cr2)", "value": "2.7 mg/dL"}, {"field": "Time between both creatinine measurements", "value": "24 hours"}, {"field": "Black race", "value": "No"}], "final_answer": "23.5 mL/min", "notes": "KeGFR of 30 mL/min is 90% specific (71% sensitive) for AKI, according to one small retrospective study (O'Sullivan 2017)"}, {"order": 2, "name": "CKD-EPI Equations for Glomerular Filtration Rate (GFR)", "inputs": [{"field": "Equation", "value": "2021 CKD-EPI Creatinine"}, {"field": "Sex", "value": "Male"}, {"field": "Age", "value": "62 years"}, {"field": "Serum creatinine", "value": "2.7 mg/dL"}], "final_answer": "26 ml/min/1.73 m²", "notes": "26 ml/min/1.73 m²\nEstimated GFR by 2021 CKD-EPI Creatinine\nStage IV\nCKD stage by CKD-EPI Creatinine"}, {"order": 3, "name": "Mayo Quadratic eGFR", "inputs": [{"field": "Gender", "value": "Male"}, {"field": "Age", "value": "62 years"}, {"field": "Creatinine", "value": "2.7 mg/dL"}], "final_answer": "23.1 mL/min/1.73m²", "notes": "eGFR\n23.1 mL/min/1.73m²"}, {"order": 4, "name": "Creatinine Clearance (Cockcroft-Gault Equation)", "inputs": [{"field": "Sex", "value": "Male"}, {"field": "Age", "value": "62 years"}, {"field": "Weight", "value": "175 lb"}, {"field": "Creatinine", "value": "2.7 mg/dL"}, {"field": "Height", "value": "69 in"}], "final_answer": "32 mL/min", "notes": "32 mL/min\nCreatinine clearance, original Cockcroft-Gault\n30 mL/min\nCreatinine clearance modified for overweight patient, using adjusted body weight of 74 kg (164 lbs).\n28.4-29.8 mL/min\nNote: This range uses IBW and adjusted body weight. Controversy exists over which form of weight to use."}, {"order": 5, "name": "CrCl from 24h Urine", "inputs": [{"field": "Urine Creatinine", "value": "95 mg/dL"}, {"field": "Plasma Creatinine", "value": "2.7 mg/dL"}, {"field": "Urine Volume", "value": "1200 mL/24 h"}], "final_answer": "29.32 mL/min", "notes": "Creatinine Clearance\n29.32 mL/min"}, {"order": 6, "name": "Clinical outcomes in CKD with severely decreased GFR", "inputs": [{"field": "Age", "value": "62 years"}, {"field": "Sex", "value": "Male"}, {"field": "Race", "value": "White"}, {"field": "eGFR", "value": "25 mL/min/1.73 m²"}, {"field": "Systolic Blood Pressure", "value": "138 mmHg"}, {"field": "History of Cardiovascular Disease", "value": "No"}, {"field": "Diabetes", "value": "Yes"}, {"field": "Urine Albumin to Creatinine", "value": "320 mg/g"}, {"field": "Smoking History", "value": "Former"}, {"field": "Risk Horizon", "value": "2 years"}], "final_answer": "Kidney replacement therapy (KRT): 13.7%\nCardiovascular event (CVD): 9.4%\nDeath: 8.9%", "notes": "2-year risks summary (Events are not exclusive)\nKidney replacement therapy (KRT): 13.7%\nCardiovascular event (CVD): 9.4%\nDeath: 8.9%\n2-year risks breakdown (Events are exclusive)\nCKD G4+ no event: 73.0%\nKRT only: 10.5%\nKRT after CVD: 0.4%\nCVD only: 6.2%\nCVD after KRT: 0.9%\nDEATH only: 5.5%\nDEATH after KRT: 1.5%\nDEATH after CVD: 1.6%\nDEATH after KRT and CVD: 0.4%"}, {"order": 7, "name": "Chronic Kidney Disease Management: BC Guidelines", "inputs": [{"field": "Sex?", "value": "Male"}, {"field": "Age?", "value": "62 years"}, {"field": "eGFR?", "value": "25 mL/min/1.73 m²"}, {"field": "Urine Albumin to Creatinine Ratio?", "value": "36 mg/mmol"}, {"field": "Patient Location?", "value": "British Columbia (BC)"}, {"field": "Diabetes?", "value": "Yes"}], "final_answer": "14.3%", "notes": "Risk of progression to kidney failure requiring dialysis or transplantation (using the Kidney Failure Risk Equation):\nOver 2-Years:\n14.3%\nOver 5-Years:\n38.3%\nFor patients with CKD Stage 4, we consider a 2-year risk of kidney failure of 0-10 % as low risk, 10-20 % as intermediate risk and > 20 % as high risk\nInterpretation of eGFR\nGFR values of <60 mL/min which are persistent (present for ≥ 3 months) indicate chronic kidney disease\nCKD Staging\nG4A3\nNeed for Specialist Referral?\nReferral suggested\nFrequency of Evaluation\n4 or more times per year\nBlood Pressure Target\n130/80 mm Hg\nAntihypertensive Agents\nIn the setting of albuminuria, consider the use of an ACE inhibitor or ARB\nGlycemic Control Target\nA1C target is typically 7.0% but may not be appropriate for all populations\nAdvice on Glycemic Control\nMeasure A1C q 3-6 months or as clinically indicated.\nLong-acting sulfonylureas may be associated with hypoglycemia with unstable eGFR, especially those below 45. If current hypoglycemia, or unstable eGFR consider using short-action sulfonylureas or non-sulfonylureas.\nIn those with unstable eGFR or acute changes in clinical condition, metformin should be held, avoided, or reduced.\nLipids\nManage lipids in accordance with relevant guideline (eg KDIGO lipid guidelines)\nCheck lipids once to establish baseline and once after therapy initiated\nIn patients with CKD, consider use of statins and lipid lowering strategies irrespective of LDL levels.\nSmoking\nEncourage smoking cessation\nVaccinations\nIn patients with CKD consider annual influenza vaccine.\nAlso consider pneumococcal vaccine with once-only revaccination five years after initial vaccination.\nSecondary Hyperparathyroidism\nManagement of secondary hyperparathyroidism and interpretation of PTH values is out of scope of this tool\nAnemia\nIn patients with CKD, check iron stores (including ferritin and iron saturation) in patients with Hb lower than the normal range. If ferritin <100 or iron saturation <0.2, treat with supplemental iron.\nESAs are considered in CKD if Hb is lower than 90-100 g/L in an individual who is iron replete.\nLaboratory Monitoring\nHbA1C every 3 months; Check CBC, Electrolytes, Ca, Phosphate, Albumin, creatinine/eGFR every 2 months, Urine ACR, Ferritin/Fe Saturation every 4 months\nAdditional indications for referral to nephrology\nPresence of active urine sediments (red blood cell casts or cellular casts and/or protein), constitutional symptoms, or unexplained severity of kidney dysfunction.\nAKI or abrupt sustained fall in eGFR\nGFR < 30 mL/min\nPersistent finding of ACR >30 mg/mmol\nRapid and sustained deterioration in kidney function (a decline of eGFR >10-15% within 12 month period) warrants urgent referral to a nephrologist or internist, irrespective of eGFR values.\nProgressive CKD\nCKD and hypertension refractory to treatment\nPersistent abnormalities of serum potassium\nHereditary kidney disease\nWhere there is no obvious etiology for kidney disease and primary care provider believes knowing etiology may impact care plan. Note: occasionally screening for etiology will identify serious systemic disease or early stages of acute illness."}, {"order": 8, "name": "Residual Kidney Function", "inputs": [{"field": "Urine Creatinine Concentration?", "value": "95 mg/dL"}, {"field": "Plasma Creatinine Concentration?", "value": "2.7 mg/dL"}, {"field": "Urine Urea Nitrogen Concentration?", "value": "520 mg/dL"}, {"field": "Plasma Urea Nitrogen Concentration?", "value": "48 mg/dL"}, {"field": "Volume of 24-Hour Urine?", "value": "1200 mL"}], "final_answer": "19.2 mL/min", "notes": "Residual Kidney Clearance\n19.2 mL/min"}]}
{"task_id": "medmcp-calc_095_7fce7ba7", "task_scenario": "Postoperative Nausea and Vomiting (PONV)", "task_category": "Clinical Medicine / Emergency, Critical Care & Perioperative / Anesthesia & Perioperative Medicine", "patient_id": "P095_7fce7ba7", "task_description": "Scenario: A perioperative team is preparing an adult patient for general anesthesia and aims to minimize postoperative nausea and vomiting (PONV) while ensuring cardiac and hepatic safety when selecting prophylactic and rescue antiemetics. The workflow uses multiple calculators to first stratify PONV risk and then tailor antiemetic choices and dosing based on QT-related and hepatic safety considerations. Step-by-step calculator use: 1) Begin with the Apfel Score for Postoperative Nausea and Vomiting to categorize baseline PONV risk (low, moderate, high) and determine whether prophylaxis is indicated. 2) If the Apfel score indicates moderate risk or the team desires a second model to refine risk, apply the Koivuranta Score for Postoperative Nausea and Vomiting; treat patients as high risk if Koivuranta is high, otherwise maintain moderate-risk planning. 3) For patients requiring pharmacologic prophylaxis or who are likely to need rescue with agents that may prolong QT, obtain a baseline ECG and calculate the corrected QT using the QTc (Fridericia) Correction Calculator; the corrected QT value will be carried forward as an input into the next calculator. 4) Use the Tisdale Risk Score for QT Prolongation, incorporating the corrected QTc, to quantify risk of drug-induced QT prolongation when considering agents such as ondansetron or droperidol. Branching decisions: If Tisdale risk is high, avoid QT-prolonging antiemetics and choose alternatives (for example, dexamethasone or an NK1 antagonist) while emphasizing non-QT-prolonging rescue strategies; if Tisdale risk is low or moderate, QT-prolonging agents may be used with caution. 5) If antiemetics metabolized by the liver are planned, use the Child-Pugh Score for Cirrhosis to assess hepatic impairment and adjust antiemetic dosing and agent selection accordingly (e.g., lower maximum doses or selection of agents with safer hepatic profiles). 6) Implement prophylaxis intensity and agent selection based on the combined risk outputs: low-risk patients may receive minimal or no prophylaxis and focus on rescue strategies; moderate-risk patients receive single-agent or dual-agent prophylaxis; high-risk patients receive multimodal prophylaxis tailored by QT and hepatic safety outputs. During postoperative rescue, re-apply Tisdale considerations if additional QT-prolonging agents are contemplated, and adhere to Child-Pugh-based dosing if hepatic impairment is present.", "fuzzy_question": "I am evaluating a patient undergoing general anesthesia and want to minimize postoperative nausea and vomiting while avoiding cardiac and hepatic safety issues. First, I want a realistic estimate of baseline risk using standard clinical factors (sex-related risk, smoking status, history of nausea or motion sickness, and anticipated postoperative opioid use) to decide whether minimal, moderate, or upfront prophylaxis is warranted. If the estimate is borderline, I would apply a second validated assessment; if that reclassifies the patient as clearly high risk, I would plan as high risk, and if it supports an intermediate level, I would proceed with a moderate approach.\n\nBecause some antiemetics can prolong the QT interval, I want a preoperative ECG, interpret the QT with appropriate rate correction, and carry the corrected value forward when judging susceptibility to drug-induced QT issues. Incorporating concurrent medications (especially QT-active agents), electrolyte status, bradycardia, heart failure, age-related risk, and the baseline QT, I want an overall assessment of how risky it would be to use agents such as ondansetron or droperidol. If that risk appears high, I would avoid QT-prolonging choices and base prophylaxis and rescue on options that do not, such as dexamethasone or an NK1 receptor antagonist, and emphasize non-QT-prolonging rescue strategies. If it appears low to moderate, I would use QT-active agents with caution, thoughtful dosing, and monitoring.\n\nIf there is any suggestion of chronic liver disease or abnormal recent laboratory results, I want to stage hepatic severity using bilirubin, albumin, INR, and the presence of ascites or encephalopathy, then adjust antiemetic selection and cap doses for medications dependent on hepatic metabolism.\n\nPutting it together: if the overall nausea risk is low, I would keep prophylaxis minimal or focus on rescue. If it is moderate, I would use monotherapy up front or a dual-agent combination. If it is high, I would use a multimodal regimen from the start, with the specific agents and dosing shaped by QT and hepatic considerations. Postoperatively, if rescue is needed and any option may affect the QT interval, I would reassess QT risk at that time before administration and adhere to dose limits appropriate to hepatic status.\n\nWhat is your take on this? How would you reason it through, and would you reach the same plan? I need evidence-based risk stratification supported by formal calculations rather than clinical intuition; the approach should be backed by solid calculations and able to withstand scrutiny.", "required_calculators": ["Apfel Score for Postoperative Nausea and Vomiting", "Koivuranta Score for Postoperative Nausea and Vomiting", "QTc (Fridericia) Correction Calculator", "Tisdale Risk Score for QT Prolongation", "Child-Pugh Score for Cirrhosis"], "calculator_answers": [{"order": 1, "name": "Apfel Score for Postoperative Nausea and Vomiting", "inputs": [{"field": "Gender", "value": "Male", "score": 0}, {"field": "Smoking status", "value": "Nonsmoker", "score": 1}, {"field": "History of motion sickness or PONV", "value": "No", "score": 0}, {"field": "Use of postoperative opioids", "value": "Yes", "score": 1}], "final_answer": 2, "notes": "2 points\nApfel Score\n39 %\n24-hour risk of PONV"}, {"order": 2, "name": "Koivuranta Score for Postoperative Nausea and Vomiting", "inputs": [{"field": "Sex", "value": "Male", "score": 0}, {"field": "Smoking status", "value": "Nonsmoker", "score": 1}, {"field": "History of PONV", "value": "No", "score": 0}, {"field": "History of motion sickness", "value": "No", "score": 0}, {"field": "Duration of surgery ≥60 minutes", "value": "Yes (planned 90 minutes)", "score": 1}], "final_answer": 2, "notes": "Koivuranta score = 2/5 (nonsmoker + duration ≥60 min). Consistent with moderate risk; does not upgrade to high."}, {"order": 3, "name": "QTc (Fridericia) Correction Calculator", "inputs": [{"field": "Measured QT interval", "value": "400 ms"}, {"field": "Heart rate", "value": "72 bpm"}, {"field": "RR interval (derived)", "value": "0.833 s"}], "final_answer": "425 ms", "notes": "QTcF = 400 ms / (0.833)^(1/3) ≈ 425 ms. Baseline ECG otherwise normal."}, {"order": 4, "name": "Tisdale Risk Score for QT Prolongation", "inputs": [{"field": "Age ≥68 years", "value": "No (Age 62 years)", "score": 0}, {"field": "Sex (Female)", "value": "No (Male)", "score": 0}, {"field": "Patient on loop diuretic", "value": "No", "score": 0}, {"field": "Potassium ≤3.5 mEq/L", "value": "No (K 4.2 mEq/L, drawn pre-op within 24h)", "score": 0}, {"field": "Admission QTc ≥450 msec", "value": "No", "score": 0}, {"field": "Being admitted for acute myocardial infarction", "value": "No", "score": 0}, {"field": "Being admitted for sepsis", "value": "No", "score": 0}, {"field": "Being admitted for heart failure", "value": "No", "score": 0}, {"field": "Number of QTc-prolonging drugs given", "value": "1 (ondansetron planned for PONV prophylaxis/rescue)", "score": 3}], "final_answer": 3, "notes": "3 points\nTisdale Risk Score for QTc\nLow risk\nLow risk for QT prolongation; always consider that higher risk may develop depending on clinical course and drug interactions and pharmacokinetics"}, {"order": 5, "name": "Child-Pugh Score for Cirrhosis", "inputs": [{"field": "Total bilirubin", "value": "0.8 mg/dL", "score": 1}, {"field": "Serum albumin", "value": "4.2 g/dL", "score": 1}, {"field": "INR", "value": "1.0", "score": 1}, {"field": "Ascites", "value": "None", "score": 1}, {"field": "Hepatic encephalopathy", "value": "None", "score": 1}], "final_answer": 5, "notes": "5 points\nChild Class A\nLife Expectancy : 15-20 years\nAbdominal surgery peri-operative mortality: 10%"}]}
{"task_id": "medmcp-calc_096_8b1a036e", "task_scenario": "Rheumatoid Arthritis and Lupus Activity", "task_category": "Clinical Medicine / Medicine & Organ Systems / Orthopedics, Rheumatology & Immunology", "patient_id": "P096_8b1a036e", "task_description": "Clinical scenario: A patient with known systemic lupus erythematosus develops persistent, symmetric inflammatory synovitis and morning stiffness, raising concern for rheumatoid arthritis overlap. The goal is to confirm RA classification, quantify both RA and lupus disease activity, and choose the most appropriate RA composite index in the context of potential lab confounding, while incorporating patient-reported fatigue to inform a treat-to-target plan. Step-by-step workflow: First, apply the ACR/EULAR 2010 Rheumatoid Arthritis Classification Criteria to determine whether RA is present in the setting of inflammatory synovitis. If RA classification is met, proceed with RA activity scoring; if not met, defer RA scoring and prioritize lupus activity assessment, with reassessment of RA classification at follow-up. Next, measure lupus activity using the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) to stratify SLE severity, because lupus activity can influence interpretation of inflammatory markers and RA scoring choices. Then, collect patient-reported outcomes with the Patient Activity Scale II (PAS II) for RA to capture global symptom burden; the patient global output from PAS II will be used as the patient-reported global input required by subsequent RA composite indices. Calculate age-adjusted acute-phase reactants using the Age-Adjusted ESR/CRP for Rheumatoid Arthritis; use these adjusted values to decide which DAS28 variant to employ and to supply the ESR or CRP input when needed. RA activity quantification proceeds with conditional branching: If laboratory markers are available and SLEDAI-2K indicates low lupus activity (labs likely reflect RA inflammation), compute the Simple Disease Activity Index (SDAI) for Rheumatoid Arthritis using joint counts, clinician global, CRP (age-adjusted), and the patient global from PAS II; also compute the selected Disease Activity Score-28 variant (DAS28-ESR if adjusted ESR is deemed more reliable; otherwise DAS28-CRP), using joint counts, the corresponding age-adjusted acute-phase reactant, and the PAS II patient global. If laboratories are unavailable or SLEDAI-2K indicates moderate–high lupus activity (labs may be confounded), compute the Clinical Disease Activity Index (CDAI) for Rheumatoid Arthritis, which relies solely on clinical data and the PAS II patient global; consider skipping DAS28 if the age-adjusted reactants appear unreliable, or compute the chosen DAS28 variant cautiously if Age-Adjusted ESR/CRP suggests acceptable reliability. Finally, administer the Shortened Modified Fatigue Impact Scale (MFIS) to quantify the noninflammatory fatigue burden, which helps interpret the patient-reported global and informs supportive management if RA and SLE activity are low but fatigue remains prominent. Integrate outputs—RA classification status, RA activity category, lupus activity category, and fatigue impact—to form a unified treat-to-target plan and establish follow-up using the same indices for reproducible monitoring.", "fuzzy_question": "I’m seeing a patient with established lupus who has recently developed persistent, symmetric inflammatory synovitis with morning stiffness. I’m not certain if this represents an RA overlap or lupus-driven arthritis, and I want to be thoughtful about how we sort this out and set a treat-to-target plan.\n\nBefore labeling this as RA, I want to confirm formal RA classification in the setting of active synovitis. If criteria are met, we’ll characterize RA activity. If they are not, we’ll hold off on RA scoring, focus first on the current lupus status, and then revisit RA classification at follow-up.\n\nIn parallel, I need a structured assessment of current lupus activity because lupus can skew inflammatory markers, which will affect how we interpret RA activity. The lupus activity level will guide whether to use lab-inclusive RA scores or stick to clinical-only measures.\n\nI also want the patient’s perspective front and center. Please capture symptom burden with a brief arthritis activity questionnaire that yields a single patient global assessment; I’d like to use that same global rating as the patient-reported input within the RA composite measures. On our side, we’ll provide a clinician global impression and the 28-joint tender and swollen counts.\n\nRecent labs include ESR/CRP. ESR can drift upward with age, so let’s adjust interpretation of these acute-phase reactants for potential age-related effects and decide which one (ESR or CRP) is more trustworthy in this context. That decision should guide which version of the 28-joint RA score we use, and the adjusted values should be the ones we plug in when we need an inflammatory marker.\n\nIf lupus activity is low and the labs look reliable, I’m inclined to use a lab-inclusive RA composite that brings together tender and swollen joint counts, our clinician global, CRP, and the patient’s global. Alongside that, I’d also like a 28-joint RA score using whichever reactant (ESR or CRP) appears more dependable after adjustment, together with joint counts and the patient global.\n\nIf lupus activity is moderate to high or the labs are unavailable/unreliable, let’s rely on the clinical-only RA composite based on joint counts plus clinician and patient global scores. We can still consider the 28-joint score if, after adjustment, the reactants seem acceptable, but let’s interpret it cautiously in that context.\n\nSeparately, fatigue is prominent, and I don’t want to overcall inflammation if the fatigue is largely noninflammatory. Please have the patient complete a short fatigue impact questionnaire so we can tease apart fatigue that’s driving the global score from true inflammatory activity. That will be especially important if both RA and lupus activity come back low but fatigue remains significant.\n\nOnce all this is assembled, I’d like a unified read: whether RA classification is met, the RA activity category, the lupus activity category, and how significant the fatigue impact is. Use that to propose a treat-to-target plan, including targets, therapy intensity, and timing for reassessment. At follow-up, let’s stick with the same measures so we can track change in a reproducible way.\n\nI really need this grounded in solid, quantitative work rather than gut feeling. Whatever approach you take, make sure the numbers and thresholds are sound and the reasoning holds up to scrutiny.", "required_calculators": ["ACR/EULAR 2010 Rheumatoid Arthritis Classification Criteria", "Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K)", "Patient Activity Scale II (PAS II) for RA", "Age-Adjusted ESR/CRP for Rheumatoid Arthritis", "Clinical Disease Activity Index (CDAI) for Rheumatoid Arthritis", "Simple Disease Activity Index (SDAI) for Rheumatoid Arthritis", "Disease Activity Score-28 for Rheumatoid Arthritis with ESR (DAS28-ESR)", "Disease Activity Score-28 for Rheumatoid Arthritis with CRP (DAS28-CRP)", "Shortened Modified Fatigue Impact Scale (MFIS)"], "calculator_answers": [{"order": 1, "name": "ACR/EULAR 2010 Rheumatoid Arthritis Classification Criteria", "inputs": [{"field": "Joint involvement", "value": ">10 joints (at least 1 small joint)", "score": 5}, {"field": "Serology", "value": "High-positive anti-citrullinated protein antibody (anti-CCP)", "score": 3}, {"field": "Acute-phase reactants", "value": "Abnormal CRP or abnormal ESR", "score": 1}, {"field": "Duration of symptoms", "value": "≥6 weeks", "score": 1}], "final_answer": 10, "notes": "Definite RA\n10 points"}, {"order": 2, "name": "Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K)", "inputs": [{"field": "Recent onset seizure", "value": "No", "score": 0}, {"field": "Psychosis", "value": "No", "score": 0}, {"field": "Organic brain syndrome", "value": "No", "score": 0}, {"field": "Visual disturbance", "value": "No", "score": 0}, {"field": "New onset sensory or motor neuropathy involving cranial nerves", "value": "No", "score": 0}, {"field": "Lupus headache", "value": "No", "score": 0}, {"field": "New onset stroke", "value": "No", "score": 0}, {"field": "Vasculitis", "value": "No", "score": 0}, {"field": "Arthritis", "value": "No", "score": 0}, {"field": "Myositis", "value": "No", "score": 0}, {"field": "Heme-granular or RBC urinary casts", "value": "No", "score": 0}, {"field": "Hematuria", "value": "No", "score": 0}, {"field": "Proteinuria >0.5 g/24 hours", "value": "No", "score": 0}, {"field": "Pyuria", "value": "No", "score": 0}, {"field": "Inflammatory-type rash", "value": "No", "score": 0}, {"field": "Alopecia", "value": "No", "score": 0}, {"field": "Oral or nasal mucosal ulcers", "value": "No", "score": 0}, {"field": "Pleurisy", "value": "No", "score": 0}, {"field": "Pericarditis", "value": "No", "score": 0}, {"field": "Low complement", "value": "No", "score": 0}, {"field": "High DNA binding", "value": "No", "score": 0}, {"field": "Temp >38°C", "value": "No", "score": 0}, {"field": "Platelets <100 x 10^9/L", "value": "No", "score": 0}, {"field": "WBC <3 x 10^9/L", "value": "No", "score": 0}], "final_answer": 0, "notes": "0 points\nAuthors recommend a cutoff of 3 or 4 to define active disease and the need to increase therapy (see Evidence for details)."}, {"order": 3, "name": "Patient Activity Scale II (PAS II) for RA", "inputs": [{"field": "Stand up from a straight chair (HAQ-II)", "value": "With some difficulty"}, {"field": "Walk outdoors on flat ground (HAQ-II)", "value": "With some difficulty"}, {"field": "Get on and off the toilet (HAQ-II)", "value": "Without any difficulty"}, {"field": "Reach and get down a 5-pound object from just above the head (HAQ-II)", "value": "With much difficulty"}, {"field": "Open car doors (HAQ-II)", "value": "With some difficulty"}, {"field": "Do outside work (such as yard work) (HAQ-II)", "value": "With much difficulty"}, {"field": "Wait in a line for 15 minutes (HAQ-II)", "value": "With some difficulty"}, {"field": "Lift heavy objects (HAQ-II)", "value": "With much difficulty"}, {"field": "Move heavy objects (HAQ-II)", "value": "With much difficulty"}, {"field": "Go up 2 or more flights of stairs (HAQ-II)", "value": "With some difficulty"}, {"field": "Pain Visual Analog Scale (0-10)", "value": 6.0}, {"field": "Patient Global Assessment of Disease Activity (0-10)", "value": 6.0}], "final_answer": 5.44, "notes": "5.44 points\nPAS II\nModerate\nDisease activity"}, {"order": 4, "name": "Age-Adjusted ESR/CRP for Rheumatoid Arthritis", "inputs": [{"field": "Sex", "value": "Female"}, {"field": "Age", "value": 48}], "final_answer": "29.0 mm/hr", "notes": "29.0 mm/hr\nESR upper limit of normal\n1.6 mg/dL\nCRP upper limit of normal"}, {"order": 5, "name": "Clinical Disease Activity Index (CDAI) for Rheumatoid Arthritis", "inputs": [{"field": "Tender joint count (28)", "value": 8}, {"field": "Swollen joint count (28)", "value": 6}, {"field": "Patient global assessment (0-10)", "value": 6.0, "score": 6}, {"field": "Clinician global assessment (0-10)", "value": 5.5, "score": 5.5}], "final_answer": 27.5, "notes": "27.5 points\nHigh Severity of RA per CDAI"}, {"order": 6, "name": "Simple Disease Activity Index (SDAI) for Rheumatoid Arthritis", "inputs": [{"field": "Tender joint count (28)", "value": 8}, {"field": "Swollen joint count (28)", "value": 6}, {"field": "C-reactive protein (CRP) (mg/L)", "value": 12}, {"field": "Patient global assessment (0-10)", "value": 6.0, "score": 6}, {"field": "Clinician global assessment (0-10)", "value": 5.5, "score": 5.5}], "final_answer": 26.7, "notes": "26.7 points\nHigh Severity of RA per SDAI"}, {"order": 7, "name": "Disease Activity Score-28 for Rheumatoid Arthritis with ESR (DAS28-ESR)", "inputs": [{"field": "Tender Joint Count (28)", "value": 8}, {"field": "Swollen Joint Count (28)", "value": 6}, {"field": "Erythrocyte Sedimentation Rate (ESR) (mm/hr)", "value": 28}, {"field": "Global Health (0-10 cm VAS)", "value": 6.0}], "final_answer": 5.4, "notes": "5.4 points\nHigh severity of RA per DAS28-ESR"}, {"order": 8, "name": "Disease Activity Score-28 for Rheumatoid Arthritis with CRP (DAS28-CRP)", "inputs": [{"field": "Tender joint count (28)", "value": 8}, {"field": "Swollen joint count (28)", "value": 6}, {"field": "C-reactive protein (CRP) (mg/L)", "value": 12}, {"field": "Global health (0-10 cm VAS)", "value": 6.0}], "final_answer": 4.99, "notes": "4.99 points\nModerate severity of RA per DAS28-CRP"}, {"order": 9, "name": "Shortened Modified Fatigue Impact Scale (MFIS)", "inputs": [{"field": "1. I have been less alert.", "value": "Often", "score": 3}, {"field": "9. I have been limited in my ability to do things away from home.", "value": "Sometimes", "score": 2}, {"field": "10. I have had trouble maintaining physical effort for long periods.", "value": "Often", "score": 3}, {"field": "17. I have been less able to complete tasks that require physical effort.", "value": "Often", "score": 3}, {"field": "19. I have had trouble concentrating.", "value": "Sometimes", "score": 2}], "final_answer": 13, "notes": "13 out of 20 points\nThe higher the score, the more severely impacted the patient’s daily life."}]}
{"task_id": "medmcp-calc_097_e2ae270c", "task_scenario": "Hospital-Acquired Infection Risk Assessment", "task_category": "Clinical Medicine / Medicine & Organ Systems / Infectious Diseases", "patient_id": "P097_e2ae270c", "task_description": "Scenario: A postoperative ICU patient is mechanically ventilated after major surgery. The clinical team aims to prevent hospital-acquired pneumonia and identify ventilator-associated pneumonia (VAP) early, while minimizing unnecessary antibiotics. The workflow uses two calculators to guide prevention intensity, surveillance, and diagnostic decisions.\n\nStep-by-step use of calculators:\n1) Initial risk stratification with Gupta Postoperative Pneumonia Risk to estimate the patient's baseline likelihood of developing postoperative pneumonia. This informs prevention and surveillance intensity.\n   - If the Gupta risk is high: implement enhanced prevention measures and schedule proactive VAP surveillance; plan to apply CPIS promptly upon any clinical concern.\n   - If the Gupta risk is low-to-moderate: maintain standard prevention; reserve CPIS for when clinical concern arises.\n2) When clinical concern for VAP emerges in a ventilated patient (or earlier if flagged by high Gupta risk), apply the Clinical Pulmonary Infection Score (CPIS) for Ventilator-Associated Pneumonia (VAP) to estimate the likelihood of VAP and predict the benefit of obtaining pulmonary cultures.\n   - If CPIS suggests high likelihood of VAP: obtain pulmonary cultures and initiate empiric therapy; plan reassessment for de-escalation based on culture results and clinical response.\n   - If CPIS suggests low likelihood: continue prevention and close monitoring; avoid immediate antibiotics.\n   - If CPIS is intermediate: obtain targeted cultures, intensify monitoring, and re-evaluate CPIS as the clinical picture evolves.\n\nClinical rationale: The Gupta model provides an early, structured estimate of postoperative pneumonia risk that deterministically triggers whether to deploy CPIS early or reserve it for evolving clinical concern. CPIS then directs whether cultures and empiric therapy are warranted, supporting timely diagnosis and antibiotic stewardship in hospital-acquired infection risk assessment.", "fuzzy_question": "I’m managing a patient in the ICU who remains intubated after major surgery, and I’m trying to balance two goals: stay ahead of hospital-acquired pneumonia and detect ventilator-associated pneumonia early if it’s developing, while avoiding unnecessary antibiotics.\n\nBefore deciding how aggressive to be with prevention and how closely to monitor, I want a structured estimate of the patient’s baseline risk of postoperative pneumonia based on the operative course and underlying risk factors. If that baseline appears high, I’d go beyond the usual prevention bundle, tighten the cadence of VAP assessments, and be prepared to move quickly with a bedside infection evaluation at the first sign of concern. If it appears low to moderate, I’d stick with standard prevention and reserve that bedside assessment until there’s a clear clinical signal.\n\nIf, in the near term while still on the ventilator, we see features such as fever, thicker or more purulent secretions, a new or evolving opacity on imaging, rising oxygen needs, or leukocytosis (or if the baseline profile was concerning enough to act earlier), I’d like to integrate those bedside findings into a single estimate of the likelihood of true VAP and the expected usefulness of obtaining respiratory cultures. If that estimate points to a high probability, I’d send lower respiratory cultures promptly and start empiric coverage, with a plan to narrow or stop based on culture results and clinical trajectory. If it points to a low probability, I’d hold antibiotics, keep prevention measures tight, and observe closely. If it falls in the intermediate range, I’d send targeted cultures, increase monitoring, and reassess as the picture evolves.\n\nPlease walk me through this step by step. First, provide a clear baseline estimate of the likelihood of postoperative pneumonia for this patient and how that should shape prevention intensity and surveillance. Then, if concern arises while ventilated, outline how to synthesize bedside findings into a probability of VAP, how that would guide decisions to obtain cultures and start (or withhold) empiric antibiotics, when to re-evaluate, and what findings would prompt escalation, de-escalation, or maintaining the current plan. I’d appreciate rough percentage estimates for both the baseline risk and the suspected VAP likelihood so these decisions are defensible. I need this supported by proper calculations rather than clinical intuition alone, with a rationale that can withstand scrutiny.", "required_calculators": ["Gupta Postoperative Pneumonia Risk", "Clinical Pulmonary Infection Score (CPIS) for Ventilator-Associated Pneumonia (VAP)"], "calculator_answers": [{"order": 1, "name": "Gupta Postoperative Pneumonia Risk", "inputs": [{"field": "Age", "value": "74 years"}, {"field": "COPD", "value": "Yes (FEV1 65% predicted; functional limitation present)"}, {"field": "Functional status", "value": "Partially dependent"}, {"field": "ASA class", "value": "4: severe systemic disease that is a constant threat to life"}, {"field": "Sepsis", "value": "None (no preoperative SIRS/sepsis/shock)"}, {"field": "Smoking within last year", "value": "Yes (active smoker within 12 months)"}, {"field": "Type of procedure", "value": "Thoracic surgery - open esophagectomy (Ivor Lewis)"}], "final_answer": "32.3 %", "notes": "Risk of postoperative pneumonia"}, {"order": 2, "name": "Clinical Pulmonary Infection Score (CPIS) for Ventilator-Associated Pneumonia (VAP)", "inputs": [{"field": "Temperature (°C)", "value": "38.7 °C", "score": 1}, {"field": "White blood cell count", "value": "13.4 ×10^9/L (bands 350 cells/µL; <500)", "score": 1}, {"field": "Tracheal secretions", "value": "≥14+ (abundant) without purulent secretions", "score": 1}, {"field": "Oxygenation, PaO₂/FiO₂ mm Hg", "value": "200 mm Hg (PaO₂ 80 mm Hg on FiO₂ 0.40)", "score": 2}, {"field": "ARDS", "value": "No"}, {"field": "Pulmonary radiography", "value": "Diffuse or patchy infiltrate (new basilar patchy opacity)", "score": 1}, {"field": "Culture of tracheal aspirate specimen", "value": "Pathogenic bacteria cultured ≤1 or no growth (initial semi-quant ≤1+, gram stain without predominant pathogen)", "score": 0}], "final_answer": 6, "notes": "If the clinical suspicion for VAP is LOW, do NOT culture sputum. Evaluate for other potential sources of infection.\nIf the clinical suspicion for VAP is HIGH, perform bronchoalveolar lavage (BAL) or mini-BAL."}]}
{"task_id": "medmcp-calc_098_b56c97da", "task_scenario": "HIV-associated Opportunistic Infection Risk", "task_category": "Clinical Medicine / Medicine & Organ Systems / Infectious Diseases", "patient_id": "P098_b56c97da", "task_description": "Scenario: A person presents with respiratory symptoms concerning for an HIV-associated opportunistic infection (OI). The clinician must quickly determine whether OI risk should be prioritized versus alternate explanations that can mimic OI. Use the following calculators in sequence to gate decisions and reduce diagnostic error.\n\nStep 1 — A-HIPI: Use A-HIPI to estimate the probability of acute HIV infection in this presentation. Rationale: if acute HIV is likely, advanced immunosuppression (and thus OI risk) is less likely at this moment.\n- If A-HIPI indicates high probability: classify current OI risk as de-prioritized (acute HIV likely) and proceed along non-OI pathways.\n- If A-HIPI indicates low probability (or HIV is already known and chronic): proceed to Step 2.\n\nStep 2 — Stevenson HF Class: Use Stevenson HF Class to profile hemodynamics and identify congestion consistent with decompensated heart failure, a common clinical mimic of opportunistic pneumonia.\n- If the profile is “wet” (congested), down-rank OI likelihood and prioritize a cardiogenic etiology.\n- If the profile is “dry” (non-congested), maintain high concern for an OI and prioritize OI-focused evaluation and management.\n\nIntegration/Decision: Combine outputs to assign an actionable OI risk tier.\n- A-HIPI high → OI risk de-prioritized (acute HIV likely).\n- A-HIPI low AND Stevenson wet → OI risk de-prioritized (cardiogenic mimic favored).\n- A-HIPI low AND Stevenson dry → OI risk prioritized (non-cardiogenic, non-acute-HIV pathway).", "fuzzy_question": "I'm reviewing a case involving cough, shortness of breath, low-grade fevers, and a nonspecific chest exam. HIV infection is a consideration, and I'm weighing an opportunistic process against other common conditions with similar presentations. I want to be deliberate to avoid anchoring and missing a common diagnosis.\n\nFirst question: does this plausibly fit acute HIV seroconversion? If the clinical pattern and exposure history reasonably support that, I'd be less concerned about advanced immunosuppression for now and would de-emphasize classic OIs while focusing on non-OI pathways. If acute seroconversion seems unlikely—or if the infection is known or suspected to be chronic—then I want to keep OIs on the table while also considering a cardiogenic mimic that can appear similar.\n\nTo sort that out, assess hemodynamics from clinical findings, vitals, and routine labs: do they indicate clear volume overload or not? If congested (\"wet\"), I'd down-rank an OI and favor a cardiogenic explanation for the respiratory symptoms. If non-congested (\"dry\"), that keeps an OI near the top and pushes me toward an OI-focused workup and early management.\n\nUltimately, I need a practical OI priority for immediate decisions: if this looks like acute HIV, OI is de-prioritized; if acute HIV is unlikely but congestion is present, OI is again de-prioritized in favor of a cardiogenic cause; if acute HIV is unlikely and there is no congestion, OI is prioritized. Please explain how you're weighing these elements and where you land, with explicit calculations and defensible estimates at each step.", "required_calculators": ["A-HIPI", "Stevenson HF Class"], "calculator_answers": [{"order": 1, "name": "A-HIPI", "inputs": [{"field": "Age", "value": "29 years"}, {"field": "Albumin", "value": "4.3 g/dL"}, {"field": "Bulk", "value": "No bulky disease"}, {"field": "Gender", "value": "Female"}, {"field": "Hemoglobin", "value": "13.1 g/dL"}, {"field": "Lymphocyte count", "value": "1.7 x10^9/L"}, {"field": "Stage", "value": "Stage IIB"}], "final_answer": "87.19%", "notes": "Progression Free Survival at 5 years\n87.19%\nOverall Survival at 5 years\n98.15%"}, {"order": 2, "name": "Stevenson HF Class", "inputs": [{"field": "Evidence of Congestion?", "value": "No"}, {"field": "Evidence of Low Perfusion?", "value": "No"}], "final_answer": "Warm and Dry", "notes": "Clinical Class\nWarm and Dry\nAnticipated In-Hospital Mortality\n2 %"}]}
{"task_id": "medmcp-calc_099_1a26cf06", "task_scenario": "Acid-Base Disorder Analysis", "task_category": "Clinical Medicine / Medicine & Organ Systems / Nephrology & Electrolytes", "patient_id": "P099_1a26cf06", "task_description": "Clinical scenario: A patient presents with suspected metabolic acidosis and possible renal involvement. Your goal is to confirm the primary acid–base disorder, determine whether there is a high or normal anion gap, assess the adequacy of respiratory compensation, quantify the metabolic severity, and evaluate renal acidification and potassium handling to refine the diagnosis and guide immediate management.\n\nStep-by-step calculator use:\n1) Arterial Blood Gas (ABG) Analyzer: Interpret the ABG to identify acidemia or alkalemia and determine the primary process. Specifically, confirm whether there is primary metabolic acidosis (acidemia with a low bicarbonate and an appropriately directed pCO2 change). If the ABG does not indicate primary metabolic acidosis, pause this workflow and reassess for other acid–base disorders.\n2) Serum Anion Gap: If metabolic acidosis is present, calculate the serum anion gap to classify the acidosis as high-gap versus non-gap. This classification will determine subsequent testing pathways.\n3) Winters' Formula for Metabolic Acidosis Compensation: Using the confirmed metabolic acidosis, calculate the expected pCO2 to evaluate if respiratory compensation is appropriate. A measured pCO2 outside the expected range signals a concurrent respiratory disorder and alters management urgency.\n4) Base Excess: Quantify the metabolic component and the severity of the base deficit. This helps gauge the urgency of alkali therapy and informs hemodynamic and ventilatory planning.\n5) Branch if non-gap metabolic acidosis: If the serum anion gap is normal, calculate the Urine Anion Gap to differentiate renal acidification defects (positive/inappropriately high suggests impaired ammonium excretion and favors renal tubular acidosis) from extrarenal bicarbonate loss (negative/inappropriately low suggests gastrointestinal loss).\n6) Branch continuation for suspected renal tubular acidosis: If the Urine Anion Gap suggests a renal etiology, use the Transtubular Potassium Gradient (TTKG) to assess renal potassium handling. A low TTKG in the setting of hyperkalemia supports a hypoaldosteronism/type 4 RTA physiology; an inappropriately high or low TTKG can help differentiate other RTA subtypes and guide further workup.\n7) Henderson-Hasselbalch: Use the expected pCO2 from Winters’ Formula together with bicarbonate to model the target pH if ventilation is adjusted, or to cross-validate the ABG-derived bicarbonate with chemistry values. This step is useful in both high-gap and non-gap acidosis to align ventilatory targets with acid–base goals and to confirm internal consistency of measurements.\n\nKey decision points: ABG confirmation of primary metabolic acidosis determines whether to proceed. The Serum Anion Gap result triggers a branch toward renal acidification testing (Urine Anion Gap, then TTKG) if non-gap, versus skipping urine studies if high-gap. Winters’ expected pCO2 informs whether a mixed respiratory disorder exists and feeds into the Henderson–Hasselbalch modeling of pH at a target pCO2.", "fuzzy_question": "I’m seeing an adult patient with metabolic comorbidities and reduced renal function who appears acidotic on presentation. Recent labs show a rise in creatinine and a tendency toward hyperkalemia, and the ABG suggests acidemia. I’m trying to determine whether the primary problem is a metabolic acidosis, meaning bicarbonate has fallen with appropriate respiratory compensation. If the ABG doesn’t indicate a metabolic process up front, I’d pause and reframe before pursuing the wrong pathway.\n\nIf it is metabolic, I want to distinguish an increased unmeasured acids pattern from a chloride-predominant, non-gap picture. That distinction will guide us: if it’s the former, I’d prioritize evaluation for lactate/ketosis/toxins and defer urine acidification testing; if it’s the latter, we should assess how the kidneys are handling acid versus whether there is alkali loss from the gut.\n\nOn the respiratory side, I want to confirm whether the CO2 is appropriate for the degree of bicarbonate reduction. If the measured CO2 is outside the expected compensatory range, that suggests a concurrent respiratory issue - either hypoventilation or hyperventilation - and that changes the urgency and our ventilator strategy.\n\nI also need a sense of how severe the metabolic disturbance is - the degree of base deficit - to judge the need and pace for alkali therapy, and to plan hemodynamics and ventilatory targets safely.\n\nIf this turns out to be a non-gap, hyperchloremic picture, I’d like the urine electrolytes interpreted to show whether the kidneys are appropriately excreting acid (ammonium) in the setting of acidosis. A pattern suggesting poor ammonium excretion would point toward a renal tubular acidosis rather than gastrointestinal bicarbonate loss. If the urine suggests a renal tubular problem, I then want to understand distal potassium handling - whether the kidney is adequately secreting potassium in the face of elevated potassium. If distal secretion appears inappropriately low despite hyperkalemia, I’d consider low aldosterone dynamics/type 4 physiology; if it’s unexpectedly high or low in other ways, that could help sort out other subtypes and next steps.\n\nFor ventilatory planning, I’d estimate the expected pH if we set the CO2 to an appropriate target for the observed bicarbonate level, and double-check that the bicarbonate on the ABG aligns with the chemistry panel; if those don’t match, we might be dealing with sampling or timing issues.\n\nWhat’s your take on walking through this? I’m looking for a clear, stepwise approach that ties these checkpoints to immediate management decisions - ventilation settings, whether to give alkali, and whether we pursue renal versus extrarenal causes right now. I need proper calculations to support this so the plan holds up to scrutiny.", "required_calculators": ["Arterial Blood Gas (ABG) Analyzer", "Serum Anion Gap", "Winters' Formula for Metabolic Acidosis Compensation", "Base Excess", "Urine Anion Gap", "Transtubular Potassium Gradient (TTKG)", "Henderson-Hasselbalch"], "calculator_answers": [{"order": 1, "name": "Arterial Blood Gas (ABG) Analyzer", "inputs": [{"field": "pH", "value": "7.34"}, {"field": "PₐCO₂", "value": "31 mm Hg"}, {"field": "HCO₃-", "value": "16 mEq/L"}, {"field": "Sodium", "value": "140 mEq/L"}, {"field": "Chloride", "value": "114 mEq/L"}, {"field": "Albumin", "value": "4.0 g/dL"}, {"field": "If respiratory process present, chronicity", "value": "Acute"}], "final_answer": "This is a Non-Gap Metabolic Acidosis.\nPrimary Metabolic Acidosis, with: Appropriately Compensated by Respiratory Alkalosis", "notes": "This is a Non-Gap Metabolic Acidosis.\nPrimary Metabolic Acidosis, with: Appropriately Compensated by Respiratory Alkalosis"}, {"order": 2, "name": "Serum Anion Gap", "inputs": [{"field": "Sodium", "value": "140 mEq/L"}, {"field": "Chloride", "value": "114 mEq/L"}, {"field": "Bicarbonate", "value": "16 mEq/L"}, {"field": "Albumin", "value": "4.0 g/dL"}], "final_answer": "10.0 mEq/L", "notes": "10.0 mEq/L\nAnion gap\nDelta gap: -2.0 mEq/L\nDelta ratio: -0.3; Pure normal anion gap acidosis\n10.0 mEq/L\nAlbumin corrected anion gap; suggests non-anion gap acidosis\nAlbumin corrected delta gap: -2.0 mEq/L\nAlbumin corrected delta ratio: -0.3"}, {"order": 3, "name": "Winters' Formula for Metabolic Acidosis Compensation", "inputs": [{"field": "Bicarbonate", "value": "16 mEq/L"}], "final_answer": "32 mmHg", "notes": "Expected PaCO2 ≈ 1.5 × 16 + 8 = 32 mm Hg (range ~30–34); measured PaCO2 31 mm Hg is appropriately compensated."}, {"order": 4, "name": "Base Excess", "inputs": [{"field": "pCO₂", "value": "31 mm Hg"}, {"field": "pH", "value": "7.34"}], "final_answer": "-8.5 meq/L", "notes": "Base Excess\n-8.5 meq/L\nHCO₃\n16.2 meq/L"}, {"order": 5, "name": "Urine Anion Gap", "inputs": [{"field": "Urine sodium", "value": "45 mEq/L"}, {"field": "Urine potassium", "value": "15 mEq/L"}, {"field": "Urine chloride", "value": "25 mEq/L"}], "final_answer": "35.0 mEq/L", "notes": "35.0 mEq/L\nUrine anion gap positive\nThis suggests LOW urinary NH4+ and Renal Tubular Acidosis (RTA) if >10."}, {"order": 6, "name": "Transtubular Potassium Gradient (TTKG)", "inputs": [{"field": "Urine potassium", "value": "15 mEq/L"}, {"field": "Serum potassium", "value": "5.8 mEq/L"}, {"field": "Urine osmolality", "value": "500 mOsm/kg"}, {"field": "Serum osmolality", "value": "295 mOsm/kg"}], "final_answer": 2, "notes": "Transtubular Potassium Gradient (TTKG)\nTTKG <7 in hyperkalemia suggests hypoaldosteronism"}, {"order": 7, "name": "Henderson-Hasselbalch", "inputs": [{"field": "Bicarbonate Level (HCO₃)?", "value": "16 mEq/L"}, {"field": "Partial Pressure of CO₂?", "value": "32 mm Hg"}], "final_answer": 7.32, "notes": "Expected pH\n7.32"}]}
{"task_id": "medmcp-calc_100_0f5c2d5c", "task_scenario": "Pressure Ulcer Risk", "task_category": "Clinical Medicine / Special Populations & General Tools / Geriatric Medicine", "patient_id": "P100_0f5c2d5c", "task_description": "Scenario: An older adult inpatient on a geriatric unit has limited mobility and moisture exposure. The team must evaluate pressure ulcer risk, determine whether any skin injury exists and its severity, and translate findings into a tailored prevention and early treatment plan. Workflow: Step 1) Screen overall risk with the Braden Score for Pressure Ulcers to categorize baseline risk. Decision: If not at risk, implement routine prevention and schedule periodic re-screening; stop unless condition changes. If at risk (of any degree), continue. Step 2) If any area of suspected pressure injury is found on skin assessment, apply the National Pressure Ulcer Advisory Panel Staging System (NPUAP) to classify severity. Decision: If stage 2 or higher, deep tissue injury, or unstageable, proceed directly to Emory Model (TIPSS) for intensive prevention/treatment planning; if stage 1, proceed to Emory Model (TIPSS) for targeted early interventions; if no injury is present, continue to Step 3. Step 3) For at-risk patients without a current ulcer, use A-HIPI to refine near-term risk of hospital-acquired pressure injury during this admission. Decision: If A-HIPI indicates low risk, apply standard prevention and routine monitoring; if moderate or high risk, proceed to Emory Model (TIPSS). Step 4) Use Emory Model (TIPSS) to translate Braden and A-HIPI risk categories and any NPUAP stage into a customized prevention/management bundle (e.g., support surface selection, repositioning cadence, moisture management, and shear/pressure reduction strategies) and to set monitoring and reassessment frequency. Step 5) Reassess trajectory: If Emory Model (TIPSS) prioritizes high-risk domains or if NPUAP staging worsens, repeat Braden and A-HIPI at clinically appropriate intervals and update the plan accordingly.", "fuzzy_question": "I'm evaluating a hospitalized patient with limited mobility and moisture exposure related to incontinence. I'm trying to determine the best approach to protect skin and avoid missing an early pressure injury. First, I want a bedside sense of overall baseline risk for skin breakdown—considering sensory perception, moisture, activity level, need for assistance with mobility, nutrition, and friction/shear during turns and transfers. If the patient appears not at risk, routine prevention and periodic rechecks are acceptable; but with any meaningful risk, we should go deeper.\n\nOn the head-to-toe skin assessment, if any area might be pressure-related, I’d like a clear call on severity: non-blanchable redness, a shallow open area, deeper tissue loss, purple/maroon discoloration suggesting deep tissue damage, or a wound with an obscured base where depth can’t be determined. If it’s anything beyond early redness—or if depth is unclear—I’d initiate a more intensive prevention/early treatment bundle. Even with early redness, I’d still start targeted measures immediately. If the skin is entirely intact, I’d still refine the likelihood of developing a hospital-acquired lesion over the next few days on the ward.\n\nFor an at-risk patient with intact skin, can we get a near-term read on risk during this admission, factoring in perfusion/oxygenation, hemodynamic stability, nutrition, presence of devices, tolerance of turning, and similar contributors? If that short-term risk looks modest, I’m comfortable with standard prevention and routine monitoring. If it is moderate or high, I’d escalate to a structured bundle.\n\nFrom there, please translate the risk picture and any staging into a concrete plan: select an appropriate support surface; set the repositioning cadence and off-loading (including heels); lay out moisture control (barrier products, containment, wicking/absorbent layers); and specify how to reduce friction/shear (transfer techniques, head-of-bed angle, slide sheets, prophylactic dressings at bony points). Also set how often to recheck the skin and reassess the plan over the next several days.\n\nLooking ahead, if the plan highlights high-risk domains (e.g., moisture or mobility) or if any lesion worsens, I’d want to repeat the baseline and near-term risk assessment at reasonable intervals and update the plan accordingly. What’s your take on this case, and how would you reason it through step-by-step? Am I missing anything key? I need proper, evidence-based calculations—beyond clinical intuition—so the approach can withstand scrutiny.", "required_calculators": ["Braden Score for Pressure Ulcers", "National Pressure Ulcer Advisory Panel Staging System (NPUAP)", "A-HIPI", "Emory Model (TIPSS)"], "calculator_answers": [{"order": 1, "name": "Braden Score for Pressure Ulcers", "inputs": [{"field": "Sensory perception", "value": "Slightly limited: responds to verbal commands but cannot always communicate discomfort or need to be turned, OR has sensory impairment limiting ability to feel pain/discomfort in 1-2 extremities (+3)", "score": 3}, {"field": "Moisture", "value": "Very moist: skin is often but not always moist; linen must be changed at least once a shift (+2)", "score": 2}, {"field": "Activity", "value": "Bedfast: confined to bed (+1)", "score": 1}, {"field": "Mobility", "value": "Completely immobile: does not make even slight changes in body or extremity position without assistance (+1)", "score": 1}, {"field": "Nutrition", "value": "Probably inadequate: rarely eats complete meal and generally eats only about 1/2 of any food offered; protein intake includes only 3 servings of meat or dairy products daily; occasionally will take dietary supplement (+2)", "score": 2}, {"field": "Friction and shear", "value": "Problem: requires moderate to maximum assistance in moving; complete lifting without sliding against sheets is impossible; frequently slides down in bed or chair, requiring frequent repositioning with maximum assistance (+1)", "score": 1}], "final_answer": 10, "notes": "10 points\nBraden Score\nHigh risk"}, {"order": 2, "name": "National Pressure Ulcer Advisory Panel Staging System (NPUAP)", "inputs": [{"field": "Clinical Description of Pressure Ulcer", "value": "Non-blanchable erythema of intact skin over sacrum (approx. 3 x 4 cm), warm to touch, non-blanching after 3 seconds; no blister or skin break."}], "final_answer": 1, "notes": "Stage\n1"}, {"order": 3, "name": "A-HIPI", "inputs": [{"field": "Age", "value": "65 years"}, {"field": "Albumin", "value": "3.4 g/dL"}, {"field": "Bulk", "value": "No bulky disease"}, {"field": "Gender", "value": "Female"}, {"field": "Hemoglobin", "value": "11.6 g/dL"}, {"field": "Lymphocyte count", "value": "1.1 x10^9/L"}, {"field": "Stage", "value": "Stage III"}], "final_answer": "67.58%", "notes": "Progression Free Survival at 5 years\n67.58%\nOverall Survival at 5 years\n81.97%"}, {"order": 4, "name": "Emory Model (TIPSS)", "inputs": [{"field": "Total Bilirubin", "value": "0.8 mg/dL"}, {"field": "ALT", "value": "22 U/L"}, {"field": "Pre-TIPSS Hepatic Encephalopathy", "value": "No"}, {"field": "Urgency of TIPSS", "value": "Elective"}], "final_answer": 0, "notes": "Score\n0\nRisk Category\nLow Risk\nEstimated Mortality Rates after TIPSS:\nEstimated 3-month Mortality Rates after TIPSS\n10 %\nEstimated 12-month Mortality Rates after TIPSS\n30-33 %\nEstimated 36-month Mortality Rates after TIPSS\n30 %"}]}
{"task_id": "medmcp-calc_101_ceebfe44", "task_scenario": "Spine and Joint Function Scoring", "task_category": "Clinical Medicine / Medicine & Organ Systems / Orthopedics, Rheumatology & Immunology", "patient_id": "P101_ceebfe44", "task_description": "Scenario: A person with chronic axial musculoskeletal pain, stiffness, and functional limitation requires integrated spine and joint function scoring to clarify diagnosis, quantify inflammatory disease activity, capture patient-reported disability, and identify safety risks (falls and fragility fracture) that will shape treatment and rehabilitation. Workflow steps: First, classify the condition using the ASAS Criteria for Axial Spondyloarthritis (SpA). If the ASAS criteria are met, proceed down the axial spondyloarthritis pathway; if not met and rheumatoid arthritis features are suspected, quantify severity with the Patient Activity Scale (PAS) for RA to guide RA-focused management. Within the axial spondyloarthritis pathway, select the appropriate Ankylosing Spondylitis Disease Activity Score variant (ASDAS-CRP or ASDAS-ESR) based on available data. Next, obtain the BASDAI to capture patient-reported disease activity. Compare ASDAS with BASDAI: if BASDAI is high while ASDAS indicates low activity, administer the REVISED FIBROMYALGIA IMPACT QUESTIONNAIRE (FIQR) to evaluate a fibromyalgia overlay that may be inflating symptom scores and to redirect management toward non-inflammatory pain strategies; if BASDAI and ASDAS are concordant, proceed without FIQR. Independently of the diagnostic branch, quantify neck-specific functional limitations with the Neck Disability Index (NDI) to inform targeted rehabilitation and activity modification. Evaluate balance and fall risk using the Berg Balance Scale (BBS). Then assess bone fragility using the Dubbo Osteoporotic Fracture Risk. Integrate BBS and Dubbo results to plan safety interventions: if BBS indicates high fall risk and Dubbo suggests elevated fracture risk, prioritize fall-prevention measures and bone-protective strategies; if fall risk is high but fracture risk low, emphasize balance and home safety; if fall risk is low but fracture risk high, focus on bone health while maintaining routine mobility training. Throughout, use classification and activity scores (ASAS, ASDAS-CRP/ASDAS-ESR, BASDAI) together with FIQR and NDI to tailor pharmacologic therapy and physical therapy goals, and use BBS and Dubbo outputs to mitigate preventable harm.", "fuzzy_question": "I’m seeing a patient with long‑standing axial pain, stiffness, and day‑to‑day functional limits. I’m not certain if this is axial spondyloarthritis or another inflammatory arthritis. I’d like to start by checking whether the patient meets accepted international criteria for axial spondyloarthritis. If they do, let’s stay on that track and grade inflammatory activity with the standard lab‑anchored axial score—use the CRP‑based version if available; if not, use the ESR‑based version. Alongside that, include the usual patient‑reported index for axial symptoms to capture the patient’s perspective.\n\nHere’s where I’m torn: if the lab‑anchored activity looks low but the patient‑reported index is still high, I’m concerned about a fibromyalgia overlay driving symptoms. In that case, please screen with the updated impact questionnaire for fibromyalgia to help pivot toward non‑inflammatory pain strategies if needed. If the two activity measures generally track together, we can skip that and continue on the inflammatory pathway. On the other hand, if the axial spondyloarthritis criteria aren’t met and the clinical picture leans more toward rheumatoid arthritis (e.g., small‑joint symptoms with supportive serology), then quantify severity with a straightforward RA patient activity scale to guide RA‑focused management instead.\n\nRegardless of the final label, neck symptoms are a major contributor to disability, so use the standard neck disability questionnaire to anchor rehab goals and activity modification. I’m also concerned about safety: balance appears impaired, and I don’t want to miss a preventable fall. Please do the common clinic balance assessment to grade fall risk, and also estimate longer‑term osteoporotic fracture risk with a validated model. Then integrate those two: if fall risk is high and fracture risk is elevated, prioritize fall‑prevention measures and bone‑protective strategies; if falls are high but bone risk looks low, focus on balance training and home safety; if balance is fine but bone risk is high, emphasize bone health while keeping routine mobility work.\n\nAs we pull this together, use the classification decision plus both activity measures (the lab‑anchored score and the patient‑reported index), the fibromyalgia screen when indicated, and the neck disability results to fine‑tune medications and set precise physical therapy targets. And use the balance and fracture risk outputs to prevent avoidable harm.\n\nWhat’s your take on this? Available labs give us some traction, and looking ahead to the next appointment I want to be confident we’re steering in the right direction. I need proper, defensible numbers behind each of these steps—not just gut feeling—so please back the reasoning with solid calculations that will hold up to scrutiny.", "required_calculators": ["ASAS Criteria for Axial Spondyloarthritis (SpA)", "Patient Activity Scale (PAS) for RA", "Ankylosing Spondylitis Disease Activity Score with CRP (ASDAS-CRP)", "Ankylosing Spondylitis Disease Activity Score with ESR (ASDAS-ESR)", "BASDAI", "REVISED FIBROMYALGIA IMPACT QUESTIONNAIRE (FIQR)", "Neck Disability Index (NDI)", "Berg Balance Scale (BBS)", "Dubbo Osteoporotic Fracture Risk"], "calculator_answers": [{"order": 1, "name": "ASAS Criteria for Axial Spondyloarthritis (SpA)", "inputs": [{"field": "current_age_years", "value": 55}, {"field": "age_at_onset_years", "value": 34}, {"field": "back_pain_duration_months", "value": 252}, {"field": "entry_criterion_back_pain_>=3_months_and_onset_<45y", "value": "Yes"}, {"field": "sacroiliitis_on_mri_active_inflammation", "value": "Yes (bilateral SI joint BME on STIR, consistent with active sacroiliitis)"}, {"field": "sacroiliitis_on_radiograph", "value": "No definite radiographic sacroiliitis reported"}, {"field": "hla_b27_status", "value": "Positive"}, {"field": "inflammatory_back_pain_features", "value": "Yes (improves with exercise, not rest; nocturnal pain; morning stiffness >60 min)"}, {"field": "peripheral_arthritis", "value": "No"}, {"field": "enthesitis", "value": "Yes (Achilles insertion tenderness episodic)"}, {"field": "uveitis", "value": "No"}, {"field": "dactylitis", "value": "No"}, {"field": "psoriasis", "value": "No"}, {"field": "inflammatory_bowel_disease", "value": "No"}, {"field": "good_response_to_nsaids", "value": "Yes (noted within 48 hours previously)"}, {"field": "family_history_spa", "value": "No known"}, {"field": "elevated_crp", "value": "No (CRP normal-low)"}], "final_answer": "Axial SpA", "notes": "Axial SpA\nMeets ASAS criteria for axial SpA classification."}, {"order": 2, "name": "Patient Activity Scale (PAS) for RA", "inputs": [{"field": "self_dress_shoelaces_buttons", "value": "With some difficulty"}, {"field": "shampoo_hair", "value": "With some difficulty"}, {"field": "stand_up_from_straight_chair", "value": "With some difficulty"}, {"field": "get_in_out_of_bed", "value": "With some difficulty"}, {"field": "cut_own_meat", "value": "With some difficulty"}, {"field": "lift_full_cup_or_glass", "value": "With some difficulty"}, {"field": "open_new_milk_carton", "value": "With some difficulty"}, {"field": "walk_outdoors_flat_ground", "value": "With some difficulty"}, {"field": "climb_five_steps", "value": "With much difficulty"}, {"field": "wash_and_dry_body", "value": "With some difficulty"}, {"field": "take_tub_bath", "value": "With much difficulty"}, {"field": "get_on_off_toilet", "value": "With some difficulty"}, {"field": "reach_5_lb_object_from_above_head", "value": "With much difficulty"}, {"field": "bend_down_pick_up_clothing_from_floor", "value": "With much difficulty"}, {"field": "open_car_doors", "value": "With some difficulty"}, {"field": "open_previously_opened_jars", "value": "With much difficulty"}, {"field": "turn_faucets_on_off", "value": "With some difficulty"}, {"field": "run_errands_and_shop", "value": "With some difficulty"}, {"field": "get_in_out_of_car", "value": "With some difficulty"}, {"field": "do_chores_vacuum_yard_work", "value": "With much difficulty"}, {"field": "devices_for_dressing", "value": "No"}, {"field": "devices_for_arising", "value": "No"}, {"field": "devices_for_eating", "value": "No"}, {"field": "devices_for_walking", "value": "No"}, {"field": "devices_for_hygiene", "value": "No"}, {"field": "devices_for_reaching", "value": "No"}, {"field": "devices_for_gripping", "value": "No"}, {"field": "needs_help_dressing_grooming", "value": "No"}, {"field": "needs_help_arising", "value": "No"}, {"field": "needs_help_eating", "value": "No"}, {"field": "needs_help_walking", "value": "No"}, {"field": "needs_help_hygiene", "value": "No"}, {"field": "needs_help_reaching", "value": "No"}, {"field": "needs_help_gripping_opening", "value": "No"}, {"field": "needs_help_errands_chores", "value": "No"}, {"field": "pain_vas_0_10", "value": 6}, {"field": "patient_global_assessment_0_10", "value": 6}], "final_answer": 5.8, "notes": "5.80 points\nPAS\nModerate\nDisease activity"}, {"order": 3, "name": "Ankylosing Spondylitis Disease Activity Score with CRP (ASDAS-CRP)", "inputs": [{"field": "back_pain_vas_0_10", "value": 4, "score": 4}, {"field": "duration_morning_stiffness_vas_0_10", "value": 2, "score": 2}, {"field": "patient_global_activity_vas_0_10", "value": 3, "score": 3}, {"field": "peripheral_pain_swelling_vas_0_10", "value": 2, "score": 2}, {"field": "crp", "value": "1.2 mg/L"}], "final_answer": 1.5, "notes": "1.5 points\nASDAS-CRP\nLow\nDisease activity"}, {"order": 4, "name": "Ankylosing Spondylitis Disease Activity Score with ESR (ASDAS-ESR)", "inputs": [{"field": "back_pain_vas_0_10", "value": 4, "score": 4}, {"field": "duration_morning_stiffness_vas_0_10", "value": 2, "score": 2}, {"field": "patient_global_activity_vas_0_10", "value": 3, "score": 3}, {"field": "peripheral_pain_swelling_vas_0_10", "value": 2, "score": 2}, {"field": "esr", "value": "7 mm/hr"}], "final_answer": 1.7, "notes": "1.7 points\nASDAS-ESR\nLow\nDisease activity"}, {"order": 5, "name": "BASDAI", "inputs": [{"field": "q1_fatigue_0_10", "value": 7}, {"field": "q2_spinal_pain_0_10", "value": 7}, {"field": "q3_peripheral_joint_pain_swelling_0_10", "value": 5}, {"field": "q4_tender_areas_0_10", "value": 6}, {"field": "q5_morning_stiffness_severity_0_10", "value": 7}, {"field": "q6_morning_stiffness_duration_0_10", "value": 7}], "final_answer": 6.4, "notes": "BASDAI\n6.4"}, {"order": 6, "name": "REVISED FIBROMYALGIA IMPACT QUESTIONNAIRE (FIQR)", "inputs": [{"field": "function_brush_comb_hair_0_10", "value": 2}, {"field": "function_walk_20_min_0_10", "value": 6}, {"field": "function_prepare_homemade_meal_0_10", "value": 3}, {"field": "function_vacuum_scrub_sweep_0_10", "value": 7}, {"field": "function_lift_carry_groceries_0_10", "value": 6}, {"field": "function_climb_one_flight_stairs_0_10", "value": 6}, {"field": "function_change_bedsheets_0_10", "value": 7}, {"field": "function_sit_45_min_0_10", "value": 5}, {"field": "function_shop_for_groceries_0_10", "value": 6}, {"field": "overall_impact_goals_prevented_0_10", "value": 7}, {"field": "overall_impact_overwhelmed_0_10", "value": 6}, {"field": "symptom_pain_0_10", "value": 7}, {"field": "symptom_energy_0_10", "value": 7}, {"field": "symptom_stiffness_0_10", "value": 7}, {"field": "symptom_sleep_quality_0_10", "value": 6}, {"field": "symptom_depression_0_10", "value": 5}, {"field": "symptom_memory_problems_0_10", "value": 5}, {"field": "symptom_anxiety_0_10", "value": 5}, {"field": "symptom_tenderness_to_touch_0_10", "value": 6}, {"field": "symptom_balance_problems_0_10", "value": 4}, {"field": "symptom_environmental_sensitivity_0_10", "value": 4}], "final_answer": 57, "notes": "The Total FIQR Score\n57"}, {"order": 7, "name": "Neck Disability Index (NDI)", "inputs": [{"field": "pain_intensity", "value": "The pain is fairly severe at the moment (+3)", "score": 3}, {"field": "personal_care", "value": "I can look after myself normally, but it causes extra pain (+1)", "score": 1}, {"field": "lifting", "value": "Pain prevents me from lifting heavy weights, but I can manage light to medium weights if conveniently positioned (+3)", "score": 3}, {"field": "reading", "value": "I can read as much as I want with moderate pain in my neck (+2)", "score": 2}, {"field": "headaches", "value": "I have moderate headaches, which come frequently (+3)", "score": 3}, {"field": "concentration", "value": "I have a fair degree of difficulty in concentrating when I want to (+2)", "score": 2}, {"field": "work", "value": "I can do most of my usual work, but no more (+2)", "score": 2}, {"field": "driving", "value": "I can drive my car as long as I want with moderate pain in my neck (+2)", "score": 2}, {"field": "sleeping", "value": "My sleep is moderately disturbed (2–3 hrs sleepless) (+3)", "score": 3}, {"field": "recreation", "value": "I am able to engage in a few of my usual recreation activities because of pain in my neck (+3)", "score": 3}], "final_answer": 24, "notes": "24 points\nNDI\nModerate\nNeck disability level"}, {"order": 8, "name": "Berg Balance Scale (BBS)", "inputs": [{"field": "sitting_to_standing_score_0_4", "value": "Able to stand independently using hands", "score": 3}, {"field": "standing_unsupported_score_0_4", "value": "Able to stand 2 minutes with supervision", "score": 3}, {"field": "sitting_with_back_unsupported_score_0_4", "value": "Able to sit safely and securely for 2 minutes", "score": 4}, {"field": "standing_to_sitting_score_0_4", "value": "Controls descent by using hands", "score": 3}, {"field": "transfers_score_0_4", "value": "Able to transfer safely with definite need of hands", "score": 3}, {"field": "standing_unsupported_eyes_closed_score_0_4", "value": "Able to stand 10 seconds with supervision", "score": 3}, {"field": "standing_unsupported_feet_together_score_0_4", "value": "Able to place feet together independently and stand 1 minute with supervision", "score": 3}, {"field": "reach_forward_outstretched_arm_score_0_4", "value": "Can reach forward 12 cm (5 inches) safely", "score": 3}, {"field": "pick_up_object_from_floor_score_0_4", "value": "Able to pick up slipper but needs supervision", "score": 3}, {"field": "turn_to_look_behind_score_0_4", "value": "Looks behind one side only, other side shows less weight shift", "score": 3}, {"field": "turn_360_degrees_score_0_4", "value": "Able to turn 360 degrees safely but slowly", "score": 2}, {"field": "alternate_foot_on_step_score_0_4", "value": "Able to stand independently, and complete 8 steps in >20 seconds", "score": 3}, {"field": "standing_one_foot_in_front_score_0_4", "value": "Able to take small step independently and hold 30 seconds", "score": 2}, {"field": "standing_on_one_leg_score_0_4", "value": "Able to lift leg independently and hold ≥3 seconds", "score": 2}], "final_answer": 40, "notes": "40 points\nBBS\nIncreased\nFall risk"}, {"order": 9, "name": "Dubbo Osteoporotic Fracture Risk", "inputs": [{"field": "gender", "value": "Female"}, {"field": "age_years", "value": 60}, {"field": "t_score_positive_or_negative", "value": "Negative"}, {"field": "t_score_value", "value": -2.1}, {"field": "number_of_prior_fractures_since_age_50", "value": 0}, {"field": "number_of_falls_past_12_months", "value": 2}], "final_answer": "0.1 %", "notes": "Estimated 5-Year Risk of Hip Fracture\n0.1 %\nEstimated 10-Year Risk of Hip Fracture\n0.2 %\nEstimated 5-Year Risk of Osteoporotic/Fragility Fracture\n1.9 %\nEstimated 10-Year Risk of Osteoporotic/Fragility Fracture\n4 %"}]}
{"task_id": "medmcp-calc_102_4cc6c9bc", "task_scenario": "Electrolyte Correction", "task_category": "Clinical Medicine / Medicine & Organ Systems / Nephrology & Electrolytes", "patient_id": "P102_4cc6c9bc", "task_description": "Clinical scenario: A critically ill adult presents with severe hyperglycemia, volume depletion, an abnormal serum sodium, and a metabolic acidosis. The goals are to determine true tonicity, classify and treat the sodium disorder safely, address acid-base disturbances, and ensure balanced fluid administration while avoiding overly rapid corrections. Step-by-step workflow: 1) Start with Sodium Correction for Hyperglycemia to adjust the measured sodium for the degree of hyperglycemia; this reveals the true sodium level driving tonicity and prevents misclassification of hyponatremia or hypernatremia. 2) Use Serum Osmolality/Osmolarity next, inputting the corrected sodium to estimate expected osmolarity and compare it to measured osmolality. This establishes whether the patient’s state is hypotonic, isotonic, or hypertonic and whether an osmolar gap suggests unmeasured solutes. Decision branch A (tonicity and sodium): If corrected sodium and osmolality indicate hypotonic hyponatremia, proceed to Sodium Correction Rate in Hyponatremia and Hypernatremia to select appropriate fluid (isotonic vs hypertonic saline) and a safe correction rate/volume based on clinical context. If instead corrected sodium shows hypernatremia or hypertonicity, use Free Water Deficit in Hypernatremia to calculate the amount of free water needed, then apply Sodium Correction Rate in Hyponatremia and Hypernatremia to set the route and safe correction rate to avoid osmotic demyelination or cerebral edema. Decision branch B (acid-base): 3) Interpret the Arterial Blood Gas (ABG) Analyzer to classify the acid-base disorder. If a non-gap metabolic acidosis is present, use Urine Anion Gap to differentiate renal acidification defects (positive urine anion gap) from extrarenal bicarbonate losses (negative urine anion gap). 4) If acidosis is severe or the urine anion gap suggests renal acid retention, compute the Bicarbonate Deficit to estimate the bicarbonate required and integrate base therapy into the fluid plan. Decision branch C (calcium): 5) If hypoalbuminemia or hyperalbuminemia is suspected, run Calcium Correction for Hypoalbuminemia and Hyperalbuminemia so total calcium is not misinterpreted. If corrected total calcium is low or ABG indicates alkalemia (which lowers ionized calcium), use Predicting Ionized Hypocalcemia in Critical Care to estimate the likely ionized calcium and its probability of being below threshold, guiding whether immediate calcium replacement is warranted while awaiting direct ionized calcium measurement. Integration and monitoring: 6) Use Body Fluid Balance Calculator by Inputs and Outputs to track the cumulative net isotonic sodium load (from saline and any bicarbonate solutions) and net free water administration versus ongoing losses. Reconcile the planned volumes from the sodium and free-water calculators with real-time inputs and outputs to ensure the actual rate of sodium and tonicity change remains within targets. Re-evaluate periodically: as tonicity, acid-base status, and calcium estimates change, re-run the relevant calculators to adjust therapy safely.", "fuzzy_question": "I’m seeing a critically ill patient with very high glucose, apparent volume depletion, an abnormal sodium level, and a metabolic acidosis on recent labs. I’m trying to figure out the safest way to get their fluids and electrolytes back on track without overcorrecting anything.\n\nBecause the glucose is sky-high, I’m worried the sodium we’re seeing may be misleading. I want to account for the glucose effect so we understand what the “real” sodium is that’s actually driving water shifts and tonicity. Once we have a better handle on that, I’d like to sanity-check the overall tonicity: estimate what the osmolality should be from the main solutes using that adjusted sodium and compare it to the measured value, to decide whether they’re truly hypo-, iso-, or hypertonic and whether there’s any meaningful osmolar gap suggesting unmeasured substances.\n\nDepending on where that lands: if they’re truly hypotonic and hyponatremic after adjusting for glucose, I want help deciding between isotonic versus hypertonic saline and setting a correction target and volume that fits the clinical picture. If instead they’re actually hypernatremic or overall hypertonic, I’d like to work out how much free water they’re missing and choose the route and pace that safely brings them back without risking osmotic demyelination or cerebral edema. I’m torn between moving fast for perfusion and being very cautious about the rate of change, so I want explicit guardrails for the next several hours and the first day.\n\nOn the acid-base front, I want to read the gas carefully to sort out the pattern. If this looks like a non-gap metabolic acidosis, I’d use urine electrolytes to sort out whether the kidney is retaining acid versus ongoing GI bicarbonate losses. If it’s severe or points toward renal acid retention, I’d like to quantify how much bicarbonate they truly need and fold that into the fluid plan so we’re not overshooting sodium or tonicity while trying to buffer the acidosis.\n\nCalcium-wise, albumin may be off here, and the pH is shifting; I don’t want to misread a total calcium. Let’s adjust for albumin and, given the pH effect on ionized calcium, estimate how likely the ionized level is to be low enough to matter right now. That would guide whether to give calcium up front while we wait for a direct ionized calcium.\n\nThroughout, I want a tight handle on inputs and outputs so we know our cumulative net isotonic sodium load (from saline and any bicarbonate solutions) and net free water relative to ongoing losses. I’d like to reconcile what we plan to give with what’s actually happening on the floor, making sure the sodium and tonicity are changing at the pace we intend. As numbers evolve, we should loop back and update the plan so we stay within safe targets.\n\nWhat’s your take on how to approach this? I really need proper calculations on this—can’t make this decision based on gut feeling alone. Whatever approach you suggest, make sure it’s backed by solid calculations. This needs to hold up to scrutiny.", "required_calculators": ["Sodium Correction for Hyperglycemia", "Serum Osmolality/Osmolarity", "Arterial Blood Gas (ABG) Analyzer", "Urine Anion Gap", "Bicarbonate Deficit", "Sodium Correction Rate in Hyponatremia and Hypernatremia", "Free Water Deficit in Hypernatremia", "Calcium Correction for Hypoalbuminemia and Hyperalbuminemia", "Predicting Ionized Hypocalcemia in Critical Care", "Body Fluid Balance Calculator by Inputs and Outputs"], "calculator_answers": [{"order": 1, "name": "Sodium Correction for Hyperglycemia", "inputs": [{"field": "Sodium", "value": "133 mEq/L"}, {"field": "Glucose", "value": "820 mg/dL"}], "final_answer": "150 mEq/L", "notes": "145 mEq/L\nCorrected Sodium\n(Katz, 1973)\n150 mEq/L\nCorrected Sodium\n(Hillier, 1999)"}, {"order": 2, "name": "Serum Osmolality/Osmolarity", "inputs": [{"field": "Sodium", "value": "145 mEq/L"}, {"field": "BUN", "value": "36 mg/dL"}, {"field": "Glucose", "value": "820 mg/dL"}, {"field": "Serum alcohol concentration", "value": "0 mg/dL"}, {"field": "Measured serum osm", "value": "352 mOsm/kg"}], "final_answer": "348 mOsm/kg Calculated", "notes": "348 mOsm/kg Calculated Serum Osm\nNormal serum osmolality = 285-295 mOsm/kg\n4.0 mOsm/kg Osm Gap\nNormal Serum Osm Gap (Measured-Calculated) is -14 to +10."}, {"order": 3, "name": "Free Water Deficit in Hypernatremia", "inputs": [{"field": "Sex", "value": "Male"}, {"field": "Age range", "value": "Adult"}, {"field": "Weight", "value": "180 lbs"}, {"field": "Sodium", "value": "145 mEq/L"}, {"field": "Sodium desired", "value": "140 mEq/L"}], "final_answer": "1.7 L", "notes": "1.7 L\nFree Water Deficit"}, {"order": 4, "name": "Sodium Correction Rate in Hyponatremia and Hypernatremia", "inputs": [{"field": "Sex", "value": "Male"}, {"field": "Age range", "value": "Adult"}, {"field": "Weight", "value": "180 lbs"}, {"field": "Serum sodium", "value": "145 mEq/L"}, {"field": "Fluid type", "value": "0.45% saline (77 mmol/L Na)"}, {"field": "Rate of sodium correction", "value": "0.25 mEq/L/hr"}], "final_answer": "184 mL/hr", "notes": "184 mL/hr\nFluid rate to increase Na by 0.25 mmol/L/hr with 0.45% saline\nNOTE: Na is within normal. Confirm correction is needed."}, {"order": 5, "name": "Arterial Blood Gas (ABG) Analyzer", "inputs": [{"field": "pH", "value": "7.24"}, {"field": "PₐCO₂", "value": "24 mm Hg"}, {"field": "HCO₃-", "value": "10 mEq/L"}, {"field": "Sodium", "value": "133 mEq/L"}, {"field": "Chloride", "value": "112 mEq/L"}, {"field": "Albumin", "value": "2.8 g/dL"}, {"field": "If respiratory process present, chronicity", "value": "Acute"}], "final_answer": "This is a Non-Gap Metabolic Acidosis.\nPrimary Metabolic Acidosis, with: Appropriately Compensated by Respiratory Alkalosis", "notes": "This is a Non-Gap Metabolic Acidosis.\nPrimary Metabolic Acidosis, with: Appropriately Compensated by Respiratory Alkalosis"}, {"order": 6, "name": "Urine Anion Gap", "inputs": [{"field": "Urine sodium", "value": "40 mEq/L"}, {"field": "Urine potassium", "value": "20 mEq/L"}, {"field": "Urine chloride", "value": "25 mEq/L"}], "final_answer": "35.0 mEq/L", "notes": "35.0 mEq/L\nUrine anion gap positive\nThis suggests LOW urinary NH4+ and Renal Tubular Acidosis (RTA) if >10."}, {"order": 7, "name": "Bicarbonate Deficit", "inputs": [{"field": "Weight", "value": "180 lbs"}, {"field": "Bicarbonate", "value": "10 mEq/L"}], "final_answer": "457.2 mEq", "notes": "457.2 mEq\nBicarbonate Deficit"}, {"order": 8, "name": "Calcium Correction for Hypoalbuminemia and Hyperalbuminemia", "inputs": [{"field": "Calcium", "value": "7.8 mg/dL"}, {"field": "Albumin", "value": "2.8 g/dL"}, {"field": "Normal albumin: 4 g/dL or 40 g/L", "value": "4 g/dL"}], "final_answer": "8.8 mg/dL", "notes": "8.8 mg/dL\nCorrected Calcium\nEquivalent to 2.2 mmol/L"}, {"order": 9, "name": "Predicting Ionized Hypocalcemia in Critical Care", "inputs": [{"field": "Serum calcium", "value": "7.8 mg/dL"}, {"field": "Serum Albumin", "value": "2.8 g/dL"}, {"field": "Serum sodium", "value": "133 mEq/L"}, {"field": "Serum chloride", "value": "112 mEq/L"}, {"field": "Serum total carbon dioxide", "value": "10 mEq/L"}], "final_answer": "1.14 mM", "notes": "iCa point estimate\n1.14 mM\nLower limit of 95% PI of iCa\n1.02 mM\nUpper limit of 95% PI of iCa\n1.25 mM\nProbability that iCa is under 1.10mM\n19.32 %"}, {"order": 10, "name": "Body Fluid Balance Calculator by Inputs and Outputs", "inputs": [{"field": "Gastric", "value": "0 mL"}, {"field": "Biliary", "value": "0 mL"}, {"field": "Pancreatic", "value": "0 mL"}, {"field": "Small bowel", "value": "0 mL"}, {"field": "Diarrhea, nonosmotic", "value": "0 mL"}, {"field": "Sorbitol-based osmotic diarrhea", "value": "0 mL"}, {"field": "Lactulose-based osmotic diarrhea", "value": "0 mL"}, {"field": "Osmotic diarrhea - PEG", "value": "0 mL"}, {"field": "Pleural or peritoneal fluid", "value": "0 mL"}, {"field": "Wound drainage", "value": "0 mL"}, {"field": "Dialysis net ultrafiltrate", "value": "0 mL"}, {"field": "Urine", "value": "1800 mL"}, {"field": "Insensible losses", "value": "800 mL"}, {"field": "Other body fluid", "value": "0 mL"}, {"field": "Packed RBCs", "value": "0 mL"}, {"field": "Plasma, cryoprecipitate, platelets, or IVIG", "value": "0 mL"}, {"field": "5%, 20%, 25% albumin", "value": "0 mL"}, {"field": "0.9% saline", "value": "0 mL"}, {"field": "0.45% saline", "value": "0 mL"}, {"field": "Plasma-lyte A", "value": "0 mL"}, {"field": "Ringer’s lactate", "value": "1500 mL"}, {"field": "D5W", "value": "1000 mL"}, {"field": "NaHCO₃ concentrate", "value": "50 mL"}, {"field": "100 mEq NaHCO₃ in 1L D5W", "value": "0 mL"}, {"field": "Injectable sodium phosphates", "value": "0 mL"}, {"field": "TPN", "value": "0 mL"}, {"field": "Pulmocare", "value": "0 mL"}, {"field": "Nutren 2.0", "value": "0 mL"}, {"field": "Fibersource HN", "value": "0 mL"}, {"field": "Impact Peptide1.5", "value": "0 mL"}, {"field": "Nutren Pulmonary", "value": "0 mL"}, {"field": "Isosource HN", "value": "0 mL"}, {"field": "Diabetisource AC", "value": "0 mL"}, {"field": "Novasource Renal", "value": "0 mL"}, {"field": "Osmolyte", "value": "0 mL"}, {"field": "Jevity", "value": "0 mL"}, {"field": "Replete Fiber", "value": "0 mL"}, {"field": "Ensure", "value": "0 mL"}, {"field": "Nepro", "value": "0 mL"}, {"field": "Peptamen", "value": "0 mL"}, {"field": "Suplena", "value": "0 mL"}, {"field": "Vivonex RTF", "value": "0 mL"}, {"field": "TwoCal HN", "value": "0 mL"}, {"field": "Beneprotein", "value": "0 mL"}, {"field": "Renalcal", "value": "0 mL"}, {"field": "Other enteral solution", "value": "0 mL"}], "final_answer": "831 mL", "notes": "831 mL\n0.9% saline (Net Gain)\n-881 mL\nFree H2O (Net Loss)"}]}
{"task_id": "medmcp-calc_103_1facf764", "task_scenario": "Stroke & Neurologic Emergencies", "task_category": "Clinical Medicine / Emergency, Critical Care & Perioperative / Emergency Medicine & Trauma", "patient_id": "P103_1facf764", "task_description": "Scenario: A patient presents to the emergency department as a stroke alert with sudden focal neurologic deficits and a known last-known-well. You must rapidly confirm a likely stroke versus a mimic, quantify neurologic severity, rule out intracranial hemorrhage, and decide on intravenous thrombolysis and/or endovascular therapy (EVT). Use the following calculators in sequence, with branching based on imaging results and eligibility.\n\nStep 1 – Screen for stroke vs mimic: Use the Recognition of Stroke in the Emergency Room (ROSIER) Scale to determine if the presentation is likely a true stroke. If ROSIER is negative (suggesting a mimic), pivot to alternative non-stroke workup and stop this workflow. If ROSIER is positive, continue.\n\nStep 2 – Quantify neurologic severity: Use the NIH Stroke Scale/Score (NIHSS) to establish baseline stroke severity. This score will later be used as a required input for risk prediction after thrombolysis and for EVT benefit prediction.\n\nStep 3 – Assess likelihood of large-vessel occlusion (LVO): Use the Field Assessment Stroke Triage for Emergency Destination (FAST-ED) to gauge LVO probability based on the focused cortical signs. If FAST-ED is high, pre-alert for emergent vascular imaging and potential EVT while proceeding to neuroimaging.\n\nStep 4 – Non-contrast head CT branch point:\n- If CT shows intracerebral hemorrhage (ICH):\n  • Use the ABC/2 Formula for Intracerebral Hemorrhage Volume to estimate hematoma volume, which helps determine need for neurosurgical consultation and level of care.\n  • Then use the Intracerebral Hemorrhage (ICH) Score to estimate mortality risk and to guide the intensity of monitoring and escalation of care.\n  • End the ischemic stroke pathway here; manage per hemorrhage protocols.\n- If CT shows no hemorrhage (suspected ischemic stroke): proceed to Step 5.\n\nStep 5 – Estimate ischemic core: Use the Alberta Stroke Program Early CT Score (ASPECTS) to quantify early ischemic changes. A higher ASPECTS suggests smaller core and supports reperfusion therapy. If ASPECTS is very low (extensive core), consider deferring IV thrombolysis and EVT and prioritize supportive care; otherwise continue.\n\nStep 6 – Determine IV thrombolysis eligibility: Use tPA Contraindications for Ischemic Stroke to systematically confirm inclusion/exclusion criteria. If contraindications are present, skip IV thrombolysis and move to EVT consideration (if LVO). If eligible, proceed to dosing.\n\nStep 7 – Dose thrombolytic: Use the Tenecteplase (TNK) Dosing for Ischemic Stroke Calculator to calculate the correct TNK dose. Administer per protocol and immediately proceed to post-lysis risk stratification and EVT planning as applicable.\n\nStep 8 – Anticipate post-thrombolysis hemorrhage risk: Use the SEDAN Score for Post-tPA Hemorrhage, incorporating the baseline NIHSS and CT findings, to predict symptomatic ICH risk and tailor monitoring intensity (e.g., ICU-level vs step-down frequency of neuro checks and BP targets).\n\nStep 9 – EVT candidacy and expected benefit (if CTA/MRA demonstrates anterior circulation LVO and ASPECTS is acceptable): Use the Pittsburgh Response to Endovascular therapy (PRE) Score, leveraging the previously obtained NIHSS and clinical variables, to estimate likelihood of benefit from EVT. If PRE suggests favorable response, proceed to emergent thrombectomy activation; if unfavorable, consider individualized medical management.\n\nThis workflow ensures rapid differentiation of stroke from mimics, efficient imaging-driven branching between hemorrhagic and ischemic care, safe thrombolysis selection and dosing, and evidence-informed EVT decisions, while using earlier scores (NIHSS, ASPECTS) as inputs for later risk/benefit tools.", "fuzzy_question": "I’m evaluating a patient brought in as a stroke alert with sudden focal neurologic deficits and a clearly established last-known-well. I need to quickly distinguish a true acute stroke from a mimic (such as seizure with postictal deficit, migraine, syncope, or hypoglycemia). If it doesn’t fit stroke, I will immediately pivot to a non-stroke workup and stop the stroke pathway. If it does appear to be a stroke, I need a standardized baseline neurologic severity score from the usual stroke exam to anchor decisions and inform subsequent risk predictions.\n\nEarly on, I also want an estimate of the likelihood of a proximal large-vessel occlusion—focusing on cortical signs like gaze deviation, aphasia, and neglect—so we can prioritize vascular imaging and notify the thrombectomy team while proceeding to the scanner.\n\nOnce there is a non-contrast head CT, there are two paths:\n- If there is intracranial hemorrhage, I need a rapid hematoma volume estimate from CT dimensions to guide urgency of neurosurgical involvement and determine level of care. I also want a mortality risk estimate that incorporates clinical status and key imaging features (volume, location, and any intraventricular extension) to frame prognosis and monitoring intensity. From that point, management should follow a hemorrhage pathway rather than ischemic therapies.\n- If there is no hemorrhage and ischemia is suspected, please grade early ischemic changes to estimate the extent of the core. If the early changes are very extensive, we may need to step back from reperfusion strategies and focus on supportive care. If the changes are limited, we should continue.\n\nAssuming the scan shows no bleed and the core burden is acceptable, I want a disciplined screen for intravenous thrombolysis. This includes confirming time from last-known-well within guideline windows, blood pressure and whether it can be safely lowered, any prior intracranial hemorrhage, recent surgery or active bleeding, platelet status, anticoagulation status with relevant labs or timing of the last dose, extremes of glucose, seizure at onset, and red flags such as infective endocarditis or suspected aortic dissection. If any of these exclude thrombolysis, skip the lytic and, if a proximal occlusion remains likely, proceed toward a mechanical option. If eligible, I am inclined to use tenecteplase—calculate a weight-based dose with the appropriate maximum cap and specify the administration plan.\n\nImmediately after administration, I want a quantified estimate of the risk for symptomatic intracranial hemorrhage that incorporates initial severity, early CT changes (including a hyperdense vessel if present), age-related risk, and glucose. Use that to tailor level of care (ICU-level vs step-down), neuro check frequency, and blood pressure targets in the first day.\n\nIn parallel, if vascular imaging shows an anterior circulation large-vessel occlusion and early CT changes are not extensive, I’d like a reasoned prediction of expected benefit from thrombectomy using the initial severity and baseline factors. If the benefit appears favorable, proceed rapidly; if not, justify a more conservative approach.\n\nPlease keep these elements connected—use the initial severity and early CT grading to inform both bleeding risk after thrombolysis and the anticipated benefit from thrombectomy. And if at the outset the presentation is inconsistent with a true stroke, stop the stroke pathway and redirect to a mimic workup.\n\nI need evidence-based calculations with transparent intermediate values to support these decisions and ensure the approach stands up to scrutiny.", "required_calculators": ["Recognition of Stroke in the Emergency Room (ROSIER) Scale", "NIH Stroke Scale/Score (NIHSS)", "Field Assessment Stroke Triage for Emergency Destination (FAST-ED)", "Alberta Stroke Program Early CT Score (ASPECTS)", "tPA Contraindications for Ischemic Stroke", "Tenecteplase (TNK) Dosing for Ischemic Stroke Calculator", "SEDAN Score for Post-tPA Hemorrhage", "Pittsburgh Response to Endovascular therapy (PRE) Score"], "calculator_answers": [{"order": 1, "name": "Recognition of Stroke in the Emergency Room (ROSIER) Scale", "inputs": [{"field": "Loss of consciousness or syncope", "value": "No", "score": 0}, {"field": "Seizure activity", "value": "No", "score": 0}, {"field": "Asymmetric facial weakness", "value": "Yes (right facial droop)", "score": 1}, {"field": "Asymmetric arm weakness", "value": "Yes (right arm weaker)", "score": 1}, {"field": "Asymmetric leg weakness", "value": "Yes (right leg weaker)", "score": 1}, {"field": "Speech disturbance", "value": "Yes (aphasia)", "score": 1}, {"field": "Visual field defect", "value": "Yes (right homonymous hemianopia)", "score": 1}], "final_answer": 5, "notes": "5 points\nROSIER Score\nStroke possible"}, {"order": 2, "name": "NIH Stroke Scale/Score (NIHSS)", "inputs": [{"field": "1A: Level of consciousness", "value": "Alert; keenly responsive (0)", "score": 0}, {"field": "1B: Ask month and age", "value": "0 questions right (2)", "score": 2}, {"field": "1C: 'Blink eyes' & 'squeeze hands'", "value": "Performs 0 tasks (2)", "score": 2}, {"field": "2: Horizontal extraocular movements", "value": "Forced gaze palsy: cannot be overcome (2) — eyes deviate left", "score": 2}, {"field": "3: Visual fields", "value": "Complete hemianopia (2) — right field loss", "score": 2}, {"field": "4: Facial palsy", "value": "Partial paralysis (lower face) (2) — right", "score": 2}, {"field": "5A: Left arm motor drift", "value": "No drift for 10 seconds (0)", "score": 0}, {"field": "5B: Right arm motor drift", "value": "No effort against gravity (3)", "score": 3}, {"field": "6A: Left leg motor drift", "value": "No drift for 5 seconds (0)", "score": 0}, {"field": "6B: Right leg motor drift", "value": "Drift, hits bed (2)", "score": 2}, {"field": "7: Limb Ataxia", "value": "No ataxia (0)", "score": 0}, {"field": "8: Sensation", "value": "Mild-moderate loss (1) — decreased pinprick right side", "score": 1}, {"field": "9: Language/aphasia", "value": "Severe aphasia (2)", "score": 2}, {"field": "10: Dysarthria", "value": "Mild-moderate dysarthria (1)", "score": 1}, {"field": "11: Extinction/inattention", "value": "No abnormality (0)", "score": 0}], "final_answer": 19, "notes": "19 points\nNIH Stroke Scale"}, {"order": 3, "name": "Field Assessment Stroke Triage for Emergency Destination (FAST-ED)", "inputs": [{"field": "Facial palsy", "value": "Partial or complete paralysis (+1)", "score": 1}, {"field": "Arm weakness", "value": "No effort against gravity or no movement (+2) — right arm", "score": 2}, {"field": "Speech changes", "value": "Severe, global aphasia or mute (+2)", "score": 2}, {"field": "Eye deviation", "value": "Forced deviation (+2) — eyes left", "score": 2}, {"field": "Denial/neglect", "value": "Absent (0)", "score": 0}], "final_answer": 7, "notes": "7 points\nFAST-ED Score\n~60% or higher\nLikelihood of LVOS"}, {"order": 4, "name": "Alberta Stroke Program Early CT Score (ASPECTS)", "inputs": [{"field": "Caudate (C) early ischemic change", "value": "No", "score": 0}, {"field": "Internal Capsule (IC) early ischemic change", "value": "No", "score": 0}, {"field": "Lentiform nucleus (L) early ischemic change", "value": "No", "score": 0}, {"field": "Insular Ribbon (I) early ischemic change", "value": "Yes", "score": -1}, {"field": "M1 (anterior MCA cortex) early ischemic change", "value": "No", "score": 0}, {"field": "M2 (lateral to insular ribbon) early ischemic change", "value": "Yes", "score": -1}, {"field": "M3 (posterior MCA cortex) early ischemic change", "value": "No", "score": 0}, {"field": "M4 (anterior rostral to M1) early ischemic change", "value": "No", "score": 0}, {"field": "M5 (lateral rostral to M3) early ischemic change", "value": "No", "score": 0}, {"field": "M6 (posterior rostral to M3) early ischemic change", "value": "No", "score": 0}], "final_answer": 8, "notes": "8 points\n~40% of patients with ASPECTS ≥8 will have mRS 0-1 at 90 days."}, {"order": 5, "name": "tPA Contraindications for Ischemic Stroke", "inputs": [{"field": "Age ≥18", "value": "Yes (68 years)"}, {"field": "Clinical diagnosis of ischemic stroke causing neurological deficit", "value": "Yes"}, {"field": "Time of symptom onset <4.5 hours", "value": "Yes (95 minutes from LKW)"}, {"field": "Intracranial hemorrhage on CT (absolute contraindication)", "value": "No"}, {"field": "Clinical presentation suggests subarachnoid hemorrhage (absolute)", "value": "No"}, {"field": "Neurosurgery, head trauma, or stroke in past 3 months (absolute)", "value": "No"}, {"field": "Uncontrolled hypertension (>185 mmHg SBP or >110 mmHg DBP) (absolute)", "value": "No (SBP 172 mmHg, DBP 98 mmHg pre-treatment)"}, {"field": "History of intracranial hemorrhage (absolute)", "value": "No"}, {"field": "Known intracranial AVM, neoplasm, or aneurysm (absolute)", "value": "No"}, {"field": "Active internal bleeding (absolute)", "value": "No"}, {"field": "Suspected/confirmed endocarditis (absolute)", "value": "No"}, {"field": "Known bleeding diathesis: Platelet count <100,000 (absolute)", "value": "No (210,000 /µL)"}, {"field": "Known bleeding diathesis: Heparin within 48 hours with elevated aPTT (absolute)", "value": "No (aPTT 30 s; no recent heparin)"}, {"field": "Known bleeding diathesis: Warfarin with INR >1.7 (absolute)", "value": "No (INR 1.0; not on warfarin)"}, {"field": "Known bleeding diathesis: Current use of direct thrombin or factor Xa inhibitors (absolute)", "value": "No"}, {"field": "Abnormal blood glucose <50 mg/dL (absolute)", "value": "No (156 mg/dL)"}, {"field": "Intra-axial intracranial neoplasm (absolute)", "value": "No"}, {"field": "Gastrointestinal (GI) malignancy (absolute)", "value": "No"}, {"field": "Gastrointestinal (GI) hemorrhage within the last 21 days (absolute)", "value": "No"}, {"field": "Intracranial or intraspinal surgery within the last 3 months (absolute)", "value": "No"}, {"field": "CT brain imaging shows extensive regions of clear hypoattenuation (absolute)", "value": "No (ASPECTS 8; <1/3 territory)"}, {"field": "Stroke known or suspected to be associated with aortic arch dissection (absolute)", "value": "No"}, {"field": "Only minor or rapidly improving stroke symptoms (relative/warning)", "value": "No"}, {"field": "Major surgery or serious non-head trauma in the previous 14 days (relative/warning)", "value": "No"}, {"field": "History of gastrointestinal or urinary tract hemorrhage within 21 days (relative/warning)", "value": "No"}, {"field": "Seizure at stroke onset (relative/warning)", "value": "No"}, {"field": "Recent arterial puncture at a noncompressible site (relative/warning)", "value": "No"}, {"field": "Recent lumbar puncture (relative/warning)", "value": "No"}, {"field": "Post myocardial infarction pericarditis (relative/warning)", "value": "No"}, {"field": "Pregnancy (relative/warning)", "value": "No"}, {"field": "Additional warning >3 hours: Age >80 years", "value": "No (68 years)"}, {"field": "Additional warning >3 hours: History of prior stroke and diabetes", "value": "No (no prior stroke; diabetes status not prohibitive)"}, {"field": "Additional warning >3 hours: Any active anticoagulant use (even with INR <1.7)", "value": "No"}, {"field": "Additional warning >3 hours: NIHSS >25", "value": "No (NIHSS 19)"}, {"field": "Additional warning >3 hours: CT shows multilobar infarction (>1/3 hemisphere)", "value": "No"}, {"field": "Vital signs (pre-lysis) SBP/DBP", "value": "172/98 mmHg"}, {"field": "Serum glucose", "value": "156 mg/dL"}, {"field": "Platelet count", "value": "210,000 /µL"}, {"field": "INR", "value": "1.0"}, {"field": "aPTT", "value": "30 seconds"}, {"field": "Last-known-well time", "value": "14:10 local"}, {"field": "Door time", "value": "15:35 local"}], "final_answer": "Patient eligible for tPA.", "notes": "Patient eligible for tPA."}, {"order": 6, "name": "Tenecteplase (TNK) Dosing for Ischemic Stroke Calculator", "inputs": [{"field": "Weight", "value": "180 lb"}], "final_answer": "4.1 mL", "notes": "4.1 mL, equivalent to 20.5 mg\nTenecteplase dosing\n5.9 mL, equivalent to 29.5 mg\nWaste, to be discarded"}, {"order": 7, "name": "SEDAN Score for Post-tPA Hemorrhage", "inputs": [{"field": "Blood sugar", "value": "145-216 mg/dL (156 mg/dL) (+1)", "score": 1}, {"field": "Early infarct signs on initial CT", "value": "Yes (+1)", "score": 1}, {"field": "Hyperdense cerebral artery sign on initial CT", "value": "Yes (+1) — hyperdense left M1", "score": 1}, {"field": "Age > 75 years", "value": "No (0) — age 68", "score": 0}, {"field": "NIH Stroke Scale (NIHSS) ≥ 10", "value": "Yes (+1) — NIHSS 19", "score": 1}], "final_answer": 4, "notes": "4 points\n12.3% risk of symptomatic ICH. (ECASS-II definition.)"}, {"order": 8, "name": "Pittsburgh Response to Endovascular therapy (PRE) Score", "inputs": [{"field": "Age", "value": "68 years"}, {"field": "NIHSS Score", "value": "19 points"}, {"field": "ASPECTS Score", "value": "8 points"}], "final_answer": 26, "notes": "26 points\nLikely to benefit from endovascular therapy."}]}
{"task_id": "medmcp-calc_104_eee8fb88", "task_scenario": "Febrile Neutropenia", "task_category": "Clinical Medicine / Medicine & Organ Systems / Hematology & Oncology", "patient_id": "P104_eee8fb88", "task_description": "Scenario: A patient actively receiving cytotoxic chemotherapy presents with fever. The clinical team must rapidly confirm febrile neutropenia, determine sepsis severity, stratify risk for serious complications, decide on inpatient versus outpatient management, and document toxicity severity for future oncology planning.\n\nStep 1 — Immediate severity screen: Use the SIRS, Sepsis, and Septic Shock Criteria at triage to classify acute illness severity. If septic shock criteria are met, route to a high-risk inpatient pathway and defer risk scores intended for stable patients. If sepsis without shock is present, treat as high risk; if neither is present, proceed to the next steps for risk stratification of a clinically stable presentation.\n\nStep 2 — Confirm neutropenia: Calculate the Absolute Neutrophil Count (ANC) to establish whether neutropenia is present. If neutropenia is not present, exit this febrile neutropenia workflow and manage fever per general sepsis protocols. If neutropenia is present, continue.\n\nStep 3 — Grade toxicity: Use the Common Terminology Criteria for Adverse Events (CTCAE), entering the ANC from Step 2 to assign a neutropenia grade and to document febrile neutropenia severity. If CTCAE indicates the most severe grade of neutropenia, treat as high risk for complications and proceed with inpatient management; otherwise continue to formal risk indices.\n\nStep 4 — Global complication risk: For patients who are hemodynamically stable by Step 1 and not at the most severe CTCAE neutropenia grade by Step 3, apply the MASCC Risk Index for Febrile Neutropenia to estimate the risk of serious complications and to screen for eligibility for outpatient management.\n\nStep 5 — Stable low-risk refinement: If MASCC suggests low risk and clinical stability is maintained (as per Step 1), apply the Clinical Index of Stable Febrile Neutropenia (CISNE) to refine outpatient eligibility among stable patients. If MASCC indicates high risk, do not use CISNE and manage as inpatient.\n\nDisposition and planning: If both MASCC and CISNE support low risk, consider outpatient-oriented pathways; otherwise, plan inpatient management. Regardless of disposition, retain the CTCAE grade in the record to inform oncology dose modifications and future prophylaxis planning. The outputs from earlier steps act as gates for later tools: the SIRS/sepsis assessment determines whether MASCC/CISNE are appropriate; the ANC result is the input to CTCAE; the CTCAE grade determines whether MASCC should be applied; MASCC determines whether to proceed to CISNE.", "fuzzy_question": "I’m evaluating a patient receiving chemotherapy who presents with fever, and I’m trying to determine how acutely ill they are and whether this is febrile neutropenia. I want to be careful about two things up front: first, are we looking at sepsis—especially shock—on initial assessment; and second, do we actually have neutropenia driving the fever.\n\nRight now, I’m not certain if sepsis or shock criteria are met. Please frame the acute illness severity from the bedside picture—vitals, mental status, perfusion, need for fluids or pressors, and early labs like lactate. If they look like shock, I don’t want to consider any outpatient pathways; that’s high risk and they need to be managed as such. If they have sepsis without shock, I’m still leaning toward high-risk inpatient care. Only if neither sepsis nor shock is present and they’re truly stable should we move on to more nuanced risk stratification.\n\nIn parallel, I need to confirm whether this is actually neutropenic fever. Pull the absolute neutrophil count from the CBC with differential (using neutrophils and bands). If the count doesn’t support neutropenia, then we should step off the febrile neutropenia track and handle this as general sepsis with the usual source workup and broad-spectrum coverage. If they are neutropenic, let’s keep going.\n\nOnce we have the count, I want to classify how severe the neutropenia and the febrile neutropenia are using standard oncology toxicity grading. If the count puts them in the most severe category, that alone should push us to inpatient management given the risk of complications. If it’s not the worst grade and they remain hemodynamically steady, then I’d like a formal estimate of their overall risk of serious complications using a validated febrile neutropenia risk index that helps decide if outpatient care could even be on the table.\n\nIf that broad risk assessment suggests they might be low risk—and they still look clinically stable at the bedside—I’d like to refine that further with the tool specifically meant for stable oncology patients to decide who can safely go home. But if the earlier risk assessment points to higher risk, let’s not do the refinement step and just plan to admit.\n\nBottom line on disposition: I’m only comfortable with an outpatient-oriented plan if both the broad risk assessment and the stability-focused refinement support low risk and the patient remains stable; otherwise, we admit. And regardless of where they go, please make sure the neutropenia/febrile neutropenia toxicity grade is clearly documented so oncology can adjust future dosing and consider prophylaxis for upcoming cycles.\n\nThe order here really matters for me: I don’t want to use any outpatient risk tools until we’re confident they’re not in shock; the neutrophil count anchors the toxicity grade; that toxicity grade determines whether it’s even appropriate to use the global complication risk index; and only if that looks low do we use the stability-focused tool.\n\nWhat’s your take on this case, and how would you reason through it? I need proper calculations to support the assessment—this can’t rely on clinical intuition alone. The approach should be backed by solid calculations that hold up to scrutiny.", "required_calculators": ["SIRS, Sepsis, and Septic Shock Criteria", "Absolute Neutrophil Count (ANC)", "Common Terminology Criteria for Adverse Events (CTCAE)", "MASCC Risk Index for Febrile Neutropenia", "Clinical Index of Stable Febrile Neutropenia (CISNE)"], "calculator_answers": [{"order": 1, "name": "SIRS, Sepsis, and Septic Shock Criteria", "inputs": [{"field": "temperature_c", "value": "38.4 C"}, {"field": "heart_rate_bpm", "value": "88 bpm"}, {"field": "respiratory_rate", "value": "18 breaths/min"}, {"field": "paco2_mm_hg", "value": "38 mmHg"}, {"field": "wbc_count", "value": "1.0 x10^3/uL"}, {"field": "bands_percent", "value": "2 %"}, {"field": "sirs_temp_criterion", "value": "Yes (temp > 38 C)"}, {"field": "sirs_hr_criterion", "value": "No (HR <= 90)"}, {"field": "sirs_rr_or_paco2_criterion", "value": "No (RR <= 20 and PaCO2 >= 32)"}, {"field": "sirs_wbc_or_bands_criterion", "value": "Yes (WBC < 4,000/uL)"}, {"field": "suspected_or_present_infection", "value": "No at triage (source undetermined)"}, {"field": "systolic_bp_mm_hg", "value": "116 mmHg"}, {"field": "lactate_mmol_l", "value": "1.6 mmol/L"}, {"field": "severe_sepsis_criteria", "value": "No (no hypotension or lactic acidosis)"}, {"field": "septic_shock_criteria", "value": "No (no hypotension after fluids/pressors not required)"}, {"field": "mental_status", "value": "Alert and oriented"}, {"field": "perfusion", "value": "Warm, capillary refill 2 sec"}, {"field": "oxygen_saturation", "value": "98 % on room air"}, {"field": "Evidence of ≥2 organs failing", "value": "No"}], "final_answer": "This patient meets SIRS criteria.", "notes": "This patient meets SIRS criteria."}, {"order": 2, "name": "Absolute Neutrophil Count (ANC)", "inputs": [{"field": "percent_neutrophils", "value": "48 %"}, {"field": "percent_bands", "value": "2 %"}, {"field": "wbc_count_x10^3_per_uL", "value": "1.0"}], "final_answer": "500 cells/µL", "notes": "500 cells/µL\nAbsolute Neutrophil Count\nModerate neutropenia"}, {"order": 3, "name": "Common Terminology Criteria for Adverse Events (CTCAE)", "inputs": [{"field": "CTCAE term", "value": "Febrile neutropenia"}, {"field": "Febrile neutropenia", "value": "ANC <1000/mm3 with a single temperature of >38.3 °C (101 °F) or a sustained temperature of ≥38 °C (100.4 °F) for more than one hour"}], "final_answer": "Grade 3", "notes": "Grade 3\nCTCAE\nSevere\nSeverity"}, {"order": 4, "name": "MASCC Risk Index for Febrile Neutropenia", "inputs": [{"field": "burden_of_illness", "value": "None or mild (+5)", "score": 5}, {"field": "hypotension_sbp_lt_90_mm_hg", "value": "No (+5)", "score": 5}, {"field": "active_copd", "value": "No (+4)", "score": 4}, {"field": "type_of_cancer", "value": "Solid tumor (+4)", "score": 4}, {"field": "dehydration_requiring_iv_fluids", "value": "No (+3)", "score": 3}, {"field": "status_at_onset_of_fever", "value": "Outpatient (+3)", "score": 3}, {"field": "age_years", "value": "52 (<60 -> +2)", "score": 2}], "final_answer": 26, "notes": "26 points\nLow risk for poor outcome. Consider oral and/or outpatient empiric antibiotic therapy after discussion with oncology."}, {"order": 5, "name": "Clinical Index of Stable Febrile Neutropenia (CISNE)", "inputs": [{"field": "ecog_performance_status", "value": "1 (score 0)", "score": 0}, {"field": "stress_induced_hyperglycemia", "value": "No (initial glucose 113 mg/dL) -> score 0", "score": 0}, {"field": "copd_on_therapy", "value": "No (score 0)", "score": 0}, {"field": "cardiovascular_disease_history", "value": "No (score 0)", "score": 0}, {"field": "nci_mucositis_grade", "value": "1 (score 0)", "score": 0}, {"field": "monocytes_absolute", "value": "220 cells/uL (>=200 -> score 0)", "score": 0}], "final_answer": 0, "notes": "0 points\nConsider discharge with oral antibiotics after discussion with oncology.\nLow risk\nRisk category I\n1.1% risk of complications within a minimum of 7 days (hypotension, organ failure, etc.—see Facts & Figures for details)"}]}
{"task_id": "medmcp-calc_105_2cfb1b50", "task_scenario": "Anthropometrics and Obesity Management", "task_category": "Clinical Medicine / Medicine & Organ Systems / Endocrinology & Metabolism", "patient_id": "P105_2cfb1b50", "task_description": "Clinical scenario: A patient presents for comprehensive obesity management within Clinical Medicine / Medicine & Organ Systems / Endocrinology & Metabolism _ Anthropometrics and Obesity Management. The clinical goal is to quantify anthropometrics and visceral adiposity, screen for cardiometabolic and hepatic risk, estimate insulin resistance and diabetes risk, then tailor a practical energy and physical activity plan while staging the severity of obesity-related health impairments to guide intervention intensity.\n\nStep-by-step workflow and decision logic:\n1) Use the BMI Calculator (Body Mass Index and BSA) to establish baseline BMI classification for obesity and provide a size-based context for subsequent risk assessments.\n2) Apply the Body Roundness Index (BRI) to estimate percent body fat and visceral adipose tissue (VAT). This refines risk beyond BMI by identifying central adiposity.\n   - If BMI indicates obesity or BRI shows high VAT, proceed to metabolic risk screening (Metabolic Syndrome and HOMA-IR). If BMI is not in the obesity range and VAT is low, you may skip directly to energy planning (IBW/Adjusted BW → BEE) and a general lifestyle plan.\n3) Run the Metabolic Syndrome (IDF) calculator using the required clinical and laboratory inputs to determine whether the patient meets criteria for metabolic syndrome.\n4) Use HOMA-IR (Homeostatic Model Assessment for Insulin Resistance) to approximate insulin resistance.\n   - If Metabolic Syndrome (IDF) is present or HOMA-IR is elevated, continue with organ-specific and diabetes risk screening (Fatty Liver Index and AUSDRISK). If both are negative, proceed to energy planning (IBW/Adjusted BW → Basal Energy Expenditure).\n5) Calculate the Fatty Liver Index to estimate the probability of fatty liver disease.\n   - If Fatty Liver Index suggests high probability, plan hepatic evaluation and ensure this risk is incorporated into final staging (EOSS). If low probability, continue with the management pathway.\n6) Use the Australian Type 2 Diabetes Risk (AUSDRISK) Assessment Tool to quantify future diabetes risk.\n   - If AUSDRISK indicates high risk or the patient has established diabetes, apply the Physical Activity Decision Tool for Patients Living with Diabetes to tailor exercise readiness, progression, and safety. If risk is low and diabetes is absent, provide general physical activity guidance without this tool.\n7) Compute Ideal Body Weight and Adjusted Body Weight to generate both IBW and adjusted body weight values for planning.\n   - Deterministic input linkage: If BMI shows obesity or BRI indicates high VAT, select adjusted body weight as the weight parameter for the energy calculation to avoid overestimation; otherwise use actual weight.\n8) Use Basal Energy Expenditure to estimate daily energy needs; then prescribe a structured energy deficit based on goals (e.g., gradual weight loss), using the weight selection from step 7 as the explicit input.\n9) Apply the Edmonton Obesity Staging System (EOSS) to integrate clinical impairments (e.g., results from Metabolic Syndrome, HOMA-IR, Fatty Liver Index, and diabetes risk) and assign an obesity stage.\n   - If EOSS ≥ Stage 2, intensify therapy (e.g., anti-obesity pharmacotherapy and/or referral for bariatric evaluation) in addition to lifestyle intervention. If EOSS Stage 0–1, prioritize lifestyle measures with close follow-up.\n\nThis sequence connects anthropometric characterization to pathophysiologic and organ-specific risk, then to practical energy and activity planning, and finally to severity staging that determines the intensity of care.", "fuzzy_question": "I’m evaluating a patient for comprehensive weight management. I want to ground the plan by first clarifying weight-for-height and overall body size so we’re aligned on risk and goals. I’m not focused solely on total weight; central adiposity is a particular concern. Alongside BMI and a general sense of overall body size, I’d like a waist-and-height–based assessment that approximates percent body fat and the likely proportion of visceral versus subcutaneous fat. My concern is that BMI alone may under- or overstate risk if excess weight is concentrated centrally.\n\nHere’s the approach I’m considering. If findings indicate obesity or if waist-derived measures suggest substantial central adiposity, I don’t want to miss cardiometabolic risk. In that case, please assess whether criteria are met for the standard risk cluster that incorporates waist circumference, blood pressure, triglycerides, HDL, and fasting glucose, and use fasting insulin with glucose to gauge insulin resistance. If neither the cluster nor insulin resistance appears concerning, we can proceed directly into energy and activity planning without extra detours.\n\nIf the cluster is present or insulin resistance is elevated, then before setting targets I want to understand organ-specific and future diabetes risk. Please use routinely available clinical variables (waist/BMI, triglycerides, and a liver enzyme) to estimate the likelihood of fatty liver; if that probability appears high, I want a plan for hepatic evaluation and for that to inform how we stage overall severity. I also want a validated clinical risk estimate for future type 2 diabetes based on noninvasive factors such as anthropometrics and family history. If diabetes risk is high, or if diabetes is already established, tailor exercise guidance accordingly—screen readiness, set progression, and address safety around hypoglycemia risk and complications such as neuropathy or retinopathy. If diabetes risk is low and there’s no established diabetes, general physical activity guidance with progressive targets should be sufficient.\n\nFor nutrition planning, I want both an “ideal” weight reference and an “adjusted” weight to anchor energy prescriptions. If obesity thresholds are clearly met or the waist-based assessment indicates high visceral fat, use the adjusted weight to estimate resting energy needs to avoid overestimation; otherwise, use actual weight. From there, estimate resting needs and translate that into a practical daily energy prescription with an appropriate deficit for gradual weight loss, paired with an activity plan that is realistic week to week.\n\nFinally, I don’t want to stop at labeling by BMI. Please integrate the overall picture—findings from the risk cluster, insulin resistance, fatty liver likelihood, and diabetes risk—and synthesize a clinical stage of obesity severity that reflects metabolic, mechanical, and mental health impacts. If severity is higher, we should escalate intensity (including consideration of medication for weight management and possibly surgical referral) in addition to lifestyle work. If severity is lower, a lifestyle-first approach with close follow-up makes more sense.\n\nWhat is the clinical reasoning here, step by step? Walk through the calculations and what they mean at each stage so we can justify the path chosen. The approach should be backed by solid calculations and able to withstand scrutiny.", "required_calculators": ["BMI Calculator (Body Mass Index and BSA)", "Body Roundness Index (BRI)", "Metabolic Syndrome (IDF)", "HOMA-IR (Homeostatic Model Assessment for Insulin Resistance)", "Fatty Liver Index", "Australian Type 2 Diabetes Risk (AUSDRISK) Assessment Tool", "Physical Activity Decision Tool for Patients Living with Diabetes", "Ideal Body Weight and Adjusted Body Weight", "Basal Energy Expenditure", "Edmonton Obesity Staging System (EOSS)"], "calculator_answers": [{"order": 1, "name": "BMI Calculator (Body Mass Index and BSA)", "inputs": [{"field": "Weight", "value": "262 lb"}, {"field": "Height", "value": "69 in"}], "final_answer": "38.7 kg/m²", "notes": "38.7 kg/m²\nBody Mass Index (Class 2 obesity)\n2.41 m²\nBody Surface Area"}, {"order": 2, "name": "Body Roundness Index (BRI)", "inputs": [{"field": "Waist circumference", "value": "45 in"}, {"field": "Height", "value": "69 in"}], "final_answer": 6.66, "notes": "6.66\nBRI\n1.48 (1.30-1.69)\nHR of All-Cause Mortality (95%CI)"}, {"order": 3, "name": "Metabolic Syndrome (IDF)", "inputs": [{"field": "Central Obesity or BMI > 30kg/m²?", "value": "Yes (BMI 38.7 kg/m^2; waist 45 in)"}, {"field": "Sex", "value": "Male"}, {"field": "Triglycerides", "value": "212 mg/dL"}, {"field": "HDL", "value": "38 mg/dL"}, {"field": "Blood Pressure", "value": "136/88 mmHg"}, {"field": "Fasting Blood Glucose", "value": "103 mg/dL"}, {"field": "Type 2 Diabetes", "value": "No"}], "final_answer": "Diagnosis Established", "notes": "Metabolic Syndrome\nDiagnosis Established"}, {"order": 4, "name": "HOMA-IR (Homeostatic Model Assessment for Insulin Resistance)", "inputs": [{"field": "Insulin", "value": "18 uIU/mL"}, {"field": "Glucose", "value": "103 mg/dL"}], "final_answer": 4.6, "notes": "Several studies suggest a cut-off of >2 for any insulin resistance, but \"normal\" values appear to vary greatly by population."}, {"order": 5, "name": "Fatty Liver Index", "inputs": [{"field": "BMI", "value": "38.7 kg/m^2"}, {"field": "Waist circumference", "value": "45 in"}, {"field": "GGT", "value": "64 U/L"}, {"field": "Triglycerides", "value": "212 mg/dL"}], "final_answer": 98, "notes": "98\nFatty Liver Index\nHigh risk\nFatty liver ruled in (LR+ = 4.3)"}, {"order": 6, "name": "Australian Type 2 Diabetes Risk (AUSDRISK) Assessment Tool", "inputs": [{"field": "Age (years)", "value": "45-54", "score": 4}, {"field": "Sex", "value": "Male", "score": 3}, {"field": "Ethnicity", "value": "Other"}, {"field": "Parental history of diabetes", "value": "Yes", "score": 3}, {"field": "History of high blood glucose", "value": "Yes", "score": 6}, {"field": "Use of antihypertensive medications", "value": "No", "score": 0}, {"field": "Current smoker", "value": "No", "score": 0}, {"field": "Physical inactivity", "value": "Yes", "score": 2}, {"field": "Obesity parameter", "value": "Waist circumference"}, {"field": "Waist circumference", "value": "45 in"}], "final_answer": 25, "notes": "25 points\nHigh risk. Investigate for possible diabetes.\n1 in 3\n5-year risk of developing Type 2 DM"}, {"order": 7, "name": "Physical Activity Decision Tool for Patients Living with Diabetes", "inputs": [{"field": "Does your patient currently have symptoms of angina that would limit participation in physical activity?", "value": "No"}, {"field": "Days/Week Of Moderate To Vigorous Intensity Activity", "value": "2 days/week"}, {"field": "Minutes/Day Of Moderate To Vigorous Intensity Activity", "value": "25 minutes/day"}, {"field": "Days/Week of Resistance Training", "value": "0 days/week"}], "final_answer": "50 mins/week of Moderate-Vigorous Physical Activity (MVPA)", "notes": "MVPA Calculation\n50 mins/week of Moderate-Vigorous Physical Activity (MVPA)\nAdd MVPA score to the patient care flow sheet or medical record.\nKey Counselling Tips\nAdvise patient of benefits of reducing sedentary behaviour for diabetes management.\nWork with patient to set an MVPA goal. If available, make referral to specific program, facility or qualified exercise professional to assist with their exercise prescription.\nResistance training needed\nAdvise patient of benefits of resistance activities for diabetes management and recommend the brochure:\nIntroductory Resistance Program\nConsult with patient\nAcknowledge barriers, identify potential sources of motivation and recommend the brochure:\nBenefits of Physical Activity"}, {"order": 8, "name": "Ideal Body Weight and Adjusted Body Weight", "inputs": [{"field": "Sex", "value": "Male"}, {"field": "Height", "value": "69 in"}, {"field": "Actual body weight", "value": "262 lb"}], "final_answer": "155.9 lbs", "notes": "155.9 lbs\nIdeal Body Weight\nEquivalent to 70.7 kg\nActual body weight is 168% (1.68x) ideal body weight\n198.3 lbs\nAdjusted Body Weight\nEquivalent to 90.0 kg"}, {"order": 9, "name": "Basal Energy Expenditure", "inputs": [{"field": "Sex", "value": "Male"}, {"field": "Weight", "value": "198.4 lb (Adjusted Body Weight)"}, {"field": "Height", "value": "69 in"}, {"field": "Age", "value": "48 years"}, {"field": "Activity level", "value": "Sedentary (little to no exercise)"}], "final_answer": "1856 kcal/day", "notes": "1856 kcal/day\nBasal Energy Expenditure\nNote: stress, activity, illness, trauma, burns, cancers can increase daily caloric requirement.\n2227 kcal/day\nHarris-Benedict recommended caloric intake"}, {"order": 10, "name": "Edmonton Obesity Staging System (EOSS)", "inputs": [{"field": "Obesity-related risk factors", "value": "Established (e.g., metabolic syndrome, dyslipidemia, elevated BP)", "score": 2}, {"field": "Physical symptoms or functional limitations", "value": "Mild (some dyspnea on exertion, occasional aches/fatigue)", "score": 1}, {"field": "Psychological symptoms", "value": "Mild (well-being impairment without major QoL impact)", "score": 1}], "final_answer": "Stage 2", "notes": "Stage 2\nEOSS"}]}
{"task_id": "medmcp-calc_106_8dc455b7", "task_scenario": "Primary Prevention of Cardiovascular Disease", "task_category": "Clinical Medicine / Medicine & Organ Systems / Cardiovascular Medicine", "patient_id": "P106_8dc455b7", "task_description": "Scenario: An adult with no known atherosclerotic cardiovascular disease (ASCVD) presents for a preventive visit. The clinician needs to estimate short- and long-term cardiovascular risk, determine whether lipid-lowering therapy is indicated, tailor the intensity of lifestyle interventions, and address diabetes-specific vascular protection when applicable.\n\nWorkflow steps and rationale:\n1) Start with lipid assessment using \"LDL Calculated\" to derive LDL cholesterol from the available lipid profile. Decision point: If LDL is markedly elevated (severe hypercholesterolemia range), proceed directly to statin decisioning in Step 5; otherwise continue to global risk estimation.\n2) Choose the appropriate 10-year risk estimator based on patient characteristics:\n   - If the patient has type 2 diabetes, use \"Systematic Coronary Risk Evaluation 2-Diabetes (SCORE2-Diabetes)\" to estimate 10-year CVD risk.\n   - If the patient is an older adult, use \"Systematic Coronary Risk Evaluation 2-Older Persons (SCORE2-OP)\" for age-adjusted 10-year CVD risk.\n   - Otherwise, use \"ASCVD (Atherosclerotic Cardiovascular Disease) 2013 Risk Calculator from AHA/ACC\" to estimate 10-year hard ASCVD risk.\n   The resulting 10-year risk category (low, borderline, intermediate, high) is then used to determine the next step.\n3) Refine risk when needed with \"Predicting Risk of Cardiovascular Disease EVENTs (PREVENT)\":\n   - If the 10-year risk from Step 2 is borderline or intermediate, run PREVENT to quantify both 10-year and 30-year CVD risk. Decision point: If PREVENT shows high long-term (30-year) risk despite borderline/intermediate 10-year risk, treat as higher-risk and proceed to statin decisioning in Step 5; otherwise continue to lifestyle planning in Step 6.\n4) For patients with diabetes, apply \"Reducing Vascular Risk in Patients Living with Diabetes\" to determine whether vascular protective therapy is indicated. Decision point: If indicated, this result triggers pharmacotherapy planning in Step 5; if not indicated, proceed to lifestyle optimization in Step 6.\n5) Determine statin therapy using \"ASCVD (Atherosclerotic Cardiovascular Disease) Risk Algorithm including Known ASCVD from AHA/ACC\" (set to primary prevention):\n   - Inputs and triggers include: LDL from Step 1 (e.g., markedly elevated LDL triggers high-intensity statin), diabetes status and output from Step 4 (diabetes may warrant at least moderate-intensity statin), and risk category from Step 2/3 (high short-term or high long-term risk warrants statin initiation/intensification). The algorithm provides statin intensity recommendations aligned to these prior outputs.\n6) Tailor lifestyle intervention intensity:\n   - Use \"Exercise Capacity (METs)\" to quantify baseline cardiorespiratory fitness. Decision point: Lower METs results trigger a more intensive, supervised exercise prescription; higher METs support a standard lifestyle plan.\n   - Apply the \"Early Cardiovascular Health Risk Score\" to summarize current cardiovascular health and set personalized lifestyle goals and follow-up, leveraging prior risk findings and fitness status.\n\nThis sequence ensures that LDL thresholds and risk estimates deterministically guide subsequent calculators and decisions, integrating pharmacologic and non-pharmacologic strategies for primary prevention.", "fuzzy_question": "I’m seeing an adult with no known coronary or cerebrovascular disease for a preventive visit, and I’m trying to get a clean, defensible read on where they sit short-term and long-term so we can make the right calls on meds and lifestyle. I don’t want to miss someone who needs treatment, but I also don’t want to overreach if their true risk is low.\n\nTo start, let’s ground this in their lipids. Please confirm the LDL from the current panel—if direct LDL is not reported, use the standard approach to estimate it from the lipid panel. If LDL is in a very high range consistent with severe hypercholesterolemia, that likely answers the statin question and we can move straight to choosing an appropriate intensity. If it’s not that high, then frame their overall risk before committing.\n\nFor the short-term outlook, use a validated tool that fits who they are. If they have type 2 diabetes, prefer a diabetes-focused primary-prevention cardiovascular risk estimate. If they’re older, use an option calibrated for older adults to avoid misclassification. Otherwise, a standard primary-prevention estimate should do. What matters most is the category—low, borderline, intermediate, or high—since that drives next steps more than the exact percentage.\n\nIf they come out borderline or intermediate, I’m especially concerned about the person whose short-term number looks modest but whose trajectory over the coming decades is not. In that situation, please provide both their short-term and a longer-term cardiovascular risk projection. If long-term risk is clearly high despite a borderline/intermediate short-term read, treat more like a higher-risk patient when making medication decisions. If the long-term picture is reassuring, lean harder on lifestyle.\n\nIf they have diabetes, also check whether they meet criteria for added vascular protection beyond LDL lowering—consider whether they warrant an SGLT2 inhibitor or a GLP-1 receptor agonist for cardiovascular benefit, ACE/ARB when indicated, and whether low-dose aspirin makes sense based on overall risk and bleeding profile. If they meet those criteria, that would push toward pharmacotherapy even if the short-term estimate isn’t high; if not, focus more on optimizing lifestyle.\n\nBringing it all together, I need a clear recommendation on statins in this primary-prevention context: start or not, and at what intensity. Please anchor that in the LDL you verified, whether diabetes is present and whether they qualify for additional vascular-protective therapy, and the risk categories from both the short-term and longer-term view. If LDL is in the severe range, expect a high-intensity statin. If there’s diabetes, at least moderate intensity is usually the floor unless there’s a reason to go higher. If either the short-term or long-term risk is high, lean toward initiation or intensification. If everything lines up as low risk, make the case for deferring medication.\n\nSeparately, I want the lifestyle plan to match their baseline capacity. If we have any recent exercise test or a reasonable way to estimate aerobic fitness (even a MET-based estimate), use that to guide how aggressive we should be. Lower capacity would nudge toward a more supervised or structured exercise prescription; if fitness looks decent, a standard plan is fine. Please roll all of this into an overall cardiovascular health snapshot with concrete lifestyle targets and a sensible follow-up cadence consistent with their risk and fitness.\n\nCan you walk me through this step by step—confirm the LDL you derive from the labs (or estimate when needed), identify the short-term risk category using the most appropriate model, determine whether long-term risk is high when the short-term risk is borderline or intermediate, assess eligibility for diabetes-related vascular protection, specify your statin plan and intensity, and then outline a tailored lifestyle approach based on fitness and an overall cardiovascular health summary? I need this grounded in validated calculations and risk thresholds, not gut feel, so the reasoning would stand up to scrutiny.", "required_calculators": ["LDL Calculated", "Systematic Coronary Risk Evaluation 2-Diabetes (SCORE2-Diabetes)", "Systematic Coronary Risk Evaluation 2-Older Persons (SCORE2-OP)", "ASCVD (Atherosclerotic Cardiovascular Disease) 2013 Risk Calculator from AHA/ACC", "Predicting Risk of Cardiovascular Disease EVENTs (PREVENT)", "Reducing Vascular Risk in Patients Living with Diabetes", "ASCVD (Atherosclerotic Cardiovascular Disease) Risk Algorithm including Known ASCVD from AHA/ACC", "Exercise Capacity (METs)", "Early Cardiovascular Health Risk Score"], "calculator_answers": [{"order": 1, "name": "LDL Calculated", "inputs": [{"field": "Total Cholesterol", "value": "230 mg/dL"}, {"field": "HDL Cholesterol", "value": "42 mg/dL"}, {"field": "Triglycerides", "value": "180 mg/dL"}], "final_answer": "152.0 mg/dL", "notes": "152.0 mg/dL\nCalculated LDL level\nBorderline high LDL level according to ATP III guidelines. See Evidence for cutoffs and target LDL levels according to risk."}, {"order": 2, "name": "Systematic Coronary Risk Evaluation 2-Diabetes (SCORE2-Diabetes)", "inputs": [{"field": "Sex", "value": "Male"}, {"field": "Age", "value": "70 years"}, {"field": "Smoking", "value": "Other (non-current)"}, {"field": "SBP", "value": "138 mm Hg"}, {"field": "Diabetes", "value": "Yes (type 2)"}, {"field": "Total cholesterol", "value": "230 mg/dL"}, {"field": "HDL cholesterol", "value": "42 mg/dL"}, {"field": "Age at diabetes diagnosis", "value": "64"}, {"field": "HbA1c", "value": "60 mmol/mol (7.6%)"}, {"field": "eGFR", "value": "78 mL/min/1.73 m^2"}, {"field": "Risk region", "value": "Moderate"}], "final_answer": "21.0 %", "notes": "21.0 %\n10-year risk of CVD"}, {"order": 3, "name": "Systematic Coronary Risk Evaluation 2-Older Persons (SCORE2-OP)", "inputs": [{"field": "Sex", "value": "Male"}, {"field": "Age", "value": "70 years"}, {"field": "Diabetes", "value": "Yes"}, {"field": "Smoking", "value": "Other (non-current)"}, {"field": "SBP", "value": "138 mm Hg"}, {"field": "Total cholesterol", "value": "230 mg/dL"}, {"field": "HDL cholesterol", "value": "42 mg/dL"}, {"field": "Risk region", "value": "Moderate"}], "final_answer": "22.5 %", "notes": "22.5 %\n10-year risk of CVD"}, {"order": 4, "name": "ASCVD (Atherosclerotic Cardiovascular Disease) 2013 Risk Calculator from AHA/ACC", "inputs": [{"field": "Age", "value": "70 years"}, {"field": "Diabetes", "value": "Yes"}, {"field": "Sex", "value": "Male"}, {"field": "Smoker", "value": "No"}, {"field": "Total cholesterol", "value": "230 mg/dL"}, {"field": "HDL cholesterol", "value": "42 mg/dL"}, {"field": "Systolic blood pressure", "value": "138 mm Hg"}, {"field": "Treatment for hypertension", "value": "Yes"}, {"field": "Race", "value": "White (optional)"}], "final_answer": "45.4%", "notes": "High-intensity statin recommended because of known diabetes and 10-year risk ≥7.5%. If LDL <70mg/dl (1.81 mmol/L), additional factors like lifestyle and risk-benefits can be considered before starting statins.\nTo view statin dosages by intensity, see Evidence section.\n45.4%\nRisk of cardiovascular event (coronary or stroke death or non-fatal MI or stroke) in next 10 years.\n13.0%\n10-year cardiovascular risk if risk factors were optimal."}, {"order": 5, "name": "Predicting Risk of Cardiovascular Disease EVENTs (PREVENT)", "inputs": [{"field": "Model", "value": "Base"}, {"field": "Sex", "value": "Male"}, {"field": "Age", "value": "70 years"}, {"field": "Total cholesterol", "value": "230 mg/dL"}, {"field": "HDL cholesterol", "value": "42 mg/dL"}, {"field": "SBP", "value": "138 mm Hg"}, {"field": "Diabetes", "value": "Yes"}, {"field": "Current smoker", "value": "No"}, {"field": "eGFR", "value": "78 mL/min/1.73 m^2"}, {"field": "Using anti-hypertensive medication", "value": "Yes"}, {"field": "Using statins", "value": "No"}, {"field": "BMI", "value": "29 kg/m^2"}], "final_answer": "25.93 %", "notes": "25.93 %\n10-Year Total CVD Risk\n10-Year ASCVD Risk: 17.99%\n10-Year Heart Failure Risk: 14.12%\n10-Year Coronary Heart Disease Risk: 11.27%\n10-Year Stroke Risk: 8.78%\n46.27 %\n30-Year Total CVD Risk\n30-Year ASCVD Risk: 32.75%\n30-Year Heart Failure Risk: 32.24%\n30-Year Coronary Heart Disease Risk: 21.73%\n30-Year Stroke Risk: 17.00%"}, {"order": 6, "name": "Reducing Vascular Risk in Patients Living with Diabetes", "inputs": [{"field": "Cardiovascular Disease?", "value": "No (no known ASCVD)"}, {"field": "Microvascular Disease?", "value": "Yes (albuminuria present)"}, {"field": "Diabetes Type?", "value": "Type 2"}, {"field": "Diabetes Duration >15 Years?", "value": "No (6 years)"}, {"field": "A1c Above Target (>7.0%)?", "value": "Yes (7.6%)"}, {"field": "Age?", "value": "70 years"}, {"field": "Does the Patient Have at Least One of These Risk Factors?", "value": "Yes (albuminuria, hypertension, dyslipidemia)"}], "final_answer": "Statin Recommended\nYes", "notes": "Statin Recommended\nYes\nRecommended even if the baseline blood pressure or LDL-C is at target. Dose adjustments or additional lipid therapy warranted if lipid target (LDL-C <2.0 mmol/L) not being met.\nCautions: Potentially embryopathic – discontinue prior to conception. Try to achieve targets in Canadian Cardiovascular Society guidelines, prescribe up to maximally tolerated and approved dose.\nACEi/ARB Recommended\nYes\nPrescribe at doses with demonstrated vascular protection [eg. perindopril 8 mg once daily (EUROPA trial), ramipril 10 mg once daily (HOPE trial), telmisartan 80 mg once daily (ONTARGET trial)].\nCautions: Potentially embryopathic – discontinue prior to conception (used to treat hypertension) or upon detection of pregnancy (used to treat CKD). Caution if hypotensive.\nASA Recommended\nNot routinely recommended\nLiraglutide, Empagliflozin or Canagliflozin Recommended\nNo"}, {"order": 7, "name": "ASCVD (Atherosclerotic Cardiovascular Disease) Risk Algorithm including Known ASCVD from AHA/ACC", "inputs": [{"field": "History of ASCVD", "value": "No"}, {"field": "LDL Cholesterol ≥190mg/dL (4.92 mmol/L)", "value": "No"}, {"field": "Age", "value": "70"}, {"field": "Diabetes", "value": "Yes"}, {"field": "Sex", "value": "Male"}, {"field": "Total Cholesterol", "value": "230 mg/dL"}, {"field": "HDL Cholesterol", "value": "42 mg/dL"}, {"field": "Systolic Blood Pressure", "value": "138 mm Hg"}, {"field": "Treatment for Hypertension", "value": "Yes"}, {"field": "Smoker", "value": "No"}, {"field": "Race", "value": "White"}], "final_answer": "45.4 %", "notes": "45.4 %\nRisk of cardiovascular event (coronary or stroke death or non-fatal MI or stroke) in next 10 years.\nHigh-intensity statin recommended because of known diabetes and 10-year risk >7.5%.\nIf LDL <70mg/dl (1.81 mmol/L), additional factors like lifestyle and risk-benefits can be considered before starting statins\nTo view statin dosages by intensity, see Evidence section."}, {"order": 8, "name": "Exercise Capacity (METs)", "inputs": [{"field": "Gender", "value": "Male"}, {"field": "Treadmill Speed", "value": "3.0 mph"}, {"field": "Treadmill Grade", "value": "10%"}, {"field": "Age", "value": "70 years"}], "final_answer": "7.43 mL/kg/min METs", "notes": "Exercise Capacity\n7.43 mL/kg/min METs\nPredicted Exercise Capacity\n7 mL/kg/min METs"}, {"order": 9, "name": "Early Cardiovascular Health Risk Score", "inputs": [{"field": "BP at rest?", "value": "138/86 mmHg"}, {"field": "BP-Post Mild Exercise (mmHg)?", "value": "150/88 mmHg"}, {"field": "Carotid intima-media thickness test (CIMT)?", "value": "0.78 mm; no plaque"}, {"field": "Abdominal Aorta Ultrasound?", "value": "Max diameter 2.2 cm; no aneurysm"}, {"field": "Retinal Photography?", "value": "No diabetic retinopathy"}, {"field": "Microalbuminuria (mg/mmol)?", "value": "5.0 mg/mmol"}, {"field": "Pro-BNP (pg/dl)?", "value": "60 pg/mL"}, {"field": "ECG 12 Lead?", "value": "Normal sinus rhythm; no ischemic changes"}, {"field": "Cardiac Ultrasound of LV Mass Index LVMI (g/m2)?", "value": "95 g/m^2"}, {"field": "C1 Large Vessel Endothelial Function?", "value": "RHI 2.1 (normal)"}], "final_answer": "ECVHRS = 4-10: Intermediate Risk", "notes": "ECVHRS\nECVHRS = 4-10: Intermediate Risk"}]}
{"task_id": "medmcp-calc_107_09745015", "task_scenario": "Chemotherapy Dose Intensity Calculations", "task_category": "Clinical Medicine / Medicine & Organ Systems / Comprehensive Oncology", "patient_id": "P107_09745015", "task_description": "Clinical scenario: A patient with a solid tumor is planned for combination chemotherapy that includes a platinum agent dosed by target AUC and a partner drug dosed by body surface area (e.g., a taxane). The clinical objective is to set a safe, effective initial dose intensity and define contingency adjustments based on organ-function risk before treatment starts. Workflow: 1) Begin with Emory Model (TIPSS) to stratify portal hypertension-related risk that could impact tolerability. The model’s risk category is used to choose between a standard-intensity pathway versus a conservative-intensity pathway. If Emory risk is high, proceed with a reduced-intensity plan; if low, proceed with standard-intensity. 2) Use Body Surface Area Based Dosing to calculate the initial dose for the BSA-dosed agent. If the prior Emory risk branch was high, apply a proportional reduction to the BSA-derived dose to reflect conservative intensity; if low, use the full BSA-derived dose. Additionally, if the calculated BSA suggests extremes where institutional capping or rounding rules would apply, follow those rules and carry forward the adjusted dose to the next step. 3) Use Carboplatin AUC Dosing (Calvert) to determine the carboplatin dose from the selected target AUC. If the Emory risk branch was high or the BSA-based agent required dose capping/reduction, select a lower target AUC to maintain balanced overall regimen intensity; otherwise, select a standard target AUC. 4) Integrate the outputs: finalize the initial cycle’s dose intensity plan by aligning the BSA-based agent dose with the AUC-based carboplatin dose so that the combination achieves the intended relative intensity under either the standard or conservative pathway. Rationale: Emory TIPSS informs upfront intensity selection, the BSA calculator provides precise dosing for the non-platinum agent, and the Calvert AUC method provides precise carboplatin dosing; together they enable coherent, risk-adjusted planning of combination chemotherapy dose intensity.", "fuzzy_question": "I’m evaluating a patient with a solid tumor who is planned for a platinum–taxane regimen. I want to set a safe starting intensity, but there is uncertainty about portal hypertension risk given variable platelet counts and inconclusive imaging. This determination will guide a conservative versus standard start. If risk appears higher, I would open conservatively; if lower, I’m comfortable with usual intensity.\n\nFor the taxane, I’d base the starting dose on body size; if we opt for a conservative approach, I’d use a proportional reduction rather than a flat cut. If the clinic’s usual caps or rounding rules apply at body-size extremes, we’ll apply those and carry the adjusted value forward as the reference for subsequent planning.\n\nFor the platinum, I’d use a target exposure guided by renal function. If the partner drug is dialed back or portal hypertension concerns favor caution, I’d choose a lower target to keep the regimen balanced; otherwise, I’d use the standard target and then translate that target and renal function into the dose.\n\nI want the two agents aligned so the combination is balanced—avoiding overshooting one while undershooting the other. Looking ahead to the next appointment, please outline an initial cycle plan that reflects either pathway and predefines how we would adjust if renal, hepatic, or platelet parameters shift before day 1 or between early visits. What is the best way to reason through this? If anything is missing, I’d rather catch it now than after the first cycle.\n\nI need an evidence-based framework with solid calculations to support the decision and withstand scrutiny.", "required_calculators": ["Emory Model (TIPSS)", "Body Surface Area Based Dosing", "Carboplatin AUC Dosing (Calvert)"], "calculator_answers": [{"order": 1, "name": "Emory Model (TIPSS)", "inputs": [{"field": "Total Bilirubin?", "value": "2.3 mg/dL"}, {"field": "ALT?", "value": "78 U/L"}, {"field": "Pre-TIPSS Hepatic Encephalopathy?", "value": "Yes"}, {"field": "Urgency of TIPSS?", "value": "Elective"}], "final_answer": 1, "notes": "Score\n1\nRisk Category\nModerate Risk\nEstimated Mortality Rates after TIPSS:\nEstimated 3-month Mortality Rates after TIPSS\n25 %\nEstimated 12-month Mortality Rates after TIPSS\n51-57 %\nEstimated 36-month Mortality Rates after TIPSS\n>60 %"}, {"order": 2, "name": "Body Surface Area Based Dosing", "inputs": [{"field": "BSA Based Dose", "value": "175 mg/m2"}, {"field": "Weight", "value": "82 kg"}, {"field": "Height", "value": "168 cm"}, {"field": "Select either", "value": "Mosteller"}, {"field": "Desired dose unit", "value": "mg"}], "final_answer": "342.33 mg", "notes": "Dose\n342.33 mg"}, {"order": 3, "name": "Carboplatin AUC Dosing (Calvert)", "inputs": [{"field": "Age?", "value": "61 years"}, {"field": "Weight?", "value": "82 kg"}, {"field": "Creatinine?", "value": "1.0 mg/dL"}, {"field": "Target AUC?", "value": "4"}, {"field": "Gender?", "value": "Female"}], "final_answer": "405.9 mg", "notes": "Total Dose\n405.9 mg"}]}
{"task_id": "medmcp-calc_108_dd0e5e42", "task_scenario": "Acute Ischemic Stroke Assessment", "task_category": "Clinical Medicine / Neurology & Mental Health / Neurosurgery & Neurology", "patient_id": "P108_dd0e5e42", "task_description": "Scenario: A patient with sudden focal neurological deficits arrives within a potential reperfusion window after EMS pre-notification. The clinical team must rapidly differentiate stroke from mimics, quantify severity, determine eligibility for intravenous thrombolysis and/or endovascular therapy, measure procedural success if performed, and document functional outcomes.\n\nWorkflow steps:\n1) Use the Field Assessment Stroke Triage for Emergency Destination (FAST-ED) score from EMS or compute on arrival to estimate likelihood of large vessel occlusion (LVO). A high FAST-ED triggers immediate activation for vascular imaging and potential thrombectomy evaluation while standard stroke imaging proceeds for all.\n2) In the ED, apply the Recognition of Stroke in the Emergency Room (ROSIER) Scale to distinguish stroke from common mimics. If ROSIER is negative, pivot to mimic workup and exit the stroke pathway; if positive, continue with emergent stroke care.\n3) Quantify neurologic deficit with the NIH Stroke Scale/Score (NIHSS). This establishes a baseline, informs urgency and prognosis, and will be used with imaging results downstream.\n4) Obtain non-contrast head CT and calculate the Alberta Stroke Program Early CT Score (ASPECTS) to estimate early ischemic changes in the MCA territory. ASPECTS informs intravenous thrombolysis safety considerations and is used with NIHSS to assess endovascular benefit.\n5) Evaluate eligibility for lytic therapy using the tPA Contraindications for Ischemic Stroke tool, incorporating clinical data and the CT assessment. If contraindications are present, skip lytics and proceed directly to the LVO pathway as appropriate; if eligible, select a thrombolytic agent per institutional protocol:\n   - If alteplase is used: dose with the tPA (Alteplase) Dosing for Ischemic Stroke Calculator.\n   - If tenecteplase is used: dose with the Tenecteplase (TNK) Dosing for Ischemic Stroke Calculator.\n6) If FAST-ED suggested LVO and vascular imaging confirms an anterior circulation LVO, assess expected endovascular benefit with the Pittsburgh Response to Endovascular therapy (PRE) Score, which requires the earlier NIHSS and ASPECTS. A favorable PRE score supports proceeding to thrombectomy; an unfavorable score prompts reassessment of risks, benefits, and alternatives.\n7) For patients undergoing thrombectomy, document reperfusion success using the TICI Score immediately post-procedure to standardize the revascularization result and guide post-procedural care decisions.\n8) At discharge and/or follow-up, measure disability using the Modified Rankin Scale for Neurologic Disability to quantify functional outcome, inform rehabilitation planning, and provide a benchmark for quality metrics.\n\nKey dependencies and decision points:\n- ROSIER positive is required to advance to definitive stroke treatment steps.\n- FAST-ED high result deterministically triggers the LVO/thrombectomy evaluation branch (with PRE Score) after imaging confirms LVO.\n- ASPECTS and NIHSS feed directly into the PRE Score to judge endovascular benefit.\n- tPA Contraindications result (eligible vs ineligible) deterministically selects the lytic dosing branch (alteplase or TNK) or bypasses lytics toward EVT-only management.", "fuzzy_question": "I’m evaluating a patient who presented with sudden focal neurologic deficits after prehospital notification and appears to be within a potential reperfusion window. I want to move quickly while minimizing the chance of a mimic. Please walk through this as you would at the bedside.\n\nStart with the usual prehospital/arrival screening tool to estimate the likelihood of a proximal large-vessel occlusion. If the probability is high, activate vascular imaging immediately while the standard non-contrast head CT proceeds for all patients.\n\nIn the ED, perform the typical stroke-versus-mimic assessment (seizure, hypoglycemia, migraine, peripheral facial palsy, etc.). If findings point away from stroke, pivot to the appropriate mimic workup and step off the stroke pathway. If findings support stroke, continue emergent care.\n\nObtain a formal baseline neurologic severity score using the standard scale, with the exact total and itemized components, to set urgency and prognostic context; then pair this with imaging. Review the non-contrast head CT and quantify early ischemic changes in the MCA territory using the standard regional tally, reporting the total and the involved regions. Use this to judge thrombolytic safety and, combined with clinical severity, the potential benefit of endovascular therapy.\n\nNext, complete the usual thrombolytic safety checklist—onset-to-treatment interval, blood pressure, bleeding risk, recent procedures, key laboratory parameters, anticoagulant exposure, and prior intracranial events—and clearly state eligibility. If eligible, choose between alteplase and tenecteplase per local practice and provide the precise weight-based dose and administration plan. If not a candidate, bypass thrombolysis and continue down the large-vessel route as appropriate.\n\nIf early screening suggested a large-vessel problem and vascular imaging confirms an anterior circulation occlusion, estimate expected benefit from thrombectomy by integrating the baseline severity with the extent of early changes on CT. If favorable, proceed; if unfavorable, pause and reassess risks, benefits, alternatives, and goals of care.\n\nFor anyone taken to the angiography suite, document the immediate reperfusion result using the standard angiographic grade so post-procedure care decisions are clear. At discharge or early follow-up, provide the standardized functional disability rating to capture outcome, guide rehabilitation planning, and support quality metrics.\n\nDependencies: the ED stroke-versus-mimic screen determines whether to remain on the stroke pathway; a high large-vessel screen should trigger rapid thrombectomy evaluation once imaging confirms an anterior occlusion; baseline severity and CT early changes directly inform the estimate of endovascular benefit; and the thrombolytic safety determination leads either to precise thrombolytic dosing or a mechanical-therapy-only approach.\n\nPlease talk through this step by step with exact, guideline-based calculations and clear reasoning at each stage. Decisions should be reproducible and defensible.", "required_calculators": ["Field Assessment Stroke Triage for Emergency Destination (FAST-ED)", "Recognition of Stroke in the Emergency Room (ROSIER) Scale", "NIH Stroke Scale/Score (NIHSS)", "Alberta Stroke Program Early CT Score (ASPECTS)", "tPA Contraindications for Ischemic Stroke", "tPA (Alteplase) Dosing for Ischemic Stroke Calculator", "Tenecteplase (TNK) Dosing for Ischemic Stroke Calculator", "Pittsburgh Response to Endovascular therapy (PRE) Score", "TICI Score", "Modified Rankin Scale for Neurologic Disability"], "calculator_answers": [{"order": 1, "name": "Field Assessment Stroke Triage for Emergency Destination (FAST-ED)", "inputs": [{"field": "Facial palsy", "value": "Partial or complete paralysis (+1)", "score": 1}, {"field": "Arm weakness (affected side)", "value": "No effort against gravity or no movement (+2) — left arm", "score": 2}, {"field": "Speech changes", "value": "Absent (0)", "score": 0}, {"field": "Eye deviation", "value": "Forced deviation (+2) — eyes deviated right", "score": 2}, {"field": "Denial/neglect", "value": "Does not recognize own hand or orients only to one side of the body (+2)", "score": 2}], "final_answer": 7, "notes": "7 points\nFAST-ED Score\n~60% or higher\nLikelihood of LVOS"}, {"order": 2, "name": "Recognition of Stroke in the Emergency Room (ROSIER) Scale", "inputs": [{"field": "Loss of consciousness or syncope", "value": "No (0)", "score": 0}, {"field": "Seizure activity", "value": "No (0)", "score": 0}, {"field": "Asymmetric facial weakness", "value": "Yes (+1)", "score": 1}, {"field": "Asymmetric arm weakness", "value": "Yes (+1)", "score": 1}, {"field": "Asymmetric leg weakness", "value": "Yes (+1)", "score": 1}, {"field": "Speech disturbance", "value": "Yes (+1) — mild dysarthria", "score": 1}, {"field": "Visual field defect", "value": "Yes (+1) — left homonymous hemianopia", "score": 1}], "final_answer": 5, "notes": "5 points\nROSIER Score\nStroke possible"}, {"order": 3, "name": "NIH Stroke Scale/Score (NIHSS)", "inputs": [{"field": "1A: Level of consciousness", "value": "0 (Alert)", "score": 0}, {"field": "1B: LOC questions", "value": "0 (Both correct)", "score": 0}, {"field": "1C: LOC commands", "value": "0 (Performs both)", "score": 0}, {"field": "2: Horizontal gaze", "value": "2 (Forced gaze deviation to right)", "score": 2}, {"field": "3: Visual fields", "value": "2 (Complete left hemianopia)", "score": 2}, {"field": "4: Facial palsy", "value": "2 (Partial paralysis, lower face)", "score": 2}, {"field": "5A: Left arm motor", "value": "3 (No effort against gravity)", "score": 3}, {"field": "5B: Right arm motor", "value": "0 (No drift)", "score": 0}, {"field": "6A: Left leg motor", "value": "2 (Some effort against gravity)", "score": 2}, {"field": "6B: Right leg motor", "value": "0 (No drift)", "score": 0}, {"field": "7: Limb ataxia", "value": "0 (None)", "score": 0}, {"field": "8: Sensation", "value": "1 (Mild–moderate sensory loss on left)", "score": 1}, {"field": "9: Best language", "value": "0 (No aphasia)", "score": 0}, {"field": "10: Dysarthria", "value": "1 (Mild–moderate)", "score": 1}, {"field": "11: Extinction/inattention", "value": "2 (Profound left neglect)", "score": 2}], "final_answer": 15, "notes": "15 points\nNIH Stroke Scale"}, {"order": 4, "name": "Alberta Stroke Program Early CT Score (ASPECTS)", "inputs": [{"field": "Hemisphere", "value": "Right MCA territory"}, {"field": "Caudate (C)", "value": "No (0)", "score": 0}, {"field": "Internal Capsule (IC)", "value": "No (0)", "score": 0}, {"field": "Lentiform nucleus (L)", "value": "No (0)", "score": 0}, {"field": "Insular Ribbon (I)", "value": "Yes (-1)", "score": -1}, {"field": "M1 (anterior MCA cortex)", "value": "No (0)", "score": 0}, {"field": "M2 (lateral to insula)", "value": "Yes (-1)", "score": -1}, {"field": "M3 (posterior MCA cortex)", "value": "No (0)", "score": 0}, {"field": "M4 (anterior rostral)", "value": "No (0)", "score": 0}, {"field": "M5 (lateral rostral)", "value": "Yes (-1)", "score": -1}, {"field": "M6 (posterior rostral)", "value": "No (0)", "score": 0}], "final_answer": 7, "notes": "7 points\n~27% of patients with ASPECTS <8 will have mRS 0-1 at 90 days."}, {"order": 5, "name": "tPA Contraindications for Ischemic Stroke", "inputs": [{"field": "Age ≥18", "value": "Yes (68 years)"}, {"field": "Clinical diagnosis of ischemic stroke causing neurological deficit", "value": "Yes"}, {"field": "Time of symptom onset <4.5 hours", "value": "Yes (onset-to-needle ~2.0 hours)"}, {"field": "Intracranial hemorrhage on CT", "value": "No"}, {"field": "Clinical presentation suggests subarachnoid hemorrhage", "value": "No"}, {"field": "Neurosurgery, head trauma, or stroke in past 3 months", "value": "No"}, {"field": "Uncontrolled hypertension (>185 SBP or >110 DBP)", "value": "No (triage BP 174/98 mmHg)"}, {"field": "History of intracranial hemorrhage", "value": "No"}, {"field": "Known intracranial AVM, neoplasm, or aneurysm", "value": "No"}, {"field": "Active internal bleeding", "value": "No"}, {"field": "Suspected/confirmed endocarditis", "value": "No"}, {"field": "Known bleeding diathesis - Platelet count <100,000", "value": "No (platelets 215,000/μL)"}, {"field": "Known bleeding diathesis - Heparin within 48h with elevated aPTT", "value": "No (aPTT 29 s, no heparin)"}, {"field": "Known bleeding diathesis - Warfarin with INR >1.7", "value": "No (INR 1.0, not on warfarin)"}, {"field": "Known bleeding diathesis - Direct thrombin or factor Xa inhibitor use", "value": "No"}, {"field": "Abnormal blood glucose (<50 mg/dL)", "value": "No (124 mg/dL)"}, {"field": "Intra-axial intracranial neoplasm", "value": "No"}, {"field": "Gastrointestinal (GI) malignancy", "value": "No"}, {"field": "GI hemorrhage within the last 21 days", "value": "No"}, {"field": "Intracranial or intraspinal surgery within the last 3 months", "value": "No"}, {"field": "CT shows extensive regions of clear hypoattenuation", "value": "No (ASPECTS 7)"}, {"field": "Stroke associated with aortic arch dissection (known/suspected)", "value": "No"}, {"field": "Only minor or rapidly improving stroke symptoms", "value": "No"}, {"field": "Major surgery or serious non-head trauma in previous 14 days", "value": "No"}, {"field": "History of GI or urinary tract hemorrhage within 21 days", "value": "No"}, {"field": "Seizure at stroke onset", "value": "No"}, {"field": "Recent arterial puncture at a noncompressible site", "value": "No"}, {"field": "Recent lumbar puncture", "value": "No"}, {"field": "Post myocardial infarction pericarditis", "value": "No"}, {"field": "Pregnancy", "value": "No"}, {"field": "Additional warning >3 hr: Age >80 years", "value": "No"}, {"field": "Additional warning >3 hr: Prior stroke and diabetes", "value": "No"}, {"field": "Additional warning >3 hr: Any active anticoagulant use", "value": "No"}, {"field": "Additional warning >3 hr: NIHSS >25", "value": "No (NIHSS 15)"}, {"field": "Additional warning >3 hr: CT multilobar infarction >1/3 hemisphere", "value": "No"}], "final_answer": "Patient eligible for tPA.", "notes": "Patient eligible for tPA."}, {"order": 6, "name": "tPA (Alteplase) Dosing for Ischemic Stroke Calculator", "inputs": [{"field": "Weight", "value": "176 lb (80 kg)"}], "final_answer": "7.2 mg", "notes": "7.2 mg\nBolus dose, given IV over 1 min\n64.8 mg\nInfusion, given IV over 60 mins\n28.0 mg\nWaste, to be discarded"}, {"order": 7, "name": "Tenecteplase (TNK) Dosing for Ischemic Stroke Calculator", "inputs": [{"field": "Weight", "value": "176 lb (80 kg)"}], "final_answer": "4.0 mL", "notes": "4.0 mL, equivalent to 20.0 mg\nTenecteplase dosing\n6.0 mL, equivalent to 30.0 mg\nWaste, to be discarded"}, {"order": 8, "name": "Pittsburgh Response to Endovascular therapy (PRE) Score", "inputs": [{"field": "Age", "value": "68 years"}, {"field": "NIHSS Score", "value": "15 points"}, {"field": "ASPECTS Score", "value": "7 points"}], "final_answer": 28, "notes": "28 points\nLikely to benefit from endovascular therapy."}, {"order": 9, "name": "TICI Score", "inputs": [{"field": "Perfusion (TICI grade)", "value": "Complete filling of all of the expected vascular territory is visualized, but the filling is slower than normal."}], "final_answer": "2b", "notes": "TICI Grade\n2b"}, {"order": 10, "name": "Modified Rankin Scale for Neurologic Disability", "inputs": [{"field": "Patient's Baseline Activity", "value": "2 (Slight disability; able to look after own affairs without assistance)", "score": 2}], "final_answer": 2, "notes": "2 points\nModified Rankin Scale"}]}
{"task_id": "medmcp-calc_109_5499be20", "task_scenario": "Cirrhosis Severity and Transplantation", "task_category": "Clinical Medicine / Medicine & Organ Systems / Gastroenterology & Hepatology", "patient_id": "P109_5499be20", "task_description": "Scenario: An adult with decompensated cirrhosis and ascites is undergoing evaluation for liver transplantation after a recent hospitalization. The team must quantify chronic liver disease severity, verify portal hypertensive physiology driving ascites, assess for acute-on-chronic liver failure, determine oncologic transplant eligibility if hepatocellular carcinoma (HCC) is present, consider transjugular intrahepatic portosystemic shunt (TIPS) as a bridge when appropriate, and complete pre-transplant cardiovascular and nutritional risk stratification along with readmission and (if applicable) alcohol relapse risk planning.\n\nStep 1 — Child-Pugh Score for Cirrhosis Mortality: Classify baseline hepatic reserve and decompensation severity to frame overall prognosis and help decide urgency of transplant referral versus continued medical optimization.\n\nStep 2 — MELD Na (UNOS/OPTN): Quantify transplant priority and short-term mortality risk on the waitlist. Decision trigger: If MELD-Na meets listing prioritization thresholds or is high, proceed on the transplant listing pathway (activate Steps 5, 7, 8, and 9 as appropriate). If not, continue with portal hypertension assessment (Step 3) and optimization while monitoring for listing eligibility.\n\nStep 3 — Serum Ascites Albumin Gradient (SAAG): Confirm portal hypertensive physiology in ascites. Decision trigger: If SAAG is consistent with portal hypertension, retain TIPS as a potential bridge (Step 6) if symptoms remain refractory; if not consistent, pivot away from TIPS and reassess differential for ascites, which may alter transplant timing and candidacy considerations.\n\nStep 4 — CLIF-C ACLF (Acute-on-Chronic Liver Failure): During acute decompensation, estimate short-term mortality due to organ failures. Decision trigger: If predicted short-term mortality is high (advanced ACLF), fast-track transplant evaluation and avoid elective TIPS (skip Step 6) due to procedural risk; if ACLF risk is lower, TIPS (Step 6) may remain a feasible bridge when indicated.\n\nStep 5 — Milan Criteria for Liver Transplantation: If HCC is present, determine transplant eligibility based on tumor burden. Decision trigger: Within criteria → proceed with listing; outside criteria → consider downstaging/bridging therapy prior to listing decisions.\n\nStep 6 — Emory Model (TIPSS): For refractory portal hypertensive complications while awaiting transplant, assess periprocedural risk and likelihood of benefit from TIPS. This step is gated by Step 3 (SAAG consistent with portal hypertension) and Step 4 (CLIF-C ACLF not severely elevated). If acceptable risk, use TIPS as a bridge to reduce decompensation while on the waitlist; otherwise avoid.\n\nStep 7 — Cardiovascular Risk in Orthotopic Liver Transplantation (CAR-OLT): For patients moving forward with listing (per Steps 1–2 and Step 5 if HCC), estimate perioperative cardiovascular risk to plan additional testing and optimization before transplant.\n\nStep 8 — Malnutrition Universal Screening Tool (MUST): Screen for malnutrition to guide pre-transplant nutritional optimization, which can reduce waitlist morbidity and improve post-transplant outcomes. Apply regardless of listing status, with higher intensity interventions if listing is anticipated (from Step 2).\n\nStep 9 — Mumtaz Score for Readmission in Cirrhosis: Estimate 30-day readmission risk to structure transitional care, early follow-up, and supportive services while on the waitlist or under ongoing medical management.\n\nStep 10 — Alcohol Relapse Risk after Liver Transplant: If the etiology is alcohol-related, assess relapse risk to inform transplant candidacy decisions, counseling, and addiction medicine engagement; this may influence timing of listing and required support interventions.\n\nConditional branches summary: (a) MELD-Na high triggers immediate transplant pathway steps (5, 7–9); (b) SAAG consistent with portal hypertension and not severe ACLF (CLIF-C) activates TIPS risk assessment (6); (c) HCC presence triggers Milan (5) to determine listing eligibility and need for downstaging; (d) Alcohol-related etiology triggers relapse risk assessment (10), potentially modifying the listing plan.", "fuzzy_question": "Managing a patient with decompensated cirrhosis and significant ascites. We are moving toward a liver transplant evaluation, but I’m weighing how aggressively to proceed versus continuing medical optimization. I need a clear picture of baseline hepatic function and near-term risks to sequence decisions appropriately.\n\nFirst, I want a grounded assessment of hepatic reserve and the severity of decompensation based on standard labs (bilirubin, albumin, INR) and clinical features such as control of ascites and encephalopathy. That should frame prognosis and whether urgent listing is warranted or if we can extend medical therapy.\n\nNext, I need the short‑term transplant priority on the waitlist using the standard variables (kidney function, bilirubin, clotting profile, sodium). If that priority appears high, I’d like to proceed on the transplant pathway promptly; if lower, let’s keep optimizing, monitor closely, and prepare contingencies.\n\nFor the ascites, I want to confirm it is driven by portal hypertension. Please review the difference between serum and ascitic albumin from paracentesis. If this supports portal pressure, we can keep a shunt option in mind as a bridge if symptoms remain refractory; if not, we should reconsider the ascites differential, which could alter timing and candidacy for transplant.\n\nGiven the current decompensation, I also want a structured look at whether this is acute‑on‑chronic liver failure with additional organ failures. Check for brain involvement, hemodynamics, respiratory status, renal function, and coagulation. If short‑term mortality risk is high, we should fast‑track transplant and avoid elective shunting given procedural risks; if lower, a shunt may still be reasonable as a bridge if symptoms are difficult to control.\n\nIf there is any suggestion of hepatocellular carcinoma on imaging or labs, determine whether tumor burden meets standard transplant criteria. If within criteria, proceed; if not, discuss downstaging or bridging therapies and whether that could bring candidacy into range before listing.\n\nIf the ascites mechanism appears portal‑hypertensive and acute organ failure risk is acceptable, I’d like your assessment of a shunt as a bridge: realistically weigh peri‑procedural risk and the likelihood of benefit (ascites control, encephalopathy risk, overall trajectory) while awaiting transplant. If the balance does not favor it, we will defer.\n\nFor anyone moving toward listing, I also need a careful look at perioperative cardiovascular risk—age, diabetes, prior heart disease, functional capacity, and existing findings from ECG/echo—and recommendations for additional testing or optimization before surgery.\n\nNutrition is often a concern. Please screen for malnutrition based on weight changes, body mass index, and the impact of acute illness, and suggest a plan. If listing seems likely, I’d prefer to escalate nutrition support early.\n\nWe are also aiming to reduce readmissions. Based on the clinical profile and course to date, estimate short‑term readmission risk and outline practical steps—early clinic follow‑up, home services, education, medication support, and scheduling for paracentesis if needed—to maintain stability after discharge.\n\nIf alcohol contributes to the liver disease, please include a thoughtful relapse risk assessment—history of use, duration of sobriety, supports, and treatment engagement—so we can plan counseling and addiction medicine involvement, which may affect timing and conditions for listing.\n\nOperationally, if waitlist priority is high, let’s move forward with listing; in that case I’ll need tumor eligibility clarified, the perioperative cardiac risk plan, the nutrition strategy, and the readmission plan ready. If the ascites albumin gradient supports portal hypertension and acute organ failure risk is acceptable, I want your candid view on whether a shunt would meaningfully stabilize the situation while awaiting transplant. If tumor burden is outside standard criteria, propose a viable downstaging path and how it fits into timing. If alcohol is part of the picture, integrate relapse risk and supports into the plan from the outset.\n\nI need proper calculations for this—decisions should not rely on clinical intuition alone. Whatever approach you suggest, please back it with solid calculations to withstand scrutiny.", "required_calculators": ["Child-Pugh Score for Cirrhosis Mortality", "MELD Na (UNOS/OPTN)", "Serum Ascites Albumin Gradient (SAAG)", "CLIF-C ACLF (Acute-on-Chronic Liver Failure)", "Milan Criteria for Liver Transplantation", "Emory Model (TIPSS)", "Cardiovascular Risk in Orthotopic Liver Transplantation (CAR-OLT)", "Malnutrition Universal Screening Tool (MUST)", "Mumtaz Score for Readmission in Cirrhosis", "Alcohol Relapse Risk after Liver Transplant"], "calculator_answers": [{"order": 1, "name": "Child-Pugh Score for Cirrhosis Mortality", "inputs": [{"field": "Bilirubin (Total)", "value": "5.2 mg/dL", "score": 3}, {"field": "Albumin", "value": "2.6 g/dL", "score": 3}, {"field": "INR", "value": "1.9", "score": 2}, {"field": "Ascites", "value": "Moderate (tense ascites, requires large-volume paracentesis)", "score": 3}, {"field": "Encephalopathy", "value": "Grade 1-2 (Grade 1, mild)", "score": 2}], "final_answer": 13, "notes": "13 points\nChild Class C\nLife Expectancy : 1-3 years\nAbdominal surgery peri-operative mortality: 82%"}, {"order": 2, "name": "MELD Na (UNOS/OPTN)", "inputs": [{"field": "Dialysis at least twice in the past week", "value": "No"}, {"field": "Creatinine", "value": "1.3 mg/dL"}, {"field": "Bilirubin", "value": "5.2 mg/dL"}, {"field": "INR", "value": "1.9"}, {"field": "Sodium", "value": "128 mEq/L"}], "final_answer": 27, "notes": "27 points\nMELD Score (2016)*\n19.6%\nEstimated 3-Month Mortality"}, {"order": 3, "name": "Serum Ascites Albumin Gradient (SAAG)", "inputs": [{"field": "Albumin concentration of serum", "value": "2.6 g/dL"}, {"field": "Albumin concentration of ascitic fluid", "value": "0.9 g/dL"}], "final_answer": "1.7 g/dL", "notes": "1.7 g/dL\nSAAG\nPortal hypertension is likely the cause of ascites, with 97% accuracy."}, {"order": 4, "name": "CLIF-C ACLF (Acute-on-Chronic Liver Failure)", "inputs": [{"field": "Age", "value": "56 years"}, {"field": "WBC count", "value": "11.2 x10^3/uL"}, {"field": "Bilirubin (category)", "value": "<6 mg/dL", "score": 1}, {"field": "Bilirubin (value)", "value": "5.2 mg/dL"}, {"field": "Creatinine (category)", "value": "<2 mg/dL", "score": 1}, {"field": "Creatinine (value)", "value": "1.3 mg/dL"}, {"field": "Brain (West-Haven Grade for HE)", "value": "Grade 1", "score": 2}, {"field": "INR (category)", "value": "<2.0", "score": 1}, {"field": "INR (value)", "value": "1.9"}, {"field": "Circulatory (MAP)", "value": "78 mmHg (no vasopressors)", "score": 1}, {"field": "Respiratory metric used", "value": "PaO2/FiO2 ratio"}, {"field": "PaO2", "value": "95 mmHg"}, {"field": "FiO2", "value": "0.21"}, {"field": "PaO2/FiO2 ratio", "value": "452", "score": 1}], "final_answer": 47, "notes": "47 points\nCLIF-C ACLF Score\n21.6% probability of death at 1 month\n38.3% probability of death at 3 months\n43.3% probability of death at 6 months\n52.0% probability of death at 1 year"}, {"order": 5, "name": "Milan Criteria for Liver Transplantation", "inputs": [{"field": "Single tumor with diameter <=5 cm", "value": "Yes (single 3.8 cm lesion, segment 8)", "score": 1}, {"field": "Up to 3 tumors each with diameter <=3 cm", "value": "No", "score": 0}, {"field": "Extra-hepatic involvement", "value": "No", "score": 1}, {"field": "Major vessel involvement", "value": "No", "score": 1}], "final_answer": "Criteria met", "notes": "Criteria met\nMilan Criteria fulfilled. Patient is a viable transplant candidate."}, {"order": 6, "name": "Emory Model (TIPSS)", "inputs": [{"field": "Total Bilirubin", "value": "5.2 mg/dL"}, {"field": "ALT", "value": "46 U/L"}, {"field": "Pre-TIPSS Hepatic Encephalopathy", "value": "Yes (Grade 1)"}, {"field": "Urgency of TIPSS", "value": "Elective"}], "final_answer": 2, "notes": "Score\n2\nRisk Category\nModerate Risk\nEstimated Mortality Rates after TIPSS:\nEstimated 3-month Mortality Rates after TIPSS\n25 %\nEstimated 12-month Mortality Rates after TIPSS\n51-57 %\nEstimated 36-month Mortality Rates after TIPSS\n>60 %"}, {"order": 7, "name": "Cardiovascular Risk in Orthotopic Liver Transplantation (CAR-OLT)", "inputs": [{"field": "Sex", "value": "Male", "score": 0}, {"field": "Current age, years", "value": "56", "score": 2}, {"field": "Race", "value": "White", "score": 7}, {"field": "Working status", "value": "Not working for income", "score": 10}, {"field": "Education level", "value": "High school or less", "score": 5}, {"field": "Atrial fibrillation", "value": "No", "score": 0}, {"field": "Respiratory failure on ventilator at transplant", "value": "No", "score": 0}, {"field": "Pulmonary hypertension", "value": "No", "score": 0}, {"field": "HCC", "value": "Yes", "score": 0}, {"field": "Hypertension", "value": "Yes", "score": 4}, {"field": "Diabetes", "value": "Yes (type 2)", "score": 4}, {"field": "Heart failure", "value": "No", "score": 0}], "final_answer": 32, "notes": "32 points\nCAR-OLT Score\n30 %\nHigh cardiovascular risk in orthotopic liver transplantation"}, {"order": 8, "name": "Malnutrition Universal Screening Tool (MUST)", "inputs": [{"field": "BMI", "value": "22.2 kg/m2 (Height 175 cm; Weight 68 kg)", "score": 0}, {"field": "Unplanned weight loss in past 3-6 months", "value": "6.8% over 3 months (from 73 kg to 68 kg)", "score": 1}, {"field": "Acutely ill and no nutritional intake for >5 days", "value": "Yes", "score": 2}], "final_answer": 3, "notes": "3 points\nMUST Score\nHigh risk\nTreat (unless detrimental or no benefit is expected from nutritional support, e.g. imminent death); refer to dietitian, improve and increase overall intake, increase frequency of monitoring according to local policy"}, {"order": 9, "name": "Mumtaz Score for Readmission in Cirrhosis", "inputs": [{"field": "Age, years", "value": "56", "score": 4}, {"field": "Primary payer", "value": "Medicaid", "score": 5}, {"field": "Elixhauser Comorbidity Index", "value": ">=3 (HTN, type 2 diabetes, depression)", "score": 2}, {"field": "Non-alcoholic etiology of cirrhosis", "value": "No (alcohol-related)", "score": 0}, {"field": "Ascites", "value": "Yes", "score": 5}, {"field": "Hepatic encephalopathy", "value": "Yes", "score": 4}, {"field": "Variceal bleeding", "value": "No", "score": 0}, {"field": "Hepatocellular carcinoma", "value": "Yes", "score": 3}, {"field": "Paracentesis during admission", "value": "Yes", "score": 4}, {"field": "Hemodialysis during admission", "value": "No", "score": 0}, {"field": "Disposition", "value": "Home health care", "score": 1}], "final_answer": 28, "notes": "28 points\nMumtaz Score\n41.9 %\n30-day readmission risk"}, {"order": 10, "name": "Alcohol Relapse Risk after Liver Transplant", "inputs": [{"field": "Duration of Heavy Drinking", "value": "22 years"}, {"field": "Number of Daily Drinks", "value": "10 drinks/day (~120 g ethanol/day) prior to abstinence"}, {"field": "Prior Alcoholism Inpatient Treatments", "value": "1"}, {"field": "Psychiatric Disorder", "value": "Yes (major depressive disorder, mild; on SSRI and therapy)"}, {"field": "Abstinence", "value": "7 months continuous, documented (negative PEth/clinic monitoring)"}], "final_answer": 1, "notes": "High Risk Alcoholism Relapse Score\n1\nRelapse Rate\n18 %\nMean Time to Relapse\n30 Months"}]}
{"task_id": "medmcp-calc_110_2a81dd4f", "task_scenario": "Respiratory Mechanics and Weaning/Extubation", "task_category": "Clinical Medicine / Emergency, Critical Care & Perioperative / Critical Care", "patient_id": "P110_2a81dd4f", "task_description": "Scenario: An intubated ICU patient with improving hypoxemic respiratory failure is being considered for a spontaneous breathing trial (SBT) and potential extubation. The team aims to ensure adequate oxygenation, optimized ventilator settings, acceptable respiratory mechanics, and a safe post-extubation plan.\nStep-by-step calculator use and rationale:\n1) Arterial Blood Gas (ABG) Analyzer: First, interpret overall oxygenation, ventilation, and acid–base status to confirm physiologic stability for weaning consideration. ABG results supply the arterial oxygen value needed for subsequent oxygenation metrics.\n2) Horowitz Index for Lung Function (P/F Ratio): Use the arterial oxygen value and current FiO₂ to quantify oxygenation. This determines whether oxygenation is adequate for SBT readiness. If results suggest inadequate oxygenation, proceed to Step 3 to further characterize the gas exchange defect; otherwise continue to Step 4.\n3) A-a O₂ Gradient: Characterize the degree of shunt and V/Q mismatch using the same ABG and ventilator data. If the gradient is markedly elevated or oxygenation is marginal, plan PEEP personalization and lung recruitment assessment in Step 7; if acceptable, continue to ventilator optimization in Step 4.\n4) Endotracheal Tube (ETT) Depth and Tidal Volume Calculator: Confirm appropriate ETT position and ensure lung-protective tidal volume targeting by height to minimize overdistension before assessing mechanics.\n5) Static Lung Compliance (Cstat) Calculation: Evaluate elastic properties at the set protective tidal volume to understand the lung’s distensibility and readiness for SBT.\n6) Pulmonary Resistance: Assess airway resistance to distinguish obstructive loading from elastic limitations. Decision branch: If compliance is low or resistance is high, optimize ventilator strategy and airway care, then recheck Steps 5–6 before proceeding. If mechanics are acceptable, continue.\n7) Recruitment to Inflation Ratio: For patients with suboptimal oxygenation (from Steps 2–3) or mechanics suggesting derecruitment, characterize lung recruitability to personalize PEEP. If recruitability is favorable, increase PEEP accordingly; if poor, avoid aggressive PEEP escalation. After any adjustments, proceed to noninvasive oxygenation tracking during SBT.\n8) SpO₂/FiO₂ Ratio: During the SBT, trend noninvasive oxygenation to ensure stability under reduced support. Decision branch: If the ratio deteriorates or fails to meet accepted SBT targets, abort the SBT and return to reassessment/optimization (Steps 4–7). If stable, proceed.\n9) Rapid Shallow Breathing Index (RSBI): Near the end of the SBT, calculate RSBI to estimate the likelihood of successful extubation. Decision branch: If RSBI is favorable and SpO₂/FiO₂ remains stable, proceed to extubation; otherwise, defer extubation and optimize.\n10) ROX Index for Intubation after HFNC: If extubating to high-flow nasal cannula, monitor early post-extubation success. Decision branch: If the ROX Index is low or trending down, escalate respiratory support and reassess for potential reintubation; if reassuring, continue de-escalation.\nThis sequence creates deterministic links: ABG results feed the P/F Ratio and A-a O₂ Gradient; those oxygenation metrics trigger the need for Recruitment to Inflation Ratio-guided PEEP; protective tidal volume is set before measuring Cstat and resistance; SBT decisions depend on combined SpO₂/FiO₂ and RSBI outputs; post-extubation safety is monitored with the ROX Index.", "fuzzy_question": "I'm evaluating an intubated patient with improving hypoxemic respiratory failure in intensive care. We're considering a spontaneous breathing trial and possible extubation soon, but I want to be sure we're not rushing it. My main concerns are whether oxygenation is adequate on current settings, whether the ventilator strategy is optimized, and whether mechanics and the post-extubation plan are safe.\n\nHere's how I'm thinking it through. I'd start with a recent arterial blood gas to confirm overall stability: pH, CO2, and oxygenation should be coherent for someone we're about to wean. That oxygenation assessment will anchor how we judge gas exchange on the ventilator.\n\nFrom there, I want a realistic sense of oxygenation relative to the fraction of inspired oxygen provided. If it looks weaker than expected for a trial, I'd examine the alveolar-arterial oxygen gradient to distinguish shunt from ventilation-perfusion mismatch. If the gradient is wide or oxygenation seems marginal, we should individualize support, including adjusting end-expiratory pressure, and consider a brief recruitment maneuver. If oxygenation looks acceptable, I'd move on.\n\nBefore judging mechanics, I want to make sure basics aren't tripping us up. Is the tube positioned appropriately, and are we targeting a protective tidal volume for size so we aren't overdistending while assessing behavior? Once those are right, I want to evaluate lung compliance at the set tidal volume and assess airway loading. If the lungs are stiff or the airways tight, I'd optimize ventilation and airway care (suctioning, bronchodilators if appropriate, recheck settings) and reassess before proceeding. If those parameters are reasonable, we can keep going.\n\nIf earlier oxygenation or mechanics suggest derecruitment, I'd assess recruitability: do the lungs open meaningfully with incremental pressure, or are we risking overinflation? If recruitable, I'm comfortable nudging end-expiratory pressure up and checking for improvement; if not, I wouldn't chase high pressures. After adjustments, I'd track oxygenation noninvasively while we reduce support and observe in real time.\n\nDuring the spontaneous breathing trial, I'd monitor saturation trends relative to the oxygen percentage provided. If that relationship deteriorates or doesn't meet accepted thresholds for a low-support trial, I'd stop and optimize rather than push ahead. If oxygenation remains steady, I'd continue.\n\nNear the end of the trial, I'd assess for rapid, shallow breathing that predicts fatigue, focusing on the relationship between rate and tidal volume. If that pattern looks favorable and oxygenation holds under reduced support, I'd proceed with extubation. If not, we should defer and keep optimizing.\n\nIf we extubate to high-flow nasal cannula, I'd watch closely in the early post-extubation period for trends in oxygenation, oxygen requirement, and respiratory rate. If the composite picture looks unstable or worsens, we should escalate support quickly and keep a low threshold for reintubation. If it's reassuring and improving, we can de-escalate.\n\nWhat's your take on this sequence for this case? I need proper calculations to support the decision-making, not just clinical intuition. Whatever approach you suggest, please back it with solid calculations to withstand scrutiny.", "required_calculators": ["Arterial Blood Gas (ABG) Analyzer", "Horowitz Index for Lung Function (P/F Ratio)", "A-a O₂ Gradient", "Endotracheal Tube (ETT) Depth and Tidal Volume Calculator", "Static Lung Compliance (Cstat) Calculation", "Pulmonary Resistance", "Recruitment to Inflation Ratio", "SpO₂/FiO₂ Ratio", "Rapid Shallow Breathing Index (RSBI)", "ROX Index for Intubation after HFNC"], "calculator_answers": [{"order": 1, "name": "Arterial Blood Gas (ABG) Analyzer", "inputs": [{"field": "pH", "value": "7.44"}, {"field": "PaCO₂", "value": "37 mm Hg"}, {"field": "HCO₃-", "value": "25 mEq/L"}, {"field": "Sodium", "value": "140 mEq/L"}, {"field": "Chloride", "value": "104 mEq/L"}, {"field": "Albumin", "value": "3.6 g/dL"}, {"field": "If respiratory process present, chronicity", "value": "Acute"}], "final_answer": "Primary Respiratory Alkalosis, Acute, with: Secondary Metabolic Alkalosis", "notes": "Primary Respiratory Alkalosis, Acute, with: Secondary Metabolic Alkalosis"}, {"order": 2, "name": "Horowitz Index for Lung Function (P/F Ratio)", "inputs": [{"field": "PaO2", "value": "92 mm Hg"}, {"field": "FiO2", "value": "35 %"}], "final_answer": "262.9 mmHg", "notes": "262.9 mmHg\nHorowitz Index (P/F ratio)\nMild\nSeverity of ARDS\n27 %\nMortality"}, {"order": 3, "name": "A-a O₂ Gradient", "inputs": [{"field": "Atmospheric pressure", "value": "760 mm Hg"}, {"field": "PaO₂", "value": "92 mm Hg"}, {"field": "FiO₂", "value": "35 %"}, {"field": "PaCO₂", "value": "37 mm Hg"}, {"field": "Age (for expected A-a gradient)", "value": "58 years"}], "final_answer": "111.3 mm Hg", "notes": "111.3 mm Hg\nA-a Gradient\n18.5 mm Hg\nExpected A-a Gradient for Age"}, {"order": 4, "name": "Endotracheal Tube (ETT) Depth and Tidal Volume Calculator", "inputs": [{"field": "Height", "value": "70 in"}, {"field": "Gender", "value": "Male"}], "final_answer": "22 cm", "notes": "22 cm\nETT depth from front teeth\n438 mL\nTidal volume if target is 6 mL/kg, IBW 73 kg\n584 mL\nTidal volume if target is 8 mL/kg, IBW 73 kg"}, {"order": 5, "name": "Static Lung Compliance (Cstat) Calculation", "inputs": [{"field": "Corrected/delivered tidal volume (ΔV)", "value": "460 mL"}, {"field": "Plateau pressure (Pplat)", "value": "22 cm H₂O"}, {"field": "PEEP", "value": "8 cm H₂O"}], "final_answer": "32.9 mL/cm H₂O", "notes": "32.9 mL/cm H₂O\nStatic Lung Compliance (Cstat)\nNormal static lung compliance is 50-100 mL/cm H₂O"}, {"order": 6, "name": "Pulmonary Resistance", "inputs": [{"field": "Mean Pulmonary Artery Pressure", "value": "18 mmHg"}, {"field": "Pulmonary Capillary Wedge Pressure", "value": "12 mmHg"}, {"field": "Pulmonary Flow (Cardiac Output)", "value": "6.0 L/min"}, {"field": "Units", "value": "Wood units"}], "final_answer": "1 Wood Units", "notes": "Pulmonary Vascular Resistance\n1 Wood Units\nTotal Pulmonary Resistance\n3 Wood Units"}, {"order": 7, "name": "Recruitment to Inflation Ratio", "inputs": [{"field": "Airway Opening Pressure", "value": "5 cmH2O"}, {"field": "High PEEP", "value": "12 cmH2O"}, {"field": "Set Tidal Volume (VT)", "value": "460 mL"}, {"field": "VT exhaled @ high PEEP", "value": "455 mL"}, {"field": "Low PEEP", "value": "8 cmH2O"}, {"field": "VT exhaled from high to low PEEP", "value": "220 mL"}, {"field": "Plateau Pressure (at low PEEP)", "value": "22 cmH2O"}], "final_answer": 0, "notes": "Recruitment to Inflation Ratio\n0\nThis value represents the ratio between the compliance of the recruited lung to that of the respiratory system. Values ≥ 0.5 suggest more potential for lung recruitment with respect to lung inflation.\nLung Recruitability\nLow Recruiter"}, {"order": 8, "name": "SpO₂/FiO₂ Ratio", "inputs": [{"field": "SpO2", "value": "95 %"}, {"field": "FiO2", "value": "30 %"}], "final_answer": 316.7, "notes": "316.7\nS/F Ratio"}, {"order": 9, "name": "Rapid Shallow Breathing Index (RSBI)", "inputs": [{"field": "Respiratory rate", "value": "20 breaths/min"}, {"field": "Tidal volume", "value": "380 mL"}], "final_answer": "53 breaths/min/L", "notes": "53 breaths/min/L\nLikely successful extubation by RSBI.\nConsider all patient factors before extubating (see Pearls/Pitfalls for suggestions). 97% sensitive, original study."}, {"order": 10, "name": "ROX Index for Intubation after HFNC", "inputs": [{"field": "SpO₂", "value": "95 %"}, {"field": "FiO₂", "value": "40 %"}, {"field": "Respiratory rate", "value": "20 breaths/min"}], "final_answer": 11.88, "notes": "11.88 points\nROX Index\nLow risk of progressing to intubation"}]}
{"task_id": "medmcp-calc_111_a11ef0f2", "task_scenario": "Nutrition and Metabolic Support", "task_category": "Clinical Medicine / Emergency, Critical Care & Perioperative / Critical Care", "patient_id": "P111_a11ef0f2", "task_description": "Clinical scenario: An intensive care patient requires initiation of nutrition support while undergoing active fluid and electrolyte management typical of early critical illness. The care team must tailor energy delivery and carbohydrate provision, monitor for hyperglycemia-related shifts in sodium, and safely correct any sodium and free water abnormalities, integrating these plans with maintenance fluids to avoid rapid osmotic changes. Step-by-step workflow using calculators: 1) Use the Nutrition Risk in the Critically Ill (NUTRIC) Score to triage nutrition urgency. If high risk, target early, near-full nutrition; if lower risk, begin with a conservative ramp-up. This risk output determines how aggressively to plan energy and macronutrient delivery. 2) Apply the BMI Calculator (Body Mass Index and BSA) to determine BMI and categorize body habitus. If BMI indicates obesity, proceed to adjusted weight selection; if not, use actual or ideal weight as clinically appropriate. The BMI category deterministically triggers the next step’s weight strategy. 3) Run Ideal Body Weight and Adjusted Body Weight to generate the weight metric that will be used for nutrition and fluid calculations. If obesity is present, use adjusted body weight; otherwise, use ideal or actual weight per unit policy. This output is the required input for the energy calculation. 4) Calculate Basal Energy Expenditure with the selected weight to set a daily energy target. This target then informs how much carbohydrate to deliver via enteral/parenteral routes. 5) Check the planned carbohydrate provision using the Glucose Infusion Rate (GIR). If GIR is above safe thresholds, reduce carbohydrate intensity or modify infusion strategy; if within range, proceed. GIR acts as a decision trigger for carbohydrate adjustments and for the next step if hyperglycemia is present. 6) Conditional: If hyperglycemia is present or GIR remains high despite adjustments, apply Sodium Correction for Hyperglycemia to obtain a corrected sodium status. This corrected value will be used to classify sodium status and guide fluid therapy decisions. If no hyperglycemia, use the uncorrected sodium status for subsequent steps. 7) Estimate Total Body Water (Watson Formula) to provide the physiologic volume basis for water deficit calculations. TBW is a required input for free water deficit planning. 8) Branch based on corrected sodium status: • If hypernatremia is present, use Free Water Deficit in Hypernatremia with TBW to quantify the replacement volume needed. • If hyponatremia is present, skip free water deficit and proceed directly to safe correction planning. • If sodium status is in the desired range, bypass correction steps and go to maintenance fluid integration. 9) Use Sodium Correction Rate in Hyponatremia and Hypernatremia to select the appropriate fluid type, rate, and volume for safe correction based on the branch above. In hypernatremia, the free water deficit amount feeds into the correction plan; in hyponatremia, this tool provides the recommended correction parameters given the clinical context and desired rate. 10) Calculate Maintenance Fluids Calculations to set baseline daily fluids. Integrate maintenance fluids with nutrition-related fluids (including dextrose) and any correction fluids from step 9 to finalize the daily plan, ensuring total fluid and sodium changes remain within safe correction limits. The outputs from earlier steps (selected weight, energy target, GIR-informed carbohydrate plan, corrected sodium status, TBW-derived deficit) deterministically drive fluid type, volume, and rate selections to achieve coordinated nutrition and metabolic support.", "fuzzy_question": "I’m seeing a ventilated ICU patient early in critical illness who needs to start nutrition while fluids, sodium, and significant glucose variability are being actively managed. I’m torn between early, near-full feeding versus a gradual ramp-up, and I want to avoid osmotic swings and worsening hyperglycemia.\n\nHere’s how I’m thinking through it, and I’d like a plan with clinical reasoning and key calculations at each step:\n\n- First, assess nutrition risk to determine whether to be aggressive with early near-full feeds or use a conservative ramp; this will set targets for energy and macronutrient delivery.\n- Characterize body habitus from height and weight. If obesity is present, use an adjusted weight; otherwise use actual or ideal weight as clinically appropriate. This choice drives all downstream dosing.\n- From the chosen weight, estimate resting energy needs to set a defensible daily energy target. Use this to guide carbohydrate delivery via enteral and/or parenteral routes.\n- Translate the energy goal into a carbohydrate plan and check that dextrose intensity per kilogram per minute stays within a safe range. If it appears excessive, or if hyperglycemia persists despite adjustments, reduce carbohydrate or modify the infusion strategy.\n- If hyperglycemia is present or dextrose intensity remains high, interpret sodium with a glucose-related correction to understand the corrected sodium before making fluid decisions. If glucose is not a concern, use the measured sodium directly.\n- Estimate total body water based on sex, age, height, and weight to anchor water deficit calculations and fluid planning.\n- If corrected sodium is high, quantify free water deficit and outline a cautious replacement plan.\n- If corrected sodium is low, do not calculate a deficit; instead set a conservative correction pace suited to the clinical context.\n- If corrected sodium is within range, skip correction and integrate maintenance fluids with nutrition.\n- For any correction, choose fluid type(s), rate, and volume to move sodium safely. In hypernatremia, use the free water estimate to guide how much and how fast to replace; in hyponatremia, set targets that avoid overshoot. Please outline expected sodium movement over the next day to prevent rapid shifts.\n- Pull the full day together: maintenance fluids plus nutrition (including the dextrose component) and any correction fluids. Provide total daily volume and an estimate of net sodium change, ensuring the plan keeps sodium correction within safe limits and avoids osmotic complications.\n- Tie each decision back to prior steps—the selected weight, energy target, carbohydrate intensity, sodium handling in the setting of hyperglycemia, and estimated total body water—so the plan is internally consistent.\n\nWhat’s your take? I need proper calculations—this can’t be based on gut feeling. Whatever approach you suggest should be backed by solid calculations and able to withstand scrutiny.", "required_calculators": ["Nutrition Risk in the Critically Ill (NUTRIC) Score", "BMI Calculator (Body Mass Index and BSA)", "Ideal Body Weight and Adjusted Body Weight", "Basal Energy Expenditure", "Glucose Infusion Rate (GIR)", "Sodium Correction for Hyperglycemia", "Total Body Water (Watson Formula)", "Free Water Deficit in Hypernatremia", "Sodium Correction Rate in Hyponatremia and Hypernatremia", "Maintenance Fluids Calculations"], "calculator_answers": [{"order": 1, "name": "Nutrition Risk in the Critically Ill (NUTRIC) Score", "inputs": [{"field": "Age (years)", "value": 58, "score": 1}, {"field": "APACHE II", "value": 22, "score": 2}, {"field": "SOFA Score (initial)", "value": 8, "score": 1}, {"field": "Number of comorbidities", "value": 2, "score": 1}, {"field": "Days in hospital to ICU admit", "value": 1, "score": 1}], "final_answer": 6, "notes": "6 points\nNUTRIC Score\nHigh risk\n~30% mortality at 28 days.\nConsider aggressive nutrition therapy (enteral or parenteral)."}, {"order": 2, "name": "BMI Calculator (Body Mass Index and BSA)", "inputs": [{"field": "Weight (lbs)", "value": 254}, {"field": "Height (in)", "value": 69}], "final_answer": "37.5 kg/m²", "notes": "37.5 kg/m²\nBody Mass Index (Class 2 obesity)\n2.37 m²\nBody Surface Area"}, {"order": 3, "name": "Ideal Body Weight and Adjusted Body Weight", "inputs": [{"field": "Sex", "value": "Male"}, {"field": "Height (in)", "value": 69}, {"field": "Actual body weight (lbs)", "value": 254}], "final_answer": "155.9 lbs", "notes": "155.9 lbs\nIdeal Body Weight\nEquivalent to 70.7 kg\nActual body weight is 163% (1.63x) ideal body weight\n195.1 lbs\nAdjusted Body Weight\nEquivalent to 88.5 kg"}, {"order": 4, "name": "Basal Energy Expenditure", "inputs": [{"field": "Sex", "value": "Male"}, {"field": "Weight (lbs)", "value": 195}, {"field": "Height (in)", "value": 69}, {"field": "Age (years)", "value": 58}, {"field": "Activity level", "value": "Sedentary (little to no exercise)"}], "final_answer": "1767 kcal/day", "notes": "1767 kcal/day\nBasal Energy Expenditure\nNote: stress, activity, illness, trauma, burns, cancers can increase daily caloric requirement.\n2120 kcal/day\nHarris-Benedict recommended caloric intake"}, {"order": 5, "name": "Glucose Infusion Rate (GIR)", "inputs": [{"field": "Dextrose concentration (g/dL)", "value": 10}, {"field": "Infusion rate (mL/hr)", "value": 75}, {"field": "Weight (lbs)", "value": 195}], "final_answer": "1.4 mg/kg/min", "notes": "1.4 mg/kg/min\nGIR"}, {"order": 6, "name": "Sodium Correction for Hyperglycemia", "inputs": [{"field": "Sodium (mEq/L)", "value": 146}, {"field": "Glucose (mg/dL)", "value": 320}], "final_answer": "151 mEq/L", "notes": "150 mEq/L\nCorrected Sodium\n(Katz, 1973)\n151 mEq/L\nCorrected Sodium\n(Hillier, 1999)"}, {"order": 7, "name": "Total Body Water (Watson Formula)", "inputs": [{"field": "Height (cm)", "value": 175}, {"field": "Weight (kg)", "value": 115}, {"field": "Sex", "value": "Male"}, {"field": "Age (years)", "value": 58}], "final_answer": "54.39 L", "notes": "Total Body Water\n54.39 L"}, {"order": 8, "name": "Free Water Deficit in Hypernatremia", "inputs": [{"field": "Sex", "value": "Male"}, {"field": "Age range", "value": "Adult"}, {"field": "Weight (lbs)", "value": 254}, {"field": "Sodium (mEq/L) — use if >140", "value": 151}, {"field": "Sodium desired (mEq/L)", "value": 145}], "final_answer": "2.9 L", "notes": "2.9 L\nFree Water Deficit"}, {"order": 9, "name": "Sodium Correction Rate in Hyponatremia and Hypernatremia", "inputs": [{"field": "Sex", "value": "Male"}, {"field": "Age range", "value": "Adult"}, {"field": "Weight (lbs)", "value": 254}, {"field": "Serum sodium (mEq/L)", "value": 151}, {"field": "Fluid type", "value": "5% Dextrose in water (0 mmol/L Na)"}, {"field": "Rate of sodium correction (mEq/L/hr)", "value": 0.4}], "final_answer": "186 mL/hr", "notes": "R186 mL/hr\nFluid rate to decrease Na by 0.4 mmol/L/hr with D5W"}, {"order": 10, "name": "Maintenance Fluids Calculations", "inputs": [{"field": "Weight (lbs)", "value": 156}], "final_answer": "111 mL/hr", "notes": "111 mL/hr\nMaintenance fluids\n166 mL/hr\nMaintenance fluids x 1.5\n1418 mL\nFluid bolus (20 mL/kg)"}]}
{"task_id": "medmcp-calc_112_7f22b5c4", "task_scenario": "Pediatric Emergency Resuscitation", "task_category": "Clinical Medicine / Special Populations & General Tools / Pediatrics & Neonatology", "patient_id": "P112_7f22b5c4", "task_description": "Scenario: A pediatric patient presents to the emergency department after blunt trauma with depressed consciousness, risk of airway compromise, and possible hemodynamic instability. The resuscitation team must rapidly secure the airway, assess shock, decide on neuroimaging, optimize oxygenation and ventilation, and protect cerebral perfusion, with contingency planning for post-traumatic seizures. Step-by-step workflow using calculators: 1) Start with the Pediatric Glasgow Coma Scale (pGCS) to establish neurologic status and airway protection capability. If the pGCS indicates inability to protect the airway or severe impairment, proceed immediately to intubation planning. If the pGCS is adequate for airway protection, defer intubation and continue to hemodynamic assessment. 2) If intubation is indicated, use the Pediatric Endotracheal Tube (ETT) Size calculator to select an appropriate ETT size for the child. 3) After selecting the tube, apply the Endotracheal Tube (ETT) Depth and Tidal Volume Calculator to determine optimal insertion depth and an initial target tidal volume based on patient height, ensuring safe placement and lung-protective ventilation settings. 4) Once ventilated, use the Oxygenation Index to gauge the severity of respiratory failure under current ventilator settings. If the Oxygenation Index is elevated, escalate respiratory support (e.g., adjust ventilator strategy or consider advanced modalities). If the Oxygenation Index is acceptable, continue conventional ventilation and move to circulatory assessment. 5) Evaluate shock using the Shock Index, Pediatric Age-Adjusted (SIPA) to detect occult hemodynamic instability. If SIPA is elevated, initiate fluid resuscitation and vasoactive support as needed; if SIPA is normal, proceed with ongoing monitoring. 6) After initial resuscitation, calculate the Mean Arterial Pressure (MAP) to quantify perfusion status and to provide a required input for cerebral perfusion assessment. 7) Apply the Pediatric NEXUS II Head CT Decision Instrument for Blunt Trauma to determine whether head CT is warranted. If CT is recommended, obtain imaging and, if severe traumatic brain injury is confirmed and intracranial pressure monitoring is placed, proceed to cerebral perfusion evaluation. If CT is not recommended, continue close neurologic observation and skip the cerebral perfusion step. 8) If intracranial pressure monitoring is in place, use the Cerebral Perfusion Pressure calculator with the previously computed MAP to determine CPP. If CPP is below target, intensify strategies to raise MAP or lower intracranial pressure (e.g., optimize sedation, ventilation, and vasoactive support). If CPP is adequate, maintain current therapy and ongoing monitoring. 9) If a post-traumatic seizure is observed or seizure prophylaxis is indicated based on the clinical picture after imaging, use the Fosphenytoin Load calculator to determine an appropriate loading dose prior to maintenance therapy. Conditional branches: • Airway branch: If pGCS indicates poor airway protection, intubate and apply ETT size and depth/tidal volume calculators before proceeding to oxygenation evaluation; if pGCS is adequate, defer intubation and continue with shock assessment and imaging decisions. • Imaging/ICP branch: If NEXUS II recommends CT and severe TBI with ICP monitoring is present, compute CPP using MAP; if CT is not recommended or ICP monitoring is not in place, skip CPP. • Oxygenation branch: If Oxygenation Index is high, escalate respiratory support; if acceptable, continue conventional ventilation. • Seizure branch: If seizure occurs or prophylaxis is indicated, calculate fosphenytoin load; if not, continue standard neuroprotective care.", "fuzzy_question": "Evaluating a pediatric patient in the ED after blunt trauma who is drowsy with irregular respirations and at risk for airway compromise with possible early shock. I’m aiming for a sensible, stepwise approach without missing anything critical.\n\nFirst, I want a structured assessment of responsiveness to determine whether the patient can protect the airway. If that suggests the airway is not safe, I would proceed directly to intubation. If the patient appears capable of airway protection, I would defer intubation, continue working on circulation and imaging decisions, and observe closely.\n\nIf intubation is required, I’ll need guidance to choose an appropriately sized endotracheal tube for a pediatric patient and confirm correct insertion depth. Once the tube is placed, I want to set an initial lung‑protective tidal volume based on body size and verify that the starting ventilator settings are safe. After initiating mechanical ventilation, I want a quantitative assessment of oxygenation under the current settings; if that assessment is concerning, we should adjust the ventilator strategy or escalate support, and if it’s acceptable, continue conventional ventilation and proceed.\n\nFor circulation, I want an age‑adjusted assessment of whether heart rate relative to blood pressure indicates occult shock. If findings are concerning, we’ll start fluid boluses and add vasoactive support as needed; if reassuring, we’ll continue close monitoring. After the initial resuscitation, I want to follow mean arterial pressure to better gauge perfusion and have it available if brain perfusion targets become relevant.\n\nI’m also weighing the need for urgent head CT. Let’s apply a validated pediatric decision aid for blunt head injury to guide that decision. If it points toward imaging, we’ll obtain the scan; if severe injury is identified and an intracranial pressure monitor is placed, then I want to calculate cerebral perfusion pressure and determine whether it’s within target range. If it’s low, we should raise systemic pressure or lower intracranial pressure by optimizing sedation, ventilation, and vasoactives; if it’s adequate, we’ll maintain the current plan. If the decision aid suggests no CT or no ICP monitor is placed, we’ll continue close neurologic checks and omit the brain perfusion step.\n\nFinally, there’s a real possibility of early post‑traumatic seizures. If a seizure occurs or if prophylaxis is appropriate based on the clinical course and imaging, I’ll need the correct fosphenytoin loading dose before establishing a maintenance plan.\n\nCan you walk through each of these decisions for this pediatric patient with specific targets and calculations at each step, not just general advice? I need evidence‑based calculations so the plan holds up to scrutiny.", "required_calculators": ["Pediatric Glasgow Coma Scale (pGCS)", "Pediatric Endotracheal Tube (ETT) Size", "Endotracheal Tube (ETT) Depth and Tidal Volume Calculator", "Oxygenation Index", "Shock Index, Pediatric Age-Adjusted (SIPA)", "Mean Arterial Pressure (MAP)", "Pediatric NEXUS II Head CT Decision Instrument for Blunt Trauma", "Cerebral Perfusion Pressure", "Fosphenytoin Load"], "calculator_answers": [{"order": 1, "name": "Pediatric Glasgow Coma Scale (pGCS)", "inputs": [{"field": "Age", "value": "12 years (>2 years)"}, {"field": "Eye response", "value": "Open to pain only (+2)", "score": 2}, {"field": "Verbal response", "value": "Incomprehensible words/sounds (+2)", "score": 2}, {"field": "Motor response", "value": "Withdraws to pain (+4)", "score": 4}], "final_answer": 8, "notes": "8 points\nGlasgow Coma Score\nE(2) V(2) M(4)\nGlasgow Coma Scale"}, {"order": 2, "name": "Pediatric Endotracheal Tube (ETT) Size", "inputs": [{"field": "Age", "value": "12 years"}], "final_answer": "7.0 mm tube", "notes": "7.0 mm tube\nPredicted Uncuffed Tube Size\n6.0 mm tube\nPredicted Cuffed Tube Size"}, {"order": 3, "name": "Endotracheal Tube (ETT) Depth and Tidal Volume Calculator", "inputs": [{"field": "Height", "value": "62 in"}, {"field": "Gender", "value": "Female"}], "final_answer": "20 cm", "notes": "20 cm\nETT depth from front teeth\n300 mL\nTidal volume if target is 6 mL/kg, IBW 50 kg\n400 mL\nTidal volume if target is 8 mL/kg, IBW 50 kg"}, {"order": 4, "name": "Oxygenation Index", "inputs": [{"field": "FiO₂", "value": "60 %"}, {"field": "Mean airway pressure (PAW) units", "value": "mm Hg"}, {"field": "Mean airway pressure (PAW)", "value": "7.4 mm Hg"}, {"field": "PaO2", "value": "80 mm Hg"}], "final_answer": 8, "notes": "Diagnostic Result\n8\nOxygenation Index"}, {"order": 5, "name": "Shock Index, Pediatric Age-Adjusted (SIPA)", "inputs": [{"field": "Age", "value": "12 years"}, {"field": "Maximum heart rate", "value": "138 beats/min"}, {"field": "Minimum systolic blood pressure", "value": "88 mm Hg"}], "final_answer": 1.57, "notes": "1.57\nSIPA\nElevated\nMaximum normal SIPA for age of 12 years is 1.0\n25.1 %\nRisk of blunt injury"}, {"order": 6, "name": "Mean Arterial Pressure (MAP)", "inputs": [{"field": "Systolic BP", "value": "92 mm Hg"}, {"field": "Diastolic BP", "value": "56 mm Hg"}], "final_answer": "68 mm Hg", "notes": "68 mm Hg\nMean Arterial Pressure (MAP)"}, {"order": 7, "name": "Pediatric NEXUS II Head CT Decision Instrument for Blunt Trauma", "inputs": [{"field": "Evidence of skull fracture", "value": "No"}, {"field": "Scalp hematoma", "value": "Yes"}, {"field": "Neurologic deficit", "value": "No"}, {"field": "Abnormal level of alertness", "value": "Yes"}, {"field": "Abnormal behavior", "value": "No"}, {"field": "Persistent vomiting", "value": "No"}, {"field": "Coagulopathy", "value": "No"}], "final_answer": "High risk", "notes": "Diagnostic Result\nHigh risk\nConsider CT"}, {"order": 8, "name": "Cerebral Perfusion Pressure", "inputs": [{"field": "MAP", "value": "68 mm Hg"}, {"field": "ICP", "value": "25 mm Hg"}], "final_answer": "43 mmHg", "notes": "Low CPP. Consider interventions to increase MAP or decrease ICP (see Next Steps for details)."}, {"order": 9, "name": "Fosphenytoin Load", "inputs": [{"field": "Desired Concentration", "value": "15 µg/mL"}, {"field": "Actual Concentration", "value": "0 µg/mL"}, {"field": "Weight", "value": "50 kg"}], "final_answer": "570.7 mg", "notes": "Loading Dose\n570.7 mg"}]}
{"task_id": "medmcp-calc_113_c83ab657", "task_scenario": "Pleural Effusion and Pulmonary Nodules", "task_category": "Clinical Medicine / Medicine & Organ Systems / Respiratory & Thoracic Medicine", "patient_id": "P113_c83ab657", "task_description": "Scenario: A patient presents with dyspnea. Imaging reveals a unilateral pleural effusion and an incidental solitary pulmonary nodule. The clinician must determine the effusion type, identify malignant versus infectious causes with prognostic implications to guide interventions, and concurrently risk-stratify the pulmonary nodule to plan appropriate follow-up or tissue diagnosis. Step-by-step workflow: 1) After diagnostic thoracentesis, apply Light's Criteria for Exudative Effusions to classify the pleural effusion as exudative or transudative, as this determines the next diagnostic and management path. If transudative, manage the likely systemic cause and proceed to nodule risk assessment in step 4. If exudative, advance to step 2. 2) For exudative effusions, decide the likely pathway: infectious versus malignant. 2a) If pleural infection is suspected or confirmed, use the RAPID Score for Pleural Infection to stratify mortality risk and guide the urgency/intensity of drainage, antimicrobial therapy, and escalation decisions; then continue to step 4 for nodule evaluation. 2b) If malignant pleural effusion is suspected or confirmed, first compute the LENT Prognostic Score for Malignant Pleural Effusion to estimate overall survival. If the LENT risk category is intermediate or high, then calculate the PROMISE Score for Malignant Pleural Effusion to refine 3-month mortality risk and align procedure choice (e.g., pleurodesis versus indwelling catheter) and follow-up planning with near-term prognosis. If the LENT category is low, proceed with MPE management without PROMISE or optionally use PROMISE for additional confirmation. 3) If neither infection nor malignancy is immediately evident in an exudative effusion, continue diagnostic evaluation while proceeding to step 4 for nodule risk assessment. 4) For the solitary pulmonary nodule, use the Solitary Pulmonary Nodule (SPN) Malignancy Risk Score (Mayo Clinic Model) to estimate malignancy probability on the basis of clinical and radiographic features. Use the resulting risk category to select the appropriate branch of the Fleischner Society Guidelines for Incidental Pulmonary Nodules to determine the imaging interval, need for advanced characterization, or expeditious tissue diagnosis. If the Mayo model indicates low risk, apply the guideline’s surveillance path with longer-interval follow-up. If intermediate risk, apply the guideline’s short-interval imaging and consider further evaluation. If high risk, use the guideline’s pathway prioritizing expedited diagnostic procedures. Integration: The Light’s classification deterministically selects the effusion pathway (infectious vs malignant vs transudative). Within the malignant pathway, the LENT result determines whether PROMISE is needed to refine near-term prognosis. The Mayo SPN output directly determines which branch of the Fleischner recommendations to apply. Together, these steps align procedural choices for the effusion and the intensity/timing of nodule work-up into a single coherent care plan.", "fuzzy_question": "I’m evaluating a patient with shortness of breath; imaging shows a pleural effusion and an incidental pulmonary nodule. We’ve obtained diagnostic pleural fluid, and I’m trying to interpret it in a way that drives decisions. First, I need to determine whether the fluid behaves more like an exudate or a transudate based on the customary protein and LDH relationships between pleural fluid and serum; that distinction will set the course. If it appears transudative, I’ll focus on the likely systemic driver while concurrently assessing the nodule’s cancer risk. If it comes out exudative, the key question is whether we’re dealing with infection or malignancy.\n\nIf the picture points to pleural infection, I need a clear sense of short‑term risk using standard clinical factors used in empyema/complicated parapneumonic effusions, so I can match the urgency and intensity of drainage, choose antibiotic strategy, and decide early whether to escalate (intrapleural therapy or surgical referral) rather than wait and see.\n\nIf the effusion seems malignant—or cytology/biopsy confirms it—I want an estimate of overall survival using readily available clinical and laboratory features. If that initial outlook indicates intermediate or higher risk, please add a focused near‑term mortality estimate using more detailed clinical and biomarker inputs, so we can align procedure choice (pleurodesis versus an indwelling catheter) and follow‑up cadence with the expected trajectory. If the initial outlook suggests low risk, I’m comfortable proceeding with standard malignant effusion management without that extra layer, unless it would meaningfully change near‑term planning.\n\nIf the exudate doesn’t clearly fit infection or cancer right away, keep the diagnostic workup moving (cultures, cytology, further sampling as needed), but don’t delay the nodule assessment.\n\nFor the pulmonary nodule, I want a validated malignancy probability estimate that takes into account age, smoking history, size, location, and edge characteristics. Then, use that risk to choose the appropriate path from contemporary society guidance for incidental nodules—longer‑interval surveillance when the risk is low; short‑interval imaging and potential additional characterization when it’s intermediate; and a more expedited route to tissue diagnosis (and/or PET‑CT) when it’s high.\n\nPlease knit this together into one coherent plan—effusion pathway determined by the fluid profile, procedure choices matched to prognosis if it’s malignant, and the nodule work‑up intensity paced to its estimated risk—so we’re not over‑ or under‑treating as we plan the next visit and the near future.\n\nI really need proper calculations on this—clinical intuition isn’t enough. Whatever approach you suggest, make sure it’s backed by solid calculations so it holds up to scrutiny.", "required_calculators": ["Light's Criteria for Exudative Effusions", "RAPID Score for Pleural Infection", "LENT Prognostic Score for Malignant Pleural Effusion", "PROMISE Score for Malignant Pleural Effusion", "Solitary Pulmonary Nodule (SPN) Malignancy Risk Score (Mayo Clinic Model)", "Fleischner Society Guidelines for Incidental Pulmonary Nodules"], "calculator_answers": [{"order": 1, "name": "Light's Criteria for Exudative Effusions", "inputs": [{"field": "Total serum Protein", "value": "6.8 g/dL"}, {"field": "Pleural fluid Protein", "value": "4.2 g/dL"}, {"field": "Serum LDH", "value": "180 U/L"}, {"field": "Pleural fluid LDH", "value": "690 U/L"}, {"field": "Upper limit of normal serum LDH", "value": "220 U/L"}], "final_answer": "At least one of Light’s Criteria has been met; according to one study, this was 98% sensitive for exudative effusion.", "notes": "At least one of Light’s Criteria has been met; according to one study, this was 98% sensitive for exudative effusion."}, {"order": 2, "name": "RAPID Score for Pleural Infection", "inputs": [{"field": "BUN, serum", "value": "12 mg/dL", "score": 0}, {"field": "Age, years", "value": "68 years", "score": 1}, {"field": "Purulent pleural fluid", "value": "No", "score": 1}, {"field": "Infection source", "value": "Community-acquired", "score": 0}, {"field": "Serum albumin", "value": "3.8 g/dL", "score": 0}], "final_answer": 2, "notes": "2 points\nRAPID Score\nLow risk\n1.5% mortality at 3 months"}, {"order": 3, "name": "LENT Prognostic Score for Malignant Pleural Effusion", "inputs": [{"field": "Pleural fluid LDH, U/L", "value": "690 U/L", "score": 0}, {"field": "ECOG Score", "value": "1 (symptomatic but ambulatory)", "score": 1}, {"field": "Serum neutrophil-to-lymphocyte ratio", "value": "6.5", "score": 0}, {"field": "Tumor type", "value": "Lung", "score": 2}], "final_answer": 3, "notes": "3 points\nLENT Score\nModerate risk\n130 days median survival"}, {"order": 4, "name": "PROMISE Score for Malignant Pleural Effusion", "inputs": [{"field": "Previous chemotherapy", "value": "No"}, {"field": "Previous radiotherapy", "value": "No"}, {"field": "Hemoglobin, g/dL", "value": "12.9 g/dL"}, {"field": "Serum WBC count, 10⁹ cells/L", "value": "9.2 x10^9/L"}, {"field": "C-reactive protein, IU/L", "value": "38 mg/L"}, {"field": "ECOG performance status", "value": "0-1"}, {"field": "Cancer type", "value": "Lung"}, {"field": "TIMP1, ng/mg protein", "value": "Unknown"}], "final_answer": 19, "notes": "19 points\nClinical PROMISE Score\n<25 %\nRisk of mortality at 3 months"}, {"order": 5, "name": "Solitary Pulmonary Nodule (SPN) Malignancy Risk Score (Mayo Clinic Model)", "inputs": [{"field": "Age", "value": "68 years"}, {"field": "Nodule diameter", "value": "12 mm"}, {"field": "Current or former smoker", "value": "Yes"}, {"field": "Extrathoracic cancer diagnosis ≥5 years prior", "value": "No"}, {"field": "Upper lobe location of tumor", "value": "Yes"}, {"field": "Nodule spiculation", "value": "Yes"}, {"field": "FDG-PET", "value": "PET not performed"}], "final_answer": "49.4 %", "notes": "49.4 %\nProbability of malignancy\nOne study suggests watchful waiting only at very low post-test probabilities (<2%), biopsy at \"lower\" post-test probabilities (2% to 20%), and surgery at higher post-test probabilities (>70%). See Next Steps."}, {"order": 6, "name": "Fleischner Society Guidelines for Incidental Pulmonary Nodules", "inputs": [{"field": "Nodule type", "value": "Solid"}, {"field": "Number of nodules", "value": "Single"}, {"field": "Risk level", "value": "High"}, {"field": "Size", "value": ">8 mm (>250 mm³)"}], "final_answer": "Consider CT at 3 months, PET/CT, or tissue sampling", "notes": "Consider CT at 3 months, PET/CT, or tissue sampling"}]}
{"task_id": "medmcp-calc_115_2050a822", "task_scenario": "Neonatal Sepsis Risk", "task_category": "Clinical Medicine / Special Populations & General Tools / Pediatrics & Neonatology", "patient_id": "P115_2050a822", "task_description": "Scenario: A newborn with maternal intrapartum risk factors is evaluated shortly after birth for early-onset sepsis risk. The clinical team aims to avoid unnecessary antibiotics while ensuring early recognition and treatment of sepsis or septic shock if the infant deteriorates. The workflow below sequences multiple pediatric and neonatal tools so that earlier outputs drive later decisions.\n\nStep 1 – Initial perinatal risk estimation: Use the Neonatal Early-Onset Sepsis Calculator to quantify baseline risk from maternal factors and the infant’s initial clinical status. Follow its recommended starting plan (e.g., observation frequency, need for cultures, empiric therapy).\n\nBranch A (elevated perinatal risk or symptoms at presentation): If the Neonatal Early-Onset Sepsis Calculator recommends empiric therapy or indicates elevated risk, immediately assess severity with the Pediatric SIRS, Sepsis, and Septic Shock Criteria to determine whether the infant meets sepsis or septic shock thresholds.\n- If the Pediatric SIRS, Sepsis, and Septic Shock Criteria indicate sepsis or septic shock, compute the Phoenix Sepsis Score to further quantify severity and guide escalation (e.g., intensity of resuscitation and level of care). Phoenix is used only because the SIRS-based classification has confirmed sepsis-level illness.\n- If the Pediatric SIRS, Sepsis, and Septic Shock Criteria are not met, continue the plan suggested by the Neonatal Early-Onset Sepsis Calculator with close observation and reassessment.\n\nBranch B (low perinatal risk and well-appearing): If the Neonatal Early-Onset Sepsis Calculator supports observation without immediate antibiotics, proceed with serial exams. If the infant later develops fever or persistent concern for infection arises in the young-infant period, apply the Step-by-Step Approach to Febrile Infants to stratify risk of invasive bacterial infection and decide on the need for admission and parenteral therapy versus continued observation.\n- If the Step-by-Step Approach classifies the infant as low risk but clinical uncertainty remains, use the Neutrophil-Lymphocyte Ratio (NLR) Calculator as an adjunctive check. A low NLR supports continued observation, while a high NLR should override the low-risk impression and trigger reassessment with the Pediatric SIRS, Sepsis, and Septic Shock Criteria.\n- If the Step-by-Step Approach indicates moderate or high risk, go directly to the Pediatric SIRS, Sepsis, and Septic Shock Criteria to determine sepsis severity; if sepsis/septic shock is confirmed, follow with the Phoenix Sepsis Score to guide escalation and resource planning.\n\nRationale for the sequence: The Neonatal Early-Onset Sepsis Calculator anchors perinatal risk and initial management. Severity assessment (Pediatric SIRS, Sepsis, and Septic Shock Criteria) is only invoked when perinatal risk or subsequent fever/illness warrants it. The Phoenix Sepsis Score is reserved for cases already meeting sepsis criteria to quantify severity and inform level-of-care decisions. The Step-by-Step Approach to Febrile Infants addresses subsequent fever in the young-infant period after the immediate perinatal window, and the NLR provides an adjunctive, rapid biomarker-driven refinement when the risk categorization is borderline or there is lingering uncertainty.", "fuzzy_question": "I’m evaluating a patient shortly after birth in the setting of perinatal risk factors, and I’m trying to balance avoiding unnecessary antibiotics with not missing early sepsis. For decision-making, I want to anchor the initial plan on the combination of the perinatal course and the infant’s early clinical appearance—something that provides a baseline risk and translates into practical steps such as exam and vital sign frequency, whether blood cultures are indicated now, and whether there is a sufficient signal to start empiric antibiotics versus close observation.\n\nIf those perinatal factors or the initial exam indicate higher risk—or if the patient is already showing concerning signs—I’d want you to apply developmentally appropriate, formal criteria to determine whether this meets sepsis or shock. If so, please also grade illness severity so we can match resuscitation intensity and select the appropriate level of care (e.g., standard nursery versus higher acuity).\n\nIf the patient starts out low risk and appears well, I’m comfortable with serial exams. However, if fever or persistent concern for infection emerges later in the early postnatal period, I’d like you to use a validated approach for febrile infants to estimate the likelihood of invasive bacterial infection and guide whether to admit and start parenteral therapy or continue observation.\n\nIf that fever framework categorizes the patient as low risk but there is residual concern, could we use a quick check from the CBC differential—the neutrophil-to-lymphocyte ratio—as a tie-breaker? A low ratio would support continued observation, whereas a high ratio should likely override the initial low-risk impression and prompt reassessment for sepsis using formal criteria.\n\nIf the fever pathway places the patient in a moderate or high risk group, let’s proceed directly to determining whether sepsis or shock definitions are met; and if they are, again, please grade severity to guide escalation and resource planning.\n\nI need proper calculations for this—decisions shouldn’t rely on clinical intuition alone. Whatever approach you suggest, make sure it’s supported by solid calculations and can withstand scrutiny.", "required_calculators": ["Neonatal Early-Onset Sepsis Calculator", "Pediatric SIRS, Sepsis, and Septic Shock Criteria", "Phoenix Sepsis Score", "Step-by-Step Approach to Febrile Infants", "Neutrophil-Lymphocyte Ratio (NLR) Calculator"], "calculator_answers": [{"order": 1, "name": "Neonatal Early-Onset Sepsis Calculator", "inputs": [{"field": "Gestational age", "value": "39w2d"}, {"field": "Highest maternal antepartum temperature", "value": "100.8 F"}, {"field": "Duration of rupture of membranes (ROM)", "value": "19.5 hours"}, {"field": "Maternal GBS status", "value": "Positive"}, {"field": "Type of intrapartum antibiotics", "value": "GBS-specific antibiotics >2 hrs prior to birth"}], "final_answer": 0.76, "notes": "0.76\nEOS risk per 1000/births\nEOS Risk after Clinical Exam (risk per 1000/births)\nWell appearing: 0.31\nEquivocal: 3.77\nClinical illness: 15.81\nClinical Recommendation\nAt birth: Routine vitals\nAfter Clinical Exam\nWell appearing: No additional care\nEquivocal: Treat empirically with antibiotics\nClinical illness: Treat empirically with antibiotics"}, {"order": 2, "name": "Step-by-Step Approach to Febrile Infants", "inputs": [{"field": "Ill appearing (abnormal Pediatric Assessment Triangle)?", "value": "No"}, {"field": "Age ≤21 days", "value": "No(Age 28 days)"}, {"field": "Leukocyturia", "value": "No(LE−, nitrite−)"}, {"field": "Procalcitonin ≥0.5 ng/mL", "value": "No(procalcitonin 0.21 ng/mL)"}, {"field": "CRP >20 mg/L or ANC >10,000/mm3", "value": "No(ANC 7,500/μL, CRP 6 mg/L)"}], "final_answer": "Low risk", "notes": "Low risk\nRisk of invasive bacterial infection 0.7%. Full sepsis workup likely not necessary."}, {"order": 3, "name": "Neutrophil-Lymphocyte Ratio (NLR) Calculator", "inputs": [{"field": "Absolute or % neutrophil count", "value": "7500 cells/μL"}, {"field": "Absolute or % lymphocyte count", "value": "1500 cells/μL"}], "final_answer": 5, "notes": "Neutrophil-Lymphocyte Ratio"}, {"order": 4, "name": "Pediatric SIRS, Sepsis, and Septic Shock Criteria", "inputs": [{"field": "Temp >38.5°C (101.3°F) or <36°C (96.8°F)", "value": "Yes"}, {"field": "Tachycardia or bradycardia (if <1 year)", "value": "Yes"}, {"field": "Tachypnea or mechanical ventilation (related to an acute process)", "value": "Yes"}, {"field": "Abnormal leukocyte count or >10% bands", "value": "No"}, {"field": "Suspected or present source of infection", "value": "Yes"}, {"field": "Cardiovascular dysfunction OR ARDS OR ≥2 other organ dysfunction", "value": "No"}, {"field": "Cardiovascular dysfunction despite adequate fluid resuscitation", "value": "No"}], "final_answer": "This patient meets sepsis criteria.", "notes": "This patient meets sepsis criteria.\nScreen for Severe Sepsis and Septic Shock physical exam findings. If present, initiate ACCM/PALS Septic Shock Algorithm (see Next Steps section).\nConsider IV fluid resuscitation, cultures, and broad-spectrum antibiotics."}, {"order": 5, "name": "Phoenix Sepsis Score", "inputs": [{"field": "Age", "value": "<1 month"}, {"field": "Enter PaO2 or SpO2?", "value": "SpO₂"}, {"field": "Is SpO2 ≤97%?", "value": "Yes"}, {"field": "SpO₂", "value": "96 %"}, {"field": "FiO2", "value": "21 %"}, {"field": "Respiratory support", "value": "None"}, {"field": "Vasoactive medications", "value": "None", "score": 0}, {"field": "Lactate", "value": "2.3 mmol/L", "score": 0}, {"field": "MAP", "value": "52 mm Hg"}, {"field": "Platelets", "value": "225 x 10^3/μL", "score": 0}, {"field": "INR", "value": "1.1", "score": 0}, {"field": "D-dimer", "value": "0.6 mg/L FEU", "score": 0}, {"field": "Fibrinogen", "value": "285 mg/dL", "score": 0}, {"field": "GCS", "value": "15; pupils reactive", "score": 0}], "final_answer": 0, "notes": "0 points\nPhoenix Sepsis Score\nDoes not meet sepsis criteria."}]}
{"task_id": "medmcp-calc_116_93b69ce8", "task_scenario": "Acute Kidney Injury (AKI) and Electrolytes", "task_category": "Clinical Medicine / Emergency, Critical Care & Perioperative / Critical Care", "patient_id": "P116_93b69ce8", "task_description": "Scenario: In a critical care setting, a patient with shock physiology develops oliguria, rising creatinine, and concurrent electrolyte disturbances (dysnatremia, hyperkalemia) with metabolic acidosis after exposure to diuretics. The ICU team must rapidly classify AKI severity, determine likely etiology (prerenal vs intrinsic), correct sodium safely, address acidosis and potassium derangements, and decide whether to initiate continuous renal replacement therapy (CRRT) and how to dose it. Workflow steps using the selected calculators:\n1) Urine Output and Fluid Balance: Calculate hourly and 24-hour urine output and net fluid balance. This provides the urine output metric needed for staging and guides subsequent fluid choices.\n2) KDIGO AKI Staging: Enter the urine output from step 1 with the change in creatinine to stage AKI. Branch: If Stage 2 or Stage 3, prepare for escalated monitoring and consider RRT triggers; if Stage 1 or no AKI, continue close observation and etiologic workup.\n3) Kinetic Estimated Glomerular Filtration Rate (keGFR): With acutely changing creatinine, estimate dynamic GFR to inform medication dosing, predict trajectory, and weigh the urgency of RRT. A very low keGFR strengthens the case for early CRRT if complications are present.\n4) Fractional Excretion of Urea (FEUrea): If the patient has received diuretics, use FEUrea to differentiate prerenal physiology from intrinsic kidney injury. Branch: If FEUrea suggests prerenal physiology, prioritize judicious volume repletion; if intrinsic, limit fluids and focus on renal support.\n5) Fractional Excretion of Sodium (FENa): If no recent diuretics or natriuretic agents were used, use FENa instead of FEUrea for the same diagnostic goal. Branch: If FENa suggests prerenal physiology, plan volume repletion; if intrinsic, avoid unnecessary fluids.\n6) Serum Anion Gap: Assess for metabolic acidosis and categorize it (gap vs non-gap). Decision trigger: If a metabolic acidosis is present and contributing to instability, proceed to alkali planning; if not, continue to potassium and sodium-specific management.\n7) Bicarbonate Deficit: If metabolic acidosis is confirmed in step 6 and alkali therapy is appropriate, calculate the bicarbonate deficit to guide dosing and infusion plans, especially if using bicarbonate as a bridge while arranging RRT.\n8) Transtubular Potassium Gradient (TTKG): In hyperkalemia, assess whether the kidney is appropriately excreting potassium. Branch: If TTKG indicates poor renal K secretion and hyperkalemia persists despite medical therapy, this supports escalation to RRT on top of the KDIGO stage and acidosis severity.\n9) Sodium Correction Rate in Hyponatremia and Hypernatremia: If dysnatremia is present, use this to select the safest IV fluid type, rate, and volume for the desired correction pace. The decision from steps 4–5 (prerenal vs intrinsic) informs whether to give isotonic solutions or restrict fluids; the urine output and net balance from step 1 help set net fluid goals while avoiding overcorrection.\n10) CRRT Dosing Calculator: If any of the following are present—KDIGO Stage 3 with refractory metabolic acidosis (steps 6–7), persistent hyperkalemia with inadequate renal K excretion (step 8), or progressive volume overload with oliguria (steps 1–2)—proceed to CRRT and use this calculator to set an appropriate effluent dose for solute and fluid control. The keGFR from step 3 and ongoing urine output from step 1 inform the intensity and goals of therapy.", "fuzzy_question": "I’m seeing an ICU patient in shock who has become oliguric, with rising creatinine, dysnatremia, hyperkalemia, and metabolic acidosis after prior diuretic exposure. I’m trying to determine the current severity of kidney dysfunction and whether this is primarily a reversible perfusion issue or an intrinsic problem that requires renal support.\n\nFirst, I want to clarify what the kidneys are doing: document hourly urine output and 24-hour totals along with net fluid balance. These data will drive AKI staging and how aggressively to proceed with fluid administration or restriction.\n\nBased on urine output and the degree of creatinine rise, I want to formally stage the AKI using standard criteria. If the patient falls into a moderate-to-severe category, we should escalate monitoring and anticipate dialysis triggers. If it is mild or borderline, we maintain close surveillance and focus on determining the cause.\n\nBecause creatinine is changing quickly, I’d like a dynamic assessment of filtration rather than a steady-state estimate. If real-time filtration is very low, that supports moving toward continuous dialysis sooner, given the complications.\n\nThe patient has had diuretics, so I’ll rely on urea handling to differentiate prerenal physiology from intrinsic kidney injury. If findings suggest volume responsiveness, prioritize careful repletion. If they indicate intrinsic injury, avoid unnecessary fluids and focus on renal support. If there has not been recent natriuretic exposure, fractional excretion of sodium could also help address the same question.\n\nOn acid–base evaluation, I want to categorize the acidosis—gap or non-gap—and assess its contribution to instability. If significant and bicarbonate therapy is chosen, I’d like an estimate of the base needed and a sensible infusion plan, potentially as a bridge while arranging dialysis.\n\nFor hyperkalemia, I’d like to determine whether the kidneys are appropriately secreting potassium in the distal nephron. If not, and potassium remains elevated despite standard medical therapy, that would favor moving toward continuous dialysis.\n\nI’m also concerned about the sodium disturbance. We need a safe correction rate and the right fluid choice—hypertonic versus isotonic or fluid restriction—guided by whether this appears prerenal or intrinsic. Urine output and net balance will help set the net fluid goal to avoid overcorrection or overshoot.\n\nIf continuous dialysis is needed, please set appropriate targets for solute clearance and fluid removal. The plan should reflect the real-time level of filtration and any ongoing urine output. Triggers include severe AKI with refractory acidosis, persistent hyperkalemia without adequate renal potassium excretion, or progressive volume overload with oliguria.\n\nWhat’s your take on this? Please reason through it step by step and provide precise calculations and rationale at each point—AKI staging tied to urine output and creatinine, a dynamic filtration estimate, how you’re distinguishing prerenal from intrinsic injury in the context of diuretics, how you categorize the acidosis and plan alkali if needed, whether the kidneys are handling potassium appropriately, the safest sodium correction strategy, and how you’d set the intensity of continuous dialysis if indicated. The approach should be based on solid calculations and be defensible.", "required_calculators": ["Urine Output and Fluid Balance", "KDIGO AKI Staging", "Kinetic Estimated Glomerular Filtration Rate (keGFR)", "Fractional Excretion of Urea (FEUrea)", "Fractional Excretion of Sodium (FENa)", "Serum Anion Gap", "Bicarbonate Deficit", "Transtubular Potassium Gradient (TTKG)", "Sodium Correction Rate in Hyponatremia and Hypernatremia", "CRRT Dosing Calculator"], "calculator_answers": [{"order": 1, "name": "Urine Output and Fluid Balance", "inputs": [{"field": "Weight", "value": "176 lb"}, {"field": "Total urine output", "value": "240 mL"}, {"field": "Hours", "value": "24 hours"}, {"field": "Fluid intake", "value": "4200 mL"}], "final_answer": "0.1 cc/kg/hr", "notes": "0.1 cc/kg/hr\nNormal output for adult patients: 0.5-1.0 cc/kg/hr\nNormal output for pediatric patients: 1.0-2.0 cc/kg/hr\n3960 mL\nFluid Balance"}, {"order": 2, "name": "KDIGO AKI Staging", "inputs": [{"field": "Baseline serum creatinine", "value": "1.0 mg/dL"}, {"field": "Current serum creatinine", "value": "4.2 mg/dL"}, {"field": "Weight", "value": "80 kg"}, {"field": "Urine output rate", "value": "0.125 mL/kg/h"}, {"field": "Duration of oliguria", "value": "24 hours"}, {"field": "Anuria duration", "value": "0 hours"}], "final_answer": "Stage 3", "notes": "Serum creatinine 3.0 times baseline or Increase in serum creatinine to ≥4.0 mg/dl (≥353.6 mmol/l) or Initiation of renal replacement therapy or in patients <18 years, decrease in eGFR to <35 ml/min per 1.73 m² or Urine output <0.3 ml/kg/h for ≥24 hours or anuria for ≥12 hours"}, {"order": 3, "name": "Kinetic Estimated Glomerular Filtration Rate (keGFR)", "inputs": [{"field": "Sex", "value": "Male"}, {"field": "Age", "value": "58 years"}, {"field": "Baseline creatinine", "value": "1.0 mg/dL"}, {"field": "First recorded creatinine (Cr1)", "value": "2.6 mg/dL"}, {"field": "Second recorded creatinine (Cr2)", "value": "4.2 mg/dL"}, {"field": "Time between both creatinine measurements", "value": "12 hours"}, {"field": "Black race", "value": "No"}], "final_answer": "0.0 mL/min", "notes": "KeGFR of 30 mL/min is 90% specific (71% sensitive) for AKI, according to one small retrospective study (O'Sullivan 2017)"}, {"order": 4, "name": "Fractional Excretion of Urea (FEUrea)", "inputs": [{"field": "BUN or serum urea", "value": "68 mg/dL"}, {"field": "Serum creatinine", "value": "4.2 mg/dL"}, {"field": "Urine urea", "value": "220 mg/dL"}, {"field": "Urine creatinine", "value": "110 mg/dL"}], "final_answer": "12.4 %", "notes": "12.4 %\nFEUrea <35% suggests pre-renal disease"}, {"order": 5, "name": "Fractional Excretion of Sodium (FENa)", "inputs": [{"field": "Serum sodium", "value": "128 mEq/L"}, {"field": "Serum creatinine", "value": "4.2 mg/dL"}, {"field": "Urine sodium", "value": "48 mEq/L"}, {"field": "Urine creatinine", "value": "110 mg/dL"}], "final_answer": "1.4 %", "notes": "1.4 %\nFENa\nIndeterminate\nCan be seen with either prerenal or intrinsic states."}, {"order": 6, "name": "Serum Anion Gap", "inputs": [{"field": "Sodium", "value": "128 mEq/L"}, {"field": "Chloride", "value": "92 mEq/L"}, {"field": "Bicarbonate", "value": "12 mEq/L"}, {"field": "Albumin", "value": "2.6 g/dL"}], "final_answer": "24.0 mEq/L", "notes": "24.0 mEq/L\nAnion gap\nDelta gap: 12.0 mEq/L\nDelta ratio: 1.0; Pure anion gap acidosis\n27.5 mEq/L\nAlbumin corrected anion gap; suggests high anion gap acidosis\nAlbumin corrected delta gap: 15.5 mEq/L\nAlbumin corrected delta ratio: 1.3"}, {"order": 7, "name": "Bicarbonate Deficit", "inputs": [{"field": "Weight", "value": "176 lb"}, {"field": "Bicarbonate", "value": "12 mEq/L"}], "final_answer": "383.2 mEq", "notes": "383.2 mEq\nBicarbonate Deficit"}, {"order": 8, "name": "Transtubular Potassium Gradient (TTKG)", "inputs": [{"field": "Urine potassium", "value": "12 mEq/L"}, {"field": "Serum potassium", "value": "6.2 mEq/L"}, {"field": "Urine osmolality", "value": "500 mOsm/kg"}, {"field": "Serum osmolality", "value": "280 mOsm/kg"}], "final_answer": 1, "notes": "Transtubular Potassium Gradient (TTKG)\nTTKG <7 in hyperkalemia suggests hypoaldosteronism"}, {"order": 9, "name": "Sodium Correction Rate in Hyponatremia and Hypernatremia", "inputs": [{"field": "Sex", "value": "Male"}, {"field": "Age range", "value": "Adult"}, {"field": "Weight", "value": "176 lb"}, {"field": "Serum sodium", "value": "128 mEq/L"}, {"field": "Fluid type", "value": "2% saline (341 mmol/L Na)"}, {"field": "Rate of sodium correction", "value": "0.3 mEq/L/hr"}], "final_answer": "69 mL/hr", "notes": "69 mL/hr\nFluid rate to increase Na by 0.3 mmol/L/hr with 2% saline"}, {"order": 10, "name": "CRRT Dosing Calculator", "inputs": [{"field": "Patient Weight", "value": "80 kg"}, {"field": "Desired Dialysis Dose", "value": "25 mL/kg/h"}], "final_answer": "2000 ml/hr", "notes": "Calculated Dialysis Dose\n2000 ml/hr"}]}
{"task_id": "medmcp-calc_117_5d931920", "task_scenario": "Acute Kidney Injury (AKI) Differentiation", "task_category": "Clinical Medicine / Medicine & Organ Systems / Nephrology & Electrolytes", "patient_id": "P117_5d931920", "task_description": "Clinical scenario: An adult is admitted with new-onset acute kidney injury (AKI) and decreased urine output. There is recent exposure to potential nephrotoxins, possible diuretic use, and uncertain contribution from volume depletion, intrinsic tubular injury, or urinary tract obstruction. The care team must rapidly stage severity, determine the likely etiology (prerenal vs intrinsic vs postrenal), and identify complications that require urgent intervention.\n\nStep-by-step calculator workflow and rationale:\n1) KDIGO AKI Staging: First, classify AKI severity using changes in kidney function and urine output. This establishes immediate triage needs and helps determine the urgency of subsequent steps.\n2) Kinetic Estimated Glomerular Filtration Rate (keGFR): Because kidney function is acutely changing, estimate the dynamic GFR. If KDIGO stage is severe or the trajectory suggests rapid change, prioritize keGFR now to inform medication dosing, contrast decisions, and the urgency of downstream testing.\n3) BUN Creatinine Ratio: Obtain an early, coarse signal of prerenal vs intrinsic physiology. A higher ratio pushes suspicion toward prerenal causes; a lower ratio reduces that likelihood.\n4) Fractional Excretion of Urea (FEUrea) OR 5) Fractional Excretion of Sodium (FENa): Choose based on diuretic exposure. If recent diuretics were given, use FEUrea; otherwise, use FENa. These tests refine the prerenal vs intrinsic distinction beyond the BUN/Cr ratio.\n6) Licurse Score for Renal Ultrasound: Use this when postrenal obstruction remains a concern, particularly if the BUN/Cr ratio and FEUrea/FENa are discordant or inconclusive. A higher score triggers urgent renal ultrasound to assess for hydronephrosis and need for urologic intervention.\n7) Acute Interstitial Nephritis (AIN) Risk Calculator: If FEUrea/FENa point toward intrinsic AKI, use this to quantify the probability of AIN among intrinsic etiologies and decide on early cessation of offending agents and potential biopsy discussion.\n8) Serum Anion Gap: Evaluate for metabolic acidosis as a complication of AKI and to screen for associated processes (e.g., toxin or muscle breakdown). An elevated gap increases concern for severe intrinsic injury and/or concurrent etiologies.\n9) McMahon Score for Rhabdomyolysis: If the anion gap is elevated or there is clinical suspicion for muscle breakdown, use this score to predict AKI-related risk and mortality, informing intensity of monitoring and need to anticipate dialysis.\n10) Transtubular Potassium Gradient (TTKG): If hyperkalemia is present—especially with high McMahon score and/or very low keGFR—calculate TTKG to assess renal potassium secretion. A low TTKG suggests impaired distal potassium handling and supports escalation of medical therapy and/or dialysis planning.\n\nKey decision links (if/else dependencies):\n- If KDIGO stage is severe or there is rapid change, then keGFR is calculated immediately to guide emergent decisions.\n- Use FEUrea if on diuretics; otherwise use FENa. Then integrate with BUN/Cr ratio:\n  • If BUN/Cr plus FEUrea/FENa both support prerenal physiology, treat as prerenal and re-evaluate after resuscitation.\n  • If FEUrea/FENa support intrinsic AKI, proceed to the AIN Risk Calculator.\n  • If results are discordant or equivocal, calculate the Licurse Score to adjudicate need for urgent renal ultrasound.\n- If the anion gap is elevated, calculate the McMahon Score to evaluate rhabdomyolysis risk.\n- If McMahon Score is high or keGFR is markedly reduced and hyperkalemia is present, calculate TTKG to determine adequacy of renal potassium excretion and urgency of escalation.", "fuzzy_question": "I’m evaluating a hospitalized patient with new acute kidney injury and decreasing urine output. Recent labs indicate a rise in creatinine, urine output has declined, and there has been exposure to potential nephrotoxins; there may have been recent diuretic use. Volume status is unclear at the bedside, and I’m weighing a volume-responsive process, intrinsic tubular/interstitial injury, or a post-renal obstruction.\n\nFirst, I want a clear sense of current severity, anchored in the tempo of creatinine rise and the urine output trend, because that will set the urgency for everything else. If this appears severe or rapidly evolving, I’d like a real-time read on effective filtration capacity rather than relying on steady-state assumptions, so we can dose medications safely, decide about any contrast study, and set the pace for the rest of the workup.\n\nBig picture, I’m trying to separate prerenal from intrinsic and postrenal. As an early clue, I want to see whether urea is disproportionately elevated relative to creatinine. Given possible diuretic exposure, I’d prioritize a urea-based excretion index; if diuretics aren’t a factor, a sodium excretion index would be more helpful. I want these interpreted together: if both support a volume-responsive process, we should treat along those lines and then recheck labs and urine output to confirm improvement. If they point toward intrinsic kidney injury, I’d like a structured estimate of the likelihood of interstitial nephritis based on medication history and urine/exam findings, so we can stop likely offenders early and consider whether this warrants a biopsy discussion. If the signals are mixed or inconclusive, I’d prefer a quick bedside risk check to decide how urgently to obtain a renal ultrasound to look for hydronephrosis and whether to involve urology early.\n\nIn parallel, I’m concerned about complications. I want to know if there’s a meaningful anion gap metabolic acidosis, since that would raise concern for more severe injury or a concurrent process like a toxin or muscle breakdown. If that gap is up or there’s clinical suspicion for muscle injury, I’d like a structured risk estimate for rhabdomyolysis-related complications to guide monitoring intensity and readiness if dialysis might be needed. And if potassium is elevated—especially if the real-time filtration estimate is very low or rhabdomyolysis risk looks high—I want to know whether the distal nephron is excreting potassium appropriately; if it isn’t, that would push us to escalate medical therapy and consider dialysis.\n\nWhat’s your take on this case, and how would you reason through it step by step? I need evidence-based, calculation-supported risk stratification—this can’t rest on clinical intuition alone. Whatever approach you suggest, please back it with solid calculations so it stands up to scrutiny.", "required_calculators": ["KDIGO AKI Staging", "Kinetic Estimated Glomerular Filtration Rate (keGFR)", "BUN Creatinine Ratio", "Fractional Excretion of Urea (FEUrea)", "Fractional Excretion of Sodium (FENa)", "Licurse Score for Renal Ultrasound", "Acute Interstitial Nephritis (AIN) Risk Calculator", "Serum Anion Gap", "McMahon Score for Rhabdomyolysis", "Transtubular Potassium Gradient (TTKG)"], "calculator_answers": [{"order": 1, "name": "KDIGO AKI Staging", "inputs": [{"field": "baseline_serum_creatinine", "value": "0.9 mg/dL"}, {"field": "current_serum_creatinine", "value": "2.3 mg/dL"}, {"field": "patient_weight", "value": "80 kg"}, {"field": "urine_output_last_6_hours", "value": "200 mL"}, {"field": "urine_output_last_12_hours", "value": "360 mL"}, {"field": "urine_output_last_24_hours", "value": "760 mL"}], "final_answer": "Stage 2", "notes": "Serum creatinine 2.0–2.9 times baseline or <0.5 ml/kg/h for ≥12 hours"}, {"order": 2, "name": "Kinetic Estimated Glomerular Filtration Rate (keGFR)", "inputs": [{"field": "sex", "value": "Male"}, {"field": "age", "value": "62 years"}, {"field": "baseline_creatinine", "value": "0.9 mg/dL"}, {"field": "first_recorded_creatinine_Cr1", "value": "1.6 mg/dL"}, {"field": "second_recorded_creatinine_Cr2", "value": "2.3 mg/dL"}, {"field": "time_between_measurements", "value": "12 hours"}, {"field": "black_race", "value": "No"}], "final_answer": "2.6 mL/min", "notes": "2.6 mL/min\nKeGFR of 30 mL/min is 90% specific (71% sensitive) for AKI, according to one small retrospective study (O'Sullivan 2017)"}, {"order": 3, "name": "BUN Creatinine Ratio", "inputs": [{"field": "BUN", "value": "48 mg/dL"}, {"field": "creatinine", "value": "2.3 mg/dL"}], "final_answer": 20.87, "notes": "20.87\nBUN creatinine ratio"}, {"order": 4, "name": "Fractional Excretion of Urea (FEUrea)", "inputs": [{"field": "BUN", "value": "48 mg/dL"}, {"field": "serum_creatinine", "value": "2.3 mg/dL"}, {"field": "urine_urea", "value": "500 mg/dL"}, {"field": "urine_creatinine", "value": "50 mg/dL"}], "final_answer": "47.9 %", "notes": "47.9 %\nFEUrea >35% suggests intrinsic renal disease"}, {"order": 5, "name": "Fractional Excretion of Sodium (FENa)", "inputs": [{"field": "serum_sodium", "value": "137 mEq/L"}, {"field": "serum_creatinine", "value": "2.3 mg/dL"}, {"field": "urine_sodium", "value": "18 mEq/L"}, {"field": "urine_creatinine", "value": "50 mg/dL"}], "final_answer": "0.6 %", "notes": "0.6 %\nFENa\nPrerenal\ne.g., Hypovolemia, heart failure, renal artery stenosis, sepsis (anything causing decreased effective renal perfusion). Remember, contrast-induced nephropathy will often look pre-renal."}, {"order": 6, "name": "Licurse Score for Renal Ultrasound", "inputs": [{"field": "history_of_hydronephrosis", "value": "No"}, {"field": "Race", "value": "Non-black", "score": 1}, {"field": "History of recurrent urinary tract infections", "value": "No", "score": 0}, {"field": "Diagnosis consistent with possible obstruction", "value": "No", "score": 0}, {"field": "History of congestive heart failure", "value": "No", "score": 1}, {"field": "History of sepsis or prerenal acute kidney injury, use of pressors, or hypotension", "value": "No", "score": 1}, {"field": "Exposure to nephrotoxic medications prior to acute kidney injury", "value": "No", "score": 1}], "final_answer": 4, "notes": "4 points\nLicurse Score\nHigh risk\n4.9 %\nRisk of hydronephrosis requiring stent or nephrostomy (20.9% risk of hydronephrosis on imaging)"}, {"order": 7, "name": "Acute Interstitial Nephritis (AIN) Risk Calculator", "inputs": [{"field": "creatinine", "value": "2.3 mg/dL"}, {"field": "BUN", "value": "48 mg/dL"}, {"field": "urine_specific_gravity", "value": "1.014"}, {"field": "urine_dipstick_protein", "value": "1+ or lower"}, {"field": "local_prevalence_of_AIN_among_all_biopsies", "value": "0.23"}], "final_answer": "25.20 %", "notes": "25.20 %\nProbability of AIN"}, {"order": 8, "name": "Serum Anion Gap", "inputs": [{"field": "sodium", "value": "137 mEq/L"}, {"field": "chloride", "value": "100 mEq/L"}, {"field": "bicarbonate", "value": "18 mEq/L"}, {"field": "albumin", "value": "3.2 g/dL"}], "final_answer": "19.0 mEq/L", "notes": "19.0 mEq/L\nAnion gap\nDelta gap: 7.0 mEq/L\nDelta ratio: 1.2; Pure anion gap acidosis\n21.0 mEq/L\nAlbumin corrected anion gap; suggests high anion gap acidosis\nAlbumin corrected delta gap: 9.0 mEq/L\nAlbumin corrected delta ratio: 1.5"}, {"order": 9, "name": "McMahon Score for Rhabdomyolysis", "inputs": [{"field": "age", "value": "62 years", "score": 1.5}, {"field": "sex", "value": "Male", "score": 0}, {"field": "initial_creatinine", "value": "2.3 mg/dL", "score": 3}, {"field": "initial_calcium", "value": "8.6 mg/dL", "score": 0}, {"field": "initial_CPK", "value": "8500 U/L", "score": 0}, {"field": "rhabdo_secondary_to_seizures_syncope_exercise_statins_or_myositis", "value": "Yes (statin-associated suspected)", "score": 0}, {"field": "initial_phosphate", "value": "5.8 mg/dL", "score": 3}, {"field": "initial_bicarbonate", "value": "18 mEq/L", "score": 2}], "final_answer": 9.5, "notes": "9.5 points\nRhabdomyolysis Risk Score\nNot low risk\nRecommend initiating renal protective therapy. McMahon Scores ≥6 are 86% sensitive for identifying patients who will require RRT (52% risk of death or AKI requiring RRT at scores ≥10)."}, {"order": 10, "name": "Transtubular Potassium Gradient (TTKG)", "inputs": [{"field": "urine_potassium", "value": "25 mEq/L"}, {"field": "serum_potassium", "value": "6.1 mEq/L"}, {"field": "urine_osmolality", "value": "420 mOsm/kg"}, {"field": "serum_osmolality", "value": "295 mOsm/kg"}], "final_answer": 3, "notes": "Transtubular Potassium Gradient (TTKG)\nTTKG <7 in hyperkalemia suggests hypoaldosteronism"}]}
{"task_id": "medmcp-calc_118_6d2f5cfd", "task_scenario": "Growth and Development Assessment", "task_category": "Clinical Medicine / Special Populations & General Tools / Pediatrics & Neonatology", "patient_id": "P118_6d2f5cfd", "task_description": "Scenario: A child presents for routine growth and development assessment. The clinical team needs a structured, age-appropriate workflow that accounts for possible prematurity, uses validated anthropometric norms across infancy and childhood, and links growth findings to functional development. The workflow below outlines how to select and sequence multiple calculators to form a cohesive evaluation, with decision points that adjust subsequent steps.\n\nStep-by-step workflow:\n1) Determine gestational maturity: Use the Gestational Age calculator to identify whether the child was born preterm or term. If preterm, derive a corrected age for interpretation; if term, use chronological age. This output will directly determine the age input for subsequent infant growth percentiles.\n2) Infant anthropometrics (<36 months):\n   - Use the CDC/NCHS Infant Length for Age Percentiles (<36 months) with corrected/chronological age to assess linear growth (stature trajectory via Z-score/percentile).\n   - Use the CDC/NCHS Infant Head Circumference for Age Percentiles (<36 months) to evaluate brain growth and cranial development.\n   - Use the CDC/NCHS Infant Weight for Length Percentiles (< 36 months) to assess nutritional status relative to body length.\n   Decision trigger (infancy): If weight-for-length or head circumference results are flagged outside the normal range, proceed immediately to functional assessment (Step 5) to determine the impact of growth deviation on daily activity; otherwise continue routine monitoring and age-appropriate follow-up.\n3) Transition to childhood (≥2 years; overlap management for 24–36 months): When the child reaches ≥2 years, begin using child/teen CDC references in addition to infant charts if still within 24–36 months to ensure continuity of trend assessment.\n4) Childhood/Adolescence anthropometrics (2–20 years):\n   - Use the BMI Calculator (Body Mass Index and BSA) to estimate adiposity for children ≥2 years.\n   - Based on sex, select the appropriate CDC growth charts:\n     • If the child is male: use CDC Height for Age Percentiles for Boys (2 - 20 years), then CDC Weight for Age Percentiles for Boys (2-20 years).\n     • If the child is female: use CDC Height for Age Percentiles for Girls (2 - 20 years), then CDC Weight for Age Percentiles for Girls (2 - 20 years).\n   Decision trigger (childhood/adolescence): If BMI or height/weight-for-age results show Z-scores/percentiles outside the expected range, proceed to functional assessment (Step 5) now; otherwise, continue routine surveillance.\n5) Functional development assessment (any age when triggered, and routinely at well visits): Use the Lansky Play-Performance Scale for Pediatric Functional Status to quantify activity level and performance. This helps interpret whether growth deviations are affecting daily function and informs the intensity of follow-up and intervention.\n6) Synthesis and plan: Integrate findings across steps. For infants, corrected age-based percentiles differentiate nutritional versus constitutional patterns and highlight cranial growth concerns. For older children, BMI and sex-specific CDC charts clarify stature-versus-weight discordance. Functional scores contextualize growth metrics with real-world activity, guiding frequency of monitoring, nutrition counseling, and developmental follow-up.", "fuzzy_question": "I’m seeing a pediatric patient for a routine growth and development visit, and I want to ensure we’re interpreting the growth trajectory correctly without missing factors that could affect everyday function. Gestational age at birth is uncertain, so before proceeding I’m considering whether to correct for prematurity. If preterm, I’d use corrected age before interpreting infant growth curves; if term, I’d use chronological age. That choice will determine how we read the early growth data.\n\nUsing the clinically appropriate age reference, can we outline where this patient falls for linear growth, head circumference, and weight relative to length during infancy? I’d like percentiles and distance from the mean to visualize the trajectory, not just a single point. If weight-for-length or head size is outside expected ranges, I’d prefer to move quickly to a brief, standardized activity/play assessment to see whether growth deviations are affecting day-to-day play and activity now. If those infant measures are reassuring, we can continue routine monitoring.\n\nThe patient is approaching the transition from infant to older-child growth standards, and that handoff can be messy. During the typical overlap period, I’d like to review both the infant and older-child references in parallel for a few visits to maintain continuity of the trend. Once in the older-child range, please include an age- and sex-adjusted BMI percentile to gauge adiposity (and include body surface area if you routinely document it). Then plot height and weight on the appropriate sex-specific curves. Again, if BMI or the height/weight pattern falls outside expectations, let’s pivot to a functional check now rather than later. Even when things look normal, I still prefer to capture a brief, structured snapshot of play and activity at well visits to anchor our baseline.\n\nWhen synthesizing, please help distinguish normal constitutional patterns from true nutrition concerns in infants by using corrected-age percentiles where appropriate and commenting on cranial growth. For older children, clarify whether there’s a mismatch between stature and weight that might alter counseling. Then link the growth picture with the activity score to guide follow-up frequency, appropriate nutrition coaching, and whether to add developmental follow-up.\n\nWhat’s your take on this case? Please walk me through the reasoning step by step with quantified percentiles and deviations from expected so we can justify the plan. I need proper calculations—this can’t rest on clinical intuition alone. Whatever approach you suggest, ensure it’s supported by solid calculations and can withstand scrutiny.", "required_calculators": ["Gestational Age", "CDC/NCHS Infant Length for Age Percentiles (<36 months)", "CDC/NCHS Infant Head Circumference for Age Percentiles (<36 months)", "CDC/NCHS Infant Weight for Length Percentiles (< 36 months)", "BMI Calculator (Body Mass Index and BSA)", "CDC Height for Age Percentiles for Boys (2 - 20 years)", "CDC Weight for Age Percentiles for Boys (2-20 years)", "CDC Height for Age Percentiles for Girls (2 - 20 years)", "CDC Weight for Age Percentiles for Girls (2 - 20 years)", "Lansky Play-Performance Scale for Pediatric Functional Status"], "calculator_answers": [{"order": 1, "name": "Gestational Age", "inputs": [{"field": "Current Date", "value": "2023-07-05"}, {"field": "Due Date", "value": "2023-08-15"}], "final_answer": "34 Weeks 1 Day", "notes": "End of 1st Trimester\nJanuary 31, 2023\nCurrent Gestational Age\n34 Weeks 1 Day"}, {"order": 2, "name": "CDC/NCHS Infant Length for Age Percentiles (<36 months)", "inputs": [{"field": "Sex", "value": "Male"}, {"field": "Age", "value": "2.0 months"}, {"field": "Length", "value": "56.5 cm"}], "final_answer": "9.342%", "notes": "Z Score\n-1.32\nPercentile\n9.342%"}, {"order": 3, "name": "CDC/NCHS Infant Head Circumference for Age Percentiles (<36 months)", "inputs": [{"field": "Sex", "value": "Male"}, {"field": "Age", "value": "2.0 months"}, {"field": "Head Circumference", "value": "39.4 cm"}], "final_answer": "21.186%", "notes": "Z Score\n-0.80\nPercentile\n21.186%\nHead Circumference for Age Percentile Interpretation\nPercentile ≥3 and <97: Normal head circumference"}, {"order": 4, "name": "CDC/NCHS Infant Weight for Length Percentiles (< 36 months)", "inputs": [{"field": "Sex", "value": "Male"}, {"field": "Length", "value": "56.5 cm"}, {"field": "Weight", "value": "5.3 kg"}], "final_answer": "74.215%", "notes": "Z Score\n0.65\nPercentile\n74.215%\nWeight for Length Percentile Interpretation\nPercentile ≥5 and <95: Healthy weight"}, {"order": 5, "name": "CDC/NCHS Infant Length for Age Percentiles (<36 months)", "inputs": [{"field": "Sex", "value": "Male"}, {"field": "Age", "value": "9.0 months"}, {"field": "Length", "value": "71.0 cm"}], "final_answer": "31.207%", "notes": "Z Score\n-0.49\nPercentile\n31.207%"}, {"order": 6, "name": "CDC/NCHS Infant Head Circumference for Age Percentiles (<36 months)", "inputs": [{"field": "Sex", "value": "Male"}, {"field": "Age", "value": "9.0 months"}, {"field": "Head Circumference", "value": "44.6 cm"}], "final_answer": "24.51%", "notes": "Z Score\n-0.69\nPercentile\n24.51%\nHead Circumference for Age Percentile Interpretation\nPercentile ≥3 and <97: Normal head circumference"}, {"order": 7, "name": "CDC/NCHS Infant Weight for Length Percentiles (< 36 months)", "inputs": [{"field": "Sex", "value": "Male"}, {"field": "Length", "value": "71.0 cm"}, {"field": "Weight", "value": "8.6 kg"}], "final_answer": "38.974%", "notes": "Z Score\n-0.28\nPercentile\n38.974%\nWeight for Length Percentile Interpretation\nPercentile ≥5 and <95: Healthy weight"}, {"order": 8, "name": "CDC/NCHS Infant Length for Age Percentiles (<36 months)", "inputs": [{"field": "Sex", "value": "Male"}, {"field": "Age", "value": "18.0 months"}, {"field": "Length", "value": "81.5 cm"}], "final_answer": "38.974%", "notes": "Z Score\n-0.28\nPercentile\n38.974%"}, {"order": 9, "name": "CDC/NCHS Infant Head Circumference for Age Percentiles (<36 months)", "inputs": [{"field": "Sex", "value": "Male"}, {"field": "Age", "value": "18.0 months"}, {"field": "Head Circumference", "value": "47.8 cm"}], "final_answer": "48.405%", "notes": "Z Score\n-0.04\nPercentile\n48.405%\nHead Circumference for Age Percentile Interpretation\nPercentile ≥3 and <97: Normal head circumference"}, {"order": 10, "name": "CDC/NCHS Infant Weight for Length Percentiles (< 36 months)", "inputs": [{"field": "Sex", "value": "Male"}, {"field": "Length", "value": "81.5 cm"}, {"field": "Weight", "value": "11.3 kg"}], "final_answer": "58.317%", "notes": "Z Score\n0.21\nPercentile\n58.317%\nWeight for Length Percentile Interpretation\nPercentile ≥5 and <95: Healthy weight"}, {"order": 11, "name": "CDC/NCHS Infant Length for Age Percentiles (<36 months)", "inputs": [{"field": "Sex", "value": "Male"}, {"field": "Age", "value": "24.0 months"}, {"field": "Length", "value": "86.8 cm"}], "final_answer": "40.517%", "notes": "Z Score\n-0.24\nPercentile\n40.517%"}, {"order": 12, "name": "CDC/NCHS Infant Head Circumference for Age Percentiles (<36 months)", "inputs": [{"field": "Sex", "value": "Male"}, {"field": "Age", "value": "24.0 months"}, {"field": "Head Circumference", "value": "49.1 cm"}], "final_answer": "60.642%", "notes": "Z Score\n0.27\nPercentile\n60.642%\nHead Circumference for Age Percentile Interpretation\nPercentile ≥3 and <97: Normal head circumference"}, {"order": 13, "name": "CDC/NCHS Infant Weight for Length Percentiles (< 36 months)", "inputs": [{"field": "Sex", "value": "Male"}, {"field": "Length", "value": "86.8 cm"}, {"field": "Weight", "value": "12.8 kg"}], "final_answer": "71.904%", "notes": "Z Score\n0.58\nPercentile\n71.904%\nWeight for Length Percentile Interpretation\nPercentile ≥5 and <95: Healthy weight"}, {"order": 14, "name": "CDC/NCHS Infant Length for Age Percentiles (<36 months)", "inputs": [{"field": "Sex", "value": "Male"}, {"field": "Age", "value": "30.0 months"}, {"field": "Length", "value": "92.5 cm"}], "final_answer": "53.983%", "notes": "Z Score\n0.10\nPercentile\n53.983%"}, {"order": 15, "name": "CDC/NCHS Infant Head Circumference for Age Percentiles (<36 months)", "inputs": [{"field": "Sex", "value": "Male"}, {"field": "Age", "value": "30.0 months"}, {"field": "Head Circumference", "value": "49.6 cm"}], "final_answer": "57.535%", "notes": "Z Score\n0.19\nPercentile\n57.535%\nHead Circumference for Age Percentile Interpretation\nPercentile ≥3 and <97: Normal head circumference"}, {"order": 16, "name": "CDC/NCHS Infant Weight for Length Percentiles (< 36 months)", "inputs": [{"field": "Sex", "value": "Male"}, {"field": "Length", "value": "92.5 cm"}, {"field": "Weight", "value": "14.2 kg"}], "final_answer": "70.194%", "notes": "Z Score\n0.53\nPercentile\n70.194%\nWeight for Length Percentile Interpretation\nPercentile ≥5 and <95: Healthy weight"}, {"order": 17, "name": "BMI Calculator (Body Mass Index and BSA)", "inputs": [{"field": "Weight", "value": "28.22 lb"}, {"field": "Height", "value": "33.90 in"}], "final_answer": "17.3 kg/m²", "notes": "17.3 kg/m²\nBody Mass Index (Underweight)\n0.55 m²\nBody Surface Area"}, {"order": 18, "name": "CDC Height for Age Percentiles for Boys (2 - 20 years)", "inputs": [{"field": "Age", "value": "24.0 months"}, {"field": "Height", "value": "86.1 cm"}], "final_answer": "41.294%", "notes": "Z Score\n-0.22\nPercentile\n41.294%\nHeight for Age Percentile Interpretation\nPercentile ≥5 and <95: Normal stature"}, {"order": 19, "name": "CDC Weight for Age Percentiles for Boys (2-20 years)", "inputs": [{"field": "Age", "value": "24.0 months"}, {"field": "Weight", "value": "12.8 kg"}], "final_answer": "51.595%", "notes": "Z Score\n0.04\nPercentile\n51.595%"}, {"order": 20, "name": "BMI Calculator (Body Mass Index and BSA)", "inputs": [{"field": "Weight", "value": "31.31 lb"}, {"field": "Height", "value": "36.14 in"}], "final_answer": "16.9 kg/m²", "notes": "16.9 kg/m²\nBody Mass Index (Underweight)\n0.60 m²\nBody Surface Area"}, {"order": 21, "name": "CDC Height for Age Percentiles for Boys (2 - 20 years)", "inputs": [{"field": "Age", "value": "30.0 months"}, {"field": "Height", "value": "91.8 cm"}], "final_answer": "54.776%", "notes": "Z Score\n0.12\nPercentile\n54.776%\nHeight for Age Percentile Interpretation\nPercentile ≥5 and <95: Normal stature"}, {"order": 22, "name": "CDC Weight for Age Percentiles for Boys (2-20 years)", "inputs": [{"field": "Age", "value": "30.0 months"}, {"field": "Weight", "value": "14.2 kg"}], "final_answer": "66.276%", "notes": "Z Score\n0.42\nPercentile\n66.276%"}, {"order": 23, "name": "Lansky Play-Performance Scale for Pediatric Functional Status", "inputs": [{"field": "Patient Description", "value": "Fully active, normal"}], "final_answer": 100, "notes": "100 points\nAble to carry on normal activity; no special care is needed.\nSee definitions of the Lansky Scale in the About section."}]}
{"task_id": "medmcp-calc_119_60934cc5", "task_scenario": "Tuberculosis Screening and Treatment Monitoring", "task_category": "Clinical Medicine / Medicine & Organ Systems / Infectious Diseases", "patient_id": "P119_60934cc5", "task_description": "Scenario: An ambulatory patient with recent exposure risk is evaluated for tuberculosis infection. The clinician must interpret screening results, differentiate latent infection from active disease risk, and, if treatment is indicated, plan a safe regimen and monitoring strategy that accounts for body size, renal function, hepatic status, and potential QT-prolonging therapies. Step-by-step calculator use: 1) Start with TB Skin Test Interpretation to classify the tuberculin skin test as positive or negative based on risk status and measured induration. 2) Decision point A: If negative and the patient has no compelling risk factors, conclude the screening workflow and document the result. If positive (or high-risk), proceed to pre-treatment planning and safety assessments while concurrently evaluating for active disease by standard clinical means. 3) For positive/high-risk cases, quantify body size: use the Body Mass Index (BMI) Calculator to determine obesity status. 4) Use Ideal Body Weight (Devine) to compute IBW; if BMI indicates obesity, calculate Adjusted Body Weight so that an appropriate dosing weight is available. The IBW number is a required input to the Adjusted Body Weight step; the BMI output deterministically triggers whether Adjusted Body Weight is needed. 5) Feed the selected weight (actual, IBW, or adjusted per the BMI/Devine steps) into Creatinine Clearance (Cockcroft-Gault) to estimate renal function for dosing of renally cleared TB drugs. 6) Compute the Child-Pugh Score to stratify hepatic impairment risk and tailor the regimen and monitoring intensity for hepatotoxic agents. 7) Decision point B: If active TB is suspected/confirmed, use the CrCl and Child-Pugh outputs to select and dose first-line agents safely; if latent TB is likely, use Child-Pugh to prefer regimens with lower hepatotoxicity and set a monitoring plan. 8) If resistance risk or alternative regimens that may prolong QT are being considered, run the Corrected QT Interval (QTc) Calculator before initiating those agents; Decision point C: if QTc is prolonged, avoid or substitute QT-prolonging drugs and plan closer cardiac monitoring; if normal, proceed. 9) Monitoring: Reassess BMI (significant weight change), Cockcroft-Gault (renal changes), Child-Pugh (hepatic changes), and QTc (when adding QT-prolonging drugs) during therapy to adjust dosing and maintain safety.", "fuzzy_question": "I am evaluating an adult patient with a TB exposure. A skin test was placed, and interpretation is uncertain given the overall risk profile and the induration size. If it does not meet the positivity threshold and there are no compelling risk factors, I would document and stop; if it is positive or risk remains high, I want to move ahead with treatment planning while, in parallel, ensuring we are not missing active disease (symptoms, exam, chest imaging, sputum when indicated). There may be obesity, so dosing requires careful consideration.\n\nIf therapy is indicated, please size the patient thoughtfully. Assess weight relative to height to determine whether obesity is present. Start with an expected lean or ideal weight for height; if obesity is present, use an adjusted dosing weight rather than total body weight; otherwise use actual or height-based weight as appropriate. Use the selected dosing weight to estimate renal drug clearance with a standard bedside approach that incorporates demographic factors and serum creatinine, since several TB agents rely on renal handling. At the same time, stage hepatic risk using bilirubin, albumin, INR, and the presence of ascites or encephalopathy to guide regimen selection and monitoring intensity.\n\nIf evaluation points to active TB, select and dose the standard multidrug regimen guided by the renal and hepatic assessments. If this appears to be latent infection, favor liver-sparing options and outline a monitoring plan aligned with hepatic risk. If resistance is possible or alternatives with QT effects are under consideration, obtain a baseline ECG with a corrected QT; if it is prolonged, avoid or substitute QT-prolonging drugs and plan closer rhythm follow-up; if it is normal, proceed.\n\nOver follow-up visits, if there are meaningful changes in body weight, kidney function, liver tests, or if new QT-prolonging medications are added, revisit body size, refresh the renal clearance estimate using the same weight logic, restage hepatic risk, and repeat the ECG as needed to keep dosing safe.\n\nI need this supported by explicit calculations rather than clinical intuition. Whatever approach is proposed should be grounded in validated formulas and calculations that can withstand scrutiny.", "required_calculators": ["TB Skin Test Interpretation", "BMI and BSA (Mosteller)", "Ideal Body Weight", "Ideal Body Weight and Adjusted Body Weight", "CrCl Cockroft-Gault", "Child-Pugh Score for Cirrhosis Mortality", "Corrected QT Interval (QTc)"], "calculator_answers": [{"order": 1, "name": "TB Skin Test Interpretation", "inputs": [{"field": "Induration size", "value": "8 mm"}, {"field": "Known HIV+", "value": "No"}, {"field": "Recent contact with person infected with TB?", "value": "Yes"}, {"field": "Organ transplant recipient?", "value": "No"}, {"field": "CXR findings of fibrotic lung disease suggestive of TB?", "value": "No"}, {"field": "Immunocompromised?", "value": "No"}, {"field": "Recent immigrant from high-prevalence country (<5 yrs)?", "value": "No"}, {"field": "Injection drug user?", "value": "No"}, {"field": "Resident of high-risk congregate setting?", "value": "No"}, {"field": "Mycobacteriology laboratory personnel?", "value": "No"}, {"field": "Has clinical condition that puts them at high risk?", "value": "No"}, {"field": "Children < 4 years?", "value": "No"}, {"field": "Child or adolescent exposed to adult at high risk?", "value": "No"}], "final_answer": "TB skin test is positive. Please see additional info for causes of false positive results.", "notes": "Result\nTB skin test is positive. Please see additional info for causes of false positive results."}, {"order": 2, "name": "BMI and BSA (Mosteller)", "inputs": [{"field": "Height", "value": "175 cm"}, {"field": "Weight", "value": "95 kg"}], "final_answer": "31.02 kg/m²", "notes": "Body Mass Index\n31.02 kg/m²\nWeight Category\nObese Category\nBody Surface Area\n2.149 m²\nObesity Class\nObesity class I"}, {"order": 3, "name": "Ideal Body Weight", "inputs": [{"field": "Sex", "value": "Male"}, {"field": "Height", "value": "175 cm"}], "final_answer": "70.46 kg (155.35 lbs)", "notes": "Ideal Body Weight\n70.46 kg (155.35 lbs)"}, {"order": 4, "name": "Ideal Body Weight and Adjusted Body Weight", "inputs": [{"field": "Actual body weight", "value": "95 kg"}, {"field": "Sex", "value": "Male"}, {"field": "Height", "value": "175 cm"}], "final_answer": "80.3 kg", "notes": "70.5 kg\nIdeal Body Weight\nEquivalent to 155.3 lbs\nActual body weight is 135% (1.35x) ideal body weight\n80.3 kg\nAdjusted Body Weight\nEquivalent to 177.0 lbs"}, {"order": 5, "name": "CrCl Cockroft-Gault", "inputs": [{"field": "Age", "value": "42 years"}, {"field": "Sex", "value": "Male"}, {"field": "Serum creatinine", "value": "1.0 mg/dL"}, {"field": "Weight for calculation", "value": "80.3 kg (adjusted body weight)"}], "final_answer": "109.3 mL/min", "notes": "Creatinine Clearance Estimate\n109.3 mL/min"}, {"order": 6, "name": "Child-Pugh Score for Cirrhosis Mortality", "inputs": [{"field": "Total bilirubin", "value": "0.8 mg/dL", "score": 1}, {"field": "Serum albumin", "value": "4.2 g/dL", "score": 1}, {"field": "INR", "value": "1.0", "score": 1}, {"field": "Ascites", "value": "None", "score": 1}, {"field": "Hepatic encephalopathy", "value": "None", "score": 1}], "final_answer": 5, "notes": "5 points\nChild Class A\nLife Expectancy : 15-20 years\nAbdominal surgery peri-operative mortality: 10%"}, {"order": 7, "name": "Corrected QT Interval (QTc)", "inputs": [{"field": "Measured QT interval", "value": "380 ms"}, {"field": "Heart rate", "value": "72 bpm"}, {"field": "Correction formula", "value": "Bazett"}, {"field": "Paper speed, mm/sec", "value": "25"}], "final_answer": "416 msec", "notes": "416 msec\nCorrected QT Interval (QTc)"}]}
